<SEC-DOCUMENT>0001390478-19-000017.txt : 20190322
<SEC-HEADER>0001390478-19-000017.hdr.sgml : 20190322
<ACCEPTANCE-DATETIME>20190322080630
ACCESSION NUMBER:		0001390478-19-000017
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190322
DATE AS OF CHANGE:		20190322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		19698424

	BUSINESS ADDRESS:	
		STREET 1:		15 WEST 38TH STREET
		STREET 2:		10TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018
		BUSINESS PHONE:		(917) 438-4353

	MAIL ADDRESS:	
		STREET 1:		15 WEST 38TH STREET
		STREET 2:		10TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sls-20181231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF95C3693C1D9EB3A5E068068246EE622"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Helvetica,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Helvetica,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Helvetica,sans-serif;font-size:14pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">For the fiscal year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">For the transition period from _________ to _________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: 001-33958</font></div><div style="line-height:120%;text-align:center;"><img src="sellas-logoa05.jpg" alt="sellas-logoa05.jpg" style="height:56px;width:173px;"></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:Helvetica,sans-serif;font-size:16pt;font-weight:bold;">SELLAS Life Sciences Group, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">20-8099512</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(State of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">15 West 38</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">&#32;Street, 10</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">&#32;Floor, New York, NY 10018</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Address of principal executive officers)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">(917)&#160;438-4353</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Registrant's telephone number, including area code)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:35%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section (12(b) of the Exchange Act:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common Stock, $0.0001 Par Value per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">The Nasdaq Capital Market</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section (12(g) of the Exchange Act: None</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167;229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or other information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:4px;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;&#160;No</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">The aggregate market value of the registrant's common stock, $0.0001 per value per share, held by non-affiliates of the registrant on June 29, 2018, the last business day of the registrant's most recently completed second fiscal quarter, was $14,425,577 (based on the closing sales price of the registrant's common stock on that date). Shares of the registrant's common stock held by each officer and director and each person who owns 5% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. As of </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">March&#160;21, 2019</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">, SELLAS Life Sciences Group, Inc. had outstanding </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">23,176,475</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;shares of common stock, $0.0001 par value per share, exclusive of treasury shares.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant&#8217;s Proxy Statement for its 2019 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sE5C8A6935E068A65BA36806824F486BC"></a></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Some of the information contained in this annual report on Form 10-K may include forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;will&#8221; and similar statements of a future or forward-looking nature identify forward-looking statements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections entitled "Business - Overview - Recent Developments," &#8220;Risk Factors,&#8221; &#8220;Legal Proceedings,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; in this annual report on Form 10-K, which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sD9F00EFE67CF907FEEA6806824C1ADAC"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FORM 10-K - Annual Report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">For the Year Ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">PART I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#se1d5b4c53538429da8f55cf1246eacdb"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#se1d5b4c53538429da8f55cf1246eacdb">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 1A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s25e071a358034543a2502c43f3f8f682"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s25e071a358034543a2502c43f3f8f682">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 1B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sed06ef676db44a169b79060feda38621"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sed06ef676db44a169b79060feda38621">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3a89d76d794e4dc39cdef242b3145f95"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3a89d76d794e4dc39cdef242b3145f95">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s57ff62bf763747f1b49d4d0f03318d2d"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s57ff62bf763747f1b49d4d0f03318d2d">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sb47006b139e04d2f9e215a59ac34af2d"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sb47006b139e04d2f9e215a59ac34af2d">82</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">PART II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s924e5131bbf04ce2aabb57fc2a1bab75"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s924e5131bbf04ce2aabb57fc2a1bab75">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sde531ded542f4a4a9adc04a67ba5b6c9"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sde531ded542f4a4a9adc04a67ba5b6c9">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s0117FBEBE1CD0F914552806829D534F2"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s0117FBEBE1CD0F914552806829D534F2">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 7A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3091b9c070a14eed8643b6741a7a23e0"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3091b9c070a14eed8643b6741a7a23e0">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3F0B1D2A6003E4575B8E8068254680BB"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3F0B1D2A6003E4575B8E8068254680BB">104</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD104E45D8E93DA75963180682A9E19FD"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD104E45D8E93DA75963180682A9E19FD">142</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 9A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAA63A69EB925413E294880682ACE44F7"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAA63A69EB925413E294880682ACE44F7">142</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 9B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#se9fb5119dec94e02acbaf2996adbf8f4"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#se9fb5119dec94e02acbaf2996adbf8f4">143</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">PART III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s1F4A6C0E801E21EF814080682B219446"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s1F4A6C0E801E21EF814080682B219446">145</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s202157F85DF96D352F1680682B45E1CA"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s202157F85DF96D352F1680682B45E1CA">145</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sDFBF2A13EEFBB053AD6A80682B811F11"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sDFBF2A13EEFBB053AD6A80682B811F11">145</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s75A4E5E1FB232BFED02480682BA6597E"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s75A4E5E1FB232BFED02480682BA6597E">145</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s5AFF3C10102427082DF580682BCA6EC9"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s5AFF3C10102427082DF580682BCA6EC9">145</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">PART IV</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAC5C48BB86A58FABE5BC80682C289EF3"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAC5C48BB86A58FABE5BC80682C289EF3">146</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Item 16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3c66c006e25f457480f57706ab783966"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3c66c006e25f457480f57706ab783966">151</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s064503BB066BDA4E4C5880682C65433A"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s064503BB066BDA4E4C5880682C65433A">152</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The names &#8220;SELLAS Life Sciences Group, Inc.,&#8221; &#8220;SELLAS,&#8221; the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this annual report on Form 10-K are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this prospectus are the property of their respective owners. We do not intend the use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either, of these other companies. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s80d60ef1fea24601b8c99ab6fb2ec9ab"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="se1d5b4c53538429da8f55cf1246eacdb"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1. BUSINESS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Overview </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Galinpepimut-S, or GPS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our lead product candidate, galinpepimut-S, or GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2018, following discussions with the U.S. Food and Drug Administration, or FDA, regarding a clinical trial design and biostatistical plan, we commenced preparations for a Phase 3 trial for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission, or CRem2, following successful completion of second-line antileukemic therapy. This trial is expected to serve as the basis for a Biologics License Application, or BLA, submission, subject to positive results.  We are currently ready to start this Phase 3 trial, pending receipt of funding. The study is expected to enroll approximately 116 patients at approximately 50 clinical sites in the United States and Europe and is contemplated to have a planned interim safety and futility analysis after 80 events (deaths). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In December 2018, we initiated a Phase 1/2 multi-arm ("basket" type) clinical study of GPS in combination with Merck &amp; Co., Inc.&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab). We plan to enroll approximately 90 patients at up to 20 centers in the United States. The initial tumor types to be treated will be AML (in patients having achieved partial response as their best hematological response after four cycles of therapy with hypomethylating agents), and ovarian cancer (second or third line), to be followed by triple negative breast cancer, or TNBC, (second line), small cell lung cancer, or SCLC, (second line), and colorectal cancer (third or fourth line). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS was granted Orphan Drug Product Designations from the FDA as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, malignant pleural mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nelipepimut-S or NPS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Nelipepimut-S, or NPS, is a cancer immunotherapy targeting the human epidermal growth factor receptor, or HER2, expressing cancers. Data presented in 2018 from our Phase 2b clinical trial of the combination of trastuzumab (Herceptin&#174;) plus NPS in HER1/2+ breast cancer patients in the adjuvant setting to prevent recurrences showed a clinically and statistically significant improvement in the disease-free survival, or DFS, rate for the TNBC cohort at 24 months for patients treated with NPS plus trastuzumab of 92.6% compared to 70.2% for those treated with trastuzumab alone. In October 2018, the Data Safety Monitoring Board, or DSMB, unanimously concluded that the final analysis of the Phase 2b study data, with a median follow-up of 26 months, confirmed that TNBC patients should be the key target population for the development of trastuzumab plus NPS in the adjuvant setting in early-stage HER2 1+/2+ breast cancer patients.  We are having ongoing discussions with the FDA in the first half of 2019 to define an optimal path for further development of the combination of NPS plus trastuzumab in TNBC and expect to complete these discussions the first half of 2019. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">FBP-targeting bivalent vaccine (GALE-301/-302)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE 302 are cancer immunotherapies that target the E39 peptide derived from the folate binding protein, or FBP. In a Phase 1/2a investigator sponsored trial, or IST, assessing GALE-301 in ovarian and endometrial cancers, we observed improvement in the 24-month DFS rate, in a small number of patients treated with the optimal dose. We are evaluating GALE-301/302 for potential internal development in a Phase 2 setting for ovarian cancer, strategic partnership, or other type of candidate rationalization. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The chart below summarizes the current status of our clinical development pipeline: </font></div><div style="line-height:120%;text-align:center;"><img src="pipeline03152019.jpg" alt="pipeline03152019.jpg" style="height:390px;width:597px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Recent Developments </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2019, we engaged Cantor Fitzgerald &amp; Co. to explore a wide range of strategic alternatives to further our business plan, with the ultimate objective being an outcome that is in the best interest of shareholders.  Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment/financing or a funded collaboration or partnership.  To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 6, 2019, we entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to 3,800,000 of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of $1.10 per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately 3,800,000 shares of common stock at an exercise price of $1.40 per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately 1.2 million warrants for gross proceeds of $1.3 million and approximately 1.2 million New Warrants were issued. We may receive aggregate gross proceeds of up to approximately $4.2 million from the cash exercise if all of the warrants under the Exercise Agreement are exercised.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Merger of SELLAS Life Sciences Group Ltd. and Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, we completed the business combination with the privately held Bermuda exempted company, Sellas Life Sciences Group Ltd., or Private SELLAS, in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&#160;7, 2017 and amended November&#160;5, 2017, or the Merger Agreement, among SELLAS Life Sciences Group, Inc., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. We refer to this business combination throughout this annual report on Form 10-K as the Merger. Immediately after the Merger the former Private SELLAS shareholders owned approximately 67.5% of our fully diluted common stock, and the pre-Merger shareholders owned the remaining approximately 32.5%. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As a result of the Merger, our business is now substantially comprised of the business of Private SELLAS, and although we are considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired our company in the Merger. Consequently, the Merger is accounted for as a reverse acquisition. Upon completion of the Merger, we changed our name from &#8220;Galena Biopharma, Inc.&#8221; to &#8220;SELLAS Life Sciences Group, Inc.,&#8221; our common stock began trading on The Nasdaq Capital Market under a new ticker symbol &#8220;SLS&#8221; on January 2, 2018 and our financial statements became those of Private SELLAS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As used in this annual report on Form 10-K, the words &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; and &#8220;SELLAS&#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the Merger.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">The Cancer Immunotherapy Industry </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Overview </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current treatments for cancer include surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy and immunotherapy. Cancer immunotherapy is an approach to cancer treatment that harnesses the body&#8217;s natural immune system response to fight and/or prevent tumor growth while keeping normal cells unaffected or delivering certain immune system components in order to inhibit the spread of cancer. In recent years, cancer immunotherapy drugs have emerged as a new mode of cancer treatment, alongside more established options such as surgery, chemotherapy, targeted therapy and radiation therapy.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Either as monotherapy or in combination therapies, immunotherapies may produce long-term remissions or even operational &#8220;cures&#8221; for cancers that have often been fatal until recently. A July 2016 report by Kelly Scientific Publications estimates that immunotherapies may eventually be used in as many as 60% of cases of advanced cancer. Additionally, a recent Allied Market Research report on the estimated entire market value of oncology drugs in 2020 suggests that cancer immunotherapies could represent up to 71% of that total value. Thus, cancer immunotherapy is an important and rapidly emerging field, which has led to exciting new clinical research studies and garnered the attention of investors, biotechnology and pharmaceutical companies, regulatory agencies, payors and hospital systems, cancer patients and their families and the general public at large.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Market</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the 2018 &#8220;Global Oncology Trends&#8221; report by the IQVIA Institute, the global market for cancer drugs (including immunotherapy drugs) is expected to reach $200&#160;billion by the end of 2022, growing at a compound annual growth rate, or CAGR of 10-13% between 2017 and 2022. According to a 2018 report by Data Bridge Market Research (Pune, India), MarketsandMarkets, the global cancer immunotherapy market is expected to reach $202.89 billion by 2025, growing at a CAGR of 14.1% during the forecast period of 2018 to 2025. Approximately 90% of the immunotherapy market is comprised of immune synapse modulators (which includes checkpoint inhibitors and immune synapse co-stimulators), which leaves approximately 10% for other major immunotherapies, which include peptide cancer active immunizers such as our product candidates, GPS and NPS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Products/Pipeline</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Galinpepimut-S (GPS)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Overview </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS is a WT1-targeting peptide-based cancer immunotherapeutic being developed as a monotherapy and in combination with other therapeutic agents to treat different types of cancers that result from uninhibited tumor cell growth.  GPS targets malignancies and tumors characterized by an overexpression of the WT1 protein. The WT1 protein is one of the most widely expressed cancer proteins in multiple malignancies. A 2009 pilot project regarding the prioritization of cancer antigens (substances that evoke an immune response) conducted by the National Cancer Institute, or NCI, a division of the National Institutes of Health, or NIH, ranked the WT1 protein as a top priority for immunotherapy. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">WT1 is a protein that resides in the cell&#8217;s nucleus and participates in the process of cancer formation and progression. As such, it is classified as an &#8220;oncogene.&#8221; WT1 plays a key role in the development of the kidneys in fetal life, but then almost disappears from normal organs and tissues. In a wide variety of cancers (20 or more cancer types), WT1 becomes detectable again in at least 50% of tumor pathology specimens in the cells of these cancers. WT1 appears in large amounts (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, becomes &#8220;overexpressed&#8221;) in numerous hematological malignancies, including AML, MM and CML, as well as in many solid malignancies such as MPM, gastrointestinal cancers (such as colorectal cancer), glioblastoma multiforme, TNBC, ovarian cancer and SCLC. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following figure shows the ratio of samples testing positive for WT1 to those testing negative for WT1 in a number of different malignancies. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">WT1 EXPRESSION FREQUENCY ACROSS VARIOUS CANCERS </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">(Positive samples / Total samples) </font></div><div style="line-height:120%;"><img src="wt1cancersa01.jpg" alt="wt1cancersa01.jpg" style="height:480px;width:684px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Mechanism of Action in Immune System</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS is a multi-peptide product that has been modified to enhance the degree and duration of the immune response against the WT1 protein. The modification is based on the fact that two of the four peptides in the peptide mixture comprising GPS are deliberately mutated in a single amino acid residue. These mutated peptides are recognized by the immune system as non-self-entities and are therefore less likely to induce immune tolerance. After administration of these mutated peptides, the patients become immunized against the corresponding native versions of these peptides (which are expressed by the tumor cells), and thus, are able to cross-react against them, which concept is called the heteroclitic principle.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe that GPS has a mechanism of action that involves direct activation of the patient&#8217;s immune system specifically and solely against the WT1 protein. Although the immune system is designed to identify foreign or abnormal proteins expressed on tumor cells, this process is often defective in cancer patients. Typically, patients harboring WT1-positive malignancies have very few or no T cells specifically reactive or responsive to, and therefore activated by, WT1. T cells are involved in both sensing and killing abnormal cells, in addition to coordinating the activation of other cells in an immune response. T cells can be classified into two major subsets, CD4 cells and CD8 cells.  CD8 cells are characterized by a CD8 protein on their cell surface that allow them to recognize, bind and kill cells infected by cancer cells. CD4 cells, known as helper T cells, are critical to providing the signals necessary for sustained CD8 cell responses and are also capable of exerting direct anti-tumor activity. GPS is designed to elicit both CD4 and CD8 cell immune responses. We believe that the activation of CD8 cells by GPS could lead to direct cancer cell killing, or cytotoxicity, and the eventual establishment of immunologic memory against a WT1-expressing cancer. This occurs by two mechanisms: (i) conversion of some of the activated CD8 cells to CD8 memory cells, and (ii) activation of CD4 cells and the eventual creation of CD4 terminal effective memory cells. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe that, with respect to the conversion of activated CD8 cells, the GPS stimulated CD8 cells transform into cytotoxic T-lymphocytes, or CTLs, which are expected to be able to attack and destroy specifically WT1-positive cancer cells. Each CTL typically destroys one WT1-positive cancer cell, but they have been shown to be able to kill up to 10 to 20 WT1-positive cancer cells. Further, with respect to the activation of CD4 cells, we believe that CD4 cells are stimulated to produce WT1-specific, helper T cells, which are able to in turn activate CTLs and B cells. The B-cells &#8220;helped&#8221; by the helper T cells produce antibodies to specific WT1 epitopes. The anti-cancer effect is considered to be a result of a combination of all of the above actions, as well as possible additional, less clear mechanisms involving other immune cell types (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, natural killer cells) that are not as widely understood. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following diagram illustrate GPS&#8217; mechanism of action: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="gpsmoa.jpg" alt="gpsmoa.jpg" style="height:305px;width:285px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS cannot be administered to patients in a water-soluble form, and so it is given under the skin, or subcutaneously. If administered on its own, GPS would rapidly degrade and would not have the opportunity to activate the immune system. Therefore, GPS is mixed with Montanide&#8482;, a commercially available, non-specific immune adjuvant composed of a natural metabolizable oil and a very refined emulsifier, creating a dense emulsion.  Montanide is co-administered with GPS by subcutaneous injection to optimally activate cellular and humoral immune responses in vaccinated patients. Additionally, prior to the administration of GPS, patients receive another immune adjuvant, granulocyte-macrophage colony-stimulating factor, or GM-CSF, to non-specifically stimulate and activate antigen-presenting cells, or APCs, in the vicinity of the subcutaneous injection of GPS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">After subcutaneous injection, the WT1 peptides within GPS disperse locally underneath the injection site and at local lymph nodes and are ingested by APCs. Digested peptide fragments are then presented on the surface of APCs to CD8 and CD4 lymphocytes while simultaneously associated on the cell membrane with major histocompatibility complexes, or MHC, human leukocyte antigen, or HLA molecules. This process activates the CD4 and CD8 cells and sensitizes them to the key 25 epitopes of WT1, thus initiating the process of short- and long-term T-cell-mediated immunity against WT1.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Key Features </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the key features of GPS: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:64%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Key&#160;features&#160;of&#160;an&#160;Optimal&#160;Cancer&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Active Immunizer Therapeutic</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">GPS Properties and Clinical Strategy</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Selecting the right target antigen and</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">epitopes within that antigen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Four peptides and 25 epitopes selected optimally with the objective of ensuring:</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- optimal MHC complex presentation;</font></div><div style="padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- specificity across different HLA types;</font></div><div style="padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- production of both CD4 and CD8 activated cells; and</font></div><div style="padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="padding-bottom:1px;padding-left:53px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- the ability to apply the heteroclitic principle, as described above, to overcome tolerance.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Optimal T-cell engagement leading to</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">cancer cell destruction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Immune response data from the final analysis of the Phase I clinical study of GPS in MM in 12&#160;evaluable patients that were presented at the 44</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;Annual Meeting of the European Society for Blood and Marrow Transplantation, or EBMT, in 2018 (Dr.&#160;Kohne et al.) showed 75% frequency of either CD8+ or CD4+ responses to an all-pool mixture of WT1-derived antigens after completion of the 12 vaccinations per the study protocol. This evidence of multi-epitope, broad cross-reactivity along the full-length of the WT1 protein is suggestive of epitope spreading, as it emerged across epitopes against which the patients were not specifically immunized. These data corroborate the results of an earlier analysis in mid-2017 and strongly suggest stimulation of T cells towards intracellular antigen fragments from GPS-induced destruction of tumor cells, which effect is a hallmark of an effective vaccine, e.g., that it is targeting the right epitopes chosen by design.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Overcoming the barriers of an</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">adverse/immunosuppressive tumor</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">micro-environment, or TME</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The GPS monotherapy clinical studies are in the setting of complete remission, or CRem, and minimal residual disease, or MRD, whereby no bulky or measurable tumor deposits exist. This is typically seen after successful frontline therapy in select cancer types for which such debulking standard therapies exist (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, AML or MPM). In these settings, the tumor micro-environment, or TME, is substantially absent. We are also pursuing combination therapy with checkpoint inhibitors in tumor settings whereby measurable disease exists, as contemporaneous checkpoint inhibition would abrogate the immunosuppressive effects of the TME.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Overcoming or mitigating immune</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">tolerance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Heteroclitic peptides are those in which mutations have been deliberately introduced in the amino acid sequence. The use of heteroclitic peptide in an active immunizer, such as GPS, increases immunogenicity without changes in the antigenicity profile, as well as strengthens MHC binding of the peptide to produce cytotoxic CD8 cells that continue to recognize the corresponding native peptide sequence. This is believed to be a key factor differentiating GPS from essentially all previously developed peptide vaccines, and applies a highly innovative technology platform, peptide heteroclicity, in a clinical late-stage cancer immunotherapeutic candidate product.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Addressing the broadest possible</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">candidate patient population</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS has activity across multiple HLA types that could allow treatment of a vast majority of global patient populations harboring WT1-positive malignancies.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Potential Key Differentiators </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS&#8217; potential key differentiators as compared to other active immunization or vaccine-type approaches, as well as compared to immunotherapy approaches more generally, are as follows: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">heteroclitic peptides may offer increased immune response and less potential for tolerance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">multivalent oligopeptide mixture potentially drives differentiated immunotherapeutic efficacy, targeting 25 key epitopes of WT1; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">potentially applicable to 20 or more cancer types worldwide and the vast majority of HLA types; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">CRem or MRD status (after initial tumor debulking with preceding standard therapy) is the preferred setting for GPS monotherapy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;not directly competitive with current clinical standard of care therapies, but rather believed to complement them in the maintenance setting; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">potential for combination approaches with other cancer immunotherapies, due to tolerable adverse event profile; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">anticipated cost-effective manufacturing; allogeneic, &#8220;off-the-shelf,&#8221; vialed subcutaneously administered drug that is not patient-specific; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">positive Phase 2 clinical data on effectiveness (based on overall survival, or OS, in AML and progression-free survival, or PFS, in MM) with good tolerability and a favorable safety profile. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Development Program for GPS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications.  We are currently exploring the potential role for GPS in both monotherapy and combination therapy environments:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">GPS monotherapy</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: Phase 2 clinical trials of GPS as monotherapy for AML, MPM and MM have been completed and we are planning (pending funding availability) a Phase 3 registrational trial in AML. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">GPS combination therapy</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: A Phase 1/2a clinical trial of GPS in combination with nivolumab (Opdivo</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) for ovarian cancer has been completed. The clinical trial was independently sponsored by MSK.  In December 2018, we initiated a Phase 1/2 multi-arm ("basket" type) clinical trial of GPS in combination with the anti-PD-1 therapy Keytruda (pembrolizumab) in collaboration with a Merck&#160;&amp; Co., Inc., Kenilworth, N.J., U.S. subsidiary (known as MSD outside the United States and Canada), or Merck. The purpose of the basket trial is to determine if the administration of GPS in combination with pembrolizumab has the potential to demonstrate clinical activity in the presence of macroscopic disease, where monotherapy with either agent would have a more limited effect. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Targeted Indications </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">GPS Monotherapy for Acute Myeloid Leukemia (AML)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current AML Treatment Therapies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">AML is an aggressive and highly lethal blood cancer characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. Its symptoms include fatigue, shortness of breath, bruising and bleeding, and increased risk of infection. The cause of AML is unknown, and the disease is typically fatal within weeks or months if untreated. AML most commonly affects adults, and its incidence increases with age. Until recently, the overall treatment landscape for AML had remained static for decades, as numerous targeted and antiproliferative agents were unsuccessful in according meaningful long-term clinical benefits, including increments in survival. Standard treatments included chemotherapy as well as hypomethylating agents, or HMAs, while select patients could have also undergone a hematopoietic, or blood-forming, stem cell transplant, or allo-HSCT. Recently approved agents that target mutations of the isocitrate dehydrogenase, or IDH, type-1 and -2 proteins and the FMS-like tyrosine-protein kinase, or FLT3, proteins, as well as the novel fixed-combination of chemotherapy Vyxeos and the CD33-targeting antibody-drug conjugate gemtuzumab ozogamicin, as well as the B-cell lymphoma 2 (bcl-2) inhibitor venetoclax, have led to modest incremental improved patient outcomes.  Nonetheless, the goal of upfront therapy for AML is to achieve a state of CRem. CRem is defined per consensus criteria by the European Leukemia Net, whereby the hematologic and clinical features of the disease are no longer detected. Other than a successful completion of an allo-HSCT in AML, we are not aware of any therapies that have shown any meaningful long-term benefit after patients achieve a CRem status. Without allo-HSCT, once the disease relapses, second-line therapies can be given, but these have shown very limited positive clinical impact to date and their benefit is transitory; eventually AML patients who do not undergo an allo-HSCT generally succumb to AML or complications associated with it.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The AML indication was chosen for first-in-human clinical studies of GPS for the following reasons: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">AML presents a clinical setting in which CRem status can be achieved with standard upfront therapy; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the high degree of unmet medical need in AML and the absence of an effective maintenance therapy over the decades after initial upfront induction until and immediately after achievement of CRem status, particularly in patients older than 60 years of age; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the almost universal expression of WT1 in leukemic blasts, which are AML&#8217;s malignant cells, as well as leukemic stem cells, or LSCs, cells that are or become extremely resistant to standard chemotherapy or targeted agent approaches and which can be realistically eradicated only with immunotherapy methods (including allo-HSCT). LSCs have been shown to be susceptible to targeting by cytotoxic T cells (CD8 and CD4 cells) stimulated against leukemia-associated antigens and we predicted this would be the case for GPS; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the fact that WT1 has been associated with the actual development of leukemia; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the positive correlation between the level of expression of WT1 and the prognosis in AML; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the fact that the level of expression of WT1 can be followed over time in patients during and after therapy, including immunotherapy, as a method of monitoring for MRD; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">early evidence from mouse models that vaccination with peptides against select WT1 antigenic epitopes leads to detection of immune response; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">early evidence that human immunocytes sensitized ex-vivo to peptides contained in GPS were able to recognize naturally presented WT1 peptides on the surface of several leukemia cell lines; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">early anecdotal (at the time) clinical data showing antileukemic activity of WT1 monovalent vaccines in the Japanese population (albeit restricted to HLA-A*2401 type), as well as a dendritic cell vaccine in the Netherlands (independent of HLA haplotype); </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a predictive assumption of very low to negligible degree of clinical toxicity with a WT1-targeted immunotherapy such as GPS, due to the fact that WT1 in normal, non-cancerous, tissues is both expressed at extremely low levels and limited in number of organs and tissues, but also due to the fact that WT1 fragments, or peptide epitopes, in normal cells are presented to host APCs in a different manner than are WT1 fragments produced in cancer cells; of note, WT1 expression in normal tissues of adults is limited to the podocyte layer of the glomerulus (kidney), Sertoli cells (testis), granulosa cells (ovary), decidual cells (uterus), mesothelial cells (peritoneum, pleura), mammary duct and lobule (breast), and blood-forming (hematopoietic) progenitor cells (CD34+ cells in the bone marrow); and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the advent of modern immunotherapeutics in cancer and the promise of an innovative, off-the-shelf immunotherapy for AML, a disease that has historically been associated with dearth of deep and sustained responses to checkpoint inhibitors. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS has been granted Fast Track and Orphan Drug designations by the FDA for the treatment of AML.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">AML Clinical Data </font></div><div style="line-height:120%;text-align:left;text-indent:40px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In an initial pilot clinical trial in AML, a total of nine adult patients of all ages with de novo AML were treated with upfront standard chemotherapy and were able to achieve their first complete remission, or CRem1. Administration of GPS resulted in a median OS that was at least 35 months from the time of GPS administration. In this study, specifically for patients who were 60 years and older (n=5), median OS was at least 33 months from the time of GPS administration or approximately 43&#160;months from the time of initial AML diagnosis. The mean time of follow-up was 30 months from the time of diagnosis at the time of this analysis for all patients. Of the eight patients tested for immunologic response, seven, or 87.5%, demonstrated a WT1-specific immune response. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In a subsequent Phase 2 clinical trial in AML, a total of 22 adult patients of all ages with de novo AML were treated with upfront standard chemotherapy and were able to achieve CRem1. Most patients also received one to four cycles of &#8220;consolidation&#8221; chemotherapy per standard AML treatment guidelines. GPS was then administered within three months from the completion of the consolidation chemotherapy regimen in up to 12 total doses: six initial doses (priming immunization) followed by six additional &#8220;booster&#8221; immunizations over a total period of up to 15 months to qualifying patients (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, patients who were clinically stable and did not show disease recurrence after the first six injections). This Phase 2 clinical trial met its primary endpoint of an actual OS rate of at least 34%, measured three years into the clinical trial (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, percentage of patients alive after three years of follow-up). An actual OS rate of 47.4% was demonstrated at three years post-GPS treatment, exceeding historical published data of OS of 20% to 25% by 2.4- to 1.9-fold (or 240% to 190%), respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS administration was also shown to improve OS in comparison to historical data in patients in CRem1. Administration of GPS resulted in a median OS that was poised to exceed 67.6 months from the time of initial AML diagnosis in patients of all ages, which represents a substantial improvement compared to best standard therapy. Only five of the 22 patients underwent allo-HSCT and an ad hoc statistical analysis failed to show a significant effect of the transplant upon OS (either in median survival times or survival rates at specific landmark time-points). In this study, the patients&#8217; median age was 64 years old. The most frequent toxicities were mild to moderate local skin reactions and inflammation, as well as fatigue, which were self-limited and responded to local supportive measures and analgesics. None of the patients developed significant serious or high grade systemic adverse reactions (including anaphylaxis) attributable to GPS.  GPS elicited WT1-specific immune responses in 88% of patients, including CD4 and CD8 T-cell responses. Further, the heteroclitic principle was confirmed, in that immune responses were seen against the native version of the two mutated WT1 peptides within the GPS mixture. The results showed a trend in improved clinical outcomes in patients who mounted an immune response with GPS compared to those patients who did not. Importantly, a preplanned subgroup analysis for the cohort of 13 patients within the clinical trial who were 60 years of age or older demonstrated a median OS of 35.3 months from time of initial diagnosis. Comparable historical populations have a median OS ranging from 9.5 to 15.8 months from initial diagnosis, which represents a 2.25 to 3.75-fold improvement in OS associated with GPS therapy in the CR1 maintenance setting as contrasted   to these historical cohorts of broadly comparable patients. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">An additional Phase 2 clinical trial of GPS was performed at the H. Lee Moffitt Cancer Center&#160;&amp; Research Institute, or Moffitt. This Phase 2 trial included 10 AML patients who had received first-line therapy for their disease, who then experienced relapse and were subsequently treated with second-line chemotherapy and achieved a CRem2. This group of patients had a more advanced disease in comparison to those treated in the Phase 2 clinical trial discussed above, and typically demonstrated a historical OS of less than ~8 months, even with post-CRem2 allo-HSCT. In the Moffitt trial, the efficacy of GPS (measured as median OS from the time of administration of a maintenance therapy to immediately after achievement of CRem2) was compared with that of &#8220;watchful waiting&#8221; in a cohort of 15 contemporaneously treated (but not matched by randomization) broadly comparable patients treated by the same clinical team at Moffitt. GPS administration resulted in a median OS of 16.3 months (495 days) compared to 5.4 months (165&#160;days) from the time of achievement of CRem2. This was a statistically significant difference (P=0.0175). Two of 14 AML patients demonstrated relapse-free survival of more than one year. Both such patients were in CRem2 at time of GPS administration, with duration of their remission exceeding duration of their CRem1, strongly suggesting a potential benefit based on immune response mechanisms. GPS was well-tolerated in this clinical trial. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">AML Planned Phase 3 Clinical Trial</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are planning a Phase 3 registrational study for GPS in AML pending funding availability. This study is planned to be a 1:1 randomized, open-label study comparing GPS in the maintenance setting to investigators&#8217; choice of best available treatment, or BAT, in adult AML adult patients (age &gt;18 yrs) who have achieved their second hematologic (morphological) complete remission, with or without thrombocytopenia (CRem2/CRem2p; with &#8220;p&#8221; designating platelets), after second-line antileukemic therapy and who are deemed ineligible for or unable to undergo allo-HSCT. This study will serve as the basis for a biologics license application, or BLA, submission, subject to positive results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Phase 3 study is expected to enroll approximately 116 patients at approximately 50 clinical sites in the United States and Europe. The primary endpoint is OS and secondary endpoints include leukemia-free survival, antigen-specific T-cell immune response dynamics over time and rates of achievement of MRD negativity. The study will have a planned interim safety and futility analysis after 80 events (deaths). The key features and schema of this study are shown in the following graphic: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="gpsinamlincr2studyschemarevi.jpg" alt="gpsinamlincr2studyschemarevi.jpg" style="height:512px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">GPS Monotherapy in Other Indications </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Malignant Pleural Mesothelioma (MPM)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">MPM is an asbestos-related cancer that forms on the protective tissues that cover many of the internal organs. The most common area affected is the lining of the lungs and abdomen, though it can also form around the lining of the heart. Most cases are traced to job-related exposures to asbestos and it can take approximately 40 years between exposure and cancer formation. Symptoms may include shortness of breath, a swollen abdomen, chest wall pain, cough, feeling tired, and weight loss. MPM is generally resistant to radiation and chemotherapy, and long-term survival is rare, even in cases where aggressive upfront debulking multimodality therapy (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, extirpative surgery, chemotherapy and in some cases radiotherapy, often described as &#8220;trimodality therapy&#8221; when used to treat MPM) are used. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A randomized, double-blind, placebo-controlled Phase 2 clinical trial in MPM patients enrolled a total of 41 patients at MSK and M.D. Anderson Cancer Center.  Data from this Phase 2 clinical trial was presented in 2016. Based on an initial analysis of 40 patients who were eligible at the time with a median follow-up of 16.3 months, a median OS of 24.8 months was seen for GPS-treated MPM patients, compared to a median OS of 16.6 months for patients in the control arm. For patients with a basic reproductive ratio tumor resection and subsequent treatment with GPS, a significant survival benefit was observed compared to those who received a placebo, with a median OS of 39.3 months compared to 24.8 months (HR: 0.415) in favor of GPS. In a subsequent analysis for the entire cohort (n=41) in August 2016, with a median follow-up of 17.2 months, a median OS of 22.8 months was observed for GPS-treated MPM patients, compared to a median OS of 18.3 months for patients in the control arm. In the datasets from both of these analyses, GPS was shown to induce WT1-specific CD8 and CD4 T-cell activation. There were no clinically significant severe adverse events in this study. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Multiple Myeloma (MM)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">MM is a cancer formed by malignant plasma cells, and its cause is unknown. The overgrowth of plasma cells in the bone marrow crowds out normal blood-forming cells, causing low blood counts and anemia (a shortage of red blood cells). MM&#160;can also cause a shortage of platelets (cells responsible for normal blood clotting) and lead to increased bleeding and bruising, along with problems fighting infections due to low white cell counts and/or lower levels of infection-fighting antibodies. MM causes a host of organ problems and symptoms, including fatigue, bone pain, fractures, circulatory problems (in small vessels of the brain, eye retina, heart, bowel, etc.) and kidney failure. Treatment for MM includes chemotherapy, glucocorticoids, drugs that modulate the immune system (immunomodulatory drugs, or IMiDs), radiation and autologous stem cell transplants, or ASCTs. The prognosis in MM is highly variable and depends on numerous risk factors, some related to the biology of the disease, others to the host (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, age and functional status). Consequently, median survival can vary from up to at least 15 years in non-high-risk patients who achieve CRems, as defined by the International Myeloma Working Group, or IMWG, criteria, to approximately three years (from time of initial treatment) in patients with MM who achieve less than partial response, or PR, after ASCT. There are patients with MM who fare even more poorly than described above. For example, those in the immediately aforementioned group who also have high-risk cytogenetics at baseline may survive on average less than three years. Similarly, patients who are ineligible for ASCT and are managed only with chemotherapy and long-term IMiD maintenance (with up to nine cycles of lenalidomide) who also achieve less than CRems and remain MRD-positive demonstrate a three-year OS rate of only about 55%; these landmark three-year OS rates decrease by approximately 40 to 50% in patients who also have high-risk cytogenetics at baseline. Despite significant therapeutic advances in the management of MM, the prognosis of patients with high-risk cytogenetics at the time of diagnosis remains quite poor, even when they successfully complete an ASCT, particularly if such patients continue to have evidence of MRD. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have reported comprehensive final data from a Phase 2 study for GPS in 19 patients with MM. All non-progression events were confirmed and remained ongoing as of the time of the latest presentation (median follow-up at 20 months for survivors). The data indicate promising clinical activity among MM patients with high-risk cytogenetics at initial diagnosis who also remain MRD(+) after successful frontline therapy (induction regimen followed by ASCT). This subgroup of MM patients, when serially assessed per IMWG criteria, typically relapse/progress within 12 to 14 months after ASCT, even when they receive maintenance therapy with IMiDs such as thalidomide or proteasome inhibitors such as bortezomib. Of note, 18&#160;of the 19 patients received lenalidomide maintenance starting after the first three GPS administrations following ASCT; the remaining single patient received bortezomib under the same schedule. All patients had evidence of at least MRD after ASCT, while 15 of the 19 also had high-risk cytogenetics at diagnosis. Combined, these characteristics typically result in low PFS rates that do not exceed 12 to 14 months following ASCT, even while on maintenance therapy with IMiDs or proteasome inhibitors, which are the current standards of care. As of June&#160;2017, median PFS with GPS was 23.6 months, while median OS had not been reached. Our results compare favorably with an unmatched cohort of broadly comparable MM patients with high-risk cytogenetics published by the Spanish PETHEMA group from the PETHEMA Network No.&#160;2005-001110-41 trial. Our GPS therapy demonstrated a 1.87-fold increase in median PFS, as well as a 1.34-fold increase in the PFS rate at 18 months compared to the aforementioned historical cohort, which included MM patients with high-risk cytogenetics and MRD(+) post-ASCT and on continuous intensive maintenance with thalidomide +/- bortezomib. The safety profile was devoid of grade 3/4/5 treatment-related adverse events.  Immune response data showed that up to 91% of patients had successfully developed T-cell (CD8 or CD4) reactivity to any of the four peptides within the GPS mixture, while up to 64% of patients demonstrated immune response positivity (CD4/CD8) against more than one WT1 peptide (multivalent responses). Moreover, multifunctional cross-epitope T-cell reactivity was observed in 75% of patients to antigenic epitopes against which hosts were not specifically immunized, in a pattern akin to epitope spreading. Further, a distinctive link was shown between the evolution of immune responses and changes in clinical response status (achievement of CR/very good partial response clinical status per IMWG criteria) over time following treatment with GPS, with each patient being used as his or her own control for each longitudinal comparison. This association has not been previously described for a peptide vaccine in MM. We believe that these results offer mechanistic underpinnings for immune activation against WT1 in patients with aggressive, high-risk MM, and support the potential antimyeloma activity of GPS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">GPS Combination Therapy with PD-1 blocker (nivolumab) for Ovarian Cancer </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Epithelial cancer of the ovary, or ovarian cancer, is a relatively common gynecologic cancer that develops insidiously, and hence is associated with vague or no symptoms that would urge patients to seek medical attention. Not surprisingly, most women with ovarian cancer present with advanced (at least locally or regionally, and often systemically spread) disease. Ovarian cancer is managed with initial surgical resection followed by platinum-based chemotherapy. During the past decade, incremental advances in chemotherapy, and the introduction of targeted therapies (such as poly-ADP-ribose polymerase inhibitors and several others) and specially formulated compounds (such as liposomal anthracyclines) have resulted in improved survival and in more effective treatment of relapsed disease. In addition, a better understanding of genetic risk factors, along with aggressive screening, has permitted a tailored approach to preventive strategies, such as bilateral salpingo-oophorectomy in selected women along in specific patient populations genetically predisposed to this cancer (such as those harboring genetic alterations of the BRCA gene family). Although a complete clinical remission following initial chemotherapy can be anticipated for many patients, a review of &#8220;second-look&#8221; laparotomy, when it was often performed as a matter of routine care, indicates that less than 50% of patients are actually free of disease. Furthermore, nearly half of patients with a negative &#8220;second-look&#8221; procedure relapse and require additional treatment. Many patients will achieve a CRem2 clinical response with additional chemotherapy. However, almost all patients will relapse after a short remission interval of nine to 11 months. Effective strategies, such as introduction of novel immunotherapies, to prolong remission or to prevent relapse are required, as subsequent remissions are of progressively shorter duration until chemotherapy resistance broadly develops, leading to eventual disease-related demise. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Ovarian cancer represents an intriguing opportunity to study both the clinical and immunologic effects of GPS in another solid tumor. Additionally, therapeutic targeting of WT1 through immune pathways has largely not been pursued by others to date for this indication and ovarian cancer remains &#8220;incurable&#8221; once it advances and becomes disseminated, even in the face of significant advances in the field. Ovarian cancer was chosen as a target indication for the following reasons: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ovarian cancer presents a clinical setting whereby MRD status can be achieved with standard upfront therapy both immediately after first line therapy, but also after effective debulking of the &#8220;first relapse.&#8221; The latter subgroup of patients (after successful second line treatment/first salvage, lacking demonstrable macroscopic residual disease) would be optimal candidates for GPS therapy, as no standard maintenance therapy exists for such patients and the subsequent relapse patterns and metrics are known and predictable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the high levels of expression of WT1 in ovarian cancer cells. In fact, WT1 expression is so frequent that pathologists routinely use immunohistochemical stains for WT1 (with a standardized convention for describing expression and determining as &#8220;positive&#8221; or &#8220;negative&#8221;) to help distinguish epithelial ovarian cancers from other tumors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">preliminary evidence that WT1 expression may be linked to prognosis in ovarian cancer and that it may play an anti-apoptotic role in ovarian cancer cell lines; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the high degree of unmet medical need in ovarian cancer patients after first (or subsequent) successful &#8220;salvage&#8221; debulking therapy and the absence of effective therapies for such patients; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a predictive assumption of very low to negligible degree of clinical toxicity with a WT1-targeted immunotherapy such as GPS due to the fact that WT1 in normal, non-cancerous tissues is both expressed at extremely low levels and limited in number of organs and tissues, but also due to the fact that WT1 fragments, or peptide epitopes, in normal cells are presented to host APCs in a different manner than are WT1 fragments produced in cancer cells. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS was studied in combination with nivolumab, a PD-1 immune checkpoint inhibitor, in an open-label, non-randomized Phase 1/pilot clinical trial, which was independently sponsored by MSK. The aim of the study was to evaluate the safety and efficacy of this combination in patients with WT1-expressing (WT1+) recurrent ovarian, fallopian tube or primary peritoneal cancer who were in second or greater clinical remission (after their successful first or subsequent &#8220;salvage&#8221; therapy). Eligible patients were devoid of macroscopic residual or recurrent disease, i.e., were free of locally or distantly metastatic deposits detectable by imaging modalities (CT, MRI and/or PET scan). This Phase 1/pilot clinical trial enrolled 11 patients with recurrent ovarian cancer who were in second or greater clinical remission at MSK, of whom 10 were evaluable. Patients enrolled in the clinical trial received the combination therapy during the clinical trial&#8217;s 14-week treatment period. Individuals who had not progressed by the end of this period also received a maintenance course of GPS. In this study, treatment was continued until disease progression or toxicity. Information on the primary endpoint of this clinical trial, which was the safety of repeated GPS administrations, for a total of six doses, in combination with seven infusions of nivolumab was presented at the ASCO 2018 annual meeting (O&#8217;Cearbhaill RE, et al). The secondary endpoint of the study was immune response, and the exploratory endpoints included landmark one-year PFS rate compared to historical controls and correlative analyses between clinical and immune responses. Exploratory efficacy interim data from this pilot trial showed that GPS, when combined with a PD-1 inhibitor, in this case nivolumab, demonstrated PFS of 64% at one year in an intent to treat the group of 11 evaluable patients with WT1+ ovarian cancer in second or greater remission. Among patients who received at least three doses of GPS in combination with nivolumab, PFS at one year was 70% (7/10).  The historical rates with best standard treatment do not exceed 50% in this disease setting. The most common adverse events were Grade 1 or 2, including fatigue and injection site reactions. Dose limiting toxicity, or DLT, was observed in one patient, following the second dose of the combination. No additional adverse event burden was observed for the combination as compared to nivolumab monotherapy.  The combination induced a high frequency of T- and B-cell immune responses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">GPS Combination Therapy with PD1 blocker (pembrolizumab) for Other Cancers </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Given the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD1 blocker), we entered into a Phase 1/2 Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck&#8217;s anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and safety. This is a Phase 1/2 open-label, non-comparative, multicenter, multi-arm study of patients with WT1-positive advanced cancers, including both hematologic malignancies and solid tumors. The initial tumor types to be treated are AML (patients unable to attain deeper morphological response than PR on hypomethylating agents and who are either ineligible for or unable to undergo allo-HSCT and ovarian cancer (second or third line), to be followed by TNBC (second line), SCLC (second line), and colorectal cancer (third or fourth line). This clinical study was initiated in December 2018 and we plan to enroll approximately 90 patients in up to 20 centers in the United States only. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The purpose of this five-arm &#8220;basket&#8221; trial is to determine if the administration of GPS in combination with pembrolizumab has the potential to demonstrate clinical activity in the presence of macroscopic disease, where monotherapy with either agent would have a more limited effect. The negative influence of TME factors on the immune response is predicted to be mitigated by PD1 inhibition (by pembrolizumab), thus allowing the patients&#8217; own immune cells to invade and destroy cancerous growth deposits specifically sensitized against WT1 (by concomitantly-administered GPS). The key features and schema of this study are shown in the graphic below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="mrkcombotrialfeaturesandsche.jpg" alt="mrkcombotrialfeaturesandsche.jpg" style="height:513px;width:684px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NPS (nelipepimut-S) </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our other cancer immunotherapy product, NPS, utilizes a targeted approach and is being developed to potentially: (i) prevent secondary recurrence of HER2, positive breast cancer and (ii) prevent ductal carcinoma in situ, or DCIS, from becoming invasive breast cancer. Our programs for NPS primarily target patients in the adjuvant, or after-surgery, setting who have relatively healthy immune systems but may still have residual disease. MRD, or micrometastases, that are undetectable by current radiographic scanning technologies, can result in breast cancer recurrence. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NPS is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NPS vaccine is combined with GM-CSF (Sargramostim) for injection in between the layers of the skin epidermis, i.e., intradermal administration. Data has shown that an increased presence of circulating tumor cells, or CTCs, may predict reduced DFS, and OS, suggesting a presence of isolated micrometastases, not detectable clinically, but, over time, can lead to recurrence of cancer, most often in distant sites. After binding to the specific HLA molecules on antigen presenting cells, the NPS sequence stimulates specific cytotoxic T-lymphocytes, or CTLs, causing significant clonal expansion. These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">NPS Therapy for Breast Cancer </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to NCI, over 260,000 women in the United States are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the United States, metastatic breast cancer remains incurable. Approximately 75% to 80% of breast cancer patients test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients have a HER2-directed, approved treatment option, i.e., trastuzumab, available after their initial standard of care. The patients are defined as having tumors demonstrating a level of HER2 expression of 3+ by immunohistochemistry, or IHC, (HER2 IHC 3+), or HER2 IHC 2+ but also being positive by HER2 gene amplification by fluorescence in situ hybridization, or FISH. This leaves the majority of breast cancer patients with low-to-intermediate HER2 expression by IHC (IHC 1+, 2+ by IHC) with tumors that are not HER2-amplified by FISH ineligible for targeted therapy with trastuzumab and without an effective targeted treatment option to prevent cancer recurrence.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2018 we announced positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b IST clinical trial of trastuzumab +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.  A pre-specified interim analysis, conducted by the DSMB of the efficacy and safety data for the study in an overall population of 275 patients as well as the two primary study target patient populations (node-positive and TNBC) after a median follow-up of 19 months, demonstrated:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:52px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:28px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a clinically meaningful difference in median DFS in favor of the active arm (NPS + trastuzumab), a primary endpoint of the study, with hazard ratios of 0.67 and 0.61 in the intent to treat, or ITT, and modified ITT, or mITT, populations (i.e., those who received at least one dose of vaccine or control) as well as a 34.9% and 39.5% reduction in relative risk of recurrence in the active versus control arms in the ITT and mITT populations, respectively;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:52px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:52px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:28px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a clinically meaningful and also statistically significant difference between the two arms in the cohort of patients (n= 98) with TNBC, with a hazard ratio of 0.26 and a p-value of 0.023 in favor of the NPS + trastuzumab combination with a 70.4% reduction in relative risk of recurrence in the active arm versus control;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:52px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:52px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:28px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a clinically meaningful and statistically significant difference between the two arms in favor of the combination in the cohort of patients not receiving hormonal therapy (n = 110), with a hazard ratio of 0.24 and a p-value of 0.009 with a 74.1% reduction in relative risk of recurrence in the active arm versus control;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:52px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:52px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:28px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no notable differences between treatment arms; and </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:52px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:28px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">that the addition of NPS to trastuzumab did not result in any additional cardiotoxicity compared to trastuzumab alone.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:52px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Based on these results, the DSMB recommended that we expeditiously seek regulatory guidance from the FDA for further development of the combination of GPS plus trastuzumab for TNBC.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In October 2018, we announced the following final data at the 26-month median follow-up of the NPS +/- trastuzumab Phase 2b trial for the TNBC cohort, which confirmed the previously reported positive data:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">clinically and statistically significant efficacy in the TNBC cohort, with a p-value of 0.013 and a 75.2% reduction in risk of relapse or death;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">clinically meaningful difference in median DFS in favor of the active arm (patients treated with NPS + trastuzumab) in the TNBC cohort at 24 months for patients of 92.6% compared to 70.2% for those treated with trastuzumab alone; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">in all HER2 low-expressing breast cancer patients, the DFS rate was also in favor of the NPS plus trastuzumab combination (89.8%) as compared to trastuzumab alone (83.8%).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The DSMB, in October 2018, unanimously concluded that the final analysis of the Phase 2b study data with a median follow-up of 26 months confirmed that TNBC patients should be the key target population for the development of trastuzumab plus NPS in the adjuvant setting in early-stage HER2 1+/2+ breast cancer patients and again recommended that we expeditiously seek regulatory guidance for further development for TNBC. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November and December 2018 we announced the following positive data from a preplanned secondary efficacy analysis across HLA allele subgroups from the Phase 2b IST study:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the data analysis confirmed the therapeutic potential of NPS in patients with early-stage TNBC in the adjuvant setting across HLA types A-02, -03, -24 and -26, which cover approximately 80-85% of the North American/European populations and 86-90% of Asian/Pacific basin populations;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">in the subgroup of TNBC patients with the HLA-A24+ allele type, which is highly prevalent in the Asian population, treated with the combination of NPS and trastuzumab (n=47), the p-value is 0.003 with a 90.6% relative reduction in risk of relapse or death at 24 months and a hazard ratio of 0.08 in favor of the active (combination) arm;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">TNBC patients with the HLA-A24+ allele type had a significant improvement in DFS both by log-rank and landmark (24 month) analysis despite the lowest predicted binding potential between the E75 (NPS) antigen and this HLA-type; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a clinically meaningful and statistically significant decrease in the number of clinically detectable relapses in the TNBC cohort with the combination of trastuzumab and NPS (7.5%) versus trastuzumab alone (27.3%) (p=0.004).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In a Type C meeting with the FDA in late 2018, we discussed several key points of the clinical and regulatory strategy for NPS in combination with trastuzumab for TNBC, a registration-enabling Phase 3 trial design and biostatistical plan. We expect a further meeting in the first half of 2019 to reach agreement for a final development program for NPS in TNBC. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second IST for NPS plus trastuzumab is a Phase 2 study in high-risk HER2 3+ breast cancer patients who are defined as patients with HER2 3+ (&#8220;classic&#8221; HER2+) breast cancer who have completed neoadjuvant therapy with an approved regimen that includes trastuzumab and who have failed to achieve a pathological complete response, meaning they have microscopic evidence of residual disease at the time of their primary surgery and are therefore at an increased risk of disease recurrence. The protocol for this study specified that the patients also should be HLA A2+ or HLA A3+. This multi-center, prospective, randomized, single-blinded Phase 2 clinical trial is fully enrolled with 100&#160;patients actively participating. The rationale for this study is based on the fact that HER2 3+ patients with high risk features are known to have higher recurrence rates than all other HER2 3+ breast cancer patients. Eligible patients are being randomized to receive NPS + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is DFS. Funding for this trial was awarded through the Congressionally Directed Medical Research Program, funded through the Department of Defense, via a breast cancer research program breakthrough award. In February 2017, the DSMB reported that there were no safety concerns with the trial and the trial is not futile. The pre-specified interim safety analysis was also completed on 50 patients and demonstrated that the combination is well tolerated with no&#160;increased cardiotoxicity associated with giving NPS in combination with trastuzumab. The recommendation from the DSMB was to continue the HER2 3+ trial unmodified. Top-line data is expected by the end of 2019. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NPS was previously granted Fast Track designation by the FDA for the adjuvant treatment of patients with early stage breast cancer with low to intermediate HER2 expression following standard of care upfront therapy (surgery plus chemotherapy +/- radiotherapy).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">NPS for Ductal Carcinoma In Situ of the Breast (DCIS)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">DCIS is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct and have not spread outside the duct to other tissues in the breast. DCIS is the most common type of breast neoplasm with malignant potential. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive. Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen. According to the American Cancer Society, in the United States, there were over 60,000 diagnoses of DCIS in 2015. We are supporting a Phase 2 IST to evaluate women diagnosed with DCIS who are HLA-A2+ or A3+ positive, who express HER2 at IHC 1+, 2+, or 3+ levels, and who are pre or post-menopausal. This clinical study was initiated in February 2018. Patients are being randomized to one of two arms: NPS plus GM-CSF or GM-CSF alone. The trial is sponsored and operationalized by the NCI, studying NPS&#8217;s potential clinical effects in earlier stage disease. The trial has an immunological (rather than clinical) endpoint evaluating NPS peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T-cell) response in vaccinated patients. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">FBP-targeting bivalent vaccine (GALE-301 and GALE-302) </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE-302 are cancer immunotherapies that target the E39 peptide derived from FBP receptor-alpha. FBP is a well-validated therapeutic target that is highly over-expressed in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. Current treatments after surgery for these diseases are principally with platinum-based chemotherapeutic agents. These patients suffer a high recurrence rate and most relapse with an extremely poor prognosis. GALE-301 and GALE-302 are immunogenic peptides that consist of a peptide derived from FBP combined with GM-CSF for the prevention of cancer recurrence in the adjuvant setting. GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as J65 (or E39&#8217;; E39-prime). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In a Phase 1/2a IST, assessing GALE-301 in ovarian and endometrial cancers, we observed improvement in the 24-month DFS in a small number of patients treated with the optimal dose. Patients receiving the highest dose of E39 vaccine showed a 24-month DFS of 77.9% compared to 40% for the patients in the control arm. We are evaluating GALE-301/302 for potential internal development in a Phase 2 setting for ovarian cancer, strategic partnership, or other types of product rationalizations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2016, the FDA granted two Orphan Drug Product Designations for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39) and one for GALE-302 (J65). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Strategic Collaborations and License Agreements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive License Agreement-Memorial Sloan Kettering Cancer Center </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In September 2014, we entered into a license agreement with Memorial Sloan Kettering Cancer Center, or MSK, under which we were granted an exclusive license to develop and commercialize MSK&#8217;s WT1 peptide vaccine technology. The MSK original license agreement was first amended in October 2015, further amended in August&#160;2016, amended and restated in May 2017 and again amended and restated in October 2017. In connection with the entry of the original license agreement and its amendments, MSK was issued or assigned an aggregate of 4,846 ordinary shares of Private SELLAS common stock for the year ended December&#160;31, 2017. These common stock shares were converted into our common stock shares upon the Merger. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the terms of the current amended and restated MSK license agreement, we agreed to pay minimum royalty payments in the amount of $0.1&#160;million each year commencing in 2015 and research funding costs of $0.2&#160;million in each year and for three years commencing in January 2016. We also agreed to pay MSK a mid-six digit amount over a one year period in exchange for MSK&#8217;s agreement to further amend and restate the MSK license agreement in October 2017. In addition, to the extent certain development and commercial milestones are achieved, we also agreed to pay MSK up to $17.4&#160;million in aggregate milestone payments for each licensed product, and for each additional patent licensed product, up to $2.8&#160;million in additional milestone payments. We also agreed to pay MSK a tiered royalty in the mid-single digits in the event of commercial sales of any licensed products and agreed to raise $25.0&#160;million in gross proceeds no later than December&#160;31, 2018. We raised this amount from the proceeds received from the sale of our Series A Convertible Preferred stock in March 2018 and our underwritten public offering of shares of common stock, pre-funded warrants to purchase shares of common-stock, and warrants to purchase shares of common stock in July 2018. Under the terms of the agreement, we achieved a clinical development milestone at the end of the fourth quarter of 2018, triggering a $0.5 million payment in the first quarter of 2019. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unless terminated earlier in accordance with its terms, the MSK license agreement as amended and restated, will continue on a country-by-country and licensed product-by-licensed product basis, until the later, of: (a)&#160;expiration of the last valid claim embracing such licensed product; (b)&#160;expiration of any market exclusivity period granted by law with respect to such licensed product; or (c)&#160;ten years from the first commercial sale in such country. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Merck&#160;&amp; Co., Inc. Clinical Trial Collaboration and Supply Agreement </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In September 2017, we entered into a clinical trial collaboration and supply agreement through a Merck subsidiary, whereby we agreed with the Merck subsidiary to collaborate on a clinical program to evaluate GPS as it is administered in combination with their PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Phase 1/2 clinical trial utilizes a combination of GPS plus pembrolizumab in patients with WT1+ relapsed or refractory tumors. Specifically, the study is designed to explore the following cancer indications: AML, ovarian, triple-negative breast, small cell lung, and colorectal (arm enriched in but not exclusive to patients with microsatellite instability-low tumors). This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pembrolizumab alone in comparable patient populations. This trial was initiated in December 2018. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Advaxis, Inc. Research and Development Collaboration Agreement </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2017, we entered into a research and development collaboration agreement with Advaxis whereby we agreed to collaborate on a research program to evaluate, through a &#8220;proof of principle&#8221; trial or trials (&#8220;PoP Clinical Trial&#8221;), a clinical candidate comprised of the combination of Advaxis&#8217; proprietary Lm-based antigen delivery technology and GPS. Unless terminated earlier in accordance with its terms, the Advaxis agreement will expire upon the earlier of: (a)&#160;completion of the PoP Clinical Trial or (b)&#160;a decision by the parties to cease further development of the clinical candidate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and filing any investigational new drug, or IND, cost-sharing for preparation of the IND, and we being responsible for the costs (exclusive of product costs) of conducting the PoP Clinical Trial. We also agreed to make certain non-refundable milestone payments to Advaxis having an aggregate amount of up to $108.0&#160;million, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain targets, we agreed to make non-refundable sales milestone payments up to $250.0 million and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low teens if net sales exceed $1.0&#160;billion. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. License Agreement </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In September 2006, we acquired rights and assumed obligations under a license agreement among Apthera, Inc., our wholly owned subsidiary, the University of Texas M.D. Anderson Cancer Center, or MDACC, and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., or HJF, which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the license agreement we agreed to pay MDACC and HJF up to $3.8 million in aggregate milestone payments to the extent certain development and commercial milestones are reached and a $0.2 million annual maintenance fee. We also agreed to pay MDACC and HJF a tiered royalty in the mid-single digits in the event of any commercial sales of licensed products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Manufacturing </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We do not own or operate manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for all of our required raw materials, active pharmaceutical ingredients, and finished product candidate for our clinical trials. We do not have any current contractual arrangements for the manufacture of commercial supplies of any product candidates. We currently employ internal resources and third-party consultants to manage our manufacturing contractors. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Sales and Marketing </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not yet defined our sales, marketing or product distribution strategy for our product candidates or any future product candidates. Our future commercial strategy may include the use of strategic partners, distributors, a contract sale force, or the establishment of our own commercial and specialty sales force, as well as similar strategies for regions and territories outside the United States. We plan to further evaluate these alternatives as we approach approval for the use of our product candidates for one or more indications. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Intellectual Property </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our commercial success depends in part on our ability to avoid infringing the proprietary rights of third parties, our ability to obtain and maintain proprietary protection for our technologies where applicable and to prevent others from infringing our proprietary rights. We seek to protect our proprietary technologies by, among other methods, evaluating relevant patents, establishing defensive positions, monitoring European Union oppositions and pending intellectual property rights, preparing litigation strategies in view of the U.S. legislative framework and filing U.S. and international patent applications on technologies, inventions and improvements that are important to our business. Patents and other intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights through available means, including filing and prosecuting patent applications in the United States and other countries, protecting trade secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information and know-how. Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we do not believe patent protection is appropriate or obtainable. It is our policy to operate without knowingly infringing on, or misappropriating, the proprietary rights of others. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">An international patent law treaty, or PCT, provides a unified procedure for filing patent applications to protect inventions in each of its contracting states. Thus, a single PCT application can be converted into a national stage patent application in any of the more than 145 PCT contracting states, and is considered a simple, cost-effective means for seeking patent protection in numerous regions or countries. This nationalization (converting into an application in any of the contracting states) typically occurs 18 months after the PCT application filing date. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The term of individual patents depends upon the legal term of the patents in countries in which they are obtained. In most countries, including the United States, the patent term is generally 20 years from the earliest date of filing a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following chart summarizes our intellectual property rights:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:15%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Product Candidate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Product Candidate Component</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Jurisdiction</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Claims</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Scope</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Latest Estimated Patent Exclusivity Period</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-A1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition&#160;of Matter</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1&#160;issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">03/22/2026*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-A1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Australia, Switzerland, Germany,&#160;Spain, France,&#160;Great Britain,&#160;Italy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11/30/2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-A1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter&#160;and&#160;Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11/30/2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptides WT1-427 long and WT1-331 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/26/2031*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptides WT1-427 long and WT1-331 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">WT1-expressing cancer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/17/2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptides&#160;WT1-427&#160;long and WT1-331 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/17/2026**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide&#160;WT1-427&#160;long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Australia, Switzerland, Germany,&#160;Spain, France, Great Britain, Ireland, Italy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/17/2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-331 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Switzerland, Germany,&#160;Spain, France, Great Britain, Ireland, Italy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/17/2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-427 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/17/2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptides WT1-427 long and WT1-331 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1&#160;pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10/17/2026**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-product peptide</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12/21/2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide&#160;WT1-122A1&#160;long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">02/20/2033*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-122A1 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">04/10/2027**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:15%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-122A1 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Austria, Belgium, Switzerland, Germany, Spain, Finland, France, Great Britain, Greece, Ireland, Italy, Netherlands, Poland, Romania, Turkey</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15&#160;issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4/10/2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Peptide WT1-122A1 long</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Europe, Canada, Hong Kong</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4/10/2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not&#160;applicable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-product peptide</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 issued, 1 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1/15/2034</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-product peptide</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Australia, Canada, China, Europe, Japan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">01/15/2034**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not&#160;applicable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">PCT</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composition of Matter and Method of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">06/30/2038***</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States, Australia, Canada, China, Europe, Hong Kong, Japan, Korea</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Recurrence&#160;of cancers expressing low to intermediate levels of HER2/neu</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Methods of Use</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7&#160;pending and 11 issued</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">and Mexico</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; in combination with trastuzumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States and Australia</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">HER2/neu expressing cancer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Methods of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; in combination with trastuzumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Triple-negative breast cancer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Methods of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2039</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States and PCT</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancers expressing low levels of FBP (IHC 0 or 1+)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dosage Regimen</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2 pending</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2037</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 &amp; GALE-302 Combination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States, Canada, Europe, and Japan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancers expressing Folate Binding Protein (FBP)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compositions&#160;&amp; Methods of Use</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 pending and 8 issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 &amp; GALE-302 Combination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancers expressing Folate Binding Protein (FBP)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Combination Dosage Regimen</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 allowed</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2036</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:41px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Includes patent term adjustment </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:41px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Projected expiration date of pending application, if granted </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:41px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">***</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Projected expiration date of non-provisional application to be filed from provisional application </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Each of the above-referenced pending or issued patents has been licensed by us. To our knowledge, there are no contested proceedings or third-party claims relating to any of the above pending or issued patents. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Competition </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancer immunotherapy has become a significant growth area for the biopharmaceutical industry, attracting large pharmaceutical companies as well as small niche players. Generally, our principal competitors in the cancer immunotherapy market comprise both companies with currently approved products for various indications, such as manufacturers of approved bispecific antibodies, CAR-T cells, and checkpoint inhibitors, as well as companies currently engaged in cancer immunotherapy clinical development. The large and medium-size players who have successfully obtained approval for cancer immunotherapy products include Bristol-Myers Squib Company, Merck&#160;&amp; Co., Inc., Genentech, Inc. (a subsidiary of Roche Holding AG), AstraZeneca PLC, Celgene Corporation, Johnson&#160;&amp; Johnson/Janssen Pharmaceuticals, Amgen, Novartis, Acerta Pharmaceuticals (a subsidiary of AstraZeneca), Juno Therapeutics, Inc. (a subsidiary of Celgene), Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc. and Pfizer, Inc./EMD Serono, Inc. Most of these companies, either alone or together with their collaborative partners, have substantially greater financial resources than we do.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Companies developing novel products with similar indications to those we are pursuing are expected to influence our ability to penetrate and maintain market share. Principal competitors for our AML indication include both companies with currently approved products in AML, such as AbbVie/Genentech (the holders of rights to VENCLEXTA), Agios Pharmaceuticals, Inc. (the holder of U.S. rights to TIBSOVO), Novartis AG (the holder of rights to RYDAPT), Astellas (the holder of rights to XOSPATA), Celgene (the holder of rights to VIDAZA and IDHIFA), Otsuka (the holder of rights to DACOGEN), among others, as well as those with front-line chemotherapy drugs and maintenance therapies such as Jazz Pharmaceuticals plc (the holder of rights to VYXEOS), as well as Pfizer (the holder of rights to MYLOTARG and DAURISMO), among others, as well as companies with drugs currently in development in AML, such as Stemline Therapeutics (the holder of rights to ELZONRIS) and Novartis AG (the holder of rights to ODOMZO), among several others. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the chance of long-term DFS. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted drug trastuzumab (HERCEPTIN) - alone or in combination with pertuzumab (PERJETA), both manufactured and marketed by Roche/Genentech may be given to patients with tumors with high expression of HER2 (IHC 3+), as well as other novel targets such as MUC1, which may be useful in treating breast cancer.  In addition, the FDA recently approved the first ever immunotherapy regimen for breast cancer to the Roche/Genentech PD-L1 checkpoint inhibitor atezolizumab (TECENTRIQ), combined with Celgene&#8217;s nab-paclitaxel (ABRAXANE) for TNBC that cannot be removed with surgery and is locally advanced or metastatic.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There are a number of cancer vaccines in development for breast cancer, including but not limited toTPIV200 (Marker Therapeutics, Inc.), AE-37 (Antigen Express), and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, and AE-37 has published data in the HER2 breast cancer patient population, there is no guarantee that any of these compounds will not in the future be indicated for treatment of low-to-intermediate HER2 breast cancer patients and become directly competitive with NPS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, and also have greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for cancer immunotherapy products and achieving widespread market acceptance. Our competitors&#8217; treatments may be more effectively marketed and sold than any products we may commercialize, thus causing limited market share before we can recover the expenses of developing and commercializing of our cancer immunotherapy product candidate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These activities may lead to consolidated efforts that allow for more rapid development of cancer immunotherapy product candidates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, the ability to work with specific clinical contract organizations due to conflict of interest, and also the conduct of trials in the ability to recruit clinical trial sites and subjects for our clinical trials. &#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, price and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are viewed as safer, more convenient or less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our current product candidates or any other future product candidate, which could result in our competitors establishing a strong market position before we are able to enter the market. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Government Regulation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. Along with third-party contractors, we will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of its current or future product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is begun; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">preparation of and submission to the FDA of a  BLA, after completion of all pivotal clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">satisfactory completion of an FDA Advisory Committee review, if applicable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigations to assess compliance with current Good Clinical Practices, or GCP; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States, which must be updated annually when significant changes are made. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our current or future product candidates will be granted on a timely basis, if at all. Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by a DSMB organized by the clinical trial sponsor, which provides authorization for whether or not a clinical trial may move forward at designated check points based on access to certain data from the clinical trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical trial results to public registries. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Phase 1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Phase 2</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Phase 3</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Phase 4</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">BLA Submission and Review by the FDA </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to FDA, and the sponsor of an approved BLA is also subject to annual product and establishment user fees. These fees are typically increased annually. A waiver of user fees may be obtained under certain limited circumstances. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Once a BLA has been submitted, the FDA&#8217;s goal is to review the application within ten months after it accepts the application for filing, or, if the application relates to an unmet medical need in a serious or life-threatening indication, six months after the FDA accepts the application for filing. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. The FDA may not grant approval on a timely basis, or at all, and we may encounter difficulties or unanticipated costs in its efforts to secure necessary governmental approvals, which could delay or preclude us from marketing its products. After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter may request additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a product candidate with Fast Track designation, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A Fast Track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. We have obtained Fast Track designation for GPS in AML, MPM, and MM, and for NPS in TNBC. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the Accelerated Approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, a sponsor may seek FDA designation of its product candidate as a Breakthrough Therapy, if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application. Breakthrough designation also allows the sponsor to file sections of the BLA for review on a rolling basis. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fast Track, Priority Review and Breakthrough Therapy designations do not change the standards for approval but may expedite the development or approval process. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Orphan Drugs </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Product Designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan Drug Product Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Product Designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If a product that has Orphan Drug Product Designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug Product Designation are tax credits for certain research and a waiver of the BLA application user fee. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A drug with Orphan Drug Product Designation may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received Orphan Drug Product Designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We have obtained Orphan Drug Product Designation for GPS in AML, MPM and MM and for GALE-301/ GALE-302. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services and state and local governments. Our promotional and scientific/educational programs must comply with the federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, the False Claims Act, or FCA, the Veterans Health Care Act, physician payment transparency laws, privacy laws, security laws, and additional state laws similar to the foregoing. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal Anti-Kickback Statute prohibits, among other things, the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. The government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham research or consulting and other financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Many states have similar laws that apply to their state health care programs as well as private payors. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. Actions under the FCA may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the FCA can result in significant monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multibillion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. In addition, companies have been forced to implement extensive corrective action plans, and have often become subject to consent decrees or corporate integrity agreements, restricting the manner in which they conduct their business. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, also created federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers for payments or other transfers of value made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certain states also mandate implementation of commercial compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and other healthcare professionals. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may also be subject to data privacy and security regulation by both the federal government and the states in which it conducts its business. HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to it, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Coverage and Reimbursement </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. Although we currently believe that third-party payors will provide coverage and reimbursement for our product candidates, if approved, these third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of our product candidates.  Seeking coverage and reimbursement from third-party payors can be time consuming and expensive. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Regulation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to regulations in the United States, we are and will be subject, either directly or through our distribution partners, to a variety of regulations in other jurisdictions governing, among other things, clinical trials and commercial sales and distribution of our products, if approved.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have processes that require the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, or CTA, must be submitted to the competent national health authority and to independent ethics committees in each country in which a company plans to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trials may proceed in that country.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national implementation of underlying E.U. legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">To obtain regulatory approval of a new drug or medicinal product in the European Union, a sponsor must obtain approval of a marketing authorization application. The way in which a medicinal product can be approved in the European Union depends on the nature of the medicinal product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The centralized procedure results in a single marketing authorization granted by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated as &#8220;orphan drugs&#8221; and (iv) advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used for human drugs which do not fall within the above mentioned categories if the human drug (a) contains a new active substance which was not authorized in the European Community; or (b) the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization in the centralized procedure is in the interests of patients or animal health at the European Community level.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application by the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or CHMP), with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated; the absence of an appropriate alternative therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The mutual recognition procedure, or MRP, for the approval of human drugs is an alternative approach to facilitate individual national marketing authorizations within the European Union. The MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products, and is based on the principle of recognition of an already existing national marketing authorization by one or more member states.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The characteristic of the MRP is that the procedure builds on an already existing marketing authorization in a member state of the E.U. that is used as reference in order to obtain marketing authorizations in other E.U. member states. In the MRP, a marketing authorization for a drug already exists in one or more member states of the E.U. and subsequently marketing authorization applications are made in other European Union member states by referring to the initial marketing authorization. The member state in which the marketing authorization was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently applied for act as concerned member states.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The MRP is based on the principle of the mutual recognition by European Union member states of their respective national marketing authorizations. Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member states. In such case, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement of the agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Should any Member State refuse to recognize the marketing authorization by the reference member state, on the grounds of potential serious risk to public health, the issue will be referred to a coordination group. Within a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The opinion of this EMA Committee is then forwarded to the Commission, for the start of the decision-making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human Medicinal Products or Veterinary Medicinal Products, as appropriate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the other applicable regulatory requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Corporate Information </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our principal executive offices are located at 15 West 38</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Street, 10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Floor, New York, NY 10018, and our phone number is (917) 438-4353. Our website address is www.sellaslife.com. We do not incorporate the information on our website into this annual report on Form 10-K, and you should not consider such information part of this annual report on Form 10-K. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We were incorporated on April&#160;3, 2006 in Delaware as Argonaut Pharmaceuticals, Inc. On November&#160;28, 2006, we changed our name to RXi Pharmaceuticals Corporation and began operations January 2007. On September&#160;26, 2011, we changed our name to Galena Biopharma, Inc., or Galena.  In December 2017, we completed the Merger with Private SELLAS and changed our name to &#8220;SELLAS Life Sciences Group, Inc.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><a name="s25e071a358034543a2502c43f3f8f682"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1A. RISK FACTORS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">You should consider carefully the risks and uncertainties described below, together with all of the other information in this annual report on Form 10-K. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This&#160;annual report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face as described below and elsewhere in this annual report on Form 10-K. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Relating to Our Financial Position and Need for Additional Capital</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are a clinical stage biopharmaceutical company focused on development of novel cancer immunotherapies for a broad range of cancer indications.  Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory approval or become commercially viable.  We do not have any products approved by regulatory authorities and have not generated any revenues from collaboration and licensing agreements or product sales to date, and have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses.  As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception.  For the years ended December 31, 2018 and 2017, we reported a net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and $23.8 million respectively, and as of December 31, 2018 and 2017, we had an accumulated deficit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$81.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and $54.2 million respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We do not expect to generate revenues for many years, if at all.  We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates and any additional product candidates we may acquire, and potentially begin to commercialize product candidates that may achieve regulatory approval.  We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Our expenses will further increase as we: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">conduct additional clinical trials of our lead product, GPS, including the Phase 3 clinical trials evaluating GPS for AML and other cancers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">continue to develop immunotherapy programs for NPS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">pursue research and development of our other product candidates, including GALE-301 (a vaccine against the E39 peptide derived from the folate binding protein, or FBP) and GALE-302 (a vaccine against the J65 peptide derived from FBP); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">in-license or acquire the rights to, and pursue development of, other products, product candidates or technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">hire additional clinical, manufacturing, quality control, quality assurance and scientific personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seek marketing approval for any product candidates that successfully complete clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">develop our outsourced manufacturing and commercial activities and establish sales, marketing and distribution capabilities, if we receive, or expect to receive, marketing approval for any product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">maintain, expand and protect our intellectual property portfolio; and </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">add operational, financial and management information systems and personnel. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We need significant additional financing to fund our operations and complete the development and, if approved, the commercialization of our product candidates. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect our existing cash as of December 31, 2018, together with the gross proceeds of up to $4.2 million we may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable us to fund our operating expenses through June 2019. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, we will need to raise additional capital earlier than anticipated to fund our operations. Our existing cash will not be sufficient to complete development and obtain regulatory approval for any of our lead product candidates, and we will need to raise significant additional capital to help us do so. In addition, our operating plan may change as a result of many factors currently unknown to us, and we may need additional funds sooner than planned.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect to expend substantial resources for the foreseeable future to continue the clinical development and manufacturing of our product candidates and the advancement and expansion of our preclinical research pipeline, in particular the Phase 1/2 basket study of GPS in combination with pembrolizumab and our planned Phase 3 study of GPS in AML. These expenditures will include costs associated with research and development, potentially acquiring new product candidates or technologies, conducting preclinical studies and clinical trials and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our future capital requirements depend on many factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the scope, progress, results and costs of our ongoing and planned development programs for our product candidates, as well as any additional clinical trials we undertake to obtain data sufficient to seek marketing approval for our product candidates in any indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates if our clinical trials are successful; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the cost of commercialization activities for our product candidates, if any of these product candidates are approved for sale, including marketing, sales and distribution costs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the cost of manufacturing our product candidates for clinical trials in preparation for regulatory approval, including the cost and timing of process development, manufacturing scale-up and validation activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements; </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:left;text-indent:0px;"><font style="padding-bottom:12px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:24px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the costs to in-license future product candidates or technologies; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the costs in defending and resolving future derivative and securities class action litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our operating expenses; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the emergence of competing technologies or other adverse market developments. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional funds may not be available when we need them on terms that are acceptable to us, or at all.  We have no committed source of additional capital. If adequate funds are not available to us on a timely basis, we may not be able to continue as a going concern or we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates or target indications, or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have announced that we are considering strategic alternatives in order to maximize shareholder value, including financings, strategic alliances, acquisitions, or the possible sale of the Company. We may not be able to identify or consummate any suitable strategic alternatives.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have announced that we are considering all strategic alternatives that may be available to us, to maximize shareholder value, including financings, strategic alliances, acquisitions, or the possible sale of the Company. We currently have no agreements or commitments to engage in any specific strategic transactions, and our exploration of various strategic alternatives may not result in any specific action or transaction.  To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Furthermore, if we determine to engage in a strategic transaction, we cannot predict the impact that such strategic transaction might have on our operations or stock price.  We also cannot predict the impact on our stock price if we fail to enter into a transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may seek additional capital through a variety of means, including through private and public equity offerings and debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or through the issuance of shares under management or other types of contracts, or upon the exercise or conversion of outstanding derivative securities, the ownership interests of our stockholders will be diluted, and the terms of such financings may include liquidation or other preferences, anti-dilution rights, conversion and exercise price adjustments and other provisions that adversely affect  the rights of our stockholders, including rights, preferences and privileges that are senior to those of our holders of common stock in the event of a liquidation.  For example, in March and May 2018, we issued convertible preferred stock which contained rights, preferences and privileges which were senior to those of holder of our common stock.  Such preferred stock is no longer outstanding.  In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of our common stock. Debt financing, if available, could include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures, entering into licensing arrangements, or declaring dividends and may require us to grant security interests in our assets, including our intellectual property, and for our subsidiaries to guarantee our obligations. If we raise additional funds through collaborations, strategic alliances, or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, products or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">There is substantial doubt about our ability to continue as a going concern. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December&#160;31, 2018, we had a cash balance of approximately $5.3 million. In addition, we had outstanding accounts payable and accrued expenses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. We expect our existing cash as of December 31, 2018, together with the gross proceeds of up to $4.2 million we may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable us to fund our operating expenses and capital expenditure requirements through June 2019. In the event that we are unable to obtain additional financing, we may be unable to continue as a going concern. There is no guarantee that we will be able to secure additional financing. Changes in our operating plans, our existing and anticipated working capital needs, defense costs related to our ongoing legal proceedings and any additional legal proceedings we might become subject to in the future, the acceleration or modification of our development activities, any near-term or future expansion plans, increased expenses, potential acquisitions or other events may further affect our ability to continue as a going concern. See Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information on our assessment. Similarly, the report of our independent registered public accounting firm on our consolidated financial statements as of and for the year ended December 31, 2018 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we cannot continue as a viable entity, our securityholders may lose some or all of their investment in us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We currently have no source of revenues. We may never generate revenues or achieve profitability. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Currently, we do not generate any revenues from product sales or otherwise. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when we will generate revenues or become profitable, if at all. Our ability to generate revenues from product sales and achieve profitability will depend on our ability to successfully commercialize products, including our current product candidates, and other product candidates that we may develop, in-license or acquire in the future. Our ability to generate revenues and achieve profitability also depends on a number of additional factors, including our ability to: &#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">successfully complete development activities, including the necessary clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">complete and submit either BLAs or NDAs to the FDA and obtain U.S. regulatory approval for indications for which there is a commercial market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">complete and submit applications to foreign regulatory authorities in Europe, Asia and other jurisdictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">obtain regulatory approval in territories with viable market sizes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">obtain coverage and adequate reimbursement from third parties, including government and private payors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">set commercially viable prices for our products, if any; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">establish and maintain supply and manufacturing relationships with reliable third parties and/or build our own manufacturing facility and ensure adequate, legally globally compliant manufacturing of bulk drug substances and drug products to maintain that supply; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">develop distribution processes for our product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">develop commercial quantities of our product candidates, once approved, at acceptable cost levels;                                      obtain additional funding, if required to develop and commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves, in the markets in which we choose to commercialize on our own;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">achieve market acceptance of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">attract, hire and retain qualified personnel; and</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">protect our rights in our intellectual property portfolio.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our revenues for any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as our estimates, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenues from sales of such products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved product candidate. As a result, even if we generate revenues, we may not become profitable and may need to obtain additional funding to continue operations.  If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Tax Cut and Jobs Act, enacted on December 22, 2017, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a single rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted taxable income (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), providing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reduction of tax credits under the Orphan Drug Act). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the Tax Act.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December&#160;31, 2018, we had federal and state net operating loss carryforwards of approximately $19.7 million and $3.7 million, respectively. The federal and state NOL carryforwards will begin to expire, if not utilized, beginning in 2027. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Act, federal NOLs incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the Tax Act,</font><font style="font-family:Helvetica,sans-serif;font-size:12pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">or whether any further regulatory changes may be adopted in the future that could minimize its applicability. In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, and certain corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in the ownership of its equity over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. The Merger constituted an ownership change and as such, our ability to use our NOL carryforwards is materially limited, which may harm our future operating results by effectively increasing our future tax obligations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to the Development and Regulatory Approval of Our Product Candidates </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Clinical-stage biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which may entail substantial risk. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are currently a clinical-stage biopharmaceutical company with product candidates in clinical development. The success of our product candidates will depend on several factors, including the following: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">designing, conducting and successfully completing preclinical development activities, including preclinical efficacy and IND-enabling studies, for our product candidates or product candidates we are interested in in-licensing or acquiring, including product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">designing, conducting and completing clinical trials for our product candidates with positive results; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">receipt of regulatory approvals from applicable authorities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">making arrangements with third-party manufacturers, receiving regulatory approval of our manufacturing processes and our third-party manufacturers&#8217; facilities from applicable regulatory authorities and ensuring adequate supply of drug product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">manufacturing our product candidates at an acceptable cost; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">effectively launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">achieving acceptance of our product candidates, if approved, by patients, the medical community and third-party payors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">effectively competing with other therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">if our products candidates are approved, obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">complying with all applicable regulatory requirements, including FDA current Good Clinical Practices, or GCP, current Good Manufacturing Practices, or cGMP, and standards, rules and regulations governing promotional and other marketing activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">maintaining a continued acceptable safety profile of the products during development and following approval; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">maintaining and growing an organization of scientists and business people who can develop and commercialize our products and technology. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could materially harm our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our lead product candidate, GPS, represents a new therapeutic approach that presents significant challenges. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our future success is substantially dependent on the successful development of WT1 peptide immunotherapies in general and GPS in particular. Because this program represents a new approach to cancer immunotherapy for the treatment of cancer and other diseases, developing and commercializing GPS subjects us to a number of challenges, including: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">obtaining regulatory approval from the FDA and other regulatory authorities, which have very limited experience with the development and commercialization of WT1 cancer immunotherapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">obtaining the components required for the administration of GPS (i.e., GPS, granulocyte macrophage-colony stimulating factor, or GM-CSF, and Montanide) from three separate sources, the subsequent separate storage requirements for each of these components and the delivery of these components to the administration location; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">utilizing GPS in combination with other therapies, which may increase the risk of adverse side effects; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process GPS; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;developing a manufacturing process used in connection with GPS that will yield a satisfactory product that is safe, effective, scalable and profitable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">obtaining coverage and adequate reimbursement from third-party payors and government authorities. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Moreover, public perception of safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to the novel treatment mechanics. Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional educational upfront costs and training. Physicians may not be willing to undergo training to adopt this novel therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh our costs. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which could delay or prevent the start of clinical trials for our product candidates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Identifying and qualifying patients to participate in clinical trials of our current and future product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. If we experience delays in our clinical trials, the timeline for obtaining regulatory approval of our product candidates will most likely be delayed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Many factors may affect our ability to identify, enroll and maintain qualified patients, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">eligibility criteria of our ongoing and planned clinical trials with specific characteristics appropriate for inclusion in our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">design of the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">size and nature of the patient population;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">patients&#8217; perceptions as to risks and benefits of the product candidate under study</font><font style="font-family:Helvetica,sans-serif;font-size:12pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">and the participation in a clinical trial generally in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the availability and efficacy of competing therapies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">pendency of other trials underway in the same patient population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">willingness of physicians to participate in our planned clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">severity of the disease under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">proximity of patients to clinical sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">patients who do not complete the trials for personal reasons; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">issues with contract research organizations, or CROs, and/or with other vendors that handle our clinical trials.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For example, in our planned AML, Phase 3 clinical trial for GPS, only patients who meet specific inclusion criteria will enter the study. Primary entry restrictions include being greater than or equal to 60 years of age, having received upfront treatment with chemotherapy agents only, having achieved complete remission or CRem, as well as demonstrating adequate hematologic recovery. The estimated prevalence of AML is 12,000 to 20,000 cases in the United States (across all ages) and only a subset of this group satisfies the enrollment criteria for our AML Phase 3 clinical trial. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may not be able to initiate or continue to support clinical trials of our product candidates for one or more indications, or any future product candidates if we are unable to locate and enroll a sufficient number of eligible participants in these trials as required by the FDA or other regulatory authorities. Even if we are able to enroll a sufficient number of patients in our clinical trials, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our trials may be delayed or our trials could become too expensive to complete. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we experience delays in the completion of, or termination of, any clinical trials of our current or future product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials would likely increase our overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our existing product candidates in clinical trials, and any other product candidates that may advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of an investigational drug. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier preclinical studies or clinical trials. Any of our product candidates that are in, or may advance to, clinical trials may not succeed in clinical trials despite promising preclinical data. For example, with respect to GPS, a broadly similar anti-cancer peptide immunotherapeutic against melanoma-specific antigen being developed by GlaxoSmithKline for advanced unresectable melanoma initially produced positive efficacy data in a Phase 2 clinical study, but subsequently failed to prove more beneficial than placebo in a controlled, blinded and randomized Phase 3, registration-enabling clinical trial in the same indication in patients after tumor resection. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Despite the results reported in earlier preclinical studies or clinical trials for our product candidates, we do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market GPS or any of our product candidates for a particular indication, either as a monotherapy or in combination, in any particular jurisdiction. Efficacy data from prospectively designed trials may differ significantly from those obtained from retrospective subgroup analyses. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for GPS may be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our current or future product candidates, the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical trials.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical testing is expensive and can take many years to complete, with the outcome inherently uncertain. Failure can occur at any time during the clinical trial process. Before obtaining approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Prior to initiating clinical trials, a sponsor must complete extensive preclinical testing of a product candidate, including, in most cases, preclinical efficacy experiments as well IND-enabling toxicology studies. These experiments and studies may be time-consuming and expensive to complete. The necessary preclinical testing may not be completed successfully for a preclinical product candidate and a potentially promising product candidate may therefore never be tested in humans. Once it commences, clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We may experience numerous unforeseen events during drug development that could delay or prevent our ability to receive marketing approval or commercialize our product candidates. In particular, clinical trials of our product candidates may produce inconclusive or negative results. We have limited data regarding the safety, tolerability and efficacy of GPS administered as monotherapy or in combination with PD-1 inhibitors. For a further discussion of the safety risks in our trials, see the risk factor herein entitled "Our current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval." Clinical trials also require the review and oversight of an institutional review board, or IRB. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB review and approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may experience delays in our ongoing or future clinical trials, and we do not know whether planned clinical trials will begin or enroll subjects on time, will need to be redesigned or will be completed on schedule, if at all. There can be no assurance that the FDA will not put clinical trials of any of our product candidates on clinical hold in the future. Clinical trials may be delayed, suspended or prematurely terminated for a variety of reasons, such as: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a clinical trial design that we are able to execute; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in obtaining IRB approval or the approval of other reviewing entities, including comparable foreign regulatory authorities, to conduct a clinical trial at each site; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">withdrawal of clinical trial sites from our clinical trials or the ineligibility of a site to participate in our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in recruiting and enrolling suitable subjects to participate in a trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in subjects completing a trial or returning for post-treatment follow-up; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">failure of our third-party clinical trial managers, CROs, clinical trial sites, contracted laboratories or other third-party vendors to satisfy their contractual duties, meet expected deadlines or return trustworthy data; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">delay or failure in adding new trial sites; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">interim results or data that are ambiguous or negative or are inconsistent with earlier results or data; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">alteration of trial design necessitated by re-evaluation of design assumptions based upon observed data; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">feedback from the FDA, the IRB, DSMB or a comparable foreign regulatory authority, or results from earlier stage or concurrent preclinical studies and clinical trials, that might require modification to the protocol for a trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a decision by the FDA, the IRB, a comparable foreign regulatory authority, or us, or a recommendation by a DSMB or comparable foreign regulatory authority, to suspend or terminate clinical trials at any time for safety issues or for any other reason; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">unacceptable risk-benefit profile, unforeseen safety issues or adverse side effects; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">failure to demonstrate a benefit from using a product candidate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">difficulties in manufacturing or obtaining from third parties sufficient quantities of a product candidate to start or to use in clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">lack of adequate funding to continue a trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional studies or increased expenses associated with the services of our CROs and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">changes in governmental regulations or administrative actions or lack of adequate funding to continue a clinical trial. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we experience delays in the completion or termination of any clinical trial of our product candidates, the approval and commercial prospects of such product candidates will be harmed, delaying our ability to generate product revenues from such product candidate and our costs will most likely increase. The required regulatory approvals may also be delayed, thereby jeopardizing our ability to commence product sales and generate revenues and the period of commercial exclusivity for our products may be decreased. Regulatory approval of our product candidates may be denied for the same reasons that caused the delay. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Risks associated with operating in foreign countries could materially adversely affect our product development. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may conduct future studies in countries outside of the United States Consequently, we may be subject to risks related to operating in foreign countries. Risks associated with conducting operations in foreign countries include: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries; </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">more stringent privacy requirements for data to be supplied to our operations in the United States, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, General Data Protection Regulation in the European Union; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign taxes, including withholding of payroll taxes; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Undesirable side effects caused by our current or future product candidates, their delivery methods or dosage levels could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval or termination of clinical trials by the FDA or other comparable foreign regulatory authority; an independent DSMB that is governing our clinical trials; or an IRB, that approves and, monitors biomedical research to protect the rights and welfare of human subjects. For example, although no high-grade delayed type hypersensitivity in the skin or systemic anaphylaxis events have been noted after GPS administration in patients treated in our clinical studies to date, it is theoretically possible that such toxicities, or other type of adverse events, may occur in future clinical studies. As a result of safety or toxicity issues that we may experience in our clinical trials, or negative or inconclusive results from the clinical trials of others for drug candidates similar to our own, we may not receive approval to market any product candidates, which could prevent us from ever generating revenues or achieving profitability. Results of our trials could reveal an unacceptably high severity and incidence of side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may have a material adverse effect on our business, results of operations, financial condition, cash flows and future prospects. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including that: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">we may be forced to suspend marketing of such product; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">regulatory authorities may withdraw their approvals of such product; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of such products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">we may be required to conduct post-marketing studies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">we may be required to change the way the product is administered; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">we could be sued and held liable for harm caused to subjects or patients; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our reputation may suffer. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our product development program may not uncover all possible adverse events that patients who take our product candidates may experience. The number of subjects exposed to product candidates and the average exposure time in the clinical development program may be inadequate to detect rare adverse events, or chance findings, that may only be detected once the product is administered to more patients and for greater periods of time. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trials by their nature utilize a sample of the potential patient population. However, with a limited number of subjects and limited duration of exposure, we cannot be fully assured that rare and severe side effects of our product candidates will be uncovered. Such rare and severe side effects may only be uncovered with a significantly larger number of patients exposed to our product candidates. If such safety problems occur or are identified after our product candidates reaches the market, the FDA may require that we amend the labeling of the product or recall the product, or may even withdraw approval for the product. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our future success is dependent on the regulatory approval of our product candidates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our business is dependent on our ability to obtain regulatory approval for our product candidates in a timely manner. We cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two well-controlled Phase 3 trials, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements.  Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our current and future product candidates could fail to receive regulatory approval from the FDA.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not obtained regulatory approval for any product candidate and it is possible that our existing product candidates or any future product candidates will not obtain regulatory approval, for many reasons, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">disagreement with the regulatory authorities regarding the scope, design or implementation of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">failure to demonstrate that a product candidate is safe and effective for our proposed indication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">failure of clinical trials to meet the level of statistical significance required for approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">disagreement with our interpretation of data from preclinical studies or clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a BLA, NDA or other submission or to obtain regulatory approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the insufficiency of a single Phase 3 clinical trial of GPS in AML for regulatory approval in that indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The FDA or a comparable foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval or additional studies, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We currently have Orphan Drug exclusivity for certain product candidates, and may seek Orphan Drug Product designation for additional product candidates or indications, which might not be received or provide the intended benefit thereof. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as Orphan Drugs. Under the Orphan Drug Act, the FDA may designate a product as an Orphan Drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States We have received Orphan Drug Product designations from the FDA for GPS in AML, MPM and MM as well as Orphan Medicinal Product designations from the EMA for GPS in AML, MPM and MM. We also have received Orphan Drug Product designation for GALE-301 and GALE-302 from the FDA. Although we have received Orphan Drug Product designation for GPS, GALE-301 and GALE-302, there is no guarantee that these products will be successfully approved by the FDA, that they will be commercially successful in the marketplace, or that another product will not be approved for the same indication ahead of our product candidate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if we obtain Orphan Drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an Orphan Drug is approved, the FDA can subsequently approve a new drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, Orphan Drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We currently have Fast Track designation for certain product candidates and may seek Fast Track designation for additional product candidates or indications, which might not be received or provide the intended benefits thereof. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply to the FDA for Fast Track designation, which may or may not be granted by the FDA. The FDA has given us Fast Track designation for GPS in AML and MPM and for NPS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">However, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to regulations in the United States, to market and sell our product candidates in the European Union, United Kingdom, many Asian countries and other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. We may not be able to obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Clinical trials accepted in one country may not be accepted by regulatory authorities in other countries. In addition, many countries outside the United States require that a product be approved for reimbursement before it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country may not receive reimbursement approval in that country. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our current or future product candidates by regulatory authorities in the European Union, United Kingdom, Asia or elsewhere, the commercial prospects of that product candidate may be significantly diminished, our business prospects could decline and this could materially adversely affect our business, results of operations and financial condition. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Even if our current and future product candidates receive regulatory approval, they may still face future development and regulatory difficulties. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if we obtain regulatory approval for a product candidate, that approval would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance by us and/or our contract manufacturing organizations, or CMOs, and CROs for any post-approval clinical trials that we may conduct. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may require labeling changes or establishment of a risk evaluation and mitigation strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with Good Manufacturing Practices, or cGMP, Good Clinical Practices, or GCP, and other regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">issue warning letters or untitled letters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seek an injunction or impose civil or criminal penalties or monetary fines; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">suspend or withdraw regulatory approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">suspend any ongoing clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">refuse to approve pending applications or supplements to applications filed by us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our products and generate revenues. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the DOJ, the Office of Inspector General of HHS, state attorneys general, members of Congress and the public. Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be heavily scrutinized by comparable foreign regulatory authorities. Violations, including actual or alleged promotion of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA, as well as prosecution under the federal False Claims Act. Any actual or alleged failure to comply with labeling and promotion requirements may have a negative impact on our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product, we will remain subject to ongoing regulatory requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if our product candidates are approved, we will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing clinical trials and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Manufacturers and manufacturers&#8217; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring quality control and manufacturing procedures conform to cGMP, regulations and corresponding foreign regulatory manufacturing requirements. Accordingly, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA submission to the FDA or any other type of domestic or foreign marketing authorization application.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any regulatory approvals we receive for any of our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm the clinical benefit for our products. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or it disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">issue warning letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">impose civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">suspend or withdraw regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">suspend any of our ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">refuse to approve pending applications or supplements to approved applications submitted by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">require a product recall.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any government investigation of alleged violations of law would require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and the value of our business and our operating results would be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Manufacturing </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have limited to no manufacturing, sales, marketing or distribution capability and must rely upon third parties for such. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have agreements with various third-party manufacturing facilities for production of our product candidates for research and development and testing purposes. We depend on these manufacturers to meet our deadlines, quality standards and specifications. Our reliance on third parties for the manufacture of our active pharmaceutical ingredient and drug product and, in the future, any approved products, creates a dependency that could severely disrupt our research and development, our clinical testing, and ultimately our sales and marketing efforts if the source of such supply proves to be unreliable or unavailable. If the contracted manufacturing source is unreliable or unavailable, we may not be able to manufacture clinical drug supplies of our product candidates, and our preclinical and clinical testing programs may not be able to move forward and our entire business plan could fail. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Both the active pharmaceutical ingredient and drug product for our product candidates are currently single sourced. We believe these single sources are currently capable of supplying all anticipated needs of our proposed clinical studies, as well as initial commercial introduction. If we are able to commercialize our products in the future, there is no assurance that our manufacturers will be able to meet commercialized scale production requirements in a timely manner or in accordance with applicable standards or cGMP. Once the nature and scope of additional indications and their commensurate drug product demands are established, we will seek secondary suppliers of both the active pharmaceutical ingredient and drug product for our product candidates, but we cannot assure that such secondary suppliers will be found on terms acceptable to us, or at all. &#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We  and our CMOs will need to conduct significant development work for each product candidate for each target indication for studies, trials and commercial launch readiness. For example, the processes by which GPS is manufactured were initially developed by MSK for clinical purposes. Concurrent with the license of GPS, we acquired certain supplies intended for clinical use from MSK. These MSK clinical supplies may not be adequate for future clinical studies. We intend to improve the existing processes for GPS in connection with more advanced clinical trials or commercialization</font><font style="font-family:Helvetica,sans-serif;font-size:12pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">efforts we may undertake in the future. Developing commercially viable manufacturing processes is a difficult, expensive and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including cost overruns, potential problems with process scale-up, process reproducibility, stability issues, consistency and timely availability of reagents or raw materials. The manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, and numerous other factors. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additionally, the process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including but not limited to: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reduced production yields, product defects, and other supply disruptions due to deviations, even minor, from normal manufacturing and distribution processes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">unexpected product defects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">microbial, viral, or other contaminations in our product candidates or in the manufacturing facilities in which our product candidates are made, which may result in the closure of such manufacturing facilities for an extended period of time to allow for the investigation and remediation of the contamination;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">adverse impact on the active ingredient of GPS as a result of potential contamination from the presence of heavy metals which can lead to higher than acceptable rates of impurities resulting in the active ingredient being unacceptable for use; and</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">adverse impact on the manufacturing of GPS as a result of potential contamination from excess water and oxygen which can lead to higher than acceptable levels of impurities resulting in the drug product being unacceptable for use.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of our drug substance and drug product, which could delay the development of our product candidates. We may also have to write off inventory, incur other charges and expenses for supply of drug product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community, and cancer treatment centers, which could adversely affect our ability to operate our business and our results of operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">In the clinical trials using GPS and NPS, GM-CSF is also administered and its availability is dependent upon a third-party manufacturer, which may or may not reliably provide GM-CSF, thus jeopardizing the completion of the trials. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Some of our product candidates are administered in combination with GM-CSF, which is available in both liquid and lyophilized forms exclusively from one manufacturer. We will continue to be dependent on that manufacturer for our supply of GM-CSF in connection with the ongoing GPS and NPS trials and the potential commercial manufacture of these programs. We have not entered into a dedicated supply agreement with the manufacturer for GM-CSF, and instead rely on purchase orders to meet our supply needs. Any temporary interruptions or discontinuation of the availability of GM-CSF, or any determination by us to change the GM-CSF used with GPS or NPS, could have a material adverse effect on our clinical trials and any commercialization of the assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If any of our CMOs&#8217; clinical manufacturing facilities are damaged or destroyed or production at such facilities is otherwise interrupted, our business and prospects would be negatively affected. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If our CMOs&#8217; manufacturing facilities or the equipment in them is damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace it at all. In the event of a temporary or protracted loss of this facility or equipment, we might not be able to transfer manufacturing to another CMO. Even if we could transfer manufacturing to another CMO, the shift would likely be expensive and time-consuming, particularly because the new facility would need to comply with the necessary regulatory requirements and we would need FDA approval before selling any products manufactured at that facility. Such an event could delay our clinical trials or reduce our product sales. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although we currently maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Dependence on Third Parties and Our License Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, or if we lose any of our CROs or other key third-party vendors, we may not be able to obtain regulatory approval for or commercialize our current or future product candidates on a timely basis, if at all. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our internal capacity for clinical trial execution and management is limited and therefore we rely heavily on third parties. We have relied upon and plan to continue to rely upon third-party CROs, vendors and contractors to monitor and manage data for our ongoing preclinical and clinical programs. For example, our collaborating investigators at MSK, along with their clinical and clinical operations teams, manage the conduct of the ongoing clinical trials for GPS as well as perform the analysis, publication and presentation of data and results related to this program. We also rely on collaborating investigators, along with their clinical and clinical operations teams, at MSK for the collection and transfer of various types of follow-up data regarding studies previously conducted by MSK. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We plan to rely on CROs and other third-party vendors for all currently contemplated clinical studies, with services to be rendered by such CROs ranging from, in the case of assorted Phase 2 trials, specific and need-tailored (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, data management and biostatistics) only to, in the case of our immune combination (PD1 blocker) Phase 2 trials and our planned Phase 3 trial for GPS in AML, all-encompassing. We rely on these parties for the execution of our preclinical studies and clinical trials, including the proper and timely conduct of our clinical trials, and we control only some aspects of their activities. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results or data in a timely manner or may fail to perform at all.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">While we have agreements governing the commitments of our third-party vendor services, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If our company, or any of our partners or CROs, fail to comply with applicable regulations and good clinical practices, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our regulatory applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with applicable requirements. In addition, our clinical trials must be conducted with product produced under cGMP and other requirements. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, clinicaltrials.gov, within a specified timeframe. Failure to comply also would violate federal requirements in the United States and could result in other penalties, which would delay the regulatory approval process and result in adverse publicity. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our CROs, third-party vendors and contractors are not our employees, and except for remedies available to us under our agreements with such CROs, third-party vendors and contractors, we cannot control whether or not they devote sufficient time and resources, including experienced staff, to our ongoing clinical, nonclinical and preclinical programs. They may also have relationships with other entities, some of which may be our competitors. If CROs, third-party vendors and contractors do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our current or future product candidates. CRO, vendor or contractor errors could cause our results of operations and the commercial prospects for our current or future product candidates to be harmed, our costs to increase and our ability to generate revenues to be delayed. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If any of our relationships with our third-party CROs, third-party vendors or contractors terminate, we may not be able to enter into arrangements with alternative CROs, third-party vendors or contractors on a timely basis, on commercially reasonable terms or at all. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our CROs, third-party vendors and contractors have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs, third-party vendors and contractors have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO, third-party vendor or contractor commences work and the new CRO, third-party vendor or contractor may not provide the same type or level of services as the original provider.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new technologies in the future, our ability to develop new products would be harmed, and if we fail to meet our obligations under our license agreements, we may lose the ability to develop our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently are dependent on licenses from third parties for technologies relating to our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, funding, royalty, diligence, sublicensing, insurance and other obligations on us. If our license with respect to any of these technologies is terminated for any reason, the development of the products contemplated by the licenses would be delayed, or suspended altogether, while we seek to license similar technology or develop new non-infringing technology. The costs of obtaining new licenses are high. For example, we are entirely dependent on our license from MSK to allow us to develop and commercialize our lead product candidate, GPS, and any loss of or challenge to our license agreement with MSK could have a material and adverse effect on our business and result of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under certain license agreements that we have already entered into, we have minimum dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract partners and other obligations to maintain certain licenses. If we fail to meet such requirements under any of our licenses or if we fail to comply with any other obligations under these licenses, we may be in breach of our obligations under such agreements, which may result in the loss of the technology licensed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, our business depends on our ability to license therapeutic compounds from third parties. If we fail to meet our obligations under our license agreements, we may lose the ability to develop our product candidates, which would adversely affect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have in-licensed a significant portion of our intellectual property from MSK. If we breach our license agreement with MSK, we could lose the ability to continue the development and potential commercialization of GPS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We do not currently own any patents or patent applications related to our lead product candidate, GPS. GPS is licensed-in from MSK and includes an exclusive license to United States and foreign patent applications. Under the MSK license agreement, we are subject to various obligations, including diligence obligations with respect to funding, development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales, as well as other material obligations. If there is any conflict, dispute, disagreement or issue of nonperformance between us and MSK regarding our rights or obligations under the license agreements, including any such conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations under any such agreement, we may be liable to pay damages and MSK may have a right to terminate the affected license. In 2018, we did not make certain required payments to MSK, which entitles MSK to terminate the license agreement if we are unable to make such payments after notice. To date, we have not received such a notice from MSK. The loss of our license agreement with MSK could materially adversely affect our ability to proceed to utilize the affected intellectual property in our development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for GPS and our ability to commercialize GPS. The risks described elsewhere pertaining to our patents and other intellectual property rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain and enforce these rights could have a material adverse effect on our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not realize the benefits of our strategic alliances that we may form in the future. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will complement or augment our existing business. These relationships, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. If we license products or acquire businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new strategic alliances agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials even after we sell or otherwise dispose of the products. In some cases, these hazardous materials and various wastes resulting from their use will be stored at our contractors or manufacturers&#8217; facilities pending use and disposal. We cannot completely eliminate the risk of contamination, which could cause injury to our employees and others, environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we expect that the safety procedures utilized by our third-party contractors and manufacturers for handling and disposing of these materials will generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this will be the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources. We do not currently carry biological or hazardous waste insurance coverage and our property and casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize some or all of our product candidates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential partners&#8217; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that we have generated, and the perceived risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. We cannot necessarily control the amount or timing of resources that our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract partners do not fulfill their obligations to us. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we may receive notices from third parties from time to time alleging that our technology or product candidates infringe upon the intellectual property rights of those third parties. Any assertion by third parties that our activities or product candidates infringe upon the intellectual property rights of third parties may adversely affect our ability to secure strategic partners or licensees for our technology or product candidates or our ability to secure or maintain manufacturers for our compounds. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain and enforce patent rights or other intellectual property rights that cover our product candidates and that are of sufficient breadth to prevent third parties from competing against us. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our success with respect to our product candidates will depend in part on our ability to obtain and maintain patent protection in the United States and abroad, to preserve our trade secrets, and to prevent third parties from infringing upon our proprietary rights. We seek to protect our proprietary position by filing in the United States and in certain foreign jurisdictions patent applications related to our novel technologies and product candidates that are important to our business. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In addition, we may not pursue or obtain patent protection in all major markets. Moreover, in some circumstances, we do not have the right to control the preparation, filing or prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties or covering technology that a collaboration or commercialization partner may develop. In some circumstances, our licensors have the right to enforce the licensed patents without our involvement or consent, or to decide not to enforce or to allow us to enforce the licensed patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors fail to maintain such patents, or lose rights to those patents, the rights that we have licensed may be reduced or eliminated and our ability to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign jurisdictions may not protect our rights to the same extent as the laws of the United States For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. Moreover, the U.S. Patent and Trademark Office, or USPTO, might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. As a result, the issuance, scope, validity, term, enforceability and commercial value of our patent rights are highly uncertain.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our pending and future patent applications, and any collaboration or commercialization partner&#8217;s pending and future patent applications, may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During prosecution of any patent application, the issuance of any patents based on the application may depend upon our or their ability to generate additional preclinical or clinical data that support the patentability of our proposed claims. We or any collaboration or commercialization partner may not be able to generate sufficient additional data on a timely basis, or at all. Moreover, changes in either the patent laws or interpretation of the patent laws in the United States or other countries may diminish the value of our or a collaboration or commercialization partner&#8217;s patents or narrow the scope of our or their patent protection.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Changes in either the patent laws or in the interpretations of patent laws in the United States or abroad may diminish the value of our intellectual property. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in particular the first-to-file provision and our implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement of or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances in certain situations. From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress, or interpretation by the USPTO may change the standards of patentability and any such changes could have a negative impact on our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Some cases decided by the U.S. Supreme Court have involved questions of when claims reciting abstract ideas, laws of nature, natural phenomena and/or natural products are eligible for a patent, regardless of whether the claimed subject matter is otherwise novel and inventive. These cases include</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;Association for Molecular Pathology v. Myriad Genetics, Inc.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, 569 U.S. 576 (2013), also known as the Myriad decision;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;Alice Corp. v. CLS Bank International</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, 573 U.S. 13-298 (2014), also known as the Alice decision; and</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, also known as the Prometheus decision, 566 U.S. 66 (2012). The full impact of these decisions is not yet known. In view of these and subsequent court decisions, the USPTO has issued materials to patent examiners providing guidance for determining the patent eligibility of claims reciting laws of nature, natural phenomena, or natural products. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our current product candidates include products, or components, derived to various extents from nature; therefore, these decisions and their interpretation by the courts and the USPTO may impact prosecution, defense, and enforcement of certain types of patent claims in our patent portfolio. In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change or be interpreted in unpredictable ways that would weaken our ability to obtain some patent claims or to enforce patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend patents that may issue in procedures in the USPTO or in U.S. courts. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">While we intend to take actions reasonably necessary to enforce our patent rights, we may not be able to detect infringement of our own or in-licensed patents, which may be especially difficult for methods of manufacturing or formulation products.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We depend, in part, on our licensors and collaborators to protect a substantial portion of our proprietary rights. In addition, third parties may challenge our in-licensed patents and any of our own patents that we may obtain, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to enforce or defend intellectual property rights is very complex, expensive, and may divert our management&#8217;s attention from our core business and may result in unfavorable results that could adversely affect our ability to prevent third parties from competing with us. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If another party has reason to assert a substantial new question of patentability against any of our claims in our own and in-licensed patents, the third party can request that the patent claims be reexamined, which may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement suits, and interference and reexamination proceedings, we may become a party to patent opposition proceedings where either the patentability of the inventions subject of our patents are challenged, or we are challenging the patents of others. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful. As the medical device, biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our commercial product and/or product candidates infringe their patent rights. If a third-party&#8217;s patents were found to cover our commercial product and product candidates, proprietary technologies or our uses, we or our collaborators could be enjoined by a court and required to pay damages and could be unable to continue to commercialize our products or use our proprietary technologies unless we or it obtained a license to the patent. A license may not be available to us or our collaborators on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable relief, which could prohibit us from making, using or selling our commercial product and product candidates pending a trial on the merits, which could be years away. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may face competition sooner than expected after the expiration of our composition of matter patent protection for such products. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our composition of matter patents for certain of our product candidates have expired or will expire prior to any product approval. We intend to seek data exclusivity or market exclusivity for our GPS as well as our NPS, GALE-301 and GALE-302 product candidates provided under the Federal Food, Drug and Cosmetic Act, or FDCA, and similar laws in other countries. We believe that these product candidates will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, or BPCIA. Under the BPCIA, an application for a biosimilar product or BLA cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on our similarity to an existing brand product. The law is complex and continues to be interpreted and implemented by the FDA. There is also a risk that the U.S. Congress could amend the BPCIA to shorten this exclusivity period, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if, as we expect, GPS, NPS, GALE-301 and GALE-302 are considered to be reference products eligible for 12 years of exclusivity under the BPCIA or qualify for five years of exclusivity as drugs under the FDCA, another company could market competing products if the FDA approves a full BLA or full NDA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In some countries outside of the United States, peptide vaccines, such as GPS, NPS, GALE-301 and GALE-302, are regulated as chemical drugs rather than as biologics and may or may not be eligible for non-patent exclusivity. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If we are sued for infringing the intellectual property rights of third parties, such litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our commercial success depends, in part, on us and our collaborators not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our current and future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as our product pipeline grows, the risk increases that our product candidates may be subject to claims of infringement of third parties&#8217; patent rights as it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult.  If any issued third-party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until such patent expired. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate.  We could be prevented from commercializing a product candidate or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.  In addition, parties making claims against us may also obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. we may also elect to enter into license agreements in order to settle patent infringement claims prior to litigation, and any such license agreement may require us to pay royalties and other fees that could be significant. During the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our product candidates, programs or intellectual property could be diminished. Accordingly, the market price of our shares of common stock may decline. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Filing, prosecuting, enforcing and defending patents on our current and future product candidates in all countries throughout the world would be prohibitively expensive. We or our licensors&#8217; intellectual property rights in certain countries outside the United States may be less extensive than those in the United States In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the United States Consequently, we and our licensors may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in countries outside the United States, or from selling or importing infringing products made using our and our licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patent(s) to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection but where enforcement is not as strong as that in the United States These infringing products may compete with our product candidates in jurisdictions where we or our licensors have no issued patents or where we do not have exclusive rights under the relevant patent(s), or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our licensors to stop the infringement of our and our licensors&#8217; patents or marketing of competing products in violation of our and our licensors&#8217; proprietary rights generally. Proceedings to enforce our and our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our and our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could put our and our licensors&#8217; patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuit that we or our licensors initiate, and even if we or our licensors are successful the damages or other remedies awarded, if any, may not be commercially meaningful. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business and on our stock price. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Third parties may infringe our patents, the patents of our licensors, or misappropriate or otherwise violate our or our licensors&#8217; intellectual property rights. We and our licensors&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In the future, we or our licensors may elect to initiate legal proceedings to enforce or defend our or our licensors&#8217; intellectual property rights, to protect our or our licensors&#8217; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights or that our intellectual property rights are invalid. In addition, third parties may initiate legal proceedings against us or our licensors to challenge the validity or scope of intellectual property rights we own or control. The proceedings can be expensive and time-consuming. Many of our or our licensors&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors can. Accordingly, despite our or our licensors&#8217; efforts, we or our licensors may not be able to prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect our rights as fully as in the United States Litigation could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217; patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our or our licensors&#8217; patents at risk of being invalidated, held unenforceable or interpreted narrowly. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interference or derivation proceedings provoked by third parties, brought by us or our licensors or collaborators, or brought by the USPTO or any non-U.S. patent authority may be necessary to determine the priority of inventions or matters of inventorship with respect to our or our licensors&#8217; patents or patent applications. We may also become involved in other proceedings, such as reexamination or opposition proceedings, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;review, post-grant review or other pre-issuance or post-grant proceedings in the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property of others. An unfavorable outcome in any such proceeding could require us or our licensors to cease using the related technology and commercializing the affected product candidate, or to attempt to license rights to it from the prevailing party. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our business could be harmed if the prevailing party does not offer us or our licensors a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our or our licensor&#8217;s patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current and future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of shares of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Although we have taken steps to protect our trade secrets and unpatented know-how, by entering into confidentiality agreements with third parties, and proprietary information and invention agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proprietary trade secrets and unpatented know-how are also very important to our business. We also have limited control over the protection of trade secrets used by our licensors, collaborators and suppliers. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time consuming, and the outcome is unpredictable. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their other clients or former employers. As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our commercial product and product candidates, many of whom were previously employed at or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these types of claims. Even if we are successful in defending against any such claims, any such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected, and our business could be harmed. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our current or future product candidates, thus eroding our competitive position in the market. Trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants, and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the United States Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could materially adversely affect our business, results of operations and financial condition. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Commercialization of Our Current and Future Product Candidates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our commercial success depends upon attaining significant market acceptance of our current and future product candidates, if approved, among physicians, patients, healthcare payors and cancer treatment centers. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Even if we obtain regulatory approval for any of our current or future product candidates, the products may not gain market acceptance among physicians, healthcare payors, patients or the medical community, including cancer treatment centers. Market acceptance of any product candidates for which we receive approval depends on a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the clinical indications and patient populations for which the product candidate is approved; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the clinical indications and patient populations for which the product candidate is approved; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">acceptance by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the adoption of novel immunotherapies by physicians, hospitals and third-party payors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the potential and perceived advantages of product candidates over alternative treatments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the safety of product candidates seen in a broader patient group, including our use outside the approved indications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">any restrictions on use together with other medications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the prevalence and severity of any side effects; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">product labeling or product insert requirements of the FDA or other regulatory authorities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the timing of market introduction of our products as well as competitive products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the development of manufacturing and distribution processes for commercial scale manufacturing for our novel WT1 peptide cancer immunotherapy product candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the cost of treatment in relation to alternative treatments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the availability of coverage and adequate reimbursement from third-party payors and government authorities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">relative convenience and ease of administration; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the effectiveness of our sales and marketing efforts and those of our collaborators. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If any of our current and future product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors or cancer treatment centers, we will not be able to generate significant revenues, which would compromise our ability to become profitable. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Even if we are able to commercialize our current or future product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government health administration authorities, private health insurers and other organizations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Third-party payors determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefit and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if coverage is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain regulatory approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain regulatory approval. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Recently enacted and future legislation, including potentially unfavorable pricing regulations may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our current or future product candidates and affect the prices we may obtain. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our current or future product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. In the United States, the European Union, United Kingdom and other potentially significant markets for our current and future product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.  Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain international jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Affordable Care Act, or ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Recent changes in the U.S. administration could lead to repeal of or changes in some or all of the ACA, and complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be difficult to predict its full impact and influence on our business.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and will remain in effect through 2025 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the demand for our product candidates, if we obtain regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our ability to receive or set a price that we believe is fair for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the level of taxes that we are required to pay; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the availability of capital.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Price controls may be imposed in foreign markets, which may adversely affect our future profitability. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Healthcare Compliance Regulations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.  If we or they are unable to comply with these provisions, we may become subject to civil and criminal investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with healthcare providers, healthcare entities, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, develop and will market, sell and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following: </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the federal healthcare Anti-Kickback Statute which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">federal civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws, which impose criminal and civil penalties, and can be enforced through civil whistleblower or qui tam actions, prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information on entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, and their respective business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable health information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the federal physician sunshine requirements under the Affordable Care Act which requires certain manufacturers of drugs, devices, biologics and medical supplies, with certain exceptions, to report annually to HHS information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">and other healthcare providers and their immediate family members and applicable group purchasing organizations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; certain state and local laws which require the registration of pharmaceutical sales representatives; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Many of the regulatory provisions that we are subject to include criminal provisions. If we are unable to comply with these provisions in the operation of our business we may become subject to civil and criminal investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Qui tam lawsuit filed under the False Claims Act can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;relators&#8221; or &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of health care companies to have to defend such qui tam actions and pay substantial sums to settle such actions. A qui tam action had been filed against us and others as described in the settlement agreement with DOJ and USAO NJ. As set forth in that settlement agreement, for a release of all claims against us and our officers and directors and dismissal with prejudice of the qui tam lawsuit, the relator received a portion of the $7.551 million payment to the federal government. As a result of the payment of the settlement amount, the federal government and the relator will dismiss with prejudice their claims against us in the qui tam lawsuit. In a separate settlement agreement, we paid $0.30 million in cash to the relator&#8217;s counsel for the statutory mandated attorney&#8217;s fees. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid programs. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti- Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only Medicare and Medicaid programs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims acts to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws including qui tam provisions. The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosures. Manufacturers must also disclose investment interests held by physicians and their family members.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the United States, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states such as Massachusetts and Vermont imposed an outright ban on certain gifts to physicians. These laws could affect our product promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and gift bans also will impose administrative, cost and compliance burdens on us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and integrity oversight and reporting obligations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have been involved in multiple legal and governmental proceedings, and may in the future be involved in proceedings, relating to the commercial activities of our predecessor that could adversely affect our financial condition and our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our predecessor company, Galena, was involved in multiple legal and governmental proceedings, including stockholder class actions, both state and federal, some of which are ongoing. These legal and governmental actions, which we refer to as the Galena Legacy Matters, included allegations relating to federal securities law violations, claims under the False Claims Act and Anti-Kickback Statute, claims regarding breaches of contract, and other stockholder allegations, including claims of breaches of fiduciary duty by our former directors, and fentanyl related litigation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In December 2015, we announced we had received a subpoena from the U.S. Attorney&#8217;s Office for the District of New Jersey, or the USAO NJ, requesting the production of a broad range of documents pertaining to marketing and promotional practices related to Abstral, a fentanyl or synthetic opioid product, that we sold to Sentynl Therapeutics Inc., or Sentynl, in November 2015. In January 2016, we announced that the U.S. Attorney&#8217;s Office of New Jersey, of USAO NJ and the Department of Justice, or DOJ, were conducting a criminal and civil investigation of us, which came to involve criminal investigations with respect to possibly one or more then-current and/or former employees. On September 8, 2017, the DOJ announced a civil settlement agreement with our company regarding certain of the marketing and promotional practices at issue in the USAO NJ and DOJ&#8217;s investigation. The settlement involved a civil resolution agreement and a civil payment of approximately $7.551 million, plus interest accrued since the date of reaching an agreement in principle in return for a release of federal government claims against our company in connection with the covered conduct in investigation. The civil payment was fully paid by us on or about December 29, 2017. The settlement did not include releases of criminal claims by the USAO NJ and DOJ or claims by state agencies or administrative claims by the Department of Health and Human Services, or HHS, but each of these government authorities indicated that they had no present intention to pursue claims in connection with the investigation. A qui tam action had been filed against us and others as described in our settlement agreement with DOJ and USAO NJ. As set forth in that settlement agreement, for a release of all claims against us and our former officers and directors and dismissal with prejudice of the qui tam lawsuit, the relator received a portion of the $7.551 million payment to the federal government. As a result of the payment of the settlement amount, the federal government and the relator filed a stipulation of dismissal with prejudice as to their claims against us in the qui tam lawsuit. In a separate settlement agreement, we paid $0.3 million in cash to the relator&#8217;s counsel for the statutorily mandated attorney&#8217;s fees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York, or USAO SDNY, in February 2018, seeking documents related to specific prescribing physicians for Abstral who have been subsequently indicted, to which we responded. To our knowledge, we are not a target or subject of that investigation and have had no further interaction with the USAO SDNY with regard to the matter after responding to the subpoena.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation led by the U.S. Attorney&#8217;s Office for the Southern District of Alabama, or the SDAL, of two of the high-prescribing physicians for Abstral (fentanyl) sublingual tablets resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between us and the defendant physicians&#8217; pharmacy as well as their ownership of our common stock. The criminal trial, which began on January 4, 2017, concluded with a jury verdict on February 23, 2017 finding these physicians guilty on 19 of 20 counts. In May 2017, one physician was sentenced to 20 years in prison, and the other physician was sentenced to 21 years in prison. At the end of the SDAL case, SDAL dismissed count 18 of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. To our knowledge, we were not a target or subject of that investigation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There continues to be significant litigation and governmental activity generally in the fentanyl and opioid area, and this activity is expected to continue and may increase in the future. We cannot assure you we will not become subject to additional significant legal or governmental proceedings relating to Galena&#8217;s former Abstral business in the future. Moreover, in addition to these ongoing and prior matters, we may be exposed to claims, or other legal or governmental actions in the future relating to violations of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or Affordable Care Act, or any other applicable state or federal statutes or regulations, and thereby be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There can be no assurance that we will not be exposed to other liabilities or risks, including potential liabilities and risks not currently known to us, resulting from the prior operations of Galena. We can make no assurances as to the time or resources that will need to be devoted to the Galena Legacy Matters, or any new or future matters resulting from the prior operations of Galena or their outcome, or the impact, if any, that these matters or any resulting legal or governmental proceedings may have on our business or financial condition but any further action in respect of any such matter by a governmental agency could have a material adverse effect on our results of operation and our business and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We face an inherent risk of product liability exposure related to the testing of our current or future product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">decreased demand for any product candidates or products that we may develop; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">termination of clinical trial sites or entire clinical trial programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">injury to our reputation and significant negative media attention; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">withdrawal of clinical trial participants; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">significant costs to defend the related litigation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">substantial monetary awards to trial subjects or patients; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">loss of revenue; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">diversion of management and scientific resources from our business operations; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the inability to commercialize any products that we may develop. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We face product liability exposure from prior sales of Abstral and Zuplenz (ondansetron) and, if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Because we previously sold Abstral and Zuplenz (ondansetron), an anti-emetic, oral soluble film for chemotherapy-induced nausea we are exposed to possible product liability claims.  In November 2015, Galena sold the rights to Abstral to Sentynl, and in December 2015, Galena sold the rights to Zuplenz to Midatech Pharma, PLC, or Midatech. Under the respective asset purchase agreements with Sentynl and Midatech, our future obligations under our former agreements with Orexo AB and MonoSol Rx have been assumed by Sentynl and Midatech, respectively, except that we will continue to be responsible for chargebacks, rebates, patient assistance and certain other product distribution channel liabilities related to Abstral and Zuplenz for a specified period of time post-closing. We are also required to indemnify Sentynl and Midatech for contractual or product liability claims arising from actions occurring prior to the sale date. With respect to Zuplenz, we will continue to be responsible for any downstream returns from end user customers or returns from wholesalers from inventory existing as of December 24, 2015 that was sold by us prior to December 24, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We do not consider our responsibilities with regard to Sentynl and Midatech to be material, but if substantial unknown liabilities were to arise, it could have a material adverse effect on our financial condition. If we cannot successfully defend ourselves against product liability claims we could incur substantial liabilities, regardless of merit or eventual outcome. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a material adverse effect on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to our Business Operations </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reports, which would harm our business, the trading price of our common stock and our ability to raise additional capital in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of Common Stock, and which could impact our ability to raise capital in the future. In addition, any future testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&#8220;SOX&#8221;), or any required subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are required, pursuant to Section 404 of SOX, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting as of December 31, 2018. However, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. Under the supervision and with the participation of our Chief Executive Officer and Vice President - Finance our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the guidelines in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2018. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions for our current product candidates. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. Competition could result in reduced sales and pricing pressure on our current or future product candidates, if approved, which in turn would reduce our ability to generate meaningful revenues and have a negative impact on our results of operations. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before we do and impair our ability to commercialize our product candidates. The biotechnology industry, including the cancer immunotherapy market, is intensely competitive and involves a high degree of risk. We compete with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the United States and worldwide are numerous and include pharmaceutical and biotechnology companies, educational institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than ours. Some of our competitors may develop and commercialize products that compete directly with those incorporating our technology or may introduce products to market earlier than our products or on a more cost-effective basis. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our technology. Our company and our collaborators may face competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including the potentially dominant patent positions of others. An inability to successfully complete our product development or commercializing those product candidates could result in our having limited prospects for establishing market share or generating revenue from our technology. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There are several agents in clinical development in similar settings to our planned Phase 3 AML clinical development program for GPS. The most advanced of these products is oral Vidaza (azacytidine) (also known as CC-486), under development by Celgene Corporation, which is anticipated to report results from a registration-enabling Phase 3 study (named the QUAZAR or CC-486-AML-001 study) by the end of 2019. There are several of other investigational immunotherapies advancing through Phase 2 and Phase 3 trials for target indications that we believe are also potential target indications for GPS. If these or other therapies are successful in their development, it could negatively impact our ability to enroll our clinical trials and could negatively impact the commercial potential of GPS.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are also planning a clinical development program in combination with cancer checkpoint inhibitors. This is a highly competitive field, with hundreds of such combination trials with various checkpoint inhibitors ongoing. If one or more of these combinations produce positive results in indications that we believe are targets for GPS (either in combination or in stand-alone administration) this could increase the difficulty for us to conduct our trials and could negatively impact our path to regulatory approval and our ability to successfully commercialize our products. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Many of our competitors or potential competitors have significantly greater established presence in the market, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or potentially advantageous to our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As a result of these factors, these competitors may obtain regulatory approval of their products before we are able to obtain patent protection or other intellectual property rights, which will limit our ability to develop or commercialize our current or future product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and cheaper than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover the expenses of development and commercialization. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We enter into various contracts in the normal course of our business in which we may be required to indemnify the other party to the contract under certain specific scenarios. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreement. With respect to our collaboration agreements, we indemnify our collaborators from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we indemnify them from claims arising from the good faith performance of their services. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Should our obligations under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage for any claim, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage for the claim or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Significant disruptions of information technology systems, computer system failures or breaches of information security could adversely affect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property). We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicious attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our internal computer systems, and those of MSK, our CROs, our CMOs, and other business vendors on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our current and future product candidates could be delayed and our business could be otherwise adversely affected. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We will likely need to grow the size of our organization in the future, and we may experience difficulties in managing this growth. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2018, we had eight full-time employees. Depending on the outcome of our review of our strategic alternatives, we may need to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. As our development and commercialization plans and strategies continue to develop, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources may increase. Our management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including: &#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">managing our clinical trials effectively; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">identifying, recruiting, maintaining, motivating and integrating additional employees; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">improving our managerial, development, operational, information technology, and finance systems; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">expanding our facilities. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively, as well as our ability to develop a sales and marketing force when appropriate for our company. To that end, we must be able to manage our development efforts and preclinical studies and clinical trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. The failure to accomplish any of these tasks could prevent us from successfully growing our company. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain qualified board members. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these rules and regulations has increased, and will likely continue to increase, our legal and financial compliance costs, make some activities more difficult, time-consuming or costly, and place significant strain on our personnel, systems and resources. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time. This could result in continuing uncertainty regarding compliance matters, higher administrative expenses and a diversion of management&#8217;s time and attention. Further, if our compliance efforts differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. Being a public company that is subject to these rules and regulations also makes it more expensive for us to obtain and retain director and officer liability insurance, and we may in the future be required to accept reduced coverage or incur substantially higher costs to obtain or retain adequate coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors and qualified executive officers. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have in the past, and may in the future, become involved in securities class action litigation that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the past, securities class action or stockholder derivative litigation often follows certain significant business transactions, such as the sale of a business division or announcement of a merger. Additionally, securities class action or stockholder derivative litigation has become common in our industry following the announcement of negative data or adverse events. We have in the past, and may in the future, become involved in this type of litigation. Litigation often is expensive and diverts management&#8217;s attention and resources, which could adversely affect the continuing company&#8217;s business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are highly dependent upon our personnel, including Dr.&#160;Angelos&#160;M. Stergiou (M.D., Sc.D. h.c.), our President and Chief Executive Officer, and member of our board of directors. Our employment agreement with Dr.&#160;Stergiou does not prevent him from terminating his employment with us at any time. The loss of Dr.&#160;Stergiou&#8217;s services could impede the achievement of our research, development and commercialization objectives. We have not obtained, do not own, nor are we the beneficiary of, key-person life insurance. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Governance changes, becoming subject to enhanced regulatory requirements and increased responsibilities associated with becoming a public company may influence our management personnel and our employees to terminate their employment with us. To enhance our ability to retain our executive management personnel, we have entered into retention agreements with certain executive officers and may find it beneficial to enter into additional retention agreements with other key personnel in the future, potentially increasing payroll and operating expenses. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees. The loss of any member of our senior management team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm our operating results. Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If we and our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from us or our third-party manufacturers&#8217; use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although we maintain workers&#8217; compensation insurance to cover the costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials with a policy limit that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Risks Relating to Ownership of Our Common Stock </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We need to secure additional capital which may cause dilution to you and our existing stockholders, provide subsequent investors with rights and preference that are senior to yours, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We will need to raise additional capital in the future. If we raise funds through the issuance of debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise funds through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute our stockholders and, similar to some of our past financings, may contain terms that could result in additional further significant dilution in the future. Debt financing, if available, could include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures, entering into licensing arrangements, or declaring dividends, and may require us to grant security interests in our assets, including our intellectual property and for our subsidiaries to guarantee our obligations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The market price and trading volume of shares of our common stock may be volatile. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The market price of shares of our common stock has exhibited substantial volatility recently. Between January&#160;2, 2018 and December 31, 2018, the trading price of shares of our common stock as reported on Nasdaq ranged from a low of $0.80 to a high of $11.09. The market price of shares of our common stock could continue to fluctuate significantly for many reasons, including the following factors: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of regulatory developments or technological innovations by us or our competitors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of business or strategic transactions or our success in finalizing such a transaction; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of legal or regulatory actions against us or any adverse outcome of any such actions; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">changes in our relationships with our licensors, licensees and other strategic partners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">low volume in the number of shares of our common stock traded on Nasdaq;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our quarterly operating results; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of dilutive financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">announcements of additional potential reverse stock split; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">developments in patent or other technology ownership rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">government regulation of drug pricing; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Factors beyond our control may also have an impact on the market price of shares of our common stock. For example, to the extent that other companies within our industry experience declines in their stock prices, the market price of shares of our common stock may decline as well. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Future sales in the public market of shares of our common stock, including shares referred to in the foregoing risk factors or shares issued upon exercise of our outstanding stock options or warrants, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December&#160;31, 2018, we had reserved for issuance 394,321 shares of our common stock issuable upon the exercise of outstanding stock options at a weighted-average exercise price of $37.09 per share, 12,759 shares of our common stock issuable upon settlement of outstanding RSUs, and 17,698,061 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $5.47 per share. We also issued $1,250,000 of shares of our common stock as a settlement payment. Upon exercise or conversion, the underlying shares, similar to those issued as the settlement payment, may be resold into the public market. In the case of outstanding securities that have exercise or conversion prices that are below the market price of our common stock from time to time, our stockholders would experience dilution upon the exercise or conversion of these securities. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certain of our securityholders have registration rights and they can require us, subject to certain limitations, to register their securities for resale, or require us to include their securities for resale in any offering of our common stock we may propose. Any such resales into the public market could place downward pressure on the price of our common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have issued and may in the future issue additional preferred stock, and the terms of such preferred stock may reduce the value of our common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are authorized to issue up to five&#160;million shares of preferred stock in one or more series. Our Board of Directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue shares of preferred stock, it could affect stockholder rights or reduce the market value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and provisions of Delaware law could delay or prevent a change of control. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Anti-takeover provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws may discourage, delay or prevent a merger or other change of control that stockholders may consider favorable or may impede the ability of the holders of our common stock to change our management and may be constrained by other contractual agreements with third parties. These provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws, among other things: &#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">divide our Board of Directors into three classes, with members of each class to be elected for staggered three-year terms; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">limit the right of securityholders to remove directors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">prohibit stockholders from acting by written consent; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">authorize our Board to issue preferred stock in one or more series, without stockholder approval. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, Section&#160;203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire, or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation shall not engage in any business combination with that corporation, including by merger, consolidation or acquisitions of additional shares for a three-year period following the date on which that person or our affiliate crosses the 15% stock ownership threshold. Section&#160;203 could operate to delay or prevent a change of control of us. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">If our common stock becomes subject to the penny stock rules, it may be more difficult to sell our common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system). The OTC Bulletin Board does not meet such requirements and if the price of our common stock is less than $5.00 and our common stock is no longer listed on a national securities exchange such as Nasdaq, our stock may be deemed a penny stock. The penny stock rules require a broker-dealer, at least two business days prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver to the customer a standardized risk disclosure document containing specified information and to obtain from the customer a signed and date acknowledgment of receipt of that document. In addition, the penny stock rules require that prior to effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive: (i)&#160;the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&#160;a written agreement to transactions involving penny stocks; and (iii)&#160;a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have never declared or paid cash dividends on our common stock and we do not anticipate paying cash dividends on our common stock in the foreseeable future. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our business requires significant funding. We currently plan to invest all available funds and future earnings in the development and growth of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future and are prohibited by the terms of our outstanding indebtedness from paying dividends on any common stock, except with the prior consent of our lenders. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of potential gain for the foreseeable future. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sed06ef676db44a169b79060feda38621"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3a89d76d794e4dc39cdef242b3145f95"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;2. PROPERTIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We lease our headquarters in New York, New York. The lease covers approximately 3,700 square feet of office space and expires in July 2020. Our monthly rent is $31,000 per month, which includes basic services. Our monthly rent increases to $32,000 per month on August 1, 2019 through July 2020. We believe that our facility is adequate for our current needs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><a name="s57ff62bf763747f1b49d4d0f03318d2d"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;3. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our predecessor company, Galena was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which we are now subject as a result of the Merger. They are as follows: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;On February 13, 2017, putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral&#174; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the Court and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint and on December 21, 2018, Plaintiffs filed their opposition to the motion to dismiss. On January 18, 2019, the Company filed a reply in support of its motion.  The Company&#8217;s motion to dismiss the amended complaint is currently pending in the U.S. District Court for the District of New Jersey.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in U.S. District Court for the Northern District of California against the Company&#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018 refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On October 29, 2018, the defendants in the August 2018 lawsuit notified the plaintiff of their intent to file a motion to dismiss the lawsuit.  On November 15, 2018, the defendants in the August 2018 lawsuit filed a motion to dismiss the complaint.  On December 17, 2018, the plaintiff filed an amended complaint.  The defendants filed a motion to dismiss the amended complaint on January 31, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 13, 2016, we filed a complaint in the Circuit Court for the County of Multnomah for the State of Oregon against Aon Risk Insurance Services West, Inc.&#160;as described in Note 10 in the Notes to Consolidated Financial Statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sb47006b139e04d2f9e215a59ac34af2d"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;4. MINE SAFETY DISCLOSURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><a name="s5A481966FEACA53965CB80682515D1C6"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s924e5131bbf04ce2aabb57fc2a1bab75"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our common stock is listed on The NASDAQ Capital Market under the symbol SLS. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Holders</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of February 28, 2019, there were approximately 118 holders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of individual stockholders represented by these holders of record.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Dividends</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During 2018, we paid $0.5 million in cash dividends to the holders of our Series A Convertible Preferred stock issued in our March 2018 private placement. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We expect to retain future earnings, if any, for use in our development activities and the operation of our business. The payment of any future dividends will be subject to the discretion of our Board of Directors and will depend, among other things, upon our results of operations, financial condition, cash requirements, prospects and other factors that our board of directors may deem relevant. Additionally, our ability to pay future dividends may be restricted by the terms of any debt financing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the period covered by this annual report, there were no sales by us of unregistered securities that were not previously reported by us in a Quarterly Report on Form 10-Q or Current Report on Form 8-K. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Purchases of Equity Securities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the year ended December 31, 2018, we did not purchase any of our equity securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sde531ded542f4a4a9adc04a67ba5b6c9"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 6. SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><a name="s0117FBEBE1CD0F914552806829D534F2"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">You should read the following discussion in conjunction with the consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this annual report on Form&#160;10-K.&#160;This discussion contains forward-looking statements within the meaning of federal securities laws. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contained in such forward-looking statements, including those discussed in the section &#8220;Risk Factors&#8221; in Part I &#8212; Item&#160;1A of this annual report on Form&#160;10-K.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Please see Part I, Item 1 &#8220;Business&#8212; Strategic Collaboration and License Agreements&#8221; and Note 6 to our audited consolidated financial statements appearing elsewhere in this annual report on Form&#160;10-K&#160;for more information relating to such arrangements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sd70aebf6713643c2bd548c168f1752b6"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 6, 2019, we entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to 3,800,000 of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of $1.10 per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately 3,800,000 shares of common stock at an exercise price of $1.40 per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately 1.2 million warrants for gross proceeds of $1.3 million and approximately 1.2 million New Warrants were issued. Under the terms of the Warrant Exchange Agreement, we may receive aggregate gross proceeds of up to approximately $4.2 million from the cash exercise if all of the warrants under the Exercise Agreement are exercised.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2019, we engaged Cantor Fitzgerald &amp; Co. as a financial advisor to explore a wide range of strategic alternatives, with the ultimate objective being an outcome that is in the best interest of our shareholders.  Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment/financing or a funded collaboration or partnership. To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, we consummated an underwritten public offering of 6,845,000 shares of common stock and 4,675,000 pre-funded warrants exercisable for shares of common stock, and accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. At closing, we received aggregate net proceeds from the offering of approximately $21.6 million, after deducting underwriting discounts and commissions and offering expenses.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, following the consummation of the underwritten public offering, the holders of our shares of Series A convertible preferred stock exchanged an aggregate of $7,871,186 of stated value and accrued but unpaid dividends on their shares for an aggregate of 3,748,184 shares of our common stock and warrants to purchase an aggregate of 3,748,184 shares of our common stock. As a result of such exchange, there are no longer any shares of Series A convertible preferred stock issued and outstanding. The warrants have an exercise price of $2.10 per share and a term of five years. In addition, pursuant to certain anti-dilution provisions included in warrants issued to the holders of our Series A convertible preferred stock in March and May 2018, or PIPE warrants, the exercise price of the PIPE Warrants was automatically adjusted to $2.10 per share from the original exercise price of $6.59 per share.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:41px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 5, 2018, we entered into a settlement agreement with JGB (Cayman) Newton, Ltd., or JGB, regarding our counterclaims against JGB that were asserted in the litigation originally commenced by JGB in April 2018.  As part of the settlement, JGB paid us approximately $6.6 million in exchange for a full discharge of all counterclaims asserted by us against JGB in the litigation. We and JGB also agreed to terminate the senior secured debenture agreement and all related agreements, and JGB released all of its interests in the collateral for the senior secured debenture. See Note 8 to the consolidated financial statements for a description of the litigation and settlement agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:41px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s11877A5E3FE0EC4F6DE5806829F44CCA"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Galinpepimut-S, or GPS</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our lead product candidate, galinpepimut-S, or GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2018, following discussions with the U.S. Food and Drug Administration, or FDA, regarding a clinical trial design and biostatistical plan, we commenced preparations for a Phase 3 trial for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of their second complete remission, or CRem2, following successful completion of second-line antileukemic therapy. This trial is expected to serve as the basis for a Biologics License Application, or BLA, submission, subject to positive results. We are currently ready to start this Phase 3 trial, pending receipt of sufficient funding. We plan to enroll approximately 116 patients at approximately 50 clinical sites in the United States and Europe and is contemplated to have a planned interim safety and futility analysis after 80 events (deaths). </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In December 2018, we initiated a Phase 1/2 multi-arm (&#8216;basket&#8217; type) clinical study of GPS in combination with Merck &amp; Co., Inc.&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab).  We plan to enroll approximately 90 patients at up to 20 centers in the United States. The initial tumor types to be treated will be AML (in patients having achieved partial response as their best hematological response after four cycles of therapy with hypomethylating agents), and ovarian cancer (second or third line), to be followed by triple negative breast cancer, or TNBC, (second line), small cell lung cancer, or SCLC (second line), and colorectal cancer (third or fourth line). </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GPS was granted Orphan Drug Product Designations from the FDA as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, malignant pleural mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Nelipepimut-S or NPS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Nelipepimut-S, or NPS, is a cancer immunotherapy targeting the human epidermal growth factor receptor, or HER2, expressing cancers. In 2018 we presented data from our Phase 2b study of the combination of trastuzumab plus NPS in HER 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that showed a clinically and statistically significant improvement in the DFS rate for the TNBC cohort at 24 months for patients treated with NPS plus trastuzumab of 92.6% compared to 70.2% for those treated with trastuzumab alone. In October 2018, the DSMB, unanimously concluded that the final analysis of the Phase 2b study data, with a median follow-up of 26 months, confirmed that TNBC patients should be the key target population for the development of trastuzumab plus NPS in the adjuvant setting in early-stage HER2 1+/2+ breast cancer patients.  We are having ongoing discussions with the FDA to define an optimal path for further development of the combination of NPS plus trastuzumab in TNBC and expect to complete these discussions in the first half of 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">FBP-targeting bivalent vaccine (GALE-301/-302)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE 302 are cancer immunotherapies that target the E39 peptide derived from the folate binding protein, or FBP. In a Phase 1/2a investigator sponsored trial, or IST, assessing GALE-301 in ovarian and endometrial cancers, we observed a clinically meaningful improvement in the 24-month rate of disease-free survival. We are evaluating GALE-301/302 for potential internal development, strategic partnership, or other type of product candidate rationalization. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Financial Position</font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At December&#160;31, 2018, we had cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. We have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable operations. We incurred net losses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the years ended December&#160;31, 2018 and 2017, respectively. Our accumulated deficit as of December&#160;31, 2018 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$81.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and we expect to continue to incur substantial losses in future periods. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our operating expenses will increase substantially as we continue to advance our product candidates assuming we receive sufficient funding to continue our ongoing studies and initiate our planned studies. We anticipate that our expenses will increase as we: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">complete our Phase 2 clinical trials and initiate our Phase 3 clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">continue the research, development and scale-up manufacturing capabilities to optimize products and dose forms for which we may obtain regulatory approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">maintain, expand and protect our global intellectual property portfolio; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">hire additional clinical, manufacturing, and scientific personnel; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">add, acquire of develop operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts. </font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of product candidates. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect that our existing cash as of December&#160;31, 2018, together with the gross proceeds of up to $4.2 million we may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable us to fund our operating expenses through June 2019</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, we will need to raise additional capital earlier than anticipated to fund our operations.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Collaboration and License Agreements </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although we currently have a number of collaborations with corporate partners for the development of our products in various territories worldwide, the following collaborations and license agreements are those that are most significant to us from a financial statement perspective and where significant ongoing collaboration activity exists. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Memorial Sloan Kettering Cancer Center </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In September 2014, we entered into a license agreement with MSK, under which we were granted an exclusive license to develop and commercialize MSK&#8217;s WT1 peptide vaccine technology. The MSK original license agreement was first amended in October 2015, further amended in August 2016, amended and restated in May 2017 and further amended and restated in October 2017. In connection with the entry of the original license agreement and its amendments, MSK was issued or assigned an aggregate of 4,846 ordinary shares of common stock of the privately held Bermuda exempted company, Sellas Life Sciences Group Ltd., or Private SELLAS, during the year ended December 31, 2017. These shares of common stock were converted into shares of our common stock upon the merger by and among Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS, or the Merger.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the terms of the current amended and restated MSK license agreement, we agreed to pay minimum royalty payments in the amount of $0.1&#160;million each year commencing in 2015 and research funding costs of $0.2&#160;million in each year and for three years commencing in January 2016. We also agreed to pay MSK a mid-six digit amount over a one year period in exchange for MSK&#8217;s agreement to further amend and restate the MSK license agreement in October 2017. In addition, to the extent certain development and commercial milestones are achieved, we also agreed to pay MSK up to $17.4&#160;million in aggregate milestone payments for each licensed product, and for each additional patent licensed product, up to $2.8&#160;million in additional milestone payments. We also agreed to pay MSK a tiered royalty in the mid-single digits in the event of commercial sales of any licensed products and agreed to raise $25.0&#160;million in gross proceeds no later than December&#160;31, 2018. We raised this amount from the proceeds received from the sale of our Series A Convertible Preferred stock in March 2018 and our underwritten public offering of shares of common stock, pre-funded warrants to purchase shares of common-stock, and warrants to purchase shares of common stock in July 2018. Under the terms of the agreement, we achieved a clinical development milestone the end of the fourth quarter of 2018 triggering a $0.5 million payment in the first quarter of the 2019. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unless terminated earlier in accordance with its terms, the MSK license agreement, as amended and restated, will continue on a country-by-country and licensed product-by-licensed product basis, until the later of: (a)&#160;expiration of the last valid claim embracing such licensed product; (b)&#160;expiration of any market exclusivity period granted by law with respect to such licensed product; or (c)&#160;ten (10) years from the first commercial sale in such country. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with MSK, please read Note 6,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;Collaborative and License Agreements,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Merck &amp; Co., Inc. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In September 2017, we entered into a clinical trial collaboration and supply agreement through a Merck &amp; Co. ("Merck") subsidiary, whereby we agreed with the Merck subsidiary to collaborate on a research program to evaluate GPS as it is administered in combination with Merck's PD1 blocker pembrolizumab (Keytruda) in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab in patients with WT1+ relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: AML, ovarian, triple-negative breast, small cell lung, and colorectal. This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pembrolizumab alone in comparable patient populations. This trial was initiated in December 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Advaxis, Inc. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2017, we entered into a research and development collaboration agreement with Advaxis, Inc. whereby we agreed to collaborate in a research program to evaluate, through a &#8220;proof of principle," or PoP, trial, a clinical candidate comprised of the combination of Advaxis&#8217; proprietary Lm-based antigen delivery technology and GPS, our WT1 peptide. Unless terminated earlier in accordance with its terms, the Advaxis agreement will expire upon the earlier of: (a)&#160;completion of the PoP trial, (b)&#160;a decision by the parties to cease further development of the clinical candidate or (c)&#160;early termination pursuant to the terms of the Advaxis agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and filing any IND, cost-sharing for preparation of the IND, and us being responsible for the costs (exclusive of product costs) of conducting the PoP trial. We also agreed to make certain non-refundable milestone payments to Advaxis having an aggregate amount of up to $108.0&#160;million, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain targets, we agreed to make non-refundable milestone payments of up to $250.0&#160;million and royalty payments based on specified royalty rates, with a maximum rate capped at a percentage rate in the low double digits if net sales exceed $1.0&#160;billion. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In conjunction with the Merger and the acquisition of NPS, we acquired rights and assumed obligations under a license agreement among Apthera, Inc., our wholly owned subsidiary, the University of Texas M.D. Anderson Cancer Center, or MDACC, and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., or HJF, which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the license agreement we agreed to pay MDACC and HJF up to $3.8 million in aggregate milestone payments to the extent certain development and commercial milestones are reached and a $0.2 million annual maintenance fee. We also agreed to pay MDACC and HJF a tiered royalty in the mid-single digits in the event of commercial sales of any licensed product.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Components of Results of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">manufacturing expenses; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">outsourced professional scientific development services; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">employee-related expenses, which include salaries, benefits and stock-based compensation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">payments made under our license agreements agreement, under which we acquired certain intellectual property; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">expenses relating to certain regulatory activities, including filing fees paid to regulatory agencies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">laboratory materials and supplies used to support our research activities; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">allocated expenses, utilities and other facility-related costs. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The successful development of our current and future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any current or future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of our clinical trials, which vary significantly over the life of a project as a result of many factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the number of clinical sites included in the trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the length of time required to enroll suitable patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the number of patients that ultimately participate in the trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the number of doses patients receive; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the duration of patient follow-up; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the results of clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the expenses associated with manufacturing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the receipt of marketing approvals; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the commercialization of current and future product candidates. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Cancer immunotherapy product commercialization may take several years and millions of dollars in development costs. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development activities are central to our business model. Cancer immunotherapy product candidates in the later stages of clinical development generally have higher development costs than those in the earlier stages of clinical development, primarily due to the increased size and duration of the later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we initiate additional and late stage clinical trials and as our research and development relate personnel costs increase, including stock-based compensation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative Expense </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include facility related costs, patent filing and prosecution costs, professional fees for business development, accounting, consulting, legal and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC reporting requirements, investor relations costs, and director and officer insurance premiums associated with being a public company.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We anticipate that our general and administrative expenses will decrease as we focus on managing outside service providers in order to preserve capital as we explore strategic alternatives. If and when we believe that regulatory approval of a product candidate appears likely, we anticipate that an increase in payroll and expenses will occur as a result of our preparation for commercial operations, particularly as it relates to the sales and marketing of such product candidate. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">In Process Research and Development Impairment Charge</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">This charge relates to the impairment charge recognized in connection with the abandonment of our GALE-401 IPR&amp;D asset.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Severance Costs Related to the Merger</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance costs include employee-related costs associated with severance payments to certain former Galena employees which were incurred in connection with the Merger.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense), net consists of changes in fair value of our warrant liability, changes in fair value of our contingent consideration, loss on settlement of liability-classified warrants, and interest expense, net.  Interest expense, net primarily reflects interest expense incurred on our convertible term notes and other loans held with current and former stockholders, offset by the interest earned from our cash and cash equivalents.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><a name="sEE4F71F1CCDA90EFC92580681D2C9960"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Results of Operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Years Ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;and 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our results of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">years ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(dollars in thousands)</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,767</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,067</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development impairment charge</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance costs related to Merger</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses and operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(31,089</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,050</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(29,048</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,501</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,547</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax expense (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(27,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, our net loss was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net loss was primarily attributable to an increase in operating loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, primarily driven by a one-time non-cash charge of $9.6 million for impairment of in-process research and development, partially offset by an increase in non-operating income of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and an increase in income tax benefit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Further analysis of the changes and trends in our operating results are discussed below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. As compared to the prior period, research and development expenses experienced a $1.4 million increase in clinical and regulatory consulting, a $1.0 million increase in licensing fees, and a $1.4 million increase in clinical expenses driven by startup costs related to the Phase 1/2 basket trial of GPS in combination with pembrolizumab (Keytruda</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">in multiple tumor types during 2018, and ongoing costs incurred related to the Phase 2b trial of NPS in combination with trastuzumab (Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">). These increases were partially offset by a $0.8 million decrease in compensation and benefits, including stock-based compensation, a $0.2 million decrease in manufacturing expenses, and $0.3 million in other expenses. We anticipate that our research and development expenses will increase in the future as we continue to advance our product candidates into and through clinical trials, including the basket trial of GPS in combination with pembrolizumab and our Planned 3 trial of GPS in AML.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expenses were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The $2.3 million decrease was primarily driven by a decrease in compensation and employee benefits of $1.1 million, including stock-based compensation, and a $4.5 million decrease in banking and advisory fees that were incurred in 2017 related to the Merger.  These decreases were partially offset by a $1.2&#160;million increase in outside services and public company costs, a $1.2 million increase in insurance premiums, $0.4 million increase in rebates and returns of former commercial products, and a $0.5 million increase in other expenses. Such increases during 2018 are a result of an increase in accounting, consulting, and tax-related services associated with maintaining compliance with Nasdaq and SEC reporting requirements, investor relations costs, and director and officer insurance premiums associated with being a public company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Asset Impairment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2014, Galena, our predecessor-in-interest, acquired the worldwide rights to develop and commercialize anagrelide CR formulation (GALE-401) through its acquisition of Mills Pharmaceuticals, LLC, or Mills. The license agreement (&#8220;BVI Agreement&#8221;) for GALE-401 between Mills and BioVascular, Inc. (&#8220;BioVascular&#8221;) provides that Mills may terminate the BVI Agreement by providing 60 days written notice to BioVascular. On December 5, 2018, our Board of Directors approved the termination of the BVI Agreement and we, on behalf of Mills, provided written notice of such termination to BioVascular and confirmed that Mills will no longer support or pursue the filing, prosecution, or maintenance of any patent covered in the BVI Agreement. We previously disclosed that management had been evaluating GALE-401, among other items, for potential internal development, strategic partnership, or other types of product rationalizations and determined that further development of GALE-401 is outside of the scope of our core focus on cancer immunotherapy/cancer vaccine development. We recognized asset impairment expenses of approximately $9.6 million for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Included in the asset impairment expenses are a non-cash charge of approximately $9.1 million for impairment of intangible assets recorded as in-process research and development and an additional $0.5 million of milestone payments recorded as deposits and other assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Severance Costs related to Merger</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There were no severance costs related to the Merger for the year ended December 31, 2018. Severance costs incurred during the year ended December 31, 2017 include employee-related costs for severance of certain former Galena employees of approximately $1.9 million. The amount was paid by Galena prior to the consummation of the Merger and subsequently recognized as an expense by the combined company immediately following the closing of the Merger. Such termination resulted in contingent consideration being paid out in the form of severance based on change of control provisions in their employment agreements. Their employment agreements all required both a change of control and termination of employment, or a double trigger in connection with the payment of such severance amounts. Since there was a change of control as a result of the Merger and Galena terminated all employees prior to the closing, with both provisions of the double trigger were satisfied and the severance is treated as an action triggered by the accounting acquirer, Private SELLAS. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense), net for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">years ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,032</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,032</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on settlement of liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gain on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,041</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase in our net non-operating income (expense) during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily due to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gain arising from the decrease in the fair value of liability-classified warrants to acquire shares of our common stock and a $0.8 million gain on extinguishment of debt. The decrease in the estimated fair value of our warrant liability was primarily due to the decrease in our common stock price. The $0.8 million gain on extinguishment of debt relates to the settlement with JGB, the holder of our former senior secured debenture. As a result of the settlement, the $0.8 million of additional interest that was due at maturity was forgiven. See Note 10 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for a description of the litigation and settlement agreement.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These amounts were partially offset by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of the contingent consideration liability and a $0.7 million loss on settlement of liability-classified awards. The change in the estimated fair value of the contingent consideration during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reflects an adjusted probability and time-line for the potential approval of NPS associated with the positive interim data from the Phase 2b investigator-sponsored clinical trial of trastuzumab +/- NPS in HER2 1+/2+ breast cancer patients that was announced on April 2, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The $0.7 million loss on settlement of liability-classified warrants relates to warrants to acquire shares of common stock issued by Galena in February 2017 that were assumed in the Merger. During the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a total of 534,333 of the liability-classified warrants were canceled under various warrant exchange agreements, as further described herein. We issued 54,343 shares of our common stock in exchange for the surrender and cancellation of warrants to acquire 121,667 shares of our common stock and $1.0 million in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire 412,667 shares of our common stock, as described in Note 12 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. The fair value of the consideration exchanged which totaled approximately $1.3 million exceeded the fair value of the warrant liability of the canceled warrants by $0.7 million and is recorded as loss on settlement of liability-classified warrants in the consolidated statement of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">year ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">years ended December 31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017 primarily consists of interest expense incurred on our long-term debt, partially offset by nominal interest earned from our cash and cash equivalents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of warrant liability, changes in fair value of contingent consideration, the loss on settlement of liability-classified warrants, and the gain on extinguishment of debt are all non-cash in nature. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Income Tax Expense (Benefit)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the year ended December 31, 2018 we recognized an income tax benefit of $1.4 million primarily attributable to the intangible asset impairment charge. For the year ended December 31, 2017, we recognized income tax expense of $0.3 million.</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><a name="sE615940FE079D171CC4180682A68A69B"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not generated any revenue from product sales or collaboration and licensing agreements in the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017. Since inception, we have incurred net losses, used net cash from our operations, and have funded substantially all of our operations through proceeds from sale of debt and equity securities. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 6, 2019, we entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to 3,800,000 of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of $1.10 per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately 3,800,000 shares of common stock at an exercise price of $1.40 per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately 1.2 million warrants for gross proceeds of $1.3 million and approximately 1.2 million New Warrants were issued. Under the terms of the Warrant Exchange Agreement, we may receive aggregate gross proceeds of up to approximately $4.2 million from the cash exercise if all of the warrants under the Exercise Agreement are exercised.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, we completed an underwritten public offering, or the July 2018 Offering, pursuant to which we sold (i) 6,845,000 shares of common stock, (ii) 4,675,000 pre-funded warrants exercisable for shares of common stock and (iii) accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $2.10 per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of $2.0999 per pre-funded warrant and accompanying common stock warrant. Each common stock warrant sold with the shares of common stock represents the right to purchase one share of our common stock at an exercise price of $2.10 per share. The common stock warrants are exercisable immediately and will expire five years from the date of issuance, or on July 16, 2023. The pre-funded warrants are exercisable immediately, have an exercise price of $0.0001 per share, and will expire on July 16, 2023, five years from the date of issuance. The net proceeds to us from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately $21.6 million.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March&#160;7, 2018, we entered into a securities purchase agreement to issue an aggregate of 10,700 shares of Series A convertible preferred stock, and warrants to acquire 1,383,631 shares of our common stock in a private placement transaction to a select group of institutional investors. The sale of the Series A convertible preferred stock completed in two tranches and resulted in net proceeds to us, after deducting the underwriting discounts and commissions and other estimated offering expenses, of $9.6 million. We completed the first tranche for approximately $6.0 million gross proceeds on March&#160;9, 2018. We completed the second tranche of the remaining $4.7 million gross proceeds on May 1, 2018, following stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, in the first half of 2018, JGB redeemed $2.8 million of outstanding principal under that certain senior secured debenture that was satisfied with 659,529 shares of our common stock and redeemed $0.6 million of outstanding principal, which we satisfied in cash. As a result of the redemptions, we transferred $1.8 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund our ongoing operations. Pursuant to the terms of the settlement agreement in the JGB litigation described in Note 10 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, JGB made a one-time payment to the Company of $6.6 million in November 2018. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$81.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and restricted cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, we had accounts payable and accrued expenses and other current liabilities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. These matters raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of any current or future product candidates in development. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">This going concern assumption is based on management&#8217;s assessment of the sufficiency of our current and future sources of liquidity considering whether or not it is probable we will be able to meet our obligations as they become due for at least one year from the date our consolidated financial statements are available to be issued, and if not, whether our liquidation is imminent. Our management believes that our cash of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, together with the gross proceeds of up to $4.2 million we may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable us to fund our operating expenses through June 2019. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, we will need to raise additional capital earlier than anticipated to fund our operations.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We will require substantial additional financing to fund our operations thereafter and to commercially develop any current or future product candidates. Alternatively, we will be required to scale back our plans and place certain activities on hold. We currently do not have any commitments to obtain additional funds (other than in connection with the warrant exercise agreement) and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. In addition to evaluating strategic alternatives, our management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities, payments from potential strategic research and development collaborations, and licensing and/or marketing arrangements with pharmaceutical companies. Additionally, we continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to our late- and early-stage pipeline candidates. There can be no assurance that these future funding efforts will be successful. If we cannot obtain the necessary funding, we will need to delay, scale back or eliminate some or all of our research and development programs; consider other various strategic alternatives, including a merger or sale; or cease operations. However, at this stage our management does not believe liquidation is imminent. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2019, we engaged Cantor Fitzgerald &amp; Co. to explore a wide range of strategic alternatives to continue our business plan, with the ultimate objective being an outcome that is in the best interest of shareholders.  Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment into the Company, a sale, license or other disposition of corporate assets, a funded collaboration or partnership, or a financing which would allow the Company to continue with its current business plan of developing its development plans for its lead product candidates.  To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our future operations are highly dependent on a combination of factors, including (i)&#160;the timely and successful completion of additional financing or other strategic alternatives discussed above, (ii)&#160;our ability to complete revenue-generating partnerships with pharmaceutical companies, (iii)&#160;the success of our research and development activities, (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v)&#160;regulatory approval and market acceptance of our proposed future products. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our cash flows from operating, investing, and financing activities for the years ended December 31, 2018 and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(amounts in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Twelve Months Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(30,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,989</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Operating Activities</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily attributable to our net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This amount was offset by various net non-cash charges of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was comprised of a $9.1 million impairment of the Company's IPR&amp;D asset associated with the GALE-401 product candidate, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of our contingent consideration liability, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of common stock issued in connection with litigation settlements, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;loss on settlement of liability-classified warrants, and $0.4 million in non-cash stock-based compensation expense. These amounts were partially offset by a gain of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the decrease in the fair value of liability-classified warrants and a $0.8 million gain on extinguishment of debt. The net change in our operating assets and liabilities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;is primarily attributable to a decrease in our accounts payable and accrued expenses. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities of $11.0&#160;million during the year ended December&#160;31, 2017 was primarily attributable to our net loss of $23.8 million. This amount was offset by various&#160;non-cash&#160;charges of $6.7 million, which was comprised of&#160;non-cash interest, stock-based compensation, losses on extinguishment of debt and payables, the fair value of shares issued in exchange for research and development services and Merger related charges, among others. The net change in our operating assets and liabilities of $6.0 million is primarily attributable to the $8.4&#160;million increase in our accounts payable as we extend payables until we receive additional financing to be able to meet our obligations when they become due, offset by a $2.4 million decrease in accrued expenses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Investing Activities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash provided by investing activities was $1.8 million of unrestricted cash and cash equivalents and $10.4 million of restricted cash and cash equivalents for the year ended December 31, 2017, which was acquired as a result of the Merger. There were no such activities in 2018. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Financing Activities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of net cash from financing activities for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily attributable to $21.6 million in net proceeds from the sale of common stock and common stock warrants, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net proceeds from the sale of the Series A convertible preferred stock and warrants, partially offset by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in principal payments on our previously outstanding senior secured debenture. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of net cash from financing activities for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily attributable to $6.0 million in net proceeds from the sale of shares of our common stock, partially offset by $0.5 million in principal payments on long-term debt.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="s735453E2D77F2C5F65C280682A8D77FB"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We acquire product candidates still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the product candidate in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development life-cycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). We also typically have to make royalty payments based upon a percentage of the sales of the product candidate in the event that regulatory approval for marketing is obtained. Because of the contingent nature of these payments, they are not included in the table of contractual obligations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the event that multiple milestones are reached in the same period, the aggregate charge to expense could be material to the results of operations in any one period. In addition, these arrangements often give us the discretion to terminate development of the product candidate, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the product candidate successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2018, we had the following noncancelable contractual commitments:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Payments due by period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">1-3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">3-5 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Contractual obligations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating lease </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1) </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating lease obligations reflect our obligation to make payments in connection with our corporate headquarters in New York, NY.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not entered into any off-balance sheet financing arrangements other than operating leases as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. The preparation of our consolidated financial statements and related disclosures requires our management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. We base such estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">While our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing elsewhere in this annual report on Form10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Valuation of Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In conjunction with the Merger, we recorded intangible assets related to in-process research and development, or IPR&amp;D. We had total intangible assets of $8.5 million and $17.6 million as of December 31, 2018 and 2017, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The identifiable intangible assets are measured at their respective fair values as of the acquisition date and may be subject to revision within the measurement period, which may be up to one year from the acquisition date. The models used in valuing these intangible assets require the use of significant estimates and assumptions including but not limited to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">estimates of revenue and operating profits related to products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the probability of success for unapproved product candidates considering their stages of development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the time and resources needed to complete the development and approval of product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the life of the potential commercialized products and associated risks, including the inherent difficulties and uncertainties in developing a product candidate such as obtaining FDA and other regulatory approvals; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">risks related to the viability of and potential alternative treatments in any future target markets.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe the fair values used to record intangible assets acquired in connection with a business combination using information known and knowable and are based upon reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets related to IPR&amp;D are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. During the period the assets are considered indefinite-lived, they are not amortized but are tested for impairment on an annual basis as well as between annual tests if we become aware of any events or changes that would indicate that it is more likely than not that the fair value of the IPR&amp;D is below their respective carrying amounts. The fair value of our indefinite-lived intangible assets is dependent on assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions and changes to our assumptions could have a significant impact on our results of operations in any given period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets with finite useful lives are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. We have a single reporting unit and all goodwill relates to that reporting unit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We perform our annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by the FASB Accounting Standards Update No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&#8217;s goodwill is less than the carrying value of the reporting unit&#8217;s goodwill. We did not recognize any impairment of goodwill during the years ended December 31, 2018 and 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accrued Research and Development Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers require advance payments; however, some invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Vendors in connection with preclinical development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">the production of preclinical and clinical trial materials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">CROs in connection with clinical trials; and investigative sites in connection with clinical trials.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or prepaid accordingly. Although we do not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Valuation of Contingent Consideration</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Acquisitions may include contingent consideration payments based on the achievement of certain future financial performance measures of the acquired company (earnout). Contingent consideration is required to be recognized at fair value as of the acquisition date. We estimate the fair value of these liabilities based on financial projections of the acquired companies and estimated probabilities of achievement. We believe our estimates and assumptions are reasonable; however, there is significant judgment involved. We evaluate, on a routine, periodic basis, the estimated fair value of the contingent consideration and changes in estimated fair value, subsequent to the initial fair value estimate at the time of the acquisition, are reflected in income or expense in the consolidated statements of comprehensive loss. Changes in the fair value of contingent consideration obligations may result from changes in discount periods and rates, changes in the timing of development milestones achieved and changes in probability assumptions with respect to the likelihood of achieving the various earnout criteria. Any changes in the estimated fair value of contingent consideration may have a material impact on our operating results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We account for stock-based compensation by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense on a straight-line basis over the vesting term. We account for stock-options issued to non-employees by valuing the award using the Black-Scholes model and re-measuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached. Because the fair market value of options granted to non-employee sis subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Black-Scholes model requires us to make certain assumptions regarding: (i) the expected volatility in the market price of our shares; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if we revise our assumptions and estimates, our stock-based compensation expense could change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Given our limited history as a publicly traded company following the Merger on December 29, 2017, we did not have sufficient trading data to calculate volatility based on our own common stock, and the expected volatility was calculated as of each grant date based on a peer group of publicly traded companies. The expected term of the stock options was determined based upon the simplified approach for employees, allowed under SEC Staff Accounting Bulletin No. 110, which assumes that the stock options will be exercised evenly from vesting to expiration. As data associated with future exercises is obtained, the expected term of future grants will be adjusted accordingly. For non-employee awards, we use the remaining contractual term.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We measure compensation for RSUs based on the price of our shares at the grant date and we recognize the expense on a straight-line basis over the vesting period. The expense relating to RSUs that contain both a service and a performance condition is estimated and adjusted on a quarterly basis based upon our assessment of the probability that the performance condition would be met. As a result, if we revise such assessment, our stock-based compensation expense could change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivative Financial Instruments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the normal course of business, from time to time, we issue warrants and options to vendors as consideration to perform services. We may also issue warrants as part of a debt or equity financing. We do not enter into any derivative contracts for speculative purposes.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We recognize all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. During the year ended December&#160;31, 2018, we issued warrants to purchase approximately 1,383,631 shares of common stock, in connection with sale of equity securities which the holders of such warrants have an option to put the warrants back to us in certain events. In accordance with ASC Topic 815-40, &#8220;Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Stock&#8221; (&#8220;ASC&#160;815-40&#8221;), the fair value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to us in certain events, as defined, and the warrants are determined not to be indexed to the Company&#8217;s own stock.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The derivative liabilities are remeasured each period end to the estimated fair value. The fair value of our derivative liabilities is estimated using the appropriate pricing model, with the following assumptions used for the initial measurement of warrants granted:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83.14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There were no warrants granted in 2017 accounted for as liabilities. The Company&#8217;s expected common stock price volatility assumption is based upon the volatility of a basket of companies that we consider comparable to us. The expected life assumptions for the warrants are estimated to coincide with the contractual terms of the warrants.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU No. 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years.  An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date.  The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU No. 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. We estimate that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,337</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Notes 9, the Company was required to maintain a minimum of the lesser of $18.5 million or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained $10.2 million of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of December&#160;31, 2018. In addition, the Company maintained $0.1 million and $0.2 million as of December&#160;31, 2018 and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div><a name="s3091b9c070a14eed8643b6741a7a23e0"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are exposed to certain market risks relating primarily to interest rate risk on our cash and cash equivalents and risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. We manage such risks by investing primarily in money market mutual funds. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we are exposed to foreign currency exchange rate fluctuations relating to payments we make to certain vendors and suppliers and license partners using foreign currencies. We do not hedge against foreign currency risks. Consequently, changes in exchange rates could adversely affect our operating results and stock price. Such losses have not been significant to date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></div><hr style="page-break-after:always"><div><a name="s3F0B1D2A6003E4575B8E8068254680BB"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160; 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s894108f1a15844a4a811c6c7ec7d070e"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s894108f1a15844a4a811c6c7ec7d070e">105</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3BDF3E71C0733BF2B41D8068158495BD"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Balance Sheets as of December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3BDF3E71C0733BF2B41D8068158495BD">106</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s09D594BB7CDD0BAC07D9806815BEEF8A"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Statements of Operations for the years ended December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s09D594BB7CDD0BAC07D9806815BEEF8A">107</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE26A158815C48D5C700080681636EABD"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE26A158815C48D5C700080681636EABD">108</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sA29625981B38B335C611806816F91098"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sA29625981B38B335C611806816F91098">110</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s4B83D5DDC5D7FB16CC33806826BFA07E"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s4B83D5DDC5D7FB16CC33806826BFA07E">111</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></div><hr style="page-break-after:always"><div><a name="s894108f1a15844a4a811c6c7ec7d070e"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SELLAS Life Sciences Group, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Opinion on the Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of SELLAS Life Sciences Group, Inc. (the &#8220;Company&#8221;) as of December 31, 2018 and 2017, the related consolidated statements of operations, stockholders&#8217; equity and cash flows for each of the years then ended and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December&#160;31, 2018 and 2017, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Going Concern Uncertainty</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">financial statements are free of material misstatements, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our audits</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included performing procedures to assess the risks of material misstatement of the consolidated</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ Moss Adams LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">San Francisco, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have served as the Company&#8217;s auditor since 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></div><hr style="page-break-after:always"><div><a name="s3BDF3E71C0733BF2B41D8068158495BD"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">13,087</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">17,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">33,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,755</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">24,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">357</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Long-term debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,670</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">31,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Commitments and contingencies (Note 10)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at December 31, 2018 and December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 22,026,476 shares issued and outstanding at December 31, 2018; 5,766,891&#160;shares issued and outstanding at December&#160;31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">87,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">56,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(81,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(54,185</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities and stockholders&#8217; equity </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">33,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></div><hr style="page-break-after:always"><div><a name="s09D594BB7CDD0BAC07D9806815BEEF8A"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,772</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development impairment charge</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance costs related to Merger</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses and operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(31,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,032</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on settlement of liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gain on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(266</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(462</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(29,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax expense (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(27,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend arising from beneficial conversion feature of convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,436</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impact of anti-dilution protection on liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend on conversion of 2015 Sely Note</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(41,251</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,429</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Per share information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10.44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted-average common shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,077,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,340,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></div><hr style="page-break-after:always"><div><a name="sE26A158815C48D5C700080681636EABD"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:29%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Preferred Stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Total Stockholders' Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,268,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(30,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued in connection with amendments to MSK license</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">83,594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued upon conversion of 2015 Shareholder Notes and accrued interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">330,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Sale of common shares to related parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,534,711</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued in connection with settlement of related party payables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">96,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued upon the acceleration for restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">46,373</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued upon cancellation of Equilibria restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">58,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued in connection with acquisition of Galena</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,588,605</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">12,486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">12,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of assumed options issued in connection with acquisition of Galena</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">632,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">119,672</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">941</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">941</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares issued to MSK for anti-dilution provisions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">7,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(23.754</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(23,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,766,891</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">56,254</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(54,185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,070</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock and common stock warrants, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,845,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon exercise of pre-funded warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,049,783</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of Series A convertible preferred stock, net of offering costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Beneficial conversion feature arising from Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Conversion of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">499,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(7,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,748,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(8,654</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(8,654</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Impact of anti-dilution protection on liability-classified warrants<br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (CONTINUED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:29%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Total Stockholders' Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Convertible preferred stock dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock as repayment of principal and interest on long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">715,277</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with litigation settlements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">228,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon conversion of promissory notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">118,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with warrant exchange agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">54,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(27,670</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(27,670</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,026,476</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">87,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(81,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></div><hr style="page-break-after:always"><div><a name="sA29625981B38B335C611806816F91098"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(27,670</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,754</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Adjustment to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gain on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-cash In-process research and development impairment charge</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,316</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-cash stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of common stock issued in exchange for services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of common stock issued in connection with litigation settlements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of shares issued for incentive fee to Equilibria</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">941</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,032</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on settlement of liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Severance costs paid by Galena</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,883</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,374</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(30,422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash acquired from acquisition of Galena</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Net cash used from investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from issuance of common stock, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dividends paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(487</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Principal payments on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,123</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,047</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash received during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,436</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Repayment of interest and principal on long-term debt through issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Reclassification of warrant liabilities upon exchange for shares of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">285</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impact of anti-dilution protection on liability-classified warrants</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt issued in connection with warrant exchange agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">966</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares issued in connection with acquisition of Galena</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of options assumed in connection with acquisition of Galena</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Related party payable settled in shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Memorial Sloan Kettering Cancer Center payable settled in shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares issued upon conversion of 2015 Shareholder Notes and accrued interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares issued upon conversion of 2015 Sely Note and accrued interest to Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,064</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></div><hr style="page-break-after:always"><div><a name="s4B83D5DDC5D7FB16CC33806826BFA07E"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="sF9F7B458909C86A1E2878068175B355E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">1.  Organization and Description of Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SELLAS Life Sciences Group, Inc. (the "Company," or &#8220;SELLAS&#8221;) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As used in this annual report on Form 10-K, the words the &#8220;Company,&#8221; and &#8220;SELLAS&#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&#160;7, 2017 and amended November&#160;5, 2017 (the "Merger Agreement"), among the Galena, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company&#8217;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Immediately prior to the Merger, Galena effected a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-for-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reverse stock split of its outstanding common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS&#8217; securityholders at an exchange ratio of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43.9972</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&#8220;RSUs&#8221;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&#8217;s common stock. Accordingly, immediately after the Merger, there were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,766,891</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock outstanding, with the former Private SELLAS securityholders owning </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">67.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company&#8217;s fully diluted common stock, and the Company&#8217;s pre-Merger securityholders owning the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The number of shares and per share amounts of common stock in the accompanying consolidated financial statements and notes to the consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon completion of the Merger, the Company&#8217;s name changed from &#8220;Galena Biopharma, Inc.&#8221; to &#8220;SELLAS Life Sciences Group, Inc.," the Company&#8217;s financial statements became those of Private SELLAS, and the Company's common stock began trading on The Nasdaq Capital Market under the new ticker symbol &#8220;SLS&#8221; on January&#160;2, 2018. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></div><hr style="page-break-after:always"><div><a name="sCDBBC2F8CB942811BA5180681767CAD3"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">2.  Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company completed an underwritten public offering (the "July 2018 Offering"), and issued (i) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock, (ii) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;pre-funded warrants exercisable for shares of common stock and (iii) accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the July 2018 Offering, on March&#160;7, 2018, the Company entered into a securities purchase agreement to issue shares of its Series A convertible preferred stock (&#8220;Series A Convertible Preferred&#8221;) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of Series A Convertible Preferred and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;year warrants to acquire an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share was completed in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;tranches and resulted in aggregate gross proceeds to the Company of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company completed the first tranche for approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gross proceeds on March&#160;9, 2018. The Company completed the second tranche of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gross proceeds on May 1, 2018, following stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2019, the Company engaged Cantor Fitzgerald &amp; Co. to explore a wide range of strategic alternatives to continue the Company's business plan, with the ultimate objective being an outcome that is in the best interest of the Company's shareholders.  Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment into the Company, a sale, license or other disposition of corporate assets, a funded collaboration or partnership, or a financing which would allow the Company to continue with its current business plan of developing its development plans for its lead product candidates. To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company had cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and a restricted cash balance of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company had outstanding accounts payable and accrued expenses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company expects its existing cash as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, together with the gross proceeds of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;the Company may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable the Company to fund its operating expenses through June 2019. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, the Company will need to raise additional capital earlier than anticipated to fund our operations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s616065E30437D4B2A0488068177E2729"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">3.  Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and our wholly owned subsidiaries, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Private SELLAS, SLSG US, Inc., Sellas Life Sciences Limited, Sellas Life Sciences Group UK Ltd., Apthera, Inc., and Mills Pharmaceuticals, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company&#8217;s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (&#8220;LIBOR&#8221;) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets are comprised of identifiable in-process research and development (&#8220;IPR&amp;D&#8221;) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&amp;D asset associated with the GALE-401 product candidate and recorded an impairment charge of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was equal to the acquired value of GALE-401 of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;recorded as deposits and other assets related to upfront milestone payments. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. See Note 5 for further discussion of the Company's intangible assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&#8217;s goodwill is less than the carrying value of the reporting unit&#8217;s goodwill. The Company did not recognize any impairment of goodwill during the years ended December 31, 2018 and 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Severance Costs Related to Merger</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognized and paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of exit costs during 2017 related to severance benefits for certain former Galena employees terminated immediately prior to the consummation of the Merger.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Fees and Insurance Recoveries</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Stock-based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#8212; Stock Compensation&#8221; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non-Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC740-10&#8221;). </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC740-10 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the Company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 22, 2017 the President of the United States signed into law the Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;). This legislation makes significant changes in the United States tax laws including, but not limited to, reducing the corporate tax rate to 21% starting in 2018. The 2017 Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of 21%. For the years ended December 31, 2018 and December 31, 2017, the Company recognized an income tax benefit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and an income tax expense of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. As such, the Company completed the analysis based on legislative updates relating to the Act currently available, and no material adjustments have been recorded as of December 31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">986</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has no items of comprehensive income or loss other than net loss.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Convertible Instruments</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU No. 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU No. 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,337</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></div><hr style="page-break-after:always"><div><a name="sAEDC461E3E419C07160A8068179381F8"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">4. Acquisition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting, whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Private SELLAS, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Private SELLAS that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:585px;"></td><td style="width:8px;"></td><td style="width:86px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of the Company's pre-Merger shares outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Estimated fair value of the Company's pre-Merger stock options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:585px;"></td><td style="width:8px;"></td><td style="width:86px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets acquired:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,812</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34,775</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities assumed:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,300</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration of Apthera, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,673</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Qualitative factors supporting the recognition of goodwill due to the Merger include the Company&#8217;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company. The goodwill is not deductible for income tax purposes.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&#8217;s results of operations for any future period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss (in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-recurring&#160;pro forma transaction costs directly attributable to the Merger were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended December&#160;31, 2017 and have been deducted from the net loss presented above. The costs deducted from the year ended December&#160;31, 2017 period included a success fee and other transaction costs&#160;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">119,672</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock with a fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a fee to Equilibria Capital Management Limited (&#8220;Equilibria&#8221;). Additionally, the Company incurred approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in severance costs as a result of resignations of executive officers immediately prior to the Merger. These costs are excluded from the pro forma financial information for the year ended December&#160;31, 2017. The Company excluded a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;impairment charge incurred by the Company as well as combined transaction costs from Galena and the Company in the amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the pro forma financial information for the year ended December&#160;31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div><a name="s27821f137f9f4b199f23e286cc109f68"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">5. Goodwill and Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company completes its annual impairment test on October 1 each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company's goodwill balance at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets consist of IPR&amp;D acquired as part of the Merger. IPR&amp;D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE-302</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company's IPR&amp;D assets consist of the NPS program for the prevention of cancer recurrent in breast cancer patients, and the GALE-301 and GALE-302 programs for the prevention of cancer recurrent in ovarian and endometrial cancer patients in the adjuvant setting. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&amp;D asset associated with the GALE-401 product candidate and recorded an impairment charge of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was equal to the acquired value of GALE-401 of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;recorded as deposits and other assets related to upfront milestone payments associated with that product candidate. The abandonment also resulted in an income tax benefit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></div><hr style="page-break-after:always"><div><a name="scbacc348a93f4dc787260a80a5b67145"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">6. Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period. These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Memorial Sloan Kettering Cancer Center</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 4, 2014, (the &#8220;MSK Effective Date&#8221;) the Company entered into a license agreement (the &#8220;Original MSK License Agreement&#8221;) with MSK under which the Company was granted an exclusive license to develop and commercialize MSK&#8217;s WT1 peptide vaccine technology. Under the terms of the Original MSK License Agreement, the Company is required to obtain certain levels of financing. If such financing is not met, MSK will have the right to terminate the Original MSK License Agreement with prior written notice, unless the Company manages to overcome the shortfall during the term of the notice period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the consideration for the rights, privileges and licenses granted under the Original MSK License Agreement, the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,199</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares to MSK representing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company&#8217;s fully diluted share capital as of the MSK Effective Date, which obligation was satisfied by assignment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,599</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares from each of the Company&#8217;s President, Chief Executive Officer, and co-founder, Dr. Angelos M. Stergiou, and the Company&#8217;s other co-founder, Dr. Miltiadis Sougioultzoglou (M.D.), to MSK, for which they received no consideration. Additionally, the Company was obligated to pay upfront license fees in an amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company recognized this amount as research and development expense during the year ended December 31, 2014, as it had no alternative future use. The Company would further be obligated to pay minimum royalty payments in the amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;each year commencing in 2015 and research funding costs of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in each year and for three years commencing in January 2015. In addition, to the extent certain development and commercial milestones are achieved, the Company will be required to pay MSK up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$17.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in milestone payments for each licensed product, in addition to royalties in the event of commercial sales of any licensed products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Original MSK License Agreement, unless terminated earlier in accordance with the terms of the Original MSK License Agreement, will continue on a country-by-country and licensed product-by-licensed product basis, until the later of: (i) expiration of the last valid claim embracing such licensed product; (ii) expiration of any market exclusivity period granted by law with respect to such licensed product; or (iii) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) years from the first commercial sale in such country.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 30, 2015, the Company and MSK entered into the License Amendment, Waiver and Share Issuance Agreement (the &#8220;First MSK Amendment&#8221;). The First MSK Amendment extended the date required for the Company to obtain financing from August 1, 2015 to December 31, 2016, modified the amount of required financing and waived past non-compliance with certain related provisions of the Original MSK License Agreement. In exchange for the First MSK Amendment, the Company agreed to issue an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,867</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares to MSK, which represented </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the fully diluted share capital of the Company at such date. The First MSK Amendment added certain anti-dilution protection clauses and entitled MSK to additional shares to the extent the Company was not able to obtain the required financing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 10, 2016, the Company and MSK entered into the Second License Amendment, Waiver and Agreement (the &#8220;Second MSK Amendment&#8221;). The Second MSK Amendment extended further the date required for the Company to obtain financing from December 31, 2016 to June 30, 2017, amended the anti-dilution provisions of the First MSK Amendment and waived past non-compliance with certain related provisions of the First MSK Amendment. Under the Second MSK Amendment, outstanding obligations of the Company to MSK in an amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,815</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares effective November 1, 2016 upon the Company&#8217;s re-domiciliation to Bermuda. In consideration for this amendment and pursuant to the anti-dilution provisions in the Original MSK License Agreement as amended by the First MSK Amendment and the Second MSK Amendment, the Company </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">issued MSK </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30,314</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;additional shares and incurred accordingly </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of research and development expense, which reflected the fair value of the Company&#8217;s shares at such date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 25, 2017, the Company and MSK entered into an Amended and Restated Exclusive License Agreement (the &#8220;MSK A&amp;R License Agreement&#8221;). Under the MSK A&amp;R License Agreement, the Company expanded its license under the original MSK License Agreement, as amended, to include a license to commercially develop certain additional WT1 peptides through a program of exploiting certain patents and other rights covering such peptides.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The MSK A&amp;R License Agreement, among other changes, added certain milestone payments for each additional patent licensed product as defined in the MSK A&amp;R License Agreement, and amended the milestone payments due upon commencement of the Phase 3 AML and mesothelioma clinical trials from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In consideration for the MSK A&amp;R License Agreement, the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,799</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares to MSK. Pursuant to a side letter to the MSK A&amp;R License Agreement, dated May 25, 2017 (the &#8220;MSK Side Letter&#8221;), MSK converted the next milestone payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was due June 30, 2017, into shares. Further, in consideration for the MSK Side Letter, Dr. Stergiou, the Company&#8217;s Chief Executive Officer, assigned </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,399</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of his shares to MSK, for which Dr. Stergiou received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash consideration.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 11, 2017, the Company and MSK entered into a second Amended and Restated Exclusive License Agreement (the &#8220;Second MSK A&amp;R License Agreement&#8221;). Under the Second MSK A&amp;R License Agreement, the Company and MSK extended the dates for the Company to have obtained necessary financing, and certain milestone dates, in exchange for increased milestone payments, clarification regarding MSK&#8217;s anti-dilution rights, and termination of the MSK Side Letter dated May 25, 2017. In connection with the Second MSK A&amp;R License Agreement, the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74,795</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares to MSK. Prior to the Merger, the Company issued an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares to MSK in connection with their anti-dilution rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the year ended December 31, 2018 the Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of expenses relating to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of milestone payments, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in licensing fees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of guaranteed minimum royalty payments and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of research funding costs.  For the year ended December 31, 2017, the Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of expenses relating to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of milestone payments, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of guaranteed minimum royal payments and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of research funding costs. Such expenses have been included in research and development costs. Further, under the Second MSK Amendment, the Company is obligated to pay MSK </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in milestone payments in two equal installments, within </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;days following the initiation of its Phase 3 AML and mesothelioma clinical studies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Merck &amp; Co., Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 21, 2017, the Company entered into a clinical trial collaboration and supply agreement through a Merck &amp; Co., Inc. subsidiary, Merck Sharp &amp; Dohme B.V. (&#8220;Merck subsidiary&#8221;), whereby the Company agreed with the Merck subsidiary to collaborate in a research program to evaluate GPS as it is administered in combination with Merck&#8217;s PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors.  The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab in patients with WT1+ relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: AML, ovarian, triple-negative breast, small cell lung, and colorectal (arm enriched in but not exclusive to patients with microsatelite instability-low tumors). This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pembrolizumab alone in comparable patient populations. This trial was initiated in December 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Advaxis, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 24, 2017, the Company and Advaxis, Inc. (&#8220;Advaxis&#8221;) entered into a research and development collaboration agreement, whereby both parties will collaborate in a research program to evaluate, through a &#8220;proof of principle&#8221; trial or trials (&#8220;PoP Clinical Trial&#8221;), a clinical candidate comprised of the combination of Advaxis&#8217; proprietary </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Lm-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">based antigen delivery technology and the Company&#8217;s patented WT1 targeted heteroclitic peptide antigen mixture (GPS). The term of the Advaxis agreement will expire upon the earlier of: (a) completion of the PoP Clinical Trial, (b) a decision by the parties to cease further development of the clinical candidate and (c) early termination of the Advaxis agreement pursuant to the terms thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and filing any investigational new drug application (&#8220;IND&#8221;), cost-sharing for preparation of the IND, and the Company being responsible for the costs (exclusive of product costs) of conducting the PoP Clinical Trial. The Company also agreed to make certain non-refundable milestone payments to Advaxis having an aggregate amount of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$108.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain targets, the Company agreed to make non-refundable sales milestone payments up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low double digits if net sales exceed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 11, 2006, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a United States patent covering the nelipepimut-S peptide vaccine ("NPS") and several United States and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, the Company is required to pay an annual maintenance fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for clinical milestone payments, and to pay a tiered royalty in the mid-single digits based on sales of NPS or other therapeutic products developed from the licensed technologies.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s73F5CD0E90476FDAA6D8806817A728C9"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">7.  Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company did not transfer any financial instruments into or out of Level 3 classification during the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  See Note 12 for a reconciliation of the changes in the fair value of the warrant liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the change in the fair value of the contingent consideration liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration acquired as part of the Merger</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,032</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&#8217;s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;based on the achievement of certain development and commercial milestones relating to NPS. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial of trastuzumab (Herceptin&#174;) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></div><hr style="page-break-after:always"><div><a name="s57E2CA645FE16215C99D806817E79440"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">8.  Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Value-added tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rebates and returns of former commercial products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sBB3420F7DE592664DD8A80681801DDB8"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">9.  Debt</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current portion of Senior Secured Debenture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-current portion of Senior Secured Debenture</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Senior Secured Debenture</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company's predecessor company, Galena, entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with JGB (Cayman) Newton, Ltd. ("JGB") pursuant to which Galena sold to JGB, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;original issue discount, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;senior secured debenture (the "Senior Secured Debenture") and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,333</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The maturity date of the Senior Secured Debenture was November&#160;10, 2018, with accrued interest at&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company&#8217;s common stock, or a combination of cash and the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:1pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#160;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash and cash equivalents in a restricted account. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the outstanding principal balance of the Senior Secured Debenture was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition to the outstanding principal balance, the Senior Secured Debenture had&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of additional interest that was included in the current portion of long-term debt as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. During the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, JGB redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal, which the Company satisfied with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">659,529</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock and redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of restricted cash into unrestricted cash and cash equivalents, which was used to fund the Company&#8217;s ongoing operations. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2018, JGB commenced a lawsuit against the Company, as described in Note 10. On November 5, 2018, the parties to the JGB lawsuit entered into a settlement agreement, which required, among other things, that JGB make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, representing the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Short-term Convertible Promissory Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company issued convertible promissory notes in the principal amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in exchange for the surrender and cancellation of warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock pursuant to the February 2017 public offering by Galena. The convertible promissory notes accrued interest at a rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per annum and were convertible into shares of the Company's common stock at a conversion price equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. In November of 2018, the Company paid the remaining principal and interest of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to settle the debt. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was no principal balance and accrued interest outstanding.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></div><hr style="page-break-after:always"><div><a name="s0C282856D685A82DF7CC8068183231F4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">10. Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company is now subject as a result of the Merger. The Company is also involved in litigation matters as follows: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 13, 2016, Galena filed a complaint against Aon Risk Insurance Services West, Inc. in the Circuit Court for Multnomah County, Oregon.&#160;The complaint seeks damages related to Galena&#8217;s coverage dispute with a certain insurer, including the amounts Galena was required to contribute to the settlements of In re Galena Biopharma, Inc. Derivative Litigation and In re Galena Biopharma, Inc. Securities Litigation as a direct result of certain insurer&#8217;s failure to pay its full policy limits. On November 30, 2018, the Company amended its complaint to seek punitive damages.&#160;Trial is scheduled to begin on May 6, 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February&#160;13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint and on December 21, 2018, plaintiffs filed their opposition to the motion to dismiss. On January 18, 2019, the Company filed a reply in support of its motion. The Company's motion to dismiss the amended complaint is currently pending in the U.S. District Court for the District of New Jersey.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in the U.S. District Court for the Northern District of California against the Company&#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018, refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On November 15, 2018, the defendants in the August 2018 lawsuit filed a motion to dismiss the complaint. On December 17, 2018, the plaintiff filed an amended complaint. The defendants filed a motion to dismiss the amended complaint on January 31, 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section&#160;225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena&#8217;s former board of directors and former interim chief executive officer regarding the proposals to amend Galena&#8217;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&#160;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On July&#160;24, 2017, Galena entered into a binding settlement term sheet, involving</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,250,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in unrestricted shares of common stock. The Court enforced the settlement term sheet on November&#160;30, 2017. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys&#8217; fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from its insurance carrier for previous amounts paid by the Company in excess of its retention amount and recorded the amount as a reduction to general and administrative expense in the Company's consolidated statement of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants certain members of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, inclusive of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;excess amount removed from the restricted account. The entire settlement amount was received in November 2018. The Company offset approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of legal fees incurred during the year ended December 31, 2018 previously recorded in general and administrative expense in the consolidated statement of operations with proceeds from the settlement. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Consideration related to Development, Regulatory and Commercial Milestone Payments and Business Combinations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. For additional information on the Company&#8217;s commitments under collaboration and license agreements read Note 6 to these consolidated financial statements. For additional information on the Company&#8217;s commitments of contingent consideration read Note 7 to these consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Commitments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company rents office space under a&#160;non-cancelable&#160;operating lease. Rental expense amounted to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the years ended December&#160;31, 2018 and 2017, respectively. The Company&#8217;s contractual obligations that may require future cash payments as of December&#160;31, 2018 under the&#160;non-cancelable&#160;operating lease are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></div><hr style="page-break-after:always"><div><a name="s28EE7708A6BF41283B26806818463F26"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">11.  Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Series A Convertible Preferred </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March&#160;7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share at an aggregate purchase price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Series A Convertible Preferred was initially convertible into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,844,835</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock based on an initial conversion price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.80</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At the first closing of the Series A Convertible Preferred on March&#160;9, 2018, the Company issued an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,987</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">774,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The second closing of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,713</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">609,445</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock, for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, occurred on May 1, 2018 following receipt of stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders") had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and in Note 2 above, the Series A Holders exchanged an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7,871,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock and warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock. Following such exchange, there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and that amount is recorded as a deemed dividend in the consolidated statements of operations during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was automatically adjusted to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share from the original exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The Company recognized the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the consolidated statements of operations during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred generated a beneficial conversion feature (&#8220;BCF&#8221;), which arose as the equity security was issued with an embedded conversion option that was beneficial to the investor or in the money at inception because the conversion option had an effective conversion price that was less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a deemed dividend in the consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a deemed dividend related to the second closing on May 1, 2018.&#160;These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company completed the July 2018 Offering, issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per pre-funded warrant and common stock warrant.  Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance.  The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contracts in an Entity&#8217;s own Equity</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(&#8220;ASC 815-40&#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock reserved for future issuance are as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:84%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s9740BB4267A6A4F635198068187EB79F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">12.  Warrants to Acquire Shares of Common Stock</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:26%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Canceled/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2018 Offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Pre-funded July 2018 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2017 Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(542</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">534,334</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,613</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">121,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock, as described in Note 11. The fair value of the common stock and promissory notes exchanged totaled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which exceeded the fair value of the warrant liability of the warrants canceled by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and is recorded as loss on settlement of liability-classified warrants in the consolidated statement of operations for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Liabilities </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 offering, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share of common stock, subject to standard adjustments for certain transactions affecting the Company&#8217;s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:25%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">94.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">829.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">94.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">888.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Adjustment to exercise price of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Equity</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company issued warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316,163</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the its common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December&#160;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90.10%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk free rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 11.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s0B04047266077A688A5D8068194CD6AB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">13.  Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split described in Note 1. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017 Equity Incentive Plan </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,686,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger.  Upon the consummation of the Merger, the Company assumed approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,171</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares subject to outstanding common stock options granted under the Company&#8217;s 2016 Incentive Plan that remained exercisable through December 29, 2018 for former Company employees and directors. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The number of shares reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1&#160;of each year, for a period of not more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, commencing on January 1, 2018 and ending on (and including) January&#160;1, 2027, in an amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31&#160;of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1&#160;of a given year to provide that there will be no January 1&#160;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,686,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;on January 1, 2019. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock were reserved for future grants under the Company&#8217;s 2017 Equity Incentive Plan. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;common stock options granted under the 2017 Equity Incentive Plan for the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:85%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80.83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average grant date fair value of options granted during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.73</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;stock options granted during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur, therefore, outstanding stock options equal vested and expected to vest stock options.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.13</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes stock option activity of the Company for the year ended December 31, 2018:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted Average Remaining Contractual Term (in years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,240.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.01</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable stock options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.23</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">RSUs with Time-Based and Performance-Based Conditions </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and&#160;non-employees&#160;pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i)&#160;continued service either over a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year measurement period or at the end of the required service period and (ii)&#160;the achievement of a liquidity event. The initial vesting date for these RSUs was February&#160;27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of December&#160;31, 2018 and December 31, 2017, there were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;RSUs outstanding with a weighted average grant date fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$52.94</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company&#8217;s control and not deemed probable until it occurs. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017 Employee Stock Purchase Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also has an employee stock purchase plan (&#8220;ESPP&#8221;) which allows employees to contribute up to&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;of their cash earnings, subject to certain maximums, to be used to purchase shares of the Company&#8217;s common stock on each semi-annual purchase date. On each offering date, each eligible employee, pursuant to an offering made under the ESPP, will be granted a right to purchase up to that number of shares of common stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board of Directors, but in either case not exceeding fifteen percent (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) of such employee&#8217;s earnings (as defined by the Board of Directors in each offering) during the period that begins on the offering date (or such later date as the Board of Directors determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. As of December&#160;31, 2018, the Board of Directors has not established the various parameters under the ESPP and no shares have been delivered under the ESPP. There are approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock reserved for issuance under the ESPP, plus the number of shares of common stock that are automatically added on January 1st&#160;of each year for a period of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, commencing on the first January 1, 2018 and ending on (and including) January&#160;1, 2027, in an amount equal to the lesser of (i) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31st&#160;of the preceding calendar year, and (ii)&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s685baea16bc04009a9c691d44fee25a3"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">14.  Income Taxes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The loss before income taxes is as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non - U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(29,048</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of federal and state income tax expense are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(570</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax assets and liabilities are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,464</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,028</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Licensing deduction deferral</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,410</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,658</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development not subject to future amortization for tax purposes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">U.S. federal statutory income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State and local taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax rate change and true-up</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At December 31, 2018, the Company had domestic federal and state net operating loss carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$19.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, available to reduce future taxable income, which expire beginning in 2027. The Company also had federal research and development tax credit carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, available to reduce future tax liabilities and which expire at various dates beginning in 2035. The income tax expense for the year ended December 31, 2018 and 2017 relates to both the indefinite lived deferred tax liabilities and the December 22, 2017 enactment of the Tax Cuts and Jobs Act. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the provisions of the Internal Revenue Code, the net operating losses (&#8220;NOL&#8221;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, as defined under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. Utilization of the net operating loss and tax credits carryforwards may be limited by &#8220;ownership change&#8221; rules, as defined in Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In assessing the need for a valuation allowance the Company may utilize indefinite-lived deferred tax liabilities from an indefinite-lived intangible asset as a future source of income.&#160;The Company&#8217;s IPR&amp;D, as recorded in acquisition accounting, can be utilized as a source of income arising from the future reversal of temporary difference that can be offset against post 2017 indefinite-lived NOLs.&#160;Therefore, the Company is permitted to offset the indefinite-lived DTL up to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;percent limitation for NOL&#8217;s generated subsequent to January 1, 2018. The valuation allowance increased by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the year ended December 31, 2018 as a result of the impairment of one of the Company's indefinite-lived intangible assets and changes in the Company's state apportionment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to tax examinations for the 2014 tax year and beyond. The Company does not recognize tax benefits that are not more-likely-than-not to be supported based upon the technical merits of the tax position taken. In assessing its unrecognized tax benefits, the Company has analyzed its tax return filing positions in all of the federal, state and foreign filing jurisdictions where it is required to file income tax returns, as well as all open years in those jurisdictions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table indicates the changes to the Company&#8217;s unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Beginning of the Year - unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Increase/(Decrease) - prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Increase - current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">End of the Year - unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The unrecognized tax benefits, if recognized and in absence of full valuation allowance, would impact the income tax provision by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$55,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company does not believe that it is reasonably possible that its unrecognized tax benefits would significantly change in the following 12 months. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in the near term. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 22, 2017, the 2017 Tax Cuts and Jobs Act (Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring the Company's U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of the Company's deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allowed the Company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. As a result, the Company previously provided a provisional estimate of the effect of the Tax Act in the Company's financial statements. In the fourth quarter of 2018, we completed our analysis to determine the effect of the Tax Act and recorded no material adjustments as of December 31, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s23c98d0572f946d187d815d0aa903235"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">15.  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Management and Strategic Collaboration Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective in June 2016, the Company and Equilibria Capital Management ("Equilibria"), a company incorporated in Bermuda and a significant stockholder of the Company, entered into the management and strategic collaboration agreement. Under the Equilibria collaboration agreement, Equilibria, amongst other services, was engaged to provide certain strategic, management and capital raising advice to the Company. The Equilibria collaboration agreement was effective for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years and renewable thereafter only upon the mutual written agreement of both parties. The Equilibria collaboration agreement provided that it would automatically terminate upon the closing of an IPO or a strategic sale. During the term of the Equilibria collaboration agreement, the Company, in exchange for the services received, paid Equilibria a quarterly fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the &#8220;Equilibria Management Fee&#8221;). The Equilibria Management Fee can be paid in cash or, at the mutual agreement of the parties, in shares of the Company at a valuation equal to the Company&#8217;s most recent financing round. In addition to the Equilibria Management Fee, the Company agreed to pay Equilibria any expenses reasonably incurred in performing the services agreed. For the years ended December 31, 2017, the Company had incurred and paid in cash </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, of Equilibria Management Fees. These amounts are included in general and administrative expense in the consolidated statements of operations. As of December 31, 2017, the Company had an outstanding payable to Equilibria of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The management and strategic collaboration agreement was terminated upon consummation of the Merger in December 2017. There were no Equilibria Management Fees incurred during the year ended December 2018 and there was no outstanding payable as of December 31, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD9F00EFE67CF907FEEA6806824C1ADAC"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the provision of the management and strategic collaboration services, the Company also agreed to pay Equilibria an incentive fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the post-money market value of the Company on the date of its IPO. Such fee would be payable in shares with a per-share price equal to the price set for the sale of the Company&#8217;s shares to other investors in its IPO. The Company and Equilibria may have jointly agreed to settle the incentive fee earlier, if deemed appropriate for achieving a successful IPO, through either a cash payment, issuance of shares, or a combination of the two. In the event that the Company was sold as part of a strategic sale, the incentive fee would be equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the gross value paid by the purchaser in cash.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2017, the Company and Equilibria entered into an amendment of the Equilibria collaboration agreement. Under the amendment, in the event that the Company entered into a reverse merger transaction in lieu of an initial public offering, the incentive fee to Equilibria was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the post-merger fully diluted market value of the Company immediately after the closing of the reverse merger transaction, payable in a combination of cash and shares of common stock of the Company. The cash payment was based on the per share price equaling the intrinsic value of the Company&#8217;s shares in the Merger. The share-based component of the incentive fee was based on the post-closing fully diluted number of shares outstanding.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2017, the Company and Equilibria further amended the Equilibria collaboration agreement to fix the compensation payable to Equilibria in connection with the completion of the Merger, described above in Note 1. Accordingly, upon consummation of the Merger on December 29, 2017, the Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in fees to Equilibria and issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">119,672</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock to Equilibria at a fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. These amounts are included in general and administrative expense in the consolidated statements of operations. Also, upon consummation of the Merger and pursuant to the amended Equilibria collaboration agreement, such agreement was terminated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Other Related Party Transactions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s Chief Executive Officer, Dr. Angelos M. Stergiou (M.D., ScD h.c.) is a significant stockholder of the Company owning </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company&#8217;s outstanding share capital as of December 31, 2018 and 2017, respectively. Further transactions involving the Company and Dr. Stergiou are described in Note 6.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6F9F668C97F90740A9F980681990FAAB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">16.  Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 6, 2019, the Company entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,800,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,800,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;New Warrants were issued. The Company may receive aggregate gross proceeds of up to approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the cash exercise if all of the warrants under the Exercise Agreement are exercised.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141</font></div></div><hr style="page-break-after:always"><div><a name="sD104E45D8E93DA75963180682A9E19FD"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sAA63A69EB925413E294880682ACE44F7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;9A. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The term &#8220;disclosure controls and procedures&#8221; means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer who is also acting as our principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer who is also acting as our acting principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a&#160;&#8211; 15(e) and 15d &#8211; 15(e)). Based upon that evaluation, our principal executive officer who is also acting as our principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer who is also acting as our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our principal executive officer who is also acting as our principal financial officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, but not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our Chief Executive Officer and Vice President, Finance and Corporate Controller, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Remediation of Previously Issued Material Weakness</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the audit of our 2017 consolidated financial statements, we had a material weakness in our internal control over financial reporting due to our lack of sufficient management and personnel with appropriate expertise in GAAP and SEC rules and regulations with respect to financial reporting during the year ended December 31, 2017. At that time, we had only one designated finance and accounting employee and relied primarily on consultants to provide many accounting, book-keeping, and administrative services. This reflects the fact that prior to the Merger, Private SELLAS was a small privately-held company, and that in connection with the Merger, Private SELLAS historical operations, and not those of the predecessor company, represented virtually the entirety of the combined business. In addition, following the Merger, which occurred on December 29, 2017, our accounting and financial systems, as well as personnel, were replaced by those of Private SELLAS.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In order to remedy this material weaknesses, during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we hired three full-time additional finance and accounting personnel, including a Chief Financial Officer, to build out our financial reporting team and further develop and document accounting policies and procedures. Our Chief Financial Officer has since left the Company and we have engaged our former interim Chief Financial Officer as a consultant. Additionally, during the first quarter of 2018, we engaged a consulting firm to assist us in evaluating and documenting the design of our internal control over financial reporting, including disclosure controls and procedures. Over the course of 2018 the Company successfully implemented a system of internal control over financial reporting appropriate to the Company's operation and financial reporting objectives. Under the supervision and with the participation of our Chief Executive Officer and Vice President, Finance and Corporate Controller, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the guidance outlined in&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Attestation Report of the Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">This report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm pursuant to Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act, which exempts smaller reporting companies from the auditor attestation requirement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Changes in Internal Control over Financial Reporting </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other than the remedial activities described above, there has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the year ended December 31, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="se9fb5119dec94e02acbaf2996adbf8f4"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;9B. OTHER INFORMATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 21, 2019, the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;Compensation Committee&#8221;), after consultation with the Board of Directors, approved a new employment agreement with Dr. Angelos Stergiou, the President and Chief Executive Officer of the Company (the &#8220;New Agreement&#8221;).  The New Agreement will be effective as of July 1, 2019 at which time it will replace and supersede the Employment Agreement between the Company and Dr. Stergiou, dated September 1, 2016 (the &#8220;Prior Agreement&#8221;).  The Prior Agreement shall continue in accordance with its terms until June 30, 2019.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the New Agreement and upon the effectiveness thereof, Dr. Stergiou&#8217;s annual base salary shall be $525,000.  Dr. Stergiou shall be eligible for an annual incentive bonus with a target opportunity equal to 50% of his then current base salary, based on the achievement of certain performance objectives set by the Board of Directors or the Compensation Committee in consultation with Dr. Stergiou. Dr. Stergiou is also eligible to be granted equity compensation at the sole discretion of the Board of Directors or Compensation Committee.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The New Agreement further provides for certain severance arrangements for Dr. Stergiou.  In the event that Dr. Stergiou is terminated without &#8220;cause&#8221; or leaves for &#8220;good reason,&#8221; other than termination for a &#8220;change of control&#8221; (each as defined in the New Agreement), the Company will pay Dr. Stergiou (a) in equal installments over the twelve (12) month period following the sixty (60) day period after the termination date (i) an amount equal to eighteen (18) months of Dr. Stergiou&#8217;s then base salary, less employment-related withholdings and deductions and (ii) an amount equal to a pro-rated portion of Dr. Stergiou&#8217;s annual short-term incentive compensation at his target level for the year in which his employment terminates, without regard to whether the performance goals have been met, less standard withholdings and deductions; and (b) should he elect to continue participation, reimbursement for the monthly premium to continue the Company&#8217;s medical and dental plans until the earlier of (x) the last calendar day of the eighteen (18) month anniversary following the month in which the date of termination occurred and (y) the end of the calendar month in which Dr. Stergiou becomes eligible to receive group health plan coverage under another employee benefit plan.  In the event that Dr. Stergiou&#8217;s employment is terminated within one month prior to or within one year following a &#8220;change in control&#8221; event by the Company without &#8220;cause&#8221; or by Dr. Stergiou for &#8220;good reason,&#8221; the Company will (i) pay to Mr. Stergiou in equal installments over the twelve (12) month period following a sixty (60) day period after the termination date (A) an amount equal to twenty-four (24) months of Dr. Stergiou&#8217;s then current base salary, less standard employment related withholdings and deductions; and (B) an amount equal to one-and-one-half (1.5) times Dr. Stergiou&#8217;s target bonus for the year in which his employment terminates, without regard to whether performance goals have been met, less employment related withholdings and deductions; (ii) should he elect to continue participation, reimbursement for the monthly premium to continue the Company&#8217;s medical and dental plans until the earlier of (x) the last calendar day of the eighteen (18) month anniversary following the month in which the date of termination occurred and (y) the end of the calendar month in which Dr. Stergiou becomes eligible to receive group health plan coverage under another employee benefit plan; and (iii) provide that the then-unvested portion of any equity awards held by Dr. Stergiou shall immediately vest in full and become exercisable or free from forfeiture or repurchase, as applicable, as of the date of termination.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Dr. Stergiou agreed to certain confidentiality, non-solicitation and assignment of intellectual property obligations.  Dr. Stergiou shall also be subject to certain non-competition obligations for a period of one (1) year following the termination of his employment.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The foregoing description of the New Agreement does not purport to be complete and is qualified in its entirety by reference to the New Agreement, which will be filed as an exhibit to the Company&#8217;s quarterly report on Form 10-Q for the quarter ending March 31, 2019.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144</font></div></div><hr style="page-break-after:always"><div><a name="sC268747FA2B48A242D0280682AF1DAF2"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART III</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s1F4A6C0E801E21EF814080682B219446"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by item 10 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2018 fiscal year pursuant to Regulation&#160;14A for its 2019 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s202157F85DF96D352F1680682B45E1CA"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;11. EXCUTIVE COMPENSATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by item 11 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2018 fiscal year pursuant to Regulation&#160;14A for its 2019 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sDFBF2A13EEFBB053AD6A80682B811F11"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by item 12 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2018 fiscal year pursuant to Regulation&#160;14A for its 2019 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s75A4E5E1FB232BFED02480682BA6597E"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by item 13 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2018 fiscal year pursuant to Regulation&#160;14A for its 2019 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s5AFF3C10102427082DF580682BCA6EC9"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The information required by item 10 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2018 fiscal year pursuant to Regulation&#160;14A for its 2019 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s33d2b483678f48458b5d14a37883b01e"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART IV</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></div><hr style="page-break-after:always"><div><a name="sAC5C48BB86A58FABE5BC80682C289EF3"></a></div><div><br></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;15. EXHIBITS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:56%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.1^</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517336114/d452403d424b3.htm#toc452403_102"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Agreement and Plan of Merger, dated as of August&#160; 7, 2017, by and among the Registrant, Galena Bermuda Merger Sub, Ltd., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc. and SELLAS Life Sciences Group Ltd, as amended (included as Annex&#160; A to the proxy statement/prospectus/consent solicitation statement)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 8, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 12, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated By-Laws of the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Common Stock Certificate</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.2 </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated April&#160;13, 2011</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 14, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">First Amendment to Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated February&#160;15, 2012</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 28, 2012</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Registration Rights Agreement dated May 10, 2016 between the Registrant and Purchasers</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. dated May 10, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. dated May 10, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Subsidiary Guarantee dated May 10, 2016 between the Registrant and JGB Collateral LLC</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Security Agreement dated May 10, 2016 between the Registrant and JGB Collateral LLC</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated 9% Original Issue Discount Senior Secured Debenture Due November 10, 2018, issued to JGB (Cayman) Newton Ltd. as of August 22, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 23, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.10</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment Agreement, dated as of July 10, 2017, by and between JGB Cayman (Newton) Ltd. and the Registrant with respect to the 9% Original Issue Discount Senior Secured Convertible Debenture in the Original Issue Amount of $25,350,000 Issued and Sold to JGB Cayman (Newton) Ltd. by the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 11, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.11</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consent, dated as of August 7, 2017, made by JGB (Cayman) Newton Ltd., in favor of the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 8, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of warrants granted on May 8, 2013 under the Loan and Security Agreement</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 9, 2013</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.13</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September 18, 2013</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.14</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Agreement, dated as of March 18, 2015, by and among the Registrant, Computershare, Inc. and Computershare Trust Company, N.A.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 6, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 7, 2016</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:56%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.16</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant, issued by the Registrant to the Investors on July 13, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 8, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.17</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant Agreement, including the Form of Warrant, issued by the Registrant to the Investors on February 13, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">February 10, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant issued to EQC Private Markets SAC Fund Ltd &#8211; EQC Biotech Sely I Fund</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.18</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1073.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and CVI Investments, Inc., dated February 6, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.73</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.19</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1074.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Promissory Note by and between the Registrant and CVI Investments, Inc., dated February 6, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.74</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.20</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1075.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Anson Investments Master Fund LP, dated February 7, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.75</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1076.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant, Sabby&#160;Healthcare Master Fund Ltd and Sabby Volatility Warrant Master Fund Ltd, dated February 8, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.76</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.22</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1077.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.77</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1078.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Promissory Note by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.78</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.24</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1079.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master            Portfolio B, dated February 13, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.79</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.25</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1080.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Promissory Note by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.80</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.26</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1081.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Lincoln Park Capital LLC, dated February 14, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.81</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.27</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1082.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.82</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.28</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1083.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.83</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.29</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1084.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.84</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.30</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1085.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Promissory Note by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.85</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.31</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1086.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Promissory Note by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.86</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.32</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex1087.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Promissory Note by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.87</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.33</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.34</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Pre-funded Warrant in connection with July 2018 public offering</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.35</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant issued in exchange of Series A Preferred Stock in connection with July 2018 public offering</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.36</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000015/slsexhibit20180531-101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Exchange Agreement by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018 (including as Exhibit A thereto, that certain Convertible Promissory Note by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018)</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June 1, 2018</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:56%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.37</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of New Warrant issued in connection with Warrant Exercise Agreement dated March 6, 2019</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 6, 2019</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 12, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Registrant&#8217;s 2016 Incentive Plan effective as of July 14, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 22, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form Incentive Stock Option granted under the Registrant&#8217;s 2016 Incentive Plan </font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 8, 2015</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form Nonstatutory Stock Option granted under the Registrant&#8217;s 2016 Incentive Plan</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 8, 2015</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SELLAS Life Sciences Group, Ltd Stock Incentive Plan #1</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.61</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Grant and Agreement under SELLAS Life Sciences Group Ltd Stock Incentive Plan #1</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.63</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.6*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017 Equity Incentive Plan of the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.10</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.7*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017 Employee Stock Purchase Plan of the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.11</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.8*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Stock Option Grant Notice and Option Agreement under the 2017 Equity Incentive Plan.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 19, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.9*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex109.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Grant and Agreement under the 2017 Equity Incentive Plan.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.10*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Agreement by and between SELLAS Life Sciences Group AG and Angelos Stergiou, effective September 1, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.53</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.11*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Agreement by and between SELLAS Life Sciences Group AG and Gregory Torre, effective September 1, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.54</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.12*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Agreement by and between SELLAS Life Sciences Group AG and Nicholas Sarlis, effective September 19, 2016</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.55</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.13*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Agreement by and between SELLAS Life Sciences Group Ltd and Aleksey Krylov, dated October 24, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.56</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Gregory Torre, dated July&#160;31, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.57</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.15*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Nicholas Sarlis, dated August&#160;2, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.58</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Letter Employment Agreement by and between SELLAS Life Sciences Group, Inc. and Barbara Wood, dated March 14, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 19, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.17+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Patent and Technology License Agreement, dated September 11, 2006, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.18</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 1 to Patent and Technology License Agreement, dated December 21, 2007, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.19</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 2 to Patent and Technology License Agreement, dated September&#160;3, 2008, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:56%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.20</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 3 to Patent and Technology License Agreement, dated July 8, 2009, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.21+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 4 to Patent and Technology License Agreement, dated February 11, 2010, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.22+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 5 to Patent and Technology License Agreement, dated January 10, 2011, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide Therapeutics, Inc.)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Scientific Advisory Agreement between the Registrant (formerly Galena Biopharma, Inc.) and George E. Peoples, Ph.D., dated April&#160;13, 2011</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.10</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.24+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exclusive License Agreement, dated as of July 11, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Registrant (formerly Galena Biopharma, Inc.) and its wholly owned subsidiary, Apthera, Inc.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.12</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 15, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.25+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exclusive License Agreement, dated as of September 16, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Board of Regents of the University of Texas System, The University of Texas M. D. Anderson Cancer Center and the Registrant (formerly Galena Biopharma, Inc.)</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September 21, 2011</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.26+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License Agreement, effective as of April&#160;30, 2009, between Kwangdong Pharmaceutical Co., Ltd. and Apthera, Inc.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.45</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 28, 2012</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.27</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment No. 1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.46</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 28, 2012</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.28+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License and Supply Agreement, effective December 3, 2012, by and between the Registrant and ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.43</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 12, 2013</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.29+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License and Development Agreement, dated January 13, 2014, between the Registrant and Dr. Reddy&#8217;s Laboratories, Ltd.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.36</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 17, 2014</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.30+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exclusive License Agreement, dated as of December&#160;20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 17, 2014</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.31</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment of the Exclusive License Agreement by and between Mills Pharmaceuticals, LLC and BioVascular, Inc.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September 11, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.32</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License Agreement by and between SELLAS Life Sciences, Inc. and Madison Avenue Suites LLC, dated March 20, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.64</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.33+</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated Exclusive License Agreement by and between SELLAS Life Sciences Group Ltd and Memorial Sloan Kettering Cancer Center, effective October&#160;11, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">S-4/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.65</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">October 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.34</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.8</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.35</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit20180524-101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">License Agreement made as of May 19, 2018 by and between the Registrant and 38th Street Suites LLC</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 24, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.36</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000013/slsexhibit2018054-102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Surrender Agreement made as of May 19, 2018 by and between the Registrant and Madison Avenue Suites LLC</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 24, 2018</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:56%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Settlement Agreement between SELLAS Life Sciences Group, Inc. and individual named defendants, on the one hand, and JGB (Cayman) Newton, Ltd., JGB Collateral LLC, JGB Capital Offshore Ltd., JGB Partners L.P., and JGB Capital L.P., on the other hand, dated as of November 5, 2018</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">November 9, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.38</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Securities Purchase Agreement dated May 10, 2016 between the Registrant and Purchasers</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.39</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment Agreement between the Registrant and JGB (Cayman) Newton Ltd. dated August 22, 2016.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 23, 2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.40</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Waiver dated December 14, 2016 to the Securities Purchase Agreement, dated as of May 10, 2016, by and between Registrant and JGB (Cayman) Newton Ltd.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">February 7, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.41</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Waiver dated April 1, 2017 to the Securities Purchase Agreement dated as of May 10, 2016 by and between the Registrant and JGB (Cayman) Newton Ltd.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 3, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.42</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Voting Agreement by and between the Registrant and its named executive officers, Board of Directors and certain stockholders</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 12, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.43</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant issued pursuant to that certain Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 12, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.44</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/sls-20190305x8xkex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant Exercise Agreement dated March 6, 2019</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 6, 2019</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.45</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amendment Agreement dated May 1, 2017 between the Registrant and JGB (Cayman) Newton Ltd.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Code of Business Conduct and Ethics</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex211.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Subsidiaries of the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20181231ex231.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Consent of Moss Adams LLP, Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Powers of Attorney (included on signature page hereto)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20181231ex311.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended</font></a></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20181231ex312.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended</font></a></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.1**</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20181231ex321.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.INS***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Instance Document.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.SCH***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.CAL***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.DEF***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.LAB***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE***</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Indicates management contract or compensatory plans or arrangements.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The certification attached as Exhibit 32.1 pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">^</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The schedules and exhibits to this exhibit have been omitted pursuant to Item&#160;601(b)(2) of&#160;Regulation&#160;S-K.&#160;A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">***</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In accordance with Rule 406T of Regulation&#160;S-T,&#160;the Interactive Data Files in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section&#160;18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.</font></div></td></tr></table></div></div><div><a name="s3c66c006e25f457480f57706ab783966"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;16. FORM 10-K SUMMARY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></div><hr style="page-break-after:always"><div><a name="s064503BB066BDA4E4C5880682C65433A"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:36%;"></td><td style="width:10%;"></td><td style="width:7%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SELLAS Life Sciences Group, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Date: March 22, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Angelos M. Stergiou, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Angelos Stergiou and Barbara A. Wood, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this annual report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">President, Chief Executive Officer and Director</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(Principal Executive Officer and Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Angelos M. Stergiou, M.D., ScD h.c.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ John T. Burns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Vice President, Finance and Corporate Controller</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(Interim Principal Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">John T. Burns, CPA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Jane Wasman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Chair of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Jane Wasman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Stephen F. Ghiglieri</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stephen F. Ghiglieri</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ David Scheinberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">David Scheinberg, M.D., PhD.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Robert Van Nostrand</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Robert Van Nostrand</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ John Varian</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">John Varian</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>sls20181231ex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="se562ee99e7f44e4dad2d6f7d98fe9af5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:32px;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-225140), Form S-3 (Nos. 333-213908, 333-224845, and 333-226251) and Form S-8 (Nos. 333-174819, 333-182578, 333-210833, and 333-213248) of SELLAS Life Sciences Group, Inc. (the &#8220;Company&#8221;) of our report dated March 22, 2019, relating to the consolidated financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Company&#8217;s going concern uncertainty), appearing in this Annual Report on Form 10-K for the year ended December&#160;31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ Moss Adams LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">San Francisco, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 22, 2019</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sls20181231ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8F70368BCFE8C58F0CD7806833B8756B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, Angelos M. Stergiou, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Annual Report on Form 10-K of SELLAS Life Sciences Group, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March&#160;22, 2019</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Angelos M. Stergious, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(Principal Executive Officer and Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sls20181231ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE06B21719FE2546F699C806834614D24"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, Angelos M. Stergiou, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Annual Report on Form 10-K of SELLAS Life Sciences Group, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March&#160;22, 2019</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Angelos M. Stergious, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(Principal Executive Officer and Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sls20181231ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s983AF40D3B002A2FE0B7806835064480"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the accompanying Annual Report of SELLAS Life Sciences Group, Inc., (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Angelos M. Stergious, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(Principal Executive Officer and Principal Financial Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: March 22, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A signed original of this written statement required by&#160;Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>gale-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:a8496042875a4e46b6a9a1dfb2b39cd8,x:c9d63141675a49bbb15ef6c450a5962c-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:gale="http://www.galenabiopharma.com/20181231" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="gale-20181231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1March212019">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2June29t2018">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:ConvertibleDebtTwoThousandFifteenShareholderNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandSelyNoteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:ConvertibleDebtTwoThousandSelyNoteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:ConvertibleDebtTwoThousandFifteenShareholderNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandSelyNoteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:ConvertibleDebtTwoThousandSelyNoteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PreMergerSecurityholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:PreMergerSecurityholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:PrivateSELLASSecurityHoldersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:PrivateSELLASSecurityHoldersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-28</xbrli:startDate>
			<xbrli:endDate>2017-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-16</xbrli:startDate>
			<xbrli:endDate>2018-07-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3July16">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-16</xbrli:startDate>
			<xbrli:endDate>2018-07-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_SecondTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:SecondTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1March2019_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-16</xbrli:startDate>
			<xbrli:endDate>2018-07-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesANonvotingConvertibleMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-07</xbrli:startDate>
			<xbrli:endDate>2018-03-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesANonvotingConvertibleMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-07</xbrli:startDate>
			<xbrli:endDate>2018-03-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">gale:CorporateCreditCardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">gale:CorporateCreditCardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1January12019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_NPSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:NPSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE301AndGALE302Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE301AndGALE302Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE401Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_NPSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:NPSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE301AndGALE302Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE301AndGALE302Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:GALE401Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3August10th2016_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:SecondMSKAmendmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3May25th2017">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3September4th2014">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3May25th2017_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">gale:MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb24th2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_gale_AdvaxisCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:AdvaxisCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-24</xbrli:startDate>
			<xbrli:endDate>2017-02-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:SecondAmendedandRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q3September11th2006_us-gaap_TypeOfArrangementAxis_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-09-11</xbrli:startDate>
			<xbrli:endDate>2006-09-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">gale:MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-25</xbrli:startDate>
			<xbrli:endDate>2017-05-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2006Q3September11th2006_us-gaap_TypeOfArrangementAxis_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2006-09-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-04</xbrli:startDate>
			<xbrli:endDate>2014-09-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct30toOct30_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:LicenseAmendmentWaiverAndShareIssuanceAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-30</xbrli:startDate>
			<xbrli:endDate>2015-10-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-25</xbrli:startDate>
			<xbrli:endDate>2017-05-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_gale_AdvaxisCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:AdvaxisCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TitleOfIndividualAxis_gale_ChiefExecutiveOfficerCoFounderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:ChiefExecutiveOfficerCoFounderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Oct30_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:LicenseAmendmentWaiverAndShareIssuanceAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-04</xbrli:startDate>
			<xbrli:endDate>2014-09-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:SecondAmendedandRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-25</xbrli:startDate>
			<xbrli:endDate>2017-05-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct11_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:SecondMSKAmendmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-11</xbrli:startDate>
			<xbrli:endDate>2017-10-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TitleOfIndividualAxis_gale_CofounderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:CofounderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_BusinessAcquisitionAxis_gale_AptheraInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4November5th2018_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-05</xbrli:startDate>
			<xbrli:endDate>2018-11-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-10</xbrli:startDate>
			<xbrli:endDate>2016-05-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Nov10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4November2018_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-01</xbrli:startDate>
			<xbrli:endDate>2018-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2April30th_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4November10th_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-10</xbrli:startDate>
			<xbrli:endDate>2018-11-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr30_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May5th2018_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3July24_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-24</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4October23rd_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-23</xbrli:startDate>
			<xbrli:endDate>2018-10-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3October2018">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May18th2018_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-18</xbrli:startDate>
			<xbrli:endDate>2018-05-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementSecondClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesANonvotingConvertibleMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementSecondClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May2018">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Prefunded2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Prefunded2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Prefunded2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantsClassifiedAsLiabilitiesOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantsClassifiedAsLiabilitiesOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Jan1_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_IncentivePlan2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:IncentivePlan2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4January1st">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_MskLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_Dr.AngelosM.StergiouMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gale:MskLicenseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:Dr.AngelosM.StergiouMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_MskLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_Dr.AngelosM.StergiouMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gale:MskLicenseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gale:Dr.AngelosM.StergiouMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_RelatedPartyTransactionAxis_gale_EquilibriaCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gale:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1PublicFloat">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1March312019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1March312019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1March6th2019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-06</xbrli:startDate>
			<xbrli:endDate>2019-03-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2March6May31_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:WarrantExerciseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-06</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="tranche">
		<xbrli:measure>gale:tranche</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>gale:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="counterclaim">
		<xbrli:measure>gale:counterclaim</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q4YTD" id="Fact-97A69B1A2E316A8CF6D0806812C1CF7D">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q4YTD" id="Fact-BB1B037B7607A1F5D5C6806812D9435B">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q4YTD" id="Fact-38FCA9836ED19E45216FA339176B75CB">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q4YTD" id="Fact-7804A1A73437513048D3806812DD2B9F">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q4YTD" id="Fact-5DD797D4DAF931DF347B806812E19CB7">2018-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q4YTD" id="Fact-93DB215A47C38D8ADE73806812CECAF7">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q4YTD" id="Fact-6DB8CAF09150C3D5A7E5806812C304EE">0001390478</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q1March212019" decimals="INF" id="Fact-0FA3DDDB472586321293806812E00601" unitRef="shares">23176475</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2018Q4YTD" id="Fact-96DA56103050D77372A59D331346D613">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q4YTD" id="Fact-22A5895041D987A0159D806812CB12D8">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2018Q4YTD" id="Fact-8FB0AAEA8DFD21A7ABDD806812DF5FB5">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="I2018Q2June29t2018" decimals="0" id="Fact-EA6D023BA03AC83B53139D3458DACEE6" unitRef="usd">14425577</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2018Q4YTD" id="Fact-F1A53611027CEFE18EF8806812E4163B">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2018Q4YTD" id="Fact-24FAC44DFD3648B9853D999CAE96BFB8">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2018Q4YTD" id="Fact-284BB406AF9FACAFAE20806812C2CBF9">true</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2018Q4YTD" id="Fact-6875EE472C6518A4F1219D3A40172BDA">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q4YTD" id="Fact-16EE6183401FDB0879359D3B719F09A2">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="FD2018Q4YTD" id="Fact-D7F66A7EF83FEA7924D5806812C90B8D">SLS</dei:TradingSymbol>
	<gale:AccruedCompensationIncentive contextRef="FI2017Q4" decimals="-5" id="Fact-A3E2FF12EB14B47017DC9285E72F317E" unitRef="usd">100000</gale:AccruedCompensationIncentive>
	<gale:AdditionalSharesIssuedInConnectionWithLicensingAgreement contextRef="D2016Q3August10th2016_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember" decimals="INF" id="Fact-AA5545B4599B2CE4601A978723AD1AA2" unitRef="shares">30314</gale:AdditionalSharesIssuedInConnectionWithLicensingAgreement>
	<gale:AdditionalSharesIssuedInConnectionWithLicensingAgreement contextRef="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember" decimals="INF" id="Fact-A2419D29D905902E5D0E975EB1325AA1" unitRef="shares">7700</gale:AdditionalSharesIssuedInConnectionWithLicensingAgreement>
	<gale:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A1616F7768C0DC014275989560CDC7B9" unitRef="usd">-675000</gale:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion>
	<gale:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7A4171D38F6B4DE33AF4989560E324B2" unitRef="usd">-675000</gale:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion>
	<gale:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7D1630EB046E6E2B4B9A988EF0161ACD" unitRef="usd">32000</gale:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition>
	<gale:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4B795F17F60327E44BBD988EF0332460" unitRef="usd">32000</gale:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition>
	<gale:AnnualMaintenanceFee contextRef="I2006Q3September11th2006_us-gaap_TypeOfArrangementAxis_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" decimals="-5" id="Fact-28909384EB5B9AB1E513971B45AA2524" unitRef="usd">200000</gale:AnnualMaintenanceFee>
	<gale:BalanceOfRestrictedCashOverSeniorSecuredDebenture contextRef="I2018Q4November5th2018_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-830EB975CBB7BE9D37E5806815418F0C" unitRef="usd">1600000</gale:BalanceOfRestrictedCashOverSeniorSecuredDebenture>
	<gale:BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding contextRef="D2017Q4Dec29" decimals="-3" id="Fact-B5388C3D3F5FA5B696B47E7BF8BE4DC1" unitRef="usd">32000</gale:BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding>
	<gale:BusinessCombinationFairValueOfSharesOutstanding contextRef="D2017Q4Dec29" decimals="-3" id="Fact-046621C9241497E8D4317E7B32CB7180" unitRef="usd">12487000</gale:BusinessCombinationFairValueOfSharesOutstanding>
	<gale:BusinessCombinationProFormaTransactionCosts contextRef="FD2017Q4YTD" decimals="-5" id="Fact-106DBFE400A49B79FB2898C2FC458AC2" unitRef="usd">8700000</gale:BusinessCombinationProFormaTransactionCosts>
	<gale:BusinessCombinationProFormaTransactionCosts contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-5" id="Fact-0448979D92BBF91648B398C08A31ADDF" unitRef="usd">5700000</gale:BusinessCombinationProFormaTransactionCosts>
	<gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-1C695B99FFB0EF59D5727E6877AC9F9C" unitRef="usd">5692000</gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses>
	<gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-8D3D6C4E0F66F0F28F287E697F6AF1DF" unitRef="usd">1300000</gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement>
	<gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-22DAAFDE14A7F5737E317E65CB3B9F0C" unitRef="usd">10346000</gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
	<gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-C5D36DCC7AF4EBECA4527E74527D2A34" unitRef="usd">1309000</gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability>
	<gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-7DBE56A36EC6B9E297797E67165DE80D" unitRef="usd">34775000</gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6EB992D0B685B3CCD6AF806813F6EBE3" unitRef="usd">0</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3436BE9A371A2FC13DD2806813B20BD0" unitRef="usd">5302000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2017Q4YTD" decimals="-3" id="Fact-97B706766F323FBBDE6380681354A9DB" unitRef="usd">0</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0C19363ED931A485215C80681419AE64" unitRef="usd">-3032000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F20948F04D558FFA2FDB8068142FE676" unitRef="usd">0</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2018Q4YTD" decimals="-3" id="Fact-88D2C48AD5364466995280681351F838" unitRef="usd">-3032000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2018Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-31F81465475D77C23527806814D8FAF9" unitRef="usd">3032000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A6710366B20201B3D920806814DA8054" unitRef="usd">5300000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-7D7B76A59851E34D13E28068151583FF" unitRef="usd">776000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-A1AF5188FD0345D3E850806814FFCA62" unitRef="usd">4000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-0A4953B96A06898CD06C8068150AED31" unitRef="usd">4520000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ClassOfWarrantOrRightCanceled contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="0" id="Fact-55627C40CE40D1651FC0A180A8D5F565" unitRef="shares">534334</gale:ClassOfWarrantOrRightCanceled>
	<gale:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded contextRef="I2018Q3July16" decimals="INF" id="Fact-09AFE53FA26D8EAC22388068136698BA" unitRef="usdPerShare">0.0001</gale:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded>
	<gale:ClassOfWarrantOrRightExercised contextRef="D2019Q1March6th2019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-5AD188C47980C784402F92F185749727" unitRef="shares">1200000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CC4C128CDE8AD4089E17806814904C91" unitRef="shares">4050000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-CD490ED07FC630C07F7680681426D352" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-718D330619F4AA66D83580681448B67B" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-806F9DFA2A6EC9E39F2480681408E01B" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-D30D3E145857435F0AF9806814577D67" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-AC8E889A2C52D2552DCA8068140C0938" unitRef="shares">4050000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-991442BCBA858E0C49C4806814298CEA" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightNewWarrantsIssued contextRef="D2019Q1March6th2019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-12DAE7EF0FFA969C6ED69D4EB3B73B6E" unitRef="shares">1200000</gale:ClassOfWarrantOrRightNewWarrantsIssued>
	<gale:ClassOfWarrantOrRightOutstandingExercisable contextRef="I2019Q1March312019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-3CE3380EF07DF8098C729D486ECDD04F" unitRef="shares">3800000</gale:ClassOfWarrantOrRightOutstandingExercisable>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5FC3FBF8719A464F5D798068145925AD" unitRef="shares">542000</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-C06FDF1C53E775561DC0806814566368" unitRef="shares">534000</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-A232F14528C5BCA5A32C80681453C925" unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-F50BE67D9C4A67640E268068144578A5" unitRef="shares">8000</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-6E658F09C17DE5DD1267806814B34705" unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FD3B8A15C07CA1EFC5C580681434D28E" unitRef="shares">21327000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-F9429C154ABE59E5F4BB806814C50DBB" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-CB683E38233A5ED871AC8068143BED10" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-EBBCA3AB44003BCA34BD8068143D80C5" unitRef="shares">15268000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-55490CD57E69515D125A806814409517" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-DEC1E8D18DDC47E23B99806814943575" unitRef="shares">4675000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-CE4F6CCDEDA2E7BC3EDB8068149D696A" unitRef="shares">1384000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock contextRef="FD2018Q4YTD" decimals="INF" id="Fact-F8B7CE9E275DC63B220B806812D95FBE" unitRef="shares">121667</gale:ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock>
	<gale:ClassofWarrantorRightTerm contextRef="D2017Q4Dec29" id="Fact-2F459B9FA8EBB9D6CF1D806812C081E5">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" id="Fact-69DD95FD10EC1D2CBAC780681375E9FA">P5Y6M</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2018Q3" id="Fact-CACED506CDC752072FDB806813DDB619">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" id="Fact-15151E83510F0A71937CA15ECB4D07FD">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-7122EB280CCFC18A4EB380681364AF85">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClosingPriceOfCommonStock contextRef="FI2018Q4" decimals="INF" id="Fact-F12E9CEAD7813AAA02BD806814B4E5FA" unitRef="usdPerShare">1.23</gale:ClosingPriceOfCommonStock>
	<gale:CollaborationAgreementTerm contextRef="D2016Q2Jun" id="Fact-E1BC681058415CD42151A16890E67534">P3Y</gale:CollaborationAgreementTerm>
	<gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan contextRef="FI2018Q4" decimals="-3" id="Fact-F01052DAD7C11BB0AB8F806813C4C3F7" unitRef="shares">115000</gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan>
	<gale:CommonStockConversionRatio contextRef="D2017Q4Dec29_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember" decimals="INF" id="Fact-E68D8204D15AD6C9560A8068145DDA0C" unitRef="number">43.9972</gale:CommonStockConversionRatio>
	<gale:CommonStockIssuedDuringThePeriodForCancellationOfWarrants contextRef="FD2018Q4YTD" decimals="INF" id="Fact-B198245AFFB7C4DBCB788068132890F7" unitRef="shares">54613</gale:CommonStockIssuedDuringThePeriodForCancellationOfWarrants>
	<gale:CommonStockSharesAcquiredinExchangeforWarrants contextRef="FD2018Q4YTD" decimals="INF" id="Fact-AF1C40A9CE8FE3429F2D8068131C8EBC" unitRef="shares">412667</gale:CommonStockSharesAcquiredinExchangeforWarrants>
	<gale:CommonStockSharesAcquiredinExchangeforWarrants contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-51A55535F25F6B9556038068150B05DE" unitRef="shares">412667</gale:CommonStockSharesAcquiredinExchangeforWarrants>
	<gale:CommonStockSharesReservedForIssuanceAdditionalShares contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-C85C50AD6CEADA704E219C4A96EB17A0" unitRef="shares">150000</gale:CommonStockSharesReservedForIssuanceAdditionalShares>
	<gale:ConsiderationExchangedFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-04BE11F9DD99E180CC60806812CA3F0B" unitRef="usd">1200000</gale:ConsiderationExchangedFairValue>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2017Q4" decimals="-3" id="Fact-11503230385BEFD43CA78068141DEEBB" unitRef="usd">1294000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2018Q4" decimals="-3" id="Fact-86B90B46921235108298806814497056" unitRef="usd">4326000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContractResearchPayable contextRef="FI2017Q4" decimals="-3" id="Fact-A958672E29615EE66A9C8068130FD518" unitRef="usd">51000</gale:ContractResearchPayable>
	<gale:ContractResearchPayable contextRef="FI2018Q4" decimals="-3" id="Fact-927B640FBA7D80F70708806813102F61" unitRef="usd">858000</gale:ContractResearchPayable>
	<gale:ConversionwithSeriesAConvertiblePreferredStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EC3164D99A6B38954A04806813EEA5F2" unitRef="usd">0</gale:ConversionwithSeriesAConvertiblePreferredStock>
	<gale:ConversionwithSeriesAConvertiblePreferredStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2B634A5D079FB5CB9C39806813339BA4" unitRef="usd">4436000</gale:ConversionwithSeriesAConvertiblePreferredStock>
	<gale:ConvertiblePreferredStockConversionPrice contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="2" id="Fact-0323A029B809E28B3D798068148A4F6D" unitRef="usdPerShare">1.00</gale:ConvertiblePreferredStockConversionPrice>
	<gale:ConvertiblePreferredStockConversionPrice contextRef="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-E97008960D962399BF98806813F48D5C" unitRef="usdPerShare">5.80</gale:ConvertiblePreferredStockConversionPrice>
	<gale:ConvertiblePreferredStockConversionPrice contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-41F51B1263F35C0B1C9280681365EDFC" unitRef="usdPerShare">6.59</gale:ConvertiblePreferredStockConversionPrice>
	<gale:ConvertiblePreferredStockDividends contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D366E305F4AA5753C9FE80681314EAFA" unitRef="usd">487000</gale:ConvertiblePreferredStockDividends>
	<gale:ConvertiblePreferredStockDividends contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0B7A453DE7E639E724CE80681491D049" unitRef="usd">487000</gale:ConvertiblePreferredStockDividends>
	<gale:ConvertiblePreferredStockIssuedShares contextRef="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-8F9CEDC4256A685CC5B3806813D1A75F" unitRef="shares">5987</gale:ConvertiblePreferredStockIssuedShares>
	<gale:ConvertiblePreferredStockIssuedShares contextRef="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-695B729CCCD9EF2DC45580681416E1DE" unitRef="shares">4713</gale:ConvertiblePreferredStockIssuedShares>
	<gale:ConvertiblePreferredStockNumberOfTranches contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-DB1ED93C77CB762214CB8068137E5996" unitRef="tranche">2</gale:ConvertiblePreferredStockNumberOfTranches>
	<gale:DebtInstrumentCovenantLiquidityCovenant contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-BE2613B48F460A3B519580681461546A" unitRef="usd">18500000</gale:DebtInstrumentCovenantLiquidityCovenant>
	<gale:DebtInstrumentRedemptionPrincipalAmountRedeemed contextRef="FD2018Q4YTD" decimals="-5" id="Fact-A5AFE823830404AA3FC98068150ECC53" unitRef="usd">2800000</gale:DebtInstrumentRedemptionPrincipalAmountRedeemed>
	<gale:DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash contextRef="FD2018Q4YTD" decimals="-5" id="Fact-3B6D21F1B5FD46D1DD6680681520EBA8" unitRef="usd">600000</gale:DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash>
	<gale:DebtInstrumentRedemptionPrincipalAmountRedeemedShares contextRef="FI2018Q4" decimals="INF" id="Fact-71C5B0CD72EC8D939FAC806815205DEA" unitRef="shares">659529</gale:DebtInstrumentRedemptionPrincipalAmountRedeemedShares>
	<gale:DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-302FEA3AAFA60D2B1ECA98D202C6038B" unitRef="usd">675000</gale:DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance>
	<gale:DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A54D283159A3D2BBD111A143E32ED8E2" unitRef="usd">0</gale:DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance>
	<gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember" decimals="-5" id="Fact-365F256303B23C0895C8806813C7AA2E" unitRef="usd">2000000</gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock>
	<gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock contextRef="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember" decimals="-5" id="Fact-45ECAB523E08A4D772418068140271F4" unitRef="usd">2500000</gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock>
	<gale:DeemedDividendOnDebtConversion contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C7A2D9B54BBF87922C0898DAB9DC77E5" unitRef="usd">675000</gale:DeemedDividendOnDebtConversion>
	<gale:DeemedDividendOnDebtConversion contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BAF5E965B1882D6681A198DAB9F8C7F7" unitRef="usd">0</gale:DeemedDividendOnDebtConversion>
	<gale:DeferredTaxAssetsLicensingDeductionDeferral contextRef="FI2017Q4" decimals="-3" id="Fact-364090ECD948A860237D7F93C97A8EBE" unitRef="usd">2105000</gale:DeferredTaxAssetsLicensingDeductionDeferral>
	<gale:DeferredTaxAssetsLicensingDeductionDeferral contextRef="FI2018Q4" decimals="-3" id="Fact-B6DB5F3A8DEA8186B5597F93C98102D6" unitRef="usd">5961000</gale:DeferredTaxAssetsLicensingDeductionDeferral>
	<gale:DividendModificationOfWarrants contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B8F63531E8BAF46A608C80681326F05B" unitRef="usd">-491000</gale:DividendModificationOfWarrants>
	<gale:DividendModificationOfWarrants contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-BB5EFD10C86DC534BA2B806814B2D38E" unitRef="usd">-491000</gale:DividendModificationOfWarrants>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A897DB89B44CFE7A8854806814BDF994" unitRef="usd">4436000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStock>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStock contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8A22B6A5B45773BE9F91806814C760E0" unitRef="usd">4436000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStock>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-30FB4E89C6653AF74FB3806813B263EB" unitRef="usd">0</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q3QTD" decimals="-5" id="Fact-73C3411EC0937C2F744180681407C6D4" unitRef="usd">8700000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1BDE346BAD1D510C27D380681409785E" unitRef="usd">8654000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4128DFFC92DCEC3186B9806814A2FE43" unitRef="usd">8654000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="FD2017Q4YTD" decimals="3" id="Fact-FC148788EF2B050782B07F9FD99CF932" unitRef="number">-0.011</gale:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
	<gale:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="FD2018Q4YTD" decimals="3" id="Fact-5762B9090D0C11D2F5BA7F9FD9941F76" unitRef="number">0.015</gale:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5B9CBF72385A06BBA47D806814FE3C24" unitRef="usd">900000</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition contextRef="FD2018Q4YTD" id="Fact-A3E7BE80F7B1E01FC85480681511FE27">P2Y1M17D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
	<gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="FD2017Q4YTD" decimals="-3" id="Fact-271C972C55BED2A39972806813CBB4D6" unitRef="usd">449000</gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
	<gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3783F8664F716A01E0D6806813B4BBA9" unitRef="usd">0</gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
	<gale:FairValueOfStockOptionsAssumedInConnectionWithAcquisition contextRef="FD2017Q4YTD" decimals="-3" id="Fact-063D7A1EEC7D2396C51798CE36D0584B" unitRef="usd">32000</gale:FairValueOfStockOptionsAssumedInConnectionWithAcquisition>
	<gale:FairValueOfStockOptionsAssumedInConnectionWithAcquisition contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8C2D760CBD036749B51398CE36E422CA" unitRef="usd">0</gale:FairValueOfStockOptionsAssumedInConnectionWithAcquisition>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" id="Fact-FB4768864011FA09A2F080681566E95E">P4Y1M13D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember" id="Fact-CA6609E755609DFD514380681569B4D5">P2Y8M26D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" id="Fact-48055028A7D4952FEF298068128CEC8D">P3Y1M13D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" id="Fact-00D8980F3C5AD8B6D6FF8068128BB282">P2Y5M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" id="Fact-5E54C52120C2CE664F5F80681297BFD7">P4Y9M4D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C524069EC376AABCAA93806814DDD8F5" unitRef="usd">526000</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-3D05A4426A4C734EBF05806814E94A57" unitRef="usd">526000</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-A3C2E00397215A33BC178068150F4C2C" unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-2EF54A5ADB2802B2CA26806814E7DD39" unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C03279CEB2AC0A48772D8068150D0D56" unitRef="usd">491000</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-AC22AEC2E51D62A7E559806814ED8CC3" unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-439AADEABCE73E87F57980681511D5F9" unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-E4858304CDDFE3A103708068150DB820" unitRef="usd">491000</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B74F19D38B475A6434248068139A5E54" unitRef="usd">5530000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-7530F0F3ADEF4A01735B806814D82AB8" unitRef="usd">1309000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-C091B2C7A14770A0C992806814F0188C" unitRef="usd">1305000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-6AB3FF279AACE644DB69806814DACA98" unitRef="usd">4000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-BDF232FCE1AC1A199A16806814F2FE2C" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-C30491FBF97FE2642AD28068151796CB" unitRef="usd">1013000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-CA834084473904FFB7D9806814FD7E9F" unitRef="usd">3000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-FC417A10FB3FE4160EF5806814FE0BB7" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-ABE6CA5B6C3F252ED72E80681501A248" unitRef="usd">1010000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4" decimals="-3" id="Fact-5E00CBBB33B3DAF8BE3980681427B9DF" unitRef="usd">1309000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9801CB2C18620913C3688068138FAC42" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0464958044607CC0C700806813906536" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E0675B2D261B4270A99D8068136233F9" unitRef="usd">1309000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A89625AE39635C70DF848068138774EC" unitRef="usd">1309000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q4" decimals="-3" id="Fact-D8DA4DDF1EE2AEE1EAEF8068140B2B75" unitRef="usd">1013000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F6206EB1F581C77C58698068154C6B0A" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-199AFC524E35B0260A0A8068155A1DB4" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7BA4A44FBC2FC6D94DA7806815485F3A" unitRef="usd">1013000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-519D579DA78174D3ED5B8068156B3AEF" unitRef="usd">1013000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1A208EA2D86D27DA88BA806814F9B0F9" unitRef="usd">5039000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-123DE17C34C000DBBE71806814F185FA" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-A1877086364500A80DDF8068151F1063" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-36937E275067A2CC329A806814E872D2" unitRef="usd">5039000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2017Q4Dec29" decimals="2" id="Fact-278C223CE02744EB07CA806812C6CCD4" unitRef="usdPerShare">5.60</gale:FairValueofWarrantsGrantedperShare>
	<gale:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-E7822F3BA0B79BEF25B592B41BC27F06" unitRef="usd">72000</gale:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits>
	<gale:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-8F5470E25BB945EA15D092B41BAC5AF3" unitRef="usd">55000</gale:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits>
	<gale:InProcessResearchDevelopment contextRef="FI2017Q4" decimals="-3" id="Fact-DBEBBB13C0EF62464E6C806813EDAA33" unitRef="usd">17600000</gale:InProcessResearchDevelopment>
	<gale:InProcessResearchDevelopment contextRef="FI2018Q4" decimals="-3" id="Fact-1E31A80E643A614B2867806813E15D2C" unitRef="usd">8500000</gale:InProcessResearchDevelopment>
	<gale:IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash contextRef="FD2018Q4YTD" decimals="INF" id="Fact-407945F85E357397C6319289E87D9E6B" unitRef="number">0.02</gale:IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash>
	<gale:IncentiveFeePercentageEqualToPostMoneyMarketValue contextRef="FI2018Q4" decimals="INF" id="Fact-ABD6B899D5D325CB9A119287A5451916" unitRef="number">0.02</gale:IncentiveFeePercentageEqualToPostMoneyMarketValue>
	<gale:IncentiveFeePercentageEqualToPostMoneyMarketValue contextRef="I2017Q1PublicFloat" decimals="INF" id="Fact-F691C1C4E91144E0D60297AD2A9D6C4F" unitRef="number">0.02</gale:IncentiveFeePercentageEqualToPostMoneyMarketValue>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2017Q4YTD" decimals="-3" id="Fact-545B8C54DA01CC289A118068139F167A" unitRef="usd">0</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2018Q4YTD" decimals="-3" id="Fact-840D9452559073C74C2880681345D571" unitRef="usd">491000</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2018Q4YTD" decimals="-5" id="Fact-D1E3138215C8C8CFA0A48068140B97BA" unitRef="usd">500000</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-60D34A6D9331AEC035B09697F8CEEA08" unitRef="usd">-1400000</gale:IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment>
	<gale:IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-CB33F7647BDB7F6B9A02A09CDD3C6702" unitRef="usd">500000</gale:IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets>
	<gale:LiabilityClassifiedWarrantsAntidilutionProtection contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D8939AF0C5B2493036118068144AA231" unitRef="usd">0</gale:LiabilityClassifiedWarrantsAntidilutionProtection>
	<gale:LiabilityClassifiedWarrantsAntidilutionProtection contextRef="FD2018Q4YTD" decimals="-3" id="Fact-49D34FA2FEECE67CA7B780681344F928" unitRef="usd">491000</gale:LiabilityClassifiedWarrantsAntidilutionProtection>
	<gale:LicenseAgreementExpirationTerm contextRef="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" id="Fact-4A6549AAE0493FD5226C9BD12A0E4C82">P10Y</gale:LicenseAgreementExpirationTerm>
	<gale:LicenseAgreementMilestonePayments contextRef="D2006Q3September11th2006_us-gaap_TypeOfArrangementAxis_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" decimals="-5" id="Fact-1208F2909A1613DBBD659C7A2A0C2ABD" unitRef="usd">3800000</gale:LicenseAgreementMilestonePayments>
	<gale:LicenseAgreementMilestonePayments contextRef="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-E585137E4389FEFF5AF997196888F612" unitRef="usd">17400000</gale:LicenseAgreementMilestonePayments>
	<gale:LicenseAgreementMilestonePayments contextRef="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-6A4D986498C8E5B8A89B97930E9C6EF4" unitRef="usd">200000</gale:LicenseAgreementMilestonePayments>
	<gale:LicenseAgreementMilestonePayments contextRef="D2017Q4Oct11_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember" decimals="-5" id="Fact-F1C308E991DEB6B3812D9BB62ADFDBDB" unitRef="usd">700000</gale:LicenseAgreementMilestonePayments>
	<gale:LicenseAgreementMilestonePayments contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-F8CC9C10451E8FCA9F8A9BB644A2A78F" unitRef="usd">700000</gale:LicenseAgreementMilestonePayments>
	<gale:LicenseAgreementMilestonePayments contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-3F417C2359141BB6F40F9BB70832E546" unitRef="usd">500000</gale:LicenseAgreementMilestonePayments>
	<gale:LicenseAgreementOutstandingAmountPayable contextRef="D2016Q3August10th2016_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember" decimals="-5" id="Fact-C2509C294753D3F2E9BA977A077576AC" unitRef="usd">900000</gale:LicenseAgreementOutstandingAmountPayable>
	<gale:LicenseAgreementOutstandingAmountPayable contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-C8B5D58E85F6B32E85879BBBB8702672" unitRef="usd">1000000</gale:LicenseAgreementOutstandingAmountPayable>
	<gale:LicenseAgreementOutstandingAmountPayable contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-BDF156FF2602599DB9AB9BB93815E3E4" unitRef="usd">1000000</gale:LicenseAgreementOutstandingAmountPayable>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2017Q3July24_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" decimals="-3" id="Fact-2E7F3FDDF77F5E8E4A6F806812DAF38B" unitRef="usd">1250000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FBA56237F68F7A5F8ABC8068138B788C" unitRef="usd">0</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EA48866783A56DF4E30D806814429528" unitRef="usd">1250000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LongtermDebtIssuedInConnectionWithWarrantExchanges contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DEC8DF9DD939B34B8B51806813B031CB" unitRef="usd">0</gale:LongtermDebtIssuedInConnectionWithWarrantExchanges>
	<gale:LongtermDebtIssuedInConnectionWithWarrantExchanges contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2D8F3FA213F8A019DE21806813E4A019" unitRef="usd">966000</gale:LongtermDebtIssuedInConnectionWithWarrantExchanges>
	<gale:LossContingencyNumberOfCounterclaims contextRef="D2018Q2May18th2018_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="INF" id="Fact-6AC6AE471E6DE175CCE0806812BEC64E" unitRef="counterclaim">7</gale:LossContingencyNumberOfCounterclaims>
	<gale:LossContingencyNumberOfCounterclaims contextRef="D2018Q4October23rd_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="INF" id="Fact-4D3B20349532FA831B42806812F2B81C" unitRef="counterclaim">4</gale:LossContingencyNumberOfCounterclaims>
	<gale:LossOnSettlementOfLiabilityClassifiedWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-176C3E45277F4B40999C8068138FF131" unitRef="usd">0</gale:LossOnSettlementOfLiabilityClassifiedWarrants>
	<gale:LossOnSettlementOfLiabilityClassifiedWarrants contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3D4F2E04495C21FD5323806813A26DF5" unitRef="usd">727000</gale:LossOnSettlementOfLiabilityClassifiedWarrants>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C431B6C183FECFF4CA478068145C669A" unitRef="usd">0</gale:LossOnSettlementOfWarrantsLiability>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8AED1D7BAD55E235D5FD806815264542" unitRef="usd">727000</gale:LossOnSettlementOfWarrantsLiability>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2018Q4YTD" decimals="-5" id="Fact-483E9A6A21516A8742D5A1815B8E1338" unitRef="usd">700000</gale:LossOnSettlementOfWarrantsLiability>
	<gale:MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss contextRef="FD2018Q4YTD" decimals="INF" id="Fact-435A9FFFBCEF48E2410E9202F96DC807" unitRef="number">80</gale:MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss>
	<gale:MaximumNumberOfDaysToMakePayments contextRef="D2017Q4Oct11_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember" id="Fact-15C1AD128BFB472F2AA59BC7FA24CFAF">P60D</gale:MaximumNumberOfDaysToMakePayments>
	<gale:MilestoneFeePaymentsUponCommencementOfClinicalTrials contextRef="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-906AB3590B030F36D53E9C6B53386E66" unitRef="usd">300000</gale:MilestoneFeePaymentsUponCommencementOfClinicalTrials>
	<gale:MilestoneFeePaymentsUponCommencementOfClinicalTrials contextRef="D2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" decimals="-5" id="Fact-8A56F54CA29FBE5BD40D9C5FE23F6AC4" unitRef="usd">400000</gale:MilestoneFeePaymentsUponCommencementOfClinicalTrials>
	<gale:MinimumAnnualRoyaltyPayment contextRef="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-5454BD2ED3D0FA384321971266D16C58" unitRef="usd">100000</gale:MinimumAnnualRoyaltyPayment>
	<gale:MinimumAnnualRoyaltyPayment contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-F8E3C6277C409F12F5429BBA89BA64BE" unitRef="usd">100000</gale:MinimumAnnualRoyaltyPayment>
	<gale:MinimumAnnualRoyaltyPayment contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-6945CA6F5607A580E7309BB81BCF800A" unitRef="usd">100000</gale:MinimumAnnualRoyaltyPayment>
	<gale:NonrefundableMilestonePayments contextRef="D2017Q1Feb24th2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_gale_AdvaxisCollaborationAgreementMember" decimals="-5" id="Fact-63BD895B2DBBB4FD459D9767B2FA7380" unitRef="usd">108000000</gale:NonrefundableMilestonePayments>
	<gale:NonrefundableSalesMilestonePayments contextRef="D2017Q1Feb24th2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_gale_AdvaxisCollaborationAgreementMember" decimals="-5" id="Fact-37F99296FBFEA0687CD59766D2EBE6A4" unitRef="usd">250000000</gale:NonrefundableSalesMilestonePayments>
	<gale:OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage contextRef="FD2018Q4YTD" decimals="INF" id="Fact-F6FA6B7A610826F62F3092C15D7948ED" unitRef="number">0.5</gale:OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage>
	<gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan contextRef="FI2018Q4" decimals="-3" id="Fact-865551BA43B39373EBDF806813BA1373" unitRef="shares">421000</gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan>
	<gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards contextRef="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="INF" id="Fact-292E0219480972DA28A2806814E726B1" unitRef="number">0.04</gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards>
	<gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards contextRef="FD2018Q4YTD" decimals="INF" id="Fact-0DA308C8E650CC952933918CE3098154" unitRef="number">0.01</gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards>
	<gale:PercentageOfFullyDilutedShareCapital contextRef="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" decimals="3" id="Fact-34C31B5D319104907B25974AE141B2EA" unitRef="number">0.015</gale:PercentageOfFullyDilutedShareCapital>
	<gale:PercentageOfFullyDilutedShareCapital contextRef="D2015Q4Oct30toOct30_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" decimals="INF" id="Fact-2FC5D486805EB89D02F797741BD83C00" unitRef="number">0.01</gale:PercentageOfFullyDilutedShareCapital>
	<gale:PercentageOfFullyDilutedShareCapitalOwned contextRef="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PreMergerSecurityholdersMember" decimals="3" id="Fact-0FFA37458D7E60699F5B8068146BEB37" unitRef="number">0.325</gale:PercentageOfFullyDilutedShareCapitalOwned>
	<gale:PercentageOfFullyDilutedShareCapitalOwned contextRef="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember" decimals="3" id="Fact-7F494F2E1680D5798A278068146AB234" unitRef="number">0.675</gale:PercentageOfFullyDilutedShareCapitalOwned>
	<gale:PercentageOfOwnershipOutstandingShareCapital contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_MskLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_Dr.AngelosM.StergiouMember" decimals="3" id="Fact-BE71B8244043A3CD18529209AF033D17" unitRef="number">0.078</gale:PercentageOfOwnershipOutstandingShareCapital>
	<gale:PercentageOfOwnershipOutstandingShareCapital contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionAxis_gale_MskLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gale_Dr.AngelosM.StergiouMember" decimals="3" id="Fact-745B4F505F07BB2F0E089209AF0ABE71" unitRef="number">0.019</gale:PercentageOfOwnershipOutstandingShareCapital>
	<gale:PreferredStockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DF13DF24FA0878A82DC7806814A18411" unitRef="usd">9647000</gale:PreferredStockIssuedDuringPeriodValueNewIssues>
	<gale:PreferredStockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4656C0E389CE9E6FDC5D806813318773" unitRef="usd">9647000</gale:PreferredStockIssuedDuringPeriodValueNewIssues>
	<gale:ProceedsfromIssuanceofLongtermDebtandWarrantsNet contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-CA4A882AD555F2CC280E80681533C019" unitRef="usd">23400000</gale:ProceedsfromIssuanceofLongtermDebtandWarrantsNet>
	<gale:RebatesAndReturnsOfFormerCommercialProducts contextRef="FI2017Q4" decimals="-3" id="Fact-8402FF09464557496EF78068130BF0D7" unitRef="usd">223000</gale:RebatesAndReturnsOfFormerCommercialProducts>
	<gale:RebatesAndReturnsOfFormerCommercialProducts contextRef="FI2018Q4" decimals="-3" id="Fact-38EAA12747354050EE90806813122AFF" unitRef="usd">138000</gale:RebatesAndReturnsOfFormerCommercialProducts>
	<gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5A73D54804A9D92B996E806814059A40" unitRef="usd">0</gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock>
	<gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D5BE3258DDD23B62555A806813B7B4BC" unitRef="usd">285000</gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1EE9E25370920D99A84598CE36FC14D1" unitRef="usd">12487000</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2018Q4YTD" decimals="-3" id="Fact-785452F70494CE0C08AA98CE370ECD26" unitRef="usd">0</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:ReimbursementOfLegalFees contextRef="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-EC050D13C255E0542BFA80681512A903" unitRef="usd">5000000</gale:ReimbursementOfLegalFees>
	<gale:ResearchFundingCosts contextRef="FD2015Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-7B9965B259F3150F0D7A971475DE2B2F" unitRef="usd">200000</gale:ResearchFundingCosts>
	<gale:ResearchFundingCosts contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-C4BABB498FAF5361E3219C9D8E8AC957" unitRef="usd">200000</gale:ResearchFundingCosts>
	<gale:ResearchFundingCosts contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-C380BC170BD418635EEA9BBB90F3C93D" unitRef="usd">200000</gale:ResearchFundingCosts>
	<gale:ResearchFundingCosts contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-2AAF78715B2FA86F15569BBB5511E811" unitRef="usd">100000</gale:ResearchFundingCosts>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-744BD9A46CB020460EE68068137215FD" unitRef="usd">10245000</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AB9C0BA22C296CCA579980681389ABA5" unitRef="usd">0</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E6BB8661F3CBEA07014D806813B16474" unitRef="usd">0</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0A8776AA3BE5A533ABEE806813A47CCF" unitRef="usd">10245000</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedStockSharesReservedforFutureIssuance contextRef="FI2018Q4" decimals="-3" id="Fact-8D5346C7D0365B58B08A806813BA7C7B" unitRef="shares">13000</gale:RestrictedStockSharesReservedforFutureIssuance>
	<gale:RoyaltyPaymentMaximumRate contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_gale_AdvaxisCollaborationAgreementMember" decimals="-8" id="Fact-2AF5FDEA5E8999B9EA5F9C77EC920653" unitRef="usd">1000000000</gale:RoyaltyPaymentMaximumRate>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger contextRef="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_IncentivePlan2016Member" decimals="INF" id="Fact-58326A83E00CE2A75C8E806814B121B3" unitRef="shares">10171</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DE93506A717AAD31F782806812BD9A7D" unitRef="usd">0</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8A1229AE03A4C4C04996806812BAAC7E" unitRef="usd">0</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants contextRef="FD2017Q4YTD" decimals="INF" id="Fact-0F41F974A3210DCAEC9F918774B1BA9C" unitRef="number">0.15</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants>
	<gale:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D09D96DCEEC230C9345598917AAFB588" unitRef="usd">6739000</gale:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod>
	<gale:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5B66793DB434078D5C3698917ABF269B" unitRef="usd">6739000</gale:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod>
	<gale:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-605C862877216192C05498A54F67A852" unitRef="shares">632326</gale:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares>
	<gale:SharesIssuedToSettleAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-44CD30F231AE11201C6B98D0556F0C62" unitRef="usd">150000</gale:SharesIssuedToSettleAccountsPayable>
	<gale:SharesIssuedToSettleAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-03E40D2264C2EAD9C087A1440483ED96" unitRef="usd">0</gale:SharesIssuedToSettleAccountsPayable>
	<gale:SharesIssuedToSettlerRelatedPartyAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F59F38D2DBEE0E9C5AF598CE3721F131" unitRef="usd">228000</gale:SharesIssuedToSettlerRelatedPartyAccountsPayable>
	<gale:SharesIssuedToSettlerRelatedPartyAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CC4351B56BD7549EDD8398CE3736FAFD" unitRef="usd">0</gale:SharesIssuedToSettlerRelatedPartyAccountsPayable>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2014Q3September4th2014" decimals="INF" id="Fact-78786D833943F9F0B24B974CEEF634C9" unitRef="shares">13199</gale:SharesIssuedUnderLicenseAgreement>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TitleOfIndividualAxis_gale_ChiefExecutiveOfficerCoFounderMember" decimals="INF" id="Fact-EDD63FD1850737A072E79BC09747FA4A" unitRef="shares">6599</gale:SharesIssuedUnderLicenseAgreement>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TitleOfIndividualAxis_gale_CofounderMember" decimals="INF" id="Fact-DA7A1DFE16CEA4CD18B09C905FA4345D" unitRef="shares">6599</gale:SharesIssuedUnderLicenseAgreement>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2015Q4Oct30_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" decimals="INF" id="Fact-7884D4976428F5BF71DA9775ED7E6740" unitRef="shares">10867</gale:SharesIssuedUnderLicenseAgreement>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2017Q3May25th2017" decimals="INF" id="Fact-EC4D0B8ADE62376724A79BCB35952103" unitRef="shares">8799</gale:SharesIssuedUnderLicenseAgreement>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2017Q3May25th2017_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember" decimals="INF" id="Fact-B37B3BBCA015B4E19F8797554DCB2A42" unitRef="shares">74795</gale:SharesIssuedUnderLicenseAgreement>
	<gale:SharesIssuedUnderLicenseAgreement contextRef="I2017Q3May25th2017_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" decimals="INF" id="Fact-FEC12E5763C849E2ED52978E5D256034" unitRef="shares">15399</gale:SharesIssuedUnderLicenseAgreement>
	<gale:StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement contextRef="D2016Q3August10th2016_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember" decimals="INF" id="Fact-0512B0AFDEA0C0B75C5F978BA2CF714A" unitRef="shares">13815</gale:StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement>
	<gale:StockIssuedDuringPeriodSharesPrefundedWarrant contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-251AE03E9AF2494276F0806814BEE52E" unitRef="shares">4049783</gale:StockIssuedDuringPeriodSharesPrefundedWarrant>
	<gale:StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F22E081040E4A25F63CB989EB9574662" unitRef="shares">96662</gale:StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable>
	<gale:StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2579AED7DAADB4B48D6998A3007B724C" unitRef="shares">58208</gale:StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares>
	<gale:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B8D4F9801163A0DC2BE6988D4BD3101E" unitRef="usd">378000</gale:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable>
	<gale:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A0BD13E5392E5424DE09988D4C693E55" unitRef="usd">378000</gale:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable>
	<gale:StockIssuedForAntidilutionProvisions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4C82894EF33359B4F961989847C1DB6D" unitRef="usd">61000</gale:StockIssuedForAntidilutionProvisions>
	<gale:StockIssuedForAntidilutionProvisions contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9DBF29E3FAA17CFD6A35989847D02D82" unitRef="usd">61000</gale:StockIssuedForAntidilutionProvisions>
	<gale:StockIssuedForAntidilutionProvisionsShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D1F35EB3886D41732A5598A8649644A0" unitRef="shares">7700</gale:StockIssuedForAntidilutionProvisionsShares>
	<gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BDE759FC5C9F4474B7F198BE9D3000A7" unitRef="usd">900000</gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod>
	<gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3C6C947A8DF71360FEA09896BA3D4283" unitRef="usd">941000</gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod>
	<gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A7E890B1D6547AA813919896BAA80432" unitRef="usd">941000</gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod>
	<gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare contextRef="D2017Q4Dec29" decimals="INF" id="Fact-5598C80ECE465209685E9293DF2DF57C" unitRef="shares">119672</gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare>
	<gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares contextRef="FD2017Q4YTD" decimals="INF" id="Fact-8CAE3A88771CC7A74BDE98BF51244D6D" unitRef="shares">119672</gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares>
	<gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-56BB6831492B882752E798A6C336A76B" unitRef="shares">119672</gale:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares>
	<gale:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-66D67FABCB164F6B6EDA98882032960C" unitRef="shares">83594</gale:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares>
	<gale:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9FCD076D413070EE1081988BAA8308D1" unitRef="usd">388000</gale:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue>
	<gale:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0FC6840DD094BFC0EED7988BAABDBA66" unitRef="usd">388000</gale:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue>
	<gale:StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-3BE6070A14B98DB3318DA17BE679E12D">P10Y</gale:StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm>
	<gale:SuccessFeeAndOtherTransactionCosts contextRef="FD2017Q4YTD" decimals="-5" id="Fact-576F0B94A1237B675E8798BD2A495301" unitRef="usd">4800000</gale:SuccessFeeAndOtherTransactionCosts>
	<gale:UpfrontLicenseFees contextRef="D2014Q3September4th2014_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" decimals="-5" id="Fact-8338D3C938026D7AB80696FCE60F608E" unitRef="usd">1300000</gale:UpfrontLicenseFees>
	<gale:UpfrontLicenseFees contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember" decimals="-5" id="Fact-042713FD8C08BA24652C9C848B96A9FC" unitRef="usd">300000</gale:UpfrontLicenseFees>
	<gale:WarrantExchangeAgreementsAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9831D1EE2C1A0BC2E154806814C6BD12" unitRef="usd">285000</gale:WarrantExchangeAgreementsAmount>
	<gale:WarrantExchangeAgreementsAmount contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C60DE4FE9095738F46D8806814C59F4D" unitRef="usd">285000</gale:WarrantExchangeAgreementsAmount>
	<gale:WarrantExchangeAgreementsIssuanceOfCommonStock contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9A447AC21AD20411D0A9806814D343FE" unitRef="shares">54343</gale:WarrantExchangeAgreementsIssuanceOfCommonStock>
	<gale:WarrantStrikePrice contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="INF" id="Fact-DCDB426352FAF2341DCD8068156384B3" unitRef="usdPerShare">33</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember" decimals="INF" id="Fact-62F9E1D21FA360ADF0EE80681527BD94" unitRef="usdPerShare">888.22</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="INF" id="Fact-C7F6E4422993EB8612E6806815301EEE" unitRef="usdPerShare">33</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="INF" id="Fact-7A3338D84CF88000413E8068129A312F" unitRef="usdPerShare">829.88</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="INF" id="Fact-30E7A5E0BC35B7E6824580681557228E" unitRef="usdPerShare">2.10</gale:WarrantStrikePrice>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-A9C142057CD6CAA672918068128ADB44" unitRef="number">0.7929</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember" decimals="4" id="Fact-F01DB02AAD357161652380681568857C" unitRef="number">0.7246</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-17011E7805239CD070A780681290CD74" unitRef="number">0.9412</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="4" id="Fact-15E428E1CD0B9DAD8C8080681527A192" unitRef="number">0.9473</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="4" id="Fact-3BD390EA7C8A6AD5A1C380681538700B" unitRef="number">0.8880</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-96C73A5956DD2DA9BB798068128DCF67" unitRef="number">0.0209</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember" decimals="4" id="Fact-C837EED3B8F3B76DDF10806815444D13" unitRef="number">0.0200</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-D35C57405242006C44AC806815687488" unitRef="number">0.0246</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="4" id="Fact-CFF6E7D753B764703DE8806812993A1F" unitRef="number">0.0246</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="4" id="Fact-280B9E42E4068866109C806815320053" unitRef="number">0.0250</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsIssuedShares contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-F8EF84AE85926235BCB3806813FF20C8" unitRef="shares">609445</gale:WarrantsIssuedShares>
	<gale:WarrantsIssuedShares contextRef="D2018Q1Mar9_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-E258BEA968BD183174A9806813DF6B6E" unitRef="shares">774186</gale:WarrantsIssuedShares>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-A4E99A35E0BD46811ECD8068136A6499" unitRef="usd">6000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-31B696AA7397135F7DD5806813F960C8" unitRef="usd">11691000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-837A8FFCB35735F33194806813F31727" unitRef="usd">3755000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FF7F7834B7283EB8477D8068142CD1B9" unitRef="usd">3201000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-DAB5ACA0CAA83B8934C3806813E3B9DD" unitRef="usd">2219000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-44C776FF4559A4E836538068130E773B" unitRef="usd">1744000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CAD944C07CDE62DEAD2D806813092E1E" unitRef="usd">540000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-088D0ECF8BED6F2436768068142B352A" unitRef="usd">56254000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q4" decimals="-3" id="Fact-EB1375975C96DAFE84D1806814178D69" unitRef="usd">87098000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentForAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-91A252C092748C82744E806814846EA5" unitRef="usd">258000</us-gaap:AdjustmentForAmortization>
	<us-gaap:AdjustmentForAmortization contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1DB861301F834AFA2E6180681330DF73" unitRef="usd">0</us-gaap:AdjustmentForAmortization>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CE8AA78C868BFCA38F3B80681326BDA7" unitRef="usd">-4436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-07B633C6C92DEC6EB467806814C19132" unitRef="usd">-4436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8BB56678C3A56A26F11F98998FD4168E" unitRef="usd">3169000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D4C837E4F907C262FB0898998FE4F6B2" unitRef="usd">3169000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-75097C549C88C0FC3CAD806813341399" unitRef="usd">395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-65BF1F5A5CB7E86C28148068147BB08E" unitRef="usd">395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2018Q4YTD" decimals="-3" id="Fact-62CE849292D387D9024C806814D46CC9" unitRef="usd">5039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5047AA481F80B7927D748068132E014D" unitRef="usd">5039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B99B8D56CBEA13495A7E806812AA26D3" unitRef="usd">3169000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-48959BCE73D4E1D263AE806812DAA881" unitRef="usd">729000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5F49A6A37C901DFCB87780681288FEC2" unitRef="usd">2440000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BFC68C12A59EC52755728068129FD992" unitRef="usd">395000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-5C688C3E6F4CEE50ECD28068129316E4" unitRef="usd">77000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-2024457B0A8A6508314C806812E2066C" unitRef="usd">318000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-44ABB0A9C27CB33065D698CBD089EDE9" unitRef="usd">1883000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5DA5A3AEC3480FBCB03398CBD09AA736" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-453A88F395CAA71D0E59991C3F2A8258" unitRef="shares">986000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-108A4EE4419B562CA2A19919E3DF0265" unitRef="shares">10000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-D24332BC42F453B127219915CC7DE5AC" unitRef="shares">13000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-053596403C0777E5584A991530CE8EAD" unitRef="shares">963000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-63D9A73884930EB25F6B991C3C1DD164" unitRef="shares">18106000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-4F8D42D06872B74A863E9919E3CA497A" unitRef="shares">395000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-036DDA2503FFE3DE9E639915CC8CABF2" unitRef="shares">13000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-E1169A43D90628A83E60991530B7B39D" unitRef="shares">17698000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-342621D237C16A37ED55806813F8B3EB" unitRef="usd">33526000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-E5394BDC811453E28DAC8068144AD3B6" unitRef="usd">16915000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D074CF7457B245E8205B80681414F7FF" unitRef="usd">13087000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-387E2FB18C3FC980F31A806813DB6F11" unitRef="usd">5838000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-408F78012155CBBFCE11806813A80AE6" unitRef="usd">11907000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-90D529CDDEC59B34B00E806813B9BE90" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-627023E375754A2B3CC4806813A795CB" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6018A82DE8BF6EEA1AD280681392CAA7" unitRef="usd">11907000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A7152C620DEDB4E36F6480681535EC53" unitRef="usd">5195000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-64F2CE37667AC39120DE806815417E27" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B42D5BB40F21DB73227480681547B5B4" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-49A4F89E28CE36FA532980681558FB33" unitRef="usd">5195000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="FD2017Q4YTD" decimals="2" id="Fact-028DF6C45C569EFE6733806813EE264B" unitRef="usdPerShare">5.15</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-DC85DE549A01A7FB43A88068134B03F0" unitRef="usdPerShare">5.15</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E608E6FC26428351ED62806813E68701" unitRef="usd">-24089000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2017Q4Dec29" decimals="-3" id="Fact-D5861F864B61D82227FF7E7C501B20F4" unitRef="usd">12519000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-C44B8FD59899D4D998139163CF00ACE4" unitRef="usd">1294000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2011Q4_us-gaap_BusinessAcquisitionAxis_gale_AptheraInc.Member" decimals="-5" id="Fact-E6725812263D15A909848068146CD7D6" unitRef="usd">32000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-FE87B1F3519AF38FF17A7E6422620F1F" unitRef="usd">1812000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-6E0AC1C29A8BEF79D8197E74E5402971" unitRef="usd">1294000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-58DC5E9D437C39CEEEF07E66443536B0" unitRef="usd">3103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-E035572DD780E93FE41A7E6A23ACA0A2" unitRef="usd">10988000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-40DFC14694AD56538E137E736F3511F5" unitRef="usd">1673000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2017Q4" decimals="-3" id="Fact-0699B8185A207AEB6B6996855267C9D6" unitRef="usd">17600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE301AndGALE302Member" decimals="-3" id="Fact-831D8B0DF69A4F24ED9C96865DDFAB7E" unitRef="usd">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member" decimals="-3" id="Fact-7CFBB19C4F0AC0789B2A96862BA2BE37" unitRef="usd">9100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-41CE8D76344535FE3138A09CB93809C2" unitRef="usd">9100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_NPSMember" decimals="-3" id="Fact-9C09D2051FD35A34087F96866F29A043" unitRef="usd">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-525581B6EA533CF2142F968552623335" unitRef="usd">8500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE301AndGALE302Member" decimals="-3" id="Fact-126E53667C8DB13CE96D96865AD2374A" unitRef="usd">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member" decimals="-3" id="Fact-3D9F2B51D2E74E4843F296862BB87062" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_gale_NPSMember" decimals="-3" id="Fact-665C5A4CC174E74C478D96866BF97787" unitRef="usd">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-A72A55836FC9B9F069B07E669677FD44" unitRef="usd">17600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-9FB25B08E951E7636ECC7E73242A8603" unitRef="usd">22256000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-13474C49ED6A174D8F0E7E72D0D0E6BC" unitRef="usd">12519000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4AACA119D42740B19FFF80681564BEFB" unitRef="usd">12158000</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3EC164DAE7FE33BB8F7D8068129804AA" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-18C0AB74E32E4ACA41CF80681406D29B" unitRef="usd">2319000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-5" id="Fact-9CE206F2840F1C09CC6780681377F01C" unitRef="usd">5300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-60552227E632B1F332E4806813F81BAB" unitRef="usd">5337000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-955889FE450D6728FF2080681376F86C" unitRef="usd">1662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-74FC8D1D0730D870A839806813A87FAA" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-114AAE645790DA9052C5806813618E0B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B96D243F4C2828FCA6A2806813A50B84" unitRef="usd">1662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6FDBFFC38558BFD10F5A806815437342" unitRef="usd">5195000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FCBD7BF5C20D71E42CF180681541AEFE" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-54AADED23CE0864FA41280681555D5E1" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1C62D1FA908B61F4E29D80681533D5A6" unitRef="usd">5195000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="-3" id="Fact-E353D930BC5D3989528F806813353D3C" unitRef="usd">6047000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-06CB9D3A2B53873EC3D58068137AD6B5" unitRef="usd">12750000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-3F6CB8F327B022AC1D468068138CE4C5" unitRef="usd">5451000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2017Q4YTD" decimals="-3" id="Fact-89CE28F03E46A8D4F36180681391577D" unitRef="usd">6703000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BD7C8DB055E36A0B7E0080681348EE33" unitRef="usd">-7299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="INF" id="Fact-92BFF60FCE6E0250BECD806812BABF36" unitRef="usdPerShare">6.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q4Dec29" decimals="INF" id="Fact-0F3E54B1FB8820C374F280681322BE55" unitRef="usdPerShare">7.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q2May2018" decimals="INF" id="Fact-EE75CC5F98205E1F0753806813CBB852" unitRef="usdPerShare">6.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q3July16" decimals="INF" id="Fact-91E087475614E3A437D98068146C5B4A" unitRef="usdPerShare">2.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2019Q1March312019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-384A76C64E7EE5982FA092F3C99933DD" unitRef="usdPerShare">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2019Q1March312019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-BE8D96DF2963F4547B289D492843E24E" unitRef="usdPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2018Q3July16" decimals="INF" id="Fact-ACB7273877BFF5796B42806813CADD3A" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-033F4BD72EC5E6E906708068152429BF" unitRef="shares">3333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q4Dec29" decimals="INF" id="Fact-391A4A248A166F39D8F3806813214CB2" unitRef="shares">316163</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-1A5A8F3AF8F128D02C0A8068135D5C79" unitRef="shares">1383631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q3July16" decimals="INF" id="Fact-1AB3AD4F59AC94FAF0638068137E5368" unitRef="shares">11520000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2019Q1March312019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-1437C8B09DBA7529FA2AA11DB9812578" unitRef="shares">3800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4" decimals="-3" id="Fact-5876D69A9F0C2108C77D8068142DB7DD" unitRef="shares">963000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-64F1D61CAE77049CBC97806814A3E33C" unitRef="shares">316000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-D1543953552FDAC28DF9806814797F5A" unitRef="shares">567000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-C8EE62BD09595E2F53418068145AC7FE" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-3783CAD4E71D03FE008F8068143E2B7E" unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-996B6E8BC89C522B73678068148E9286" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-2F9F83730E0830FE41CB8068146F382B" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantsClassifiedAsLiabilitiesOtherMember" decimals="-3" id="Fact-FE37A80CAD37608A79D28068156BC7ED" unitRef="shares">76000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4" decimals="-3" id="Fact-87365C0B155D346527F6806813BD3344" unitRef="shares">17698000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-1770413C823B3426587880681433E501" unitRef="shares">316000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-9B2B6F55B5E41758BFE6806814813BF8" unitRef="shares">33000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-239105BE3485782A153F806814194441" unitRef="shares">15268000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-2B73E0DCC102DC9D32A18068141818C3" unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-CB6369117F455AF24B1B8068149FBADE" unitRef="shares">625000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-302FD08AEBC586A2F34F80681430ED25" unitRef="shares">1384000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-55E3901D8BCED707C42F80681442F7A2" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-FD73658B3FE2FFB103658068140754E4" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4" decimals="-3" id="Fact-6A611534B2CF3ADC1400806813C30728" unitRef="shares">18642000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-CA101387C555898C2FF39189B23339C7" unitRef="shares">265000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-6F8CBDE4FEBD9F57B677806812E9FA90" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-E2A1ED364D1F257F189B806812E72C71" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember" decimals="INF" id="Fact-D88A4C62BCFDA41BAA47806814411DAA" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-A9CEC30576AC2A41C442806812FD9D17" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-118A668E7515DC9DC972806812FF6B21" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-6DB49BA7D53B3EF92B8C806812F36975" unitRef="shares">5766891</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-5B16896A328D029B9F2C80681302DD94" unitRef="shares">22026476</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-7A85A18578CA0551748D806812F4C91E" unitRef="shares">5766891</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-EF92042B79DE9ADCA37C806812FD2737" unitRef="shares">22026476</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29" decimals="INF" id="Fact-5172311F59FC6DC2D233806814695FD6" unitRef="shares">5766891</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-BC5949E42829821069A98068140467C6" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-74BCCD44DC56822BCFAA806813F90833" unitRef="usd">2000</us-gaap:CommonStockValue>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-D0EA2352D80182B45B5F9164FBD8D655" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4DE1C0CEA4570F8FD1D980681385B804" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-79AF50989CF830558631806813947E19" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-E741BD17D186B74734AB806814EF13D5" unitRef="usd">1294000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FB6E22BE26C0B7CF21E180681378C63C" unitRef="usd">1294000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-51431B0D622ADC594754806813A53720" unitRef="usd">1294000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DC167B2AD4EAD43FE32D806815593A99" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B07D36DC16A0046A31FC8068155600F0" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-537EAED6883B9ADDE3A280681502B0A4" unitRef="usd">4326000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8FD0C7D60417D38FAB7B8068155A6607" unitRef="usd">4326000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E93455E79656DCAC0EDB8068128FEDB7" unitRef="usd">4326000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-499707EB7473244C532C8068141EACE0" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D01A23B67489F8F69E17806813C99A91" unitRef="usd">3721000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities contextRef="D2018Q3" decimals="INF" id="Fact-E0CD1E5BE223E5269E4B806813F20013" unitRef="usd">7871186</us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-0CCCF4E58CEB39961DFC80681483397A" unitRef="shares">1844835</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q3July16" decimals="INF" id="Fact-55A2B4762720A70455F480681492C5E8" unitRef="shares">3748184</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-7003E22BEEB9190BDDA380681406CDD0" unitRef="shares">3748184</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D88D53ACD6D052728730806814684545" unitRef="usd">23039000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2568397341247D68F0648068146070F0" unitRef="usd">31089000</us-gaap:CostsAndExpenses>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-096913E0B52D72A559247F8CB089CBF8" unitRef="usd">76000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-39198A1EB4A618FCBCD87F8CB08F7BE6" unitRef="usd">-106000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A070C73034FB04FB98877F8D4CD90FC4" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-635F87C1A18BC81CB3C97F8D4CFF0328" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-81B16170ADCB897089CB7F8D99D3D9CE" unitRef="usd">214000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4B9A0704135FF71D45B17F8D99B4EB62" unitRef="usd">-61000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E35396C85E8460519DCC7F8CFE10F02F" unitRef="usd">138000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-50AA3B28203BA5E1C3667F8CFE0A8573" unitRef="usd">45000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-ED12414D3DF5F25C1ADB8068152A8EEA" unitRef="usdPerShare">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-9CDEEA6B0ED3024CE190806815452045" unitRef="usd">1000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-60B084D2B7BF6CD6053580681513897B" unitRef="usd">25530000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-3E273DD775B3F2646405806815348FA9" unitRef="usd">10200000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-EBDBCE731C30A7606F058068153A247C" unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-9A08090AD6FE582CA59B806815235BB4" unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2018Q4Nov10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-1AB641DDEEDE6199F2948068150F3D52" unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="D2018Q4November10th_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-89A1A93FF11B921DC331806815312DB9" unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
	<us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-7D3CA13BE69839E8BB34A13D6F59F108" unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
	<us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="FI2017Q4" decimals="-3" id="Fact-156F6744408A913AE70D8068131EC85D" unitRef="usd">10988000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
	<us-gaap:DecreaseInRestrictedCash contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5D2FA4442D94525AD145806815258B03" unitRef="usd">1800000</us-gaap:DecreaseInRestrictedCash>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-60D065AFDCB27D8AE59A7F8DE837F5B8" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9A03D61C733CC5B2AFAE7F8DE83E6075" unitRef="usd">-747000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-40F626F42D923AB9BC0B7F8E9A6B4B50" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-802F24A6A792B291D5C87F8E9A7C9523" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0CDD0EEA9F2573F53C517F8EF084A04D" unitRef="usd">39000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-70C83DD729DD48D71B067F8EF06FA873" unitRef="usd">-1317000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-C9A2543E737B08834BFF7F9BF75AC806" unitRef="usd">3438000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-791E904E0FC051383CCF7F9BF749C21C" unitRef="usd">1785000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-B737D3478B686FD793EA806813ED4EAA" unitRef="usd">1673000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-A13FD10EA772AB17CDF0806813EFFBFB" unitRef="usd">357000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="FD2018Q4YTD" decimals="-3" id="Fact-392331E24BBE33AE24A58068142B05AB" unitRef="usd">-1316000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C791324B758B7364D0BB7F8E417D756D" unitRef="usd">39000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F2F3A10023173BDE18E87F8E418FBB12" unitRef="usd">-570000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-5C224C83B804EAB78D077F976FF65247" unitRef="usd">6423000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-3" id="Fact-405A2285A28B995643B17F976FE6511D" unitRef="usd">12838000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-4E89B516AC888B1F5FAD9D14777F2E66" unitRef="usd">1765000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-F3BFD704CA2CD97C46309D147768F232" unitRef="usd">1428000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-DDC8D32972C5247BB0FF7F9814A1EFF2" unitRef="usd">1765000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-7224A50DC239D4AC78247F9814B98F96" unitRef="usd">1428000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-9FB2ABE7585A57D2686C7F922AE7E206" unitRef="usd">1028000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-9E6502731AC7094CFE097F922AE0F96E" unitRef="usd">4464000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-4D5160259CED1F91C0C27F97110DFF6C" unitRef="usd">395000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
	<us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-58F4D3CC9AE708EEC69A7F9711073272" unitRef="usd">56000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-EB3DC1F05D1BBD2D14DD7F92864AA3C7" unitRef="usd">345000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-6DDFBD8D83B39B5E347C7F9286600394" unitRef="usd">134000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-3" id="Fact-D19DB8EF0E36AA4A22247F92D9ABA7DB" unitRef="usd">2550000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q4" decimals="-3" id="Fact-ED623919009FE4C53C4A7F92D9A49148" unitRef="usd">2223000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-E378A09020698E3461AC7F97BE89BFD9" unitRef="usd">4658000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-7DAB08BFC99C5FE608A57F97BE914D25" unitRef="usd">11410000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-E5500B52BC7FF1C3D4EB9CFE24A4001B" unitRef="usd">1673000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-9A5A9D2ECC732D7C52E69CFE24AA0073" unitRef="usd">357000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="FI2017Q4" decimals="-3" id="Fact-05833DF69AD21BB2E4BD7F9B903E36BC" unitRef="usd">3438000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
	<us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="FI2018Q4" decimals="-3" id="Fact-947AD0446D504DA389AE7F9B9039D90D" unitRef="usd">1785000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-35320E32015C2FE21D07806814140F70" unitRef="usd">925000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-000A2CE54F27AC0E87CA806813EBD70A" unitRef="usd">663000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-232B8BBD3550EADBF0FC806814311292" unitRef="usdPerShare">-10.44</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-58B48C114FC1D7B0FCFB8068140C3B1C" unitRef="usdPerShare">-3.15</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="3" id="Fact-560EDDACA3EB400771237FA1FC2175D6" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q4YTD" decimals="3" id="Fact-6F4B11E341A9CF7E88337FA1FC1AF582" unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-5560667C548D293AB72B7F9E3E7FD962" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-049526C39B3390ACEBFD7F9E3E67D561" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="3" id="Fact-F8EA833B5622346EEDB17FA15BA11D7D" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="3" id="Fact-7790602973C2EF4EB21A7FA15BAC6B73" unitRef="number">-0.235</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-C25B31DAE59790DC1DC47FA05B96CF05" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-78624213C78555E8C94E7FA05B9D0343" unitRef="number">0.139</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q4YTD" decimals="3" id="Fact-380D8BA9B222D354CB067F9EF3BEEE3A" unitRef="number">-0.344</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2018Q4YTD" decimals="3" id="Fact-99D8F5FDE43920C8EB6C7F9EF3B3736D" unitRef="number">-0.086</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="3" id="Fact-868632D5D0F568095D8E7FA0F20CA227" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2018Q4YTD" decimals="3" id="Fact-F9576A862AF8F142120B7FA0F2000047" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="3" id="Fact-B9B5AD949E89701AA4B77F9E953779C6" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="3" id="Fact-AC13D94B455C0922F9B97F9E953EB1F6" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q4YTD" decimals="3" id="Fact-6168F0214356818C705C7FA1B1E37589" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2018Q4YTD" decimals="3" id="Fact-C368089677290D6D43517FA1B1CD5CA2" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2ADAC4490B2F2E5242F88068130CBD56" unitRef="usd">566000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-6FA1E5E4459783B96F97806812FE2D84" unitRef="usd">675000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-42016C9DDBF3375B61378068137FECA5" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-58A721CE0D853E9E81B3806813713859" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-32BB910A79ADA47053598068138D9FDB" unitRef="usd">2603000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0B6FED16995951D26A088068139353DF" unitRef="usd">2603000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-EC48416F0D071CBC24AE80681546560B" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-84D04F11D2522A59BBDB8068153798F9" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BDCEB5E636E308F255018068154BBD8F" unitRef="usd">5339000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5CD93331161B21A1EB708068154A0B76" unitRef="usd">5339000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-049305985FA212B668578068144B898C" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6EB37569151B86F1BB5E8068129896DA" unitRef="usd">-5300000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-D124EA18D595BC45421280681522FFFD" unitRef="usd">800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E22481BF2F3717DB044180681389B3DB" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5C9D3B53DE48A12875218068141A39EB" unitRef="usd">766000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q4YTD_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-69B8ABE0692BC6B27608806812C387E8" unitRef="usd">800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="D2017Q4Dec29" decimals="-5" id="Fact-7819F9E7E288EE04E808929542CAAC0B" unitRef="usd">900000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-5" id="Fact-D866077D4D803F3911118068142A10CA" unitRef="usd">1900000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-3" id="Fact-B2E1A59A5100EBAA60749C5318162F44" unitRef="usd">1914000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-5" id="Fact-85B03A582D3A60B9290D8068143A7383" unitRef="usd">1900000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-3" id="Fact-1352B33EBDC7852AA8AE9C53181EE273" unitRef="usd">1914000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2017Q4Dec29_us-gaap_BusinessAcquisitionAxis_gale_GalenaBiopharmaIncMember" decimals="-3" id="Fact-15216E6318CCBBE08A117E66D420C565" unitRef="usd">1914000</us-gaap:Goodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A0FF61ED2A0F684146069D419AA9B04D" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_gale_GALE401Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-B380AD1931FF1F25CB91A096FCE80F8F" unitRef="usd">9600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="FD2018Q4YTD" decimals="-3" id="Fact-95576FE73D8A1164DDD49D41E04A2AD1" unitRef="usd">9550000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-ED9FF21C21CA62EE6E357F816B970ED1" unitRef="usd">265000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CFC627E891DB37BC882D7F816B659E26" unitRef="usd">-17179000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7AA28476B65F4D3191127F821115F9BC" unitRef="usd">-23501000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-171A1540BD62087FDE127F82108DFB6F" unitRef="usd">-29048000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8CD20C3D9C4DF5EEC36E7F81C70E524A" unitRef="usd">-23766000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2018Q4YTD" decimals="-3" id="Fact-28AAAF67FB4496D5D88B7F81C709D15E" unitRef="usd">-11869000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-362B02EE7C5E88EBE35E8068139CACCD" unitRef="usd">-23754000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6008953E0CD602EB1DB980681336EDE2" unitRef="usd">-27670000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-232F2314A3E570F0A56B9BC2B6380C7F" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-72D70F3B6CD43AD93B7880681290D91D" unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CE0B01E00963309F02969BC2B65719E0" unitRef="usd">-1400000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-80E2F18775B1EE738B9C8068142D2014" unitRef="usd">-1378000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9526095AA87F7F8EB0C78068142094FE" unitRef="usd">8366000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BE6E9206EC185B43F071806813A23D3E" unitRef="usd">-7936000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2D15002373A66D9024F08068133EBC89" unitRef="usd">-2374000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4D8A096FFA1B08DCF9C18068137A82C1" unitRef="usd">-2282000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2D71B34688244AEA491F8068143ECD7A" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4CA93C801A6EED33E0C1806813BBC6D0" unitRef="usd">-212000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2B8A40AA369A2E33E8F88068141DD879" unitRef="usd">-462000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-883A001C6426A7D4C555806813B3B9D7" unitRef="usd">-266000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A0D77A618B60B61381DE806813C6A29B" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-28AC51F81B14CE48D90A806813A6B92B" unitRef="usd">321000</us-gaap:InterestPaidNet>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0B456683E8447DB2F3A49B570A8BF9C3" unitRef="usd">941000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2018Q4YTD" decimals="-3" id="Fact-59DBA7F2DC2480C76E579B570A864642" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-310E4E4A9A4DF7D397947E85562BE0D4" unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-168C5D7C17A9A12206937E85562FF973" unitRef="usd">300000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LegalFees contextRef="FD2018Q4YTD_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-F59DD66F1773FE933FD8806812C959F1" unitRef="usd">5000000</us-gaap:LegalFees>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-CFE16DC880F08221CBA18068141E0EB3" unitRef="usd">31456000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-0B1750EFFA6454BDEBD68068140DF367" unitRef="usd">11670000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-7FC668FB9011B64D441A8068141F4E52" unitRef="usd">33526000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-AE16EB7122D0AC00E2C2806814528296" unitRef="usd">16915000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1FD444C8A6418B3D7C888068141CFE5D" unitRef="usd">24569000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4BD8B66BEF067F36AB8280681440688B" unitRef="usd">5974000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E244CC1EF1A2812CBD2680681400D76A" unitRef="usd">1300000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-86C45DFA9BB40CA1AE4C806814574C26" unitRef="usd">0</us-gaap:LitigationReserveCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-31D116FAB7DBE450FF27806814338747" unitRef="usd">8377000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-848E735941F42AC1ECD0806813221B15" unitRef="usd">8377000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FCD02BE4DEDE598D2B858068141BD842" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2DBF37EEA3D9FC21A13680681434F714" unitRef="usd">2611000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-7EF9D751FFF31350BF51806813212394" unitRef="usd">2611000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CAF1A08E28E079FB83D8806813EC567E" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-739E974E49AE8834919280681540C92D" unitRef="usd">6600000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:ManagementFeeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6DDE88D4DCE4D9952C6992A181251A9D" unitRef="usd">300000</us-gaap:ManagementFeeExpense>
	<us-gaap:ManagementFeePayable contextRef="I2017Q4Dec29_us-gaap_RelatedPartyTransactionAxis_gale_EquilibriaCollaborationAgreementMember" decimals="-5" id="Fact-9F7D1ED40FFB1FFFE63197A7EEBB02AB" unitRef="usd">100000</us-gaap:ManagementFeePayable>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-507E635EEFA21BCA2AE1806814286B89" unitRef="usd">5534000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-952F5E73F2609C076251806813A43D8E" unitRef="usd">23123000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B355AFB096A8B0A61DD9806813DD53AC" unitRef="usd">12158000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2B07E99C09B453259031806815108BA3" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-62D47714359BBBEDDEC68068141A81F5" unitRef="usd">-10989000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-535E0D2FAF35E6EEA553806813C802BA" unitRef="usd">-30422000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-70F79924DEC0AC875E898068145B2D20" unitRef="usd">-23754000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-DD7C023EF4BA92E446E3989A07D2B28D" unitRef="usd">-23754</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DA07A9AAC6E1952104C580681369A2CE" unitRef="usd">-27670000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-04EE686A83444125157D7E8837E0E482" unitRef="usd">-27670000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B0EFC04BD6AAF9CF71878068128E3B0D" unitRef="usd">-24429000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9B011516C680F9AA231F80681459DD73" unitRef="usd">-41251000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6AAC8441283F079917CA806814EBD6C4" unitRef="usd">-23501000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D0578FDC4FBCA502BECB806814490AA3" unitRef="usd">-29048000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingLeaseLiability contextRef="I2019Q1January12019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-7E9135B6599C77A37F289959A764B3D9" unitRef="usd">500000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1January12019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-EB1862A4580E896B500E9948CD071206" unitRef="usd">500000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-B4FEA44C31A462FD2EA67E842D812F4B" unitRef="usd">601000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0D8D8B6FB0666697C2ED7E835099329B" unitRef="usd">377000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-5F5ECF24658F75CB34CF7E83D3134E3C" unitRef="usd">224000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-2F337C991E981A697DA891A0B4F02C11" unitRef="usd">19700000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-83DD7DF9B490C6ACDEE891A06DD38245" unitRef="usd">3700000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3EEA4FFA6705EB39E0A08068130D20B4" unitRef="usd">191000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-40393A30F96025A8752680681300D52C" unitRef="usd">8000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetImpairmentCharges contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A96D90A3303DDBF0DBB68068131B161D" unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
	<us-gaap:OtherAssetImpairmentCharges contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CA4350E09DC3B06EF4B0806815007250" unitRef="usd">9100000</us-gaap:OtherAssetImpairmentCharges>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BD95764679AD0FBDDEE98068141589AD" unitRef="usd">-462000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8EB20AD9F2553250D6258068135FDE3A" unitRef="usd">2041000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:PaidInKindInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CDA06CE01B141EB1C46E806813B3F500" unitRef="usd">0</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-10C2C0787F6196050349806813C63F65" unitRef="usd">134000</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentForManagementFee contextRef="D2016Q2Jun" decimals="-5" id="Fact-2A4CBB1968D244F109CD92A0D2BCA087" unitRef="usd">100000</us-gaap:PaymentForManagementFee>
	<us-gaap:PaymentsForLegalSettlements contextRef="D2017Q3July24_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" decimals="-3" id="Fact-1E752E5447ABA876D6C5806812E3B7EC" unitRef="usd">50000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsOfDividends contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D9FAD5F94FB3B7743C4C8068139B836C" unitRef="usd">0</us-gaap:PaymentsOfDividends>
	<us-gaap:PaymentsOfDividends contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8A7ECA835E77F5297F3D806813A0B611" unitRef="usd">487000</us-gaap:PaymentsOfDividends>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D4E0000B62A04B3DF787806813B9B07D" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9F519572A91E85FCF5738068145A086E" unitRef="usd">4436000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-740699EE190CA53109A2806812E94067" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-A7D79E4BBDEABED60CCC806812F11757" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-9A8B9C915633AC86956B806813D935B2" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-6368AF32D2D51F50E8F1806812FAB288" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-39D8E9E693C3811FF21E806812F526DE" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-C543E693F44CCD6EA8E1806812F0C12F" unitRef="shares">17500</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-B417894DAAD2852386D38068130219EF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-6E6B326EA90EAC325D43806813088D54" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-3A1430B9BC1D578A8EC18068137FB0A4" unitRef="shares">10700</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-DE822C5D075DA39B548080681309C1E4" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-005AA6A5025B529FECC0806812FC7699" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-7496CD5F0F7A26F805D88068145492EE" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-11C3CE984F8DEBC7DAE0806813DC888F" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-41993BF7F1B389D208E08068142ECCB0" unitRef="usd">337000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FD97C822E9B7F78FB5F2806813F401DF" unitRef="usd">387000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="D2018Q3October2018" decimals="-5" id="Fact-450BB06A750415A2D219806812C5F77A" unitRef="usd">500000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E2169152084C34AA694280681380D9F1" unitRef="usd">0</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9DBE24795C6F52F60D2F80681394D9D0" unitRef="usd">186000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5A735DDF6A4A779E1BF880681334F51A" unitRef="usd">6007000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E0BFC5445BA3293FAAD580681392AD88" unitRef="usd">21564000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="-5" id="Fact-888BF1B91099BDCE4537806813E20328" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="-5" id="Fact-372232BAACA1091A15AC806813F58D35" unitRef="usd">4700000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="-5" id="Fact-58D5055DCC1299E247C1806813F89FBB" unitRef="usd">10700000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BEEA7EB3C334FC2DDD758068144C2DA0" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="FD2018Q4YTD" decimals="-3" id="Fact-99AE683C1A7C70A53D6A806813375C41" unitRef="usd">9647000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_FirstTrancheMember" decimals="-5" id="Fact-DEF4C7CDAD053A89155880681360CC1D" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_SecondTrancheMember" decimals="-5" id="Fact-F57022C9A02F88F9F7C8806813689986" unitRef="usd">4700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember" decimals="-5" id="Fact-3D4312DAFABF682C92B580681369ECF3" unitRef="usd">10700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="D2019Q1March2019_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-8248AEB1DEB73E637C3A967E29C98218" unitRef="usd">4200000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="D2019Q1March6th2019_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-DA571D34229A535114C892F492C77CDE" unitRef="usd">1300000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="D2019Q2March6May31_us-gaap_ClassOfWarrantOrRightAxis_gale_WarrantExerciseAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-E2538AD08D6A2559F3879D4E2F4AF244" unitRef="usd">4200000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProductionRelatedImpairmentsOrCharges contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2D5C82C6549D13DF669E98C201EF4F70" unitRef="usd">5200000</us-gaap:ProductionRelatedImpairmentsOrCharges>
	<us-gaap:RepaymentsOfDebt contextRef="D2018Q4November2018_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-5" id="Fact-7091089F693A2D9F60AD9D08FC498568" unitRef="usd">200000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CE1CFFBB1D856DA6D6ED806813A728AE" unitRef="usd">473000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3BF595596C0C8DE93197806814037941" unitRef="usd">7601000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2016Q3August10th2016_srt_CounterpartyNameAxis_gale_MemorialSloanKetteringCancerCenterMember_us-gaap_TypeOfArrangementAxis_gale_SecondMSKAmendmentMember" decimals="-5" id="Fact-E55F70799B2CDC211F929787A795C1DC" unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DD94B02825C6CDC7AD76806814208964" unitRef="usd">6067000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8EEA7DEED2146A6D7AF98068145B00B0" unitRef="usd">8767000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCash contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-5FE96276776BA44C4D0E8068147E0A3D" unitRef="usd">10200000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCash contextRef="I2018Q2May5th2018_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-72856F1FE6C625A713B6806812F12A54" unitRef="usd">8500000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCash contextRef="I2018Q4November5th2018_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-5419EFB2307E3AB44FEA8068130A78F5" unitRef="usd">1600000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-0DC654DD0793012B2513806814356E25" unitRef="usd">10431000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember" decimals="-5" id="Fact-BEA8700D8203A84845378068141CE5A9" unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-5" id="Fact-42A0DE2B895C59858240806813655F4F" unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-9D5F30ED70099A94B5728068141EE4BB" unitRef="usd">114000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember" decimals="-5" id="Fact-64CB4A2BEA5EF32C622180681473F7ED" unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-82372F3918F17B048EB98068140A9029" unitRef="usd">-54185000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-2C2227D69503DA164090806814455996" unitRef="usd">-81855000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2018Q3" decimals="-5" id="Fact-0E08363FB23103642B24806813625618" unitRef="usd">21600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AF6A18E9C10BF1B71D6B806813E1AADC" unitRef="shares">6845000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E045CE3C203F4A5CE98480681370EC5F" unitRef="shares">6845000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-8AA1C97142D9DF17BB8A8068135DB1F3" unitRef="shares">4675000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16" decimals="2" id="Fact-9E5D90F4862D146B1573806813DC4B8A" unitRef="usdPerShare">2.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16" decimals="INF" id="Fact-C0525A2B46A3E461A0F3806813746B7D" unitRef="usdPerShare">2.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-DB55E62450E959B73872806813777246" unitRef="usdPerShare">2.0999</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-8276A7276464C8BAEE088068146FB29C" unitRef="usdPerShare">2.0999</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1043472ADFE418E9D1588068134BEDA7" unitRef="usd">15089000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-73C3BEB6F2DFB2A2D7E6806813520BAB" unitRef="usd">12772000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SeveranceCosts1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BEB0945F4EF01DB72DA89B5A025FB495" unitRef="usd">1883000</us-gaap:SeveranceCosts1>
	<us-gaap:SeveranceCosts1 contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2ABFB8601B62828FC2B599384F6915C7" unitRef="usd">1900000</us-gaap:SeveranceCosts1>
	<us-gaap:SeveranceCosts1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-50A84DA68471965B6C1D9B5A0268F92E" unitRef="usd">0</us-gaap:SeveranceCosts1>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-547A771D3C8B01A4A38F806814291AD2" unitRef="usd">3169000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EDA7DC93EBA3B6575A1B806813C6B255" unitRef="usd">395000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-C09E4EFBE3B5E041C2B2806813472CDC" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-2277829DA1EF76B50FCB806814E55A0D" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-71BD33122DBF9293D06980681348D616" unitRef="usdPerShare">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-F8B162117F0348ECBDEC80681538EABA" unitRef="usdPerShare">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-0109DE5EEFE04C8F1852806815042F28">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-1D86D8EC82021132473F806814F7F71A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD" decimals="4" id="Fact-170FECA0D2E0B78B955D806813B5F1F4" unitRef="number">0.8083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD" decimals="4" id="Fact-98A676DBD577BB26B815806813AB1ABE" unitRef="number">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2019Q1Jan1_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-0F97AD3634B7123177FD806815220B72" unitRef="shares">1686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q4_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="-3" id="Fact-2C68621AF62AC5630FBC806814E99A66" unitRef="shares">381000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q4Dec29_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="-3" id="Fact-5D3E1742A767F35C62FA806814C2D903" unitRef="shares">1686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q4" decimals="-3" id="Fact-CC73E6EF600A947A51B3806812B0197C" unitRef="shares">53000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-F661158D0A23267EAE57806812A51115" unitRef="usdPerShare">241.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A4B85840213683D76F188068129C175F" unitRef="shares">98000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-D7B05131A02AF72392FD806814B77A4C" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="INF" id="Fact-4AE1726CB54B8E981156806814F0F3D9" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7CD625F9292CCF0E927D806812BD8021" unitRef="shares">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD" decimals="2" id="Fact-F56304D7A8D7EF3A9B0D806814B08C55" unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-493F9121030910849C67806812BC9166" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-0EBA2DD26424D58D32E7806812BBDEFF" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="-3" id="Fact-E0B7E48A6B4A08E25DAA806812AE3A43" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="-3" id="Fact-3A0AEA14FBC346961925806813C4250E" unitRef="shares">395000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-53062751AF6812276DC7806812C2243C" unitRef="usdPerShare">1240.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-8C4B68D2B207569C503F806812B1778E" unitRef="usdPerShare">37.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-8C4157AC27C388C7EC28806812A06C1E" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-9539F63CF02E1391F2F7806812A9DB03" unitRef="usdPerShare">5.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-EB6D5E10D2C63C1B5904806812E38857" unitRef="usdPerShare">5.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact-725F6138A67B5FFC9D8A806814ED2175">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD" id="Fact-BF9E721815C77BC562B48068138BFBF6">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD" id="Fact-BFFE10ED753927F5031B8068130EDE3C">P7Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2017Q4January1st" id="Fact-1B4060B62ADC3CC1A1F3806812A69D12">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-5C59E04CD5A1F46A45F5806812CC7706">P9Y0M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-B1617E9AA16E77BD070A806814D16F35">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-AF52D56A15D671B69272806815160995">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-D6BD8689DEB039C9C48A806814FBFBF6">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5B593CDFCF2582A649169678AC45E3FA" unitRef="shares">1268489</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-46E61F73BDB4AA86CC6D9678A6963FA9" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F7F13049D9CE0AC3F0848068132F073A" unitRef="shares">5766891</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-244C7F7F6EB24ACCACD98068147DCA57" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-CF19BC60CE0E5794A151806814A41F11" unitRef="shares">22026476</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-432ACFBE7DF28886F3308068147F060C" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:StockIssued1 contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" decimals="-3" id="Fact-62A4EC1E932F285969E198D65B6E71F4" unitRef="usd">1294000</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2017Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandSelyNoteMember" decimals="-3" id="Fact-6DA78AFF42823056E51E98D281AA3543" unitRef="usd">6064000</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" decimals="-3" id="Fact-0B2D07C5F100FF69C230A143DCBC21C9" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_gale_ConvertibleDebtTwoThousandSelyNoteMember" decimals="-3" id="Fact-E6A7BF042564B1554053A143E070C776" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AD532EBAA7EFEF25D81298A348C59F22" unitRef="shares">1588605</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4CDB00A3B691A29565D8989C300900D3" unitRef="shares">330551</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FB25C2D3654A7196287E806814C29CDD" unitRef="shares">118644</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3F327E1D0F71904A04A6806814C0CEF7" unitRef="shares">3748184</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-7A16A3825D5BF37227F0806814709499" unitRef="shares">-7802</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-64853910CB5787B3FB758068131DD418" unitRef="shares">499682</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-E9C3210A3285F600F792806814DE4E2E" unitRef="shares">-2898</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="D2018Q2April30th_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-5C21C38DD626F6B21F8D80681517DA25" unitRef="shares">118644</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-66E5DE9B9E1484182802989CA4BE51AD" unitRef="shares">1534711</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9B8472FDCF20AF757D7980681490957A" unitRef="shares">228672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9895CC5CB7E0B94A5B1B806813325633" unitRef="shares">715277</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-049AB9DC666B9BF787D38068147C4BB2" unitRef="shares">6845000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-446DD005A415CB57B7A680681494176B" unitRef="shares">10700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3C3E9BE165C793C0DAC198A1CD391B0B" unitRef="shares">46373</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8A45CF321C3818B297A5988DB2551AC0" unitRef="usd">12487000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7D63E04DD1F9D71F4D82988DB296A842" unitRef="usd">12486000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9B926B94F0D4DEEBA97398A937C88202" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-037F87CBA220CBB26E1D988C3BC2E6ED" unitRef="usd">1294000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9D0D1F57167489CFC907988C3BE71600" unitRef="usd">1294000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-561FC137B2BE364470298068149CC335" unitRef="usd">825000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9C3B58B9070CBE6CA55280681314A58A" unitRef="usd">825000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-59BC7762EBD85192287B806814D51A91" unitRef="usd">-8654000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4FD9BDD02AD398A23DA3806814B1D7DF" unitRef="usd">-8654000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7A3F8A39FD8A0D509B0E988C98BAD4E4" unitRef="usd">6007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-88775289409E7486E741988C99007131" unitRef="usd">6007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B708999FFE9E928B9340806814BE89EE" unitRef="usd">21564000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember" decimals="-3" id="Fact-CE88D241E853840F1332806814C53B59" unitRef="usd">1250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0B26CB39DCC93C5FEFAE806813136FD7" unitRef="usd">1250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-CFA88F2227EC977BF702806814A6EA5F" unitRef="usd">2896000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6DBEE119E022BAEC06928068132F9DE5" unitRef="usd">2896000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-613318E4D9A8C92183938068148A30B4" unitRef="usd">21563000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DED1F9554C154A407F82806814E44998" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-99E78B3C79E4F7A1EFB1806814464296" unitRef="usd">2070000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-F25E0A10C4143D22DC92806813E2E756" unitRef="usd">5245000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-3" id="Fact-CA905356C6FA364B5E859678BAB80ADE" unitRef="usd">-4997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D20FD387D6C1A26A87749678B0EDC01D" unitRef="usd">25434000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-908344AE8CA42850AD859678AE846D4F" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-420C624C1951668865B89678A93D6487" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-482881B7237BC73F4F1D9678B3759921" unitRef="usd">-30431000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-3" id="Fact-889A0C9940534ADC996D806814E66D63" unitRef="usd">2070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A4422B491C087E5E3698806814D2CF5F" unitRef="usd">56254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E440523FFA8EDEB64C048068147934CC" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-74943BF39A83D91BB9878068148DE171" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-77F7047A0C2D35B10A7E80681480D638" unitRef="usd">-54185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="-3" id="Fact-038C9455C98BCD870CB58068131520E4" unitRef="usd">5245000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B362E8075B5C64F50CA28068148269D3" unitRef="usd">87098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7F37C21F736E8B98945180681313D152" unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-71DD767AB901717E025E806813313D0B" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-5AFC87299E017BE18BFC8068147B1B62" unitRef="usd">-81855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember" decimals="4" id="Fact-DF67E21041F9A2E743CB806812FAA420" unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-ECF4680D1CB6E586893F91A298CE38A4" unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C202D4BAFE1AD0D4C7A080681300D1A3" unitRef="usd">426000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4215DBA24CF605F7583F80681310AD62" unitRef="usd">0</us-gaap:TaxesPayableCurrent>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-E3ED6656B628705ADA2A7FA8ADBB3184" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-BBC82F4610DF73DC8E937FA8A886639D" unitRef="usd">72000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-148603D6F52071B2786D7FA889621612" unitRef="usd">55000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A9E982886C85A5142E057FA902D4EA5D" unitRef="usd">17000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-586A3FA0A3CA4AECCC177FA9634591C9" unitRef="usd">28000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D3F3A4998F01ED34DFD07FA9634C60FD" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B72D19B0A4ABE7D1FF0F7FA902E918DA" unitRef="usd">44000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2018Q4YTD" decimals="-5" id="Fact-40361401CCBEBF85C04292BCF2998772" unitRef="usd">1400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="I2018Q2Apr30_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-5" id="Fact-4D5073E4A263157ABB1C80681521721A" unitRef="usd">800000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-64D0BA8C2EB65B030F40806813BC38BB" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="INF" id="Fact-0BCE529216872BB12A11806812ACB54A" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-7E4EB2CE34EB01066D85806812DC91FF" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="INF" id="Fact-099EB349CB01C34CC550806812C82F5F" unitRef="year">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" decimals="4" id="Fact-B393B2E2668DB9F7221A806813C50EDC" unitRef="number">0.9010</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="4" id="Fact-CD7BA33AE5101B0E07AC806812DE1AE7" unitRef="number">0.0220</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-0421477E81ED5B53717D8068132DB441" unitRef="shares">2340368</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q4YTD" decimals="0" id="Fact-F81C3DA0B2124C5F2F508068143DCF30" unitRef="shares">13077140</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-F2FC406EC07890D70E998068131E1727">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Adjustment to exercise price of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
	<gale:CommonStockAreReservedForFutureIssuanceTableTextBlock contextRef="FD2018Q4YTD" id="Fact-9BB6A8060D9C8A8EE3C9806813DA8F30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock reserved for future issuance are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2017 Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:CommonStockAreReservedForFutureIssuanceTableTextBlock>
	<gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-DDE0463BF9A134686BED9B995F2D9927">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock>
	<gale:ScheduleOfWarrantActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-F0225C29A952098826F68068147A8837">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Canceled/Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Pre-funded July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2017 Equilibria&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;February 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTextBlock>
	<gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-754D694AE8196A5911E7806812D8E186">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;88.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;94.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;829.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;94.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;888.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2018Q4YTD" id="Fact-ED76D8523F8159E0E8EC806812EF81F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Value-added tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Rebates and returns of former commercial products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-D861B0D8160A44133F6680681480B5B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Basis of Presentation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&amp;#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;). &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2018Q4YTD" id="Fact-F0048E84C2A36CB1F1BE806812A27A38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&amp;#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&amp;#8217;s results of operations for any future period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Year Ended December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(24,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-4CDE4E27C06C99ABB0818068129D0F9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting, whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Private SELLAS, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Private SELLAS that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:585px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:86px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Fair value of the Company's pre-Merger shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Estimated fair value of the Company's pre-Merger stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:585px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:86px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets acquired:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;34,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Litigation settlement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration of Apthera, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Qualitative factors supporting the recognition of goodwill due to the Merger include the Company&amp;#8217;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company. The goodwill is not deductible for income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&amp;#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&amp;#8217;s results of operations for any future period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Year Ended December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(24,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-recurring&amp;#160;pro forma transaction costs directly attributable to the Merger were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for the year ended December&amp;#160;31, 2017 and have been deducted from the net loss presented above. The costs deducted from the year ended December&amp;#160;31, 2017 period included a success fee and other transaction costs&amp;#160;of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;119,672&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock with a fair value of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a fee to Equilibria Capital Management Limited (&amp;#8220;Equilibria&amp;#8221;). Additionally, the Company incurred approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in severance costs as a result of resignations of executive officers immediately prior to the Merger. These costs are excluded from the pro forma financial information for the year ended December&amp;#160;31, 2017. The Company excluded a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; impairment charge incurred by the Company as well as combined transaction costs from Galena and the Company in the amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from the pro forma financial information for the year ended December&amp;#160;31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-ED1E90E8E2E3D9FB18699B9C2B8C79B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2018Q4YTD" id="Fact-559B340EDF0E454D6FB89B9BF6A0EDC0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company&amp;#8217;s financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-49C62BB46A1599B58D3096B9B84724EB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Collaboration and License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period. These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Memorial Sloan Kettering Cancer Center&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On September 4, 2014, (the &amp;#8220;MSK Effective Date&amp;#8221;) the Company entered into a license agreement (the &amp;#8220;Original MSK License Agreement&amp;#8221;) with MSK under which the Company was granted an exclusive license to develop and commercialize MSK&amp;#8217;s WT1 peptide vaccine technology. Under the terms of the Original MSK License Agreement, the Company is required to obtain certain levels of financing. If such financing is not met, MSK will have the right to terminate the Original MSK License Agreement with prior written notice, unless the Company manages to overcome the shortfall during the term of the notice period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of the consideration for the rights, privileges and licenses granted under the Original MSK License Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,199&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares to MSK representing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company&amp;#8217;s fully diluted share capital as of the MSK Effective Date, which obligation was satisfied by assignment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,599&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares from each of the Company&amp;#8217;s President, Chief Executive Officer, and co-founder, Dr. Angelos M. Stergiou, and the Company&amp;#8217;s other co-founder, Dr. Miltiadis Sougioultzoglou (M.D.), to MSK, for which they received no consideration. Additionally, the Company was obligated to pay upfront license fees in an amount equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company recognized this amount as research and development expense during the year ended December 31, 2014, as it had no alternative future use. The Company would further be obligated to pay minimum royalty payments in the amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; each year commencing in 2015 and research funding costs of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in each year and for three years commencing in January 2015. In addition, to the extent certain development and commercial milestones are achieved, the Company will be required to pay MSK up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$17.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in milestone payments for each licensed product, in addition to royalties in the event of commercial sales of any licensed products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Original MSK License Agreement, unless terminated earlier in accordance with the terms of the Original MSK License Agreement, will continue on a country-by-country and licensed product-by-licensed product basis, until the later of: (i) expiration of the last valid claim embracing such licensed product; (ii) expiration of any market exclusivity period granted by law with respect to such licensed product; or (iii) &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;) years from the first commercial sale in such country.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On October 30, 2015, the Company and MSK entered into the License Amendment, Waiver and Share Issuance Agreement (the &amp;#8220;First MSK Amendment&amp;#8221;). The First MSK Amendment extended the date required for the Company to obtain financing from August 1, 2015 to December 31, 2016, modified the amount of required financing and waived past non-compliance with certain related provisions of the Original MSK License Agreement. In exchange for the First MSK Amendment, the Company agreed to issue an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,867&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares to MSK, which represented &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the fully diluted share capital of the Company at such date. The First MSK Amendment added certain anti-dilution protection clauses and entitled MSK to additional shares to the extent the Company was not able to obtain the required financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On August 10, 2016, the Company and MSK entered into the Second License Amendment, Waiver and Agreement (the &amp;#8220;Second MSK Amendment&amp;#8221;). The Second MSK Amendment extended further the date required for the Company to obtain financing from December 31, 2016 to June 30, 2017, amended the anti-dilution provisions of the First MSK Amendment and waived past non-compliance with certain related provisions of the First MSK Amendment. Under the Second MSK Amendment, outstanding obligations of the Company to MSK in an amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were converted into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,815&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares effective November 1, 2016 upon the Company&amp;#8217;s re-domiciliation to Bermuda. In consideration for this amendment and pursuant to the anti-dilution provisions in the Original MSK License Agreement as amended by the First MSK Amendment and the Second MSK Amendment, the Company issued MSK &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30,314&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; additional shares and incurred accordingly &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of research and development expense, which reflected the fair value of the Company&amp;#8217;s shares at such date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 25, 2017, the Company and MSK entered into an Amended and Restated Exclusive License Agreement (the &amp;#8220;MSK A&amp;amp;R License Agreement&amp;#8221;). Under the MSK A&amp;amp;R License Agreement, the Company expanded its license under the original MSK License Agreement, as amended, to include a license to commercially develop certain additional WT1 peptides through a program of exploiting certain patents and other rights covering such peptides.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The MSK A&amp;amp;R License Agreement, among other changes, added certain milestone payments for each additional patent licensed product as defined in the MSK A&amp;amp;R License Agreement, and amended the milestone payments due upon commencement of the Phase 3 AML and mesothelioma clinical trials from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In consideration for the MSK A&amp;amp;R License Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,799&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares to MSK. Pursuant to a side letter to the MSK A&amp;amp;R License Agreement, dated May 25, 2017 (the &amp;#8220;MSK Side Letter&amp;#8221;), MSK converted the next milestone payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which was due June 30, 2017, into shares. Further, in consideration for the MSK Side Letter, Dr. Stergiou, the Company&amp;#8217;s Chief Executive Officer, assigned &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,399&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of his shares to MSK, for which Dr. Stergiou received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash consideration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On October 11, 2017, the Company and MSK entered into a second Amended and Restated Exclusive License Agreement (the &amp;#8220;Second MSK A&amp;amp;R License Agreement&amp;#8221;). Under the Second MSK A&amp;amp;R License Agreement, the Company and MSK extended the dates for the Company to have obtained necessary financing, and certain milestone dates, in exchange for increased milestone payments, clarification regarding MSK&amp;#8217;s anti-dilution rights, and termination of the MSK Side Letter dated May 25, 2017. In connection with the Second MSK A&amp;amp;R License Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74,795&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares to MSK. Prior to the Merger, the Company issued an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,700&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares to MSK in connection with their anti-dilution rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For the year ended December 31, 2018 the Company incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of expenses relating to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of milestone payments, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in licensing fees, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of guaranteed minimum royalty payments and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of research funding costs.  For the year ended December 31, 2017, the Company incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of expenses relating to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of milestone payments, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of guaranteed minimum royal payments and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of research funding costs. Such expenses have been included in research and development costs. Further, under the Second MSK Amendment, the Company is obligated to pay MSK &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in milestone payments in two equal installments, within &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days following the initiation of its Phase 3 AML and mesothelioma clinical studies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Merck &amp;amp; Co., Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On September 21, 2017, the Company entered into a clinical trial collaboration and supply agreement through a Merck &amp;amp; Co., Inc. subsidiary, Merck Sharp &amp;amp; Dohme B.V. (&amp;#8220;Merck subsidiary&amp;#8221;), whereby the Company agreed with the Merck subsidiary to collaborate in a research program to evaluate GPS as it is administered in combination with Merck&amp;#8217;s PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors.  The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab in patients with WT1+ relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: AML, ovarian, triple-negative breast, small cell lung, and colorectal (arm enriched in but not exclusive to patients with microsatelite instability-low tumors). This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pembrolizumab alone in comparable patient populations. This trial was initiated in December 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Advaxis, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On February 24, 2017, the Company and Advaxis, Inc. (&amp;#8220;Advaxis&amp;#8221;) entered into a research and development collaboration agreement, whereby both parties will collaborate in a research program to evaluate, through a &amp;#8220;proof of principle&amp;#8221; trial or trials (&amp;#8220;PoP Clinical Trial&amp;#8221;), a clinical candidate comprised of the combination of Advaxis&amp;#8217; proprietary &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Lm-&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;based antigen delivery technology and the Company&amp;#8217;s patented WT1 targeted heteroclitic peptide antigen mixture (GPS). The term of the Advaxis agreement will expire upon the earlier of: (a) completion of the PoP Clinical Trial, (b) a decision by the parties to cease further development of the clinical candidate and (c) early termination of the Advaxis agreement pursuant to the terms thereof.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and filing any investigational new drug application (&amp;#8220;IND&amp;#8221;), cost-sharing for preparation of the IND, and the Company being responsible for the costs (exclusive of product costs) of conducting the PoP Clinical Trial. The Company also agreed to make certain non-refundable milestone payments to Advaxis having an aggregate amount of up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$108.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain targets, the Company agreed to make non-refundable sales milestone payments up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low double digits if net sales exceed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On September 11, 2006, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&amp;#8220;MDACC&amp;#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&amp;#8220;HJF&amp;#8221;) which grants exclusive worldwide rights to a United States patent covering the nelipepimut-S peptide vaccine ("NPS") and several United States and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, the Company is required to pay an annual maintenance fee of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for clinical milestone payments, and to pay a tiered royalty in the mid-single digits based on sales of NPS or other therapeutic products developed from the licensed technologies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-511CAE83D04309484F01806812E12F7C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Legal Proceedings, Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Proceedings &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&amp;#8217;s consolidated results of operations, financial position or cash flows. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company is now subject as a result of the Merger. The Company is also involved in litigation matters as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On October 13, 2016, Galena filed a complaint against Aon Risk Insurance Services West, Inc. in the Circuit Court for Multnomah County, Oregon.&amp;#160;The complaint seeks damages related to Galena&amp;#8217;s coverage dispute with a certain insurer, including the amounts Galena was required to contribute to the settlements of In re Galena Biopharma, Inc. Derivative Litigation and In re Galena Biopharma, Inc. Securities Litigation as a direct result of certain insurer&amp;#8217;s failure to pay its full policy limits. On November 30, 2018, the Company amended its complaint to seek punitive damages.&amp;#160;Trial is scheduled to begin on May 6, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On February&amp;#160;13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&amp;#8217;s promotional practices for Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&amp;#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint and on December 21, 2018, plaintiffs filed their opposition to the motion to dismiss. On January 18, 2019, the Company filed a reply in support of its motion. The Company's motion to dismiss the amended complaint is currently pending in the U.S. District Court for the District of New Jersey.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&amp;#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&amp;#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&amp;#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in the U.S. District Court for the Northern District of California against the Company&amp;#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018, refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&amp;#8217;s behalf against the Company&amp;#8217;s former directors and, in certain of the complaints, the Company&amp;#8217;s current directors, and the Company&amp;#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On November 15, 2018, the defendants in the August 2018 lawsuit filed a motion to dismiss the complaint. On December 17, 2018, the plaintiff filed an amended complaint. The defendants filed a motion to dismiss the amended complaint on January 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section&amp;#160;225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena&amp;#8217;s former board of directors and former interim chief executive officer regarding the proposals to amend Galena&amp;#8217;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&amp;#160;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On July&amp;#160;24, 2017, Galena entered into a binding settlement term sheet, involving&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,250,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in unrestricted shares of common stock. The Court enforced the settlement term sheet on November&amp;#160;30, 2017. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys&amp;#8217; fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from its insurance carrier for previous amounts paid by the Company in excess of its retention amount and recorded the amount as a reduction to general and administrative expense in the Company's consolidated statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants certain members of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, inclusive of the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; excess amount removed from the restricted account. The entire settlement amount was received in November 2018. The Company offset approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of legal fees incurred during the year ended December 31, 2018 previously recorded in general and administrative expense in the consolidated statement of operations with proceeds from the settlement. The Company recognized a gain on extinguishment of debt of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Consideration related to Development, Regulatory and Commercial Milestone Payments and Business Combinations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. For additional information on the Company&amp;#8217;s commitments under collaboration and license agreements read Note 6 to these consolidated financial statements. For additional information on the Company&amp;#8217;s commitments of contingent consideration read Note 7 to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company rents office space under a&amp;#160;non-cancelable&amp;#160;operating lease. Rental expense amounted to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for the years ended December&amp;#160;31, 2018 and 2017, respectively. The Company&amp;#8217;s contractual obligations that may require future cash payments as of December&amp;#160;31, 2018 under the&amp;#160;non-cancelable&amp;#160;operating lease are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-EBA5E0C391493CB557579B9ECF350C11">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has no items of comprehensive income or loss other than net loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q4YTD" id="Fact-CFB17AB4CDCDCC9B3E149B9C5A42C4F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-D5FD2552130220784405806814706032">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-FB9CFA946A5E578B17398068154667DC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 10, 2016, the Company's predecessor company, Galena, entered into a securities purchase agreement (the &amp;#8220;Securities Purchase Agreement&amp;#8221;) with JGB (Cayman) Newton, Ltd. ("JGB") pursuant to which Galena sold to JGB, at a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.375%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; original issue discount, a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; senior secured debenture (the "Senior Secured Debenture") and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,333&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$23.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The maturity date of the Senior Secured Debenture was November&amp;#160;10, 2018, with accrued interest at&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company&amp;#8217;s common stock, or a combination of cash and the Company&amp;#8217;s common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company&amp;#8217;s assets, including all of the Company&amp;#8217;s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:1pt;padding-left:66px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company was required to maintain a minimum of the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash and cash equivalents in a restricted account. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the outstanding principal balance of the Senior Secured Debenture was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition to the outstanding principal balance, the Senior Secured Debenture had&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of additional interest that was included in the current portion of long-term debt as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. During the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, JGB redeemed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal, which the Company satisfied with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;659,529&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock and redeemed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of restricted cash into unrestricted cash and cash equivalents, which was used to fund the Company&amp;#8217;s ongoing operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In April 2018, JGB commenced a lawsuit against the Company, as described in Note 10. On November 5, 2018, the parties to the JGB lawsuit entered into a settlement agreement, which required, among other things, that JGB make a one-time payment to the Company of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, representing the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Short-term Convertible Promissory Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company issued convertible promissory notes in the principal amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in exchange for the surrender and cancellation of warrants to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;412,667&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock pursuant to the February 2017 public offering by Galena. The convertible promissory notes accrued interest at a rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per annum and were convertible into shares of the Company's common stock at a conversion price equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In April 2018, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal and accrued interest was converted into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;118,644&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. In November of 2018, the Company paid the remaining principal and interest of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to settle the debt. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, there was no principal balance and accrued interest outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-BB2501C019161A4F04438068147C9EB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Convertible Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q4YTD" id="Fact-EA19DB602F9EC53B5B2380681514ECD0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split described in Note 1. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;2017 Equity Incentive Plan &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,686,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger.  Upon the consummation of the Merger, the Company assumed approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,171&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares subject to outstanding common stock options granted under the Company&amp;#8217;s 2016 Incentive Plan that remained exercisable through December 29, 2018 for former Company employees and directors. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The number of shares reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1&amp;#160;of each year, for a period of not more than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, commencing on January 1, 2018 and ending on (and including) January&amp;#160;1, 2027, in an amount equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31&amp;#160;of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1&amp;#160;of a given year to provide that there will be no January 1&amp;#160;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,686,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; on January 1, 2019. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;381,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock were reserved for future grants under the Company&amp;#8217;s 2017 Equity Incentive Plan. There were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; common stock options granted under the 2017 Equity Incentive Plan for the year ended December&amp;#160;31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Years Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Options to Purchase Shares of Common Stock &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The weighted-average grant date fair value of options granted during the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.73&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. There were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; stock options granted during the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&amp;#8217;s options of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; with the average vesting term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for an average of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur, therefore, outstanding stock options equal vested and expected to vest stock options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&amp;#8217;s operating expenses over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.13&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes stock option activity of the Company for the year ended December 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,240.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;483&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;241.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The aggregate intrinsic values of outstanding and exercisable stock options at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were calculated based on the closing price of the Company&amp;#8217;s common stock as reported on the Nasdaq Capital Market on &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.23&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&amp;#8217;s common stock and the exercise price of the underlying stock options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;RSUs with Time-Based and Performance-Based Conditions &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and&amp;#160;non-employees&amp;#160;pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i)&amp;#160;continued service either over a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-year measurement period or at the end of the required service period and (ii)&amp;#160;the achievement of a liquidity event. The initial vesting date for these RSUs was February&amp;#160;27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of December&amp;#160;31, 2018 and December 31, 2017, there were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; RSUs outstanding with a weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$52.94&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company&amp;#8217;s control and not deemed probable until it occurs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;2017 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company also has an employee stock purchase plan (&amp;#8220;ESPP&amp;#8221;) which allows employees to contribute up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;of their cash earnings, subject to certain maximums, to be used to purchase shares of the Company&amp;#8217;s common stock on each semi-annual purchase date. On each offering date, each eligible employee, pursuant to an offering made under the ESPP, will be granted a right to purchase up to that number of shares of common stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board of Directors, but in either case not exceeding fifteen percent (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;) of such employee&amp;#8217;s earnings (as defined by the Board of Directors in each offering) during the period that begins on the offering date (or such later date as the Board of Directors determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. As of December&amp;#160;31, 2018, the Board of Directors has not established the various parameters under the ESPP and no shares have been delivered under the ESPP. There are approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;265,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock reserved for issuance under the ESPP, plus the number of shares of common stock that are automatically added on January 1st&amp;#160;of each year for a period of up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, commencing on the first January 1, 2018 and ending on (and including) January&amp;#160;1, 2027, in an amount equal to the lesser of (i) &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31st&amp;#160;of the preceding calendar year, and (ii)&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-3768984C083E8544D27A9B9653A9BA1D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q4YTD" id="Fact-2B2981BD223907B87DF48068146DD5E8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2017 is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration acquired as part of the Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2018Q4YTD" id="Fact-39FC82CDAB29647F5A299B9D5941CC6F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company&amp;#8217;s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (&amp;#8220;LIBOR&amp;#8221;) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-E359594F1034D7023CD48068146E1777">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company did not transfer any financial instruments into or out of Level 3 classification during the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.  See Note 12 for a reconciliation of the changes in the fair value of the warrant liability for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the years ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2017 is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration acquired as part of the Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&amp;#8217;s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; based on the achievement of certain development and commercial milestones relating to NPS. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial of trastuzumab (Herceptin&amp;#174;) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-D2B1F627ACC1F0E7A3CA9680DAE913B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Goodwill and Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company completes its annual impairment test on October 1 each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company's goodwill balance at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets consist of IPR&amp;amp;D acquired as part of the Merger. IPR&amp;amp;D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;NPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;GALE-401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;GALE-301 and GALE-302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company's IPR&amp;amp;D assets consist of the NPS program for the prevention of cancer recurrent in breast cancer patients, and the GALE-301 and GALE-302 programs for the prevention of cancer recurrent in ovarian and endometrial cancer patients in the adjuvant setting. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&amp;amp;D asset associated with the GALE-401 product candidate and recorded an impairment charge of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which was equal to the acquired value of GALE-401 of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; recorded as deposits and other assets related to upfront milestone payments associated with that product candidate. The abandonment also resulted in an income tax benefit of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2018Q4YTD" id="Fact-0ACAB814FC7EAD9E3B4C9B9A610B715B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&amp;#8217;s goodwill is less than the carrying value of the reporting unit&amp;#8217;s goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="FD2018Q4YTD" id="Fact-8B902AA5A12CA91E7F499B9B0E1EBF7C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets are comprised of identifiable in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-3B3867729F0952398DA07E89F4D8D9F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The loss before income taxes is as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non - U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(23,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(29,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(23,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of federal and state income tax expense are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Deferred expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total deferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,317&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax assets and liabilities are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Licensing deduction deferral&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,658&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In-process research and development not subject to future amortization for tax purposes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;U.S. federal statutory income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State and local taxes, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Foreign rate differential&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;34.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax rate change and true-up&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;23.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;At December 31, 2018, the Company had domestic federal and state net operating loss carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$19.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively, available to reduce future taxable income, which expire beginning in 2027. The Company also had federal research and development tax credit carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, available to reduce future tax liabilities and which expire at various dates beginning in 2035. The income tax expense for the year ended December 31, 2018 and 2017 relates to both the indefinite lived deferred tax liabilities and the December 22, 2017 enactment of the Tax Cuts and Jobs Act. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Under the provisions of the Internal Revenue Code, the net operating losses (&amp;#8220;NOL&amp;#8221;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, as defined under Sections&amp;#160;382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. Utilization of the net operating loss and tax credits carryforwards may be limited by &amp;#8220;ownership change&amp;#8221; rules, as defined in Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In assessing the need for a valuation allowance the Company may utilize indefinite-lived deferred tax liabilities from an indefinite-lived intangible asset as a future source of income.&amp;#160;The Company&amp;#8217;s IPR&amp;amp;D, as recorded in acquisition accounting, can be utilized as a source of income arising from the future reversal of temporary difference that can be offset against post 2017 indefinite-lived NOLs.&amp;#160;Therefore, the Company is permitted to offset the indefinite-lived DTL up to the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; percent limitation for NOL&amp;#8217;s generated subsequent to January 1, 2018. The valuation allowance increased by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for the year ended December 31, 2018 as a result of the impairment of one of the Company's indefinite-lived intangible assets and changes in the Company's state apportionment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to tax examinations for the 2014 tax year and beyond. The Company does not recognize tax benefits that are not more-likely-than-not to be supported based upon the technical merits of the tax position taken. In assessing its unrecognized tax benefits, the Company has analyzed its tax return filing positions in all of the federal, state and foreign filing jurisdictions where it is required to file income tax returns, as well as all open years in those jurisdictions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table indicates the changes to the Company&amp;#8217;s unrecognized tax benefits (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Beginning of the Year - unrecognized tax benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Increase/(Decrease) - prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Increase - current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;End of the Year - unrecognized tax benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The unrecognized tax benefits, if recognized and in absence of full valuation allowance, would impact the income tax provision by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$55,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$72,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company does not believe that it is reasonably possible that its unrecognized tax benefits would significantly change in the following 12 months. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in the near term. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 22, 2017, the 2017 Tax Cuts and Jobs Act (Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring the Company's U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of the Company's deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allowed the Company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. As a result, the Company previously provided a provisional estimate of the effect of the Tax Act in the Company's financial statements. In the fourth quarter of 2018, we completed our analysis to determine the effect of the Tax Act and recorded no material adjustments as of December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-2C921218427D1910BC6E9B970884D08E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC740-10&amp;#8221;). &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC740-10 &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&amp;#8217;s assumptions or changes in the Company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:LegalCostsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-2E962760AE3118F3F3079B98C82690CC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Fees and Insurance Recoveries&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
	<us-gaap:LiquidationBasisOfAccountingTextBlock contextRef="FD2018Q4YTD" id="Fact-B7E271A75B025661D9C480681368F2B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&amp;#8217;s research and development efforts will be successful. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On July 16, 2018, the Company completed an underwritten public offering (the "July 2018 Offering"), and issued (i) &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,845,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock, (ii) &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; pre-funded warrants exercisable for shares of common stock and (iii) accompanying common stock warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,520,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0999&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company&amp;#8217;s common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other offering expenses, and excluding the exercise of any warrants, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition to the proceeds from the July 2018 Offering, on March&amp;#160;7, 2018, the Company entered into a securities purchase agreement to issue shares of its Series A convertible preferred stock (&amp;#8220;Series A Convertible Preferred&amp;#8221;) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,700&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of Series A Convertible Preferred and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; year warrants to acquire an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,383,631&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.59&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share was completed in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; tranches and resulted in aggregate gross proceeds to the Company of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company completed the first tranche for approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; gross proceeds on March&amp;#160;9, 2018. The Company completed the second tranche of the remaining &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; gross proceeds on May 1, 2018, following stockholder approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2019, the Company engaged Cantor Fitzgerald &amp;amp; Co. to explore a wide range of strategic alternatives to continue the Company's business plan, with the ultimate objective being an outcome that is in the best interest of the Company's shareholders.  Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment into the Company, a sale, license or other disposition of corporate assets, a funded collaboration or partnership, or a financing which would allow the Company to continue with its current business plan of developing its development plans for its lead product candidates. To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&amp;#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&amp;#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&amp;#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and a restricted cash balance of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition, the Company had outstanding accounts payable and accrued expenses of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company expects its existing cash as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, together with the gross proceeds of up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; the Company may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable the Company to fund its operating expenses through June 2019. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, the Company will need to raise additional capital earlier than anticipated to fund our operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-C5D818C4C41582B14BB58068142641D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Pending Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2018, FASB issued ASU No. 2018-13, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Improvements to Nonemployee Share-Based Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In July 2018, the FASB issued ASU No. 2018-10, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842) - Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The new standard establishes a right-of-use&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or ROU&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU No. 2016-18 requires that restricted cash be included&amp;#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&amp;#160;In accordance&amp;#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents, restricted cash, and restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&amp;#160;31, 2017, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU&amp;#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&amp;#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="FD2018Q4YTD" id="Fact-358780B9901D6BE3BADB80681320DD40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Warrants to Acquire Shares of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Canceled/Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Pre-funded July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2017 Equilibria&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;February 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;534,334&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;54,613&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock in exchange for the surrender and cancellation of warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;121,667&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;412,667&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock, as described in Note 11. The fair value of the common stock and promissory notes exchanged totaled &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which exceeded the fair value of the warrant liability of the warrants canceled by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and is recorded as loss on settlement of liability-classified warrants in the consolidated statement of operations for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In April 2018, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal and accrued interest was converted into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;118,644&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants Classified as Liabilities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 offering, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company&amp;#8217;s common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.59&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share of common stock, subject to standard adjustments for certain transactions affecting the Company&amp;#8217;s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;88.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;94.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;829.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;94.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;888.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;72.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, because the Company has &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; present intention to pay cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Adjustment to exercise price of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants Classified as Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company issued warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316,163&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the its common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$7.42&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, maturing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December&amp;#160;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90.10%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk free rate of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.20%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 11.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2018Q4YTD" id="Fact-C5FF9E7E857FBD24594880681447E6C2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;SELLAS Life Sciences Group, Inc. (the "Company," or &amp;#8220;SELLAS&amp;#8221;) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As used in this annual report on Form 10-K, the words the &amp;#8220;Company,&amp;#8221; and &amp;#8220;SELLAS&amp;#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&amp;#160;7, 2017 and amended November&amp;#160;5, 2017 (the "Merger Agreement"), among the Galena, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company&amp;#8217;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Immediately prior to the Merger, Galena effected a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-for-&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; reverse stock split of its outstanding common stock, par value &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS&amp;#8217; securityholders at an exchange ratio of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;43.9972&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&amp;#8220;RSUs&amp;#8221;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&amp;#8217;s common stock. Accordingly, immediately after the Merger, there were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,766,891&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock outstanding, with the former Private SELLAS securityholders owning &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;67.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company&amp;#8217;s fully diluted common stock, and the Company&amp;#8217;s pre-Merger securityholders owning the remaining &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The number of shares and per share amounts of common stock in the accompanying consolidated financial statements and notes to the consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Upon completion of the Merger, the Company&amp;#8217;s name changed from &amp;#8220;Galena Biopharma, Inc.&amp;#8221; to &amp;#8220;SELLAS Life Sciences Group, Inc.," the Company&amp;#8217;s financial statements became those of Private SELLAS, and the Company's common stock began trading on The Nasdaq Capital Market under the new ticker symbol &amp;#8220;SLS&amp;#8221; on January&amp;#160;2, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-B1485BA9B740F13922427E8B414BF17C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;  Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Management and Strategic Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective in June 2016, the Company and Equilibria Capital Management ("Equilibria"), a company incorporated in Bermuda and a significant stockholder of the Company, entered into the management and strategic collaboration agreement. Under the Equilibria collaboration agreement, Equilibria, amongst other services, was engaged to provide certain strategic, management and capital raising advice to the Company. The Equilibria collaboration agreement was effective for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years and renewable thereafter only upon the mutual written agreement of both parties. The Equilibria collaboration agreement provided that it would automatically terminate upon the closing of an IPO or a strategic sale. During the term of the Equilibria collaboration agreement, the Company, in exchange for the services received, paid Equilibria a quarterly fee of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the &amp;#8220;Equilibria Management Fee&amp;#8221;). The Equilibria Management Fee can be paid in cash or, at the mutual agreement of the parties, in shares of the Company at a valuation equal to the Company&amp;#8217;s most recent financing round. In addition to the Equilibria Management Fee, the Company agreed to pay Equilibria any expenses reasonably incurred in performing the services agreed. For the years ended December 31, 2017, the Company had incurred and paid in cash &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively, of Equilibria Management Fees. These amounts are included in general and administrative expense in the consolidated statements of operations. As of December 31, 2017, the Company had an outstanding payable to Equilibria of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The management and strategic collaboration agreement was terminated upon consummation of the Merger in December 2017. There were no Equilibria Management Fees incurred during the year ended December 2018 and there was no outstanding payable as of December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For the provision of the management and strategic collaboration services, the Company also agreed to pay Equilibria an incentive fee equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the post-money market value of the Company on the date of its IPO. Such fee would be payable in shares with a per-share price equal to the price set for the sale of the Company&amp;#8217;s shares to other investors in its IPO. The Company and Equilibria may have jointly agreed to settle the incentive fee earlier, if deemed appropriate for achieving a successful IPO, through either a cash payment, issuance of shares, or a combination of the two. In the event that the Company was sold as part of a strategic sale, the incentive fee would be equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the gross value paid by the purchaser in cash.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2017, the Company and Equilibria entered into an amendment of the Equilibria collaboration agreement. Under the amendment, in the event that the Company entered into a reverse merger transaction in lieu of an initial public offering, the incentive fee to Equilibria was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the post-merger fully diluted market value of the Company immediately after the closing of the reverse merger transaction, payable in a combination of cash and shares of common stock of the Company. The cash payment was based on the per share price equaling the intrinsic value of the Company&amp;#8217;s shares in the Merger. The share-based component of the incentive fee was based on the post-closing fully diluted number of shares outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2017, the Company and Equilibria further amended the Equilibria collaboration agreement to fix the compensation payable to Equilibria in connection with the completion of the Merger, described above in Note 1. Accordingly, upon consummation of the Merger on December 29, 2017, the Company incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in fees to Equilibria and issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;119,672&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock to Equilibria at a fair value of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. These amounts are included in general and administrative expense in the consolidated statements of operations. Also, upon consummation of the Merger and pursuant to the amended Equilibria collaboration agreement, such agreement was terminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s Chief Executive Officer, Dr. Angelos M. Stergiou (M.D., ScD h.c.) is a significant stockholder of the Company owning &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.9%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.8%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company&amp;#8217;s outstanding share capital as of December 31, 2018 and 2017, respectively. Further transactions involving the Company and Dr. Stergiou are described in Note 6.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q4YTD" id="Fact-482659F85EE95C595C9B9B97C242271B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-6D0D9AD95C87100CEEAD806812F1AFE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Value-added tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Rebates and returns of former commercial products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-30D48123F8BD766703AD9912B2BF617E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Unvested restricted stock awards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2018Q4YTD" id="Fact-35C5A8D2DEE910EBC3C07E79E12DDE13">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The purchase price was calculated as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:585px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:86px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Fair value of the Company's pre-Merger shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Estimated fair value of the Company's pre-Merger stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:585px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:86px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets acquired:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;34,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Litigation settlement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration of Apthera, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-4287B6444E724EC4760580681469A09A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents, restricted cash, and restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2018Q4YTD" id="Fact-339F2A40846BFBCEC07C7F84B3488524">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of federal and state income tax expense are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Deferred expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total deferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,317&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2018Q4YTD" id="Fact-80FD1574127CC01A2D0F80681528AAA1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-0E573E526D86374D3B429CF98FA374B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax assets and liabilities are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Licensing deduction deferral&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,658&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The components of net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In-process research and development not subject to future amortization for tax purposes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The net deferred tax liabilities are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Gross deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-FB71C8DA1FE59E5977057F88162C79B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;U.S. federal statutory income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;State and local taxes, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Foreign rate differential&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;34.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax rate change and true-up&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;23.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q4YTD" id="Fact-6A7E2A8B347211D74D22806814DE95AF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Years Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q4YTD" id="Fact-3ED5099034D2EF3311888068146C19AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-855C4A2D4A7857728E987E80AA88A55B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s contractual obligations that may require future cash payments as of December&amp;#160;31, 2018 under the&amp;#160;non-cancelable&amp;#160;operating lease are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="FD2018Q4YTD" id="Fact-48C65F70C78E3F8124227F7FA9BC56B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The loss before income taxes is as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non - U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(23,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(29,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(23,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
	<us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-61AE7FB3BAEADD65DAF6968375B53CB0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets consist of IPR&amp;amp;D acquired as part of the Merger. IPR&amp;amp;D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;NPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;GALE-401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;GALE-301 and GALE-302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-87AD6F19B76F0723C3A680681500ACA5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes stock option activity of the Company for the year ended December 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,240.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;483&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;241.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-9EBDD8F9DCBA44AEB5FE806814ECF5D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q4YTD" id="Fact-146571496BC92070C0AB9B97F4CBEE8E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212; Stock Compensation&amp;#8221; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non-Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q4YTD" id="Fact-F10ABAF79571F4C93AA08068141FC211">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Basis of Presentation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&amp;#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and our wholly owned subsidiaries, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Private SELLAS, SLSG US, Inc., Sellas Life Sciences Limited, Sellas Life Sciences Group UK Ltd., Apthera, Inc., and Mills Pharmaceuticals, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company&amp;#8217;s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (&amp;#8220;LIBOR&amp;#8221;) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company&amp;#8217;s financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets are comprised of identifiable in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&amp;amp;D asset associated with the GALE-401 product candidate and recorded an impairment charge of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which was equal to the acquired value of GALE-401 of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; recorded as deposits and other assets related to upfront milestone payments. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives. See Note 5 for further discussion of the Company's intangible assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&amp;#8217;s goodwill is less than the carrying value of the reporting unit&amp;#8217;s goodwill. The Company did not recognize any impairment of goodwill during the years ended December 31, 2018 and 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Severance Costs Related to Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company recognized and paid &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of exit costs during 2017 related to severance benefits for certain former Galena employees terminated immediately prior to the consummation of the Merger.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Fees and Insurance Recoveries&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212; Stock Compensation&amp;#8221; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non-Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC740-10&amp;#8221;). &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC740-10 &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&amp;#8217;s assumptions or changes in the Company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 22, 2017 the President of the United States signed into law the Tax Cuts and Jobs Act (the &amp;#8220;2017 Tax Act&amp;#8221;). This legislation makes significant changes in the United States tax laws including, but not limited to, reducing the corporate tax rate to 21% starting in 2018. The 2017 Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of 21%. For the years ended December 31, 2018 and December 31, 2017, the Company recognized an income tax benefit of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and an income tax expense of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively. Staff Accounting Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. As such, the Company completed the analysis based on legislative updates relating to the Act currently available, and no material adjustments have been recorded as of December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Unvested restricted stock awards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has no items of comprehensive income or loss other than net loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Convertible Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Pending Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2018, FASB issued ASU No. 2018-13, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Improvements to Nonemployee Share-Based Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In July 2018, the FASB issued ASU No. 2018-10, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842) - Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The new standard establishes a right-of-use&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or ROU&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU No. 2016-18 requires that restricted cash be included&amp;#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&amp;#160;In accordance&amp;#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents, restricted cash, and restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&amp;#160;31, 2017, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU&amp;#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&amp;#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-D2B2F4A8D2E3616ACEA8806813F17158">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of preferred stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Series A Convertible Preferred &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On March&amp;#160;7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,700&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,383,631&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock, par value &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share at an aggregate purchase price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Series A Convertible Preferred was initially convertible into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,844,835&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock based on an initial conversion price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.80&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;At the first closing of the Series A Convertible Preferred on March&amp;#160;9, 2018, the Company issued an aggregate &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,987&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of Series A Convertible Preferred and warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;774,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for aggregate gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The second closing of the remaining &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,713&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Series A Convertible Preferred and warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;609,445&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock, for aggregate gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, occurred on May 1, 2018 following receipt of stockholder approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders") had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and in Note 2 above, the Series A Holders exchanged an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$7,871,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,748,184&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock and warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,748,184&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock. Following such exchange, there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and a term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and that amount is recorded as a deemed dividend in the consolidated statements of operations during the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was automatically adjusted to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share from the original exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.59&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The Company recognized the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the consolidated statements of operations during the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred generated a beneficial conversion feature (&amp;#8220;BCF&amp;#8221;), which arose as the equity security was issued with an embedded conversion option that was beneficial to the investor or in the money at inception because the conversion option had an effective conversion price that was less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a deemed dividend in the consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a deemed dividend related to the second closing on May 1, 2018.&amp;#160;These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of common stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On July 16, 2018, the Company completed the July 2018 Offering, issuing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,845,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,520,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0999&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per pre-funded warrant and common stock warrant.  Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; share of the Company&amp;#8217;s common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance.  The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contracts in an Entity&amp;#8217;s own Equity&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 815-40&amp;#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Distinguishing Liabilities from Equity,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&amp;#8217;s own stock and would be classified in permanent equity if freestanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock reserved for future issuance are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2017 Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="FD2018Q4YTD" id="Fact-DA16E5372F2C1C95290A8068142F8E3F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q4YTD" id="Fact-EB1DA6DA19FB43A98E8D806813A9A4FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company evaluated all events or transactions that occurred after &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On March 6, 2019, the Company entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,800,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,800,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.40&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; New Warrants were issued. The Company may receive aggregate gross proceeds of up to approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from the cash exercise if all of the warrants under the Exercise Agreement are exercised.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q4YTD" id="Fact-1E7432440DACE8CD8E519B9DE3FF6EC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>gale-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20181231" xmlns:gale="http://www.galenabiopharma.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2108100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2408402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2308301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://www.galenabiopharma.com/role/Acquisition">
        <link:definition>2104100 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDetails" roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails">
        <link:definition>2404405 - Disclosure - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionProFormaDetails" roleURI="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails">
        <link:definition>2404404 - Disclosure - Acquisition - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionSummaryOfPurchasePriceDetails" roleURI="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails">
        <link:definition>2404402 - Disclosure - Acquisition - Summary of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTables" roleURI="http://www.galenabiopharma.com/role/AcquisitionTables">
        <link:definition>2304301 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTotalPurchasePriceAllocationDetails" roleURI="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails">
        <link:definition>2404403 - Disclosure - Acquisition - Total Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>2103100 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails">
        <link:definition>2403404 - Disclosure - Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails">
        <link:definition>2403405 - Disclosure - Basis of Presentation and Significant Accounting Policies - Components of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>2303302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreements" roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements">
        <link:definition>2106100 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>2406401 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfStockholdersEquity" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.galenabiopharma.com/role/Debt">
        <link:definition>2109100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleDebtDetails" roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails">
        <link:definition>2409404 - Disclosure - Debt - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSeniorSecuredDebentureDetails" roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails">
        <link:definition>2409403 - Disclosure - Debt - Senior Secured Debenture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryOfDebtDetails" roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails">
        <link:definition>2409402 - Disclosure - Debt - Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.galenabiopharma.com/role/DebtTables">
        <link:definition>2309301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2107100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails">
        <link:definition>2407402 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails">
        <link:definition>2407403 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails">
        <link:definition>2405402 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsNotes" roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes">
        <link:definition>2105100 - Disclosure - Goodwill and Intangible Assets (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails">
        <link:definition>2405403 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2305301 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>2419404 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>2419405 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails">
        <link:definition>2419406 - Disclosure - Income Taxes - Components of Net Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesDetails">
        <link:definition>2419402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNotes" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesNotes">
        <link:definition>2119100 - Disclosure - Income Taxes (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails">
        <link:definition>2419409 - Disclosure - Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails">
        <link:definition>2419407 - Disclosure - Income Taxes - Schedule of Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails">
        <link:definition>2419403 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails">
        <link:definition>2419408 - Disclosure - Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables">
        <link:definition>2319301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingencies" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies">
        <link:definition>2110100 - Disclosure - Legal Proceedings, Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails">
        <link:definition>2410402 - Disclosure - Legal Proceedings, Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails">
        <link:definition>2410403 - Disclosure - Legal Proceedings, Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesTables" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables">
        <link:definition>2310301 - Disclosure - Legal Proceedings, Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.galenabiopharma.com/role/Liquidity">
        <link:definition>2102100 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityDetails" roleURI="http://www.galenabiopharma.com/role/LiquidityDetails">
        <link:definition>2402401 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusinessNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails">
        <link:definition>2401401 - Disclosure - Organization and Description of Business (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2420401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNotes" roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes">
        <link:definition>2120100 - Disclosure - Related Party Transactions (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2113100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockBasedCompensationDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails">
        <link:definition>2413403 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails">
        <link:definition>2413404 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2413402 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2413405 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2313301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2111100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails">
        <link:definition>2411403 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2411402 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables">
        <link:definition>2311301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2121100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>2421401 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStock" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock">
        <link:definition>2112100 - Disclosure - Warrants to Acquire Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails">
        <link:definition>2412405 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>2412404 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails">
        <link:definition>2412403 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails">
        <link:definition>2412402 - Disclosure - Warrants to Acquire Shares of Common Stock - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockTables" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables">
        <link:definition>2312301 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails">
        <link:definition>2412406 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Classified as Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gale_AccruedCompensationIncentive" name="AccruedCompensationIncentive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement" name="AdditionalSharesIssuedInConnectionWithLicensingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" name="AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" name="AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AdvaxisCollaborationAgreementMember" name="AdvaxisCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AmendmentAgreementMember" name="AmendmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AnnualMaintenanceFee" name="AnnualMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_AptheraInc.Member" name="AptheraInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" name="BalanceOfRestrictedCashOverSeniorSecuredDebenture" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" name="BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_BusinessCombinationFairValueOfSharesOutstanding" name="BusinessCombinationFairValueOfSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_BusinessCombinationProFormaTransactionCosts" name="BusinessCombinationProFormaTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ChiefExecutiveOfficerCoFounderMember" name="ChiefExecutiveOfficerCoFounderMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightCanceled" name="ClassOfWarrantOrRightCanceled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightNewWarrantsIssued" name="ClassOfWarrantOrRightNewWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightOutstandingExercisable" name="ClassOfWarrantOrRightOutstandingExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ClassofWarrantorRightCanceledOrExpired" name="ClassofWarrantorRightCanceledOrExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightFairValueRollForward" name="ClassofWarrantorRightFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightGranted" name="ClassofWarrantorRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightOutstandingRollForward" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" name="ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClosingPriceOfCommonStock" name="ClosingPriceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CofounderMember" name="CofounderMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CollaborationAgreementTerm" name="CollaborationAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" name="CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_CommonStockConversionRatio" name="CommonStockConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" name="CommonStockIssuedDuringThePeriodForCancellationOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockSharesAcquiredinExchangeforWarrants" name="CommonStockSharesAcquiredinExchangeforWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockSharesReservedForIssuanceAdditionalShares" name="CommonStockSharesReservedForIssuanceAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ConsiderationExchangedFairValue" name="ConsiderationExchangedFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractResearchPayable" name="ContractResearchPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ConversionwithSeriesAConvertiblePreferredStock" name="ConversionwithSeriesAConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" name="ConvertibleDebtTwoThousandFifteenShareholderNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ConvertibleDebtTwoThousandSelyNoteMember" name="ConvertibleDebtTwoThousandSelyNoteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ConvertiblePreferredStockDividends" name="ConvertiblePreferredStockDividends" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ConvertiblePreferredStockIssuedShares" name="ConvertiblePreferredStockIssuedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ConvertiblePreferredStockNumberOfTranches" name="ConvertiblePreferredStockNumberOfTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CorporateCreditCardsMember" name="CorporateCreditCardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentCovenantLiquidityCovenant" name="DebtInstrumentCovenantLiquidityCovenant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" name="DebtInstrumentRedemptionPrincipalAmountRedeemed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" name="DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" name="DebtInstrumentRedemptionPrincipalAmountRedeemedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" name="DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" name="DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DeemedDividendOnDebtConversion" name="DeemedDividendOnDebtConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DeferredTaxAssetsLicensingDeductionDeferral" name="DeferredTaxAssetsLicensingDeductionDeferral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DividendModificationOfWarrants" name="DividendModificationOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" name="DividendOnConversionOfSeriesAConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" name="DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_Dr.AngelosM.StergiouMember" name="Dr.AngelosM.StergiouMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EqcWarrantsMember" name="EqcWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EquilibriaCollaborationAgreementMember" name="EquilibriaCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" name="FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" name="FairValueOfStockOptionsAssumedInConnectionWithAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsCanceled" name="FairValueOfWarrantsCanceled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsExercisePriceAdjustment" name="FairValueOfWarrantsExercisePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsLiabilities" name="FairValueOfWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsGranted" name="FairValueofWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueofWarrantsGrantedperShare" name="FairValueofWarrantsGrantedperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_February2017WarrantsMember" name="February2017WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_FirstTrancheMember" name="FirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_GALE301AndGALE302Member" name="GALE301AndGALE302Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_GALE401Member" name="GALE401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_GalenaBiopharmaIncMember" name="GalenaBiopharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" name="ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_InProcessResearchDevelopment" name="InProcessResearchDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash" name="IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_IncentiveFeePercentageEqualToPostMoneyMarketValue" name="IncentiveFeePercentageEqualToPostMoneyMarketValue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_IncentivePlan2016Member" name="IncentivePlan2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_IncreaseDecreaseInFairValueOfWarrantLiability" name="IncreaseDecreaseInFairValueOfWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment" name="IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" name="IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_JGBActionMember" name="JGBActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_July2018OfferingMember" name="July2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LiabilityClassifiedWarrantsAntidilutionProtection" name="LiabilityClassifiedWarrantsAntidilutionProtection" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LicenseAgreementExpirationTerm" name="LicenseAgreementExpirationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LicenseAgreementMilestonePayments" name="LicenseAgreementMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_LicenseAgreementOutstandingAmountPayable" name="LicenseAgreementOutstandingAmountPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" name="LicenseAmendmentWaiverAndShareIssuanceAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsTable" name="LicenseAndCollaborationAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementIssuanceofCommonStockValue" name="LitigationSettlementIssuanceofCommonStockValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" name="LongtermDebtIssuedInConnectionWithWarrantExchanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_LossContingencyNumberOfCounterclaims" name="LossContingencyNumberOfCounterclaims" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LossOnSettlementOfLiabilityClassifiedWarrants" name="LossOnSettlementOfLiabilityClassifiedWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LossOnSettlementOfWarrantsLiability" name="LossOnSettlementOfWarrantsLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" name="MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumNumberOfDaysToMakePayments" name="MaximumNumberOfDaysToMakePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" name="MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MemorialSloanKetteringCancerCenterMember" name="MemorialSloanKetteringCancerCenterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials" name="MilestoneFeePaymentsUponCommencementOfClinicalTrials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_MinimumAnnualRoyaltyPayment" name="MinimumAnnualRoyaltyPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MskLicenseAgreementMember" name="MskLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_NPSMember" name="NPSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NonrefundableMilestonePayments" name="NonrefundableMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_NonrefundableSalesMilestonePayments" name="NonrefundableSalesMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" name="OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" name="OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_OtherWarrantIssuesMember" name="OtherWarrantIssuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PatelvsGalenabiopharmaIncMember" name="PatelvsGalenabiopharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" name="PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" name="PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageOfFullyDilutedShareCapital" name="PercentageOfFullyDilutedShareCapital" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageOfFullyDilutedShareCapitalOwned" name="PercentageOfFullyDilutedShareCapitalOwned" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_PercentageOfOwnershipOutstandingShareCapital" name="PercentageOfOwnershipOutstandingShareCapital" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PreMergerSecurityholdersMember" name="PreMergerSecurityholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PreferredStockIssuedDuringPeriodValueNewIssues" name="PreferredStockIssuedDuringPeriodValueNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_Prefunded2018OfferingMember" name="Prefunded2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PrivatePlacementFirstClosingMember" name="PrivatePlacementFirstClosingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PrivatePlacementSecondClosingMember" name="PrivatePlacementSecondClosingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PrivateSELLASSecurityHoldersMember" name="PrivateSELLASSecurityHoldersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" name="ProceedsfromIssuanceofLongtermDebtandWarrantsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_RebatesAndReturnsOfFormerCommercialProducts" name="RebatesAndReturnsOfFormerCommercialProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" name="ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilityUponExercise" name="ReclassificationOfWarrantLiabilityUponExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ReimbursementOfLegalFees" name="ReimbursementOfLegalFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ResearchFundingCosts" name="ResearchFundingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_RestrictedCashandCashEquivalentsFairValueDisclosure" name="RestrictedCashandCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_RestrictedStockSharesReservedforFutureIssuance" name="RestrictedStockSharesReservedforFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_RoyaltyPaymentMaximumRate" name="RoyaltyPaymentMaximumRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember" name="SecondAmendedandRestatedExclusiveLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecondMSKAmendmentMember" name="SecondMSKAmendmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecondTrancheMember" name="SecondTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeriesAConvertiblePreferredWarrantsMember" name="SeriesAConvertiblePreferredWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeriesANonvotingConvertibleMember" name="SeriesANonvotingConvertibleMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" name="SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" name="SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_SharesIssuedToSettleAccountsPayable" name="SharesIssuedToSettleAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_SharesIssuedToSettlerRelatedPartyAccountsPayable" name="SharesIssuedToSettlerRelatedPartyAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_SharesIssuedUnderLicenseAgreement" name="SharesIssuedUnderLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" name="StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesPrefundedWarrant" name="StockIssuedDuringPeriodSharesPrefundedWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" name="StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" name="StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" name="StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedForAntidilutionProvisions" name="StockIssuedForAntidilutionProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedForAntidilutionProvisionsShares" name="StockIssuedForAntidilutionProvisionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" name="StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare" name="StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" name="StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" name="StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" name="StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm" name="StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_SuccessFeeAndOtherTransactionCosts" name="SuccessFeeAndOtherTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" name="TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_UpfrontLicenseFees" name="UpfrontLicenseFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantExchangeAgreementsAmount" name="WarrantExchangeAgreementsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantExchangeAgreementsIssuanceOfCommonStock" name="WarrantExchangeAgreementsIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_WarrantExerciseAgreementMember" name="WarrantExerciseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantStrikePrice" name="WarrantStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_WarrantsClassifiedAsLiabilitiesOtherMember" name="WarrantsClassifiedAsLiabilitiesOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsIssuedShares" name="WarrantsIssuedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>gale-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Acquisition" xlink:href="gale-20181231.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:href="gale-20181231.xsd#AcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails" xlink:href="gale-20181231.xsd#AcquisitionProFormaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails" xlink:href="gale-20181231.xsd#AcquisitionSummaryOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:href="gale-20181231.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails" xlink:href="gale-20181231.xsd#AcquisitionTotalPurchasePriceAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements" xlink:href="gale-20181231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="gale-20181231.xsd#CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:href="gale-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20181231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gale-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="gale-20181231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Debt" xlink:href="gale-20181231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:href="gale-20181231.xsd#DebtConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:href="gale-20181231.xsd#DebtSeniorSecuredDebentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:href="gale-20181231.xsd#DebtSummaryOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtTables" xlink:href="gale-20181231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:href="gale-20181231.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:href="gale-20181231.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesNotes" xlink:href="gale-20181231.xsd#IncomeTaxesNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:href="gale-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:href="gale-20181231.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:href="gale-20181231.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="gale-20181231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="gale-20181231.xsd#OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:href="gale-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes" xlink:href="gale-20181231.xsd#RelatedPartyTransactionsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20181231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:href="gale-20181231.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:href="gale-20181231.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20181231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails" xlink:href="gale-20181231.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_02d01603-90ae-c905-6599-17bc9e28dcbf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gale_ContractResearchPayable_02d01603-90ae-c905-6599-17bc9e28dcbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_cc52048c-36c4-6827-6376-17bc9e23a62f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_cc52048c-36c4-6827-6376-17bc9e23a62f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Acquisition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e42af13-4663-babb-7e54-876bbc046779" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationFairValueOfSharesOutstanding" xlink:label="loc_gale_BusinessCombinationFairValueOfSharesOutstanding_9D91C925BD44F26F86B77E7B2B37EEAF" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e42af13-4663-babb-7e54-876bbc046779" xlink:to="loc_gale_BusinessCombinationFairValueOfSharesOutstanding_9D91C925BD44F26F86B77E7B2B37EEAF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:label="loc_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_8B98AED1DC580C9FF74B7E7BEEB5DD97" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e42af13-4663-babb-7e54-876bbc046779" xlink:to="loc_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_8B98AED1DC580C9FF74B7E7BEEB5DD97" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a49f91fe-6036-ab86-6a1a-6ac66f348274" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a49f91fe-6036-ab86-6a1a-6ac66f348274" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_AC2D36B4DB80743EAA957E65BEA38B25" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_AC2D36B4DB80743EAA957E65BEA38B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4969e367-c531-0df1-f44b-bfbc106efa7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4969e367-c531-0df1-f44b-bfbc106efa7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_588b212f-0609-2b89-932f-cbe7e57377ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_5AE1BB1A5FD979F2CA44A08C1B5A7927" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a49f91fe-6036-ab86-6a1a-6ac66f348274" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_52CDDD7AF3D00D7191147E686F7D9CCF" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_52CDDD7AF3D00D7191147E686F7D9CCF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_C2947715BF6C3F2D86EA7E696A259A4B" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_C2947715BF6C3F2D86EA7E696A259A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_463bb7a9-0d88-ff4d-ce08-6503db038fe6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_463bb7a9-0d88-ff4d-ce08-6503db038fe6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_30afdeef-aa84-8083-d81b-2bbd33114cc0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_30afdeef-aa84-8083-d81b-2bbd33114cc0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_E44E80AF855B06FBEC727E74499C7A24" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_E44E80AF855B06FBEC727E74499C7A24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ca5b5f1d-dfc3-4674-aee8-5c9edec064b4" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ca5b5f1d-dfc3-4674-aee8-5c9edec064b4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_e319bb5e-0ace-aac2-b19a-17bc9d22ab42" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_gale_InProcessResearchDevelopment_e319bb5e-0ace-aac2-b19a-17bc9d22ab42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_61ff83b4-33a0-68aa-a4ad-7dbd9b595dbf" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_61ff83b4-33a0-68aa-a4ad-7dbd9b595dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_c53143dc-fefd-4b2a-77bb-40f522645337" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LitigationReserveCurrent_c53143dc-fefd-4b2a-77bb-40f522645337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_cf2b256c-b8de-9fbc-9661-17bc9d59ca79" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_cf2b256c-b8de-9fbc-9661-17bc9d59ca79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_273ee7a0-7a7a-98e9-4dc3-2da4f56d5e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_273ee7a0-7a7a-98e9-4dc3-2da4f56d5e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_13cc8818-e792-6246-5e41-c56e1150a319" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDividends_13cc8818-e792-6246-5e41-c56e1150a319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_98ad2198-806f-6053-5326-b79be5cbb9ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_98ad2198-806f-6053-5326-b79be5cbb9ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_fa368719-52d0-6c9e-94db-e351e195f31b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_fa368719-52d0-6c9e-94db-e351e195f31b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_08057203-8e1b-1ed2-423f-88fae95e960a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AdjustmentForAmortization_08057203-8e1b-1ed2-423f-88fae95e960a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d346b6a0-4ddf-16a5-9e91-c8c6b50db7a6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d346b6a0-4ddf-16a5-9e91-c8c6b50db7a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_4b758f59-092a-4b1f-38aa-17bc9e00005e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_4b758f59-092a-4b1f-38aa-17bc9e00005e" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_325dfb9b-7e37-aaca-69c6-17bc9e14f900" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_325dfb9b-7e37-aaca-69c6-17bc9e14f900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_db5982bd-3de4-fd63-1787-cc859b87dd73" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_db5982bd-3de4-fd63-1787-cc859b87dd73" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_7f6dfe21-84a6-f0fb-b64a-17bc9de049e4" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_7f6dfe21-84a6-f0fb-b64a-17bc9de049e4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_afeaee34-507a-04b1-d222-17bc9db3c621" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_afeaee34-507a-04b1-d222-17bc9db3c621" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_049327f6-4f1a-4a0b-258d-17bc9d829e98" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_049327f6-4f1a-4a0b-258d-17bc9d829e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_bf343068-bca3-ff98-6f65-be98feaa3e15" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_SeveranceCosts1_bf343068-bca3-ff98-6f65-be98feaa3e15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_cccd0209-1cd8-b603-e355-33e3ccd4e542" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_cccd0209-1cd8-b603-e355-33e3ccd4e542" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7ff6517e-8e0a-ec1b-a9cf-c4aac7eaf350" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7ff6517e-8e0a-ec1b-a9cf-c4aac7eaf350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_d57563c0-6fc0-b615-1758-17bc9e4e60db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_d57563c0-6fc0-b615-1758-17bc9e4e60db" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_766cc8f9-d788-0e67-153c-17bc9d616c92" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_gale_LossOnSettlementOfWarrantsLiability_766cc8f9-d788-0e67-153c-17bc9d616c92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_80036452-8f22-8b77-cf8f-49eda674198d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_80036452-8f22-8b77-cf8f-49eda674198d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_63184a46-2bac-760c-5a30-fe8e316dca8f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_63184a46-2bac-760c-5a30-fe8e316dca8f" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_9D48823448558264AEDD08719566ACBF" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_9D48823448558264AEDD08719566ACBF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LiabilityClassifiedWarrantsAntidilutionProtection" xlink:label="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_7C5E155244EBB81FF333139D3950F3A3" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_7C5E155244EBB81FF333139D3950F3A3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendOnDebtConversion" xlink:label="loc_gale_DeemedDividendOnDebtConversion_8DA5B34827268C36F68298DAB02E40A2" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_gale_DeemedDividendOnDebtConversion_8DA5B34827268C36F68298DAB02E40A2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:to="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_9b7e18d2-a7d0-3db9-fed8-17bc9df74ff8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_9b7e18d2-a7d0-3db9-fed8-17bc9df74ff8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_4a556cad-a799-834d-b974-434a5dc27747" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_4a556cad-a799-834d-b974-434a5dc27747" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7eaebfe3-265e-b8d0-3c5e-69c4ef718fdc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_4a556cad-a799-834d-b974-434a5dc27747" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7eaebfe3-265e-b8d0-3c5e-69c4ef718fdc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_96EE2498A5E229F6A6757F93BF5098EF" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_96EE2498A5E229F6A6757F93BF5098EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_1e1f6357-50fc-ea2f-26cc-902e5ba55055" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_1e1f6357-50fc-ea2f-26cc-902e5ba55055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_75f459ba-7a00-3567-8314-b56ffb656f89" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_75f459ba-7a00-3567-8314-b56ffb656f89" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_BCAEA0FFBB37841DFB2F7F9FD0DB79C5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_BCAEA0FFBB37841DFB2F7F9FD0DB79C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b4d15047-d47c-676e-7447-8be27ad2f8e1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b4d15047-d47c-676e-7447-8be27ad2f8e1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a2243c4-9ac2-481f-6794-d746fea55dde" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a2243c4-9ac2-481f-6794-d746fea55dde" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_fca6e29c-36e8-0041-474c-17bc9e188ea1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_fca6e29c-36e8-0041-474c-17bc9e188ea1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_095183ea-49a5-8e05-9d99-17bc9e083754" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_095183ea-49a5-8e05-9d99-17bc9e083754" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedStockSharesReservedforFutureIssuance" xlink:label="loc_gale_RestrictedStockSharesReservedforFutureIssuance_b0fb1e12-9ec5-4083-ffa8-17bc9e475d36" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_gale_RestrictedStockSharesReservedforFutureIssuance_b0fb1e12-9ec5-4083-ffa8-17bc9e475d36" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>gale-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Acquisition" xlink:href="gale-20181231.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:href="gale-20181231.xsd#AcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails" xlink:href="gale-20181231.xsd#AcquisitionProFormaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails" xlink:href="gale-20181231.xsd#AcquisitionSummaryOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:href="gale-20181231.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails" xlink:href="gale-20181231.xsd#AcquisitionTotalPurchasePriceAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements" xlink:href="gale-20181231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="gale-20181231.xsd#CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:href="gale-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20181231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gale-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="gale-20181231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Debt" xlink:href="gale-20181231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:href="gale-20181231.xsd#DebtConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:href="gale-20181231.xsd#DebtSeniorSecuredDebentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:href="gale-20181231.xsd#DebtSummaryOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtTables" xlink:href="gale-20181231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:href="gale-20181231.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:href="gale-20181231.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesNotes" xlink:href="gale-20181231.xsd#IncomeTaxesNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:href="gale-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:href="gale-20181231.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:href="gale-20181231.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="gale-20181231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="gale-20181231.xsd#OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:href="gale-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes" xlink:href="gale-20181231.xsd#RelatedPartyTransactionsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20181231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:href="gale-20181231.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:href="gale-20181231.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20181231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails" xlink:href="gale-20181231.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Acquisition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_FA6B236CFE8460975787A1A120BA9164" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56" xlink:to="loc_gale_GalenaBiopharmaIncMember_FA6B236CFE8460975787A1A120BA9164" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationProFormaTransactionCosts" xlink:label="loc_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SuccessFeeAndOtherTransactionCosts" xlink:label="loc_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_F6081399D6B97782FC09A1A120BBD76E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_us-gaap_SeveranceCosts1_F6081399D6B97782FC09A1A120BBD76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:to="loc_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="loc_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="loc_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_628C2FB7E080F5CBFE499B43C58DC5DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A" xlink:to="loc_gale_AmendmentAgreementMember_628C2FB7E080F5CBFE499B43C58DC5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1" xlink:to="loc_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CorporateCreditCardsMember" xlink:label="loc_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:to="loc_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66BB7BCC3734970441969B43C58FC9C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66BB7BCC3734970441969B43C58FC9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_5D9A180C9C80BC6755249B43C58FA6C7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_RestrictedCash_5D9A180C9C80BC6755249B43C58FA6C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_E22091229B8E98D28BB1A19B9EDC229A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41" xlink:to="loc_us-gaap_ScenarioForecastMember_E22091229B8E98D28BB1A19B9EDC229A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A4BC658D57EE72281130A19B9EE3A980" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1" xlink:to="loc_us-gaap_SubsequentEventMember_A4BC658D57EE72281130A19B9EE3A980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_BC203A382C934995FF4FA19B9EE36468" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668" xlink:to="loc_gale_GALE401Member_BC203A382C934995FF4FA19B9EE36468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_137F625636054667B1ECA19B9EE45BAF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_137F625636054667B1ECA19B9EE45BAF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EE22EE1C7AEDAD93DB4BA19B9EE5042D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_EE22EE1C7AEDAD93DB4BA19B9EE5042D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChiefExecutiveOfficerCoFounderMember" xlink:label="loc_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:to="loc_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CofounderMember" xlink:label="loc_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:to="loc_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:label="loc_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondMSKAmendmentMember" xlink:label="loc_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember" xlink:label="loc_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdvaxisCollaborationAgreementMember" xlink:label="loc_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" xlink:label="loc_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:label="loc_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:to="loc_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:to="loc_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:to="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:to="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AC36FC2950A5ED5944E7A088FDD4CDB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8" xlink:to="loc_srt_MaximumMember_AC36FC2950A5ED5944E7A088FDD4CDB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedUnderLicenseAgreement" xlink:label="loc_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfFullyDilutedShareCapital" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_UpfrontLicenseFees" xlink:label="loc_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MinimumAnnualRoyaltyPayment" xlink:label="loc_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ResearchFundingCosts" xlink:label="loc_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementMilestonePayments" xlink:label="loc_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementExpirationTerm" xlink:label="loc_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:label="loc_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:label="loc_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E86CA13083BFDC7DD7A1A088FDD80A9D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_E86CA13083BFDC7DD7A1A088FDD80A9D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:label="loc_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementOutstandingAmountPayable" xlink:label="loc_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MaximumNumberOfDaysToMakePayments" xlink:label="loc_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_NonrefundableMilestonePayments" xlink:label="loc_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_NonrefundableSalesMilestonePayments" xlink:label="loc_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RoyaltyPaymentMaximumRate" xlink:label="loc_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:to="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:to="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18A6B5D919DEAD330A67A088FE8E521C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18A6B5D919DEAD330A67A088FE8E521C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_35022E4FB3FE278490E2A088FE8F2F0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_35022E4FB3FE278490E2A088FE8F2F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3E1F5CE7851E9A8773FDA088FE8FA3E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3E1F5CE7851E9A8773FDA088FE8FA3E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AD8B9B5EBDB033288FBAA088FE8FAD6D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_AD8B9B5EBDB033288FBAA088FE8FAD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2D8CCE1C1551B67C59ADA088FE90A061" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2D8CCE1C1551B67C59ADA088FE90A061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7896E1D90ACFFEB07F37A088FE90A608" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7896E1D90ACFFEB07F37A088FE90A608" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10A59350584CA44C6426A19AE6AF9343" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_10A59350584CA44C6426A19AE6AF9343" xlink:to="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:to="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:to="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_CB7CAB6CD620C9EE7883A19AE6A76B24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_CB7CAB6CD620C9EE7883A19AE6A76B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_7555927D56D32C7A4581A19AE6A8019F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3" xlink:to="loc_us-gaap_SecuredDebtMember_7555927D56D32C7A4581A19AE6A8019F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:to="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:to="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_00306451C291C93DAE61A19AE6AABA9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_00306451C291C93DAE61A19AE6AABA9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:to="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:to="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2867698311D2FB67D3F2A19AE6AE12F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_CommonStockMember_2867698311D2FB67D3F2A19AE6AE12F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10A59350584CA44C6426A19AE6AF9343" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:label="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:label="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:label="loc_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:label="loc_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:label="loc_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:label="loc_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:label="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:label="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:label="loc_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForAntidilutionProvisionsShares" xlink:label="loc_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForAntidilutionProvisions" xlink:label="loc_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_E5D0BFB28E6F583A7DB7A19AE6B7B8BE" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_E5D0BFB28E6F583A7DB7A19AE6B7B8BE" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendModificationOfWarrants" xlink:label="loc_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockDividends" xlink:label="loc_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExchangeAgreementsIssuanceOfCommonStock" xlink:label="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExchangeAgreementsAmount" xlink:label="loc_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="loc_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:to="loc_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="loc_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:to="loc_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:to="loc_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConversionwithSeriesAConvertiblePreferredStock" xlink:label="loc_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" xlink:label="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" xlink:label="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:label="loc_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedToSettlerRelatedPartyAccountsPayable" xlink:label="loc_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedToSettleAccountsPayable" xlink:label="loc_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:label="loc_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_93D32D294DB6F28C7646A088FD4A2DA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_93D32D294DB6F28C7646A088FD4A2DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:to="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_568C2E1B79411D179716A088FD4BD783" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_568C2E1B79411D179716A088FD4BD783" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_570DABEAC4BBC13BCD4AA088FD4BA000" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_570DABEAC4BBC13BCD4AA088FD4BA000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_06F0496975536D93D708A088FD4C37A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_06F0496975536D93D708A088FD4C37A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_9BB5B2A6339FE52E64A4A088FD4CC529" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_9BB5B2A6339FE52E64A4A088FD4CC529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:to="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:to="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:to="loc_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:to="loc_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:to="loc_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_630B4A920BADEC1CA56EA1145323E3BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_630B4A920BADEC1CA56EA1145323E3BB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="loc_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ReimbursementOfLegalFees" xlink:label="loc_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61F3ECC8F1916F780D81A1145326138C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61F3ECC8F1916F780D81A1145326138C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_088D17EEB4E349F87591A088FD65BB7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A" xlink:to="loc_us-gaap_SecuredDebtMember_088D17EEB4E349F87591A088FD65BB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:to="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_C49C29365EAAF5F83327A088FD650F9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_C49C29365EAAF5F83327A088FD650F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="loc_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AptheraInc.Member" xlink:label="loc_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F" xlink:to="loc_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_63A307C12AB8A1E6E259A088FDB0B35A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_63A307C12AB8A1E6E259A088FDB0B35A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_709294C7E8A24AAF1B39A088FDB1EB67" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_709294C7E8A24AAF1B39A088FDB1EB67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5FC66F7CE0652F41EE5EA0A133CBEBB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5FC66F7CE0652F41EE5EA0A133CBEBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_6E9F54BBCA7D2E2A01A1A088FDEA867B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4" xlink:to="loc_gale_GALE401Member_6E9F54BBCA7D2E2A01A1A088FDEA867B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0F6021016DDE33C470AAA088FDEA0B22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_Goodwill_0F6021016DDE33C470AAA088FDEA0B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0D489EA150619DE94CA9A0A080E61025" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0D489EA150619DE94CA9A0A080E61025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_BED2F2A425D1A4EE1958A088FDEBE95D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_BED2F2A425D1A4EE1958A088FDEBE95D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_F1CD012670015AFCFD40A088FDEB9697" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_F1CD012670015AFCFD40A088FDEB9697" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_NPSMember" xlink:label="loc_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:to="loc_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:to="loc_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE301AndGALE302Member" xlink:label="loc_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:to="loc_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_791E11E555280B77A6FB9B43C5567BC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_791E11E555280B77A6FB9B43C5567BC9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:to="loc_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:to="loc_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:label="loc_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:label="loc_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:label="loc_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_FF325917F2777FEF5B35A088FD39C028" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372" xlink:to="loc_us-gaap_SecuredDebtMember_FF325917F2777FEF5B35A088FD39C028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_4422CE10D20B11A04FE9A088FD3998C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B" xlink:to="loc_gale_AmendmentAgreementMember_4422CE10D20B11A04FE9A088FD3998C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:to="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:to="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:to="loc_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:to="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:to="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:to="loc_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossContingencyNumberOfCounterclaims" xlink:label="loc_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_801A7F0D032D6ADE8979A088FD3C7228" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_RestrictedCash_801A7F0D032D6ADE8979A088FD3C7228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_4C0EA56D8F672F2999FBA088FD3D9CC4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_4C0EA56D8F672F2999FBA088FD3D9CC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A81A0282871AEF24BB92A088FD3DB035" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A81A0282871AEF24BB92A088FD3DB035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:to="loc_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:to="loc_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:to="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:to="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:to="loc_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:to="loc_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:to="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:to="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:to="loc_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondTrancheMember" xlink:label="loc_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:to="loc_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockNumberOfTranches" xlink:label="loc_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:to="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivateSELLASSecurityHoldersMember" xlink:label="loc_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:to="loc_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PreMergerSecurityholdersMember" xlink:label="loc_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:to="loc_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:to="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:to="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:to="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_6196CD156F2E9FE1C61480681C786BC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:to="loc_gale_GalenaBiopharmaIncMember_6196CD156F2E9FE1C61480681C786BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockConversionRatio" xlink:label="loc_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:to="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:to="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_Dr.AngelosM.StergiouMember" xlink:label="loc_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:to="loc_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EquilibriaCollaborationAgreementMember" xlink:label="loc_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:to="loc_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MskLicenseAgreementMember" xlink:label="loc_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:to="loc_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CollaborationAgreementTerm" xlink:label="loc_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AccruedCompensationIncentive" xlink:label="loc_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:label="loc_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash" xlink:label="loc_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfOwnershipOutstandingShareCapital" xlink:label="loc_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:to="loc_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:to="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:to="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:to="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentivePlan2016Member" xlink:label="loc_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:to="loc_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:to="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:to="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:to="loc_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:to="loc_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:to="loc_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_AB7C3A1B4F832A16D070A148387C24AA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_AB7C3A1B4F832A16D070A148387C24AA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesReservedForIssuanceAdditionalShares" xlink:label="loc_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm" xlink:label="loc_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:to="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:to="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A4BAD23838EC21693D55A0DE21621803" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:to="loc_us-gaap_WarrantMember_A4BAD23838EC21693D55A0DE21621803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EB3AA4C0B3762979E82DA0DE216200EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:to="loc_us-gaap_CommonStockMember_EB3AA4C0B3762979E82DA0DE216200EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:to="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:to="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_09F616AC7AAE51467446A0DE21634591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_09F616AC7AAE51467446A0DE21634591" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_291F36F7A1FCC27C6191A0DE216335EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_291F36F7A1FCC27C6191A0DE216335EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_4E796232DE6657DE56E8A0DE2164FD42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269" xlink:to="loc_gale_PurchaseAgreementMember_4E796232DE6657DE56E8A0DE2164FD42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivatePlacementFirstClosingMember" xlink:label="loc_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:to="loc_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivatePlacementSecondClosingMember" xlink:label="loc_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:to="loc_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_906EC7FCE85C808351DCA0DE21660553" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_PreferredStockSharesIssued_906EC7FCE85C808351DCA0DE21660553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3C05F079F3414AA509F3A0DE2166DBFA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3C05F079F3414AA509F3A0DE2166DBFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_2219120C71D9C0A56109A0DE216719EC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_2219120C71D9C0A56109A0DE216719EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockIssuedShares" xlink:label="loc_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsIssuedShares" xlink:label="loc_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_273561739FB48D110849A0DE2169D956" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_273561739FB48D110849A0DE2169D956" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_4472A2DA3F7DD8175ACAA0DE216A766D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ClassofWarrantorRightTerm_4472A2DA3F7DD8175ACAA0DE216A766D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" xlink:label="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6D304CED17C7E931B444A0DE216C6C1F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6D304CED17C7E931B444A0DE216C6C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C946BC0AC7D339D758F7A0DE216C0E66" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C946BC0AC7D339D758F7A0DE216C0E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1F8993BCAF6124BE1896A0DE216D31ED" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1F8993BCAF6124BE1896A0DE216D31ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_18F322143A072A59DBA1A0DE216DBC4A" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_18F322143A072A59DBA1A0DE216DBC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C5AE5FF847EFD33BB53FA0DE216E8F1D" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C5AE5FF847EFD33BB53FA0DE216E8F1D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_677683571FE895AF632FA1213C70D102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1" xlink:to="loc_us-gaap_ScenarioForecastMember_677683571FE895AF632FA1213C70D102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:to="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:to="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6" xlink:to="loc_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExerciseAgreementMember" xlink:label="loc_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306" xlink:to="loc_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_0D3E3B64128158CB2697A088FAFB259B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D" xlink:to="loc_us-gaap_SubsequentEventMember_0D3E3B64128158CB2697A088FAFB259B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_867E0FB37AD9FD8F0A02A088FAFC1222" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_867E0FB37AD9FD8F0A02A088FAFC1222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_76FEEF9A8874DB8FD74FA088FAFC7F07" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_76FEEF9A8874DB8FD74FA088FAFC7F07" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightNewWarrantsIssued" xlink:label="loc_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_A3A534068DE5313D54B8A088FC73F25A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A3A534068DE5313D54B8A088FC73F25A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_303EC61D6BF6A139E7E8A088FC72E661" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_303EC61D6BF6A139E7E8A088FC72E661" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_FADF05BB7CB58D4FBB3AA088FC72EDFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:to="loc_gale_February2017WarrantsMember_FADF05BB7CB58D4FBB3AA088FC72EDFB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_419B5E7D27233246A535A088FC73D713" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:to="loc_gale_OtherWarrantIssuesMember_419B5E7D27233246A535A088FC73D713" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A3A534068DE5313D54B8A088FC73F25A" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsCanceled" xlink:label="loc_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_C5E19373BE3B8A852BBAA0DBCA5A4A33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_C5E19373BE3B8A852BBAA0DBCA5A4A33" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_A96A857B47DA29163C95A0DBCA5ABF0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_February2017WarrantsMember_A96A857B47DA29163C95A0DBCA5ABF0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_4E5569B0D4EFF0D31D62A0DBCA5AD40E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_OtherWarrantIssuesMember_4E5569B0D4EFF0D31D62A0DBCA5AD40E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsClassifiedAsLiabilitiesOtherMember" xlink:label="loc_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_DDBF8D0E82FD2C900FD9A14838C108DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:to="loc_gale_February2017WarrantsMember_DDBF8D0E82FD2C900FD9A14838C108DB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_E62B37FF2A8175E29FDFA14838C2D8FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_E62B37FF2A8175E29FDFA14838C2D8FC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightCanceled" xlink:label="loc_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" xlink:label="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" xlink:label="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConsiderationExchangedFairValue" xlink:label="loc_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_July2018OfferingMember" xlink:label="loc_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_Prefunded2018OfferingMember" xlink:label="loc_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EqcWarrantsMember" xlink:label="loc_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightCanceledOrExpired" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2AAFA453E00B366A664AA088FC55D8DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2AAFA453E00B366A664AA088FC55D8DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4D78510758A733320CB3A088FC568D2A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4D78510758A733320CB3A088FC568D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_3957CD4C01AB6CED24B5A088FC562A8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_3957CD4C01AB6CED24B5A088FC562A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110936489E531A006FDBA088FC5611A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110936489E531A006FDBA088FC5611A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AAF968B17FEA4E57C788A088FC5CE968" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AAF968B17FEA4E57C788A088FC5CE968" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_B5B6B57E27D22B464614A088FC5C63C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_gale_ClassofWarrantorRightTerm_B5B6B57E27D22B464614A088FC5C63C0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_EBCC7BFFEAA5537F85A4A088FC5CFDDF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_EBCC7BFFEAA5537F85A4A088FC5CFDDF" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>gale-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:type="arc" />
    <link:label id="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C_terseLabel_en-US" xlink:label="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2018 Offering</link:label>
    <link:label id="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C_label_en-US" xlink:label="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:label id="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C_documentation_en-US" xlink:label="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_July2018OfferingMember" xlink:label="loc_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:to="lab_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:type="arc" />
    <link:label id="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3_terseLabel_en-US" xlink:label="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded 2018 Offering</link:label>
    <link:label id="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3_label_en-US" xlink:label="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded 2018 Offering [Member]</link:label>
    <link:label id="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3_documentation_en-US" xlink:label="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded 2018 Offering [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_Prefunded2018OfferingMember" xlink:label="loc_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:to="lab_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:type="arc" />
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279_terseLabel_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279_label_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Warrants [Member]</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279_documentation_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:to="lab_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:type="arc" />
    <link:label id="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A_terseLabel_en-US" xlink:label="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equilibria</link:label>
    <link:label id="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A_label_en-US" xlink:label="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eqc Warrants [Member]</link:label>
    <link:label id="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A_documentation_en-US" xlink:label="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eqc Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_EqcWarrantsMember" xlink:label="loc_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:to="lab_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:type="arc" />
    <link:label id="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1_terseLabel_en-US" xlink:label="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena February 2017</link:label>
    <link:label id="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1_label_en-US" xlink:label="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February 2017 Warrants [Member]</link:label>
    <link:label id="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1_documentation_en-US" xlink:label="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">February 2017 Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:to="lab_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:type="arc" />
    <link:label id="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C_terseLabel_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Other</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C_label_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C_documentation_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:to="lab_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:to="lab_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:to="lab_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled/Expired (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightCanceledOrExpired" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:to="lab_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:to="lab_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:to="lab_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:to="lab_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F_label_en-US" xlink:label="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:to="lab_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:to="lab_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:to="lab_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2_label_en-US" xlink:label="lab_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:to="lab_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:to="lab_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:to="lab_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:type="arc" />
    <link:label id="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2_terseLabel_en-US" xlink:label="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Non-voting Convertible</link:label>
    <link:label id="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2_label_en-US" xlink:label="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Non-voting Convertible [Member]</link:label>
    <link:label id="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2_documentation_en-US" xlink:label="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Non-voting Convertible [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:to="lab_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:type="arc" />
    <link:label id="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C_terseLabel_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A- Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C_label_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A- Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C_documentation_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:to="lab_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:type="arc" />
    <link:label id="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89_terseLabel_en-US" xlink:label="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Tranche</link:label>
    <link:label id="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89_label_en-US" xlink:label="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89_documentation_en-US" xlink:label="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:to="lab_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:type="arc" />
    <link:label id="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518_terseLabel_en-US" xlink:label="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Tranche</link:label>
    <link:label id="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518_label_en-US" xlink:label="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Tranche [Member]</link:label>
    <link:label id="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518_documentation_en-US" xlink:label="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondTrancheMember" xlink:label="loc_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:to="lab_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009_verboseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:to="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:to="lab_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:to="lab_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (USD per share)</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:to="lab_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number Of Tranches</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number Of Tranches</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockNumberOfTranches" xlink:label="loc_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:to="lab_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="lab_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:to="lab_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs related to Merger</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses and operating loss</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:to="lab_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:type="arc" />
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1_negatedTerseLabel_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on settlement of liability-classified warrants</link:label>
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1_label_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Warrants Liability</link:label>
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1_documentation_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Warrants Liability</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:to="lab_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:to="lab_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from beneficial conversion feature of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:type="arc" />
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E_negatedLabel_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E_label_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E_documentation_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:to="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:type="arc" />
    <link:label id="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F_negatedTerseLabel_en-US" xlink:label="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F_label_en-US" xlink:label="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Classified Warrants, Anti-dilution Protection</link:label>
    <link:label id="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F_documentation_en-US" xlink:label="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Classified Warrants, Anti-dilution Protection</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LiabilityClassifiedWarrantsAntidilutionProtection" xlink:label="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:to="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:type="arc" />
    <link:label id="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E_negatedTerseLabel_en-US" xlink:label="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend on conversion of 2015 Sely Note</link:label>
    <link:label id="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E_label_en-US" xlink:label="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Dividend On Debt Conversion</link:label>
    <link:label id="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E_documentation_en-US" xlink:label="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Dividend On Debt Conversion</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendOnDebtConversion" xlink:label="loc_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:to="lab_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:to="lab_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:to="lab_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:to="lab_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:type="arc" />
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D_terseLabel_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D_label_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Patent Application Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D_documentation_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents And Patent Application Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:to="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Fees and Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E" xlink:to="lab_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of the Year - unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase/(Decrease) - prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(Decrease) - prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase - current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of the Year - unrecognized tax benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01_label_en-US" xlink:label="lab_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:label id="lab_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01_documentation_en-US" xlink:label="lab_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementsAbstract" xlink:label="loc_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:to="lab_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:to="lab_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17_label_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17_documentation_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:to="lab_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right canceled</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Canceled</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Canceled</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightCanceled" xlink:label="loc_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:to="lab_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665_terseLabel_en-US" xlink:label="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for cancellation of warrants (in shares)</link:label>
    <link:label id="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665_label_en-US" xlink:label="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Issued During The Period For Cancellation Of Warrants</link:label>
    <link:label id="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665_documentation_en-US" xlink:label="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Issued During The Period For Cancellation Of Warrants</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" xlink:label="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:to="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surrender and cancellation of warrants (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Surrendered and Canceled to Purchase Common Stock</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Surrendered and Canceled to Purchase Common Stock</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" xlink:label="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:to="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162_terseLabel_en-US" xlink:label="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock acquired in exchange for warrants (in shares)</link:label>
    <link:label id="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162_label_en-US" xlink:label="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Acquired in Exchange for Warrants</link:label>
    <link:label id="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162_documentation_en-US" xlink:label="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Acquired in Exchange for Warrants</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:to="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:type="arc" />
    <link:label id="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA_terseLabel_en-US" xlink:label="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of consideration exchanged</link:label>
    <link:label id="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA_label_en-US" xlink:label="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Exchanged, Fair Value</link:label>
    <link:label id="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA_documentation_en-US" xlink:label="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration Exchanged, Fair Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConsiderationExchangedFairValue" xlink:label="loc_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:to="lab_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:type="arc" />
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4_terseLabel_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Warrants Liability</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:to="lab_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9_terseLabel_en-US" xlink:label="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Classified As Liabilities, Other</link:label>
    <link:label id="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9_label_en-US" xlink:label="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Classified As Liabilities, Other [Member]</link:label>
    <link:label id="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9_documentation_en-US" xlink:label="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Classified As Liabilities, Other [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsClassifiedAsLiabilitiesOtherMember" xlink:label="loc_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:to="lab_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:type="arc" />
    <link:label id="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strike price (in usd per share)</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633_label_en-US" xlink:label="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:to="lab_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:type="arc" />
    <link:label id="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2_terseLabel_en-US" xlink:label="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc</link:label>
    <link:label id="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2_label_en-US" xlink:label="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2_documentation_en-US" xlink:label="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:to="lab_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A_label_en-US" xlink:label="lab_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:to="lab_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B_totalLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Including Goodwill</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Including Goodwill</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Litigation Settlement</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Litigation Settlement</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration of Apthera, Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liability</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liability</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the Company's pre-Merger shares outstanding</link:label>
    <link:label id="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF_label_en-US" xlink:label="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Fair Value Of Shares Outstanding</link:label>
    <link:label id="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF_documentation_en-US" xlink:label="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Fair Value Of Shares Outstanding</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationFairValueOfSharesOutstanding" xlink:label="loc_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:to="lab_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of the Company's pre-Merger stock options outstanding</link:label>
    <link:label id="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE_label_en-US" xlink:label="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Estimated Fair Value Of Stock Options Outstanding</link:label>
    <link:label id="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE_documentation_en-US" xlink:label="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Estimated Fair Value Of Stock Options Outstanding</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:label="loc_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:to="lab_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:to="lab_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726_verboseLabel_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:to="lab_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="lab_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal and interest expense, debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:to="lab_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_9903E9944B9CF813319D9D221FC8E24C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B1F141C93B95A987B1D89D221FD4832C" xlink:type="arc" />
    <link:label id="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE_label_en-US" xlink:label="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE" xlink:to="lab_gale_ContractResearchPayable_B8E646B7AF098953EDAD9D221FDEF2BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value-added tax</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E" xlink:to="lab_us-gaap_TaxesPayableCurrent_BA89591C1A6F21B7486C9D221FE6D22E" xlink:type="arc" />
    <link:label id="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE_terseLabel_en-US" xlink:label="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and returns of former commercial products</link:label>
    <link:label id="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE_label_en-US" xlink:label="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates And Returns Of Former Commercial Products</link:label>
    <link:label id="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE_documentation_en-US" xlink:label="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates and returns of former commercial products</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE" xlink:to="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_DD6D95782A6A05F32AC19D221FEFECEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_E2ADE0B4F58D81E1BF069D221FF69FE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_9A33A49ED2A63A78BAD09D221FFDB3F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:to="lab_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:to="lab_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:to="lab_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:type="arc" />
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4_terseLabel_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equity Plan</link:label>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4_label_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4_documentation_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:to="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:type="arc" />
    <link:label id="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB_terseLabel_en-US" xlink:label="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Plan 2016</link:label>
    <link:label id="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB_label_en-US" xlink:label="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB_documentation_en-US" xlink:label="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Plan 2016 [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentivePlan2016Member" xlink:label="loc_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:to="lab_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23_label_en-US" xlink:label="lab_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:to="lab_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_A5348A18133A6E01A98AA1483877305E_terseLabel_en-US" xlink:label="lab_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_A5348A18133A6E01A98AA1483877305E_label_en-US" xlink:label="lab_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:to="lab_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A_label_en-US" xlink:label="lab_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:to="lab_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5_label_en-US" xlink:label="lab_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:to="lab_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:to="lab_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:to="lab_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options assumed in merger (in shares)</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:type="arc" />
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4_terseLabel_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage increase in number of shares available for future issuance under stock based awards</link:label>
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4_label_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4_documentation_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:to="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:type="arc" />
    <link:label id="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9_terseLabel_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing price of the Company's common stock (in USD per share)</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9_label_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9_documentation_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:to="lab_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, outstanding, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award percentage earning of participants</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E_terseLabel_en-US" xlink:label="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares reserved for issuance</link:label>
    <link:label id="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E_label_en-US" xlink:label="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Reserved For Issuance, Additional Shares</link:label>
    <link:label id="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E_documentation_en-US" xlink:label="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Reserved For Issuance, Additional Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesReservedForIssuanceAdditionalShares" xlink:label="loc_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:to="lab_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:type="arc" />
    <link:label id="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33_terseLabel_en-US" xlink:label="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation arrangement by share-based payment award, equity instruments other than options, employee stock purchase plan issuance term</link:label>
    <link:label id="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33_label_en-US" xlink:label="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Employee Stock Purchase Plan Issuance Term</link:label>
    <link:label id="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33_documentation_en-US" xlink:label="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Employee Stock Purchase Plan Issuance Term</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm" xlink:label="loc_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:to="lab_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9" xlink:to="lab_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE_terseLabel_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock are Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE_label_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Are Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE_documentation_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:to="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:to="lab_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:to="lab_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:type="arc" />
    <link:label id="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B_verboseLabel_en-US" xlink:label="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">JGB Action</link:label>
    <link:label id="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B_label_en-US" xlink:label="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JGB Action [Member]</link:label>
    <link:label id="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B_documentation_en-US" xlink:label="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JGB Action</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:to="lab_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:type="arc" />
    <link:label id="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5_terseLabel_en-US" xlink:label="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5_label_en-US" xlink:label="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5_documentation_en-US" xlink:label="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:to="lab_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:type="arc" />
    <link:label id="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC_terseLabel_en-US" xlink:label="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Agreement</link:label>
    <link:label id="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC_label_en-US" xlink:label="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Agreement [Member]</link:label>
    <link:label id="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC_documentation_en-US" xlink:label="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amendment Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:to="lab_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:to="lab_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed coupon rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23_terseLabel_en-US" xlink:label="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt and warrants</link:label>
    <link:label id="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23_label_en-US" xlink:label="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Warrants, Net</link:label>
    <link:label id="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23_documentation_en-US" xlink:label="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Warrants, Net</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:to="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment of interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C_verboseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, compensating cash balance</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C_label_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:to="lab_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:to="lab_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:to="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption, principal amount redeemed, shares</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Shares</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:to="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt amount redeemed, settled in cash</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Settled In Cash</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Settled In Cash</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:to="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in restricted cash</link:label>
    <link:label id="lab_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5_label_en-US" xlink:label="lab_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="loc_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:to="lab_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930_label_en-US" xlink:label="lab_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:to="lab_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:type="arc" />
    <link:label id="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A_terseLabel_en-US" xlink:label="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance of restricted cash over senior secured debenture</link:label>
    <link:label id="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A_label_en-US" xlink:label="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Of Restricted Cash Over Senior Secured Debenture</link:label>
    <link:label id="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A_documentation_en-US" xlink:label="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Of Restricted Cash Over Senior Secured Debenture</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:to="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:type="arc" />
    <link:label id="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576_terseLabel_en-US" xlink:label="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on reimbursement of legal fees</link:label>
    <link:label id="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576_label_en-US" xlink:label="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Of Legal Fees</link:label>
    <link:label id="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576_documentation_en-US" xlink:label="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement Of Legal Fees</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ReimbursementOfLegalFees" xlink:label="loc_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:to="lab_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A" xlink:to="lab_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:to="lab_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:type="arc" />
    <link:label id="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E_terseLabel_en-US" xlink:label="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dr. Angelos M. Stergiou</link:label>
    <link:label id="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E_label_en-US" xlink:label="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Angelos M. Stergiou [Member]</link:label>
    <link:label id="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E_documentation_en-US" xlink:label="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dr. Angelos M. Stergiou [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_Dr.AngelosM.StergiouMember" xlink:label="loc_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:to="lab_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:type="arc" />
    <link:label id="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE_terseLabel_en-US" xlink:label="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equilibria Collaboration Agreement</link:label>
    <link:label id="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE_label_en-US" xlink:label="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equilibria Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE_documentation_en-US" xlink:label="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equilibria Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_EquilibriaCollaborationAgreementMember" xlink:label="loc_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:to="lab_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:type="arc" />
    <link:label id="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68_terseLabel_en-US" xlink:label="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Msk License Agreement</link:label>
    <link:label id="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68_label_en-US" xlink:label="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Msk License Agreement [Member]</link:label>
    <link:label id="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68_documentation_en-US" xlink:label="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Msk License Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MskLicenseAgreementMember" xlink:label="loc_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:to="lab_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:type="arc" />
    <link:label id="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9_terseLabel_en-US" xlink:label="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, term</link:label>
    <link:label id="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9_label_en-US" xlink:label="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:label id="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9_documentation_en-US" xlink:label="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CollaborationAgreementTerm" xlink:label="loc_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:to="lab_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for management fee</link:label>
    <link:label id="lab_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D_label_en-US" xlink:label="lab_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Management Fee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:to="lab_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management fee expense</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:to="lab_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:type="arc" />
    <link:label id="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D_terseLabel_en-US" xlink:label="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation incentive</link:label>
    <link:label id="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D_label_en-US" xlink:label="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Compensation Incentive</link:label>
    <link:label id="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D_documentation_en-US" xlink:label="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Compensation Incentive</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AccruedCompensationIncentive" xlink:label="loc_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:to="lab_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:type="arc" />
    <link:label id="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1_terseLabel_en-US" xlink:label="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive fee percentage equal to post money market value</link:label>
    <link:label id="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1_label_en-US" xlink:label="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Fee Percentage Equal To Post Money Market Value</link:label>
    <link:label id="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1_documentation_en-US" xlink:label="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Fee Percentage Equal To Post Money Market Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:label="loc_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:to="lab_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:type="arc" />
    <link:label id="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651_terseLabel_en-US" xlink:label="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive fee percentage equal to gross value paid by purchaser in cash</link:label>
    <link:label id="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651_label_en-US" xlink:label="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Fee Percentage Equal To Gross Value Paid By Purchaser In Cash</link:label>
    <link:label id="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651_documentation_en-US" xlink:label="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Fee Percentage Equal To Gross Value Paid By Purchaser In Cash</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash" xlink:label="loc_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:to="lab_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:type="arc" />
    <link:label id="lab_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management fee payable</link:label>
    <link:label id="lab_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741_label_en-US" xlink:label="lab_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Fee Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:to="lab_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB_terseLabel_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for incentive fee payment in connection with acquisition during period share</link:label>
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB_label_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Share</link:label>
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB_documentation_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Share</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:to="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:type="arc" />
    <link:label id="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D_terseLabel_en-US" xlink:label="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership outstanding share capital</link:label>
    <link:label id="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D_label_en-US" xlink:label="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Ownership Outstanding Share Capital</link:label>
    <link:label id="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D_documentation_en-US" xlink:label="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Ownership Outstanding Share Capital</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfOwnershipOutstandingShareCapital" xlink:label="loc_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:to="lab_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="lab_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:to="lab_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:type="arc" />
    <link:label id="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73_terseLabel_en-US" xlink:label="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Exercise Agreement</link:label>
    <link:label id="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73_label_en-US" xlink:label="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exercise Agreement [Member]</link:label>
    <link:label id="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73_documentation_en-US" xlink:label="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exercise Agreement</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExerciseAgreementMember" xlink:label="loc_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:to="lab_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="lab_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Exercisable</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Outstanding, Exercisable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:to="lab_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367_verboseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:to="lab_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, new warrants issued (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, New Warrants Issued</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, New Warrants Issued</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightNewWarrantsIssued" xlink:label="loc_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:to="lab_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:to="lab_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="lab_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:to="lab_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:type="arc" />
    <link:label id="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0_terseLabel_en-US" xlink:label="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer Co-Founder</link:label>
    <link:label id="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0_label_en-US" xlink:label="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer Co-Founder [Member]</link:label>
    <link:label id="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0_documentation_en-US" xlink:label="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chief Executive Officer Co-Founder [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ChiefExecutiveOfficerCoFounderMember" xlink:label="loc_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:to="lab_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:type="arc" />
    <link:label id="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155_terseLabel_en-US" xlink:label="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-founder</link:label>
    <link:label id="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155_label_en-US" xlink:label="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-founder [Member]</link:label>
    <link:label id="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155_documentation_en-US" xlink:label="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-founder [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CofounderMember" xlink:label="loc_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:to="lab_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E_terseLabel_en-US" xlink:label="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First MSK Amendment</link:label>
    <link:label id="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E_label_en-US" xlink:label="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Amendment Waiver And Share Issuance Agreement [Member]</link:label>
    <link:label id="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E_documentation_en-US" xlink:label="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Amendment Waiver And Share Issuance Agreement</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:label="loc_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:to="lab_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:type="arc" />
    <link:label id="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932_terseLabel_en-US" xlink:label="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second MSK Amendment</link:label>
    <link:label id="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932_label_en-US" xlink:label="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second MSK Amendment [Member]</link:label>
    <link:label id="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932_documentation_en-US" xlink:label="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second MSK Amendment</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondMSKAmendmentMember" xlink:label="loc_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:to="lab_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:type="arc" />
    <link:label id="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933_terseLabel_en-US" xlink:label="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Amended and Restated Exclusive License Agreement</link:label>
    <link:label id="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933_label_en-US" xlink:label="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Amended and Restated Exclusive License Agreement [Member]</link:label>
    <link:label id="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933_documentation_en-US" xlink:label="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Amended and Restated Exclusive License Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember" xlink:label="loc_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:to="lab_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:type="arc" />
    <link:label id="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F_terseLabel_en-US" xlink:label="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advaxis Collaboration Agreement</link:label>
    <link:label id="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F_label_en-US" xlink:label="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaxis Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F_documentation_en-US" xlink:label="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advaxis Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AdvaxisCollaborationAgreementMember" xlink:label="loc_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:to="lab_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:type="arc" />
    <link:label id="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA_terseLabel_en-US" xlink:label="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.</link:label>
    <link:label id="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA_label_en-US" xlink:label="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [Member]</link:label>
    <link:label id="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA_documentation_en-US" xlink:label="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" xlink:label="loc_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:to="lab_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement Terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:to="lab_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:type="arc" />
    <link:label id="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E_terseLabel_en-US" xlink:label="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement</link:label>
    <link:label id="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E_label_en-US" xlink:label="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement [Member]</link:label>
    <link:label id="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E_documentation_en-US" xlink:label="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:label="loc_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:to="lab_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:to="lab_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:type="arc" />
    <link:label id="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F_terseLabel_en-US" xlink:label="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center</link:label>
    <link:label id="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F_label_en-US" xlink:label="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F_documentation_en-US" xlink:label="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:to="lab_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="lab_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:type="arc" />
    <link:label id="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8_terseLabel_en-US" xlink:label="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under license agreement</link:label>
    <link:label id="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8_label_en-US" xlink:label="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:label id="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8_documentation_en-US" xlink:label="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedUnderLicenseAgreement" xlink:label="loc_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:to="lab_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:type="arc" />
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A_terseLabel_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of fully diluted share capital</link:label>
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A_label_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital</link:label>
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A_documentation_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfFullyDilutedShareCapital" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:to="lab_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:type="arc" />
    <link:label id="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909_terseLabel_en-US" xlink:label="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909_label_en-US" xlink:label="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront License Fees</link:label>
    <link:label id="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909_documentation_en-US" xlink:label="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront License Fees</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_UpfrontLicenseFees" xlink:label="loc_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:to="lab_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:type="arc" />
    <link:label id="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD_terseLabel_en-US" xlink:label="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum annual royalty payment</link:label>
    <link:label id="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD_label_en-US" xlink:label="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Annual Royalty Payment</link:label>
    <link:label id="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD_documentation_en-US" xlink:label="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum Annual Royalty Payment</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MinimumAnnualRoyaltyPayment" xlink:label="loc_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:to="lab_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:type="arc" />
    <link:label id="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69_terseLabel_en-US" xlink:label="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding costs</link:label>
    <link:label id="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69_label_en-US" xlink:label="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Costs</link:label>
    <link:label id="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69_documentation_en-US" xlink:label="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Costs</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ResearchFundingCosts" xlink:label="loc_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:to="lab_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F_terseLabel_en-US" xlink:label="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F_label_en-US" xlink:label="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:label id="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F_documentation_en-US" xlink:label="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementMilestonePayments" xlink:label="loc_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:to="lab_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB_terseLabel_en-US" xlink:label="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement expiration term</link:label>
    <link:label id="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB_label_en-US" xlink:label="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Expiration Term</link:label>
    <link:label id="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB_documentation_en-US" xlink:label="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Expiration Term</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementExpirationTerm" xlink:label="loc_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:to="lab_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period shares conversion of debt in connection with licensing agreement</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Debt In Connection With Licensing Agreement</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Debt In Connection With Licensing Agreement</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:label="loc_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:to="lab_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:type="arc" />
    <link:label id="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706_terseLabel_en-US" xlink:label="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares issued in connection with licensing agreement</link:label>
    <link:label id="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706_label_en-US" xlink:label="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Shares Issued In Connection With Licensing Agreement</link:label>
    <link:label id="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706_documentation_en-US" xlink:label="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Shares Issued In Connection With Licensing Agreement</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:label="loc_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:to="lab_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:type="arc" />
    <link:label id="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA_terseLabel_en-US" xlink:label="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone fee payments upon commencement of clinical trials</link:label>
    <link:label id="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA_label_en-US" xlink:label="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Fee Payments Upon Commencement Of Clinical Trials</link:label>
    <link:label id="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA_documentation_en-US" xlink:label="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Fee Payments Upon Commencement Of Clinical Trials</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:label="loc_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:to="lab_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC_terseLabel_en-US" xlink:label="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement outstanding amount payable</link:label>
    <link:label id="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC_label_en-US" xlink:label="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Outstanding Amount Payable</link:label>
    <link:label id="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC_documentation_en-US" xlink:label="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Outstanding Amount Payable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementOutstandingAmountPayable" xlink:label="loc_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:to="lab_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:type="arc" />
    <link:label id="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2_terseLabel_en-US" xlink:label="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of days to make payments</link:label>
    <link:label id="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2_label_en-US" xlink:label="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Days To Make Payments</link:label>
    <link:label id="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2_documentation_en-US" xlink:label="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Days To Make Payments</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MaximumNumberOfDaysToMakePayments" xlink:label="loc_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:to="lab_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:type="arc" />
    <link:label id="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8_terseLabel_en-US" xlink:label="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable milestone payments</link:label>
    <link:label id="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8_label_en-US" xlink:label="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-refundable Milestone Payments</link:label>
    <link:label id="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8_documentation_en-US" xlink:label="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-refundable Milestone Payments</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_NonrefundableMilestonePayments" xlink:label="loc_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:to="lab_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:type="arc" />
    <link:label id="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF_terseLabel_en-US" xlink:label="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable sales milestone payments</link:label>
    <link:label id="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF_label_en-US" xlink:label="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-refundable Sales Milestone Payments</link:label>
    <link:label id="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF_documentation_en-US" xlink:label="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-refundable Sales Milestone Payments</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_NonrefundableSalesMilestonePayments" xlink:label="loc_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:to="lab_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:type="arc" />
    <link:label id="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447_terseLabel_en-US" xlink:label="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment, maximum rate</link:label>
    <link:label id="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447_label_en-US" xlink:label="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment, Maximum Rate</link:label>
    <link:label id="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447_documentation_en-US" xlink:label="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payment, Maximum Rate</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_RoyaltyPaymentMaximumRate" xlink:label="loc_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:to="lab_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:type="arc" />
    <link:label id="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D_terseLabel_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D_label_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D_documentation_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:to="lab_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:to="lab_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:to="lab_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:to="lab_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:type="arc" />
    <link:label id="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:to="lab_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF_label_en-US" xlink:label="lab_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:to="lab_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:to="lab_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:to="lab_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:to="lab_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:to="lab_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:type="arc" />
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458_label_en-US" xlink:label="lab_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:to="lab_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:to="lab_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:to="lab_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at December 31, 2018 and December 31, 2017</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:to="lab_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 350,000,000 shares authorized, 22,026,476 shares issued and outstanding at December 31, 2018; 5,766,891 shares issued and outstanding at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:to="lab_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:to="lab_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:to="lab_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA_negatedTerseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants canceled</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Canceled</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Canceled</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsCanceled" xlink:label="loc_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:to="lab_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to exercise price of warrants</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants, Exercise Price, Adjustment</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants, Exercise Price, Adjustment</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:to="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Ending balance</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:type="arc" />
    <link:label id="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0_terseLabel_en-US" xlink:label="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NPS</link:label>
    <link:label id="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0_label_en-US" xlink:label="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NPS [Member]</link:label>
    <link:label id="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0_documentation_en-US" xlink:label="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NPS [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_NPSMember" xlink:label="loc_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:to="lab_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:type="arc" />
    <link:label id="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3_terseLabel_en-US" xlink:label="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GALE-401</link:label>
    <link:label id="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3_label_en-US" xlink:label="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GALE-401 [Member]</link:label>
    <link:label id="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3_documentation_en-US" xlink:label="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GALE-401 [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:to="lab_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:type="arc" />
    <link:label id="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10_terseLabel_en-US" xlink:label="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GALE-301 And GALE-302</link:label>
    <link:label id="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10_label_en-US" xlink:label="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GALE-301 And GALE-302 [Member]</link:label>
    <link:label id="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10_documentation_en-US" xlink:label="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GALE-301 And GALE-302 [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE301AndGALE302Member" xlink:label="loc_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:to="lab_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices In Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:type="arc" />
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A_terseLabel_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash equivalents</link:label>
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A_label_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A_documentation_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:to="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants potentially settleable in cash</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118_totalLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:to="lab_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss (in thousands)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:type="arc" />
    <link:label id="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000_terseLabel_en-US" xlink:label="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing deduction deferral</link:label>
    <link:label id="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000_label_en-US" xlink:label="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Licensing Deduction Deferral</link:label>
    <link:label id="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000_documentation_en-US" xlink:label="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Licensing Deduction Deferral</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:to="lab_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to Acquire Shares of Common Stock</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:type="arc" />
    <link:label id="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4_terseLabel_en-US" xlink:label="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private SELLAS Security Holders</link:label>
    <link:label id="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4_label_en-US" xlink:label="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private SELLAS Security Holders [Member]</link:label>
    <link:label id="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4_documentation_en-US" xlink:label="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private SELLAS Security Holders [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivateSELLASSecurityHoldersMember" xlink:label="loc_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:to="lab_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:type="arc" />
    <link:label id="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F_terseLabel_en-US" xlink:label="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Merger Securityholders</link:label>
    <link:label id="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F_label_en-US" xlink:label="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Merger Securityholders [Member]</link:label>
    <link:label id="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F_documentation_en-US" xlink:label="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Merger Securityholders [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PreMergerSecurityholdersMember" xlink:label="loc_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:to="lab_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356_label_en-US" xlink:label="lab_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:to="lab_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD_label_en-US" xlink:label="lab_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:to="lab_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163_terseLabel_en-US" xlink:label="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock conversion ratio</link:label>
    <link:label id="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163_label_en-US" xlink:label="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Conversion Ratio</link:label>
    <link:label id="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163_documentation_en-US" xlink:label="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Conversion Ratio</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockConversionRatio" xlink:label="loc_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:to="lab_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:type="arc" />
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30_terseLabel_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock ownership percentage</link:label>
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30_label_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital Owned</link:label>
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30_documentation_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital Owned</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:to="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:to="lab_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:type="arc" />
    <link:label id="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE_terseLabel_en-US" xlink:label="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Credit Cards</link:label>
    <link:label id="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE_label_en-US" xlink:label="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
    <link:label id="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE_documentation_en-US" xlink:label="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CorporateCreditCardsMember" xlink:label="loc_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:to="lab_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum prepayment of principle if demanded</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:to="lab_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="lab_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:to="lab_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:to="lab_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:to="lab_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:type="arc" />
    <link:label id="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755_terseLabel_en-US" xlink:label="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patel vs Galena biopharma, Inc</link:label>
    <link:label id="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755_label_en-US" xlink:label="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patel vs Galena biopharma, Inc [Member]</link:label>
    <link:label id="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755_documentation_en-US" xlink:label="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patel vs Galena biopharma, Inc [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:to="lab_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:type="arc" />
    <link:label id="lab_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD_terseLabel_en-US" xlink:label="lab_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JGB (Cayman) Newton Ltd</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:to="lab_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="lab_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642_verboseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement with issuance of common stock</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642_label_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642_documentation_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F_terseLabel_en-US" xlink:label="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, number of counterclaims</link:label>
    <link:label id="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F_label_en-US" xlink:label="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Counterclaims</link:label>
    <link:label id="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F_documentation_en-US" xlink:label="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Counterclaims</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LossContingencyNumberOfCounterclaims" xlink:label="loc_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:to="lab_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D_label_en-US" xlink:label="lab_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:to="lab_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:to="lab_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:type="arc" />
    <link:label id="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE_terseLabel_en-US" xlink:label="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apthera, Inc.</link:label>
    <link:label id="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE_label_en-US" xlink:label="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:label id="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE_documentation_en-US" xlink:label="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AptheraInc.Member" xlink:label="loc_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:to="lab_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration acquired as part of the Merger</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable, maximum amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1_label_en-US" xlink:label="lab_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:to="lab_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:type="arc" />
    <link:label id="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F_terseLabel_en-US" xlink:label="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Two Thousand Fifteen Shareholder Notes</link:label>
    <link:label id="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F_label_en-US" xlink:label="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Two Thousand Fifteen Shareholder Notes [Member]</link:label>
    <link:label id="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F_documentation_en-US" xlink:label="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Debt Two Thousand Fifteen Shareholder Notes [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="loc_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:to="lab_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:type="arc" />
    <link:label id="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27_terseLabel_en-US" xlink:label="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Two Thousand Sely Note</link:label>
    <link:label id="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27_label_en-US" xlink:label="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Two Thousand Sely Note [Member]</link:label>
    <link:label id="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27_documentation_en-US" xlink:label="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Debt Two Thousand Sely Note [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="loc_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:to="lab_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="lab_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash In-process research and development impairment charge</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:to="lab_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of research and development expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:to="lab_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:to="lab_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279_terseLabel_en-US" xlink:label="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock issued in exchange for services</link:label>
    <link:label id="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279_label_en-US" xlink:label="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Parent Company Common Stock Issued In Exchange For Services</link:label>
    <link:label id="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279_documentation_en-US" xlink:label="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of common stock warrants issued in exchange for services.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:to="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock issued in connection with litigation settlements</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock issued in connection with litigation settlements</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:type="arc" />
    <link:label id="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911_terseLabel_en-US" xlink:label="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on settlement of liability-classified warrants</link:label>
    <link:label id="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911_label_en-US" xlink:label="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Liability Classified Warrants</link:label>
    <link:label id="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911_documentation_en-US" xlink:label="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Liability Classified Warrants</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:to="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Severance costs paid by Galena</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:to="lab_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash acquired from acquisition of Galena</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:to="lab_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received during the periods for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the periods for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:to="lab_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:to="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:type="arc" />
    <link:label id="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B_terseLabel_en-US" xlink:label="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</link:label>
    <link:label id="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B_label_en-US" xlink:label="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion with Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B_documentation_en-US" xlink:label="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion with Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConversionwithSeriesAConvertiblePreferredStock" xlink:label="loc_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:to="lab_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of interest and principal on long-term debt through issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3_terseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liabilities upon exchange for shares of common stock</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" xlink:label="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:to="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D_terseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D_label_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D_documentation_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:to="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:type="arc" />
    <link:label id="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93_terseLabel_en-US" xlink:label="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issued in connection with warrant exchange agreements</link:label>
    <link:label id="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93_label_en-US" xlink:label="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt Issued In Connection With Warrant Exchanges</link:label>
    <link:label id="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93_documentation_en-US" xlink:label="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt Issued In Connection With Warrant Exchanges</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" xlink:label="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:to="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D_terseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with acquisition of Galena</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:to="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428_terseLabel_en-US" xlink:label="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of options assumed in connection with acquisition of Galena</link:label>
    <link:label id="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428_label_en-US" xlink:label="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Stock Options Assumed In Connection With Acquisition</link:label>
    <link:label id="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428_documentation_en-US" xlink:label="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Stock Options Assumed In Connection With Acquisition</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:label="loc_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:to="lab_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:type="arc" />
    <link:label id="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C_terseLabel_en-US" xlink:label="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party payable settled in shares</link:label>
    <link:label id="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C_label_en-US" xlink:label="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued To Settler Related Party Accounts Payable</link:label>
    <link:label id="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C_documentation_en-US" xlink:label="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued To Settler Related Party Accounts Payable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedToSettlerRelatedPartyAccountsPayable" xlink:label="loc_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:to="lab_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:type="arc" />
    <link:label id="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30_terseLabel_en-US" xlink:label="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Memorial Sloan Kettering Cancer Center payable settled in shares</link:label>
    <link:label id="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30_label_en-US" xlink:label="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued To Settle Accounts Payable</link:label>
    <link:label id="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30_documentation_en-US" xlink:label="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued To Settle Accounts Payable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedToSettleAccountsPayable" xlink:label="loc_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:to="lab_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816_label_en-US" xlink:label="lab_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:to="lab_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:type="arc" />
    <link:label id="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417_terseLabel_en-US" xlink:label="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</link:label>
    <link:label id="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417_label_en-US" xlink:label="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Dividend Associated With Conversion Of Note And Common Stock Warrant Issuance</link:label>
    <link:label id="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417_documentation_en-US" xlink:label="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Dividend Associated With Conversion Of Note And Common Stock Warrant Issuance</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:label="loc_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:to="lab_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:to="lab_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:type="arc" />
    <link:label id="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03_terseLabel_en-US" xlink:label="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront milestone payments, deposits and other assets</link:label>
    <link:label id="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03_label_en-US" xlink:label="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Upfront Milestone Payments, Deposits And Other Assets</link:label>
    <link:label id="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03_documentation_en-US" xlink:label="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Upfront Milestone Payments, Deposits And Other Assets</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:to="lab_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:to="lab_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:to="lab_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development not subject to future amortization for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:type="arc" />
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB_terseLabel_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2017 Incentive Plan (in shares)</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB_label_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Reserved For Future Issuance Under Companies Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB_documentation_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan.</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:to="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F_terseLabel_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F_label_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F_documentation_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:to="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:type="arc" />
    <link:label id="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E_terseLabel_en-US" xlink:label="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units (in shares)</link:label>
    <link:label id="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E_label_en-US" xlink:label="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock, Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E_documentation_en-US" xlink:label="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock, Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedStockSharesReservedforFutureIssuance" xlink:label="loc_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:to="lab_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reserved for future issuance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:type="arc" />
    <link:label id="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6_terseLabel_en-US" xlink:label="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement First Closing</link:label>
    <link:label id="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6_label_en-US" xlink:label="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement First Closing [Member]</link:label>
    <link:label id="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6_documentation_en-US" xlink:label="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement First Closing [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivatePlacementFirstClosingMember" xlink:label="loc_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:to="lab_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:type="arc" />
    <link:label id="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C_terseLabel_en-US" xlink:label="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Second Closing</link:label>
    <link:label id="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C_label_en-US" xlink:label="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Second Closing [Member]</link:label>
    <link:label id="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C_documentation_en-US" xlink:label="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Second Closing [Member]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivatePlacementSecondClosingMember" xlink:label="loc_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:to="lab_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="lab_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of preferred stock, preference stock, and warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock converted to other securities</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Converted to Other Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:to="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock issued shares (in shares)</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued Shares</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockIssuedShares" xlink:label="loc_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:to="lab_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F_terseLabel_en-US" xlink:label="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued shares (in shares)</link:label>
    <link:label id="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F_label_en-US" xlink:label="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued Shares</link:label>
    <link:label id="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F_documentation_en-US" xlink:label="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsIssuedShares" xlink:label="loc_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:to="lab_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:type="arc" />
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB_terseLabel_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:to="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95_verboseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of warrant liability</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:to="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:type="arc" />
    <link:label id="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702_terseLabel_en-US" xlink:label="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend on beneficial conversion feature of convertible preferred stock</link:label>
    <link:label id="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702_label_en-US" xlink:label="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Dividend On Beneficial Conversion Feature Of Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702_documentation_en-US" xlink:label="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Dividend On Beneficial Conversion Feature Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" xlink:label="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:to="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant, shares to purchase</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Proceedings, Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031_label_en-US" xlink:label="lab_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:to="lab_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:to="lab_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:to="lab_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards, research</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:type="arc" />
    <link:label id="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D_terseLabel_en-US" xlink:label="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss and tax credit carryforwards limitations on use minimum change in ownership percentage</link:label>
    <link:label id="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D_label_en-US" xlink:label="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss And Tax Credit Carryforwards Limitations On Use Minimum Change In Ownership Percentage</link:label>
    <link:label id="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D_documentation_en-US" xlink:label="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss And Tax Credit Carryforwards Limitations On Use Minimum Change In Ownership Percentage</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:label="loc_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:to="lab_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:type="arc" />
    <link:label id="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557_terseLabel_en-US" xlink:label="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum indefinite lived deferred tax liability as percentage of net operating loss</link:label>
    <link:label id="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557_label_en-US" xlink:label="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Indefinite lived Deferred Tax Liability As Percentage Of Net Operating Loss</link:label>
    <link:label id="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557_documentation_en-US" xlink:label="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Indefinite lived Deferred Tax Liability As Percentage Of Net Operating Loss</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:label="loc_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:to="lab_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, deferred tax asset, increase (decrease), amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:type="arc" />
    <link:label id="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73_terseLabel_en-US" xlink:label="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact on tax provision from unrecognized tax benefits</link:label>
    <link:label id="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73_label_en-US" xlink:label="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact On Tax Provision From Unrecognized Tax Benefits</link:label>
    <link:label id="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73_documentation_en-US" xlink:label="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact On Tax Provision From Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:label="loc_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:to="lab_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:type="arc" />
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB_label_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB_documentation_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="lab_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579_label_en-US" xlink:label="lab_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:to="lab_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F_label_en-US" xlink:label="lab_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:to="lab_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:to="lab_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:to="lab_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56_label_en-US" xlink:label="lab_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:to="lab_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C_terseLabel_en-US" xlink:label="lab_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C_label_en-US" xlink:label="lab_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:to="lab_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:to="lab_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:to="lab_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:to="lab_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472_label_en-US" xlink:label="lab_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:to="lab_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:to="lab_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:to="lab_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8_label_en-US" xlink:label="lab_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:to="lab_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:to="lab_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:to="lab_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E_label_en-US" xlink:label="lab_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:to="lab_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants granted, per share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:to="lab_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State and local taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:type="arc" />
    <link:label id="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591_negatedTerseLabel_en-US" xlink:label="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591_label_en-US" xlink:label="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591_documentation_en-US" xlink:label="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:to="lab_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax rate change and true-up</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination pro forma transaction costs</link:label>
    <link:label id="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C_label_en-US" xlink:label="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Pro Forma Transaction Costs</link:label>
    <link:label id="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C_documentation_en-US" xlink:label="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Pro Forma Transaction Costs</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationProFormaTransactionCosts" xlink:label="loc_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:to="lab_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:type="arc" />
    <link:label id="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4_terseLabel_en-US" xlink:label="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fee and other transaction costs</link:label>
    <link:label id="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4_label_en-US" xlink:label="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Fee And Other Transaction Costs</link:label>
    <link:label id="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4_documentation_en-US" xlink:label="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success Fee And Other Transaction Costs</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SuccessFeeAndOtherTransactionCosts" xlink:label="loc_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:to="lab_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435_verboseLabel_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for incentive fee payment in connection with acquisition during period shares</link:label>
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435_label_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Shares</link:label>
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435_documentation_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:to="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084_verboseLabel_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for incentive fee payment in connection with acquisition during period</link:label>
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084_label_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period</link:label>
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084_documentation_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:to="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Production related impairments or charges</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685_label_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:to="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:type="arc" />
    <link:label id="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F_terseLabel_en-US" xlink:label="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F_label_en-US" xlink:label="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Income Tax Effect Of Abandonment</link:label>
    <link:label id="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F_documentation_en-US" xlink:label="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Income Tax Effect Of Abandonment</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:to="lab_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non - U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, canceled (use per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:type="arc" />
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107_terseLabel_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107_label_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107_documentation_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:to="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, granted</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, canceled</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:to="lab_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304_terseLabel_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304_label_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidation Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:type="arc" />
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability [Table Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of Senior Secured Debenture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:to="lab_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of Senior Secured Debenture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:to="lab_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:to="lab_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:to="lab_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA_terseLabel_en-US" xlink:label="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued in connection with amendments to MSK license, shares</link:label>
    <link:label id="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA_label_en-US" xlink:label="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued In Connection With Amendments To License During Period, Shares</link:label>
    <link:label id="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA_documentation_en-US" xlink:label="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued In Connection With Amendments To License During Period, Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:label="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:to="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C_terseLabel_en-US" xlink:label="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued in connection with amendments to MSK license, amount</link:label>
    <link:label id="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C_label_en-US" xlink:label="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued In Connection With Amendments To License During Period, Value</link:label>
    <link:label id="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C_documentation_en-US" xlink:label="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued In Connection With Amendments To License During Period, Value</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:label="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:to="lab_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock as result of conversion</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock, amount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with settlement of related party payables, shares</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Settlement Of Related Party Accounts Payable</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Settlement Of Related Party Accounts Payable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:label="loc_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:to="lab_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with settlement of related party payables, amount</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Settlement Of Related Party Accounts Payable</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Settlement Of Related Party Accounts Payable</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:label="loc_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:to="lab_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon the acceleration of restricted stock units, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon cancellation of Equilibria restricted stock units, shares</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Upon Cancellation Of Restricted Stock Units Shares</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Upon Cancellation Of Restricted Stock Units Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:label="loc_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:to="lab_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with acquisition of Galena, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with acquisition of Galena</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:type="arc" />
    <link:label id="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F_terseLabel_en-US" xlink:label="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assumed options issued in connection with acquisition of Galena</link:label>
    <link:label id="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F_label_en-US" xlink:label="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Stock Options Exercised In Connection With Acquisition</link:label>
    <link:label id="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F_documentation_en-US" xlink:label="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Stock Options Exercised In Connection With Acquisition</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:label="loc_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:to="lab_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:type="arc" />
    <link:label id="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A_terseLabel_en-US" xlink:label="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, shares</link:label>
    <link:label id="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A_label_en-US" xlink:label="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period Shares</link:label>
    <link:label id="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A_documentation_en-US" xlink:label="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:label="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:to="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:type="arc" />
    <link:label id="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1_terseLabel_en-US" xlink:label="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, value</link:label>
    <link:label id="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1_label_en-US" xlink:label="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period</link:label>
    <link:label id="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1_documentation_en-US" xlink:label="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:label="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:to="lab_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:type="arc" />
    <link:label id="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45_terseLabel_en-US" xlink:label="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</link:label>
    <link:label id="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45_label_en-US" xlink:label="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Deemed Dividend On Debt Conversion</link:label>
    <link:label id="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45_documentation_en-US" xlink:label="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital Deemed Dividend On Debt Conversion</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:label="loc_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:to="lab_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1_terseLabel_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena, shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:to="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8_terseLabel_en-US" xlink:label="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:to="lab_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257_terseLabel_en-US" xlink:label="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to MSK for anti-dilution provisions, shares</link:label>
    <link:label id="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257_label_en-US" xlink:label="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Anti-dilution Provisions, Shares</link:label>
    <link:label id="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257_documentation_en-US" xlink:label="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Anti-dilution Provisions, Shares</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForAntidilutionProvisionsShares" xlink:label="loc_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:to="lab_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C_terseLabel_en-US" xlink:label="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to MSK for anti-dilution provisions</link:label>
    <link:label id="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C_label_en-US" xlink:label="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Anti-dilution Provisions</link:label>
    <link:label id="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C_documentation_en-US" xlink:label="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Anti-dilution Provisions</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForAntidilutionProvisions" xlink:label="loc_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:to="lab_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:type="arc" />
    <link:label id="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E_terseLabel_en-US" xlink:label="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of offering costs</link:label>
    <link:label id="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E_label_en-US" xlink:label="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E_documentation_en-US" xlink:label="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:to="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature arising from Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:type="arc" />
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798_terseLabel_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798_label_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798_documentation_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:to="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:type="arc" />
    <link:label id="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27_terseLabel_en-US" xlink:label="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27_label_en-US" xlink:label="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend, Modification Of Warrants</link:label>
    <link:label id="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27_documentation_en-US" xlink:label="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend, Modification Of Warrants</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendModificationOfWarrants" xlink:label="loc_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:to="lab_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E_negatedTerseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock dividends</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Dividends</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Dividends</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockDividends" xlink:label="loc_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:to="lab_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:type="arc" />
    <link:label id="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D_terseLabel_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with warrant exchange agreements (in shares)</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D_label_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Issuance Of Common Stock</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D_documentation_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Issuance Of Common Stock</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExchangeAgreementsIssuanceOfCommonStock" xlink:label="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:to="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:type="arc" />
    <link:label id="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37_terseLabel_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with warrant exchange agreements</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37_label_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Amount</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37_documentation_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Amount</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExchangeAgreementsAmount" xlink:label="loc_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:to="lab_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:to="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:to="lab_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D" xlink:to="lab_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>gale-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20181231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Acquisition" xlink:href="gale-20181231.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:href="gale-20181231.xsd#AcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails" xlink:href="gale-20181231.xsd#AcquisitionProFormaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails" xlink:href="gale-20181231.xsd#AcquisitionSummaryOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:href="gale-20181231.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails" xlink:href="gale-20181231.xsd#AcquisitionTotalPurchasePriceAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="gale-20181231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements" xlink:href="gale-20181231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="gale-20181231.xsd#CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:href="gale-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20181231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="gale-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="gale-20181231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Debt" xlink:href="gale-20181231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:href="gale-20181231.xsd#DebtConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:href="gale-20181231.xsd#DebtSeniorSecuredDebentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:href="gale-20181231.xsd#DebtSummaryOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtTables" xlink:href="gale-20181231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:href="gale-20181231.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:href="gale-20181231.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="gale-20181231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesNotes" xlink:href="gale-20181231.xsd#IncomeTaxesNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:href="gale-20181231.xsd#IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:href="gale-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:href="gale-20181231.xsd#LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:href="gale-20181231.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:href="gale-20181231.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="gale-20181231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="gale-20181231.xsd#OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:href="gale-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes" xlink:href="gale-20181231.xsd#RelatedPartyTransactionsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gale-20181231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20181231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:href="gale-20181231.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:href="gale-20181231.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20181231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20181231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails" xlink:href="gale-20181231.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:href="gale-20181231.xsd#WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7CBDBA9F0643AA4C7A3680681BE6112A" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AD272045B60C82B9AA3C80681BE77022" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_943DB344F4DFEA5CFC099D10B0720B66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_943DB344F4DFEA5CFC099D10B0720B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CA28A05BFAC49BAA7A979D10B073B6BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CA28A05BFAC49BAA7A979D10B073B6BB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_1059811CDF46FC6A7AE89D10B07363BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_gale_ContractResearchPayable_1059811CDF46FC6A7AE89D10B07363BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_8661377C6E7054BCCC329D10B0739CF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_us-gaap_TaxesPayableCurrent_8661377C6E7054BCCC329D10B0739CF8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_7C84AA397417048F7F099D10B07399F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_7C84AA397417048F7F099D10B07399F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_423FEA772609628D17389D10B0735AC7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_423FEA772609628D17389D10B0735AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_88283D2FD150E2F05D8D9D10B0740D75" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B598B652DF0F193AD1BB9D10B0714843" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_88283D2FD150E2F05D8D9D10B0740D75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_17FCF1087D29750F5E0B806819FFFDC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_17FCF1087D29750F5E0B806819FFFDC8" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D573BC1CB694A3EB5515806819FF987F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_584476D157EC4587441CA088A39837C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_584476D157EC4587441CA088A39837C0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7AF49094096B1A43ED15A0928515940D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8968C1A72C1FD727C108A1A120B8C6BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8968C1A72C1FD727C108A1A120B8C6BE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D66EE3CAAA86159B47E7A1A120B98031" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_FA6B236CFE8460975787A1A120BA9164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9240C2DDAC9016F07718A1A120B94E56" xlink:to="loc_gale_GalenaBiopharmaIncMember_FA6B236CFE8460975787A1A120BA9164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0960FFD75B9E405F6BAA1A120B91F97" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationProFormaTransactionCosts" xlink:label="loc_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_BusinessCombinationProFormaTransactionCosts_E5F5EF9E18672F0A5EDAA1A120BA508C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SuccessFeeAndOtherTransactionCosts" xlink:label="loc_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_SuccessFeeAndOtherTransactionCosts_3A25D476595D6D28DC1FA1A120BB95B4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_FF3A866CDC03EA018EB2A1A120BB5435" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_4BB5616343B1F40EA2B5A1A120BBF084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_F6081399D6B97782FC09A1A120BBD76E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_us-gaap_SeveranceCosts1_F6081399D6B97782FC09A1A120BBD76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ED0A904F89DC765EA4EA1A120BAFC7D" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_EB9F8566BC2E950C53B1A1A120BB0685" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionProFormaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_D018E4A8AAB281B32553A08EC831C86F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_D018E4A8AAB281B32553A08EC831C86F" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_804DEAC4E7845A0544CBA08EC837D745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_D018E4A8AAB281B32553A08EC831C86F" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6B0E59F185F39792D927A08EC83BDAA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_D018E4A8AAB281B32553A08EC831C86F" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_49E767C9928F2B827F2FA08FED1C2BFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4C96E4091329B655DD27A088A11095E3" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationFairValueOfSharesOutstanding" xlink:label="loc_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4C96E4091329B655DD27A088A11095E3" xlink:to="loc_gale_BusinessCombinationFairValueOfSharesOutstanding_2C3B9FE8D795559F2641A088A11070DF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:label="loc_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4C96E4091329B655DD27A088A11095E3" xlink:to="loc_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_D03379A417B812F18386A088A1104ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4C96E4091329B655DD27A088A11095E3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6AE87155BF50110F8C86A088A111898F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_767E91CC195073E3E69E7E59BF01B517" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_767E91CC195073E3E69E7E59BF01B517" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_E2A81143FC219E2C332E7E61B2252F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_767E91CC195073E3E69E7E59BF01B517" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_B48AB5C705B2D3ED58E37E59BF02918F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_87AE8ACCB93AFBE61DE7A088A0EFAA8B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA48CE0DEAADAB5BA996A088A0EF8704" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4FDDBE79E6D749A805DCA088A0EF1044" xlink:to="loc_gale_GalenaBiopharmaIncMember_F240B44A8AFD13932077A088A0F0C6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6C1CAFB79FA3DBA15567A088A0EF74FF" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_007B1A4BD9B51F628CE7A088A0F3DF8A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_545ED5AC044CC91C0B0CA088A0F3F45E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_78808FC25733176FD018A088A0F340EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_C23318E32939D67E4C10A088A0F3608F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_us-gaap_Goodwill_3A9AC20D13A78ED7FB50A088A0F4724A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7B98905892096480C323A088A0F0932E" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill_7748FBBF2B6C64BB8502A08C261AB18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_DFAF02495BDA953434CCA088A0F0AE06" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_BC8A5016DD0B47DB0B23A088A0F42E7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_700973169A3B66491E66A088A0F4CB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_39DDEB132981C8E35CD7A088A0F45202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9355C9AA5BF06C8FE310A088A0F54BB8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_34AB712E16D63D8AF8DCA088A0F5178E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69D244BE6DA31A6B9C91A08D5142DC68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_F4259CE40DEDF9DF30DBA088A0F58F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_51A2081DAE0A4BE2F78BA088A0F45BD6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0956DBCC76A90FA659BCA088A0F579BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8DC4BD0A2FAD69A14E7D9B43C5A46AB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8DC4BD0A2FAD69A14E7D9B43C5A46AB7" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_46D7622851DE84ABAC7D9B43C5A57F9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05B50439D06F680130209B43C582CCC9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_068240D46E62100623839B43C582C8AD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="loc_us-gaap_WarrantMember_7F2663A7F53485A87CD19B43C5835E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C0206DA3F681CF2D58559B43C5836C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00842540F61536D6AE7C9B43C5821A90" xlink:to="loc_us-gaap_RestrictedStockMember_96875A031EF843125BE09B43C5835A1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D0AFA0623DD2AB359269B43C582973D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C6B27620088BF80DAFBC9B43C584F754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C05F402013F2415AC3C59B43C584E2E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1FDAC5FB7E06F1AE84019B43C58A8A63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1FDAC5FB7E06F1AE84019B43C58A8A63" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_74EDB9F3C3D568F7C2639B43C58CEFE1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_628C2FB7E080F5CBFE499B43C58DC5DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A9C4BC91DD1427BFA9279B43C58CA11A" xlink:to="loc_gale_AmendmentAgreementMember_628C2FB7E080F5CBFE499B43C58DC5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55B0F63974FCBB96FD219B43C58D758C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B7687C24BD27F7493E989B43C58D02D1" xlink:to="loc_us-gaap_SecuredDebtMember_28882D025354CCEB72589B43C58DF877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_D5220563C466BC4DE6089B43C58D569B" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CorporateCreditCardsMember" xlink:label="loc_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8D57D02CDA6824FE2EEA9B43C58E41C8" xlink:to="loc_gale_CorporateCreditCardsMember_B0DE6C24E0277E2C9F449B43C58E25BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D8335D405E8340C7D8029B43C58BA0CF" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66BB7BCC3734970441969B43C58FC9C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66BB7BCC3734970441969B43C58FC9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2A3CC99D0F0D89946BD89B43C58F6D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C2AD8A5462BC49FB9C059B43C58F4ACA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_D075AD51AC2D8322A61E9B43C58F2EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_5D9A180C9C80BC6755249B43C58FA6C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_F9B08D75C829815144299B43C58E603C" xlink:to="loc_us-gaap_RestrictedCash_5D9A180C9C80BC6755249B43C58FA6C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3BE753E8CB50AD8E693CA19B9EDA7346" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3BE753E8CB50AD8E693CA19B9EDA7346" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92A147F515737FF445A2A19B9EDA3F31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBBF51B23D7C13992A2EA19B9EDB96EF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5E5171D6D8BB9B437A5AA19B9EDB3A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_B80E9F9A1568786CDED2A19B9EDB744B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_E22091229B8E98D28BB1A19B9EDC229A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_414CF8D3E6FACE9272CFA19B9EDB7A41" xlink:to="loc_us-gaap_ScenarioForecastMember_E22091229B8E98D28BB1A19B9EDC229A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F4D48367638FEF33CA66A19B9EDCE9C2" xlink:to="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C5BD1546F8581B556965A19B9EDCC32D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_6FAE5A43317DA3936D83A19B9EDD85E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_AD20C57482A348A8CDE2A19B9EE2AD26" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A4BC658D57EE72281130A19B9EE3A980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F6408E7C2F1207AB0AAAA19B9EE26EA1" xlink:to="loc_us-gaap_SubsequentEventMember_A4BC658D57EE72281130A19B9EE3A980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3257EEE85E0BF8AD9B90A19B9EE346CF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_BC203A382C934995FF4FA19B9EE36468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339531966354DAB8E226A19B9EE31668" xlink:to="loc_gale_GALE401Member_BC203A382C934995FF4FA19B9EE36468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02FAF32459D7E7192A0DA19B9EDA982F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2BE68FEEE4EC65C64ED8A19B9EE4E453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_137F625636054667B1ECA19B9EE45BAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_137F625636054667B1ECA19B9EE45BAF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_048393E5BDED471A6D6FA19B9EE4CD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_SeveranceCosts1_D93AE5E827D98D9EC1CBA19B9EE4E728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EE22EE1C7AEDAD93DB4BA19B9EE5042D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_EE22EE1C7AEDAD93DB4BA19B9EE5042D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_OperatingLeaseLiability_E700D7F48D0B275BE6AEA19B9EE504AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E1369FCAB9E461DDBBD4A19B9EE4DC70" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_327BA293AD891BD69F54A19B9EE51D46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09684CD8D3A82C89EDD19B43C5A13130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_38DE9446740856D8C5409B43C5A13FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_UseOfEstimates_C995D8656F153C0EBBC89B9DE3D9AF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_320E6339A9637A31421E9B43C5A12A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2B6C816BF391A1035ADF9B9C5A227F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32029AB6B9DBED0BF8799B9C2B7CAD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ACFBCA76323529C255B99B9BF68C4BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_CAB17FD0BBBBA9723C879B9B0DE88EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_19A242104750ED1BFA089B9A60FBB95C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_07F3926F02734BCFA2B79B995F13F93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_D093A4AE09390513CAB99B98C8151751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3EF2D259175DD3A252CD9B97F4BC0588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_BDC881B9E9BCC7FFCC879B97C22FB3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3160C43E76F6C5BC3BE59B970875BC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_F6919E47B3428CBC90069B965357DE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_C132C27514E39E639F2A9B9ECEFADE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_FA338197A57D1053822F9B43C5A1C2C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_90BC432A75E4C93F1D249BBFA8F7C01F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B44889BD26145F246DE39B43C5A14077" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DCABFCDBABFEABE1361B9B43C5A2C080" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B30568E59B7D2B2C8F279B43C59D5203" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B30568E59B7D2B2C8F279B43C59D5203" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8B58491A8C26D0D0C12F9B43C59DEE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B30568E59B7D2B2C8F279B43C59D5203" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_174D87784E37A8D74D289B43C59E4796" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended">
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementsAbstract" xlink:label="loc_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAgreementsAbstract_04F2228E91C5F88DA2D0A088FDDFBD01" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5A032822C190C2D023FBA088FDDF4DA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84395C87F83B946BD779A088FDCED94B" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_C6562E677B6D3F5AC74BA088FDCF7D04" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChiefExecutiveOfficerCoFounderMember" xlink:label="loc_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:to="loc_gale_ChiefExecutiveOfficerCoFounderMember_C4135CC73D563BC2A2C3A088FDD0F6C0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CofounderMember" xlink:label="loc_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_65D6515B2B2A9A4A7EC5A088FDD0F0FA" xlink:to="loc_gale_CofounderMember_26A09E0A7F45AF32FA9AA088FDD00155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D05F310A011A964B1E9A088FDD05527" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:label="loc_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_563FBFB340ED346549C1A088FDD2EB6E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondMSKAmendmentMember" xlink:label="loc_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_SecondMSKAmendmentMember_BBD413A4A936F1E62F3DA088FDD22932" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember" xlink:label="loc_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember_06E25B45D22577A6521AA088FDD33933" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdvaxisCollaborationAgreementMember" xlink:label="loc_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_AdvaxisCollaborationAgreementMember_6DAFB09DBFABFFA08070A088FDD3341F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member" xlink:label="loc_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F1C42883FF6D3A659FA8A088FDD22E58" xlink:to="loc_gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member_F7D00894BB9111AC4B2FA088FDD3C8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_D28FA9BDC6FAF8047D13A088FDD3D511" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_EEFB4FF5BEC6B40A1BB6A088FDD3C602" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:label="loc_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_FB87A4EC3B6607A2F08DA088FDD3B8A9" xlink:to="loc_gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_43FD2411F4835B9AF4C7A088FDD30C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2739BD1781851E0FEC0EA088FDD37212" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08A01AB5135063686EB3A088FDD3BCA5" xlink:to="loc_gale_MemorialSloanKetteringCancerCenterMember_006DA9A639E6F303CFA4A088FDD36C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_CE2A151068C95389A47FA088FDD4ABE2" xlink:to="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AC36FC2950A5ED5944E7A088FDD4CDB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_656F8744EB64D72FF653A088FDD417E8" xlink:to="loc_srt_MaximumMember_AC36FC2950A5ED5944E7A088FDD4CDB5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_527F26740F7A10A04766A088FDCE5788" xlink:to="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedUnderLicenseAgreement" xlink:label="loc_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_SharesIssuedUnderLicenseAgreement_0EC432B5E8DD789DE03AA088FDD642B8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfFullyDilutedShareCapital" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_PercentageOfFullyDilutedShareCapital_4D5E47E63A4CA46D30D3A088FDD6A45A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_UpfrontLicenseFees" xlink:label="loc_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_UpfrontLicenseFees_40C3DE5DC9A97378B137A088FDD63909" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MinimumAnnualRoyaltyPayment" xlink:label="loc_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_MinimumAnnualRoyaltyPayment_984E9D54145CE0F53697A088FDD9D6CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ResearchFundingCosts" xlink:label="loc_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_ResearchFundingCosts_FDD4C1C189B2DD375C8EA088FDD77A69" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementMilestonePayments" xlink:label="loc_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAgreementMilestonePayments_614C9F66A33684F18772A088FDD7DD6F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementExpirationTerm" xlink:label="loc_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAgreementExpirationTerm_DFE996C5C00320BE2340A088FDD790EB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:label="loc_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_24ED45F6A6AA964E7CE4A088FDD8128C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:label="loc_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement_28BC9CFD159D3C236DA9A088FDD6B706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E86CA13083BFDC7DD7A1A088FDD80A9D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_E86CA13083BFDC7DD7A1A088FDD80A9D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:label="loc_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials_B50340039DFD872B2CAEA088FDD8CECA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LicenseAgreementOutstandingAmountPayable" xlink:label="loc_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_LicenseAgreementOutstandingAmountPayable_50E07E83327ACCF792B4A088FDD8FCCC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MaximumNumberOfDaysToMakePayments" xlink:label="loc_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_MaximumNumberOfDaysToMakePayments_93A2E77F5C6A47A5B1F7A088FDD79BE2" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_NonrefundableMilestonePayments" xlink:label="loc_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_NonrefundableMilestonePayments_BC7837E36926396F380FA088FDD829C8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_NonrefundableSalesMilestonePayments" xlink:label="loc_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_NonrefundableSalesMilestonePayments_EADB2FFADDD8A51BA6FCA088FDD8F0AF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RoyaltyPaymentMaximumRate" xlink:label="loc_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_RoyaltyPaymentMaximumRate_F99788405EEBA05E5040A088FDD88447" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_1876A0BEF17865C76E23A088FDD4EC17" xlink:to="loc_gale_AnnualMaintenanceFee_4A88BED8022518F477D6A088FDD77A0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:to="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B3A158AA4BF1AA5F63AC9C4C63E99407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_73DCB02D0358DA862F449C4C63E9EE98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_73DCB02D0358DA862F449C4C63E9EE98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02F8A2824421F102F6E59C4C63E9988C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50C0DF50F4119B37D3749C4C63E8156E" xlink:to="loc_us-gaap_AssetsCurrent_5F5A54349315B4A1C3FE9C4C63E9B6D9" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:to="loc_gale_InProcessResearchDevelopment_959608F83B0E39C7B16C9C4C63EA831F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_09DC36E455B2F2D107A79C4C63EAC7A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:to="loc_us-gaap_Goodwill_09DC36E455B2F2D107A79C4C63EAC7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_1C9B74C0D3B077FBF0139C4C63EA36D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72162639FF891BC1F15A9C4C63E8A8F5" xlink:to="loc_us-gaap_Assets_0A5BE2EE2C42736BB6659C4C63EAB6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84CA01B8E788EEB1C6059C4C63E7E4C6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:to="loc_us-gaap_LongTermDebtCurrent_4B8720B1D49D6EFCE4499C4C63EB5B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:to="loc_us-gaap_AccountsPayableCurrent_157893839B2D489D12009C4C63EBDA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7E24AE140382F7F1BCFF9C4C63EC0AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:to="loc_us-gaap_LitigationReserveCurrent_DAEB41EE44E2CA6708E09C4C63ECA4CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_786F56B31C576F251D509C4C63EB1A06" xlink:to="loc_us-gaap_LiabilitiesCurrent_66FE6AD72A062CDCE8649C4C63ECF247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3D802516E1926845D0569C4C63EDE67E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_A63EF0E123739D0DD2D89C4C63EDC717" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_FFA4226913D9CACBA8459C4C63ED77BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_E4C857E3CD2D93B6B8399C4C63ED9C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_Liabilities_42A6C4AF431DF02A2D2A9C4C63ED4458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_CommitmentsAndContingencies_BE78A48125E9C6ED6BD49C4C63EE85F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:to="loc_us-gaap_PreferredStockValue_87FA913B8CF55F42F83E9C4C63EE0C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:to="loc_us-gaap_CommonStockValue_1663D6516CC95A04B7279C4C63EF629D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_AF4143C393B2D0AC27FC9C4C63EF43F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D648EC0098F2D9BC49D89C4C63EF46C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87BEE71244CAF0362F4E9C4C63EED7E8" xlink:to="loc_us-gaap_StockholdersEquity_B4CD7A344CE9E3F6C75B9C4C63F08DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9056772F115FC6A3473C9C4C63EB683F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_92E7BBAF2474F51EDA089C4C63F05D70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C549190B8803232EE77FA088FE8C2118" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C549190B8803232EE77FA088FE8C2118" xlink:to="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7C2F79DED74B7FEAEDF2A088FE8DD127" xlink:to="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3BF029775E9711464728A088FE8D8C06" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_CDD46B6383DDDB3937CFA088FE8E5ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D5F1F95C8876A1E5F07EA088FE8DFEFD" xlink:to="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18A6B5D919DEAD330A67A088FE8E521C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_18A6B5D919DEAD330A67A088FE8E521C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_35022E4FB3FE278490E2A088FE8F2F0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_35022E4FB3FE278490E2A088FE8F2F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3E1F5CE7851E9A8773FDA088FE8FA3E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3E1F5CE7851E9A8773FDA088FE8FA3E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E636F10EB54BEA4795D7A088FE8FFE09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AD8B9B5EBDB033288FBAA088FE8FAD6D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_AD8B9B5EBDB033288FBAA088FE8FAD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2D8CCE1C1551B67C59ADA088FE90A061" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2D8CCE1C1551B67C59ADA088FE90A061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockSharesIssued_AB947504A19FDAD92DB4A088FE905B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7896E1D90ACFFEB07F37A088FE90A608" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12F5BF72B6E82D07DA0DA088FE8EDBBB" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7896E1D90ACFFEB07F37A088FE90A608" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4CA6385DD19149B17594A19AE6A03003" xlink:to="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8540FFE1B705F17B7A76A19AE6A62839" xlink:to="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_8C270E7D512B1D6D45D4A19AE6A7D64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_CB7CAB6CD620C9EE7883A19AE6A76B24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8684BB1091638ECB9ADDA19AE6A6CB34" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_CB7CAB6CD620C9EE7883A19AE6A76B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9B5771542083B47EFBDBA19AE6A74603" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_7555927D56D32C7A4581A19AE6A8019F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0FEB4E63DF126FF12F62A19AE6A793B3" xlink:to="loc_us-gaap_SecuredDebtMember_7555927D56D32C7A4581A19AE6A8019F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2B32743B0043E30A067EA19AE6A9EDAE" xlink:to="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_00306451C291C93DAE61A19AE6AABA9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8A5F8A8C7B07A9E84579A19AE6A9D184" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_00306451C291C93DAE61A19AE6AABA9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9EBCAA2DEA72DE9E46FCA19AE6AA98D0" xlink:to="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_PreferredStockMember_C336D59F1BB556804765A19AE6AB8AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2867698311D2FB67D3F2A19AE6AE12F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_CommonStockMember_2867698311D2FB67D3F2A19AE6AE12F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B4733DE141A8B10FD01EA19AE6AFD4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_136D04BA5E7AD479BF1AA19AE6AB1A26" xlink:to="loc_us-gaap_RetainedEarningsMember_61263FFDCD5C92295C48A19AE6AF1451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10A59350584CA44C6426A19AE6AF9343" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_265DED2635B69BE9A443A19AE6A457E8" xlink:to="loc_us-gaap_StatementLineItems_10A59350584CA44C6426A19AE6AF9343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10A59350584CA44C6426A19AE6AF9343" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_SharesOutstanding_03CE383B65E994E6761BA19AE6AF16DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAB7CF55E477B67CCE78A19AE6B0835D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:label="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_101FB0BE59487BDCCE78A19AE6B001CA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:label="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_D3CCE3B10B62B8336746A19AE6B1974C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9A705A0FCB2373A24468A19AE6B1D12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_892F79CEB4A217C9A473A19AE6B1A088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B5DF57AA8DDA811ADD40A19AE6B14F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_A639AC223E30C0B9EB64A19AE6B2927B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:label="loc_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_6A8B726FE6023CEB1CFAA19AE6B2D194" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:label="loc_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_E4328961E78E09148816A19AE6B2E8CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_FC9DCBC166914337597DA19AE6B2937C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:label="loc_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_9F7A5C5A6168BBED849AA19AE6B38B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_72AEA6CEA2E4601EFCD2A19AE6B36253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A75B9F55DDF73B2A1FB2A19AE6B40188" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:label="loc_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_9E922DFBB1E7432C0213A19AE6B4E20F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:label="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_B71E2983FBB226553F03A19AE6B4261A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:label="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_A48A902F16EF4A29FE28A19AE6B48CF1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:label="loc_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_CF35B1186D2A7A6D6F7AA19AE6B46A45" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_3E9728E2BC3DA5005DB5A19AE6B57FF1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_FEF06C2817F036BB1237A19AE6B5E1D8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForAntidilutionProvisionsShares" xlink:label="loc_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForAntidilutionProvisionsShares_96DD82E2DABA964FA616A19AE6B5A257" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForAntidilutionProvisions" xlink:label="loc_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedForAntidilutionProvisions_869A489753E26D6143A9A19AE6B6E88C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_5776B96D2A78979A5E98A19AE6B6A7DF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_25942B575EB3BD094DDEA19AE6B6FC0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2723FFEEFED70DA44586A19AE6B7D5A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8DDEF6AC58E278D2DE70A19AE6B78BF4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_D208B399F1A14381AD33A19AE6B75798" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_E5D0BFB28E6F583A7DB7A19AE6B7B8BE" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_E5D0BFB28E6F583A7DB7A19AE6B7B8BE" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendModificationOfWarrants" xlink:label="loc_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_DividendModificationOfWarrants_3841CA0AC90C21269B72A19AE6B79A27" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockDividends" xlink:label="loc_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_ConvertiblePreferredStockDividends_F597200B1C916079EA10A19AE6B86C0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExchangeAgreementsIssuanceOfCommonStock" xlink:label="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_E865DD9E4226EDE2CE13A19AE6B9ED7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExchangeAgreementsAmount" xlink:label="loc_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_WarrantExchangeAgreementsAmount_0B19FCCC1CFC9BFE800EA19AE6B96D37" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_42158C27B111170B2961A19AE6BA0A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_F4A610F93D52C79914D4A19AE6BA9DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_NetIncomeLoss_CAE4C6EDCB9CE8BC6B38A19AE6BA7F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_SharesOutstanding_2213CA7A6720CCBF96FCA19AE6BBF88D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A5175C64D7FC93CC9F14A19AE6AF4550" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E9C0ED9D0FA2F96C9A3CA19AE6BB55B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C816E94EEA790D0B91CCA153C2DEB2E0" xlink:to="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C01DC3784F9111CBADFDA153C2DE84C7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="loc_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:to="loc_gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_C7E3420CB4806B13AF1CA153C2DF517F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="loc_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FF9BBF986D4A15EBD4F4A153C2DF926F" xlink:to="loc_gale_ConvertibleDebtTwoThousandSelyNoteMember_9CB434AC3EEFC135FAABA153C2DF9D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A481E148EA8678709C3DA153C2DE94C1" xlink:to="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_DC162784050E847817C3A153C2E03F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BBC4CC5DA14483846597A153C2E10E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_7B8F604307720D75A818A153C2E1BEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_PaidInKindInterest_056083CAEBD19FC364EAA153C2E1E77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_AdjustmentForAmortization_248EB28589B4B94622D2A153C2E29763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_79B67CE71F938D8CA7DDA153C2E20719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_ShareBasedCompensation_19424443135BFFBD75C0A153C2E2E26F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_FD85F5F40D9A52FD5FC5A153C2E3F279" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_095C6F1E2A1553484909A153C2E3054F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_86BB9723893B70ADF13EA153C2E31AC8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_46B1ECEF1B914641FB2EA153C2E35AAE" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_FC8810BAC32FCBAC5689A153C2E35F07" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_2464EFEE8A2F2A49335EA153C2E4E911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_SeveranceCosts1_AF03E78CF80A671C985AA153C2E4143B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C34A062B4D5333F41CCCA153C2E10A5A" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E9C34FF0D63EE5E6EC3EA153C2E415C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_68EBF9B4658F18BBC455A153C2E57439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FDCA66D8F4C0B8873375A153C2E4DAAC" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27870306B392CAABC92EA153C2E5A2B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_13BE113FF8B803F08AB3A153C2E03001" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A389437FDCDCE8EE2430A153C2E5120C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_E54DFCF7D0AE48C05E9BA153C2E650D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_B5C1EC85EF8CEFD07438A153C2E6534A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62E9BF139C3963584FFBA153C2E692B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1292233458DCB99BF598A153C2E7F189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5F1724A37907FB526C55A153C2E7582B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_PaymentsOfDividends_AE37AF1C6337EB4E4F5CA153C2E76144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8F10C56997B652BDA0DEA153C2E89C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0AC336D9F1422C0BFBB4A153C2E60DF6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F83FE849ED0BDCECC79A153C2E882B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0FF03E0DA980D3A4C691A153C2E8E719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75180F98D1602B5B4EC2A153C2E8C393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D056611B4FFD75C8DA6A153C2E8CBD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_BCEBA6027C8D12367FEFA153C2E9A846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_462B653C7BA0E47C6E66A153C2E971CB" xlink:to="loc_us-gaap_InterestPaidNet_6EF66342426F3C2E1584A153C2E9231D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EF156F8E5D91D6665E79A153C2E0936C" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_4CB0517603973E90F5F3A153C2EAF7FF" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConversionwithSeriesAConvertiblePreferredStock" xlink:label="loc_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_ConversionwithSeriesAConvertiblePreferredStock_907DE8470D3068F6F075A153C2EA4A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_17C0ACB0EEAA715BF6FAA153C2EA075C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" xlink:label="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_516A42667A3236822C90A153C2EA5FB3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_5BA52F2919AF4617B766A153C2EA9C8D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" xlink:label="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_C75FF37F1D3BC878A3FAA153C2EB2B93" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_668723A7639BFC434686A153C2EB0D7D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:label="loc_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_9A580F5FCE02170B64EAA153C2EBD428" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedToSettlerRelatedPartyAccountsPayable" xlink:label="loc_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable_E8EDC3619A8183745F70A153C2EC811C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharesIssuedToSettleAccountsPayable" xlink:label="loc_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_SharesIssuedToSettleAccountsPayable_DB44E77AC5137BC94E85A153C2ECAE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_us-gaap_StockIssued1_6504239386C7C798DA57A153C2EC8816" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:label="loc_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_D714596BFA6BE014B0B4A153C2E9DF08" xlink:to="loc_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_3D96F18C753BFFFD52F7A153C2EC5417" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4B63F969C54D697795E1A19B9FBFAF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_34A38E7375BF486CEB20A19B9FBF7B5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0149274A53B4988883C6A1A12FCAE995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_B50E024CAB6D49DA2FA9A19B9FBF1AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_75B7166FF29D0CE32010A19B9FBE93EF" xlink:to="loc_us-gaap_CostsAndExpenses_840449635BD7DE266F2FA19B9FC018DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3C86B6A8AD17C2E40CC3A19B9FC01CAC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_EEA67BB75191D6EB8FA8A19B9FC020ED" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="loc_gale_LossOnSettlementOfWarrantsLiability_3662D1313602D44AAA2CA19B9FC14EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07067C0D081B01B430A2A19B9FC1226E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_9C85297507F156FC1A02A19B9FC1D0FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85269B37382DBFC3B72EA19B9FC07666" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9152218BBDCB56DD2B75A19B9FC189A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_FA8E03DC3A49C9C390F4A19B9FC132BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4C48947AFF7AE20231E9A19B9FC23D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_NetIncomeLoss_8D0845DE957BA4534110A19B9FC28C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_D5596C110880972DC7F6A19B9FC76267" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_19E44A97F64C254F938CA19B9FC75D8E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LiabilityClassifiedWarrantsAntidilutionProtection" xlink:label="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_F1AC6E4F02A5AABB7290A19B9FC8899F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendOnDebtConversion" xlink:label="loc_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_gale_DeemedDividendOnDebtConversion_F4ECFE90B6CADE4D6B59A19B9FC8F16E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6B741F97F846D257E22EA19B9FC85A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B9531E600C1BEA220953A19B9FBE5943" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9868B749EAEAC9CFFF75A19B9FC83B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2C2C15AF1F619E0E4217A19B9FC8175B" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_87ED98ED384C653F9ABBA19B9FC9B353" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7BB6C6F08DF2E6A58DF480681C67624E" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4C63BED14F28A66498AE80681C67B761" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F72230182444A3104BB2A088FD488B95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F72230182444A3104BB2A088FD488B95" xlink:to="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4D95F0D508E0CF08DC21A088FD49CA85" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_93D32D294DB6F28C7646A088FD4A2DA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_A8A3D5EDAB9097D9EE95A088FD49F3A5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_93D32D294DB6F28C7646A088FD4A2DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:to="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_43422F1D8D74D3DF0B3AA088FD4A9B96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CEEB78CB1C2EB17744A8A088FD4AD5C9" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_4AF6F624F5A0EDBC986DA088FD4AC726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_719DFD2C162D24AC61C7A088FD491F7B" xlink:to="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_568C2E1B79411D179716A088FD4BD783" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_568C2E1B79411D179716A088FD4BD783" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_570DABEAC4BBC13BCD4AA088FD4BA000" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_570DABEAC4BBC13BCD4AA088FD4BA000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_297C3348D2D52921BACBA088FD4B149C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BA553B996C42D2370EDA088FD4C9BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_06F0496975536D93D708A088FD4C37A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_06F0496975536D93D708A088FD4C37A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_9BB5B2A6339FE52E64A4A088FD4CC529" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_9BB5B2A6339FE52E64A4A088FD4CC529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_084F23E8A2452B250C0BA088FD4B7F34" xlink:to="loc_us-gaap_RepaymentsOfDebt_411D85E272D0031FFD4AA0C0A8C18D1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0A0D215938A396A7F3A9A114531FCAA3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0A0D215938A396A7F3A9A114531FCAA3" xlink:to="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_74D5B119A42023B27F2BA114531F416A" xlink:to="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_B204DC621A33B4C3CE43A114531FCA79" xlink:to="loc_gale_JGBActionMember_F4B25C9357F243D7220FA1145320922B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5A0FA47724B9EFA11D22A1145320143D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_52F4E9277FD16FCC1FE7A1145321ADC5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3474164528FC1BB3A0B2A114532024AA" xlink:to="loc_gale_AmendmentAgreementMember_CC099790EF21B335DAAFA114532142BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91AA9F25F69AFA9F742FA1145321D27F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_100A4C29AEB3BEC1C7ADA1145321E982" xlink:to="loc_us-gaap_SecuredDebtMember_A27D554EB032C9CADF3AA114532250F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09CCD5C297694598CEF3A114531F3D6C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7424BFBE410793F6FF72A1145322B710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7D63211DC4CEA76D6990A1145323DE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_630B4A920BADEC1CA56EA1145323E3BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_630B4A920BADEC1CA56EA1145323E3BB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_876D19CD4E5FFEEDA34DA11453236D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_4A7D2B76F85F6AC1476BA11453232C4B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_C0A767B45F566012EBF0A1145323244C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DebtInstrumentFairValue_D7F9FE87A19A7B9DE53EA11453247BA6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_659E0D16E3D786B2D963A11453242729" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_C92C56E3BEBD9CFAFF15A1145324742C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_7B8B2C11803CAA8E907AA1145324F14E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="loc_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_DecreaseInRestrictedCash_5A59E9A90A31645A5247A114532510E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_RestrictedCash_5EF2F502BB398C0857ACA11453255930" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_98433DC3F86E62270A27A1145325FB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6C3EAD4F948E49926593A1145325AF05" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ReimbursementOfLegalFees" xlink:label="loc_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_gale_ReimbursementOfLegalFees_671C58273C6968E10AC6A11453254576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61F3ECC8F1916F780D81A1145326138C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_742B2EDDDBBB1C6A7FA6A11453226A6D" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61F3ECC8F1916F780D81A1145326138C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_734DC1B11AA2C0FFE357A088FD63662F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_734DC1B11AA2C0FFE357A088FD63662F" xlink:to="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3AE4CE805929846CBFA3A088FD6487CA" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_088D17EEB4E349F87591A088FD65BB7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_73465DA21C2F7A704685A088FD64616A" xlink:to="loc_us-gaap_SecuredDebtMember_088D17EEB4E349F87591A088FD65BB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:to="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0D572385AD730F501A6BA088FD65B821" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_C49C29365EAAF5F83327A088FD650F9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1B770CB4AC3F7D47600A088FD65381B" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_C49C29365EAAF5F83327A088FD650F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CFD801AB748925AD3B48A088FD639F12" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_LongTermDebtCurrent_CB9A16D17D9D5E4A7BAFA088FD663027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_D7DEB2A4CB0973B7CB57A088FD667D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6B7F5628335F956AEA41A088FD668B0A" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_A5C8F9977763961AF04DA088FD674E7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A2945260309D78BFC19680681BB05F45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A2945260309D78BFC19680681BB05F45" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_F18D1655D0D6AB9C4EA480681BB2F521" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="gale-20181231.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityRegistrantName_ABA36E1ED63C20AC82F29D10B3C1C579" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_TradingSymbol_4E533A1269656E5AA9B99D10B3C2925F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityCentralIndexKey_02B0254EF1064051E41E9D10B3C2AEA8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_CurrentFiscalYearEndDate_2857C5FBCBB6A959594A9D10B3C339DC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityFilerCategory_7B9706494A1E317605DB9D10B3C3FC56" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_DocumentType_E66206FB06A3B807AAF59D10B3C35E9C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_DocumentPeriodEndDate_F59F802215ABFFED52E29D10B3C318AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_DocumentFiscalYearFocus_ED1AF7E2CDB3E6D9002F9D10B3C31326" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_DocumentFiscalPeriodFocus_04DC8A2EB6B00D08D9CC9D10B3C43451" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_AmendmentFlag_2272E330B3035EE953F19D10B3C4B472" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityEmergingGrowthCompany_9BD7EB44D36CD6F6FFFD9D10B3C44194" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntitySmallBusiness_76B7D7B2820C230256239D10B3C437F9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityShellCompany_CA1003FB63BE109CC5D69D10B3C524D8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityCurrentReportingStatus_C075E9372D6E0C2875FF9D3318A75547" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityVoluntaryFilers_19A0396329CE3EFFFE329D3A4330F721" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_29217C6D286A6EBA4E489D3B71798A8A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityPublicFloat_FFCC13A54184A3894B139D3458C1394E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_3A1DF2C6C3CC193F91029D10B3C1ADFB" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7A420D24A25C5C0158569D10B3C5F360" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A89CB0F4B95B5DC09A5080681AE01B54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A89CB0F4B95B5DC09A5080681AE01B54" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2D1916BE2689080D98B780681AE0564B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C657CF82CD5AC917A01AA088FDB83493" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B8F35103EAF8AF0DDBBFA088FDB91D30" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_FA7296AD7C11CDF050B9A088FDB92A41" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_C964C52F0330C5057DF5A088FDB9F3AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A74598CE101E05D48EE6A088FDBA2773" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6D73BDBEAC08DFC68BDCA088FDBA22CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_77C0DBF33CBDCBBF63DEA088FDBABC07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217D836573EB24544F77A088FDBA6DD0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DF72D5F30B28C6A524F9A088FDBB03ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64970F2E7D6D05B5FCE4A088FDB84F90" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53D974A7A9D97E60BCB5A088FDBB406F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_509E1799A558AD51FB73A088FDBC7D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ECB041AC08726DF876F7A088FDBB105E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_43FE70D62458946017C2A088FDBC6EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E7241F2D81D4E74DBF07A088FDBB1D24" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4931B5BBA96388C5CF04A088FDBC6980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D8030E23C475CC9FB0CBA088FDBD157C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_F33D9D0104DC0B198040A088FDBCB90A" xlink:to="loc_us-gaap_EquityFairValueDisclosure_959DC017080B148D2E61A088FDBD3118" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F8C3814FE3D964EF9DECA088FDAE69DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F8C3814FE3D964EF9DECA088FDAE69DB" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E7E32388619C3C9CE088A088FDAE4E6A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AptheraInc.Member" xlink:label="loc_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8F5FD17D3EE5EB462FB5A088FDAFC49F" xlink:to="loc_gale_AptheraInc.Member_218FBED59BFA5785B842A088FDAFDACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3F4330DA75B5A61B19D1A088FDAF24A5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_63A307C12AB8A1E6E259A088FDB0B35A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_340FB3B3621B0B603F3BA088FDAF6CFE" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_63A307C12AB8A1E6E259A088FDB0B35A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0D28AF19B677FABA486AA088FDAE2839" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_EC8ABA0989052A9BCC7FA088FDB194D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5F4D68E82E0689859573A0B5307813F3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_709294C7E8A24AAF1B39A088FDB1EB67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_709294C7E8A24AAF1B39A088FDB1EB67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3F72A491C9D9492713C8A088FDB1DAC6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_FDCD7CB21C00C1819814A088FDB188C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2C39E5F8925403A91B05A088FDB0B6AA" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9307C63F80CCBCE4D8AEA088FDB18B5B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9C4915B596C358D302FE80681A2C8521" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9C4915B596C358D302FE80681A2C8521" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A9A5AA3937767FB7073980681A2C4239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9C4915B596C358D302FE80681A2C8521" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E18D9A9B8E4FA0810D2780681A2D21FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CEBC3FD9FE57C081968AA088FDE96EB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CEBC3FD9FE57C081968AA088FDE96EB1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4AEADCDD2EEF174DE0EA0A0D8957182" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5FC66F7CE0652F41EE5EA0A133CBEBB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_193F2334F05DEAC1B5BCA0A15F30E29E" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5FC66F7CE0652F41EE5EA0A133CBEBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_179268718B00FB22E845A088FDE9AE99" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_6E9F54BBCA7D2E2A01A1A088FDEA867B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452EF431C0F4BC774BAAA088FDEA08C4" xlink:to="loc_gale_GALE401Member_6E9F54BBCA7D2E2A01A1A088FDEA867B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27A65B3A21446FF886BFA088FDE9ABCA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0F6021016DDE33C470AAA088FDEA0B22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_Goodwill_0F6021016DDE33C470AAA088FDEA0B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0D489EA150619DE94CA9A0A080E61025" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0D489EA150619DE94CA9A0A080E61025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_BED2F2A425D1A4EE1958A088FDEBE95D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_BED2F2A425D1A4EE1958A088FDEBE95D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_F1CD012670015AFCFD40A088FDEB9697" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets_F1CD012670015AFCFD40A088FDEB9697" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment" xlink:label="loc_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_A4169A2ABBE2E31EFD99A088FDEA5820" xlink:to="loc_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment_CE43EC0A00C1861588BEA0A33BA80F8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_408FEC676FCEFDA66F6A9B43C55DB35C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_408FEC676FCEFDA66F6A9B43C55DB35C" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D997EF4D53B51899C1149B43C55D0DBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_06B5ABFD6FF7C6DCAE649B43C5536E65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_06B5ABFD6FF7C6DCAE649B43C5536E65" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87D8880F78C20955B89C9B43C5546257" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_NPSMember" xlink:label="loc_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:to="loc_gale_NPSMember_AD193D707F0A769507B49B43C55552F0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE401Member" xlink:label="loc_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:to="loc_gale_GALE401Member_D3CEB29C1490772F3A669B43C55556A3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GALE301AndGALE302Member" xlink:label="loc_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53FD0C44B02E4F732F9C9B43C5546C4C" xlink:to="loc_gale_GALE301AndGALE302Member_43D55E7C34B59CD6B0D09B43C555AF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BAF63C0EA815F23584229B43C55420D1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_791E11E555280B77A6FB9B43C5567BC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2D8696C04B244BDF8EF59B43C555EB67" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_791E11E555280B77A6FB9B43C5567BC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_091F09DE7BB66174EAA09B43C5591ACB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_091F09DE7BB66174EAA09B43C5591ACB" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_28F5E82D3BCAB408B93A9BD1B8E1C7BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E88CA197C892DAEC79FCA0EF763A78D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E88CA197C892DAEC79FCA0EF763A78D9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_977220DA0FD59855AB03A0EF763BC4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3DB4187F7AEB847B76C5A0EF763B4585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ADADA5151F54ADF29882A0EF763B97F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D3701B5365CEE053F0BDA0EF763A6165" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67A093101376AE7231FEA0EF763CA124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E88CA197C892DAEC79FCA0EF763A78D9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D8D09542AF321F0B4204A0EF763CAC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7D079F42727D368B3CA0A0EF763DB9EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4EDD2AE2F031DF0C493DA0EF763D229D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_D46FE912C96D65055C7FA0EF763C77A6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_392FB99B4477E6AC5843A0EF763DFE5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E88CA197C892DAEC79FCA0EF763A78D9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_EB9F65D078F0F8D71B1BA0EF763D55EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_41B926593A84FFC22C8AA0EF762E3D52" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41B926593A84FFC22C8AA0EF762E3D52" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_A3E157ABE7494983438AA0EF762FA5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_A78C4F749ADB9C7DE9FEA0EF762FBD53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C018996E04E53A51A2A4A0EF7630FE37" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_gale_DeferredTaxAssetsLicensingDeductionDeferral_2F6B650FBD682CBFEA63A0EF76307000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_82131D69A6BE0AB6F0D2A0EF76302219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0905FD0371593D3904E1A0EF7630CE5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_C9C20B6AB16ECB94BBEDA0EF763000F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5DFEEB2362F2CD271FA8A0EF762EBD06" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_47C676B0D03AA5F3ED06A0EF7631DDDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_63F4A7D811BD43AF84D1A0EF762889EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_63F4A7D811BD43AF84D1A0EF762889EF" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_113D90A10E64E9CEF781A0EF76288417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_63F4A7D811BD43AF84D1A0EF762889EF" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_BF780B4F8809D6A1D83CA0EF76285B90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B48B51F019F18A0E177DA19B9CF3E703" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B48B51F019F18A0E177DA19B9CF3E703" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_494346131FC7220B9547A19B9CF3EB2D" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6590C532C37BBC9882EBA19B9CF4937F" xlink:to="loc_us-gaap_ResearchMember_28A9119EDF6412B38B99A19B9CF4E031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_B9AF7018D7C5B61B6BDBA19B9CF4BE3E" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:to="loc_us-gaap_DomesticCountryMember_0E655A52F45FF0FAD8A4A19B9CF5EE56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5941B60DD5B26773AC63A19B9CF41460" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6090B384EA8190287CBBA19B9CF54C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B68FC26198B8BBAA83C6A19B9CF3CAE1" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_92283A03C01F9079AE3DA19B9CF63C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_57779D2E32787A083236A19B9CF60603" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:label="loc_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_22F94C0AB6C1C1B7F785A19B9CF68C1D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:label="loc_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_597B44022677089934AEA19B9CF6D557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9C729E61F85216A5627CA19B9CF621C4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:label="loc_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_01F74253F1E9377A18DDA19B9CF5D9C0" xlink:to="loc_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_2159B355BA586B954744A19B9CF6EF73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0C7A008EDD4433DE694EA088FB4C5205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0C7A008EDD4433DE694EA088FB4C5205" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_20A1CC3941721EFE3534A088FB4CADF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27EA2B73D976D1571968A0F5F6055450" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_159CFB7BE8FA906A4A5DA0F5F606F037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_A02214735A990BA5DE5BA0F5F606F8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1D27FCE6297F2CE7A3C8A0F5F60B5A9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7A7F1977848680FA6C64A0F5F60CE32F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_82342BF180E285828BBAA0F5F6058CA9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_F5F5EB6E1779F5A7457EA0F5F60C0E82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_BDE58F6BA30D4CE3BFA9A0FEE33A81EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDE58F6BA30D4CE3BFA9A0FEE33A81EA" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_DD9D12772E25E459DB07A0FEE33A699A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDE58F6BA30D4CE3BFA9A0FEE33A81EA" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_51512DAB627CF6F42660A0FEE33B75D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDE58F6BA30D4CE3BFA9A0FEE33A81EA" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7E996A6F25F63DEB4D29A0FEE33B9BB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D7F2627AF7137D1E990FA088FB307891" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D7F2627AF7137D1E990FA088FB307891" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_DD228CD4809A38D2372BA088FB30C5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D7F2627AF7137D1E990FA088FB307891" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6FCE64CE452132259033A088FB30E583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D7F2627AF7137D1E990FA088FB307891" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7D454DDDA6F1267C2C82A088FB30FA61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B30020D5FA246A3757C5A0FEE32EF074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_828914475EDEC0A81491A0FEE32F2490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_74FC68AB0EB684921ABFA0FEE32F369A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences_FA383B4D05623DF9AF5BA0FEE32F8591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_858CBFD4845362D3C5E4A0FEE32FBD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_48661A924D1BBBF89C76A0FEE330D810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1D77988842799917EB39A0FEE3305B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_12CC7BC73CEF9164BB23A0FEE3308009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5DD364C18BF46365C4A6A0FEE32E9699" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D6D6FF9343140262CCFDA0FEE330CD07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4EE427A6155A343A62F0A088FB3B44ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4EE427A6155A343A62F0A088FB3B44ED" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_608CE4EF02466CB54498A088FB3BCDD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4EE427A6155A343A62F0A088FB3B44ED" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7516E6EED0E1ED236E25A088FB3B2FE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4EE427A6155A343A62F0A088FB3B44ED" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55CC71FDD934BD6BAE1BA088FB3C0ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4EE427A6155A343A62F0A088FB3B44ED" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_84433654ADE9116962C9A088FB3C639B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9E5CCF4DA24E5B4A781880681A0ECB13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9E5CCF4DA24E5B4A781880681A0ECB13" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8EA2300E679AC153D00080681A0FD605" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_12472719D3B0741CFC1CA088FD37CAC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_12472719D3B0741CFC1CA088FD37CAC3" xlink:to="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_459ED997EA4B86109F62A088FD380CFE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_FF325917F2777FEF5B35A088FD39C028" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3C0BCE2912D0AA58CA77A088FD386372" xlink:to="loc_us-gaap_SecuredDebtMember_FF325917F2777FEF5B35A088FD39C028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F924907FFD02B5282BC1A088FD39F83E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_4422CE10D20B11A04FE9A088FD3998C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_577FA389761598A0160DA088FD39EC6B" xlink:to="loc_gale_AmendmentAgreementMember_4422CE10D20B11A04FE9A088FD3998C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_9452CB3C378DE1B39BF8A088FD3A937A" xlink:to="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_362F0277D2E908EFAEC0A088FD3A5678" xlink:to="loc_us-gaap_PendingLitigationMember_93D805E76FA277F23E5DA088FD3A7162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_23E804729CD64194CC8DA088FD3B1A92" xlink:to="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_3B4AFF22C682CF592FACA088FD3B2755" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_62C6158798C8C6E5A013A088FD3BF808" xlink:to="loc_gale_JGBActionMember_0E2AD9424B12E9935EB2A088FD3BE5DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_46F1852A5AFEFAFE5D6BA088FD37B899" xlink:to="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_982F4F3DA6E6F98DB67EA088FD3C586E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_26BAFC7D90AFEB90DD24A088FD3CD642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9A8F20456F876B08DFF8A088FD3C47EC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossContingencyNumberOfCounterclaims" xlink:label="loc_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_gale_LossContingencyNumberOfCounterclaims_EC86A6B8B7A75ADD6C05A088FD3DC55F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_801A7F0D032D6ADE8979A088FD3C7228" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_RestrictedCash_801A7F0D032D6ADE8979A088FD3C7228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_4C0EA56D8F672F2999FBA088FD3D9CC4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_4C0EA56D8F672F2999FBA088FD3D9CC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LegalFees_584AE3717C1C080BF72AA088FD3CB52D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A81A0282871AEF24BB92A088FD3DB035" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A81A0282871AEF24BB92A088FD3DB035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2E8932AEB4D9C323F243A088FD3B280E" xlink:to="loc_us-gaap_LeaseAndRentalExpense_ACFF0A398A8918EF6BBDA088FD3DACB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_19A74BA7C8C9FAC9A4B3A088FD309DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_F52233BC705424543C54A088FD3016A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5FF2FA5FC200B1231BCAA088FD30FE16" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1B67CF8775EEE46D5216A088FD3093F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CFEE3957C572A002BD6BA0DE21A2C415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CFEE3957C572A002BD6BA0DE21A2C415" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2109BCC3E6C074AEE92DA0DE21A39AD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2A31443718A4B46F5CA280681A7B8D1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2A31443718A4B46F5CA280681A7B8D1E" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_00D7B4199EF0D18D2A8280681A7B9304" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C19BE3770A77B10352A1483A63885E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5AB4E85980526ECD73EAA1483A63DFC0" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_59CC956816D2C676919CA1483A6488E8" xlink:to="loc_us-gaap_ScenarioForecastMember_A2D237763D69DC7B6D12A1483A64F85C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3833EE17EB41C7FB6BA3A1483A655184" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6129BA5185E3D677C222A1483A65BBA5" xlink:to="loc_gale_PurchaseAgreementMember_09A3E4B6D0D4091D916FA1483A65445F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9943672916B0DE749079A1483A66F449" xlink:to="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:to="loc_us-gaap_CommonStockMember_B4F5C44A905D2C7F1AE4A1483A66860E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1E96DC5710F5872BC62AA1483A66609D" xlink:to="loc_us-gaap_WarrantMember_F513CA0E74FE63FB95E2A1483A6660D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542F81587C9256BE7589A1483A67DDA1" xlink:to="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_B72398C2FC10B9E41135A1483A670BA2" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9B3C89AE8EA40A9F73B5A1483A67C854" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_CDE44E651F0117D00489A1483A68007C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3D0D35A8E90608713175A1483A688496" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:to="loc_gale_FirstTrancheMember_621991313FD6542B0F52A1483A68CE89" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SecondTrancheMember" xlink:label="loc_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_242C28714DD51CCA0E92A1483A682918" xlink:to="loc_gale_SecondTrancheMember_BFEC3EC91EA750AF8D26A1483A69A518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_09E66C4F885632BE04C3A1483A635638" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6348AC0B14FFE6654109A1483A697C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C004DA3F79231ACA5100A1483A6A96BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_09E6FF00ECAAB409D0BAA1483A6AA35B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_29CDCF8FEC7C675F214CA1483A6A8009" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ClassofWarrantorRightTerm_CC3BF129C5B3493B0DA9A1483A6BD0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C6D30983ACF646F334C6A1483A6BA874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_PreferredStockSharesIssued_462A3852F97E1C8649B7A1483A6B2D96" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_E35145BD44F02A0EEE8CA1483A6B2013" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockNumberOfTranches" xlink:label="loc_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_gale_ConvertiblePreferredStockNumberOfTranches_645A7D46A57815607127A1483A6CCCB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_D74AC726D769FA4D9C69A1483A6C4D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DE3AD1A61F8F32F99EC1A1483A6C5D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ED3F6B2239F8BA45B641A1483A6CF54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_1C960CB44F7109543CF2A1483A6C013E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6FB4B714A9D214F3FEC8A1483A69670E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_DDD2E8990984AC426B86A1483A6CC165" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4F820CC22C96AA15368F80681C1E720E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4F820CC22C96AA15368F80681C1E720E" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_15DF7DA9655C7AE1143880681C1EA721" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77389B8B2489A027E5D480681C76E259" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77389B8B2489A027E5D480681C76E259" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:to="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_F0F46E8D32653A18B03C80681C76A368" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivateSELLASSecurityHoldersMember" xlink:label="loc_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:to="loc_gale_PrivateSELLASSecurityHoldersMember_B46C78CB3D7AFDF602FE80681C777BC4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PreMergerSecurityholdersMember" xlink:label="loc_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57EDC488300A15A5E50280681C7718D7" xlink:to="loc_gale_PreMergerSecurityholdersMember_DD0859E424A17202AA3780681C77B17F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:to="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_92AC991C3ACE830035B880681C774356" xlink:to="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_6196CD156F2E9FE1C61480681C786BC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3CE8D808FA5B045DDECB80681C770DBD" xlink:to="loc_gale_GalenaBiopharmaIncMember_6196CD156F2E9FE1C61480681C786BC5" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_DCC686A3446839E152A480681C76D6C8" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D00B071191635BFA6CB680681C78423F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_57C5D4D6447D4EE73F1A80681C79DFC8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockConversionRatio" xlink:label="loc_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_gale_CommonStockConversionRatio_B45FBE155E5D88142B0780681C799163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_97D2D18572E11C3DD62780681C79938C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_387288BD4EA9CDC4704D80681C78209D" xlink:to="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_D039E620D67550225CDE80681C791A30" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_AAB113FB62A4C0637942A14837B4CB59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_AAB113FB62A4C0637942A14837B4CB59" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_50DFB56550E6266C4DA4A14837B57320" xlink:to="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_Dr.AngelosM.StergiouMember" xlink:label="loc_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B25F190F982526E04F01A14837B56AF4" xlink:to="loc_gale_Dr.AngelosM.StergiouMember_982C0426F99C70AA5A0BA14837B61E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0D35FE552D77AF33CC70A14837B6D21C" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EquilibriaCollaborationAgreementMember" xlink:label="loc_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:to="loc_gale_EquilibriaCollaborationAgreementMember_4383999462D560A83EA3A14837B73CDE" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_MskLicenseAgreementMember" xlink:label="loc_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_044E3A424E0A715FC9EEA14837B6D2A4" xlink:to="loc_gale_MskLicenseAgreementMember_122FE734054F9C82E864A14837B7FF68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_F4B09E19FE562C0CAD02A14837B46AE9" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CollaborationAgreementTerm" xlink:label="loc_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_CollaborationAgreementTerm_980C33EC9DC1E5351262A16890BE3DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_PaymentForManagementFee_42155BEF313A039257FBA14837B8163D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_ManagementFeeExpense_197D4A4A1E3EE4C484E3A14837B87DEC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_AccruedCompensationIncentive" xlink:label="loc_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_AccruedCompensationIncentive_CDBE4E3A3C396399F59CA14837B8260D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:label="loc_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue_ABE8B6C9DECA437DF3A4A14837B861F1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash" xlink:label="loc_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash_5064880A61DDFB74BAC1A14837B94651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_ManagementFeePayable_501FB6B6858EA84ABB3EA14837B95741" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare" xlink:label="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare_6A080F98C8165225C80DA14837B968EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_28FC2DEDCD245B89BBCFA14837BA08D4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageOfOwnershipOutstandingShareCapital" xlink:label="loc_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_F486DDFBC3650F0FA631A14837B7978A" xlink:to="loc_gale_PercentageOfOwnershipOutstandingShareCapital_760B2055BC9C689BDB04A14837BA084D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7E51A6BB853F1A198840A088FB0DD93D" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C969116BA8EC69B658B2A088FB0DD5FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2A6F33021C8BA794B6B180681C10E010" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2A6F33021C8BA794B6B180681C10E010" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_70DE7BE42DCC1154519F80681C10C2CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BD88B54C1768E3FE1FF0A088FBF246AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BD88B54C1768E3FE1FF0A088FBF246AE" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_45B1FB223922D6E7F9A5A088FBF3FCC7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_20D1684F940A973C2521A088FBF3D91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8E51188413D2D2E6B493A088FBF3D5D2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_75CFD4B5DFD0D173AC6BA088FBF3F239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8D550B75CE1B9C51F2FDA088FBF2E07A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5CD85ADA92CF4AF16A2A088FBF467C0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D1D20FE56A6B137E3E5FA088FBF45835" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54CA4A0CA117BFA733FCA088FBE40743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EAA0D58E192C82B88C91A088FBE4421B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_BAF58AA5C10CB21F9042A088FBE4F401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BED6417766AF39C106E7A088FBE3FD7A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30598D426C3698ECCA21A088FBE43532" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1B09045BC101FF9ADEDFA1483875AD60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1B09045BC101FF9ADEDFA1483875AD60" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D6959F7FCEBB309CE5DFA1483875DABE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_01C6E3AC2593EC694B6BA14838760701" xlink:to="loc_us-gaap_SubsequentEventMember_9F7F1EA1ABA7E3DFB38AA1483876835E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D344497ED5E4451E226AA1483876D3CA" xlink:to="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:to="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_76ECE8149146D458C2EBA148387711D4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncentivePlan2016Member" xlink:label="loc_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ECCAF6D52498377008A5A148387747C3" xlink:to="loc_gale_IncentivePlan2016Member_6E0B67D5A378C5467317A148387761FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E1862CF8FA3EEF192F1BA1483877CC23" xlink:to="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:to="loc_srt_MaximumMember_E0C8FD6CB374AC0CC193A1483878DE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A5348A18133A6E01A98AA1483877305E" xlink:to="loc_srt_MinimumMember_F46095BE4A527BCE9947A148387815A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A2CFB627AAEFF2E8224BA148387825A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4934514938DADBFE084EA14838795C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_883F48E71DE039CFD4F6A148387935D7" xlink:to="loc_us-gaap_EmployeeStockMember_093865A111D827FD4E85A14838799C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72C9E6ADF9FE8D1168ECA148387523DB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_047E938C5959E07D27DEA148387A8D92" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_55421F8C01A903B13E37A148387B60CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37A25FD76EC0535795AEA148387BE9F4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_AE326AD3722FB7137F93A148387BE3A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_F8E116B2F76C64A38454A148387BB75E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C2D38FFCA442C8D0147BA148387B5AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1C0E14177A5FB8073522A148387C9BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C78D87207E0822F9ABF7A148387CD73B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5D7765EDEEBAFFA9C064A148387C8273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_AB7C3A1B4F832A16D070A148387C24AA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_AB7C3A1B4F832A16D070A148387C24AA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_411D44AB4A787AE3C96BA148387D92CB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_F58DD11DEFA77485E5B3A148387D1D14" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_ClosingPriceOfCommonStock_58723F2AB695F025635FA148387DB2A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8154C6B813AE54802CB9A148387D5C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AFF8B9768991DE01C0ECA148387D8104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94653FA5337BC0517299A148387E9EE9" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_403E1F8417BDDF053CC1A148387E4B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6400661F866C2E18A0C0A148387E0147" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesReservedForIssuanceAdditionalShares" xlink:label="loc_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_CommonStockSharesReservedForIssuanceAdditionalShares_E814150FAA283E219C31A148387F044E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm" xlink:label="loc_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_94C768CDF293E8AD55B8A148387AF3BA" xlink:to="loc_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm_C8A27004EA501F39D0A6A17BE61B2D33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DD9A5AEF826647B84723A088FBCBE2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DAC6AE3DE95F73CD57DA088FBCBE7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1B8D22D1E949560CECDAA088FBCCB9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9B40AE6E0FE453FED0F8A088FBCBEEEE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1CB228C2BFC33E871E4CA088FBCCA3F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E79BC1BE76C6AEBF3938A088FBCC73DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6890D9EF79189D50F0BA088FBCD0BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33DD5FE152C3388E4422A088FBCD9762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_648A9997B3F626CF35F2A088FBCD0753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B50B4C85B2188F1B04AFA088FBCD9C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E5BD6ADDF5038DDC5918A088FBD2B2C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03002CAB511110D3FE69A088FBD3A028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37EFC2D10F96B9F62AC5A088FBD350B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_348692F274CAB264DBD9A088FBD3942F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C42E4FBB129E8A7C1AC9A088FBD37693" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_FA2FAD0B8ABF63ACA77BA088FBD49E60" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_6847E287903F7F30DA67A088FBD4639B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_B746D81A25C9EB664E91A088FBD32107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_482567B0F2D8984BA8A8A088FBD455DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50A72EB508C941B5B747A088FBCAB24A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B3B152FAD6AEEC8D4A98A088FBD45BF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFA7BCCED67A8594EB5E80681B1CC664" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFA7BCCED67A8594EB5E80681B1CC664" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1CC3ABEAC09AB0F4BA2380681B1DCA08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFA7BCCED67A8594EB5E80681B1CC664" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70E011BD792026375FCA80681B1DADCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFA7BCCED67A8594EB5E80681B1CC664" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7C5C16D1475EDED4B52F80681B1D8342" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C79567DC178BA16A3CBB80681A491CE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C79567DC178BA16A3CBB80681A491CE4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A96890D65E2CE55E183580681A49B7D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_711CBE072B8D6C0E6DDCA088FD10E063" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_711CBE072B8D6C0E6DDCA088FD10E063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54C283E87A5E7B249374A088FD108C2E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_672EE3C375ECE93C14F1A088FD10F5FB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_40FD0E72E9BEBD05C3D0A088FD104B3F" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_RestrictedStockSharesReservedforFutureIssuance" xlink:label="loc_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:to="loc_gale_RestrictedStockSharesReservedforFutureIssuance_A0FA051BFA69907F63D6A088FD10B71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BE631E1508023BC681EA088FD0FC5BF" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CD87F29E499790D5B7FDA088FD112C1B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_A7C8AE0112C2CCB33C5AA0DE2160C643" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_A7C8AE0112C2CCB33C5AA0DE2160C643" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0BA7A07E3C5F4A0CD078A0DE216169A3" xlink:to="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A4BAD23838EC21693D55A0DE21621803" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:to="loc_us-gaap_WarrantMember_A4BAD23838EC21693D55A0DE21621803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EB3AA4C0B3762979E82DA0DE216200EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FFF60B7640CB047104B7A0DE2162C93D" xlink:to="loc_us-gaap_CommonStockMember_EB3AA4C0B3762979E82DA0DE216200EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DF607EB2FE97550AD63DA0DE21625C35" xlink:to="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_09F616AC7AAE51467446A0DE21634591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_09F616AC7AAE51467446A0DE21634591" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_291F36F7A1FCC27C6191A0DE216335EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D5816C23B678E385528DA0DE216261B4" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_291F36F7A1FCC27C6191A0DE216335EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FB4D2E7A0C0D63EEBB2AA0DE21638721" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_4E796232DE6657DE56E8A0DE2164FD42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D2BFB1A7FB924C3D356BA0DE21644269" xlink:to="loc_gale_PurchaseAgreementMember_4E796232DE6657DE56E8A0DE2164FD42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B49AD97D4DA74D3140ACA0DE2164FD65" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivatePlacementFirstClosingMember" xlink:label="loc_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:to="loc_gale_PrivatePlacementFirstClosingMember_53268238B7589F0A9952A0DE216514E6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_PrivatePlacementSecondClosingMember" xlink:label="loc_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9DA8826D640EF19D9DA4A0DE21647B6E" xlink:to="loc_gale_PrivatePlacementSecondClosingMember_D289F187CECC66126672A0DE2165120C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C294CD0B81308EA42A69A0DE21610494" xlink:to="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_C67631C7363658F6D449A0DE21666E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FA5D640AE665F26C54B5A0DE21666072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_906EC7FCE85C808351DCA0DE21660553" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_PreferredStockSharesIssued_906EC7FCE85C808351DCA0DE21660553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3C05F079F3414AA509F3A0DE2166DBFA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3C05F079F3414AA509F3A0DE2166DBFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_CA299E9553C491DE0953A0DE2166E4C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6CFA1A2C948361B97D15A0DE21676E49" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_2219120C71D9C0A56109A0DE216719EC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_2219120C71D9C0A56109A0DE216719EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_A454520A204EE10D13D9A0DE21670CE7" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePreferredStockIssuedShares" xlink:label="loc_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ConvertiblePreferredStockIssuedShares_C61EA8D78D15D9381CADA0DE21675093" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsIssuedShares" xlink:label="loc_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_WarrantsIssuedShares_7FAFE9DEF5EDF434572FA0DE2168EF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_273561739FB48D110849A0DE2169D956" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_273561739FB48D110849A0DE2169D956" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_4472A2DA3F7DD8175ACAA0DE216A766D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ClassofWarrantorRightTerm_4472A2DA3F7DD8175ACAA0DE216A766D" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D4BBD300ACA0E1D11B39A0DE216B26FB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_53845915670C4FB2FBC6A0DE216B1B95" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" xlink:label="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_A8B53D4F7F7B292AB82EA0DE216C9702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_89BA2538E3F2884B2940A0DE216CF4EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6D304CED17C7E931B444A0DE216C6C1F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6D304CED17C7E931B444A0DE216C6C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C946BC0AC7D339D758F7A0DE216C0E66" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_C946BC0AC7D339D758F7A0DE216C0E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1F8993BCAF6124BE1896A0DE216D31ED" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1F8993BCAF6124BE1896A0DE216D31ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_AB1ED8E0F5396B8E5660A0DE216DB6DC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_18F322143A072A59DBA1A0DE216DBC4A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_18F322143A072A59DBA1A0DE216DBC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C5AE5FF847EFD33BB53FA0DE216E8F1D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7A0D00C102E04A9FF38BA0DE21655097" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_C5AE5FF847EFD33BB53FA0DE216E8F1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9203ED4880C9224BCE55806819D9EBC9" xlink:to="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_20BEED063A684A60247E806819D91EDE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_94BE1DA5FC8F3C73288180681C63434A" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_FBD9FFD1666CB652362280681C648ED8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2C5FCAB5C2165A566D94A088FAF92CF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2C5FCAB5C2165A566D94A088FAF92CF4" xlink:to="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_AE7B70566EA278636B73A1212095F253" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_677683571FE895AF632FA1213C70D102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7F22E0D7E556D7E473FEA121209E7DD1" xlink:to="loc_us-gaap_ScenarioForecastMember_677683571FE895AF632FA1213C70D102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CB3147BF882E0E8D157FA11E86038DB5" xlink:to="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_985D1F31C6ED8DCA80C9A11E86056FF6" xlink:to="loc_us-gaap_CommonStockMember_A511C3239D9458287292A11EB58C8ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D2CD3EF5C814B6D28BFDA113AF4B5240" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantExerciseAgreementMember" xlink:label="loc_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0CF64DC1E7EF21A8D025A113AF4E8306" xlink:to="loc_gale_WarrantExerciseAgreementMember_4BFF74024B751DA65EC7A11446824D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4631445840C91478AD54A088FAFAB1A3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_0D3E3B64128158CB2697A088FAFB259B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0067E744B21B332FAC33A088FAFBBB1D" xlink:to="loc_us-gaap_SubsequentEventMember_0D3E3B64128158CB2697A088FAFB259B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0B6C624AE6F0CE35F642A088FAF98EEE" xlink:to="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightOutstandingExercisable" xlink:label="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_gale_ClassOfWarrantOrRightOutstandingExercisable_628CD6B93152AC8D5F60A119CA1710A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_867E0FB37AD9FD8F0A02A088FAFC1222" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_867E0FB37AD9FD8F0A02A088FAFC1222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6207D40EAD9AC2B8CCD0A11DB949529B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_76FEEF9A8874DB8FD74FA088FAFC7F07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_76FEEF9A8874DB8FD74FA088FAFC7F07" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_2C3203EBFA690FDDAC2AA122AF1DF367" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightNewWarrantsIssued" xlink:label="loc_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_FCE84B400EDB379CE654A088FAFB54E6" xlink:to="loc_gale_ClassOfWarrantOrRightNewWarrantsIssued_EDDF274DAD19C123173EA088FAFC35C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE63C3A166D343BB685980681C3EE3E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE63C3A166D343BB685980681C3EE3E1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_5D2A601668C87067DC8080681C3F1C99" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_6D421D9DE40D55BC27CCA088FC71D735" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_6D421D9DE40D55BC27CCA088FC71D735" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_74EF792BC7940C52E8DCA088FC713863" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_303EC61D6BF6A139E7E8A088FC72E661" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_303EC61D6BF6A139E7E8A088FC72E661" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_FADF05BB7CB58D4FBB3AA088FC72EDFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:to="loc_gale_February2017WarrantsMember_FADF05BB7CB58D4FBB3AA088FC72EDFB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_419B5E7D27233246A535A088FC73D713" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_131B93B87B732139045BA088FC724B67" xlink:to="loc_gale_OtherWarrantIssuesMember_419B5E7D27233246A535A088FC73D713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_A3A534068DE5313D54B8A088FC73F25A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_553D9E001A0800DECE80A088FC719972" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_A3A534068DE5313D54B8A088FC73F25A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_A3A534068DE5313D54B8A088FC73F25A" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_73E0CDE15D64F3F61FCEA088FC735DB3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueofWarrantsGranted_911F4A8B4A433C868D78A088FC7327E8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsCanceled" xlink:label="loc_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsCanceled_1D1DB7197A7311C7B5B8A088FC749ABA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_712AF10F41DB636C0A5AA088FC74E8DC" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_2269FCF9B5CD124CB00CA088FC74E58C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_E0B194F5B86BA8852F0CA088FC73C382" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_4D232C244CAE1C4B8562A088FC744B07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_EED80D2A2F413C89A690A0DBCA522D65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_EED80D2A2F413C89A690A0DBCA522D65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_29AA6859D7DADC9C1C03A0DBCA5981BD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_C5E19373BE3B8A852BBAA0DBCA5A4A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_C5E19373BE3B8A852BBAA0DBCA5A4A33" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_A96A857B47DA29163C95A0DBCA5ABF0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_February2017WarrantsMember_A96A857B47DA29163C95A0DBCA5ABF0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_4E5569B0D4EFF0D31D62A0DBCA5AD40E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_OtherWarrantIssuesMember_4E5569B0D4EFF0D31D62A0DBCA5AD40E" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsClassifiedAsLiabilitiesOtherMember" xlink:label="loc_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_32DDD11709F49B202C60A0DBCA594E95" xlink:to="loc_gale_WarrantsClassifiedAsLiabilitiesOtherMember_02B9B326929DAB6443BDA0DDEBC250B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6853B07AB2C166D7D91AA0DBCA589F0E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37E44FA87773F683D4E5A0DBCA5B9D02" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_WarrantStrikePrice_D50418389A740F58BA75A0DBCA5B9633" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD04E22C8350D22C24C2A0DBCA5B3F17" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_B5174E35BBFD98D67284A0DBCA5C6B0A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FB81CE99363414214AB8A0DBCA5B8594" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_3349D4730AEF5DC08973A0DBCA5C1599" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2E4870A8E29179ECBC4FA14838BDF07F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2E4870A8E29179ECBC4FA14838BDF07F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E40713C1603946D0FC7CA14838BDB1FD" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_FD614FA1668A07D0B9A7A14838BE0AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2D9EDDC465DDB5F12924A14838BEC918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7F93F0B8CBFAF71078EFA14838BE46B7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_440DBCA79B066F5055A8A14838BF59C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4081BE5794F014137A42A14838BFF500" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C4242324321350CD1FCAA14838BF168B" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_3C78A1339F03979B0029A14838BFFE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_242314D6280DFB9FFF13A14838C09C1A" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_B5CE7941D9BDB5225E1BA14838C00A24" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_D5E91A99AEC26F052FEEA14838C0A7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4D482E36E2AFF12776C8A14838C18DE5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_DDBF8D0E82FD2C900FD9A14838C108DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:to="loc_gale_February2017WarrantsMember_DDBF8D0E82FD2C900FD9A14838C108DB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_E62B37FF2A8175E29FDFA14838C2D8FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_199026CFB2DEEC34A1B6A14838C1F26A" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_E62B37FF2A8175E29FDFA14838C2D8FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5E7096BE75B50CADFF96A14838BDD10D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightCanceled" xlink:label="loc_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_ClassOfWarrantOrRightCanceled_44D5B77AEF5D29E4CE43A180ABEF41B8" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" xlink:label="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_E6A273378F0BD383C0EAA14838C2D665" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" xlink:label="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_C644017489B9350E437DA14838C3440F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_74F57F2F57CFFACE3FF2A14838C3A55A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_B78488B18179FCF54B92A14838C33162" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ConsiderationExchangedFairValue" xlink:label="loc_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_ConsiderationExchangedFairValue_115972C62827273F1AB9A14838C342EA" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_gale_LossOnSettlementOfWarrantsLiability_CD09DB813E908163031CA1815AF03AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_04EB4FA6857FAC9936D0A14838C436D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_8FC32A1238C8A3329A30A14838C411BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E7826E5626380E07E4B7A14838C41BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_AF99F0C188CEEDED94ABA14838C2F766" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_422B9FB59E8D47F05A5AA14838C426BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0D4175E6F6E71229D050A088FCF2C2D7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_649555796BCA73866E85A088FCF2A287" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_July2018OfferingMember" xlink:label="loc_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_July2018OfferingMember_A48D3950A9DB2B9DAABFA088FCF3F67C" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_Prefunded2018OfferingMember" xlink:label="loc_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_Prefunded2018OfferingMember_BCA03DA415DEFBE94923A088FCF334E3" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_0F9DD6E872A964F4762AA088FCF41279" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_EqcWarrantsMember" xlink:label="loc_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_EqcWarrantsMember_C328A5B18458C0B5BF22A088FCF49A9A" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_February2017WarrantsMember_A71EC4A2A95CA4733B28A088FCF45DD1" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E72AA6D6364B28C7C786A088FCF37226" xlink:to="loc_gale_OtherWarrantIssuesMember_A55EE577803CAE308071A088FCF4271C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_B8E9237022143365F2CDA088FCF27B64" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_67FC802FB31B16CCCF54A088FCF4F254" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_AD16407468D7FD01743FA088FCF5FD60" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_gale_ClassofWarrantorRightGranted_886286D6E72E29FF1202A088FCF53657" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_04A8570B3E95B9701CE3A088FCF5F858" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightCanceledOrExpired" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_gale_ClassofWarrantorRightCanceledOrExpired_3D4E659EC214ACA63583A088FCF6E400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_1846DD4CD9A0AB5D6DEBA088FCF58150" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2F35DC36B3E8FEB30F69A088FCF6A960" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A6D04FC7F13EFF95DDF480681A30EA1A" xlink:type="locator" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A6D04FC7F13EFF95DDF480681A30EA1A" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTextBlock_A772857B2B0E189FC8FD80681A3019CB" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A6D04FC7F13EFF95DDF480681A30EA1A" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0F82C8133A68A588006D80681A3013A9" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A6D04FC7F13EFF95DDF480681A30EA1A" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_4AB1AB9413A809BD92F180681A314128" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_BEE40FBAEAE7B0EDAF4CA088FC541813" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_BEE40FBAEAE7B0EDAF4CA088FC541813" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6C0C8891C4BEE84412A8A088FC55DC2B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2AAFA453E00B366A664AA088FC55D8DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2AAFA453E00B366A664AA088FC55D8DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_5F7718E3F0367C5618C8A088FC565EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4D78510758A733320CB3A088FC568D2A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4D78510758A733320CB3A088FC568D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_3957CD4C01AB6CED24B5A088FC562A8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_105642382B032A3C9F28A088FC55D298" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_3957CD4C01AB6CED24B5A088FC562A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3FC6095AA422364DC3C8A088FC55ADFE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110936489E531A006FDBA088FC5611A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110936489E531A006FDBA088FC5611A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AAF968B17FEA4E57C788A088FC5CE968" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AAF968B17FEA4E57C788A088FC5CE968" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_B5B6B57E27D22B464614A088FC5C63C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_gale_ClassofWarrantorRightTerm_B5B6B57E27D22B464614A088FC5C63C0" xlink:type="arc" />
    <link:loc xlink:href="gale-20181231.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_4567B5EE892BAC5F6B38A088FC5CF435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_EBCC7BFFEAA5537F85A4A088FC5CFDDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23DBD44F70C5C6C7D288A088FC56D429" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_EBCC7BFFEAA5537F85A4A088FC5CFDDF" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gpsinamlincr2studyschemarevi.jpg
<TEXT>
begin 644 gpsinamlincr2studyschemarevi.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:"3AMNTC /.<'M6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTMVBS1G*2*&4X(R&&0<'GI7@L.B?:]):\!YMKIL@G@K(L2GMUSM[@8SU.*]
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M#C?O4$+QSM"GD$X)/(X!/KM>!>$2NNZLDK J))WEP#G!7=*!G'(R #P,CTH
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MG<$W$$;2"Y+E2#W7=C\.@Z4 ;U>'_$743XCU%;*(\(RPKN)V[RV&;&..3M.
M<A0>1BO8M;U1=*@DNFQB)&;!.W) X7/JQP![GH:\B^$.FMJ-ZUZY8^2K,6+
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M=P.%].,GKP,;NKO?@S9S+B-I$8)@$,&!8?QL".2>X4J/0"NZAA6%0B !5
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MBK1@<9_B(&>G?..:^@*\2^*/AEM$N1J$)(2=RP*[@4D&"?F]6.67D=P  N2
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MV-9_C/6WT2TDO(@I>/9@."5^9U4YP0>A]:Y?P_\ &2WNEVW8,3@<D NAZ=,
ML"3G@@@ ?>)H YKXA_#1=%0WMJ280?G5CDKN;"D'NO(&#EAP<G)QTOP;UZ2_
M@DM9"6^SE-I)S\K@X7IT7:<<G@X& !6?X_\ B;;WMN]G:%F:4 %P"B@9RPYP
MQ) P1C!#=>HJQ\$M,>&*:Z8825D"YSD^7NR>F,9;&0>H([4 >EU\_P#PM_Y"
M,'_;3_T4]?0%?/\ \+?^0C!_VT_]%/0!] 5Y_P#&O_CSC_Z^%_\ 0)*] KG/
M'_AUM>M'@C ,JD,F3CYE//MDJ2!GC)YQU !2^$]TLVGQHIR8VD5N#P2Y?'OP
MP/'KZUV%>&?#[QPWA>1K.X!$+.=WRX>-^%)QU(XPR]1C(YR&]#NOBQI\*EUD
M9R,?*D;ACSVWA1QUY(_.@#A/C7_Q^1_]>Z_^AR5[77@6DVTGCC43(P!5G#R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<$9Z'BM"B@#S_P#X4I9_WYO^^D_^-UN^'? %IH+"6)"95!&]R6;GVX4''&0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BLG_A++/_GXA_[_ "?_ !56['5H=0SY$B2;<9\MU;&<XS@G&<&@"W11
M5>]U&*P7?,ZHI. 78*,]<9)'/% %BBLG_A++/_GXA_[_ "?_ !5:<,RS*'0@
MJP!!!R"#R"".H- #Z*** "BLR;Q/:0L4>>(,I((,J @C@@@G@BI;+7+>_;9#
M+&[ 9(1U8XZ9P">.: +U%%0W5VEHIEE9408RSD*HR<#)/'6@":BLG_A++/\
MY^(?^_R?_%5H6MVEVHEB970YPR$,IP<'!''6@":BBB@ HK,F\3VD+%'GB#*2
M"#*@((X(()X(J6RURWOVV0RQNP&2$=6..F< GCF@"]1110 45F3>)[2%BCSQ
M!E)!!E0$$<$$$\$5=M;M+M1+$RNASAD(93@X."..M $U%,FF6%2[D!5!)).
M .223T K,_X2RS_Y^(?^_P G_P 50!K45D_\)99_\_$/_?Y/_BJTX9EF4.A!
M5@""#D$'D$$=0: 'T5F3>)[2%BCSQ!E)!!E0$$<$$$\$4^U\0VUVPBBFB=SG
M"I(C,<#)P <]* -"BBB@ HHIDTRPJ7<@*H)))P !R22>@% #Z*R?^$LL_P#G
MXA_[_)_\56G#,LRAT(*L 00<@@\@@CJ#0 ^BBJ][J,5@N^9U12< NP49ZXR2
M.>* +%%9D/B>TF8(D\19B  )4))/   /)-:= !152XU:&V=8))$61\;59U#'
M)P,*3DY/ ]ZMT %%%5+'5H=0SY$B2;<9\MU;&<XS@G&<&@"W14-U=I:*9965
M$&,LY"J,G R3QUK/_P"$LL_^?B'_ +_)_P#%4 :U%9/_  EEG_S\0_\ ?Y/_
M (JM:@ HJC9:Y;W[;(98W8#)".K''3. 3QS5Z@ HHIDTRPJ7<@*H)))P !R2
M2>@% #Z*J6.K0ZAGR)$DVXSY;JV,YQG!.,X-6Z "BH;J[2T4RRLJ(,99R%49
M.!DGCK3;+48K]=\+JZ@X)1@PSUQD$\\T 6**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "LGQ9_P >=S_U[S?^@-6M63XL_P"/.Y_Z]YO_ $!J /%? O@7
M_A*O-_>^7Y6S^#?G?N_VEQC;5CQ5\.KCPLOVQ) \:.N&0,KJ>H8@9"@,, [N
MI'<\='\#/^7K_MC_ .U*[7Q[J::?8SM(?OQM&HXR6D!4 9(SC.3WP"<<4 8_
MPI\52:W \,Q+20%1N/=6!VY.>6&TY.!D8)R<FN/^-DS&[C0D[1 "!G@$NX)Q
MZG S]!Z58^"%COFGN<_<C5,8Z^8V<YSVV>G.?;FI\:_^/R/_ *]U_P#0Y* +
M&G?!MK^W2Z2<!I8E<*8^,LH8*6#GCG&<>^.U85C?7?P_NRC#TWIGY)%YPP./
MKM;&0<@C[RUZKX>\5VEI9P"2>(&.WCW+YBE@509&T'.?;&<\8S7EOCK7%\67
MJ_9E)&%B3/&\[C@\XV@EL#/;DXZ  ]WM+I;M%FC.4D4,IP1D,,@X//2O&O'W
MCZ76I386A81!BG[LY:4GY?X<Y4YPJC.[.3G("^H7<;:)8,D;?/;6I"M@=8X^
M&P<CJ,XY_&O,O@OHXN;E[ML$0)@<G(:3(!P."-H8'/J..X +&F?!*69 \\RQ
MN?X53S,# ZG<HR#D'&1Z$UE>*_AO/X8 O(GWQI@EU_=LC;@%XW$]2,$$G.<@
M8!/NM,FA692C@%6!!!&00>""#U!H X+X5>-GUE6LK@[I8E!5CG<RYP<\8RI(
M&<Y;/3())\:_^/./_KX7_P! DKA_!1&A:LMNSG:LLD)(!&[[R*"!G@OM.#D
MX.>,UW'QK_X\X_\ KX7_ - DH Y3PM\*/[>MDO?/V>9N^7RMV-K%>N\>F>E8
MNK:/=^!ID(?:[+D/$6VD!N5.5 ." 2I!&",]:]:^%O\ R#H/^VG_ *->N?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_SU_P#')/\ XFCV-3L_N#VU/NOO.@HKG_\ A/;+_GK_ ..2?_$T?\)[9?\
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M)_\ $T?\)[9?\]?_ !R3_P")H]C4[/[@]M3[K[SH**Y__A/;+_GK_P".2?\
MQ-'_  GME_SU_P#')/\ XFCV-3L_N#VU/NOO.@HKG_\ A/;+_GK_ ..2?_$T
M?\)[9?\ /7_QR3_XFCV-3L_N#VU/NOO.@HKG_P#A/;+_ )Z_^.2?_$T?\)[9
M?\]?_')/_B:/8U.S^X/;4^Z^\Z"BN?\ ^$]LO^>O_CDG_P 31_PGME_SU_\
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MH/\ MI_Z->NKH Q/$-JMI83PQC"1VLBJ,DX"QD 9//2O/_@==*KW$)/SLL;
M8/1"P8YZ<%A^?UKU6[M5NT:&09212K#)&0PP1D<]*\"T#4Y/!%\?-!.PM'(%
M_B4]QN XX#+TW#'(!H ^@Z*Q+7QM8W2B1;B( Y^^X1N#CE7P1^(]^E<_XV^)
ML.FQF*T=9)W7Y63:Z+R!DG.,XS@<\@;A@\@'G^EV_P#:>L_NBI!O'D!SE2J.
M9"01G.0O'8\<XYKW6ZM$NU,4JJZ'&5<!E.#D9!XZUY+\&/#GGR/J3_=BRB?[
MS#YCP>RG'(P=W'(KL]3^)=MI5TUA.&78%S)C<N67=C RV,$ $ Y).0 ,D P?
M$?P8CG_>63>6W]R0ED[#AN6'<\[LGC@5R7A#Q-/X,N3:7 *Q%P)4;/RYP/,&
M,\@<\9#KC_9(]B_X2RS_ .?B'_O\G_Q5>)>--57Q1?$VR@ARD:'&PN>@8Y/4
MDX!./E"@@8H ]#^-?_'G'_U\+_Z!)7+_  \^'EOXDMVN)FD#+*5 0J!@*I[J
MW/S5U'QK_P"/./\ Z^%_] DJE\(M<M["T=)I8T8SL0'=5.-B#."1QQ0!H0_!
M>R1@Q:5@""077!QV.$!P?8@^AKO:R?\ A++/_GXA_P"_R?\ Q5:<,RS*'0@J
MP!!!R"#R"".H- 'B_P %/^/R3_KW;_T..O:Z\,^$6HQ6%V[S.J*8& +L%&=Z
M'&21SQ7K%UXVL;53(UQ$0,?<<.W)QPJ9)_ >_2@#*^+%TL.GR(QP9&C5>#R0
MX?'MPI//IZUG_!3_ (\Y/^OAO_0(ZXKXA>,SXIE6VMPQB1L(!G=(S<;MOZ*,
M;N3_ 'L#UKP=X>_X1^U2U)4N,EV48!9CGZG PH)Y( X'0 &W534]*BU1##.B
MNA[,,X.",@]0<$X(P1V-6ZX31/B_:7[F*4-#EB%9^5(R N2/NDYYS\H ^_0!
MS_B7X,&%?,L69R,9CD*ACR<D/\HXXX('<YS@52^&/CN6TF33YV+0RD*I8DE&
MQA .ORGA<=!P1CG/IMUXVL;53(UQ$0,?<<.W)QPJ9)_ >_2O'?#L+:_JHFA!
MVFY,QW#H@??SC.#V]-Q SS0 [XL6K0ZA([# D6-EY'("!,^W*D<^GI7O$,RS
M*'0@JP!!!R"#R"".H->9?&O0C(L6H(/N91R,DX)RAQT !W#/'+ <\8?\./B/
M%Y26%VP1XP0CL J;% VJ6SPPY'( ( Y+'D ]-HK$NO&UC:J9&N(B!C[CAVY.
M.%3)/X#WZ5E>%/B,GB2X>UBC946,N&=AN."H(*@$#EO[QZ>_ !Y?\4O^0C/_
M -L__125Z!_PI2S_ +\W_?2?_&Z\_P#BE_R$9_\ MG_Z*2OH"@#S+7/A%:6%
MO-<(\I:*)V +)C*J2,X0<<57^!G_ "]?]L?_ &I7?^+/^/.Y_P"O>;_T!JX#
MX&?\O7_;'_VI0 ?'/_EU_P"VW_M.H?!GPOMM;M([R5Y0\F_(1D"_*[*,90GH
M/6IOCG_RZ_\ ;;_VG6U\./$-M:6$,4LT2./,RKR(K#,C$9!.>E #].^$5I82
MI<(\I:)U8 LF,J01G"#CBNB\6?\ 'G<_]>\W_H#4?\)99_\ /Q#_ -_D_P#B
MJ;XGF6:QN'0@JUM*00<@@QD@@CJ#0!P7P,_Y>O\ MC_[4KE[V%O!>J;P"L<<
MNY=HW9B<\@;^IV$KG/W@><C-=1\#/^7K_MC_ .U*L?&K01)''J*@[D/EO@$_
M*<E23G  ;(Z<EASP!0!I?%;Q(MK9"*-LM=X"E&.-@PS,",@@@A<9&0W< U7^
M#?A];6W-^<%YR0#Z(A(QTR"6!)Y(("]Q7F5O)+XGFMK1NJJD*E5R0@8G<0,9
MV@G/3@<\Y-?15I:K:(L,8PD:A5&2<!1@#)YZ4 >-?!3_ (_)/^O=O_0XZ]&^
M(FNG1K*21#MD?"(><Y;J05Q@A0Q!SU ^A\Y^"G_'Y)_U[M_Z''5CXT:\+B9+
M!"<0C<_)QN<#:,8QE5Y!Y^\1QS0!C_#GQ7;^&WDFG1V=U55,8!P,DL""RCDA
M?7IV[WOB+XXM?$T4:Q)()8W)!<*!M8?,/E<\DA>W;KZ]KHGPJLT@C%Q$3-L4
MN3(_WB,L/D8+@'@8[#J>IMS?"K3G4J(BI((!$DF1GN,L1D>X(]10!F?!K6_M
M=JUF1S;-P0."LA9AWZYW=@,8ZG->@5X5\/KH^'M3^S2%?F9X&(!(SNP,=#RZ
M@9(Z'G'4>ZT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_A#_ )>?^OR;
M_P!EKH*Y_P (?\O/_7Y-_P"RUT%75^-D4O@04445!84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_\ \Q+_
M +<__:M=!7/_ /,2_P"W/_VK5T^OH14Z>IT%%%%06%%%% !1110 4444 %%%
M% !1110 54U:Q_M"&2VSM\V-TSC.-RD9QD9QGUJW10!RG@7P+_PBOF_O?,\W
M9_!LQLW?[39SNKJZ** "N*\:_#?_ (2>9;GSO+VQA,>7NZ,QSG<O][TKM:*
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M7BSX80>()&N@[1S.%!(PR';@9*G!SM&.& X!QUSV=% 'E7_"C/\ IY_\@_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_^8E_VY_\ M6N@KG_^8E_V
MY_\ M6KI]?0BIT]3H****@L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEB ,?Q=M\-_^/"'_ +:?^C&J9Q<:*OW'%IS?H<!H5A'+J[0,BF/SK@;"H*X
M? VXQ@8X]*])UC5;?PE$)/+VHT@&V%%'S$$YQE1T7KUZ5YC::JFE:L]S+D(M
MQ."0,XW%USCT&<GOCH">*]2L+^V\3QLRJ)8TDQ^\3(+!0<@,,\!L9(!Z]N2Z
M][Q;VL*GLUU.>_X6]:?W)?\ OE/_ (NNA\3>&8O$$7DR<,,E' Y4_P!0>X[^
MQ (E_P"$8M/^>$7_ 'Z3_"LKQ/XY'AZ9(98F:-TSO4]\D;0" "1QGYA@'\\M
M')<BU+V7O'FFJ^$;WPT?M)R%0@"6)^FX8[88#G&2 ,\=QGN/A[X[;5R;2Y(,
MH!*OPNX#JN!CYAU&!RH.<8R;-]\3;%H68$NS)_JBC#.1C:205QSSR1C.,]#Q
MWPJTEKJZ^TCA8%)/3DN"H'7/3)S@],=Q6\KSIMR5FC->[)69['1117&;A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7/_ /,2_P"W/_VK705S_P#S
M$O\ MS_]JU=/KZ$5.GJ=!1114%A1110 4444 %%%% !1110 4444 %%%<H_Q
M"3?)%';W,GE2-&S10AUW(<$9#?\ U\8XH ZNBN4_X3[_ *<[S_P'_P#LJ/\
MA/O^G.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P'_\ LJ .
MKHKE/^$^_P"G.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'
M_P#LJ/\ A/O^G.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P
M'_\ LJ .KHKE/^$^_P"G.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_
M *<[S_P'_P#LJ/\ A/O^G.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$
M^_Z<[S_P'_\ LJ .KHKE/^$^_P"G.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZN
MBN4_X3[_ *<[S_P'_P#LJ/\ A/O^G.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_
M .RH_P"$^_Z<[S_P'_\ LJ .KHKE/^$^_P"G.\_\!_\ [*C_ (3[_ISO/_ ?
M_P"RH ZNBN4_X3[_ *<[S_P'_P#LJ/\ A/O^G.\_\!__ +*@#JZ*Y3_A/O\
MISO/_ ?_ .RH_P"$^_Z<[S_P'_\ LJ .KHKE/^$^_P"G.\_\!_\ [*C_ (3[
M_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'_P#LJ/\ A/O^G.\_\!__ +*@#JZ*
MY3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P'_\ LJ .KHKE/^$^_P"G.\_\!_\
M[*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'_P#LJ/\ A/O^G.\_\!__
M +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P'_\ LJ .KHKE/^$^_P"G
M.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'_P#LJ/\ A/O^
MG.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P'_\ LJ .KHKE
M/^$^_P"G.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'_P#L
MJ/\ A/O^G.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P'_\
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M_P"G.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'_P#LJ/\
MA/O^G.\_\!__ +*@#JZ*Y3_A/O\ ISO/_ ?_ .RH_P"$^_Z<[S_P'_\ LJ .
MKHKE/^$^_P"G.\_\!_\ [*C_ (3[_ISO/_ ?_P"RH ZNBN4_X3[_ *<[S_P'
M_P#LJU?#OB)->1I8U=/+D:-EE4*P90"1@$^OUSGB@#6HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .?\(?\ +S_U^3?^RUT%<_X0_P"7G_K\F_\
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M4G Y)R3W-6J*;G)[L2BD>/:'$)=9=& *M-<@@C((*R @@]J[O_A6]A_SQ_\
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M&W7:I8L1EFY( SEB3T J]13<Y-6OH%E>X51U;0X-77R[A X'3/!'()PPP1G
MS@C/0U>HI)M:CW.9_P"%;V'_ #Q_\B2?_%5OV-BE@BP1*%1!@ ?YZ^IZD\GF
MIZ*;G*6[$HI!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,MK [$EFAC)).224!))/>M&I:L[#04444@"BBL7QCK9T:UDN%(#XVID@?,W
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MKI:XO:/EOYG6W/Q=MHW"(CLF6#-P.GW2JD\@^^T@=B>*U[CQ_:0VZWNXE7.
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MF?VA)Y/^M^UMLZ?>\P[>O'7UX]:M^*]6U)1]EOBP4D'&U K8P?O( & R,C)
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MA)<,)2,Q[][-@'*'>3E03R, \$,,YQ4OCC33-IUG<C.(HT! &>)(U^8GL 5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ<FI:?%;R#*R6T8/3(R@P1D$9!Y![$ UY5X,U$^'[X+*=HW-%)]W R<<DG
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MG_Q5;&DZ'!I"^7;H$!ZXY)Y)&6.2<9.,DXZ"G*5*SLG<$IWU/'/^8M_V_?\
MM:O1OB3HHU&T:0#+P?.IX!P/O\GMMR<#J0.O2K__  A-GYOVOR_WOF;]V]_O
M9W9QNQU[8Q6Y3G63<6N@HT[)I]3R_P"$.M"-I+%C]_#H. ,@8?GJ21@XYX4G
MCOSFAE/#UZ8;U%9%+(^Y-X'HZA@.. <XR5)P,D5ZOIO@FSTR07$,>UUS@[W/
M4$'@L1T-6=8\-6^L8^T1AB,8/*MQGC<I!QR>,XSSBJ]O'F;ULQ>S=EW1S/\
MPD.B_P!V+_P&/_QNNF\-WT5];I-;ILB;=M7:%QAB#PN0,D$UF?\ "M[#_GC_
M .1)/_BJZ&VM4M5$<:A5'15 4#)R>!QUK*I*#6E_F5%2OK8\F^$/_'V__7!O
M_0TKI?B]_P >B?\ 7=?_ $!ZZ'1_"5KH[F:WCVL5*D[G;@D'&&8CJ!5K6-$A
MUA!#<+N4,& RR\@$9RI!Z$U<JT754N@E!J%C'^&__'A#_P!M/_1C5YI_S%O^
MW[_VM7L^FZ;'ID8MX1M1<X&2>I)/))/4UF_\(39^;]K\O][YF_=O?[V=V<;L
M=>V,40K1C*3[A*#:2['/?$_Q:VGK_9\8^::/+,<8",2N /4X.3V'3DY'$^#=
M4M-)?[3<J[R*?D"JI4?[7+#+>G&!UY.-OK>L>$K76'$UQ'N8*%!W.O ).,*P
M'4FJ/_"M[#_GC_Y$D_\ BJJ%:G&'+KYBE"3E<;H/Q$MM:E%K&'5V!(WJ,' R
M1\K-SC)YXXZYQGB?B]_Q]I_UP7_T-Z]"TWP39Z9(+B&/:ZYP=[GJ"#P6(Z&O
M/?B]_P ?:?\ 7!?_ $-Z=#E]K[NUA5+\FIT=G\6(&M_-E!%PHQY:@X8^H;!
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MC Z 42JQG.[O;I8%!Q6AX_XGM[62<+IV61U7Y0')WDD;0&&XYX/?D\>@]/\
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M*/6MRBASD[Z[ARHY36OAM:ZK*;AMZ,WWA&5 )[M@J>3WQUZ]228)?A5:.BQ
MN-A8E@5W-NQU)4\#'   '/<DUV5%4JLUU%R1[%$:+$T L7&^(1JF&ZD* !R,
M<\9R,8/(Q7+R_"2T<E@TJ@DG 9<#V&4)P/<D^]=M12C4E'9C<4S%\->$X?#H
M=8=Q,A!)<@GCH. !@9/;//)Z8VJ**F4G)W8))!7+_$C2CJ%DY&2T)$@ ('W<
MALY[!23ZY ^AZBBG&7*TP:NK'&_"O4A<V8AX#0NP(SDX8[PV.P.2!ZX/T$<O
MPDM')8-*H))P&7 ]AE"<#W)/O71Z+X;M]%W?9TV;\;OF9L[<X^\3ZFM.KE5:
MDW'2Y*AHDSGO#W@6VT)O-C!:3G#R') ( (&  /KC/)&<'%7/$7AJ'7T$4P/R
MG*LN R^N"0>#W!!'X@$:M%1SR;O?4KE5K'$Q?"2T0ABTK $'!9<'V.$!P?8@
M^]=C]E39Y.T;-NW;@;=N,;<=,8XQTQ4M%$JDI;L%%+8XF7X26CDL&E4$DX#+
M@>PRA.![DGWKH?#OAJ'0$,4(/S'+,V"S>F2 .!V  'XDDZM%.56<E9L2@D%>
M:?&;_EW_ .VO_M.O2ZSM9\/P:R EP@<*<CD@C/7E2#@]QT/'H**4U":;"<>:
M-CD_#/PVM7C@O'WN6C1RC%2A+*#T"@D GIGV.1FK=]\*K2Z=I073<<[4*A1]
M 5.![9P.V!Q76VMLMJBPH,*BA5')P%& ,GGI4M-UIWO<%3C;8YNS\"06ET=2
M5G\PN[8)7;F3(/&W./FXYKC/%['Q'J:6"DE$*H=KC_>E89X# <$<G*^O%>KU
M5@TN*W<S)&BNV=S*H#')R<D#)R>3[TX5FG=ZNUD*4+JQ:K*\1>&H=?013 _*
M<JRX#+ZX)!X/<$$?B 1JT5FFT[HMJYQMI\*K2W+$EVW(RC>5.-PQN&%'S#MG
M(!YQD#&MX9\(1>'=_DLY\S;G>0?NYQC"CUK<HJG5G)6;)4$CE];^'-IJSF=@
MR.Q)8QD#<3CD@AAGZ 9)).33-%^&UKI4HN%WNR_=$A4@'LV HY';/3KU (ZN
MBCVL[6N')&][&5XB\-0Z^@BF!^4Y5EP&7UP2#P>X((_$ C MOA-9PL&8R.!_
M"S  \?[*J??@BNTHHC4G%63!Q3=RCJ&AP:A$+65 8QC"CY0-O3&W!&!QQCCC
MI7*?\*AM/[\O_?2?_$5W-%$:DH[,'%,RM#T.'PY"8HR0@+.S.P].23P   .P
M&!ZY->>_#NW.L7\NH$$*I=\ @X:4D!3QDC!;D <@?0^I75LMTC0N,JZE6'(R
M&&",CGI5;1]$AT=##;KM4L6(RS<D 9RQ)Z 54:MHR[L3A=KLB]1116184444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<__P Q
M+_MS_P#:M=!7/_\ ,2_[<_\ VK5T^OH14Z>IT%%%%06%%%% !1110 4444 %
M%%% !1110 5RG@#_ )?/^PA<?^RUU=<IX _Y?/\ L(7'_LM '5T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<IX _Y?/\
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MBB@ HJ"\OX[(;Y75%)QEV"C/7&21SQ4D4HE =2"K $$'((/((([46 ?1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%>[[/NKD-Z\WF2_$]FU*]AL48?=4 '&%>5L') )&0%./3D#GG:^+,0BLXT4
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MO_BI/87,D+1HT<<DBX&Y6(4D#YLL,^OR_E6?\(?^/M_^N#?^AI3-"B$NM,&
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MG3@FJRV^0I-.#/0=+O?MT4=QC'F1JV,YQN .,\9QFK59GAC_ (]+?_KA%_Z
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M+MZ?>Q\_OTV]>/3O7=WEA'>C9*BNH.<.H89Z9P0>>:DBB$0"* %4   8  X
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MY9XSU8>+KN*VM"60 *I*D#<QRS=-VT #.1QM) QR?7HHA$ B@!5   &  .
M!VI5=*<$]QPUDV>;_&;_ )=_^VO_ +3KN/#'_'I;_P#7"+_T 5P_QF_Y=_\
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M,'.2 ,=3VHJV4HPZ((7:<NYYIX2\+MXQDEN[IWP&&2 ,L2#P&/ VX'&#@$#
MXK#\4:%+H<OV65MP5<H<\%"21@9^7G.1ZYZYR>E^&WC.'1TDMK@[5+;U;:S<
MD ,#MR>@&./7)Z5C>/?$2:[<^;$#L1 @)_BP2=V.P.>!UQR<$X'1%S]HU]DS
M?+RWZG<?%/Q(^G)';0L5>0EF*-A@J]!QR Q[@C[I'()JCI/PECG@6261Q*Z
MX"A0I90=I4Y)(/7E<].*B^,.E$&*]&<$&-N1@8RR\=<G+9[<#IWZ/3OB);2V
MPNI7 =5^>,</N&,A5)R03T.<8ZD8.,4Y1IQY?F::.3N<Q\+];F@DDTUR,!'*
M)(2I#J1E <$@'DL,'&"0.N<+P]%;:_+(^HS,LCD%6R%!X.[)*E0   !P.P["
MM7X?*;JYFUB=<1QK*Y<9VJ[<M@9).%+<<X!&>2*V-:T[2=:1[H2I&[;F+*V&
M) (YB;DY/) 4,QZ'GFY249O?6VJ[D)-Q1TWAG1(O#\+".3="S&0,Q& I1<G<
M, CY<YX&#[9/F-@4\77;SWLHBB .-TB*0,_)&N[' ZDA3TYP6S6_\+&;4H+F
MQD8^5M  &,KYH<-@D'&<9QTSSCDYYOPG;6D,\EKJ2@$':"78!75MI4[#C!S]
MXG V]>:4(\KGU8V[J/8??2Q^$KQ);*7S8]JDX=3D$X:,LN0<XSTXR#C(!KN/
MB7X=N-:2(6XW!&;<NX+U VM\Q .,$=<C/'4U6?1=$5TA&QFE8*H261^20 "5
M8@<GOC]#70^)O%\7AW9YRN?,W8V '[N,YRP]:F4VY1:3OY]2E%).^QH:/9FR
M@B@;!:.-%..F54 XSCCBFZ[J/]FP2W&0#'&Q&[H6 ^4=1U.!CJ<X%3V%X+V-
M)UR%D16&>N& (SC//-9WB_3O[1M)H<$DQD@+R2R?,HQ@YR0!CJ>U<ZUEKW-'
MMH>:>$O"[>,9);NZ=\!AD@#+$@\!CP-N!Q@X! P.*P_%&A2Z'+]EE;<%7*'/
M!0DD8&?EYSD>N>N<GI?AMXSAT=)+:X.U2V]6VLW) # [<GH!CCUR>E8WCWQ$
MFNW/FQ [$0("?XL$G=CL#G@=<<G!.!W1<_:-?9.=\O+?J>O:SXIMM&(2XD"L
MPR!AF..F<*#@>F>O..AHT;Q3;:R2EO(&91DC#*<=,X8#(]<=.,]13-8\)6NL
M.)KB/<P4*#N=> 2<85@.I-&C^$K71W,UO'M8J5)W.W!(.,,Q'4"N+]WR];_@
M;^]?I8O:GJ*:;$]Q(<+&I)Z9..@&2!DG@#N2!7DG@[3SXBU W>"J+(9FP<X)
M;<JYQC.?IE0V.:@\2>+#XHG6-W\FV5N,@MC_ &V"Y)8CH.@SC/5CW&B^+M+T
M:(6\,F%'4F.3)/=B=G)/_P!88  K=0E2@]+M_@9N2G+R1VE8_BRY@@MI/M1_
M=LI7 P6)/0*#QNSR/0C)P 36Q7FWQEB)%N^#M!D!.. 3L(&?4X./H?2L:,>:
M:1I-VBV>>V>KRV:201L528 .!CD#.!GJ!R<X/(.#D5ZAI%G;^$;)M2AQ<,P7
MY_N9#.%VC[VT#/(ZEAST &>E]INL:>EO*XB>"-1G;AU<\$A1]\,1E@,\'+;3
M@CS^YNC$'M$<M!YFX<8!*Y4/@\@D'D?3.<#'8U[73;77S,$^3S/>/#>M?VU;
MI=[=F_=\N=V-K%>N!Z>E:$LHB!=B J@DDG  ')))[5SW@74;:>W6WM6+>2B[
MLJRD%\DDYR,DY. 2!T!QBMV_LQ>QO V0LB,IQUPP(.,YYYKAFDI-;'1%W1X]
MHFGR^.[IY+AR J@DJN0!N $8R<+D$XSGH203DU4\:>%W\/.(MQ:!RS1Y/T#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*-:459#<$W<X3P)X$G\/SM/*R%6C*_(6)R64]U''%&E>!)[34#J3,GEF25L
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M9700/$,1H%7#.N "3V89.222>23R:WZ*KVDN[%RKL%%%%2,YG_A6]A_SQ_\
M(DG_ ,51_P *WL/^>/\ Y$D_^*KIJ*OVL^[)Y(]@J*YM4NE,<BAE/56 8'!R
M.#QUJ6BH*.9_X5O8?\\?_(DG_P 56G9>&;:RC-ND2;&QN!7=NP<C<6R6P3QG
M..U:=%4ZDGNV)12Z&9HOANWT7=]G39OQN^9FSMSC[Q/J:TZ**3;;NQI6,75?
M!MIJK^?-&&<@ D,RYQTSM(R?<\XP.@%12^!+*5%@,0V1EBH#..7QN)(;))P.
MI.  !Q6_13]I)=6+E78@BL4BC%L%'EA FT\C:!C!SG(QQSUK _X5O8?\\?\
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MQ+_MS_\ :M=!7/\ _,2_[<__ &K5T^OH14Z>IT%%%%06%%%% !1110 4444
M%%%% !1110 5RG@#_E\_["%Q_P"RUU=<IX _Y?/^PA<?^RT =71110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7*> /^7S_L(7'_ ++75URG@#_E\_["%Q_[+0!U=%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7/_P#,2_[<_P#VK705S_\
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M!8WR7Z+/$P9'&01_GKZCJ#P>:GJ"C#\3>+X/#Z_O#F0J2L8ZGG')Z*,]SZ'
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M1110 4444 %%%% !1110 4444 %<IX _Y?/^PA<?^RUU=<IX _Y?/^PA<?\
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M^'8I?%.H_;,$*LBR,< A0G*+GY<D[0H[GEL'!K2\[SYOA)]W2VY[+1117 =
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MDOB3_P >Z?\ 74?^@M7._#S_ (^?^ -_,5T7Q)_X]T_ZZC_T%JYWX>?\?/\
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MY_\ M6N@KG_^8E_VY_\ M6KI]?0BIT]3H****@L**** "BBB@ HHHH ****
M"BBB@ KE/ '_ "^?]A"X_P#9:ZNN4\ ?\OG_ &$+C_V6@#JZ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Y3P!_P OG_80N/\ V6NKKE/ '_+Y_P!A"X_]EH ZNBBB@ HHHH ****
M"BBJ]_=?9(WFQGRT9L9QG:"<9H;L.,7)I+=GE?C34?MMTYYQ&=@R ,;>#T_V
MLD?7\*]1TBR^PPQP<91%!V],XY/;J<GWKRWPK:MJ%W&222'WLV"WW3NR3[GC
M)[FO7:Y,(N9RGW/?X@DJ4*.&7V5=_DOU"BBBNL^?"BBB@ HHHH Y_P (?\O/
M_7Y-_P"RUT%<_P"$/^7G_K\F_P#9:Z"KJ_&R*7P(****@L**** "BBB@ K!\
M<_\ 'G)_P#_T-:WJP?'/_'G)_P  _P#0UK2A_%AZK\S.O_"EZ/\ (X#PC_Q]
M1?4_^@FO7:\B\(_\?47U/_H)KUVNK,OXB]/\SERW^&_7_(*\B\7?\?4OU'_H
M(KUVO(O%W_'U+]1_Z"*,M_B/T_R#,OX:]?\ ,])\,?\ 'M%_N+_*M2LOPQ_Q
M[1?[B_RK4KDJ?&_4ZZ?P+T.2^)/_ ![I_P!=1_Z"U<[\//\ CY_X W\Q71?$
MG_CW3_KJ/_06KG?AY_Q\_P# &_F*[Z/^Z2^9P5O][C\CT^D-+2&O-/2/"Z]O
MM/N+]!7B%>WVGW%^@KTLS^Q\_P!#S<L^W\OU)JX#XF_?B_W6_F*[^N ^)OWX
MO]UOYBN; _QH_/\ (Z<=_!E\OS$^&7WY?HO]:] KS_X9??E^B_UKT"C'?QI?
M+\@P/\&/S_,BNON-_NG^5>'U[A=?<;_=/\J\/KIRS[?R_4YLS^Q\_P!#V^T^
MXOT%35#:?<7Z"IJ\UGI(**** .<\??\ 'JWU7_T(5R?P\_X^?^ -_,5UGC[_
M (]6^J_^A"N3^'G_ !\_\ ;^8KT*'^ZS^?Z'GU_]ZA\OU/3Z***\\] ****
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MO][E\SL:***\T](**** ,_7_ /CVF_ZY2?\ H)KR32O]='_UT3_T(5ZWK_\
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M#XA_\?/_  !?YFNO+_XWR.3,/X7S.B^&W_'N_P#UU/\ Z"M=;7)?#;_CW?\
MZZG_ -!6NMK/%?QI>IIA?X,?0****P-PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N?_YB7_;G_P"U:Z"N?_YB7_;G_P"U:NGU]"*G3U.@HHHJ
M"PHHHH **** "BBB@ HHHH **** "N4\ ?\ +Y_V$+C_ -EKJZY3P!_R^?\
M80N/_9: .KHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M36+V2S7?''YF.H!P?R[UYBBV['IN22N>,U[?:?<7Z"O$*]>\.ZE)?(&>,HH
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MF>L45%:P>0H0DL1W;DFI:\QGIA1110 4444 %%%% !1110 5YA\0_P#CY_X
MO\S7IDL0E!4]#^%>9^*_"\MBWFY:1#QDY+#T!KLP#BJEVSCQZDZ=DCHOAM_Q
M[O\ ]=3_ .@K76UR'A#PH]F/-F)!SD(#QVY..I]JZ^LL4XNK)IW-<*I*E%-6
M"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_P#F)?\
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MW/1Z*P_&VI2:99R7$)VNNS!P#U=0>"".AKS_ $[QUJ6L!;2W :8%F+A4R5[
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MDN0,N9/,&#_#%E""#QP"YXY/')Z5T4(Q4>:2W=C*HVW9'IOA[51JUO'=<9=
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MRE>N#QSD'D$=.#FML-!2N[7:V1%635CH8O'.IZ21+=(QC) Q+%Y8]>&"K\V
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M+^ZM[?/V5!T_@63(RJ^G?@>E=V3B@"&ZO$M%WRLJ+G&6(4?F:DBE$H#J058
M@@Y!!Z$&O.O%D[Z_#<7!7_1;97$>?XY =ID]U R!]<UV7A/_ (\[;_KWA_\
M0%H U:IOK,$;>694#>A=<_EFL;X@:Z^D6I:+_62,$4^A;O\ A_.L -I5O&8A
M TD8&#,(2X^OF8S^(H ]$IKN$&2< =S5'0;=;>!$20RJ%X=B"2.W(KF?B5 [
M?9Y2K/;1NQG5#U'RX)'<#F@#J[;5X;H[8Y$8CLKJ3^0-6Z\T\07UCJL8@TY
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M/_1;5[C7CG@#0KBUO8I)(9%4;\LT;*!F-@.2,=:Z*#2A/T_S,JGQ1-CXS?\
M+O\ ]M?_ &G7;>%(A%:6X4 #R8SP,<E02?J2<GU-<E\6=+EOO(\F-WV^;G8I
M;&=F,X!QG%=CX=B,5K C AEAC!!&""$ ((/>E-_N8H<?C9YEX>_Y#3?]=[G^
M4E'Q>_X^T_ZX+_Z&]7-"T>>+5VG:)Q'YUP=Y1@N"'P=V,8.>/6MSXC>"WUL)
M<VX!E0;2I.-RYR,$G *DD]L@GG@ Z\\55B_(CE;@_4QXHM=B 10 J@  "V
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M!!X((/:K7PW\'W.CSO/<*$4QE1\RL22RG^$G@;><XZC&><58O&FK( IMBQ
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M$$8((0 @@]Z\V^**#[9&T#DSE5!12Q96!RF.3@MGA1@@C=U;-9T'^]?S*J?
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M;RX<D),8]AV-SM#9[>]6O&S?VJ+6[17EM$=S*J Y(^7:2O!(!!_R:[O8/2E
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M?5/E/ZCCVKII0E##V;O[WZ'%F&)I8C%\T(*"Y4K*W=ZZ&M1114F)Y_\ &O\
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MN0V!GY2A7KUP2>#QR?6N^K@?B;']I>W@3!=BX"Y&?F*!>O3)!Y/'!]*WPO\
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MY_V$+C_V6@#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P 57044>VJ=W]X>QI]E]QS_ /P@5E_SR_\ 'Y/_ (JC_A K+_GE_P"/R?\
MQ5=!11[:IW?WA[&GV7W'/_\ "!67_/+_ ,?D_P#BJ/\ A K+_GE_X_)_\570
M44>VJ=W]X>QI]E]QS_\ P@5E_P \O_'Y/_BJ/^$"LO\ GE_X_)_\57044>VJ
M=W]X>QI]E]QS_P#P@5E_SR_\?D_^*H_X0*R_YY?^/R?_ !5=!11[:IW?WA[&
MGV7W'/\ _"!67_/+_P ?D_\ BJ/^$"LO^>7_ (_)_P#%5T%%'MJG=_>'L:?9
M?<<__P (%9?\\O\ Q^3_ .*H_P"$"LO^>7_C\G_Q5=!11[:IW?WA[&GV7W'/
M_P#"!67_ #R_\?D_^*H_X0*R_P">7_C\G_Q5=!11[:IW?WA[&GV7W'/_ /"!
M67_/+_Q^3_XJC_A K+_GE_X_)_\ %5T%%'MJG=_>'L:?9?<<_P#\(%9?\\O_
M !^3_P"*H_X0*R_YY?\ C\G_ ,57044>VJ=W]X>QI]E]QS__  @5E_SR_P#'
MY/\ XJC_ (0*R_YY?^/R?_%5T%%'MJG=_>'L:?9?<<__ ,(%9?\ /+_Q^3_X
MJC_A K+_ )Y?^/R?_%5T%%'MJG=_>'L:?9?<<_\ \(%9?\\O_'Y/_BJ/^$"L
MO^>7_C\G_P 57044>VJ=W]X>QI]E]QS_ /P@5E_SR_\ 'Y/_ (JC_A K+_GE
M_P"/R?\ Q5=!11[:IW?WA[&GV7W'/_\ "!67_/+_ ,?D_P#BJ/\ A K+_GE_
MX_)_\57044>VJ=W]X>QI]E]QS_\ P@5E_P \O_'Y/_BJ/^$"LO\ GE_X_)_\
M57044>VJ=W]X>QI]E]QS_P#P@5E_SR_\?D_^*H_X0*R_YY?^/R?_ !5=!11[
M:IW?WA[&GV7W'/\ _"!67_/+_P ?D_\ BJ/^$"LO^>7_ (_)_P#%5T%%'MJG
M=_>'L:?9?<<__P (%9?\\O\ Q^3_ .*H_P"$"LO^>7_C\G_Q5=!11[:IW?WA
M[&GV7W'/_P#"!67_ #R_\?D_^*H_X0*R_P">7_C\G_Q5=!11[:IW?WA[&GV7
MW'/_ /"!67_/+_Q^3_XJC_A K+_GE_X_)_\ %5T%%'MJG=_>'L:?9?<<_P#\
M(%9?\\O_ !^3_P"*H_X0*R_YY?\ C\G_ ,57044>VJ=W]X>QI]E]QS__  @5
ME_SR_P#'Y/\ XJC_ (0*R_YY?^/R?_%5T%%'MJG=_>'L:?9?<<__ ,(%9?\
M/+_Q^3_XJC_A K+_ )Y?^/R?_%5T%%'MJG=_>'L:?9?<<_\ \(%9?\\O_'Y/
M_BJ/^$"LO^>7_C\G_P 57044>VJ=W]X>QI]E]QS_ /P@5E_SR_\ 'Y/_ (JC
M_A K+_GE_P"/R?\ Q5=!11[:IW?WA[&GV7W'/_\ "!67_/+_ ,?D_P#BJ/\
MA K+_GE_X_)_\57044>VJ=W]X>QI]E]QS_\ P@5E_P \O_'Y/_BJ/^$"LO\
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M?\\O_'Y/_BJ/^$"LO^>7_C\G_P 57044>VJ=W]X>QI]E]QS_ /P@5E_SR_\
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M7_C\G_Q5=!11[:IW?WA[&GV7W'/_ /"!67_/+_Q^3_XJC_A K+_GE_X_)_\
M%5T%%'MJG=_>'L:?9?<<_P#\(%9?\\O_ !^3_P"*H_X0*R_YY?\ C\G_ ,57
M044>VJ=W]X>QI]E]QS__  @5E_SR_P#'Y/\ XJKFE^&;?2V,L*;6(P3N8\$@
M]R?2M2BAU9M6;8*E!.Z2"BBBH+"BBB@ HHHH **** "BBB@ HHHH *Y3P!_R
M^?\ 80N/_9:ZNN4\ ?\ +Y_V$+C_ -EH ZNBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI]>W7[O K:=-5%SP^:[&,*C@^2?R?<[2BBBN<Z HHHH *;)((@78@  DDG
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M61)2;T*][XXABLSJ46'&5 0L$;<2,J>N& R<<Y R..:CDUZ?5M/^V6BE9Y"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N4\ ?\ +Y_V$+C_ -EKJZY3P!_R^?\ 80N/_9: .KHHHH X;Q]X!;6F%W;D
M"4+AE. &P#@@X^]VYX(QR,<X/AKX5RRN)+T!(U/*!@6;&,#*Y 4]SG=Q@ 9!
M'J]%:QQ$U'E(=.+=PHHHK(L**** "HI[I+?&]@NY@J[B!ECT49ZD]AUJ6L#Q
MIX:/B& 0*P5E?>,C()"L #CH#GKSCT-.*3>HG>Q:E\*6DH*&"+!!'$:@\^A
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M@HKG_P#A$/\ IYN?^_W_ -C1_P (A_T\W/\ W^_^QHY8=_P#FGV_$Z"BN?\
M^$0_Z>;G_O\ ?_8T?\(A_P!/-S_W^_\ L:.6'?\  .:?;\3H**Y__A$/^GFY
M_P"_W_V-'_"(?]/-S_W^_P#L:.6'?\ YI]OQ.@HKG_\ A$/^GFY_[_?_ &-'
M_"(?]/-S_P!_O_L:.6'?\ YI]OQ.@HKG_P#A$/\ IYN?^_W_ -C1_P (A_T\
MW/\ W^_^QHY8=_P#FGV_$Z"BN?\ ^$0_Z>;G_O\ ?_8T?\(A_P!/-S_W^_\
ML:.6'?\  .:?;\3H**Y__A$/^GFY_P"_W_V-'_"(?]/-S_W^_P#L:.6'?\ Y
MI]OQ.@HKG_\ A$/^GFY_[_?_ &-'_"(?]/-S_P!_O_L:.6'?\ YI]OQ.@HKG
M_P#A$/\ IYN?^_W_ -C1_P (A_T\W/\ W^_^QHY8=_P#FGV_$Z"BN?\ ^$0_
MZ>;G_O\ ?_8T?\(A_P!/-S_W^_\ L:.6'?\  .:?;\3H**Y__A$/^GFY_P"_
MW_V-'_"(?]/-S_W^_P#L:.6'?\ YI]OQ.@HKG_\ A$/^GFY_[_?_ &-'_"(?
M]/-S_P!_O_L:.6'?\ YI]OQ.@HKG_P#A$/\ IYN?^_W_ -C1_P (A_T\W/\
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MQHY8=_P#FGV_$Z"BN?\ ^$0_Z>;G_O\ ?_8T?\(A_P!/-S_W^_\ L:.6'?\
M .:?;\3H**Y__A$/^GFY_P"_W_V-'_"(?]/-S_W^_P#L:.6'?\ YI]OQ.@HK
MG_\ A$/^GFY_[_?_ &-'_"(?]/-S_P!_O_L:.6'?\ YI]OQ.@HKG_P#A$/\
MIYN?^_W_ -C1_P (A_T\W/\ W^_^QHY8=_P#FGV_$Z"BN?\ ^$0_Z>;G_O\
M?_8T?\(A_P!/-S_W^_\ L:.6'?\  .:?;\3H**Y__A$/^GFY_P"_W_V-'_"(
M?]/-S_W^_P#L:.6'?\ YI]OQ.@HKG_\ A$/^GFY_[_?_ &-'_"(?]/-S_P!_
MO_L:.6'?\ YI]OQ.@HKG_P#A$/\ IYN?^_W_ -C1_P (A_T\W/\ W^_^QHY8
M=_P#FGV_$Z"BN?\ ^$0_Z>;G_O\ ?_8T?\(A_P!/-S_W^_\ L:.6'?\  .:?
M;\3H**Y__A$/^GFY_P"_W_V-'_"(?]/-S_W^_P#L:.6'?\ YI]OQ.@HKG_\
MA$/^GFY_[_?_ &-5]+MFT^^-MYLLB&VWXE<MSY@'L.@_G3Y(M.S%SR35T=11
M1169H%%%% !1110 4444 %%%% !1110 5RG@#_E\_P"PA<?^RUU=<IX _P"7
MS_L(7'_LM '5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3QUH EHID4HE =2"K $$'((/((([4^@ HHHH **** "BBF2RB(%V("J"22<
M <DDGM0 ^BHK:Z2Z421L&4]&4A@<'!Y''6I: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJK>ZI%8X\Z1$W9QO8+G'7&2,XS0E<"U13(I1* ZD%6
M((.00>001VI] !1110 4444 %%%% !115.\UB"R.R65$8C.'=5..F<$CCBA*
MX%RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KG_^8E_VY_\ M6N@KG_^8E_VY_\ M6KI
M]?0BIT]3H****@L**** "BBB@ HHHH **** "BBB@ KE/ '_ "^?]A"X_P#9
M:ZNN4\ ?\OG_ &$+C_V6@#JZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M *_)O_9:Z"N?\(?\O/\ U^3?^RUT%75^-D4O@04445!84444 %%%% !1110
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M.2-I.223GGI3E1M'F3N"G=V:L=M17E'BGQ9/HVI2,K,R(!B,NWEY:$ $J#C
M)W8[^H/-4]4\,:G-$-2F<DIF3:9"'C'WBP4X"] <*<C@8&,!K#[-NUQ.IOH>
MQT5Y[\+?%4NH%[*=BY5=ZLW)QG# L3D\D8_'G  K \,>(;G3K];6XE>1?,:)
M@7+J225!&\]-V#G@XSZX*^KRO)=@]HM/,]AHKE/B5J[Z;:$QDJTDBJ&5BI7J
MQ.1SR%QVZ_A4'PP$TUNUU.[N97PN]RXVIQD9)();(/K@<>L^S]SF*YO>L=E7
MCWB-SXHU06H!VJXBXP&VQDF1N21D?,1[8XS7KTLHB!=B J@DDG  ')))[5X_
M\+H/MM\9G)+)&[Y)R2S$*<DY)X<GUS6F'T4I=D34U:1Z)XQO6T>RDEM\(T80
M+A1@#>JX ((Q@XZ5P&B^)-7UK=]G??LQN^6%<;LX^\!Z&NX^)'_'A-_VS_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3P!_P OG_80
MN/\ V6NKKE/ '_+Y_P!A"X_]EH ZNBBB@ HHHH **** "BBB@ HHHH ****
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MT* &12&3)QR.OMDJ2!GC)YQU&'\-=$N]%,D5Q&5C<!@?,5@&'!&U2>6!Y/\
ML@>F'.<9T]-&N@HQ<9=[G*_#[4CH5X\,V0NR02#.0IB!<MA<[B-I QZG'H9/
MA]:'6[]KR0#"%Y6^7*[G/RCD\$$EEZGY?Q%_QOX N+RZ:XMD#)( QP43#=&'
M+#).-Q..2?6NE^'/AA]#A<S*%EE?) ;/RJ,*#@D9R6/'8C)["JE2/(Y)ZM"C
M%W2Z(I_$7QM)HI6UM^)'4,7(! 7)  !R"20<Y& .F2<C&U;0=6N87N;B8*JQ
MN6C#E?E4$D%8UV$D>_(P">PTOB1X+GUB1+JW <A A7(4C!9@V6(!'.".HXZY
M.()+'6=75;.?$<;9$D@,>2I.>0C9Z< *%!SACC)J8.*C%JWG?<<KMN]_(C^#
M/_+Q_P!LO_:E9GB'_D-+_P!=[;^4==+\,O#=QHOG?:$V;_+V_,K9V[\_=)]1
M5'6?"5U<:H+U(\PB6!MVY!P@3<<%L\8/;Z4^>/M9._3_ ""SY%ZD?QF_Y=_^
MVO\ [3KIX-9&C:;%=L"P2WAX'&2550,]AD\GL.QZ5E?$WPW<:UY/V=-^SS-W
MS*N-VS'WB/0UJWGAU[_3ET\D))Y,0YY 9-IP<=LKC(SZ\U%XNG!/OJ59\TF<
M=I5[JWBM7:*4)%N(R,( 00VT%09.A'/<<$GOAI8RV.IQ0W#[Y5G@W-N+9R4(
MY;!. 0*W-!TG6-"1H88QM?)PS1'#$ ;@=V<@#@'*^H-$/@>^^UP7LP\PF2.2
M5MR_*0_*]1G:H'W1@?=7(%;*48MZJW2QG9M+>YN?%[_CT3_KNO\ Z ]:/PTE
M#V$0!!*F0'!Z'>QP?0X(/T(IGQ'T2;6+=8;==S"56(RJ\!6&<L0.I%<G8^#M
M3T +):$;I4_>*I3Y2#P"'^4G'<=#N'3ELHJ,J2C=)W+=U.]BC\5I$>]PF-RQ
MH'P,?-R1GU.TKSSQ@=JZSXO?\>B?]=U_] >L/PS\-[B:?S[X856#$,RN9&SG
M!P6&,_>SR>@ZDCJOB/HDVL6ZPVZ[F$JL1E5X"L,Y8@=2*IRBI05]NHDFU)]R
MCX>_Y K?]<+G^<E<+X-TBZU,R):3")@%+#S'0L.1G" Y [^F1ZUZIX.TAK*R
MCM+A0& <,IPPPSL<'&000:XF;P%?:!/YVGMN!W '<H8*<<,'PI_#(R,X4X%$
M*BO-76KTOL$HNT6/O/ASJ5Z-DMPKJ#G#RRL,],X*GGFN]\+:,=&MH[1B&9 <
MD=,LQ8@9[#.,]^N!TKB?(UZX_=L=H;@MF 8!X)ROS#'J.?3FO0=+@>WBCCD.
MYUC4,V2<L  3D\G)[GFLZTI62;3]"H)7O9_,M5PWQ>_X]$_Z[K_Z ]=S7*?$
M?1)M8MUAMUW,)58C*KP%89RQ ZD5%%I33*GK%E'X0_\ 'H__ %W;_P! 2M/X
MD?\ 'A-_VS_]&+47PXT2;1[=H;A=K&5F RK<%5&<J2.H-7_&VFR:E9R6\(W.
MVS R!T=2>20.@JI->VOTN2D^2WD87PA_X]'_ .N[?^@)7-?%[_C[3_K@O_H;
MUV?PXT2;1[=H;A=K&5F RK<%5&<J2.H-8?Q'\)76L7"S6\>Y1$JD[D7D,QQA
MF!Z$5I"4?;-WT)DG[-(O?%[_ (]$_P"NZ_\ H#UR_ACPU?ZC LMM<A(\L-@F
MD7:03D%5! )Z_0@]Z].\1Z$FN0-:OQG!5L E6'0C/Y'H2"1D9KSO3_#6KZ 6
MBML;&()*M&5)QU DP0>QX&<=P!12FO9\MTGYA./O7Z>0Z?X77U\X:XF1N@+,
M\CL%SVW*,XR2!D#/<5:^,W_+O_VU_P#:=6=+L=9NY8_M+[(DD5V^:-=P4C*_
MNN3D9X/RGOVJS\3?#=QK7D_9TW[/,W?,JXW;,?>(]#34W[2-VM+[ X^Z[)G2
M>%(A%:6X4 #R8SP,<E02?J2<GU-<W\1?&TFBE;6WXD=0Q<@$!<D  '())!SD
M8 Z9)R.KT*V:UMX87&&2*-6'!P54 C(XZUQOQ(\%SZQ(EU;@.0@0KD*1@LP;
M+$ CG!'4<=<G&5/E=378N5^70S=6T'5KF%[FXF"JL;EHPY7Y5!)!6-=A)'OR
M, GL)_@S_P O'_;+_P!J5))8ZSJZK9SXCC;(DD!CR5)SR$;/3@!0H.<,<9-7
MOAEX;N-%\[[0FS?Y>WYE;.W?G[I/J*UG)>SDKJ_D1%>\GK\SE_$THBUD.Q 5
M9K<DDX  6,DDGM7K5_(D4;O+CRPC%\C(V@'=D<Y&.W>O'O&ME]NU5K?./,DA
M7.,XW(@SCC.,U<O/#.KR1?8""T"'  >/!"GCDD,5] W3C@8&"<%)0UMH$9-.
M6@WX0_\ 'V__ %P;_P!#2G?%S2A;W"70QB9,'DYW1X!// &TJ!CT/'KU_@#P
M:= 0RRX,\H&<8.T#G:#Z_P![G!(&,XR;/Q!TH:C92#C=$/,4DD8V<MT[[=P&
M>,GMU"]JO;76VP<C]G8\Y\;>)?\ A(S;I'AF$8R$5L^;)@,@!Z@8&,9Z]37K
MVCZ:-,ACMEQB- ,@;<D#EL>I/)]S7CGPWTH:A>H3@K"#(021]W 7&.X8@^F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<IX _Y?/^PA<?\ LM=77*>
M/^7S_L(7'_LM '5T444 %%%% !1110 4444 %%%% !1110 5Y7X\TK[#<%U!
MVS#=T.,D_,,G.>>?;(&.E>J5SOCK2Q>VS.!EXOF'3H/O<GMCG ZD#Z5AB:?/
M!^6IZ>28OZOBHWVEH_GM^);\+:Q_:T"RG[X^5_\ >'?H!R,'C@9QVK7KS+X>
M:N+.8P-@"8  _P"TN=HSGODCN2<5Z;58>ISP3ZD9O@_JN)E%?"]5Z/\ RV.?
M\(?\O/\ U^3?^RUT%<_X0_Y>?^OR;_V6N@KHJ_&SS*7P(****@L**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RG@#_
M )?/^PA<?^RUU=<IX _Y?/\ L(7'_LM '5T444 %%%% !1110 4444 %%%%
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MEJ_BV+3;5=0()$BJ47H277<H)Y XZGG&#C)P"I49Q:7<:FF;E%>:?\+/N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/ '_ "^?]A"X_P#9
M:ZNN4\ ?\OG_ &$+C_V6@#JZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M.+\?)=@;HR3;D?,$!!& <[B.2I'_  'L1G!/G=>\5P?BGP%]ZYM?J8P/S*__
M !./7'9:XL3AY-\RU/ILCS>E3BJ$TH]GW]?\_O+WPS_X]W_Z[-_Z E==7(_#
M/_CW?_KLW_H"5UU=D/@CZ+\CP<:[XFM_CE_Z4PHHHIG.%%%% !1110 4444
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MY) .">QJ82CRPUV8Y)WD8=W.\>A1*@R'D(<X)POFNV>.GS #)XYQU(KIOA9
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M'T)KQW2[%+[6&BE4,AN)R0>AV[V&?49 XZ'H>*ZKPY::K+<QR7K$0QAR1NC
M.5P!MCZG."-W P<'/6GHWA*ZM]4-Z\>(3+.V[<AX</M. V><CM]:JG:GS*ZV
M%+WK:=2Y\7X@;6-\#<)@ <<@%&)&?0X&?H/2LB_O)/[#B RP9]K$Y.U5D8KS
MV *JHSQCCTKI_B/HDVL6ZPVZ[F$JL1E5X"L,Y8@=2*-%\+M)IHTVX&UBK@\A
ML$NS*?E.#@X.,\]#1&<53CY,'%N3]"/X60)'9!D.2\CEQD'#9VXXZ?* <'GG
M/0BN2\=QF#5(WM\/,QA;:2,;P<*IZ8!"J>3WSG!%7-$T/5O#+/' B2(V."X*
M9P/F +(P/8],^^ :N>%O L\]P=1U$GS%<,J[@26&"&)4D!5[*/3& HP:3C&<
MIW30M6E&QB_%[_C[3_K@O_H;U9^,4[M+#&1\BQL0V#RS'##/3@*O'49YZBKW
MQ'\)76L7"S6\>Y1$JD[D7D,QQAF!Z$5N?$#PDWB")6B/[V'<54XPV[&1GL>!
M@].QZY!&I%>S^8.+?,=#I<"6\4<<9W(L:A6R#E0  <C@Y'<<5YE\76,<D$ 4
M+$D9V8&!DG!4=L*%7@=,^XIUMIVN6T0MDR$"[1\\.0/0,3N&.W/'&,8%=-XG
M\%R:W:PPEA]H@51O8L0?E ?GKR0#D@GC'&34P2IS3;3'*\HVL94IU=X#9"VB
M6,QF/AAD+MV\$S'D#US5OX9>&[C1?.^T)LW^7M^96SMWY^Z3ZBJFDRZUIT:P
M"%'5  N]DR   !\LB\#'?)]ZZKPFEVL.;\@RER0!MX7  !V #.03QG@CGL%4
MDU%KW;/L$5=IZD^E^&K?2W::",(TG4C/KG !.%&>PP.!QP*TZX3P)I6H6D[/
M>ES&8R!OE$@W;EQP&;G&>:[NLJBM+>Y<7=;6"BBBH*"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Y__F)?]N?_ +5KH*Y__F)?]N?_ +5JZ?7T(J=/4Z"B
MBBH+"BBB@ HHHH **** "BBB@ HHHH *Y3P!_P OG_80N/\ V6NKKE/ '_+Y
M_P!A"X_]EH ZNBBB@ HHHH **** "BBB@ HHHH HZWHZ:Q"UK(2%?&2I /RL
M&'4$=1Z5!X<\.1^'XS!$6*LY;YR"<D =@..*U:*?,[6Z"LKW"BBBD,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KE/ '_+Y_V$+C_V6NKKE/ '_+Y_
MV$+C_P!EH ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_PA_R
M\_\ 7Y-_[+705S_A#_EY_P"OR;_V6N@JZOQLBE\""BBBH+"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_^
M8E_VY_\ M6N@KG_^8E_VY_\ M6KI]?0BIT]3H****@L**** "BBB@ HHHH *
M*** "BBB@ KE/ '_ "^?]A"X_P#9:ZNN4\ ?\OG_ &$+C_V6@#JZ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP965<'<Q]3D8SFNF\2ZQ_8]O)=8R47@8R-S$*N>1QDC/.<9Q7#^"/^0M=_\
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ME4!B" &.7'![X]:]7HI^WU;2UM87L]+'FWB'X6P65O)/"[EXT+#>R[<+RW1
M<X!Q[XSQ3?#7C9;73PLD9E$,@CD&2<1R;BK'(QC^ *3C@#(R!7I=%'MKJTM1
M^SL[K0\3U".#6[B/^RHY(W+9;C"J2PPXV%BH!/., #&!7I'COQ')X?@6>(*6
M:0+\X)&"K'L1SQ725@:UX4&L7$5Q,P:*$']T4R"3W+9''"\$$<8[FFZJDU?9
M?,7(TG;=FKI<[W$4<D@VNT:EEP1AB 2,'D8/8\U:HHK!F@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_\
M\Q+_ +<__:M=!7/_ /,2_P"W/_VK5T^OH14Z>IT%%%%06%%%% !1110 4444
M %%%% !1110 5RG@#_E\_P"PA<?^RUU=<IX _P"7S_L(7'_LM '5T444 %%%
M% !1110 44R641 NQ 50223@ #DDD]JX#4?C!%"Y6&(R*/XF;9GD]!M8XQR,
MX/J!5PIRGLA2DH[GH5%<OX/\=IXC+1;#'(HSMSN!7@9W8'()Y&.XQGG&A<>+
M;6WG^Q/)B8LJ[=KGE\;1D+CG([_6DZ<D[6U!235S8HHHJ1A1110 445CZ/XM
MM=8<PV\FY@I8C:Z\ @9RR@=2*:3>HKHV**Y+Q_XPD\.B(1*K-*6Y?) "XXP"
M.3NZYXQT.>-.+Q 4LAJ,JA3Y(<J2%!.W( .6P&.-O4\@$9XJO9RLGW%S*[1M
M45Y?I/BW5M;;S[>-"B<%<!4)(/=V#$C(X5N.,CGG5L_'\USJ!TX1KY0D=.,E
M_D!^;)8#&1DC&<<#)ZTZ$E?;02J)G=T445D6%%%% !1574M2CTR,W$QVHN,G
M!/4@#@ GJ:CT?6X=80S6[;E#%2<,O( .,, >A%.SM?H*ZV+U%<-X\\>2Z!*E
MO"B',>XE\GJ2   5QC;[YSVQSVT3EP&(*D@'!QD>QP2,CV)'O3E!Q2?<%)-M
M#Z***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5RG@#_E\_["%Q_P"RUU=<IX _Y?/^PA<?^RT =71110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <_X0_P"7G_K\F_\ 9:Z"N?\ "'_+S_U^3?\
MLM=!5U?C9%+X$%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC#YE"[1M)W<X'&<G/%:_P_:72]1^Q;N"TB2 <JWEJQ'4=B.#P<9]2*E\0_\
M(:7_ *[VW\HZWIQ5.;6^ES.3YHI^9VVD>(+J6SFN[F,1RQ"0JI1U!"H&!(8Y
MQG(X-<;%\4[V]!@BC0RM]WRT9B.#G"Y;)Z$=A@Y!SQZ/XG_X]+C_ *X2_P#H
M!KA/@U$";A\#<!& <<@'>2,^AP,_0>E9PY>24FBI7NE<TY?%=[86D#&%I+F8
MR [D88*L2 451DE,D=.!GGFLK4=>UG1\W<ZCRMW*XC9!NS@'8=X [$MUP"3G
MGI?'7C7_ (1U52,!II.0&/"J#R2 0>>@Z#@G/&#ROB2TU7[&\MY(GE?+NCPF
M_P"^ .43'7!X;I^5.FD[-I6;Z_H*6G5Z'1Q>,Y[ZP%[:Q"2<.$= &(4CJ0HP
M6!!' /&[DG::\W\(:K<:9*TEI'YCF,@KL9_ERI)PI!Z@<].:]!^$/_'H_P#U
MW;_T!*YKX0_\?;_]<&_]#2JC:*J*VPG=\ITOBSQM<:)%;2!$WSQDNKJW# (2
M -P(Y8\')JCX^UNXGLHB(P8KB)&D8!CM;*,!Z*"3@9))Y'&,F/XS?\N__;7_
M -IUI>(?^0*O_7"V_G'4P44H2MNQR;;DO(YKX>:Y=VFVWABWP/.-[[';;NVA
MOF!VC"\\].IXKH]*\=SW>H'365/+$DJY ;=B,,1SNQGY>>*=\(?^/1_^N[?^
M@)7->'O^0TW_ %WN?Y254E&4IZ;(2NE$[/QUXU_X1U52,!II.0&/"J#R2 0>
M>@Z#@G/&#SD?B;5[(?;9HBT!)RA0+M .3P/G4  @,^1CDYXK/^('_(33[5_J
M/W6/^N>?G^[\WWM_OZ<8KUZLWRTX1TO<I7DWKL<IXK\2W5A*EI:0>8TBAMQ#
M%>I4C P!@E26+8 (R.0:Y6]\3ZOX>Q+= %7R!O5"N>O6(@@XZ GD9X...A\:
M>-9-/E73[0!IY,#)((4OPH SC=G!^;@#'!!XY7QM::C';H]](C(9%PBA=P8J
MQYVH!P,@X)&?7K54HJRNEKWW%-[ZLT_'/B>74K-&BB_T>>,%WY;:RN,IGC&&
M&,D8;/R]*S/AYKEW:;;>&+? \XWOL=MN[:&^8':,+SSTZGBM/_F ?Y_Y^*TO
MA#_QZ/\ ]=V_] 2J;4:<E;9V$KN2]!OCOQW/X?G6")4*M&&^<,3DLP[,..*W
M_%OBI/#D0E8;V=L*FX*3W)[G '< \D#OFO/?B]_Q]I_UP7_T-ZL_&+S/-AS_
M *KRVV]/O9^?WZ;>O'IWJ8THRY/.]QN;7,2V^O:S?C[9&G[H8.P(H!  / ;]
MXP8=U)SG"GTZ/P-XY'B$-#( LZ DA0=I7.,C.<$9 ()]QW Z/2_+\J/R?]5Y
M:[.OW<#;UYZ>O/K7EOP]0-J4AMB! !*<'/,>["@;@3G)4\X. <GL5[M2,M+6
M'K%K7<O7_P 5)["YDA:-&CCDD7 W*Q"D@?-EAGU^7\J@O/'>I:1*LMU& DJ@
MB,KM&.,X8$L&]0Q.W/*]*IZ%$)=:8, 1]HN#R,\C>0?J",CT-=1\7O\ CT3_
M *[K_P"@/5M04XQMNB;R:;OL=E87@O8TG7(61%89ZX8 C.,\\U/7,_#?_CPA
M_P"VG_HQJZ:N6:Y9-&T7=)G!:KXEU*^EEM;*#:(F*[V'/RD<AGVI\RD$+@G!
MR#W&9:^/;W1)UM=148+ LQ4!@K<9!C^4@=> 23E<YZ7+[QE=ZY<M9:;M"QGF
M0[3D [6;)R-F2,8!8@9'7%<AX[M[J"=5O7623RP04&!MW-@<*O.<]OQKJIP3
M]UI;?,QE)K5-_H=[XU\97/AR9 $1H)!D9!#?*1O7(8\\@@[<<XP<&G>+_B$N
MF1126I21IOF&<D;!P20&5@=W SZ,#R*/BO<1):>6_+M(OEC/((^\V,C("DCO
MRP^M>;>%72RO(6N00@=3S\N,C*,<D?*"0V>FWGD=52IQE!2MM^(YR:E8]AU#
M7VT6T%W= >;M&43"@NW1!EFZ=R"> 6 [5Q=MXEUC55%[ @\I?X55<-M.3PY+
MG/3Y3VP/FS5[XQ>9Y4./]5YC;NGWL?)[]-W3CU[5!X>TS5'MXVMKB%82@*@*
MO'J#B(_,#G=R3NSDYJ81BH<VEV^HY-N5M3<\%>.AKB/YVU)(AN;!PI7GYADD
M@+_%G@<'/.!SQ\8:CXC=_P"SE"QQ$?\ //=ANA;S#C/RGA>G0D\&M/P)X$G\
M/SM/*R%6C*_(6)R64]U''%9%SX(O_#;/<6#EDS]U3\Y !^\A&UB,D#&22<A0
M>C2I\SM;ROL)\UE<[CPI=74\1%ZH65'V\#[PVJ=W!()))SMXSQ@8K:KE/A_X
MM;Q!$RRC][#M#,,8;=G!QV/!R.G<=<#JZPJ)J33T-8NZ"BBBH&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7*> /^7S_L(7'_LM=77*> /^7S_L(7'_ ++0!U=%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!S_A#_EY_P"OR;_V6N@KG_"'_+S_ -?DW_LM
M=!5U?C9%+X$%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7FG@C_D+7?_;?_P!'+7I=>/:7XCC\/ZE=3RABK/,OR $Y
M,H/<CCBMZ*;4DNQG4=FCU#Q!K(T:![M@6" <#C))"@9[#)Y/8=CTK@M'TK4/
M$Z/?FY:(.3Y:HS!3C(QA6&U01C."QY)!ZMM7&LQ^.+6XMK8.K*J'YPHR<[E
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M*RI*#DOU+FY69F>/-%N])B1)9S/ TF<O]X/@@#DLV-N<8.,YR <$]?=>)/\
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M4E6DK>0W!._F<]/X;?5;(6-VP,H4#>N6PRGY6R_))'WNA.6 (S7.:=X.U32
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MHH **** "BBB@ KE/ '_ "^?]A"X_P#9:ZNN4\ ?\OG_ &$+C_V6@#JZ***
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M2O,_$=I>QWT"7$B-<'R_+=0-HS(0N?D'1LD\'CUZ5U'B/4]0\/V8DEE4SM<
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M'/B2\T6*UVOLE>-O-^5&RRA,]B.I/3BK/COQ?/ILT=C;E$,JJ3(_1=SE1UR
M!@Y)!X/ &,U?LKQBEN[ZD\]FSN:Y#PYXOEU*^GL75 D/F;2H.[Y) HR2Q'0\
M\#FK/AN'4;>5DO622(QY#IM&&!QMX"'D9)R".F#U%<7H.M1:-J-Y<3'"CS\
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MD"XW;>H8YS@^E6?#>M?VU;I=[=F_=\N=V-K%>N!Z>E8'CC7KG2K.*=2(YV=
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M.W_D6N@HI>T\D/V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\
MB9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%K
MH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W
M_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>
M2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B
M9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FS
MG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_
M )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9
M?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH*
M*/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D
M6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#
MV?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?
M].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_
M /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y
M%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?]
M.W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/
M:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C
M_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?
MFSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\
M3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\
MB9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%K
MH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W
M_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>
M2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B
M9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FS
MG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_
M )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9
M?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH*
M*/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D
M6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#
MV?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?
M].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_
M /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y
M%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/:>2#V?FSG_\ B9?]
M.W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C_B9?].W_ )%KH**/
M:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?FSG_ /B9?].W_D6C
M_B9?].W_ )%KH**/:>2#V?FSG_\ B9?].W_D6C_B9?\ 3M_Y%KH**/:>2#V?
MFSG_ /B9?].W_D6C2]+N?M)O+DQ?ZGRP(M_]\-GYA]>_IQ7044>T=MD'LU?=
MA1114%A1110 4444 %%%% !1110 4444 %<IX _Y?/\ L(7'_LM=77*> /\
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M!<(1P5''&,^I KTF\L([T;)45U!SAU##/3."#SS19V$=D-D2*BDYPBA1GIG
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M"X!(!3=@XQDJP;(./3C!R.HU'QH=2M;J6S5\0J%$A!&=Q(<KCD;%PV<@C()
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MM_\ KA%_Z *X+QZK>'K^+5$Y\SDC(S\@",/NG 9"!GDYR>.*]-BB$0"* %4
M  8  X  ':N'^)=O/JIAT^&-BK.&9]C% 3E%RPS@#)+9' P1WHHR_>>3W'->
MZ1?"7324EOY,EYGP"P^8@<LVX\D,QY]UYR>G;:I.]O%))&-SK&Q5<$Y8 D#
MY.3V'-&F:<FFQ);QC"QJ .F3CJ3@ 9)Y)[DDU4\1^(X_#\8GE#%6<+\@!.2"
M>Y''%3*3J3N-+EB>0Z2MG?+)<:C/+YV>%4%F8*HYW,K D] "1C')P>.J^#T1
MB-RC AE,0((P01Y@((/>G?\ "P=,W^=]F._=NW>3%NW9SNSNSG/.>N:GM_BA
M86Q9XX75I#EBL<8+'DY)#\GD]?6NBHYRBU9ZF4>5-.YD:'JT>A:I=27)**QE
M RK'[TBLO !.".0>F*]2M;E;I%F0Y5U#*>1D,,@X//2N O/B-IMZ=\MNSL!C
M+Q1,<=<9+'CFK,7Q9LX@$6.4*H  "(  .   _2LZE.4[.SN5&2CU,_QO_P A
M:T_[8?\ HYJ/&_\ R%K3_MA_Z.:K,_Q+T^X<3/ [.N-K-%&6&#D8)?(P>1[T
M3_$O3[AQ,\#LZXVLT4988.1@E\C!Y'O5I35O=>BL)\NNI9^+W_'HG_7=?_0'
MK-\;_P#()M/^V'_HEJMWGQ0L+T;)87=0<X>.-AGIG!<\\TV?XEZ?<((7@=D7
M&U6BC*C P, O@8' ]J4(SBHJST82<7?4N:[$9=%4*"3]GMSP,\#82?H ,GT%
M,^&_B2W^SPZ?O_?_ +SY=K?WF?KC;]WGK^M-B^+-G$ BQRA5   1  !P  'Z
M53MOB#IEJPDCMBK#HRPQ*1D8/(;/2ER2<7%I[W'S*Z=RC\+9WMXKR2,;G6-"
MJX)RP$A P.3D]AS6#I*V=\LEQJ,\OG9X5069@JCG<RL"3T )&,<G!X[&R^)>
MGV.?)@=-V,[(HUSCIG#C.,U%_P +!TS?YWV8[]V[=Y,6[=G.[.[.<\YZYK2\
M^:3Y7J3962N-^#T1B-RC AE,0((P01Y@((/>F^"/^0M=_P#;?_T<M6[?XH6%
ML6>.%U:0Y8K'&"QY.20_)Y/7UIL'Q+T^W<S) ZNV=S+%&&.3DY(?)R>3[U,E
M-N3Y7J-<J2UV/0J\JM+X>%M5F>YX2;S#NPV LC>8I "DGD;3C@'//%;G_"WK
M3^Y+_P!\I_\ %U6O?B7I]]CSH'?;G&^*-L9ZXRYQG%13ISC=-.S*E*+MJ8>K
MZZNN:E;W$2D1++%&K$$!ML@8D<<??''7&"<9P-/QO_R%K3_MA_Z.:K+_ !+T
M]]F8'/E8V9BC.W&,;?G^7H.GH*)_B7I]PXF>!V=<;6:*,L,'(P2^1@\CWK3W
MKKW7HK$::ZE;XJWLC30VC,8[=U!9@&(.7^;(!PVP $#J,^XKD/$EE:0[38M)
M(H^^SC"@G[JCY5.<!CR.G3H<=U>?%"PO1LEA=U!SAXXV&>F<%SSS4'_"P=,V
M>3]F.S=NV^3%MW8QNQNQG'&>N*=-SBDN5Z!)1;>I!\69!-/;P292, DR8+#Y
MV ;@=2H4$@')R.G>/0HK![A)[B]:>1""GF!XU&W+#+/G@'D#<!GCG.*Q_$WC
M)-5NX[H(7AB Q%*-HZY;.&8$GCGIP RD#FCXE\10ZL$6&V2 J224QDY[?*JC
M'U!/H1SFHTY<JCJON$Y*[9UOQF_Y=_\ MK_[3KI?B1_QX3?]L_\ T8M<XOQ#
ML)8XXKB)YFB0#=)%&Q)P 6^9S@MC)YJY<_%2QNE,<D4C*>JLD; X.1P7QUK'
MEFN56V+O'77<Q[K3GO-$A9!GRI&=AR3M#R*<8!Z;LGL ":T]%^)EO9V:*P/G
M0QJ@CP?FV@ $-C !ZG/(YP#QF6V^*EC:J(XXI%4=%5(U R<G@/CK5.7QYI<I
M+M:DLQ)),,)))Y))+=:KEE*Z<7O<5TMF2_#2Q?1;:?4)E(C= ZC^(K&&).#C
M@Y^7)YZ],$\]XE?395^V6+M'< JPC"N!DG)P<85ESGY6VC;A1SFNL_X6]:?W
M)?\ OE/_ (NL^+QYI<1#K:D,I!!$,(((Y!!#=:(\_,Y-/Y ^6UKE;Q9+++I%
ML]P29&D4Y)!)!60H21WVXZ\^O.:W+O4[."SM+:_4F.:%"#@D*413G*G<"<X&
MT'J0>,U5O/BA87HV2PNZ@YP\<;#/3."YYYIL_P 2]/N$$+P.R+C:K11E1@8&
M 7P,#@>U+EFTO=>]] NNYSVB;;/4(H=,F=XI&0N#E>!G>&#!0V%R0<<9P/F&
M:]CKSVR^)>GV.?)@=-V,[(HUSCIG#C.,UW=A>"]C2=<A9$5AGKA@",XSSS45
M^9M-JQ5.W<GHHHK T"BBB@ KE/ '_+Y_V$+C_P!EKJZY3P!_R^?]A"X_]EH
MZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M].>MX3X4#6VH6BRQN_$H ) .0=KXZX7*KE&').,\>I_V7Y=O]CC8KB+RU?\
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MUSNS-O9?O*GFC<P]^G/. 2>,9'H7PRM88K-9(L%W)\P\;MP)X/)P .G3(.[
M+&HM!\%R65Y<7<I1HK@2C:,DXD<-@@J!C P>31X:\'SZ!=2/$R?992<J=V\
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M6M@'+QP' P"-OE*3SC!P)>YX)P.017IU36T45Y#ANWYA1116)84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<IX _P"7S_L(7'_LM=77*> /^7S_ +"%Q_[+0!U=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"$E\S]WY?E;/X]V=V[_97&-M-1;3?83:3L=-17(>+_ .T_-7[!_JO+&?\
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M[D@Y!'3'>NL\/:4-)MX[7C*( <$D;CRQ&><%B3_053A:"EW$I7;1HT4R641
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M00 48*"/<XSR?3JN4.5)]R5*[:[!1114%!1110 4444 %%%% !1110 4444
M%%%% !1110 5RG@#_E\_["%Q_P"RUU=<IX _Y?/^PA<?^RT =71110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'G_ (6BU'7K9+W[;L\S=\OV
M:)L;6*]>/3/2M7_A'=1_Y_\ _P E8O\ &CX6_P#(.@_[:?\ HUZZN@#E/^$=
MU'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C
M_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_
M !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\
M_P E8O\ &C_A'=1_Y_\ _P E8O\ &NKHH Y3_A'=1_Y__P#R5B_QH_X1W4?^
M?_\ \E8O\:ZNB@#E/^$=U'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@
M#E/^$=U'_G__ /)6+_&C_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_
M !H_X1W4?^?_ /\ )6+_ !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6
M+_&NKHH Y3_A'=1_Y_\ _P E8O\ &C_A'=1_Y_\ _P E8O\ &NKHH Y3_A'=
M1_Y__P#R5B_QH_X1W4?^?_\ \E8O\:ZNB@#E/^$=U'_G_P#_ "5B_P :/^$=
MU'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C_A'=1_Y__P#R5B_QKJZ*
M .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_ !KJZ* .4_X1W4?^?_\
M\E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\ _P E8O\ &C_A'=1_Y_\
M_P E8O\ &NKHH Y3_A'=1_Y__P#R5B_QH_X1W4?^?_\ \E8O\:ZNB@#E/^$=
MU'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C
M_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_
M !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\
M_P E8O\ &C_A'=1_Y_\ _P E8O\ &NKHH Y3_A'=1_Y__P#R5B_QH_X1W4?^
M?_\ \E8O\:ZNB@#E/^$=U'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@
M#E/^$=U'_G__ /)6+_&C_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_
M !H_X1W4?^?_ /\ )6+_ !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6
M+_&NKHH Y3_A'=1_Y_\ _P E8O\ &C_A'=1_Y_\ _P E8O\ &NKHH Y3_A'=
M1_Y__P#R5B_QH_X1W4?^?_\ \E8O\:ZNB@#E/^$=U'_G_P#_ "5B_P :/^$=
MU'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C_A'=1_Y__P#R5B_QKJZ*
M .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_ !KJZ* .4_X1W4?^?_\
M\E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\ _P E8O\ &C_A'=1_Y_\
M_P E8O\ &NKHH Y3_A'=1_Y__P#R5B_QH_X1W4?^?_\ \E8O\:ZNB@#E/^$=
MU'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C
M_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_
M !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\
M_P E8O\ &C_A'=1_Y_\ _P E8O\ &NKHH Y3_A'=1_Y__P#R5B_QH_X1W4?^
M?_\ \E8O\:ZNB@#E/^$=U'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@
M#E/^$=U'_G__ /)6+_&C_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_
M !H_X1W4?^?_ /\ )6+_ !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6
M+_&NKHH Y3_A'=1_Y_\ _P E8O\ &C_A'=1_Y_\ _P E8O\ &NKHH Y3_A'=
M1_Y__P#R5B_QH_X1W4?^?_\ \E8O\:ZNB@#E/^$=U'_G_P#_ "5B_P :/^$=
MU'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C_A'=1_Y__P#R5B_QKJZ*
M .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_ !KJZ* .4_X1W4?^?_\
M\E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\ _P E8O\ &C_A'=1_Y_\
M_P E8O\ &NKHH Y3_A'=1_Y__P#R5B_QH_X1W4?^?_\ \E8O\:ZNB@#E/^$=
MU'_G_P#_ "5B_P :/^$=U'_G_P#_ "5B_P :ZNB@#E/^$=U'_G__ /)6+_&C
M_A'=1_Y__P#R5B_QKJZ* .4_X1W4?^?_ /\ )6+_ !H_X1W4?^?_ /\ )6+_
M !KJZ* .4_X1W4?^?_\ \E8O\:/^$=U'_G__ /)6+_&NKHH Y3_A'=1_Y_\
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MQNV?FDR0.#_>5%!],DCM@YKH<'.G"WF9WM)F=X#B$6J72* %43  #  $R@
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M(RL[')7YPI52<!CC@C(YR,BG4@VHKY"C)79E?%#Q$-HTJ(!Y)2NX#)9<$%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5RGQ2_P"0=/\ ]L__ $:E=77*?%+_
M )!T_P#VS_\ 1J4 =71110 4444 %%%% !1110 4444 %%%% !7*> /^7S_L
M(7'_ ++75URG@#_E\_["%Q_[+0!U=%%% !1110 4444 %%%% !1110 4444
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M=%<I_P *MT[_ )X_^1)?_BZ/^%6Z=_SQ_P#(DO\ \70!U=%<I_PJW3O^>/\
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MW_/'_P B2_\ Q= '5T5RG_"K=._YX_\ D27_ .+H_P"%6Z=_SQ_\B2__ !=
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M^%6Z=_SQ_P#(DO\ \70!U=%<I_PJW3O^>/\ Y$E_^+H_X5;IW_/'_P B2_\
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M_A5NG?\ /'_R)+_\70!U=%<I_P *MT[_ )X_^1)?_BZ/^%6Z=_SQ_P#(DO\
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M*1R-YZ8Z#WSE?!_3DFEEN&&6B50O3 W[LGIG.%QD=B1WKK_B1_QX3?\ ;/\
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MYR.BLR;0X*\@'<0IYZ;><<XQGCCE/A;IR7EYN<9\J-G4<$;@549R#TW9'<$
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M;>PCMBSQHJM(<L54 L>3DD#D\GKZUYCXC^%#6B--:N9-N#Y; ;\8YPPX8YY
MVCC@9.,M^%?B5XI1ISDF-PQ0==K ;CSGA2 <CGYL$8R2=JE.,TYQ?JB(R<6H
MLW-5\=SVFH#355/+,D2Y(;=B0*3SNQGYN.*Z_6+PV4$LZX+1QNPSTRJDC.,<
M<5Y;XA_Y#2_]=[;^4=>E^)_^/2X_ZX2_^@&IJ02Y/-#BV^8P_A_XOE\1>;YR
MH/+V8V C[V[.<L?2L[7_ (D2:->M:LBM A3. ?,PR D@EL9!/3'/3(ZU4^#/
M_+Q_VR_]J5B^,+,7NK&!LA9)(%..N&5 <9SSS6BIP]K)6TM_D2Y/D3-SPO\
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MG&1G&?6N@_X49_T\_P#D'_[90!ZK17CGQ8TF32KM-5B)_>%3G&=LD0&.V,$
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MCG':O4-)MWMH8XI3ND2- S9)RP4!CD\G)[GF@"W1110 4444 %%%% !1110
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MW0\CH>:]CHI^W7O66_F'LWIKL>:?&;_EW_[:_P#M.NX\,?\ 'I;_ /7"+_T
M5IT5$JEX*/8I1M)LHZYI*ZO ]J_ D7&>>".5. 1G! .,\XP:^>_LK[_)VG?N
MV[<'=NSC;CKG/&.N:^B[^\%E&\[9*QHS''7"@DXSCGBO'O &G/K=]]ID&X1L
M97/(&XDE?NC&=W.. 0#Z8K;#2<8R?1&=57:1ZYH^FC3(8[9<8C0#(&W) Y;'
MJ3R?<U<HHKE;N;'B'Q+B*7\I((#",C(ZC8HR/49!'U!K1_X6]=_W(O\ OE__
M (NO7J*Z/;Q<4G&]C/V;NVF<]X'\2/X@@,\BA660J=N<' !!P<D<-CJ>F>^!
MP7PA_P"/M_\ K@W_ *&E>O45"JI*22W'R7MY'#?%[_CT3_KNO_H#U<\#68O=
M,2!LA9$F4XZX9W!QG//-=;12]I[BCYW'R^]<\,L[BX\#W?S*-P&&!^ZZ$]0V
M.AQP>Q&"."M6_$FM7/BN-[O;LM;?;\N<C<Q"]<#<WS>@"K[GYO:**T^LJZE;
M4CV6EKZ',_#?_CPA_P"VG_HQJ\D\.7EQ8R&YM<EHD+.!R"@(#9'=>1GT^]QC
M(^@:\A^$/_'V_P#UP;_T-*JE/2I*PIQUBBCXK\;2^*-ENL>U0P(0'>S.<@<X
M!Z'  '4G.>,>B>$_"9L+)K*;(:<.9-I!QO7;@'&,A0/4;LX)&*ZBBLYUKQ44
MK(N,+.[U/#K1[GP-<[W3U4Y'R.O!.UL?0Y'(. PZK5SQ'XYG\4@6<41520=J
M%G=BN3C@#*]\;>HSFO9:*KZPFTW'4GV3M:^ASW@7P\VA6PAD_P!8[%W&00"<
M# ('8 9Z\YP2,5P7PA_X^W_ZX-_Z&E>O45"K.TK]2N3;R/(?B]_Q]I_UP7_T
M-Z]>HHI3J<T8KL.,;-ON>0_"'_C[?_K@W_H:5/\ %^Q<3QW.T^68PF[MN#,<
M>QP<CUYQT./5Z*OZQ^\Y[$^S]WE.+\&>/G\0R_9VC";8BS$$G+ H.!@8')X.
M3TYXYS/B/XMNM'N%AMY-JF)6(VHW)9AG+*3T KT>BI52*E?ET[#<6U:Y5TN=
M[B*.20;7:-2RX(PQ )&#R,'L>:??V8O8W@;(61&4XZX8$'&<\\U/16=];EGB
M%YIMWX'N/.7.T'"N ?+<'G:?<XY7.1C(/ :MB\^+\TL>R.-4DQ@N26'3DA2!
M@YY&2P'0@UZO16[KQE;FC=F?LVMF>0^"/!$NKRB]N@1$&#_.,F0GYOXNJGJ2
M>O0=R/5[^S%[&\#9"R(RG'7# @XSGGFIZ*SJ57-W*C!15CYRN/,L]]H_&)!O
M7@_-'N7J,]-QZ'!_*O<?!6D?V7:11$88KN;*[3N?G!'7*C"\\\=NE;E%55K^
MT5K6)A3Y7<\A\7Z+/X=O#J4()C,GF!N2 6/S*VW& 2<8[J<9)S6G_P +F_Z=
M_P#R+_\ :Z]+HH]M&27,KV\PY&GHS#\(:W+K,37$T?EYD.P8(RA"E3D_>Z]1
M@'L*\]^$/_'V_P#UP;_T-*]>HI*JDI*VXW"[7D4==MFNK>:%!EGBD51P,EE(
M R>.M>1^"/%@\+O)'-&Q#E0V.&4INXVG&3DX.2,>_2O:J*(5%&+BU=,)0NTS
MPGQCJ\NNNE^\?EQNI2/G.?+.6YXSRW7 ';D@UZA\2/\ CPF_[9_^C%KIJ*<J
MUW'38%"U]=SAOA#_ ,>C_P#7=O\ T!*YKX0_\?;_ /7!O_0TKUZBAUOBTW#D
MV\@KB?'NNWNAR)<08:WV$,I3<H;.,LP (!W#;\PR0>/7MJ*SA)1=[7*DKH\J
MN?C!+)$42(+*5QOW9 /<A"OY DXXSGO/\+O"3QO_ &C,I5=G[K/?=D%N#G&.
MF1@ALCH*].HK1UERM15KD*#O=NYY#\2-.GTV\_M%1A79"CCD!D51@Y&,Y7(!
MX(]<$">X\97?C +IUN@1G'[Q@QP1QDYQ\J>HY)X7)SAO5Z*:KJRNM5L'L]7K
MN>:?!G_EX_[9?^U*S/$/_(:7_KO;?RCKUZBE[?WW*VZ#V?NI!7+_ !(THZA9
M.1DM"1( "!]W(;.>P4D^N0/H>HHK.,N5IEM75CYYTVV?6)8;3)ZA%PN=JEBS
M' QD#<S')Z=P!7T'%$(@$4 *H   P !P  .U/HJZU;VEM+$PARGD/PA_X^W_
M .N#?^AI7;?$C2CJ%DY&2T)$@ ('W<ALY[!23ZY ^AZBBB=;FFI@H6C8^>=-
MMGUB6&TR>H1<+G:I8LQP,9 W,QR>G< 5[KK%B9;66VB49,+HBC '*$*!T ';
MT%:-%.K6YVG:U@A3Y;GBO@CQ8/"[R1S1L0Y4-CAE*;N-IQDY.#DC'OTJGXQU
M>7772_>/RXW4I'SG/EG+<\9Y;K@#MR0:]VHJ_K"YN;EU]2?9.UKG,_$C_CPF
M_P"V?_HQ:S/A#_QZ/_UW;_T!*[FBLE4]SE\R^7WKA1116904444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7*?%+_ )!T_P#VS_\ 1J5U=<I\4O\ D'3_ /;/_P!&I0!U=%%% !1110 4
M444 %%%% !1110 4444 %%%% !7*?%+_ )!T_P#VS_\ 1J5U=<U\1[1[NPFB
MB5G<^7A4!9CB12< <]* /$CI<TMDMT,M#'/(I  ^1F6+YB>N&X'H"HYRU>Y>
M M0BOK*)X%5%5=K(O16'WAU8\GYAD[B"">37/_#'P^6L);2\B8+),V4E4J2-
MB8/.#U'!'0C@Y%8G@_3+OPA?M:^6\EO*RJTB1,5(QE'W=!M+?-R0!NZD T 8
MOCRW>YUAHHCMD>2 *V2,,4C"G(Y&#W'-=5I/@C5K::.66ZW1I(A9?/F.5# L
M,%<'(['BL+QOI=VFJ/>P02.$>%E(C=D)1$/51R,C!P:T_P#A/M9_Y\__ "7G
M_P#BJ .]\6^'UU^V>U.-Q&4)[..5.<' [' SM) ZUXU\/M)/B*[BAE(,5LA;
M:0.55RVW&"""[\Y_A)&>E>^UY%\(M#N+"[=YHI$4P, 71E&=Z'&2!SQ0!Z[5
M?4-/CU&-K>90T;C!!_SP1U!'(/(YJQ6/XNLY[VUDBM6*S$ J0Q0_*P) 8="0
M".PYY('- 'FFL?#&\T%FN-/D9EP<A&*3!>3C@C<.!TY)Z)71_#'Q])KQ:SN?
MFE12X<  %<@$$# !!88P,$=<$9;$/C#6[=3;M;LSC</,\ARV<GD%/W9QV(!!
MP.O?;^&/@&302UY<_+*ZE @(("Y!))&022HQ@X ZY)PH!E?'/_EU_P"VW_M.
MN_\ "?\ QYVW_7O#_P"@+7%?&729M0^S^1&\FWS<^6C-C.S&< XS@UW'AB%H
M;2W1P0RP1 @C!!" $$'H10!Y/X:_Y#S?]?%U_*2O5?%G_'G<_P#7O-_Z U>>
M^,? MW8W9U33P3DF0["-ZMCYN&/S!N3@9SDKMQC-?4]=UGQ$ALOL[1B3J5C>
M/(P<J7D; ![\C/3H2" 6_@9_R]?]L?\ VI63X:_Y#S?]?%U_*2O0/A[X,/AB
M)ED*M+*V6*9VX7A5&<9QDG.!UQS@&O-[BSOM*U&6_@MY'*SS%28I&0ARPS\N
M,C!R,&@#UOQC,L5E<EB /(D&2<<LI 'U)( ]3Q7!? S_ )>O^V/_ +4JCJ/]
ML^,1]G>(Q193<"IB3J<,=Y+L!U(&0, [<XSZ+X*\,CPY;+;$@N26<C."Q],]
M@ !VSC. 2: /-?BOI)T6Z%["0HNDD!  ZE=DG&,897Z\G<6/'%=W\,?#ZZ39
MH_!DN )&(]&&47. <!>QSABV#@U@_&729M0^S^1&\FWS<^6C-C.S&< XS@UW
M'AB%H;2W1P0RP1 @C!!" $$'H10!IU\_O]I_M67[%_Q\?:+C9]WU?=]_Y?NY
MZ_SKZ KR+P]H=Q%K37#12"+S[D[RC!,,),'=C&#D8]: .B\(?VSYX^W;?(VM
MG=Y6<]MOE<YSZ\8SWQ7"^/+=[G6&BB.V1Y( K9(PQ2,*<CD8/<<U[K7B_C?2
M[M-4>]@@D<(\+*1&[(2B(>JCD9&#@T ;ND^"-6MIHY9;K=&DB%E\^8Y4,"PP
M5P<CL>*L?&C6#;6R6BY!G?)X&"L>"1D\@[BI&/0\]CF_\)]K/_/G_P"2\_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\_\ _P"2L7^-'_".ZC_S_P#_ )*Q?XT =717*?\ ".ZC_P __P#Y*Q?XT?\
M".ZC_P __P#Y*Q?XT =717*?\([J/_/_ /\ DK%_C1_PCNH_\_\ _P"2L7^-
M '5T5RG_  CNH_\ /_\ ^2L7^-'_  CNH_\ /_\ ^2L7^- '5T5RG_".ZC_S
M_P#_ )*Q?XT?\([J/_/_ /\ DK%_C0!U=%<I_P ([J/_ #__ /DK%_C1_P (
M[J/_ #__ /DK%_C0!U=%<I_PCNH_\_\ _P"2L7^-'_".ZC_S_P#_ )*Q?XT
M=717*?\ ".ZC_P __P#Y*Q?XT?\ ".ZC_P __P#Y*Q?XT =717*?\([J/_/_
M /\ DK%_C1_PCNH_\_\ _P"2L7^- '5T5RG_  CNH_\ /_\ ^2L7^-'_  CN
MH_\ /_\ ^2L7^- '5T5RG_".ZC_S_P#_ )*Q?XT?\([J/_/_ /\ DK%_C0!U
M=%<I_P ([J/_ #__ /DK%_C1_P ([J/_ #__ /DK%_C0!U=%<I_PCNH_\_\
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M*?\ ".ZC_P __P#Y*Q?XT?\ ".ZC_P __P#Y*Q?XT =717*?\([J/_/_ /\
MDK%_C1_PCNH_\_\ _P"2L7^- '5T5RG_  CNH_\ /_\ ^2L7^-'_  CNH_\
M/_\ ^2L7^- '5T5RG_".ZC_S_P#_ )*Q?XT?\([J/_/_ /\ DK%_C0!U=%<I
M_P ([J/_ #__ /DK%_C1_P ([J/_ #__ /DK%_C0!U=%<I_PCNH_\_\ _P"2
ML7^-'_".ZC_S_P#_ )*Q?XT =717*?\ ".ZC_P __P#Y*Q?XT?\ ".ZC_P _
M_P#Y*Q?XT =717*?\([J/_/_ /\ DK%_C1_PCNH_\_\ _P"2L7^- '5T5RG_
M  CNH_\ /_\ ^2L7^-'_  CNH_\ /_\ ^2L7^- '5T5RG_".ZC_S_P#_ )*Q
M?XT?\([J/_/_ /\ DK%_C0!U=%<I_P ([J/_ #__ /DK%_C1_P ([J/_ #__
M /DK%_C0!U=%<I_PCNH_\_\ _P"2L7^-'_".ZC_S_P#_ )*Q?XT =717*?\
M".ZC_P __P#Y*Q?XT?\ ".ZC_P __P#Y*Q?XT =717*?\([J/_/_ /\ DK%_
MC1_PCNH_\_\ _P"2L7^- '5T5RG_  CNH_\ /_\ ^2L7^-'_  CNH_\ /_\
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MH_\ /_\ ^2L7^-5=4\$WNJQM;3WVZ-\9'V:,9P01R&!Z@=Z .UHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJCK6L1Z/"]W-G9&,G R3D@
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MSG3[F%H+C:656=75EX^ZPQD]> " %/.00,36?^0]:_\ 7NW\IZ /0***\O\
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M,0 !*A))X  !Y)H TZ**Q/$OAK^WO+BDD98%8F2-1CS,8V@MD$ $<CO[$ @
ML:1XDM]89TMW#F(@-@' SG&"0 0<'D$BM.O//AE"L-WJ*( %6<  #  #R@
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MGF@!OQ5A5].E) )4QD$C.#YBC(]#@D?0D5F>)?\ D K_ ->]K_..CQ'X*O\
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M_P"/S3?^OC_V>&M7XI?\@Z?_ +9_^C4I_BWPO+K%Q:7$94+:R[G#$@D;D/&
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M:7G1+E3$P3AF;[H+= 1ET[D_+TX% &K\4O\ D'3_ /;/_P!&I65XE_Y *_\
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M4,2Y(& K#L&Y^:MK7+)K^WFMTP&EB=03TRRD#.,\<T <EX.M_M.B>5E5WPW
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M>G."V:L_"W2C?R3JV?+:W:-B",CS",8SWPI[$<<U1\)VUI#/):ZDH!!V@EV
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M&$>3OJ5HY.YR_P (?^/M_P#K@W_H:5O:QX"CGFDN[^Y(C9R(P6"X!.X+N<D
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4^*7_(
M.G_[9_\ HU*ZNN4^*7_(.G_[9_\ HU* .KHHHH **** "BBB@ HHHH ****
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MAT(*L 00<@@\@@CJ#69XL_X\[G_KWF_] :CPG_QYVW_7O#_Z M'BS_CSN?\
MKWF_] :@#"^'>HQ6&F0/,ZHI,@!=@HSYCG&21SQ76VMVEVHEB970YPR$,IP<
M'!''6O/?AAX.@N;9+VX F:0,JK( R(JNW 4Y&2V6)]\#'S%GZ?:KX<UG[-",
M17D);8I*JI&XYQR#RC8Z;0Y X&" =[>ZC%8+OF=44G +L%&>N,DCGBBRU&*_
M7?"ZNH."48,,]<9!//-<%X"M$\5M/JUVJR%I#'&D@#K&J@-@9X_B SM!X)SE
MC3M8A7PKJ-M); )%>GRY(D&U"00H?'(!&\'@#H>?G:@#T.L^U\0VUVPBBFB=
MSG"I(C,<#)P <]*Y+QM,VK7UMHA)6&0>9( ?OA=Q"'&"!^[/?JP.,J*N^,O"
M%N+26:"-(98%,J/$@1@8_FZKM/(!'L2#C(% '85GVOB&VNV$44T3N<X5)$9C
M@9. #GI7!>)M3N->T6.Y0$EB/.Q@Y6,L&;&!@%U5CM' _P!D$UI>&9=(UORU
MMXT26)E958>7+E,[3D'+\#)^9NQ;F@"QXI\?+I=Q;V\+Q,LDI68ELF,!D!SA
MAM/+?>]/8UU%CJT.H9\B1)-N,^6ZMC.<9P3C.#7G_P 1-)ACO+#;&@\ZX/F8
M11OR\6=W'S9R>N>I]:Z;Q*\?A:SGNK6)(WV@?NT5.68(K'"X.TMG!'/3O0!K
MWNN6]@VR:6-&(R [JIQTS@D<<5;AF690Z$%6 ((.00>001U!KRWPQK.CVL"B
MZ9);A\O(TL#NVY^2-S*W3IP<$@MU)JQ\-M0BBOKFSLV+6C()$W;N"-@( ;''
MS$'(R0J\G&2 =^=<MP')ECQ$0'.]?D). &Y^4YXYQSQ5BUNTNU$L3*Z'.&0A
ME.#@X(XZUYEX+T&/5-0OGF >.*=_W;#*%F>0!B,X)4!@,@_>R,$5Z;:VB6BB
M*)51!G"H JC)R< <=: &WNHQ6"[YG5%)P"[!1GKC)(YXJQ6/XOT<ZQ:36HR6
M9,J 0,LIW*,GC!8 'V[CK6/X&\2K)IBW+\_98V5P@.<0KD ;C@DIM/7&3VZ
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M".1(P$616!;!QQ_"1G:3R#G*B@"Q\6O$:VMJUK%(OFR.JNH;]X$*ECP#D X
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M,@=3V89QP1D'J#@\$8([&K5%#G)[L%%(YG_A6]A_SQ_\B2?_ !5='%$(@$4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KE/BE_P @Z?\ [9_^C4KJZY3XI?\ (.G_ .V?_HU* .KHHHH
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M[  D^PXR< LUWQ3;:#M^TOL\S=M^5FSMQG[H/J.M<K\:_P#CSC_Z^%_] DH
M] HJOJ&H1Z=&UQ,P6-!DD_YY)Z #DG@<U#8:U#?PB\C<&$ACO.5&%)#$[@,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>1=CF92RY#;27ERN1P<'C/>O1: .4UN6'Q!ITE\T7_+O,T?G(N]?E.&'7&<
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M$L9<EEP<=-OWN!NVG(R0M-^$.CR6<$D[;ECG<&-'.<*!P^>.6R!G:N0H/0C
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M2 1:S_R'K7_KW;^4]5_'BC0M0M=7  1CLD.PD#^$L2O)8HQVCK\G<<"QK/\
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M?]M/_1KUU= 'G^C?\AZZ_P"O=?Y05J_%+_D'3_\ ;/\ ]&I6/;.;#7I X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KE/BE_P @Z?\ [9_^C4KJZY3XI?\ (.G_ .V?_HU* .KHHHH
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MA9<C@X/IP:Q_BE_R#I_^V?\ Z-2C_F#?]P__ -H4 /TCQ1+>Z8=48*)1%,V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.4^%O_(.@_[:?^C7KJZY3X6_\@Z#_MI_Z->NKH **** "BBB@ HHHH ****
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M((PQ)7'+9))&.236A10!Q^A>";G1"(X;MOLZR;O*:%6.TG)7>3D9'4@ 9)8
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M^D^*K75W>&WD5WC^\!GIG&02 &&>ZY'(YY&=:O)/AK:K::M=0QC"1K,JC).
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MAEEAB=SYF6>-&8XD8#)(STH [.RU&*_7?"ZNH."48,,]<9!//-6*\G\9: /
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M8J<X)'4>M:% !1110 445Q_POU^?6[9YKEM[B9E!VJO 1#C"@#J30!V%%%%
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MZEJ'BP3WEM<+#$LC+$AB1B< $;B02,@C)!;DG   ! /1:*** "BBB@ HHHH
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M%2<FNP\+W]S?Q&6[B$3,YV(#D[" 5W<GYN2#D*>/NB@#8KE/BE_R#I_^V?\
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M33S-?7:JMS<R,2%((522< C.,DDD;B,!<\@T 8_P]T^.;4-0N&4&2*=@A/\
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MC"]#@C<03D9JWX#\32:Q')!<@"YMGV2 =\9 ;CY<D@@@$C(R, @5M:?K$5]
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M#O3XY//$"[LDX)8ISG/R$E,<\#&!VQ@5IZ)H$&B(8;9=B%BQ&YFY( SEB3T
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MKO0,& W,O(!&<J0>A-:%%% !6?-H$$TZ7[+F>-=JMN;@'=QC.#]X]1WK0HH
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MQUXJ;PS MRJ!RTJK@G'!!8]CSA2!Z$YYQ@]'7G_QK_X\X_\ KX7_ - DH ]
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MU+A]N"0/F7J3Q@#G)QUH TZ*XJW\<WEXC7$%@[1#)4M*J,RXR"$*DG((QMW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5RGQ2_Y!T_\ VS_]&I75URGQ2_Y!T_\ VS_]&I0!U=%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445D^*==_L&V>]V[_+V_
M+NVYW,%ZX/KGI0!K45QECX_EU=0]C:M-M"^83(L2*Q4':K,/G(R0>!C@\A@:
MU?"OBZ/Q"KA5:.6$@2(XP5)SW[C((YP>.5'% &]17%0?$9KJ:>RAMV>>&0JJ
MJX 8*S!G9BH" 8'4G)8 >M;5SXF&F6OVV^7R6YS&&$C9R=J@C 8L!GV[X )H
M VZ*X^Z\9W=HIN7L7%NN"6\U/,"9^\8@,@@<E2>.<D $UT']OP>1]O\ ,7R-
MN[?VQTZ=<YXVXSGC&>* -"BN"F^)4X@.HI9DVN3AS.@)&_8"4"D@YXQS]2.:
MW_"7B&778_M$D(BC8*4(E67=G.?N@;2N,$'G/'!!H WJ*X31/B5)KB'[-:L\
MJL=R"4*JK@88R,H&6)("@$X4GMST&J^*4T>*.6X5A++M ACQ)(6.,JN,!MI/
M)X'3') (!MT5QE[XYN=)7S[RR:.$'#.DR2D9Z?* ."<#)('/K@'3U[QG%I4,
M=PH:4W&/*1/O.67*\'G'0' )!(XR<4 =!17.:9XBNI9E@N;1HED#8=9%E4%1
MG#;0-H/8D\G  ZD-UOQD;2<:?;0M/<;0S*KJBJO/WF.<'IP0 0PYR0" =+16
M/X?UF;4#(EQ;M \97JP=&##(*N  2.X'3CG.0*^L^+1:2_8;>-I[DKNV(0JJ
M..7<\+D'C@YX'&Y20#H**Y?3_&;B=;.^@-L\H_=$R+(CG."NY0 &Z8'?/8E0
MUCQKXK_X1B%;G9YFZ0)C=MZJQSG#?W?2@#H**YRP\42WKB00%;,AB+B214^5
M5)W^6?F"DC@G'RD,<#BLVW\>W.H(UU:63R0#.&:548[1\V$PQ.#D#:6R1CKD
M  ZW4;EK6)Y44NR(S!!U8J"0HP#R>G0_2J/ACQ"GB"!;N,8W9#+D$JPZ@X_,
M="00<#-:%I<?:467#+O4':XPPR,X([$=QZUPOPZ_XE5W>Z4?E5)/,C3KA3QG
M=S_"8^"<^V=U 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
MI\+?^0=!_P!M/_1KUU=<I\+?^0=!_P!M/_1KUU= !1110 4444 %%%% %'7;
M9KJWFA099XI%4<#)92 ,GCK7CG_"M[__ )X_^1(__BJ]QHK6G6E35D1.FI&'
MX)TV33+..WF&UUWY&0>KL1R"1T-;E%%9R?,VRDK*P4444AA1110!Y_\ &O\
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M(*QV%C%)Q*&=Y  B_*P&2I; .2><'C #$\;?QHF9+)0"0&G0$ XR-KG!]1D
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M9-L28XX P3=D$.68[B<C[O3@<_>!E^(?A>7Q);K;PE0RRAB7) P%8=@W/S4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!RGPM_Y!T'_ &T_]&O75URGPM_Y!T'_ &T_]&O75T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!R7BOPA+K]U;2L8_LUN=S!@6=B6!9=N-I4A5')&,L<'@5UM%% !
M1110 4444 %%%% !1110 4444 %<?XC\%2S3_P!IV$ODW)7:V[E'' YX;& .
MFU@2%. 1NKL** .$NO#6JZPIM[FYBCB,85O)0LS'/).0A&X?>VL!VVX)KL-*
MTQ-+B2UB&$C4 =,G'4G  R3R3CDDFK=% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <IX_\+3>)4BMHF18UDW.7W;N!@;0.#PS9!(R<<CFNHAA
M6%0B !5   &  .  !T I]% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*?%+_D'3_\
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MYC#@CD#[PX&7Y) !W=8_A>YN[B(M?QK'+O( 0@C;@8/#/SG/?MTJOX'\4_\
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MDZKL)(5P491D _-\N,9 [G.T ]@HHK)\3^(4\/P-=R#.W 5<@%F/0#/YGJ0
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M*4$MS9O=13C[-LCS&$5@^9!AA)G('(/'!Q[T :'AC5-2U#R;B=(!!,,D)O\
M,"E24;EBN"<=,G!Y YQUM<IX#TZY@AAEEN/,B:WCVQ>4J[<JI7YP<G XYZ]:
MZN@ HKC],U^>;5KBP9LP1PAE7:O!(BYSC)^\>I[T?%#7Y]$MDFMFV.9E4G:K
M<%'.,,".H% '845P_P 1O%%QH<MJ+?)$CMN0*"7VF/"@E6()R1QSS3[JVU98
MC>^<@D50YMDA#)\O)0/EG)(';^(X4@8- ':T5B>#O$/_  D%JET0H<Y#JIR
MRG'U&1A@#R 1R>IMZW93W:!+:;R7# EO+63(P?EPW'7!S[>] !HFOP:VAFMF
MWH&*D[67D '&& /0BM"O)/A?I5W=VSO;77DH)F!7R4DR=B?-ECGI@8]O>NV\
M6^*7TUX;*V57N;AL*&R550>78+\V.O3C 8Y^7! .EHKA]874O#T?VXW N4B(
M+Q&!8\IT8ADR01G/H "3D#!ZW2M335(DNHCE)%!'3(SU!P2,@\$9X((H MT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '*?"W_D'0?\ ;3_T:]=7
M7*?"W_D'0?\ ;3_T:]=70 4444 %%%% !1110!5U2R^W126^<>9&RYQG&X$9
MQQG&:\^_X4S_ -/'_D+_ .V5Z715PJRALR904MS,\-Z+_8MNEINW[-WS8VYW
M,6Z9/KZUIT45+;;N4E8****0!1110!Y_\:_^/./_ *^%_P#0)*V/#'ABTFM+
M=W@B+-!$23$A))0$DDCDFK'C7PI_PD\*VV_R]L@?.W=T5AC&5_O>M<Y#\,KN
M%0B:A*%4   .  .  !+P!0!2\%6BZ5J]S9VIS (SD%R0"-A[ [BC,5YP0"<D
MD$&WIETL.OW",<&2$*O!Y(2)\>W"D\^GK71>$/ T'AE28\M*X 9VQGMD #[J
MYYQR>F2<#$7B[P''XA9;D.T4\8 5UYZ-N&1D<CG!!4Y.3G % &QXAD6*VG>1
M=Z"&0LN2NX!#E<CD9'&>U>?^![5H=%NG88$BW#+R.0(@F?;E2.?3TK8N?A[<
M:BJP7=[))"HP45!&6QC&6W-N((!RP8]>A.:ZB[T99;9K"/Y$,)B7JVT%-@ZG
M)P/?GUH Q/A;_P @Z#_MI_Z->LK6?^0]:_\ 7NW\IZZKPMH7]@VR66[?Y>[Y
MMNW.YBW3)]<=:JWOA3[3?Q:KOQY,939MSG(<9W9X^_Z'I[T <)J6E/JFM7$$
M5PUNYC0AD)W-B./*##*3Q\W7^'./36NOA;<W:F*6_E=#C*NKLIP<C(,N.M=!
MXO\  Z>(BDP=HIXON2(!GJ#ST)Q@[<,,$DU4N/"%]=[5EOWV!@2(H5B8@=1N
M1L]/7(S@X.* .@T#2?[(@CM-[/Y:XW-U/^ '11S@ #)Q4/BS_CSN?^O>;_T!
MJT+2W^S(L66;8H&YSEC@8R3W)[GUJ+5K'^T(9+;.WS8W3.,XW*1G&1G&?6@#
MG_A;_P @Z#_MI_Z->LK1O^0]=?\ 7NO\H*ZKPMH7]@VR66[?Y>[YMNW.YBW3
M)]<=:JV7A3[-?RZKOSYT839MQC 09W9Y^YZ#K[4 <_\ &O\ X\X_^OA?_0)*
MV_B!XI?PW;BXB56=I%0;\[1D%B2!@GA<=1USVP9?&OA3_A)X5MM_E[9 ^=N[
MHK#&,K_>]:L>*O#,?B. VLA(YW*P_A8 @''<<D$=P>,'! !S]SX,U"_53+J#
M*P'(BCV#)QD91DW 8X)'X#)JO\%/^/.3_KX;_P! CK07P5=7 6&ZO7D@7[R+
M&(V< $;6D5BQ!S\V<Y^N"-#P5X4_X1B%K;?YFZ0OG;MZJHQC+?W?6@#G_@I_
MQYR?]?#?^@1UJ_%+_D'3_P#;/_T:E6_!7A3_ (1B%K;?YFZ0OG;MZJHQC+?W
M?6K7BG0O[>MGLMVSS-OS;=V-K!NF1Z8ZT 'A/_CSMO\ KWA_] 6N0^'5TJW^
MHPD_.TS,!@]$DD#'/3@L/S^M=UI-C_9\,=MG=Y4:)G&,[5 SC)QG'K7->)?A
MTNJS_;X)G@N#C+)D@@*5X *D$C X;&!TR2: +?Q(D6/3YRZ[AM48R1R74*V1
M_=)#8[XP>#5?P/HYETJ.TFRHEBD!P1G;*6((/(R58'V[CM5>X^'DFJNK:A=/
M/&N"(U01*2#U(4D="02 &P>&&*[6@#Q2SUN2VTR?26#^>EPL*A #CS&)*94Y
M.2D@/7.X 9!XZ"^L?^$9U&P?.4DA6W8H-K.RC8&89P1ED/4D;?\ 9&=BX^'"
MS7O]HB4K&98Y3$B8!>,<$G=@DMDD[<_,PSDYK3\:^%/^$GA6VW^7MD#YV[NB
ML,8RO][UH Y_X=?\36[O=5/S*\GEQOTRHYQMX_A$?)&??.ZO0*Q_"?AU?#UN
MMH"&*EB6"[=Q8DY(R>0,#J> *V* ///B;,L-WISN0%6<DDG  #Q$DD] *] F
MF6%2[D!5!)).  .223T KG?%_@E?$KP/(^$@9BR[2=X8KE<AE*\+C//7VK'F
M^&]R8C9I?2"#)PA3)"XVA"P<$KMXV\+WVB@#/^!]DR13W!QM=T4#OE 2?P^<
M8_'\;OP4_P"/.3_KX;_T".NPT+0HM#B%M ,*O4G[S'NQ/<G_ .L,  #/\%>%
M/^$8A:VW^9ND+YV[>JJ,8RW]WUH YKX)72M;2P@_.LVXC!Z.BA3GIR5/Y?2K
M7QDD5+$!EW%ID"G)&TX8[L=^ 5P?7/45-J/PVS<&_LYWMY'8L^!O4DD-TRO!
M(R5.X'T &*EM/ #2SK>WMP]P\3!HUVB-%([[02.H4_+MR1\V[- %3QC:M::)
MY,@P\<-NK#(."K1@C(XZUT?@Z99;*V*D$>1&,@YY50"/J""#Z'BLSXI?\@Z?
M_MG_ .C4K%T#P)*((YK.Z>!9[>,N@7>NYT7<XRPVDX'(^8=B!@  J6-O]N\0
M22QE2L*Y;G/2)8B!C/(9N1QC![C%=!KO@#SI3J%C*UO<GD[?]6Y'/S ?WB!N
MZ@XR4))-7?"/@N/P\&D+&6>4DO*P^8Y.<#).!W/)+'DGH!5;P?=6\LLEK>-'
M'*Y;8T2RA2Q+-C<V "S$\ =LY(S0!7\#>*Y[J:72KT9N(-QW@;0RA@.F%_O
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MFB,C13W!2/=B-Y08OF!SE H'4Y^O- &)HW_(>NO^O=?Y04?$?_C\TW_KX_\
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ME@=Q.0<GK6%IGP[BTMP\$UPB"3?Y:RXC)R#@KMR1@ '))(ZF@#*UG_D/6O\
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M^VG_ *->NKKE/A;_ ,@Z#_MI_P"C7KJZ "BBB@ HHHH **** "BBB@ HHHH
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M\XP>A% &]14-I=+=HLT9RDBAE.",AAD'!YZ5-0 4444 %%%% !1110 4444
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M!UR#U'*Y'<>IQF@#JZ*\O\&:3?>)((YY[F6.!-X7RG(ED^9LLSY/0X49!X7
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M%&,X^7'\(KUB&%85"( %4   8  X  '0"N"^''_'YJ7_ %\?^SS5Z!0!YO\
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M"_.$)) P?OA1A<<$\=Q-\0-3_M]+/3X"P^W,DAQRRQX!!9 >1\Q;K@%#SQD
M'=:5J U*)+E595D4, ^-V#R"=I8<CGKWYP>*Q?B/J?\ 9]A,P*[G7RP&[^8=
MK <C)"DD?3., UT4,*PJ$0 *H   P !P  .@%<%\:_\ CSC_ .OA?_0)* -O
MP^G_  CFG1?NY7*1J61%W2[I#N8!>/NECQU '.2*XGP?XG^SW=[=/!<2O)(
M-D6^1%W/\C9.5X"C&<?+C^$5ZW7G_P ./^/S4O\ KX_]GFH ZK5M<@\/HBOQ
MN^6..-<LQ X147\ .@!(!(R*H6'CR*XE2VECF@:7.PW$?EJQ&/E!R>>?Z=2
M<2R_TW7I?,Y^SVX\OMMR$STQG_6-USU]AC0^+%JLVGR.PR8VC9>3P2X3/OPQ
M'/KZT =!K^MIHD#WDH8I'MR$ +?,P48R0.I]:RK/QY%?-&D$<TBR;,O''NC0
MN =KL#@%006QG'U!%9/C&Z:[T3SI#EY(;=F. ,EFC).!QUKH/!-JMK8VZ(,
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M%>!R#D#!!KI=/U"/48UN(6#1N,@C_/!'0@\@\'FG6EJMHBPQC"1J%49)P%&
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M<MU#@2*% )&<;G5<X]1G(SQGJ".*WJKZAI\>HQM;S*&C<8(/^>".H(Y!Y'-
M'#V7@$>(K>*>\N;AVF592H<",%QN&$*L!@-CC\  <"I\(K=+::^BB.Z-)$"M
MD'*AI0IR.#D=QQ6Q#\+H$06YFN&A!!,1E'EG#;L%0HX)YXP<\@YYK8\/^$8=
M!>:6#=_I# E3MVK@L0% 48 W'CGC% '-?#C_ (_-2_Z^/_9YJ/C7_P ><?\
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M =3Z4 :%<I\4O^0=/_VS_P#1J5U=9^OZ(FMP/9RE@DFW)0@-\K!AC((ZCTH
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MN1Z@T <E_P *4L_[\W_?2?\ QNM6?PU%X=TVYMH-VTPSL2YRQ)C(R< #H .
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M_P"C4KJZY3XI?\@Z?_MG_P"C4H ZNBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *ANY&B1GC7>X4E5R%W$#A<G@9/&>U344
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MN()(0JMN7D@1<8SD?=/4=JVO$_AY/$$#6DAQNP5; )5AT(S^1Z$@D9&:UJ*
M.,T_4-5M8UM6ME=T&SSVN!L..!(5Y<C&"W\1YX!.!>\+Z OA2W>6=]TC;I9I
M""22!D\XW$#D\Y)))P,X'2U#=VJW:-#(,I(I5ADC(88(R.>E 'E7@_P_<74!
M>VBMGMFFD:+[:I>3'"9^3('W #TY![8KJ-%\43V5TFC7D4:LR9C:W)$>U5)
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M';C'R#L>]=;XST1-$T>2SB+%(]F"Y!;YIU8YP .I]* .E\)_\>=M_P!>\/\
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M>O0]QTP?5:\\\.?!^/2ITNI)3)Y9#*H39\P.5).YL@=<<9.,\9!]#H ****
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MMOHEI)>1!2\>S <$K\SJIS@@]#ZUBQ^(M2U"V6]MX8E CW$2^87D(0$E(TZ
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M=+=HLT9RDBAE.",AAD'!YZ5-63X3_P"/.V_Z]X?_ $!:?XGA::TN$0$LT$H
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M#CYCCFJ_A_7[_7EBNXDA2W;:'\POYC$'$K(%) &<A0QSQD\&L_Q+_P @%?\
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MG.,9[U;UO0(-;00W*[T#!@-S+R 1G*D'H30!H5Y_\%/^/.3_ *^&_P#0(Z]
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MP(]1R. 37:Z-H$&BKY=M&J ]<<L>21ECDG&3C)..@XJIK/@NSUEO-GB5G_O
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MD<_, C%FR2H<@L2<[ <8YS]WYL4 >9:*UO#"FS49;=F&9(Q'*1OR02/+8#&
M!W)QDXSM7U/P+I]C8Q%+!UDSAG;<&D.[.W=@ K@9 4@8YXSG/+^$M6T8VR)*
ML0ECBS)YT0+$C[Q#,#N)/*J"3C@ 8P&>'!!J6K?:=-&VWBA_>E59$8D$ !<8
MZ[3@A<E&8 D9(!H:-_R'KK_KW7^4%:OQ2_Y!T_\ VS_]&I6W#H$$,[WZKB>1
M=K-N;D#;QC.!]T=!VJ75-+CU6-K:==T;XR,D9P01R"#U [T >?\ B[59=-T>
MT:!V1G6W4E#AL>46P".1RHZ8].A-:%QX%T?3H5N)@OE[1B1IG^?Y<Y&U@&+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3X6_P#(.@_[:?\
MHUZZNN4^%O\ R#H/^VG_ *->NKH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#/NO#UM=L9988G<XRSQHS' P,D
MC/2KL,*PJ$0 *H   P !P  .@%/HH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N4^*7_(.G_[9_P#HU*ZNN4^*7_(.G_[9
M_P#HU* .KHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBN<\;>*UT"!W1H_/ 4K&[<D%PI.T$,1C/3T]J .CHK$\/\ BF'5
M(XOWL1GDC4LB.NX,5W, N2>.>.HQS7-:-_R'KK_KW7^4% 'H%%5+'5H=0SY$
MB2;<9\MU;&<XS@G&<&K= !16?_PD-MO\CSHO,W;=OF)NW9QMVYSG/&.N:T*
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M!'4&@!]%5[W48K!=\SJBDX!=@HSUQDD<\466HQ7Z[X75U!P2C!AGKC()YYH
ML457?48DD%N742L,A"P#D<\A<Y(X/Y&J-QJ<.J0S+!.@Q&P,D;JWE[E.')##
M&,$]1TZT :U%8/@W3VLH"#<FZ#N6$A.[C 7:#N?@$'OU)XK0O=<M[!MDTL:,
M1D!W53CIG!(XXH O44R&99E#H058 @@Y!!Y!!'4&HKW48K!=\SJBDX!=@HSU
MQDD<\4 6**\Z^,%VEW81RQ,KH;A<,A#*<)(#@CCK7HM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '*?"W_D'0?\ ;3_T:]=77*?"
MW_D'0?\ ;3_T:]=70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM\B@J &2%Q(,="'\O.?<DY_BR"<ZWPBU-[ZQ"R'/DR-&IY)V@*P!R3TW8'0
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M"<C<RD%0"67W.W@$@ XOQ1\7Q:W;I';!GB$H+2[&5 P5@(_F RV#D^@QUR<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*?"W_D
M'0?]M/\ T:]=77*?"W_D'0?]M/\ T:]=70 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<I\4O\ D'3_ /;/
M_P!&I75URGQ2_P"0=/\ ]L__ $:E '5T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#GWA_[\I_\31_PB=G_ ,^\/_?E/_B: #_A++/_ )^(?^_R?_%4?\)99_\
M/Q#_ -_D_P#BJ/\ A$[/_GWA_P"_*?\ Q-'_  B=G_S[P_\ ?E/_ (F@ _X2
MRS_Y^(?^_P G_P 51_PEEG_S\0_]_D_^*H_X1.S_ .?>'_ORG_Q-'_")V?\
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M_P 51_PEEG_S\0_]_D_^*H_X1.S_ .?>'_ORG_Q-'_")V?\ S[P_]^4_^)H
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MB=G_ ,^\/_?E/_B: #_A++/_ )^(?^_R?_%4?\)99_\ /Q#_ -_D_P#BJ/\
MA$[/_GWA_P"_*?\ Q-'_  B=G_S[P_\ ?E/_ (F@ _X2RS_Y^(?^_P G_P 5
M1_PEEG_S\0_]_D_^*H_X1.S_ .?>'_ORG_Q-'_")V?\ S[P_]^4_^)H /^$L
ML_\ GXA_[_)_\51_PEEG_P _$/\ W^3_ .*H_P"$3L_^?>'_ +\I_P#$T?\
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MEG_S\0_]_D_^*H_X1.S_ .?>'_ORG_Q-'_")V?\ S[P_]^4_^)H /^$LL_\
MGXA_[_)_\51_PEEG_P _$/\ W^3_ .*H_P"$3L_^?>'_ +\I_P#$T?\ ")V?
M_/O#_P!^4_\ B: #_A++/_GXA_[_ "?_ !5'_"66?_/Q#_W^3_XJC_A$[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!DGCK1:W:7:B6)E=#G#(0RG!P<$<=:X#QYK]HU[;6URV8H&D:9"KE<F-3$2
M,-R>V>"0>"17=:4(O*0VX58F4,@1=JX;YLA<#&<YZ?6@"W17/ZIX7DU.1I'N
MIDCXV) 1%MX ;+ $ODC(SC;R!UJOX2O)DGNM.FD,JVIAV.P ?;(A.&(^\1@?
M-C).2>H  .HHKFO!%V]S]K\QF;9?3JNXDX4;<*,] .PZ5TM !16?J>OP:6R1
MSR+&9=VW?PIV@$Y;H.HZD9Z#FF:5XDM]5B:ZA<&)"0S$% -H#'.\#@ YSTH
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M>V<#KD*,  YQDG/5^$M$N;"2XGNC%_I#(P6 OL# $.VU@,%N"3R2>O:B_P#
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M8XZD'N:Q;7X:I:*(HKJ[1!G"I,%49.3@!,=: .MAA6%0B !5   &  .  !T
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MP/).X<@]>A[UK?$"%2UDY W"_@ ..0#DD9]#@9^@]*W;W1$NYX;QBV^V\S:
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M-@# ^8'G(/08Q0!F7>GQWFLH9%#>59!USV83$!L>HR<>AY'(!J;Q#"HU/3W
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M&OQZY&9HPR['9&61=KJR]5(YYY'<]<'G(&G0 4444 %%9^NZ[%H<1N9SA5Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH XSQNDEU=Z?:H0%,[2$'OY 5
MNN"<[2P Z$GGU$WQ \4-HRPPI((6G<YE9/,"(F"QVC.6.0 ,$=<E>"*GQ+M1
M$UGJ+$B.VN4WX4G"LRDL2.@&P#IR6'?@ZOB[0YKLQ7MHP%S:ERBMC8X< .AS
MT) P#D?49W* </<^*[;2 +BSOKB:167,4Y9E==PW*"\8"''\74#('6O6ZYJT
MU74;MU0VJ0H&!=I)A)E<_,JB,9W8Y!/R\<]15VYN;M;N.)(U-H4)=R1O#8;
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M1QUK$\76=S]IM+VVB\[[/Y^Y?,6/_6*JCEOQ/ /2@#JZY3Q]_P N?_80M_\
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M?\>=S_U[S?\ H#4 <UI/ABXUJVCN9KN9)'A38(7*H!L&TL#R['[SG(R3@$
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M9;=PQ^ZP)SD^@]"K5+RTO?$X6VN(5M[8.IE!E$KR*IW!%V ;1D<G(/((/!!
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M5MR+>+<%X*_ZWIDYR>#G[KD>PL>'?^0CJ'_;K_Z*-7?!&@G0[2.V8 28W/@
M?,QR02"<E>%SGD =N*R)([W2KVZN8+;SH[CR<'SHX\>7'@\')ZD]ATH [6BL
M&SU2\N8IF>V$4J(3$#*D@=L-@';MP,@=2,YZC%7M FGF@1[M52<[MRIRH^8X
MQ\S=L'J: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:K
MIB:I$]K*,I(I!Z9&>A&01D'D''! -2VEO]F18LLVQ0-SG+' QDGN3W/K4U%
M!1110!S^L^"HM2E^UJ\L,NW:SV[^6S#C ;@YQC^0.<##M'\'0Z=)]I+233 $
M"2=S(ZJ?X1T '7MGDC.#BMZB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH S-*T"/39)KA2S27#[G+MGIG:HZ85<D#OCC) &+=I8):%R@.97+L2S-EB
M/XB<#   '  P *L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5GZ1HB:5YOEECY\SRMN(.&?
M&0, <<<=3[UH44 %9D^@1W%RFH.6+Q(RHN[Y!NSN;;_>(.#SC&.,@$:=% %>
M\L$O0HD!(1U< ,R_,ARN<$9 /.#D9 ..!5BBB@ HHHH **** "BBB@ HHHH
M**** *^HV2W\3V[Y"RHRDCKA@0<9SSS1IUDMA$ENF2L2*H)ZX4 #.,<\58HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *S_ .Q$^T_VAEO,\GRL9&W;OWYQC.<^^,=JT**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gpsmoa.jpg
<TEXT>
begin 644 gpsmoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $R 1X# 2(  A$! Q$!_\0
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MW- %JO)/&W[16DZ-K6I^&/">F7GQ"\<6 C^T>'M#=-UMO.%:XF<B.$="=QW
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MBFP3&0,G!4@,I%.N/CYK&J_VBOA+X6>+?$7V62-([BZCATRVNP^<O$]PZEE
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MW:\8^)%ZOQ,^+'ACX?V)\ZST2ZA\2>(Y%Y6%(B396S?[<DP$FW^Y"3W%>ST
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MX%VV]SI>C_$S3EX2_M+I=*U$KZR0N#"[>Z.@/]T4 >QT5X'9_M0:OK'C[5O
MVF_"OQ%)XOTNRAU"ZLKN]L888X)698W\[SF!!*-T!/'2M.\\$_$OXJ,;?Q;K
M5IX&\,R#$^B^%IWEO[E3_!+?,J^6I[B% QS]\4 5?$6I+\?/B-9^&-+_ -(\
M$>%K]+SQ!J"Y,-Y?1,&@T^,]'\MPLLI&0"B)U) ]R%9?A?PMI/@K0;/1-"T^
M#2])LT\N"TMDVI&OT[DG))/)))-:M !1110 4444 (> 37BVAQGXM?'B\UYR
M9/#'@0R:7IR=4GU:11]JG]_)C80@]F>7TKJ?CA\0KCX>^!WDTN-;GQ-JT\>D
MZ':G_EM?3$K'G_93F1O18V-;'PQ\"6OPT\"Z1X<M)&G%E%B:Y?[]S,Q+2S-Z
ML\C.Q]VH A^)OPSTOXH: MA?O-97EM*+K3M5LVV76GW*_<GA?LP[CHP)4@@D
M5XAXV^+WB*+X>:Y\/O$DC:#\4)#::;:WU@QBBU2&XN8[<7UF_4$!R70?-$P]
M-I/T]7@G[1<GAJZ^)GP:L/$,VG62QZQ=ZE'?7SI$8A#:2+M21L;2SRQ\ \[?
M:@#X^T?PE%\3-"U/PE8Z'H]]X#TO6)=;72=0O;Z%[V:YEF94FFAEW,@A\@X<
M-EFS73>+O 6@ZGX?TRTTKX/M\-O$F@2%]%\6?#74;<W%G*0#EHY!"TT;<!D<
MMG/4=:]EU#]AG1YH+:X\->*5N8X88XK=M8LTG?RT7;&OVJU:"8@   L[' %<
MQ?\ [.?Q.\)L?L,FI7D YWZ%X@CNAP.OV;48B2>.@G_&@#2^&_[6?C'4=+\-
M6,FGZ?XEU"S>STWQ'=7$4NF3?;KB^:U18(<.I*JCR-D@':=IKU#XX_"7Q5XR
M\8VGB+PM-9VNHV>F_8+>>XE*[?-E9+@8 Z>3(S#U9%'O7SQX!^'OC+P?K'A[
M3K+0IKKQ'JOBZ;6%@\4LFGM);65HY^T2B'S0J_:KUR%3.<#D5].-\*?'OC15
M/C/XCW-A:M_K-)\%VXTZ(_[)N7+SL/\ =9* .*\'?LYW&CW>I:;+JMUI,,>D
M265E;Z+J[V[,IO+R1/-5<$J$FBY/0EA6QX)^'OCCX>>'Y- L]$T75XM4CLY)
MK^_NLQV<J6T,$JR1;<S*/)W)M(SNP<8S2> _AQX=^&O[3MQ9>'M/^QI<^#A-
M<32323S7$@O<;Y)9&9W./4U[_0!Y'\:/AOK?CNZM7TQ;=A%I5W9MYTNS]Y)/
M:NO;IMA?GZ>M>MBEHH **** ,#Q]X=M_%W@;Q#H5XC2VFI:=<6<J(0&*R1LI
M )Z'!KE/V:]6?6O@#X N9+.\T]UT>W@:UOSF>,QH(\.=JY/R=<#/I7I->,_L
MEW5JWPA-A9WMY?PZ9K>K:?YVH',V8[Z8%3\S<#.%Y^Z%Z=* /9Z*** "BBB@
M HHHH **** "BBB@ KYP_; \,^)?%E]\-K&RUO7/#7@9-4N;GQ=J^AZ@+%[2
MSCM79'>;.53S .GXU]'UXA^V=KD>B_L]^(8Y;B&T&I2VFF>=<.$C59KF-'+,
M> -A:@#Q?P#^RC\&?B#XFU35/"'QL\>ZYK_V:**_O--\9M)<F ,?+61PN[8#
MNP#QG->J_L=>%_'G@GP]XZT+QM=:Y?6MCXIO(?#UUX@N!<7,VF#;Y+F3JP)W
M'+<UB_LAOI_B3QA\2_$VF7-O?6/FV&CP7%JZO'^YA:60*R\'YKCG'<5].4 %
M%%% 'E=_^T%86OC;7/#%IX1\6:Q=Z++%%>W.FZ:LL$9DC$B$'S Q!5AR%[$=
MJ;#^T+923!'\"^/X$Y)DD\,7.T8[G )_2JFN(?!/[27A_5%&S3O&>ER:-=$<
M+]LM=T]LQ]VB:Y7_ ( !7L- 'E$/[27AIRQET7QC;1JI9I9_"M^J@#W\JEC_
M &F_ ;+(\EQK5K%&NYI+GP[J$:@=.I@KU:DH \1\$7D7QM^+DGC6..9_"7A>
M!M/T)KJWD@^TWLJ@W5TJ2*K81-D*DC^*7%>W48[TM !7.>/&\+V_AN\N_& T
ME= MTWW,NM+&;9%]7,GR@?6NCKPS]K[QJ?#_ ,+)/#MGY+ZYXNE&C6:3(KB-
M'!-Q.5.01'"';G^+9ZT <E\/-!^!7Q@\1:K;?#6]U'P_J.FK%=RW7A:YNM*B
MECD+*KQJ-L<J90C(0KD#FO0_^%<?$SPS@^'OB?\ VQ$GW+3Q?I,5SGV,]N87
M_$AJ\@_8V^#IGO(/BI#J=]9:<UK+H>AZ.C+]FDTF,JJ2N"-V]Y8C(IS]TKQS
M7UY0!X[X+\)^.]2^,'_"5>-['0[2+3=$?2[ Z+>2SK,\LZ22R%9(U,?$48 R
MW?FO8J** /*[.X>3]J+5H6VE(O!]HR<<@M>W&[G_ ("OY5ZI7E6ARK<?M->+
MU:)1);>%]*59.<E7N;XD?FHKU6@ HHHH **** $;I7D'[-MT)M%\:P-J;:E/
M:^,-6BD62-D:VS.76$ANRJRX/0@@CK7KTGW3VKRKX&V3V>N?%)GT9M(\_P 6
MW$JR-*S_ &T&W@'GC)^4'&W X^2@#U>BBB@ HHHH **3-+0 4444 %%%% !7
MSY^U-\9+[P;;Q^&=$MM)DU&XTRZU>\O]9C\^WTVTAP!+Y/\ RU=G.U 2!E23
MG&#]!U\3?&OP3JWB+]JV/PWJ%L][8>-UL$@NHXR8X-+L]TM[;.?X6+ D9X83
M\?=- 'T%^RWX;UGPU\"_"J^([EKSQ'?VHU+4IGC2,F:?]X5V( JA0RH% P-N
M*]7IJJ(U"J %'  Z"G4 %%%% 'EG[2>DWMU\+;S6=+C,NL>&;B'Q#9(H^9WM
M7$CH/]^(2I_P.O1-!UJT\2:)8:M82B:QOK>.ZMY!T:-U#*?Q!%6YH4N(7BD4
M/&ZE65AD$'J#7D_[-LG]A^%=8\#2RE[CP9JL^D1AC\WV0D369^GD2QK_ , -
M 'KE%%% !1110 C?=-? 7QCUJ]_:#^/#Z-HURPBFN9/".BW$9R(H%(DU>^7Z
M!/*!]8U]:^J/VE_B7=?#/X6WT^DLO_"2ZK(FDZ,AZFZFRH?'I&N^0^T9KQW]
MB#X9VT<FI^,U4RZ991?\(YX?DEY9X(G_ -+N?K+."-W<1>] 'U1H&AV7AG1;
M#2=-MDL].L8$MK:",86.-%"JH^@ K0HHH **** /)_"MS;7'[2GQ"3Y4O(-"
MT>+:7&7C\R\;(7T!8C->L5POQ%^#/AKXE36U]J$-Q8:[9C_0M>TF=K34+7G.
M$F3DKZHVY3W4UR)USXF_";)UJQ/Q0\-1\_VIH\*P:S GK+:Y$=QCUB*L?^>9
MH ]HHKE?A_\ $[PS\4-).H>&M6AU&*-MDT(RD]L_=)HF >-A_=8 UU5 !111
M0 UONFO'_P!GZ&&+7_BZ8K2[MBWC.Y9VNFR)6^S6WSQ_*,)C '7D'FO8&^Z:
M\@_9_FBFU[XN".]NKPQ^,[E'6Y3 @;[-;'RX_F.4&00>.2>* /8:*** "O*_
M&/QEU&W\;/X,\%^&F\5^([>*.>_DFNUM+'3XWR4$LQ#,9&4%A&BDXP3@$9M?
M%OQYK^@ZIX8\,>$;2RN/$OB&:98Y]1W-;V5M"@::X=%(9\;D4(",EQSQ4/PS
M\ V_P_T.YM_MTVN:KJUY)J>J:HVR.75;I]I:2,*^$1 %4)T"H!SU(!B2'XT:
MY*9%USP=X;C^;[);V5C/J1NR.N^222':!Z!<]>:V/A?\6[S7=>OO!_BZRM=&
M\;6,?GB.TE+VFIVV2OVJT9L,4# JZ'YHVX.003UYF\Y6^=KCSFY$+A3<X'_+
M+Y_EV]_7!KCOB7\/8OB%!IMW;:K<:-XFTJY-UI&O:<L;2QR[75D1';:R%<K)
M&W#@=B 0 >JT5X3-\6OB#\,[2.^\?^'M)UKPW&2EUK_A&:5Y(%7.9GLY%W[
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M/[WXUY6FC^)_BE\6O&NG2^.-2\+Z#X?2SAL;7PR8HVG>:(R--*\B29P<H%4
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MLI[;;)&MQ'GRS+"X,<R G.QQC(!&" :Y:7XK>,OA2R1?$CP__:FB@[?^$O\
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M')<VQ$L+AAD,7="&/?>U>;?LK^/X8_B4C0[H=#^(6EKJEK&RX\O4+<8F1O\
M;:$KGWMVKVG]F6S-C\*5C\D0)_;.KM&BJ -IU&X(P!VQ7DD7[,GCBU^*D3Z3
M<Z-I/@[2_% \1Z9J$KR2WD22'?/:1PJ JJ6DN%W,Y^67IQ0!]8.XC4LQPHY)
MKYB_:UN-+U'PGIWQ(\/W>GZZ_@F]>'58[6[B8/9SJ$N(&89"LK>1)CK\O3FM
M[]ISPE8_%KQ-\/O 7VB^2[N-0_M>]%K=O%#'IMN09_/C!VRK(QCA57!&7)'W
M37,_!WPB/'VM?$F*P\&Z?H?P8\7:=]ATZ33Y$3[1) 7MGN/("KY8E0@H1G(B
M5B030!I_L,_$*36_AC)X0U*VN=.UKPU)L%G=QLCK8S,[VA4L%+*$S'DJO^KZ
M"OI2OF+]G7X$_$;P7X[LO$OBZ]T>U6TT>31)K?3Y)+B74E616BGD8A5C(V%L
M ,?WC#-?3M !1110 45S.I_$/0])\<:7X1N;SRM>U2SGOK2V9&Q)%"5$AWXV
M@C>."<D9QT-9O@7XR>%_B3:&Y\/7[7T'V=KH.8'3,2S20EL,!_'#(/?&>A%
M'!?M0>)=+LY/ .@:_=KI?AO5->BN=5U"Y5A;);VH^T+%))C:GF3+"HW$ C=7
MC/[;VH:A\1O^$8.@6S:_X,M(&O)=3T]6NK*69YD1XGEB5Q&1 LH#. O[[J*^
MD[SXZ^"]EJ)+R:XL[NW@GEN([&:6WMXY\>4;APA6+?D8#XX()P.:\=_:%^'/
M@?P;XT\$ZUI=O+X1OI-34:K-X9FDTV2:RF9;<S.\)528IY[9OF!R"W7F@#Q[
MPWXB^(7Q"NM9\4?"[086\126UOX6TNXO+ZVE32!<.TEYJ+".1MRHL<"K@9+#
MD<8KUS0O^";_ ,+-.\-Z<'N/$,'C2(-+>^,],UB>TU*]N68M)+(RMM.7)(!4
MX&!7=Z#^S*VD_%;P_P",+SQ5-K@T?SVA%]I=LE](\D1C EO(51I44,QVNIYP
M<\5[G0!X9^QOX8;PW\'YVFUC4/$%U>Z[JD\VJ:M()+NYV74D"-*P RVR%!^%
M>G^.?AOX8^)>FPV/BC1;36K6&7SHEN4R8GQC<C#!4X)&01P<5PW[/\_]D-X\
M\'RY6YT'Q)=R)&PP?LUVYNX''L1,Z_5#6!XL\2>/M!^-D.D2>.M'TWPD^E76
MOS?:=#!>WMX)H4:)I3,!@K*Q\PCC'2@#M=:_9Q^&?B*'3(=0\&:7<0:9:_8;
M.(1E$AM]VXQ!5(!4MR0<Y)-:E[\'/ ^H:[HVLW/A?2Y=3T:-(M/N#;J#;(G^
MK50.,)_",?+VQ7,+^T#9:OX@:U\*Z4WBW0[2VMKS4M;L+R(16T,[NL;(K',V
M!&[-M(P!W/%>?6/[7W_";6NFOH&D2:>+S4]+$5Q=?OHYK*ZNA"V2 !'-MPVS
M)P&!R>10!]-?PUY+\"T72?$GQ7T.+_CULO%4EQ".R_:;:"X=0/\ KI)(?^!5
MT7P1\8ZA\0/A+X7\1ZKY(U'4K-9Y_(3:FXD]!DX'XUSG[/4W_"01>.O%R_-;
M>(O$ES-9R#I);0+':1N/9OL[,/9A0!Z!XY\)6/C[P?K/AS4EW6&J6DEI-@9*
MAU(W#W!P0?4"O./@GXLO=8\)_P!CZV6@\5^%W&DZRGE#S(9D50DT2[3NCN$V
MRAO1R.Q ]DKQ7XA+#X!^.W@_Q23]EL_$UN_AB^NE3.RX7,]DYX/)(GBS_P!-
M%% &7\!/ >@67Q0^*NLC0["WU^T\0SVR:G!&!,8+B"VN7B9P!N7S&) (XKWZ
MO!;XR?"?X[:9J5M<.-%\>70TO4='R&2TU&.W+6]S#P"1)%$4DZ@$(>.:]YH
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M4=O/DWR_[OE>E ":+^ROX7&FZ?9^*=0UCQS#8Q)#!9ZS=[;")4 "JMG"$AP
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M:U5E"V]KGTAA")_O;SWH ]0I:** "BBB@ HHHH **** "BBB@ HHHH ****
M*]]8V^IV<]I=P1W-K.C12PRJ&21&&&5@>"""017@.CZE%^S3X@M/".O7[VWP
M_O9&'A?7+^;]SI+;>=.N)&(^7KY+,3\OR9RJY^AJJ:II-EKFGSV&HV<%_8SK
MLEMKJ)9(Y%]&5@01]: /$_$'[./P[\4>-M4\7:M8S7\NH+%->:?<:@[:=E%9
M4N9( X60LH4?-D8 XXKTO3;"P\/V4>GV%G;Z796F9$L[<+'';I\^)-JD#8?[
MO;\...;]F/PGILKR>&+_ ,0>!]S;_(\.:O+;VP;U%N2T0^FS'M2?\*1\3VT<
M:VGQA\8 K(TN;N*QGRQ['-N/EY/R]/RH 3Q1\(['6O$U[XBTCQ)KO@[7;R)/
MMMUHE[&J74:!A'/-%*KHP4<# #8XSCIYW\8O@_:1?"[QAK?BGQ7XA\9ZOI^B
MW5Y8-J.H"V@MW2%C'<QP6_EQ@AB""P9LXQVKT(_#3XI6ZM%!\5+6XC=M_GWW
MAN-IXV[D&.5$/!/!7'3BGP?LXV&K7$4_C7Q5XB\>^7*MQ]AU:Z6*P,BD$,;6
M!41@" 0KA@,4 >C^$))9O">BR3LSSO90-(TGWBQC7)/OFM>D50O I: "BBB@
M HHHH *JZIJ=IHNFW>H7UQ':V5K"\\\\IPL<:@LS$]@ ":M5XO\ '>5/'^M:
M%\+(Y=EGJP;4_$<@;;Y6D0,"Z,>WGR;(O]WS?2@#RF1=3^)6GLD;S6'B3XP7
M'#<B;2?"MN/S1GC?_OY>?[-?6>E:9:Z+IEII]C;I:V5I$D$$$8PL<:J%50/0
M  ?A7DOP'M/^$TU;7OBA/%LAUO;I_A^+;M$&CP,1$RCMYS[YC_LM&.U>RT %
M%%% !5/6-)L]>TN[T[4;6*]L;J)H)[>=0R2HP(96!Z@@U6\4^)+'P?X;U37-
M2E\C3]-MI+N>3^ZB*6/Z"O'O"7[3ENWP]AU;Q/IKIXA_MB/1)-'\/@WK-<S)
MYUNJ8/\ %$R$DD -NR0!0!CQ?!7QI#XBT+P'=7B:S\'["\35X[J\F+7R+ 0T
M&ERY_P!=$LNR02'G9$$;/4_1BJ%SCUKYZU?]K>PDO-.BTW2=0M+"]T6;5&U+
M4+&0K:2Q7T=F]O+&IR'#LRG!X(7J#6Y>?M9^"=*U:YMM0BUBPTZ/[=Y.N7&G
ML-/NC9AC<B*4'YBI4J,@;B/ES0![717B.G_M;>#]4T=+FSL-<O-3DU(:2FB6
MMFLUX;AH&N$7:CE-K1(S!M^!@@D$&O2O ?C[2/B+X7TK7M)F;[+J4 N(H;A?
M+F49(*LA.00001ZB@#I**** "BBB@ HHHH **** "BBB@ KS_P"+_P 7HO@[
MH::Q>^&];UO35S]HGT>**06PW*JEP\B'DL ,9[]*] KA/CAX)O\ XB_"W7/#
MNEO#'?7RQ")KABJ#;,CG) /930!K^'?'%KK&C+?:A;R^&[@*'FT[5Y(H[BW5
MG*(9 KL &(^7GGZU5U#XN>!])FO8;WQCH-K+9 -=)-J4*& %MH+@M\N6&.>_
M%>3_ !J^#?C7Q=XRUZX\.Q:--I/B*PTJTNYK^YDBFM39WK3DHBHPDWJY R5P
M5[YK.L/V79HY]%FN=,T.::W;Q.]U(T2LTC:A,7MR24^8A3AL].V: />W\<>'
M(]<M-%;7],76+N'[1;Z>;R,3S1XSO1,[F7'.0,4[2?&GA_7K6^N=,UO3M0MK
M!S'=S6MU'(ENP&XJ[*2%(!!Y[5\T:'^R_P",--GT;3Y8?#TMFMQHNI7.O-(Y
MU"TDL;6&%[6$>7\T;F$X;>N%ED!4YKOK'X!W</[+2_#6+^SM,UF32$M)YK>/
M_1Y9UP3YF "R.1M8XR59J /1X_BSX)DT&#6U\7:&='GN/LL6H#48?(>;./+#
M[MI;VSFLK_A=.A_\+"7P<([IM4:]6P601CRC(;,W8.[/W?*'7'7BO ?'_P"S
M/XY\?26NLMH'A?0KA?MEO)X=T/4YK.!TGAAC^T2W"P'S7_<D%?+7]VP7=D9K
MM_"'[/>O>%_B1H.L?:+.32]-N[:0_OG:0QQZ-]A/W@23YG/)SMY)S0!]$444
M4 %%%% !1110!2UC5K/0=)O=3U"XCL["SA>XN+B4X2.-%+,Q/H "?PKY0:UU
M3XD:>+4M-I_B7XOW'VBX896;2?"UN %3U1GC<+_UTO&/\->I_':6+X@Z]H?P
MN\W9INH(=8\32!MHBTJ!@?*8]O/E"Q_[BRU+\!;5O&E]KOQ1NH3&/$16UT.)
MEVFWT> D08';SF+SGVD0?PT >MZ=I]OI.GVUC9P);6EM&L,,,8PL:* %4#L
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MU+4;CXCZM:WVFR7NEVNG06:W&G6TSRM"D*G$L@>02 .WS&,*,=_IG8*4#'%
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MO*J#YA@QEN.A)Q7%IX;^*'@KP'HVE:5>^(I;#^SM'DU"2=6FN+0[9UN8X!$
MX *VX9$R57)'4T ?7%+7)?"G^V_^%>:'_P )'/-<ZU]G_P!(FN+?R)&^8[2\
M>3M;;MSDYSG..E=;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2$9I:* *]]<+8V-Q<E&<0QM(5C&6. 3@#UKYUA_:6U]
M8S]IL_#<;WNFV.I:<+:\GN7'VF9T6"6-(RQE 3.%X)W<@*37T?-&)HWC;=M9
M2IVD@\^A'2O+O!O[-_@WPE_:_FV7]NG5%CCN/[6AAE#1HQ=5(6-0YW,6+L"Q
M."30!Y!IW[2.JZU&?$\VG0,;>V\VWL=X"12);:DTN'*;]LALTXX(]\'/577Q
MR\73:A:^%[W2/"L.LWMS]GE>\OY5L/)>Q^U $E-S-C<A&,'[W3(KVB'X?^&K
M>W\B+0--BAQM\M+6,+@AUQ@#&,22#Z.WJ:\?\2^-?@CXT\2:8FJW%I?7%C<O
MB"XTR1[>5R3:;Y"T15EC;]WOSA&(&1F@#G='_:XU;5K:^OK+P6(=$LK2<!I)
MMFR:&S-QG=P#$<;1M&[!#].*MZG^TEK^E*?M>G:3=:A:Z?)JBC2=1:2RF1K1
MYHHW<IG<"ASCC#*PZXK=\4>-OA3J7AS7-1O[6QCU:32I[)QI]H'U![<Q3#9"
MPCW,NR&09 VKL(/2M;PWXB^$^G^ [.X@TS3=*TA0@DMY=.$1BDFM!.5D38/F
M, R>.0,>U '+ZM^T1XQ\)OJS:YH6A>3875WIY:RO9B7GAMX[D/\ ,@Q&8Y-I
MYR&7/0\:,?QPU2X^-&HZ?YEI)X2TBWO(YX]/BEN[RXFC^QE61(U))'VD@J,\
M D]*ZFU^(WPR\0:A86>^TEGUG$T2W6GNHD:=#&OF%XP%:5%*J'P74# (Q79:
M1\/?#'A^2T?3/#^F:>]F7:W:UM(XS"74*Y4@#&X*H..H ]* /#;[XH:['\2W
MOGUF^3PR-8M;"-;/[.8K=95C M[NSE5+E)69\B1"P 93MP&KZ1"CZ5BW'@CP
M]=>(HM?FT/3IM<B 6/4I+5#<* "!B0C=P"1U[UN4 )2T44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E %6SU2TU&2
MZ2VN$G:UE\B<(<^7( "5/OAAQ[TV]UFRT^[L;6YN8X;B^E:&VC8X,KA"Y5?<
M*K'Z U\Q>//A?XO\:>"7T/2-,AN[VVU76EO+BYE$4BS32M);3IO.W;L=?W@#
M.N!M'6LOQ)^S[X[UN^A,FAQ7.LK'?--XH;6BLDJ3630Q6XCZ@HS!=W0;=RG+
M&@#ZVO+^#3[2:ZN'\N"%#([8)PHZG KR6^^!^C66A/'<:W=1VIL9=/,OE*3M
MFOA=;L ==^%^AS7"ZS^SAJ^FOKLOA>RCL)KJXU.*V*Z@XVV<VGJD48RQVC[2
M"^.Q);O2ZA^S_P")H;E]1TN!;?5KW4K^;4+C^T'#36[WD,MNIYZ*D;84?=Y'
M\1H Z2X_9YT/1M0TV]O/$]U;W(@GT*S:18T!M[HRM-;@?Q,[N'#=08E XR#)
M>_LTOJ4*6UUXQOFL66%[FW6RA437$=D;-9=V,J/+*DH.-RYZ'%>;:1^SGXRM
MII5NM'M;RTM=;L]0MOMMY')<F1))@\X=<*X5958&15D;;@DX%:'@/]G7Q9;I
M8VOB*.YNK9-5L9]2CNM2B>"^\E9_-N D:*3N9X\^82S  ,/ER0#TNY_9TTB;
MX@6'B=+Q#+$+0SQ3V$$SRR6R!(F25E+1<!<A>NT$$<Y]3TG6++6[/[587,=W
M;B22+S(SD;XW*.OU#*P/N*^5-)_9_P#'NFWUY<:C;W.O(MT)-2LY-5ABM_$$
M?G.P&%0,"H9#^^;^'9RO-=)<?!'Q'+^SKHOA9=(:SU*SU:>_;2K34(Y52)[F
M>1(R\P*3A5E3*OMSMX8$"@#Z4W#..]5+C5K.UO;2TFN$BN;LL((F.#(5&Y@/
M4@<_05XCK'P_\7:I\-_!NE:OH%MKS:,4&IZ+#J)@AU(?9V1=LC,3^[D96(<\
ME"1G"UO:II.J_8?AMI$EB]IJ5CJ\$C%+AKE4AAMW\UO-;YBI#&,%_F)8&@#U
MRBDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (X?NU)110 4444 %%%% !1110 5')]\444 24444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mrkcombotrialfeaturesandsche.jpg
<TEXT>
begin 644 mrkcombotrialfeaturesandsche.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK
M$UOQG::(XAN9-CE0P&QVX)(SE5(Z@UMT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M3)IEA4NY 50223@ #DDD] *Y^7XB:?')Y!G7=D#(#%.<8^< ICGDYP.^,&@#
MHZ*AM;M+M1+$RNASAD(93@X."..M-U#4(].C:XF8+&@R2?\ /)/0 <D\#F@"
MQ169H?B2WUU6>V<.$.&X*D9Z<, <'L<8.#Z&M.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEK.Y>2(AE+MERK=1SR0I'4D_> X %</IL'_":ZH6?<8Y)&9LKR(T^ZIVD8R
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M!Q;*PX]"(R"/<'![52OO'FL:?CSV>/=G'F0(N<8SC,8SC(KW6O*OCG_RZ_\
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MQGC.!Q6A0!7U#4(].C:XF8+&@R2?\\D] !R3P.:\<\0_%:ZU9Q#9!HD;*@*
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MN!\P(P=W/&>!R.<\I\$YF%W(@)VF DC/!(= #CU&3CZGUK3^.?\ RZ_]MO\
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MML7C($TAVQYP<?WFP3T4>Q&XKD8-8_P@\3?;X#8R']Y;_=R>3&>G4DG:>.@
M&P5PGC[7&\47WDP_,BL(H@",,2<%L[BOS-T;C*A<]* #1-?U?89K9II$9BI.
MWS\%0#C#!RO##TS[XXT/^$EU[^[-_P" H_\ C=>MZ!HRZ+!':)R(UQGGDGEF
MP2<9))QGC.!Q6A0!X):_$?5;MA%%(SN<X5(8V8X&3@!,]*T/^$EU[^[-_P"
MH_\ C=97PM_Y",'_ &T_]%/7T!0!Q5UKEYIFD&]FXN@HSO501OEVJ2HP 0K
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MEVDIB0[SFWV ;0?F)"#@ GJ<4 >O^"->.N6D=RQ!DQM?!!^93@D@ 8+<-C'
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M/^,ETLU\$4Y,<**W!X)+/CWX8'CU]: /6O"?_'G;?]>\/_H"UY5XE_Y#R_\
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M'3_]L_\ T:E 'D_A?XAW'AN(V\*QE6<L2X8G) '9EX^6MC_A==Y_<A_[Y?\
M^.5U?P4_X\Y/^OAO_0(Z] H Q_".N-KEK'>.H5G!R!TRK%21GL<9QSCID]:V
M*** /!/BQ=--J$B,<B-8U7@< H'Q[\L3SZ^E>YZ=9+81);IDK$BJ">N%  SC
M'/%>.?&?2_LUVER%PL\8R<YRR<'C/&%V=@/QS7IO@?6%U:SAE#%F"!7+'+;T
M #9Y/)^]SR003UH Y#QM\4;C1+I[.%(RL87)<,Q)90V>&7 YQCGIG/.!@_\
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MC!S@$ <YS@88D Z7X<>"5\/QF=F6268#YDY0)U 5L D-P2> >..,GS+XI?\
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MQ2?;T8,KC:SJ(R01R-@5>!UW=]V/X:Z>[M5NT:&09212K#)&0PP1D<]*FHH
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M@F+[CP'!R "  !@8QP0<G/O=% 'EG@3X526DJWE[@&,ADC5LG<#P6(XP, @
MG/&<8*GU.BB@#RKXY_\ +K_VV_\ :==5\+?^0=!_VT_]&O7*_'/_ )=?^VW_
M +3KJOA;_P @Z#_MI_Z->@#JZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?\ X6_\A&#_ +:?^BGKZ K!
ML/ UGI\PO(8@LH+$$,^!N!!PN[:!@GC&!VK>H **** /%/@I_P ?DG_7NW_H
M<=>UUB:)X,M-$<S6T>QRI4G>[<$@XPS$=0*VZ ,GQ9_QYW/_ %[S?^@-7 ?
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M">QZ?0M8.L>!K/6)/M$\0:0@ D,ZYQTSM89/;)YQ@= *VX85A4(@ 50  !@
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MQ@MT R,*"1]W%>E67PDT^W7:Z-(<YR\C _3Y-@Q^&?>NMM;1+11%$JH@SA4
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MY96&8R<%MH.2"N'4<\X/-?0=8.L>!K/6)/M$\0:0@ D,ZYQTSM89/;)YQ@=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445GZSKD6D*))2>3@*O+'UP,CIW_ ,2*<8N3
MLA2DHJ[V-"BN/7XDQ;B#&^S'!!!;/'5<X'?^(_X=+IFIIJ:":(Y4_F#W!'8C
M_P"N.*N=&<%=HSIUZ=1V3N6Z*J:AJL6G#?,P4'IGJ>G0#D]><#BN<?XD0@@!
M'V\Y)V@CTP,G/OR,>]$*,YJZ0ZE>G3=F['745EZ-XCAU?/E$[@,E6&& SC/H
M?P)QD9Q5/_A-8?.^R;7W^9LSA<9W;?[V<9]J7LIW:ML'MJ=D[Z,Z"BBN?U3Q
MK#ILC6[JY9<9VA<<@'NP]:4(2F[)7'.I&"NW8Z"BJVHZ@NGQM/)G:@YP,GDX
M _$\?SKG?^%CV_\ =D_[Y7_XJG"E.:NE<4ZU.#LW8ZNBN:M/'T%TZQ*LF78*
M,A<98X'\5:^LZRFDIYTF<9  49))_(= 3R?UH=*::36K"-:G).2>B+U%<U:_
M$"VN&$9#KN.-SA0H^I#''^<\5TM$Z<H;JPX585-G<**I:MJJ:7&9Y,X! P,9
M))Z $C/K] :R+'QY;WCK" X+D %E&,GIT8GD\=/THC2G)72T%*M",N5O4Z2B
MBLC7/$\6C%5DW$L"<)@D =R"1U[?0THQ<G9;E3G&"N]$:]%96A>(X]:W>6&&
MS;G< /O9QT)]*U:4HN+L]PA-35UL%%%%(H**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **8QJ-F-)NP$]%5&<^M1-*?4_G4N8&A166TS>I
M_.HVG;U/YFI=9(5S8HK":X;^\?S-1M=/_>/YFI>(2Z!<Z&BN9:[?^\WYFHVO
M'_O-_P!]&I>*2Z!<ZJBN1:^D_OM_WT:B:_D_OM_WT?\ &I>,BN@<QV=%<0VH
M2_WV_P"^C_C4;:E+_?;_ +Z/^-2\?'L+F.[HKS]M3E_YZ/\ ]]'_ !J-M4F_
MYZ/_ -]M_C2>8Q[,.8]$HKS9M5F_YZ/_ -]M_C3/[6F_YZ/_ -]M_C4O,X]F
M'.>F45YH-6F_YZ/_ -]M_C3AJTW_ #T?_OMO\:7]JP_E8<YZ317G U6;_GH_
M_?;?XTX:I-_ST?\ [[;_ !I?VM#^5BYST6BO/!JDW_/1_P#OMO\ &G#4Y?\
MGH__ 'T?\:7]KP_E8<YZ#17GXU.7_GH__?1_QIPU*7^^_P#WT?\ &E_;$/Y6
M'.=]17$V^N30]&)&<_-S^IY_6M>S\4AL"5<>Z].OI_\ 7/TK6EFE">CT]1J:
M-^BFQR"0;E((/<'(IU=Z=R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRBN>@UYT^]AA^1_3C]*V+34$NONGD=CUK.5.42XU(R+-%%%06%%%% !1110
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M]SX=??\ ,AS@.IRIYR!GH<XSM/;J*[KP?XB.L(0X_>1X!(Z'.<'V/'(Z>G7
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MCV-<**OZ1J'V-\G[K<'K^?X5W9?CG1ER2^%_@5&5CL:***^B-0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSCQ;_
M ,?4G_ ?_0%KT>O./%O_ !]2?\!_] 6O1RG^,_3]4>=F_P#!C_B_1F2*=313
MJ]IGC(<*44@I14LT0X4X4T4X5++0HIPIHIPJ66APIPIHIPJ&6AXI12"E%2RT
M/%.%-%.%0RT.%**04HJ&4APIPIHIPJ&4.%**04HJ64A12BD%**EC%I:2EJ6,
M6EI*6D 4JMMY'44E%(9T&EZO]H/EO][L1WQ_7]*U*XQ6V\CJ*ZC3+W[4N?XA
MP?\ '\:YJU.VJ.FE4OHRW1116)J%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %)2TE "4AI:0T ----.--- #33#3S3#0 QJ8U/:F-0!&U1-4K5$U
M$;5&U2-4;4 1M4;5(U1M0!&:8:>:8: &&FFG&FF@!#5[2-2^QMAL[&Z^Q]?\
M_P!*HFFT =U16;H5UY\>T]4X_#M_A^%:5 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 >VW5VEHIEE9408RSD*HR<#)/'6BUNTNU$L3*Z'.&0AE.#@X(XZUYA+K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24
M)2&EI#0 TTTTXTTT --,-/-,- #&IC4]J8U $;5$U2M434 1M4;5(U1M0!&U
M1M4C5&U $9IAIYIAH 8:::<::: $--IQIM &[X7_ (_^ _UK=K"\+_Q_\!_K
M6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKTYK5_X4I9_WYO\ OI/_ (W71>)O!5MXC ,ZD.HP'0X<#.<=P1]0<9.,$YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M2EI* $I#2TAH ::::<::: &FF&GFF&@!C4QJ>U,:@"-JB:I6J)J (VJ-JD:H
MVH C:HVJ1JC:@",TPT\TPT ,---.--- "&FTXTV@#=\+_P ?_ ?ZUNUA>%_X
M_P#@/]:W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **KWNHQ6"[YG5%)P"[!1GKC)(YXJ6&99E#H058 @@Y!!Y!!
M'4&@!]%%% !152/58I96M%=3*BAF0'Y@&Z'_ #TR,_>&;= !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !113)IEA4NY 50223@ #DDD]
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M_P &IZ?H>?B_X]/U7YGJM%%%<1Z 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "DI:2@!*0TM(: &FFFG&FF@!IIAIYIAH 8U,:GM3
M&H C:HFJ5JB:@"-JC:I&J-J (VJ-JD:HVH C-,-/-,- ##333C330 AIM.--
MH W?"_\ '_P'^M;M87A?^/\ X#_6MV@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!DTRPJ7<@*H)))P !R22>@%5++7+>_;9#+&[ 9(1U8XZ9P">.:\]^
M.-TRI;P@_(S2,1@=4"A3GKP&/Y_2O,M$O9;&>.:#)E5UV@9.3G&W"X)#="!U
M!Q0!].T444 %%%% !7@]_JDLTY\3)@1B[5 @)1R$0$ XW !D&&Y/)/&*]0^)
M6L#3+&4\;I1Y:@@G._ANG0A-Q!/&1WZ%EKX0SI8TMA\YA/#MP)#\_)3LLA[9
MX'?N =1#,LRAT(*L 00<@@\@@CJ#5>^U:'3\>?(D>[./,=5SC&<9(SC(KE?A
M)K/]H60A8Y>W8H<MN;:?F4XZ@8.T=OEX]!B:7I*^+-5N;BX&8K1@@1F)!*DJ
MO&,;259BO') .X%L@$OQ<U:'4+-?(D23;<)GRW5L923&<$XS@UV'AV[2TL+>
M65E1!;PY9R%4910,D\=:X+XM^$K;3H4O($$;M*%(3A""A/W>@(V]L9R<Y/-;
M'B7_ ) *_P#7O:_SCH [V&99E#H058 @@Y!!Y!!'4&J]OJT-R[01R(TB9W*K
MJ6&#@Y4'(P>#[U4\)_\ 'G;?]>\/_H"UP'@#_D,WG_;Q_P"CUH U=&_Y#UU_
MU[K_ "@J7QEXU^P7-K#!.@0S%9P"C8 = 0Q.2F 6]._I46C?\AZZ_P"O=?Y0
M5E?$'PM;07EGM3'VNX;S?F;YMSQY[\?>/3'7Z4 >E6.K0ZAGR)$DVXSY;JV,
MYQG!.,X-6ZS-#\-V^A*R6R! YRW)8G'3EB3@=AG R?4UIT 5&U:%&:(R('C7
M<ZEUW*H .XC.0,$<GCFHK7Q#;7;"**:)W.<*DB,QP,G !STKSJY\/KKNMW$$
MC,(Q'&SJI(WA5BPA(/3."?IQ@X(T/B3X-M+2Q,\4:QO!LVE!@D,RH0QZMP<Y
M/.>_)R >A33+"I=R J@DDG  ')))Z 5F?\)99_\ /Q#_ -_D_P#BJH:3L\8:
M?'Y^XK*J;^BEFB<;ON] S(>F#@\8/3$UEM#AB^S.80&7 :$!Y!MQ@[T#$'IR
MQ^;G.1F@#NKJ[2T4RRLJ(,99R%49.!DGCK7$>$O'0N+B[2ZN(Q$DN(=S1H-N
MY^AXW# 7G)[>M5_A?:KK>FO:7(WQ"9E"Y*\#9)C*X/WB3U]NG%9/@KP9::E<
MWT,T>Y()ML8WN,#?(,9# GA1US0!W'C#3;36[=!=2A(2ZLKB1%!.UL89@000
M2>.O6NCKSSXRPK#8Q(@ 59T  &  (Y   .@%:WQ/UZ31K,M"2KRNL88'!7(+
M$C@\X4CL1G(.10!M3>)[2%BCSQ!E)!!E0$$<$$$\$5H0S+,H=""K $$'((/(
M((Z@UYEIE_H-G"+=BCDKAG:&4L3M 9@2I*YQD!2,'ISS4OPDU=?,N=/21GB1
MMT 8'.S<P8YP,9RI(XY)('WJ .].N6X#DRQXB(#G>OR$G #<_*<\<XYXHLM<
MM[]MD,L;L!DA'5CCIG )XYKS+PSX4CU^_OOM!8Q17#$Q@E59F>0*200?E&<8
MYYZXR#;^(>C1^&9+?5[5%39, ZH2F[@$  ?*H*JP; &<\@Y- &Q\3?%[:/"%
MM9E6<2J&4;&<*48\JV<#ISCT]:ZJRURWOVV0RQNP&2$=6..F< GCFO/?C)H$
M$,0OU7$\DR*S;FY C;C&<#[HZ#M7<:'X1M=#9GMHPC.,$Y9CCKC+$X'KCK@9
MZ"@"Q=>(;:T8Q2S1(XQE7D16&1D9!.>E6K6[2[42Q,KH<X9"&4X.#@CCK7E'
M@5K.Q>:UU5%%V922URH8$;<_?;*@YR<\;MRX+<8]-T32X-/0_9558Y6,GR'*
MDL!R.2 " , <8Z"@#0KBOBWK/]GV1A4X>X8(,-M;:/F8XZD8&T]OFY]#VM>?
M_$?_ (_--_Z^/_9X: .JM8$\-V@7JEM"2VQ0"VQ<L0,XRQ!/7J>3WIOA_P 6
MVVOKFW<%L9*'AQTSE3V&0,C*YX!-;%<EK'PRM+T^;"#!,""KPDK@J,+\GW0
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M@IXJ6 X4X4T4X5+$.%.%-%.%2P.@\+?Q_P# ?ZUO5@^%OX_^ _UK>KZ7+/\
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M12&+1110!V=%%%<!W!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24
MM)0 E(:6D- #3333C330 TTPT\TPT ,:F-3VIC4 1M435*U1-0!&U1M4C5&U
M $;5&U2-4;4 1FF&GFF&@!AIIIQIIH 0TVG&FT ;OA?^/_@/]:W:PO"_\?\
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M+'28=/SY$:1[L9\M%7.,XS@#.,FK= 'E5SX@70M;N)Y%8QF.-7903L#+%AR
M.F< _7C)P#=^(WC.WU&U^Q6K"66Y,>%3)(&[<. #\V5"[#AAG.*ETN%9M<O$
M< JUL 01D$%8000>H-=G:^'K:T82Q0Q(XSADC16&1@X(&>E 'G_CK2WTK1X+
M959=C1>:%)(!*L6W$$C'F$=\9QCM6PUYHMK$A1()-P4(B1K+,Q(^5=N"^X]/
MFQSPQ!-=K-"LRE' *L""",@@\$$'J#5*U\/6UHPEBAB1QG#)&BL,C!P0,]*
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M*X&/F1 %/';>RGCIR!^5 '=T5C^&?%4'B.,S0$_*<,K8#KZ9 )X/8@D'IU!
MV* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6
MDH 2D-+2&@!IIIIQIIH ::8:>:8: &-3&I[4QJ (VJ)JE:HFH C:HVJ1JC:@
M"-JC:I&J-J (S3#3S3#0 PTTTXTTT (:;3C3: -WPO\ Q_\  ?ZUNUA>%_X_
M^ _UK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M":\X\$_\?D?_  /_ - :NW"_P:GI^AY^+_CT_5?F>JT445Q'H!1110 4444
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M?*_=>9YN_P#CV8V;?]ELYW5S7Q*\9^;9QV_E,/ML,<FXGY5^97V@X^8C'/3
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M=3L8GES#N$CC;N?H,':,%>,#MZ5T?PXM$N]+ABE570^9E7 93B5B,@\=:PO
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M(XX&1T.!D<"@";4-0CTZ-KB9@L:#))_SR3T ')/ YKG/^%I:=_SV_P#(<O\
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MR <[17.>+M*BTW6+18$5%=K=B$&%SYI7( X'"CICUZDT >P5PGQBTS[59>>
MN8)%))^]M;Y" <=R5)' X]0*[NJFK6/]H0R6V=OFQNF<9QN4C.,C.,^M $7A
M_4_[4MXKK*DR1J6V?=#$?,!R>AR,9R,8/->.:]J4D6IOJ^UEAANTC9E/7RQM
M90?ER61"2.@!P3R,]7\//$PT[3YDE #V)?*-E#\V6526XW,^Y<=1P,9ZY]GX
M5$NA,2")"6N!OR,;.,@ =&B7C.02V<XP0 >H7MTMHC3.<(BEF."<!1DG YZ5
MYGX"\.)XBBGO+Q,BXN-X4;D7*[LL"&R1F1EQVQU)Z6]5\4-)H:SL2))D$63\
MY8ABCDDCJRJQR>F>N<&NJ\*:0=(M(;8Y#*F6!(.&8[F&1Q@,2![=SUJ6!Y]\
M2_!]KHMNDUO'L8S*I.YVX*N<89B.H%=0WPVT\?\ +'_R))_\75#XR?\ 'HG_
M %W7_P! >NU:HDW81S7B.PO-2<6\$@A@VJ6D&?-W9;Y1@CCA<_=//!(R*XSX
M?6@LM1N(%R5C651GKA95 STYXKU-J\S\&?\ (5N_^V__ *.6I3]U@>A-435*
MU1-7,Q$35$U2M435FQ$35$U2M435G(")JB:I6J)JR8B)JB:I6J)JS8B)JCJ1
MJCK-@.%.%-%.%0Q#A3A313A4L!PJYIVGM?MY:8SC//3%4Q6]X0_UK?[A_FM:
M8>FJE6,7LV-*['#PE+ZI^9_^)I1X3E]4_,__ !-6M5\126DK1*%PN.H.>0#Z
MUHZ'J+7Z%W !#$<9] >Y/K7H0PV$G4=-7NOT*M&]C%'A27U7\S_A5:_T9[$!
MFP03C@_X@59'BN7T7\C_ (UI>*?]4/\ ?'\C6$J&%J4IRA>\4*R:.8%.%-%.
M%>4R#H/"W\?_  '^M;U8/A;^/_@/]:WJ^ERS_=8?/\V:PV"BBBNTH**** *.
MN_\ 'O-_URD_]!-><>"?^/R/_@?_ * U>CZ[_P >\W_7*3_T$UYQX)_X_(_^
M!_\ H#5VX7^#4]/T//Q?\>GZK\SU6BBO-]1^,BV%P]J\!*Q2LA82<X5BI8*4
M'/&<9]L]ZXCT#TBBN?\ &OBO_A&(5N=GF;I F-VWJK'.<-_=]*U=)OO[0ACN
M<;?-C1\9SC<H.,X&<9]* +=%%% !1163XA\3P>'T$MPV-V=J@99B!G ']3@
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MV_=YZ_K7H%% ''_"_0)]$MGAN5V.9F8#<K<%$&<J2.H-<_KG@R[NM66_2/,
MF@;=O0<($W'!;/&#V^E>H44 >*?&O_C\C_Z]U_\ 0Y*O:AX:UJWC;38V,EL!
MM4AHERG4#+$.!C@C.,?*,KUW?B)\.YO$DR7,#H-L>PB3<.C$@@@-G.X]AC'?
M/'H% ')?#CP>WAR ^;CSIB"^#G  ^5.N"1DDD=SC) !KE'\"ZAX:NFNM-"O&
MY("Y7A-RML82$<<8RK;B!G*DUZQ10!P5G<ZW>3Q"6..&$.#(5*'*Y!(.6D;.
M 0-N.3R>XY'XU_\ 'Y'_ ->Z_P#H<E>UUY_\1/AW-XDF2Y@=!MCV$2;AT8D$
M$!LYW'L,8[YX ,+4/#6M6\;:;&QDM@-JD-$N4Z@98AP,<$9QCY1E>O8?#CP>
MWAR ^;CSIB"^#G  ^5.N"1DDD=SC) !KK:* /+_A?X,N]$N7FN8]B&%E!WHW
M)=#C"L3T!HT/P9=VNK-?O'B S3MNWH>'#[3@-GG([?6O4** ./\ BAH$^MVR
M0VR[W$RL1N5> CC.6('4BN@\/6K6EM!#(,/'#&K#(."J $9''6M"B@#S_P"%
M'A:YT'S_ +2FSS/*V_,K9V[\_=)]1UK"U'P+J.C7CW6F@;7+%2AC0 .23&4<
MXPO;@C@$8/ ]=HH \4UWP!JNK;;N<>9,^X,NZ,;%7&W^(+\V2<+P.I.6./1K
MGPTVH:8NFO\ +)]GC7J,!T52 2 W&Y><9XSBNEHH \D\':!K&B.D(79;F96D
M&Z!N"5#G.2WW1V_#FO6Z** .?\<:5<:E;E+.1HY48,-K%"P (*;@1C.<C/&0
M,XZCAYHO$4JE#G# @X-LIY]"""#[@Y':O6** .$^&O@%_#V^YN-OFR*% 4D[
M5X+ GH23C. 0-O#')KNZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I*6DH 2D-+2&@!IIIIQIIH ::8:>:8: &-3&I[4QJ (
MVJ)JE:HFH C:HVJ1JC:@"-JC:I&J-J (S3#3S3#0 PTTTXTTT (:;3C3: -W
MPO\ Q_\  ?ZUNUA>%_X_^ _UK=H **** "BBB@ HHHH **** "BBB@ HHHH
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ME:0IO(4J(U8X8MP>5R,X^7G[]=G10!YU\1K2?3;N#6X%9UA7:X49PJ[B<GG
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MTY5-P)10N-S-M^; ![=!DD\8.5K"ZEX>C^W&X%RD1!>(P+'E.C$,F2",Y]
M2<@8(!W%%<EK'C9C';?8E#RWQ_=[^44#&\OL).5S@@=,,2?EP:FL+J7AZ/[<
M;@7*1$%XC L>4Z,0R9((SGT !)R!@@'<454TK4TU2)+J(Y2101TR,]0<$C(/
M!&>""*MT %%%% !1110 56MM1BNBR1NK-&<.%8,5/(P0#P>#U]#57Q+JXT>V
MENSC,:$KD$@L>$! YP6(']1UK)^'&E-86:N[%I+@F9B3GF0 CD@'.T#.<_-G
MDB@#IZ0TM</\)-0EO[1WF=G83L,NQ8XV(<9)/'- ':FFFG&FF@!IIAIYIAH
M8U,:GM5#6=-&IPR6S8Q(A&2-V"1PV/4'D>XH L-435SWP]U?^TK-,C!A_=GC
MCY ,$<G^$C/3G/&*Z%J (VJ-JD:HVH C:HVJ1JC:@",TPT\TPT ,---.---
M"&FTXTV@#=\+_P ?_ ?ZUNUA>%_X_P#@/]:W: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK'MO%$5Q=R:6 WFQ(&)(&S!"G@YSGYQV'>@#8HHHH **** "BB
MB@ HHKFO!WBE_$37$H51;QR!(F&=S8!W$YYZ;2/E&,XY(- '2T5SECXJ:YU"
M;2B@"PQ*P;/))VD\8Z?.,>F#US\O1T %%%% !1110 45@^%?&4'B97:#<#&0
M&#@ _-G!X)&#@]\\<CID3QE UX=).X3 9!(&P_('P""3G:<\@#@\],@&]116
M/HGBB+6)9[>,,&M7VN6  )RPXP3Q\IZX[4 :K5$U5]9UF'1X_/N'")D#)R<D
M]   23]!TR>@-<;'\8[.0A2LJ@D#)5<#/<X<G ]@3Z"I: [5JB:J<^HF]MS<
MV15V9"T>1E6(_A/*X)QCDC:>HX(JCX1\1#Q!;K<8 <$JX&<!AZ9[$$'OC.,D
M@UFT(U6J)JE:HFK)B(FJ)JE:HFK)@1-435*U1-6;$1-435*U1-6<@(FJ)JE:
MHFK)B(FJ)JE:HFK-B(FJ.I&J.LV X4X4T4X5#$.%.%-%.%2P'"M?PW>I9R%Y
M#@%".A/.1Z?2L@4X4Z=1TYJ2W0)V.Y_X2.#^_P#^.M_A1_PD4']__P =;_"N
M6T_1I+WE1A?[S<#O^?3MGWKH;'PO' =SG>>V1@?ESG\\>U>M0Q.,K:J*2[N_
M^9:<F:%KJ277W"3[[6QZ]<8K/\4J/+4]]X_4'_"GW?B&*T&Q/F([+PHZ=^G3
MTSZ<5SU]J3WQ!?''0 <#.,^_:IQV,@J4J;:E)]MOU"4M+%<4X4T4X5X3,SH/
M"W\?_ ?ZUO5@^%OX_P#@/]:WJ^ERS_=8?/\ -FL-@HHHKM*"BBB@"CKO_'O-
M_P!<I/\ T$UYQX)_X_(_^!_^@-7H^N_\>\W_ %RD_P#037FGA"=;>ZC=R%4;
MLEB /N,.IKNPO\&I_70\_&:5Z?K^IZS15'^W;?\ Y[1_]_%_QH_MVW_Y[1_]
M_%_QKCY)=CN]I'NB]15'^W;?_GM'_P!_%_QH_MVW_P">T?\ W\7_ !HY)=@]
MI'NB]15'^W;?_GM'_P!_%_QH_MVW_P">T?\ W\7_ !HY)=@]I'NB]15'^W;?
M_GM'_P!_%_QH_MVW_P">T?\ W\7_ !HY)=@]I'NB]15'^W;?_GM'_P!_%_QH
M_MVW_P">T?\ W\7_ !HY)=@]I'NB]15'^W;?_GM'_P!_%_QH_MVW_P">T?\
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M6:Y<DDY))2,DDGJ37=33+"I=R J@DDG  ')))Z 5POPG"V2W6G DM;W+9;&
M0?D!QD\_NR2.V1R:A\<7<M]<K9R0W#6485G$$1;S7^\%WY'R#C..=P/&=K*
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M8D_U-N3D '!RP_+(."Q&& 4!2 'P@L;NV@+3'%N_,2,/FYY+ YX4]ASD_,,
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M &&FFG&FF@!#3:<:;0!N^%_X_P#@/]:W:PO"_P#'_P !_K6[0 4444 %%%%
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MI *]R.< G%='6#X(T$Z':1VS "3&Y\ #YF.2"03DKPN<\@#MQ6]0!Y5\#/\
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M?^__ ..K_A2CQ%/_ '__ !U?\*].KF.'J*TE*WW?DRW),T_^$1_Z:?\ CO\
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MG4OMSY'W5X7KT]>?7_ =JU_"UJ(U:X;C/ )X&!R3G_.,50U/3885!A?>Q8#
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M"T8&T. 5)(Z$1[CUS[XKVNN2\%>$)=(EN+RY,9FN7S^[!(4$EF 9@#@D]/\
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MP(FJ)JE:HFK-B(FJ)JE:HFK.0$35$U2M435DQ$35$U2M435FQ$35'4C5'6;
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M_P ?D?\ P/\ ] :NW"_P:GI^AY^+_CT_5?F>JT445Q'H!1110 4444 %%%%
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M, @D8)QVY))X 'U/8&G'#JD($I9'./\ 5G:#SVR%4<>S=N_>G+^^U8*W(7&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 8U1-4K5$U2P(FJ)JE:HFK)B(
MFJ)JE:HFK-B(FJ)JE:HFK)@1-435*U1-6;$1-435*U1-6<@(FJ)JE:HFK)B(
MFJ)JE:HFK-B(FJ.I&J.LV X4X4T4X5#$.%.%-%.%2P'"M'1=-&H/Y9. !DX'
MH0,?K6<*NZ;J+:>QD0 DC'.?4'L1Z55)P4US;=01V-MID.G#> !C'S,?PZGI
MG/;%0V_B!)Y?*!^4@8)R,MZ<_ITY'?(KDKJ]>[.Z1B?Y?@.@J,5V2S/E:5.*
M45^)7/V.YCT:&-O,"C<#GJ<?EG'^%8_B:_$I$*G.TDMZ9[<^W.?\>F,+V3&S
M>VW&,;CC'IBHQ6>)Q\9TW"$>6^XG+0<*<*:*<*\UDG0>%OX_^ _UK>K!\+?Q
M_P# ?ZUO5]+EG^ZP^?YLUAL%%%%=I04444 4==_X]YO^N4G_ *":\X\$_P#'
MY'_P/_T!J]'UW_CWF_ZY2?\ H)KSCP3_ ,?D?_ __0&KMPO\&IZ?H>?B_P"/
M3]5^9ZK1117$>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQ
MXM_X^I/^ _\ H"UZ/7G'BW_CZD_X#_Z M>CE/\9^GZH\[-_X,?\ %^C,D4ZF
MBG5[3/&0X4HI!2BI9HAPIPIHIPJ66A13A313A4LM#A3A313A4,M#Q2BD%**E
MEH>*<*:*<*AEH<*44@I14,I#A3A313A4,H<*44@I14LI"BE%(*45+&+2TE+4
ML8M+24M( HHHI#%HHHH [.BBBN [@HHHH **** "BBB@ HHHH *S]9U![-1Y
M2&21SA0 =H/JQZ #W(S[#)&A13BTG=ZBDFU9.QS_ (=\.FV)O+D[KA^23SMS
MV';.."1P!P..NOJ5PUM&\B#<RJ=H +9/887GK5FBJE4<Y<S_ *\B84U"/*OZ
M\SB?"O@U)HS)=1G<6X#$K@#O@$'DYZ^@Q[Q^+?""6Z+):H<[L,J[G)!&0>IQ
MC'ZUW5%;?7*GM.>_RZ&'U*E[/DM\^IP_B&PGOUAU*-&$J !DV_,"K9!"$$XW
M9ZYXP<=:B\027>NQY\DI'&<[3DNS9QP, \!O3'7))P!WM%$<7RV]U:;!+"<U
M_>>NYS6K6COIPB"DOY4(V@$MD%<C'7BKGA"!H+6-'!5ANR&!!^^QZ&MFBLY5
MFX.'G<UC12FI^5CCOA[826GF^8C+G9C<I7.-V>HH\-V$D-]/(R,$;S<,5(!S
M(",$C!R*[&BKEB7)S=OB1$,*HQ@K_"[G'?8)/[4\[8WE_P![:=O^JQUQCKQ]
M:/L$G]J>=L;R_P"]M.W_ %6.N,=>/K78T4?67V^SRA]57?[7,<=\0K"2[\KR
MT9L;\[5+8SMQT%'Q"L)+ORO+1FQOSM4MC.W'05V-%%/$N')I\-_Q"IA5/GU^
M*WX&#K^JS6;A%@\Z%T.< DYS@@X#<8[$<YZ\$5B^&]&>6[-[Y1AC7<0I]2N"
M #@XY)SC Z"NXHI1Q'+!Q2W5FQRP_/-2;T3NEI^9P8BN-#O);@0M*)-^-F<8
M=@W4*>1C!'],9DUK3KB.9-5@0[F12R_>*G:%*[< D8...>IXXKN**KZV[IV5
M[6?FB/JBLU=VO=>3.:M/$-U>.L:VQ0;AN9R<;<X;&0G//'7Z&J?Q"L)+ORO+
M1FQOSM4MC.W'05V-%3"NH34E%*Q<\.YTW"4F[^A1UO3?[2A>WS@L./J#D9X/
M&1S[5R>C:E=Z&IM7MV<*?EV@\9Y(W*K \G\.1[#NJ*5.MRQ<&KK<=2AS24TV
MGL95@9=3A=;E/+\S<  >=C*,9SGYN3U ^@KE]%DN]!WVHA,FYAM(SL!(QNW8
MY!XZD8QS@YKO:*<*_+S*RL^@IX?F<7S.ZZG%>$]+GM+N1YU.6C)+8^4LQ5B,
M@8SUSCC(.*[6BBHK575ES,JC25*/*CG-5U&\TZ8ND?FP-MP%'S#Y>1P,]>22
M",8 (-95]:7'BAXR\)BB0D$L<-S@L>0#T  ^7&>I].XHJX8CDLU%774B>&Y[
MIR?*];'*^*_#4EU(EY;8\Q,9' )*D;2,C!([Y/0 "FQ^)KR<"-+4B0C[S;@F
M1UX(7'M\WY]^LHH6(]U1DD[;#>']YRC)J^Y#:*RHHD.7"C<1T)QR>@[^U344
M5@W<W2L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE
M "4AI:0T ----.--- #33#3S3#0 QJ8U/:F-0!&U1-4K5$U $;5&U2-4;4 1
MM4;5(U1M0!&:8:>:8: &&FFG&FF@!#3:<:;0!N^%_P"/_@/]:W:PO"_\?_ ?
MZUNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8
M/BKQE!X95&GW$R$A0@!/RXR>2!@9'?// ZXQ;+XPV-PVU_,C&,Y=,CZ?(7.?
MPQQUH [BBF0S+,H=""K $$'((/(((Z@T^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HKA]4\<7-W/)9:7 )6@.)'D.$!!(*@$ISGH=W
M.&PI W5V5I(TJ*\B['*@LN0VTD<KD<'!XSWH FHJ&ZNTM%,LK*B#&6<A5&3@
M9)XZT^&99E#H058 @@Y!!Y!!'4&@!]%%% !1110 45SGCKQ4WAF!;E4#EI57
M!..""Q['G"D#T)SSC!Z.@ HHHH 8U1-4K5A^*/$T?AV,7$P8JSA?D )R03W(
MXXJ6!I-435*U1-63$1-435*U1-6;$1-435*U<_H?B$ZI+<0%0HMY-H(.<C+#
MG\5)^AQVR<VFTV!K-435E:)X@.IRW$)4 6\FT$'.1DCG\5)^AQVR=5JSFFG8
M1$U1-4K5$U92 B:HFJ5JB:LF(B:HFJ5JB:LV(B:HZD:HZS8#A3A313A4,0X4
MX4T4X5+ <*L6=JUVXB7JWK^=5Q72>#806>3N !^9)_I6F&I>UJQAW&E=FC9>
M&(H.7^=O?@<>W\\YJ_\ V;%_<3_OD?X5S&NZR\KM$I(13C XSC@Y]OTQCC-9
M(KNGCJ%%N$8)I?UYE<R1V=WX>BGR0-K>J].GIT_+'UKFM0TYK%MC=#T/8_Y[
MBFV>J26F-K' ['E>N>G^'-=#KRBZ@$P[;6&1SAN,>W7]*SJ*CBJ4YQCRRBKL
M3LT<P*<*:*<*\ED'0>%OX_\ @/\ 6MZL'PM_'_P'^M;U?2Y9_NL/G^;-8;!1
M117:4%%%% %'7?\ CWF_ZY2?^@FO./!/_'Y'_P #_P#0&KT?7?\ CWF_ZY2?
M^@FO./!/_'Y'_P #_P#0&KMPO\&IZ?H>?B_X]/U7YGJM%%%<1Z 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7G'BW_ (^I/^ _^@+7H]><>+?^
M/J3_ (#_ .@+7HY3_&?I^J/.S?\ @Q_Q?HS)%.IHIU>TSQD.%**04HJ6:(<*
M<*:*<*EEH44X4T4X5++0X4X4T4X5#+0\4HI!2BI9:'BG"FBG"H9:'"E%(*45
M#*0X4X4T4X5#*'"E%(*45+*0HI12"E%2QBTM)2U+&+2TE+2 ****0Q:*** .
MSHHHK@.X**** "BBB@ HHHH **C:=5&21@>]0_VG%_?'YT 6J*C2=7Y!'-24
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !24M)0 E(:6D- #3333C330 TTPT\TPT ,:F-3VIC4 1M4
M35*U1-0!&U1M4C5&U $;5&U2-4;4 1FF&GFF&@!AIIIQIIH 0TVG&FT ;OA?
M^/\ X#_6MVL+PO\ Q_\  ?ZUNT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 8/B_Q?%X9B$L@+,Y(1%(!) )SR>%' ) .,C@YKFO#GQ@CU6=+62(Q^80J
ML'W_ #$X4$;5P#TSS@XSQD@^,'AR?58X9H%+^27#*H)?Y]N"%'4#;SCD9SC&
M2/,O"?A.7Q)+Y,7"K@NY'RJ/ZD]AW]@"0 ?2%%%% !1110!Y5\<_^77_ +;?
M^TZ]%U[3(=1A>*Y"^7M8EFV_)\I&\%@0I4$X/:O.OCG_ ,NO_;;_ -IUJR>#
MM4U9&AO+Q50]H4SN!!!#$"(XP>G(/<<"@!_P7F9[)@22%G< $YP-J' ]!DD_
M4DU7L_B\;Y/W-J\D^XYCC8MA !\Y8)W)QC';)(X![70M"BT.(6T PJ]2?O,>
M[$]R?_K#   XKX)6JK;2S ?.TVTG)Z(BE1CIP6/Y_2@#I5\7K:V8U&\1H,Y_
M=MDOD,0% (4DL!D<#CD\ FL>;QU>PPF\>P81J"3F8!@ <$E"F\ =>G3GIS6?
M\7'D,ME%& Y:5B(V^X[ QA0P) (Y(Y[$\C)JQ_;.O?\ /K#_ -]#_P"/T =5
MIOB>#4;<Z@C?NE5BV1\R[1E@0,G('89SU&003@:;XZN]74SVMDSQ;F"LTZ1D
M@'KAA^>"0#D9.#5?X>^$[BRM+BQO%"),6 VL"_SIM<Y!9<8 V]\YR,8JC;7&
MH> HS"T2W-JFXJT9*LH)+?-PQ  !)RI +8W\8H [O2]6^UP+=RHT.5)99?E*
M[<[LYQQQD$XR,' KG+;QU<:FS-96;2PJ<+(T@A#=02 Z\C(/0DCC< 3BHO&'
MB./5])FN[9CA@@.#AAET#(P'0X.".A![@@G'\/ZAK-M;Q);VL/E"-=ARH)!&
M=Q'G#ELY/ Y)H ZWPCXTC\0AHRIBGB)#Q,?F&#C(R!D=CP"IX(Z$YNL?$Q=+
MNI;!HF9HU7R]A):1W"%4"A>/O=<GIP"2!6?X4T?4?[1?4KJ)(UEC*OA@1@!0
MH4*['.5&<\8W=\4[285?7KDD E8%()&<';",CT."1]"10!8E^),NGM&;VT>"
M*3'[S?O W XR @YXY7(8#)VGH>UN[I;1&FD.$C4LQP3@*,DX'/2N5^+%JLVG
MR.PR8VC9>3P2X3/OPQ'/KZU2\5S--H8=R2S06Q))R22T9))/4F@"73?B'/K1
M9K*S:2)"!N>5(N2,D8((R/9CQ@G&16UX8\5+K4#W,B&$Q.ZR+(?NE "<D@<
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MI8Q:6DI:0!1112&+1110!V=%%%<!W!1110 4A.*"<5SVJZT6)C3@=">_^?\
M/O0!>O\ 7%@X7EJQ;C5Y)^IP/;BJ5% "DYY-)110 JN4.1P?:KEMJ\D'?(]#
M5*B@#JK#65NN#PWH:T:X4''(K<T?6/\ EE)^!_S_ )_'J ;U%(#FEH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*
M6DH 2D-+2&@!IIIIQIIH ::8:>:8: &-3&I[4QJ (VJ)JE:HFH C:HVJ1JC:
M@"-JC:I&J-J (S3#3S3#0 PTTTXTTT (:;3C3: -WPO_ !_\!_K6[6%X7_C_
M . _UK=H **** "BBB@ HHKS3Q_\19["<Z;9KB0;06V[V+/M90B\CH<'()).
M !@$@'I=%>5+JNO:6RS3QM+&&P458F)!!_YY L/8] <9ST/:^-?%?_",0K<[
M/,W2!,;MO56.<X;^[Z4 =!163X6UW^WK9+W;L\S=\N[=C:Q7K@>F>E:U !11
M10 445Y%XAURXBUI;=99!%Y]L-@=@F&$>1MSC!R<^M 'KM%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MY_\ %?PM<Z]Y'V9-_E^;N^95QNV8^\1Z'I7H%%% !7'_  OT"?1+9X;E=CF9
MF W*W!1!G*DCJ#7844 <UXY\)'Q!&IB;9<0L&B?<5 )(W9P">@R"!D$#D#.<
M^UUO5XHA&]FKRA2-_GQ*I/9B@/Y@,,\XV]!VM% &)I_VZ>V?S_*2Y96V>7DJ
MI*#;NW;N0V<XR,=,US]WJNKW4#0&S3S'4J7\V(I@\?ZMF.>.,%B,\D$?+7=T
M4 <IHG@&.UL#I<WS>;EI&0D?,2"",_W<*!Q@XR5Y(K*\/#5?#J&S>!;E$QY;
MK.J8&/N_.,D#H,@8Y RN,>@44 <_X=NM0NG9[R.**+YMJJQ:3.1MR02I&,@]
M#D= *S],T">'5KB_9<020A5;<O) BXQG(^Z>H[5V%% '/^/=+DU6REMH%W2/
MLP,@9Q(I/)('0'O0OAS[=IR:;/\ *QMXT/?:RJ,'@C.U@#UP<>E=!10!YUHB
M:SX?0V?DI<(BD1OYJC!(&!\Q4E5Y&T@'L&"@5T%CHD^KVDEMJA4M,V<1'&Q?
ME*KD#JC ]2P/&2PKI:* //\ P\-5\.H;-X%N43'ENLZI@8^[\XR0.@R!CD#*
MXQT'AVZU"Z=GO(XHHOFVJK%I,Y&W)!*D8R#T.1T KH** "N*\?\ @R75GBO[
M0J+BWZ;OX@IWIC.5R&SC( .[D@"NUHH X=]6UFXC$0MHXY6.#*94* '(R$W$
M@C(/5^A^4YP-KP5X9'ARV6V)!<DLY&<%CZ9[  #MG&< DUO44 <?X*T"?3;F
M^FF7:D\VZ,[E.1OD.< DCAAUQ78444 8GC31FUFSFM8_OLH*].2C!PO) &2,
M9SQG-8_A2XU*#[/9SVZI#$A5Y/,5B0JXCPH;@\ -][.<C;79T4 >>6GAZ]\)
M7#FPC$UG*2?*,H4J<#G+XP<\#&[*C#<X(V+34]4NYE!MXH8!C>9)/,8C=\VT
MQGKCIE<9')Y KJZ* .,\=^$9]1DBU&Q8)<P CDD;AR0 >5SDD8(PP8[C@8JO
M)?ZW?*L*PQ0.<[I2ZLHYR,+ER.!@Y#YSGY>W=T4 <?\ %#0)];MDAMEWN)E8
MC<J\!'&<L0.I%=A110!Q_@K0)]-N;Z:9=J3S;HSN4Y&^0YP"2.&'7%'@K0)]
M-N;Z:9=J3S;HSN4Y&^0YP"2.&'7%=A10!QOQ0T&;6[9(;==[B96(W*O 5QG+
M$#J13/B=H4VM6R0VZ[W$RL1N5> KC.6('4BNR:HFJ6P.?\9>'!X@MVM\@."&
M0G. P]<=B"1WQG."0*YRSO-8L8S;M"DK)@)(9%Y /5@6!;(Z'Y3W;)S7?-43
M5FV(XKQ%X9NM7L5MY75[F-RY(X5L;@%!PH!VL.<8R.>N:>-0U*["P^0D)/#2
MF19 .#DA <YST!)'8\<CK6J)JAR Y/P!HTNDV[13KM8RE@,@\%5&?E)'4&F>
M%]'EL9[N65<+-+N0Y!R-SG/!..HZXKJFJ)JSE-N_F(Y;PSI$MC/=2R+A9I<H
M<@Y&YSG@G'4=<56^(=CYD N@2'@8%2,Y^8@$<$8YP<]>..M=:U<YXOT*36E2
M%"JH'W,6SNX&!@#@\$\'';FI4[S3>@=2KX&L3#;^<^2\[%R6'S8Z#)/)S]X'
M_:_$[S4]8Q& J@  8 '  '08IC5A4ES2;$R)JB:I6J)JP8B)JB:I6J)JS8B)
MJCJ1JCK-@.%.%-%.%0Q#A3A313A4L!PJQ:6CW;;$&3_GUJN*WO"'^M;_ '#_
M #6KH4U4J1B]FP2NR >')_[G_CR_XTH\.S_W/_'E_P :VM1\2_8Y#%LSMQSN
MQU /3!]:K_\ "8?],_\ Q[_[&NR=# QDXN;NOZ[%6B9X\/3_ -S_ ,>7_&HK
MG2Y+0;G7 )QU!_D:UO\ A+O^F?\ X]_]C5/5-<^WJ$VXPV<YSV(]!ZUC6IX-
M0;C)M]/ZL)J)FBGBF"GBO.9)O>%V +CO\O\ 6M^N&AF,)#J<$=#73Z7K(O/D
M/#^G8^N/\*]O*L9#D5%Z-;>?4TA+H:5%%%>N6%%%% %'7?\ CWF_ZY2?^@FO
M./!/_'Y'_P #_P#0&KT?7?\ CWF_ZY2?^@FO./!/_'Y'_P #_P#0&KMPO\&I
MZ?H>?B_X]/U7YGJM%%>?^*?BO_8-R]EY&_R]OS>;MSN4-TV'UQUKB/0/0**P
M=8\5+867]JHA92D;!2=IQ(5 R0&P1N]ZL>%M=_MZV2]V[/,W?+NW8VL5ZX'I
MGI0!K4444 %%%9/B'Q/!X?02W#8W9VJ!EF(&< ?U. "1DC- &M17*>!?'7_"
M5>;^Z\ORMG\>_._=_LKC&VCQ3X]71I%LX8VN+AN3'&3D#&><*QSCG&.G)P,9
M .KHKC_#7Q%759_L$\+P7!SA7R00%#<DA2"1D\KC ZY(%=A0 45R7B+X@#3I
MC8V\$EQ.@!=4! 4$9Z@,2>5[8Y^]GBF>$OB,FNRM9R1M#.N[Y68$';C*\A3N
MZY7;P 3F@#L**Y3Q3X]71I%LX8VN+AN3'&3D#&><*QSCG&.G)P,9B\-?$5=5
MG^P3PO!<'.%?)! 4-R2%()&3RN,#KD@4 =A1110 5YQXM_X^I/\ @/\ Z M>
MCUYQXM_X^I/^ _\ H"UZ.4_QGZ?JCSLW_@Q_Q?HS)%.IHIU>TSQD.%**04HJ
M6:(<*<*:*<*EEH44X4T4X5++0X4X4T4X5#+0\4HI!2BI9:'BG"FBG"H9:'"E
M%(*45#*0X4X4T4X5#*'"E%(*45+*0HI12"E%2QBTM)2U+&+2TE+2 ****0Q:
M*** .SHKGM,U8P'8YROYX_\ K>WY>_0*V[D=#7%.#BSLA-20M%%-=MHSZ5)1
MD:]J!B C4\GK7.U+<S><Q?U/_P"JHJ "BBB@ HHKLO[-BQMV+C&.G/Y]?QH
MXVBIKN,1NRCH&('X&H: "BBB@#I]$U$W*[6^\M:E<;IUS]G<-^!_&NQ!SS0
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M$$;<#!X9^<Y[]NE &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+GOS^=<M%&92%'4UVEO%Y2A!V% $E%%% !1110 4444 %%%% !1110 4444
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MBYDF3RVSM(;=NP0#M"Y+8)YP#CO5O3-5BU1!- ZNA[J<X. <$=0<$9!P1W%
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M "]WS;=N=S%NF3ZXZUS4/PQ;3)3/I]R\"MU0J)%S\V.K $ ' W!B.N<UW=%
M'/\ A3PE_8/F2/*\TLVW>\G?9D+@')Z''+'IQCI6)#\,6TR4SZ?<O K=4*B1
M<_-CJP! !P-P8CKG-=W10!S_ (4\)?V#YDCRO-+-MWO)WV9"X!R>AQRQZ<8Z
M5GZC\/R;HZE9SM;ROG?B-70Y 'W?E')&3G=EN>"*["B@#E+3PC=&9;BYO99
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MD_[Z7_XFNKHH^LU>X?5:/\J.4_X5Q;_WI/\ OI?_ (FC_A7%O_>D_P"^E_\
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M-Y9M:MM;\#0!!1110 5J?\)'+C'RYQUQS]>N/TK+HH =)(9"6/4G)_&FT44
M%%%6]/T\WAP.@ZF@"[X?L=[><>B]/\:Z.HX(1"H0=!4E !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB_X1ZVV>1Y,7E[MVWRTV[L8W;<8SCC/7%:%% ')?$/3EATR:&! %4(0L:X
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M][C:Q(5BIX).0,<YR2,DYK"\1_#F.V62^L)&MI51B0C[48#+$9++L!..<[%
M^[WIVD^()==TB>>=<.(9UW8P'"QGYP,8ZY!QQD'&.@ -#P'JI_LV.[N'9MJR
ML[N2S85WY/4G ']!6%X;M[KQJSZC--+! 25BC@=D^[WSC##L3@DMG[H4+5OP
MI"TVAE$!+-!<@ #))+2   =2:L?"/4TNK%8%/SP,P8'&?F8N#C.<$'&3CD'T
MH Q[V_N/ =U'YT[3VMR2#YQ9G0*PY_BY4,#Q]_D;0=I%WXGZI<64UD+5F#O(
MWR!BJN0T>U6P5!!)QR>A/2J_Q;A;5)+738@IEE=CG&74< 'C)"'DMQ_!G^$U
M8^(__'YIO_7Q_P"SPT ,U'P3>I;O<&]G:Y 9RL9;8<*3Y:J"#DMP",#' 2M/
MPYXO?4-,>_)5IX8Y=WRD+NC4L,CCJ-I...3C'0=A7GGP:F6&QE=R JSN22<
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M8T(! SSGU [ ^M4A5W3=1;3V,B $D8YSZ@]B/2G3Y.=<VW4$:8\)2^J?F?\
MXFI[30+BT.Y'4?B<?EMP:@'BV7T3\C_\52CQ9+Z)^1_^*KM4L#%W7,F5[IOV
MOGKQ)L/3D$@^YQC!_2J'BF$;%DQ\VX#/M@G%4!XKE]%_(_XU6O\ 67O@%;
M.>!_B36F(QU"5&4$VWTN-R5BF*<*:*<*\5F9T'A;^/\ X#_6MZL'PM_'_P !
M_K6]7TN6?[K#Y_FS6&P4445VE!1110!1UW_CWF_ZY2?^@FO./!/_ !^1_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I*6DH 2D-+2&@!IIIIQIIH ::8:>:8: &-3&I[4QJ (VJ)JE:HFH C
M:HVJ1JC:@"-JC:I&J-J (S3#3S3#0 PTTTXTTT (:;3C3: -WPO_ !_\!_K6
M[6%X7_C_ . _UK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*$LLPT^_'SLVQ7V[6#EB-KJ..OR@@#!'S Y)'J% !7F_ACQI<>(=3>.)P+1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 5YQXM_X^I/^ _\ H"UZ/7G'BW_CZD_X#_Z M>CE/\9^GZH\[-_X,?\
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MJO8SPI$6;*D*7#9YW?NF.<8(R2=NWMBNC\'^ I].@GTZ[,;P3C(\LDLK8P2
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MP]"LNNL& (^TW)P1GE?,(/U! (]#S7:^!/"5]HDI-U,'A$6U4$DC '*XPK*
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M'OC&2*>/AA=&[AU!YED8/'),7+ EE?)" +C:% "Y(Z=%&  #HOBE_P @Z?\
M[9_^C4K)^"O_ !YR?]?#?^@1TOQGU3[-:);!L-/(,C&<JG)YQQAMG<'\,UM?
M#G3/[/L(5(7<Z[R5[^8=RD\#)"D _3&< 4 =)2&EI#0 TTTTXTTT --,-/-,
M- #&IC4]J8U $;5$U2M434 1M4;5(U1M0!&U1M4C5&U $9IAIYIAH 8:::<:
M:: $--IQIM &[X7_ (_^ _UK=K"\+_Q_\!_K6[0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45S7CKQFOAB(-C=+)D1J<[<C&6)]
M!D<=3G QR1S]MX'U/4!Y]S?/%(V/DBW%0,#^XR*#V.T$=\G- 'HM%<UX6M[^
MP=K6\*S1!<QS @-P=H1EZDD?-GG!R"S9X\\\%VU[XO:9S>RQF,J3@L0=^[H
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M<_GCVKUJ&)QE;5127=W_ ,RTY,T+74DNON$GWVMCUZXQ6?XI4>6I[[Q^H/\
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MJUVVGVCZ+/GS8+L,N2V"I1P=H(&%SAATW;\@=37MOA/_ (\[;_KWA_\ 0%H
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MSK98]\;;MP'*G P=O_+0AL#DC/'2F^"_"MGKEH-0O29927,CR3/\NPX )##
M" 'YN<'.<8Q#X#BMXM7N$L\>0L!"X)8<&+=@L22-V><X/;C% $5_HTFLZS<V
MJ2&-'B3S2OWC'LBRHXZL<#Z9SD?*3QYX7B\(&#5+'*,DJJ4W,RGAFSDMNP0"
MK#."#VYSL:-_R'KK_KW7^4%'QK_X\X_^OA?_ $"2@!Y^%$=]&\EW(SW<P!,N
M?E5O]E>,KT&#V'R[.TOP?U"2\LB)&+>5*R+GLH5"%SZ#)QZ#@< "NXKS_P""
MG_'G)_U\-_Z!'0!S^A^&&\17E_ TC);BX8R*F SG?)Y8R01@').<\XXS@K;\
M<^'4\&>5J=@6C(D5&3<Y5AR_)W9P=N&7.",=".7>"_$<&E:A?0SL$\Z=RK,0
M$^1Y,@L>A.[C/!QC.< V/C)J:7$<6GQG?.9@=J89AA2 "H.06WC:,<\_B 2_
M%^Z6[L(9HSE))HV4X(R&C<@X//2MOX@>(VT"U,T?^L=@B' (!.2203V ..O.
M,@C-8/Q:LEL-.@MTR5BEC4$]<+$X&<8YXJY\7;"2[LP8U+>7*';'90K G'H,
MC/H.>@)I,#(M/"VE&/\ TB>.2=QEY/M()#,/F(Y (W9(W GUSTJQ\-=79S-I
M[2"1;9L1-QED!9<CDY48&.N-P&<8Q9T7P?I6M1"Y@BRIZ@R29![J1OX(_P#K
MC((-:7AO2;"T+O8["V &*2>80.H&2S8!Q[9Q[5G)Z".(\':9;:\TIU E[LR$
M;'9D; '905Y&"".=H4<*.O>:-HB:.A@B+;"[, S;MN[^$?[/YG))))-9NJ:)
M8>)XS=$KC&3+&P5A@ G<>F0H'#C*CTK-^&5[-/"\<C!XHG"QOSS@<CG!V@;2
MN0" <=L")ZIL#KVJ)JE:HFKG8B)JB:I6J)JS8B)JB:I6J)JSD!$U1-4K5$U9
M,1$U1-4K5$U9L1$U1U(U1UFP'"G"FBG"H8APIPIHIPJ6 X5L>&+1;F7#C(52
M<'!'8<@_6L<58M+M[1MZ'!_SZU5&<85(R:NDP1Z(V2..O;//^%95]I$E[PTN
M%_NJF!_Z%ST[YKGQXCG_ +__ (ZO^%*/$4_]_P#\=7_"O3JYCAZBM)2M]WY,
MMR3-/_A$?^FG_CO_ -E5/5-#^P*'W9RV,8QV)]3Z5$/$,_\ ?_\ '5_PJ*YU
M22[&UVR <] /Y"N.M4P;@U&+3Z?U<EN)7%.%-%.%><R3H/"W\?\ P'^M;U8/
MA;^/_@/]:WJ^ERS_ '6'S_-FL-@HHHKM*"BBB@"CKO\ Q[S?]<I/_037G'@G
M_C\C_P"!_P#H#5Z/KO\ Q[S?]<I/_037G'@G_C\C_P"!_P#H#5VX7^#4]/T/
M/Q?\>GZK\SU6N4T#P+_9%Y-J7F[O/\SY-F,;W#_>W'.,8Z#-=717$>@<5XS^
M&2>(Y1=+)Y3[<-A P;'0]5.<<9)/  XQSU6DV/\ 9\,=MG=Y4:)G&,[5 SC)
MQG'K5NB@ HHHH *Y_P 5^&YM:\OR+E[?9NSY>[YMV,9PZ],'UZUT%% 'FEC\
M(IM/SY%Z\>[&?+1ESC.,XE&<9-;?B7X=+JL_V^"9X+@XRR9(("E> "I!(P.&
MQ@=,DFNPHH Y3PMX"71I&O)I&N+AN!)(#D#&.,LQSCC.>G P,YZNBB@#G_%?
MAN;6O+\BY>WV;L^7N^;=C&<.O3!]>M<I8_"*;3\^1>O'NQGRT9<XSC.)1G&3
M7I=% '#ZC\.)7E>6UO)85E=G9!DC>Y))&UTXZ#D$\=3VT/"/@./P\S7)=I9Y
M 0SMQU;<<#)Y/&22QR,C&2*ZBB@ HHHH *\X\6_\?4G_  '_ - 6O1Z\U\92
M^7<R'W3_ - %>AE3M5D_[OZH\[-E>E'_ !?HS,%.J.*42=*DKV[W/&0X4HI!
M5;4[=[B-DB.USC!R1W!/(YZ5$W9-[FL%=I%P4X5P>JQW.F;=\K'=G&UV[8]<
M>M:6EZ5=.8YS+E"58@N^<<'&,8Z5QK&.4^7D=UN=CPBC'FYE8ZL4X5Y]?:C.
MDTI1VQ&['&XX #X'!.,9(&/Z5W.G7HO8UF7HP_(]".W0\4Z.)C5DXVLT%7#N
MFD][EH4X5RO@B\>Y\SS&9L;,;B3C.[UK*DGN+RZ>WCE89DD R[ #!)[>PK-X
MM<D96^(T6&?/*-]CT(4HK@+V>[T%U9Y-VX<98NIP1D8;D=N1CKP>M=9=Z\MI
M MVP^^JD*/5AD#./U_KQ1'$1E>ZLUO<<J#5K:W-84X5P=G%?:[F=9-BYP/F9
M%/)Z!0<XZ9/TR<<;7AY;JUE:VN#N0)E7Y(SD<;C@]SP>>...L1K\S6CL^I4J
M/*GJKKH=(*44@KC?L>HZP/-+^4,G"Y:,]AG !/;^(_3@TZD^7I<(0YNMCM13
MA7#>%-?G6?[#.=W+#YCEE*Y)^;G/3')/;!P,%FJZE*FHB(.P3S81M#$+@A<C
M&<<UC]87*GYV-/8OFMY7.^%**04HK1D(44HI!2BI8Q:6DI:EC%I:2EI %%%%
M(8M%%% '9T445P'<%%%% !1110 4444 %%%% '%>%9FU;4;R]<,!!BWCZ;<*
MQ+\[1DY4-UX#8.1BM75/#\^JR-ON'B@&-B6_R.2 ,LTA!/4L-H&,!3US7/\
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MVBS1G*2*&4X(R&&0<'GI7-?%+_D'3_\ ;/\ ]&I6KX3_ ./.V_Z]X?\ T!:
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M52K!!$"!R 2 20/3H.  )?A7X7MQ:1WK(K2R,S;G 8J4=E7;D?+C&<CG/?@
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M, #:!D#!SG<6'0X.?%J$=]J-U<7=O+<^2YCC2*/S8U"EERRL>IQD=MQ8XSC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZGM]< WQ7D]YJWVZ?[1,"RY^YNQ\O9<XZ>N!D\G@G-+$5O9KS8Z%+G?DCIO
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M.&8'HO\ A'-E]_::,HW0^6Z[.6YR&W!ASPHY!X&/3&W0!S5IKU_*ZI)8[$+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%0W5VEHIEE9408RSD*HR<#)/'6L__A++
M/_GXA_[_ "?_ !5 &M14-K=I=J)8F5T.<,A#*<'!P1QUJE-XGM(6*//$&4D$
M&5 01P003P10!IT4R&99E#H058 @@Y!!Y!!'4&JAURW <F6/$1 <[U^0DX ;
MGY3GCG'/% %ZBJ-EKEO?MLAEC=@,D(ZL<=,X!/'-7J "BLG_ (2RS_Y^(?\
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M $;5$U2M434 1M4;5(U1M0!&U1M4C5&U $9IAIYIAH 8:::<::: $--IQIM
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M%%<IUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0
ME(:6D- #3333C330 TTPT\TPT ,:F-3VIC4 1M435*U1-0!&U1M4C5&U $;5
M&U2-4;4 1FF&GFF&@!AIIIQIIH 0TVG&FT ;OA?^/_@/]:W:PO"_\?\ P'^M
M;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F_B"
M>3PYJ;:M<1M+;-$%5D^;RN%'? 4ELCJ 0YP2=RT_7_B%!KL$EE:Q2SR2PYVK
M'D(3QENIRAP<@$9QANX]%HH Q/!>C-HUG#:R??526Z<%V+E>"0<$XSGG&:L3
M>&+29B[P1%F)))B0DD\DDD<DUIT4 0VMHEHHBB5409PJ *HR<G ''6FVVG16
MK,\:*K2'+E5"ECR<D@<GD]?4U8HH KWNG17Z[)D5U!R ZAAGIG!!YYJQ110!
MD_\ ")V?_/O#_P!^4_\ B:UJ** *Z:=$DAN BB5A@N% <CC@MC)' _(47NG1
M7Z[)D5U!R ZAAGIG!!YYJQ10 57LM.BL%V0HJ*3DA%"C/3. !SQ5BB@"O9:=
M%8+LA144G)"*%&>F< #GBF7VDPZACSXTDVYQYB*V,XSC(.,X%6Z* *]EIT5@
MNR%%12<D(H49Z9P .>*AO=#M[]M\T4;L!@%T5CCKC)!XYJ]10!1&AVX" 11X
MB)*#8OR$G)*\?*<\\8YYJ:YTZ*Z97D16:,Y0LH8J>#D$C@\#IZ"K%% %>]TZ
M*_79,BNH.0'4,,],X(//-6*** /-/ T \0:C<ZR>4C;;$0K!3D; V2>HC R"
M/X\X'%>ET44 %4;W0[>_;?-%&[ 8!=%8XZXR0>.:O44 0VMHEHHBB5409PJ
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M--H W?"_\?\ P'^M;M87A?\ C_X#_6MV@ HHHH **** "BBB@ HHHH ****
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M\KS@]O3CN[3Q=:W<#WR2#R8B0S$,N" #C# $GD8P.2<#)H V**Y3_A:6G?\
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M5&U $9IAIYIAH 8:::<::: $--IQIM &[X7_ (_^ _UK=K"\+_Q_\!_K6[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YO\ %BR6
M_N+"W?(665U)'7#-$#C.>>:Z/Q3H$":=+;"-1'#"[(/[K(I(8'KG/4YR<G.<
MG.)\1_\ C\TW_KX_]GAKJO%G_'G<_P#7O-_Z U '-?"O0HA:QZ@PW3R;OG?Y
MF4(6C55)^Z HQQ].@ %+POI\>GZW=0PJ%009"CH-WDL<#L,D\=!T'%;OPM_Y
M!T'_ &T_]&O65HW_ "'KK_KW7^4% !K/_(>M?^O=OY3U4FTQ-?UR2*Y&]+:%
M2BG&W@(<'CD9D)P>O0Y7BK>L_P#(>M?^O=OY3U4\22R^%-2;5_+:2WGC59"H
M^X/D4C.< Y52-V V2HYY !WNHZ+#J+1O,@9H7#H>058<]01QP,CH<#(X%<%\
M7;'^T)K&VSM\V1TSC.-S1#.,C.,^M;%M\3H=1EBM[2.25I"F\A2HC5CABW!Y
M7(SCY>?OU2^(_P#Q^:;_ -?'_L\- '07FCV^@0275O#$LEO"[(VP;LJAZM]X
MYZ$YR>>:Q/A+HRQVW]HM\T]RSEG;); 8C;DDYR5+$\9)&<X!KL-6L?[0ADML
M[?-C=,XSC<I&<9&<9]:\U\%>,O\ A%%_LO4E>/8S%&*Y4*2<CY1DC<#AAN!S
MV H E^*5E_84MOJUJBHXD;>R_*&8_,H8*03N&_<>I'!/2M7XGZ++=FVNXHO.
M6VD)>,#+,&*'&W!R#MP>#C.<$9QE:E*OQ#NX$AC?[+;M)YDK A6^Z2HY!&0!
MCG< V=HV\]EXF\71^'6B,ZMY4I8%U&0I&W&1Z$%CQS\IPI[ %71?&ECXG9(E
MP90=ZI*GS IG# G*[@.1M)(&3V.+OB.ZLK I=7I0-'GRRXW,"2N2J\DD$+R
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M/BG9LRQ0"6=WS\L,3%N!GH^TGC/3/0YQ4OQ2_P"0=/\ ]L__ $:E &5XE_Y
M*_\ 7O:_SCK5_P"8-_W#_P#VA65XE_Y *_\ 7O:_SCK5_P"8-_W#_P#VA0!%
M\.+1+O2X8I55T/F95P&4XE8C(/'6L+P#H=O=7>H))%&RQSX0,BL%&^48 (X'
M Z>@KHOA;_R#H/\ MI_Z->N5T7Q+%X4OM02[W*9)-Z[1NR,NZC@\%@X(S@==
MQ!H E^)NMI!?6T%R&:VB42LJ $LQ+  JQVD?*!SS@MSS5?Q'\2-/U:U>R$,G
MW"(P40*K!<(1A^ /;MD8()%:'B]I8I;7Q-;(9$6(;HRIW!&5V+$KD ;6()Z*
M<'Y@>-67XMZ>D?FAV+8!V"-M_.,C)PF1W^;''!/&0";X67K76GQAMV8RZY?N
M Q(VGNH!"^Q4CM76U4TO4/[0C6?8\>[/RRKM<8)'*Y.,XR/;%6Z /--=+>&-
M3?6)HFDMY(P \8#&,[43)S@ DC'49#<$G*UV>AZS::ZS75L5=T&QFVE7 /S!
M?F ;:3R.Q(/<&L_4?B%;Z3</9W0:/: 5<J61@0IXV@G.21T(^4_-GBN7\'6B
M:IJ<FHV2M':1J5. %1VVA=H4;< \/@[CD M@L  !^K:';IK5M;B*,1- Q*!%
M"$XFY*XP3P/R%=U?Z?:P0&&98TME*DJ=J1C#AAD<#!;''0G@YS7%>-+U=%U:
MUU";(A\IEW#GGYP>.N!YBD\=.F3Q47CW55\6:>T]HK,EO<_,2,?*B'+@9SM^
M<=@0,D@ &@"[K/Q)TLQ?9,-+$R[2D<>U5 Q@?/LQ_L[>F.W%,^$4*W]@\,P#
MQB=@%<;EQM1L8.1C<<_7GK6A;_$JTD6."S5I)6 5(40ICY<@$D!%5<8)!(4<
MC(&:I?!3_CSD_P"OAO\ T".@"AX#T2WNKO4$DBC98Y\(&12%&^48 (X' Z>@
MJU\1O^/S3O\ KX/_ *'%6;HWB2+PK>Z@EWE3))O7:-V1EW4<'@L'!&<#KN(-
M7?B [W266L0H7CA82E<'=M8)("<!@  F&/0$CK2>X'5>*_\ CTN/^N$O_H!K
MB/AS9F]TVX@7 :1Y5&>F6B4#.,\<U?UGQNNOPFRTY3+-/&P8$%1&I7#%B<#/
M.!@XSW/ :I\+[@VUA-*JEV260A1U8B-"%& >3TZ&H>B$0>$_$\7AN/\ L^\1
MH)$+DL4)5\MP<J"2>P.""%X;H*[>TBCC11"%$>,KL "X/.1CC!SGBN/UOQ]I
M^J6S*X+,5;$;)\X8Y4$,0R*1G(.20.Q/%:?@#2I--M%2;(9F9@K=5!Z+U.,X
MW8XP201G-9S6EP-]JB:I6J)JYV(B:HFJ5JB:LV(B:HFJ5JB:LY 1-435*U1-
M63$1-435*U1-6;$1-4=2-4=9L!PIPIHIPJ&(<*<*:*<*E@.%.%-%.%2P'"GB
MF"GBI8#A3A313A4L0X4X4T4X5+ Z#PM_'_P'^M;U8/A;^/\ X#_6MZOI<L_W
M6'S_ #9K#8****[2@HHHH HZ[_Q[S?\ 7*3_ -!-><>"?^/R/_@?_H#5Z/KO
M_'O-_P!<I/\ T$UYQX)_X_(_^!_^@-7;A?X-3T_0\_%_QZ?JOS/5:R?%G_'G
M<_\ 7O-_Z U:U9/BS_CSN?\ KWF_] :N(] \-\,SMH30:Q@L@G>-AMS@!%SS
MD#<RNVT''*YY&<=GX^_Y#-G_ -N__H]JK^"]!.N:1<6R@&3SV9,@'YE2,@ D
MC!;E<YX!/;BN<L=;_M6[T_(PT'V>(\8!V2G:1R?X2,].<\8Q0!] 5S5W\1["
MT=H9)L/&Q5AY<AP5.",A<=:Z6O--6UCRYI%_LCS,2./,\O._#'Y\^2<[NO4]
M>IH ZO2_'MEJLBVT$NZ1\X&R09P"3R5 Z ]ZZ"O/_"VJ>?<HG]F?9\[OWOE[
M=ORGOY2]>G4=?PKT"@#QSXH>'IX%:_N92^ZYVQ("=B1LK'H0,,=J@X],DL3Q
MV=QK+:-HZ74?WUM80O3@NJ(&Y!!P3G&.<8K/^-?_ !YQ_P#7PO\ Z!)4NN6K
M76AJB#)%K W4#A CL>?0 G^7- &/X,^'\&NV1N[C+3W!E(D)?*G)4$@. QW
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M5&U2-4;4 1FF&GFF&@!AIIIQIIH 0TVG&FT ;OA?^/\ X#_6MVL+PO\ Q_\
M ?ZUNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9F+J94!Q\J."HX[;U8\]>2?RKL]/T^/3HUMX5"QH, #_ #R3U)/)/)YJQ10
M5P^H_"*TOY7N'>4-*[,0&3&6))QE#QS7<44 <9I?PHL[#>"9'65-K*[C&-RN
M.453G*CO56'X+V2,&+2L 02"ZX..QP@.#[$'T-=[10!7T_3X].C6WA4+&@P
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M D.,K]XG *@ '(W9:'0H[GQJTE[)/+!:AV6%(3Y3$#'S%L'(XQU;YMV"H&"
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M 4444 %%%% !1110 4444 %%%% !1110!GZ_K*Z+!)=OR(USCGDGA5R <9)
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M -\M_P#%4?\ "Q[C^['_ -\M_P#%5W/]A6__ #QC_P"_:_X4?V%;_P#/&/\
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M.2&+9.X*!D$G&0N#Z110!Y_;>#Y6T7[ JJ)Y%#D'Y23Y@D .0/FV@+ST(QG
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M'^M;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!4[>0G&#WL,RS*'0@JP!!!R"#R"".H->?^)++4?%BI9/;K;Q%P7=I(YB,=,
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M(M<_VU_:6S_1_P"_N7_GAL^[G=][CI^E '5>+/\ CSN?^O>;_P! :LKX6_\
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ML\LYV[L\$=<>H%8@IPJ%1BN7^Z7[5OF\SI;[7DEAVJ?WC* 0 <#/WNOXCO\
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M$LE\TLC-"48NS\ X(!P,#+;OF!#'!X!UOA_ ^D6UUJ-VI\UI9FD(*DL(L[L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 8U1-4K5$U2P(FJ)JE:HFK)B(FJ)JE:HFK-B(FJ)J
ME:HFK)@1-435*U1-6;$1-435*U1-6<@(FJ)JE:HFK)B(FJ)JE:HFK-B(FJ.I
M&J.LV X4X4T4X5#$.%.%-%.%2P'"G"FBG"I8#A3Q3!3Q4L!PIPIHIPJ6(<*<
M*:*OZ1I_VQ\'[J\GK^7XTZ=.522BMV"5SH="M_)B&>K?-^?3],5H445]92IJ
MG!071&Z5@HHHJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\X\6_\?4G_  '_ - 6O1Z\X\6_\?4G_ ?_ $!:]'*?XS]/
MU1YV;_P8_P"+]&9(IU-%.KVF>,API12"E%2S1#A3A313A4LM"BG"FBG"I9:'
M"G"FBG"H9:'BE%(*45++0\4X4T4X5#+0X4HI!2BH92'"G"FBG"H90X4HI!2B
MI92%%**04HJ6,6EI*6I8Q:6DI:0!1112&+6AHEOYLF[LHST[]O\ '\*SU7=P
M.IKJ-,LOLJX_B/)_P_"LZLK1-*4;R+=%%%<AU!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !24M)0 E(:6D- #3333C330 TTPT\TPT ,:F-3VIC4
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M_P"^&_PIG]DS?\\W_P"^&_PK-TY=F*Q6%.%6!I,W_/-_^^&_PIPTF;_GF_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX_W10!/14'V*/&-BX_W11]BCQC8N/]T4 3T5!]BCQC8N/]T4?8H\8V+C_=%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%9:>)K=Y?LP<>9N*X(8<CC&2,=??GM6I3E%Q
MW5B8SC+9W"BBBD4%%9%QXHAMYQ9-NWD@9 ^4%N@)Z\\= 1SR>N->JE%QM?J3
M&<97L]@HHHJ2@HHHH **** "BBB@ HHK-U+Q%!IK".9]K$9QM8\9([ ^E.,7
M)V2N*4E%7;L:5%-CD$@#*001D$<@@]#FG4AA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%87_"
M;6?_ #T_\<?_ .)IT?C.T<A1(,DXY5@.?<K@?C6GL:G\K^XS]O2_F7WHVZ**
M*S- HJ.><6ZF1CA5!)/L!D]*YK0O'(U246YC*E@<$-NY SSP.P-7&E*2;2T1
M$ZL(246]7L=31114%A1110 4444 %%%% !1110 4444 %%%4=3UN'2]OG-MW
MYQPQZ8ST!]::BY.R%*2BKO1%ZBL+_A-K/_GI_P"./_\ $U;TWQ%!J3&.%]S
M9QM8<9 [@>M4Z4TKM/[B%6IMV4E]YI4445!H%%%% !14%_=?9(WFQG8C-C.,
M[03C-9'A;Q,=;WY0*8R.ASD,6QV[ ?CUXZ5:IR<7+HB'4BI*/5F]1114%A11
M10 4444 %%<GJ/Q 6SF:#RRRHV"P;!X^]\I7L<CKSCK765<Z4H)-K<B%6$VT
MG>VX4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445B>+-;?1XEEC"DEPOS D8(8]B/2JA!SDDB9S4(N3V1MT5P-MXUO;H;HX
M58 XRL<C#/ID-6GHFOWEW,L4T.R,YRWENN,*2.2<=:UEA9Q3;MIYF,<7"325
M]?(ZNBBBL#H"BBB@ HHJEK4AC@E9201$Y!'!!"G!S32N["D[)LNT5Q'PSD)$
MRY. 4(';)W9./? _*NWJZU/V<W'L10J^U@I;7"BBBLS0**** "BBB@ HHK$M
MO%D5Q.;(!]X9ER0-N4SGG=GMZ5482E>W0F4XQM=[FW1114E!1110 4444 %%
M%% !116;XBU)M-@>X0 LNW&[..6 [$>M.,7)I+J*4E%-OH:5%>?VOCB\N\^7
M$KXQG:CMC/3HU7K#Q)?32(CP81G4,?*D& 2 3DG P*WEA9K>WWG/'&4Y;7^X
M[*BBBN<Z0HHHH ***\_TB_D?4F0NQ4R2C!8XPH<J,9Z#L.U:4Z3FI/LKF56L
MJ;BN[L>@4445F:A1110 4444 %%<CXX^U;H_L^_9AL^5OSG(^]MXQC&/^!5N
M>'?-^SQ^?GS,<[NO4[<^^,9SSZ\YK25*T%*ZUZ&4:W-4<+/3J:5%%%9FH445
MB:)XLBUAS%&'!"EOF  P"!V8^M4H2:;70F4XQ:3>KV-NBBBI*"BBB@ HHHH
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M><<<&G7C><5*6EMQ8>5J<G".M[6+'_"56N_RO-7=Z_P],_?^[^O7CK6G'()
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEMN_?GA3TVXZ@^M8\FMW^N*SP K&H ;R\ Y R<$_,2?13TP.<Y-KXF_\L?\
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M_G;%\S^]M&[ICKC/3CZ5BI*$I*4?^ =#BYQ@XRT77N3T445@= 4444 %%%%
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MU'D3[J^WS,KPM=2Z9=BURQ7>R,J\J3TW8/H0"3UVC\*E^(__ !\+_P!<E_\
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MNC#D _+^8Z$?0D'TRBB&)<;JRL^@IX52Y7=\RZGFM[;7WB-P)(RH7IE"B+G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD$8SC/:@#;HK)T3Q5:ZWD6TBN1G*\JV!CG:P!QR.<8SQG-:U !1110 4444
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MM^9!G&#G[WJ.E=!7G_Q'_P"/S3?^OC_V>&@#T"J.M:Q'H\+W<V=D8R<#).2
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M.\3:%/J[1)%.T$2EC)Y9(=ON[0",8&-W.2,X^5NP!O51UR]:PMYKA,%HHG8
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M7&>V<5IUY_X8UV]TN\71M0*R;XRT<B\DX7(RWRDC","2NXMW(YKT"@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N7\:> HO% 5BQCE0$!@H.02#AAP2!SCYA@DGFNHHH Y?P7X"B\+AF#&25P
M 6*@8 ).%') /&?F.2 >*ZBBB@ HHHH **** "O-/!5RVGZM>V<FU?.9W&2-
MQ(;>@'..4<L1UX[8->EUQ_C/X>KKK"[@;RKE.0XSABH^7.,$$$###) XP<#
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M)0DK\SLPQD ]#Z4 8NE:1K*RHUQ<Q&(,"X1%+$#G:/W2]>F<C&<\XQ536?\
MD/6O_7NW\IZ] KE]0\+RW&IP:H"OE11%2"3OR1(.!C&/G'<=Z &>)_%LMG<1
M:7:1J]Q,NX-(<1J,G)(')X5B>1CC&X\5ROCVRU7[-++<RP_9_DW1Q _WE P6
M3=][!.6]>W%=1XJ\)SWES#JEFZK/"-I$N=A7YO0$Y.X@^QR"I'.?KWA74O$,
M3Q7$T2C";(X=XC9@V279E+8 Z*,@MM/&.0!GB7_D K_U[VO\XZZKPG_QYVW_
M %[P_P#H"UFZOX7EO=,&EJ5$HBA7))V9C*$\X)Q\IQQ6/IGA+4]"006D\1C,
M?*S;CLD8#>4(3IG)7/')RI/) *5M%(_B&0IG:J O@X^7R5 R,\C>5XYYP>V1
MF:'97]S>7_\ 9\J1XN&W^8 <Y>3;C*/TY].O>NS\$^"6T5I+VX8/=3EMS+P@
M#-N( P,DD9)P,=   2:^M^!YH[L:IISI'*<;T<,$?.2Q)7.=W&1@<C=D-S0!
MB:WX'U?6T$-S/"Z!@P'W>0",Y6('H370?$>-HM*E21M[A80S8"[B)$RV!P,G
MG':B2PUB[90TUO"@SDPHSL>./EE&.OH1U/7@5J^,]$?6[22SB*AY-F"Y(7Y7
M5CG )Z#TH E\)_\ 'G;?]>\/_H"UK5QGBJXD\.Z2(U<),D4,893U/RJVTG!S
MM#$$#('/&.-CP7;S06<*W)9I2I+%RQ;YF+ '=SD @$'H1B@#;JOJ&H1Z=&UQ
M,P6-!DD_YY)Z #DG@<U8KA/B)X,N_$KH(9$6!%^X[,/GR<M\JG/& ,GCG&,G
M(!GZ)8-XYNSJ=RC?8HLB&-R,$C )V@8(R"6YZX3+!2!K?%ZQ^TV#29QY,B/C
M&<Y/EXZ\??SWZ8[YJC#H&N0J$2Y@"J   B@ #@  0< 5TMGHLU[:-9ZBZR/(
M&#-&H'!/RD9&-R]0=HP<<$C) )O!TRRV5L5((\B,9!SRJ@$?4$$'T/%<IJTR
MOKUL 02L# @'.#MF.#Z'!!^A!I^D^%-4\/H]I:S0O$?N&8.&0D<E5 8#DYP2
MPR,X&2#J^#O!SZ4\E]=OYMW-D,P)VA<C@<#T'8  !5  Y .KKRSXY0L5MG .
MT&4$XX!.P@9]3@X^A]*]3K)\3^'D\00-:2'&[!5L E6'0C/Y'H2"1D9H UJ\
MZ\?W'VC4M/M4#%XY!(<#(VM(O/'/ C8GC '.>N)=-\.:QI*FWBN(7B566/S0
MVY1GY6X0G('0%F4=,$ 5=\(^!)-.G;4KR02W+@C@?*N3R02 <[0 ,!0HRN",
M4 =G17*>.M O-7\K[%-Y6S?O_>.F<[=OW <XP>O3-7?%6A3ZFJ/:SM#+$21@
MG8W3 8#J,@<D$ $_*<T 4O$WPVM-<S)M\N4Y.^,8R3DY9>C9)R3PQQC<*J_"
M?79-5M")BS/%(5W-N)(.&&7;()!)& >!MR.03#)HVM7*K"]Q"B\AWC!\PACU
M^X "H^[MV>YSS71^%?#,?AR 6L9)YW,Q_B8@ G'8<  =@.<G)(!L45RG@70+
MS2/-^VS>;OV;/WCOC&[=]\#&<CIUQ75T >?_  X_X_-2_P"OC_V>:O0*X37?
M ,ZW1U/39EBED^\K#"<CYCPK Y(!(*GYLMG.*T-+T?49;E;J\G01QYQ# &V-
MN4J<YVG@X89W\YQMH Y*_MKNXUFY6PD6.7RD)+@$;=D61RK\YQV[=:NZIX2U
MG58VMI[B%HWQD8QG!!'(A!Z@=ZV_%_@=]1E34+-UANH_XB#A^@&2,]!D?=;<
M#M/ HN+76;K:GF6T0W#+1*[-COQ("#Z]N0.0,T 4O%NFR:9HK6TS!WC2)20,
M#B5, >RC SU.,GDUT_A/_CSMO^O>'_T!:J^*- EU>Q:Q#JTK+&"[C:I*LK,Q
M"@XS@\ <=*TM#LFL+>&W?!:*)%)'3*J <9QQQ0!Q6@PK%KMV%  \@' &.6\D
MD_4DDGU/-/UG_D/6O_7NW\IZV-/\+RV^ISZH2OE2Q!0 3OR!&.1C&/D/<]JK
M^*_"EQ=W<&IV3HLL*E2)2=I'.!@*3R&8-R.,8P>: )?BE_R#I_\ MG_Z-2N=
MT/2=:>WA:&YB6(Q(4!49"E1M!_<GD#W/UKK],TF>\@DM]3,<OFNW$8.P(0,*
M.%.0<D'EAP=V:P-#\+ZGX<5K:VE@DASE?/$@(S][ 7. 3VW$=^"30 >%_!E]
M9WIU*[FC8NA5]@R6X 48V(% V@Y'/&.Y-0Z]"LNNV@8 CR"<$9Y7SB#]00"/
M0\UT?AVPOXG:6^F1E;=MBB0;5R00=Y"MQR,'/&"235?4/"\MQJ<&J KY4414
M@D[\D2#@8QCYQW'>@#HKNU6[1H9!E)%*L,D9##!&1STKSV;2-0\$QLUFZSVJ
M!VV3##(.6)ZKD #LPR22$SS7H&HVS743Q(Q1G1E#CJI8$!A@CD=>H^M<?-IV
MMRPFW,MOE@09!YBR<GL0@4''&0N0.1SS0!T'A7Q-'XC@%U&".=K*?X6 !(SW
M'((/<'G!R!L5RXTU?!VG2)$P#112-O8*,R$'!QT)+8"@YXPO-1?#!;@V8ENG
M9VE=F4R,S,$P /O=C@L,<8(/>@#K:*** "BBB@ HHHH **** "BBB@ HHHH
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MCW8+D%OF8L<X '4^E9_B+P1!KSK<2%TECV[9(GVL I) YR.ISG&<XYH Y_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8DD$XZ;<%01R,J<$9[:9\&W^HQO<S7<D=S( 5CB=EA0_W#M)R,8&1T.3E^I
M.]HKC_A;KLNL6F^<[FCD*!C]X@*I!)[GYL9[XYR<DU_ .HRW5WJ"2.S+'/A
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M [NL?PO;7=O$5OY%DEWD@H !MP,#A4YSGM^-9GPY\6-XBMR\NWS8FVM@C)&
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M@H_V^/[M/^*<AU66UT9/O2R!VPI9E'*!NP( +DC_ &<D@=0#T*&99E#H058
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MJ 5Y.KJVI_:;"2\B++OM7D4]&&8RRG@\$>QZ]Z\]\$WNJVMJ@LK>)H26(=B
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M^O0K+KMH& (\@G!&>5\X@_4$ CT/- %BX^(=U91K=W%BZ0%@&;S 64$XR4*
MCVW;03CGD5UNGZQ%?0+>JP$3)NRQ P,9.3D@%>0W/!!JOXL_X\[G_KWF_P#0
M&KS72[J5= GR6 $FU#C;\C/'N (QD$LX/7NO08H ZNS^($^KM(;&T::*-MOF
M&58@3CL'7],Y () SBK7A;QZNLR-9S1M;W"\B.0G)&,\953G'.,=.1D9QH>"
M;5;6QMT08!A1NI/+C>QY]22?Y<5QOCPB'5K&1'(D)B4J 1A3*1G=W#[F!'H.
M>#0!T'B;XAQ^';E;29"4:(N7!Y'WP%"8Y)*@9W <\X K/N?B1<V*+<7%C(D+
M'EM^2H#!22I08//RAMN[L>]0Z]"LNNV@8 CR"<$9Y7SB#]00"/0\UU'C:U6Z
ML;A'&0(7;J1R@WJ>/0@'^?% %B_\10V5L=18DP[%8$ Y(?&W ..3D#G&,\XY
MKG;7QK?7<0NDL&,;*6!\]=Q'J%*;CGM@<\8SD5#X6TG_ (2+1DM)'8;U8!NI
M&R4[.O4#:!CCC@$=J4/B.^\&1K;WL E@C"*)H3T48'/'49"KN"9(ZG.: .ZE
MUB.W@^V39CCV!CY@PRY X(Y^;G&!DYX&37,6_CF\O$:X@L':(9*EI51F7&00
MA4DY!&-NX$\ FL_XL:JM[IT<T#[HY9DY4G##:YP1[$#(/0CD9%.AU37(5"):
M0!5   *@ #@  3< 4 =1X3\61>)(O.BX9<!T)^93_4'L>_L00-NN"^'>B7MA
M<7-Q=QJBW!W$!@3OW,?EVLV%&XYSS]W&>:[V@#R_Q?)_PD6JPZ0S,((\%U/W
M2P4R'H0>4PN<Y7)P.N?2K6T2T411*J(,X5 %49.3@#CK7GMM<M9>()%*G%Q$
M%!/' C5MPXY&8ROUSSQBO2* ,_3- @TMGD@C6,R[=VSA3M! PO0=3T SU/-<
MX?B"]].]MI]N;D1 ;G$JQIG., L""/0YYP2 0,GH/$\S0VEPZ$AE@E((.""$
M)!!'0BL+X3VJPZ?&ZC!D:1FY/)#E,^W"@<>GK0 :-\0O/N/[/O(6MI3]S>VY
M6.2, [5')'RD9#<@'. ;?B_QLOAIX$D3*3LP9MQ&P*5RV K%N&SCCI[UR_QL
M(B6VF5RLJ.^T $'^$E@PZ%2%]SG(Z58^*5JMW<Z?#(,I),RL,D9#/$",CGI0
M!JZ!XZFU>=(OLDJ02;BLS[MNW:64GY,?-@?Q$<\$]XM8^)BZ7=2V#1,S1JOE
M["2TCN$*H%"\?>ZY/3@$D"NUKSK3+59M?N'89,<(9>3P2D29]^&(Y]?6@#HO
M#/BF75%E>YMVMEB"G,I(!!W%CED3 7'/7KVK/MO'5QJ;,UE9M+"IPLC2"$-U
M!(#KR,@]"2.-P!.*M_$V9HM.G*D@X09!QPTB@CZ$$@^HXKE_#^H:S;6\26]K
M#Y0C78<J"01G<1YPY;.3P.2: .M\(^-(_$(:,J8IXB0\3'YA@XR,@9'8\ J>
M".A.%HW_ "'KK_KW7^4%1>%-'U'^T7U*ZB2-98RKX8$8 4*%"NQSE1G/&-W?
M%2Z-_P AZZ_Z]U_E!0!NZ]XHFLIUL[:V:=V3<Q#!$4$L%RQ! )VMUQT&,DX&
M:_Q$?3IDM[^V: 2XVOYJ2+DL!R<* !G+<D@8XP<U=UCQL;>X_LVUA:>X4 LH
M81HH(SR[9YY';'S ;MW%<%\2-1U&ZA O($B@\X%2K!FSM;:I(<YXSD[1R.W2
M@#N/B/K<NGV[11P-*LT4RNZYQ&-H&XX5N/F)Y(Z'GTYSX;^*+B.&"Q2T=H]S
M#SMQ"8+LS-RF/ER>-W)&!R<5W7BS_CSN?^O>;_T!JROA;_R#H/\ MI_Z->@"
M;Q!XS_L^5;*VB:XN#@LB' 13@ LV"!DD=> #DD#&:(^(+V,Z6VH6YMA*#M<R
MK(F<XP2H  ]3GC() !R.2TF]OTO[Z6RB29Q,RLTI&Y5#N%4$NAP0O3D?*O3
MJQXHL-9\21"WFMHPJN&!1T!R 1WE;CYJ /0/%7B:/PY ;J0$\[54?Q,02!GL
M."2>P'&3@'''B^^11,]@XC.TG9,KR ,1TC"AB1GH<8[XYQ;\6^%G\2VBV\C*
MLZ[7RN?+\P*01SSM.3CN.#SC!Q%\=W?A]E@U2'Y"VW[1%RA&" < $$DJ6(!4
M[>0G&" >@44R&99E#H058 @@Y!!Y!!'4&GT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Y_HW_(>NO^O=?Y05Z!6/;>%XK>[DU0%O-E0*02-F %' QG/R#N>]
M '+_ !K_ ././_KX7_T"2O0*Q_%'A>+Q)$+>8L%5PP*$ Y ([AN/FK8H \_^
M"G_'G)_U\-_Z!'3/AS,HOM20D;C.2!GD@22@G'H,C/U'K75^%_"\7AN(V\)8
MJSEB7()R0!V"\?+5+6? $&IS_;@TL4_=X9-K'Y0HZAL8 Q\N,Y.<T </\;M0
MCFD@MU8&2(2%P/X=^S;GW."<=<8/0C.[\:_^/./_ *^%_P#0)*T+GX6VEQ%Y
M#;]QD+M*2IF8G.07*GCGH .1GKDG8\4>%XO$D0MYBP57# H0#D CN&X^:@!W
MBS_CSN?^O>;_ - :LKX6_P#(.@_[:?\ HUZZB:%9E*. 58$$$9!!X((/4&N/
MT[X6V]@R%)9RL4JRA"Z[-ZXP2H0<\8SUQQF@"EHW_(>NO^O=?Y05;U7X2VFI
M2O<LTJM(Q8A&7;D\DC<K'D\]>_&!Q6[;>%XK>[DU0%O-E0*02-F %' QG/R#
MN>];% '&:I9+X%TV4V>=RD'=)\QW.RINQP,@8QQC@9!YS2LO (\16\4]Y<W#
MM,JRE0X$8+C<,(58# ;''X  X'<:AI\>HQM;S*&C<8(/^>".H(Y!Y'-<I#\+
MH$06YFN&A!!,1E'EG#;L%0HX)YXP<\@YYH Q_A%;I;37T41W1I(@5L@Y4-*%
M.1P<CN.*MZ-_R'KK_KW7^4%=+X?\(PZ"\TL&[_2&!*G;M7!8@* HP!N/'/&*
M?;>%XK>[DU0%O-E0*02-F %' QG/R#N>] #O%G_'G<_]>\W_ * U97PM_P"0
M=!_VT_\ 1KUT>HV2W\3V[Y"RHRDCKA@0<9SSS5?0-$31($LXBQ2/=@N06^9B
MQS@ =3Z4 <?HW_(>NO\ KW7^4%'QK_X\X_\ KX7_ - DKJ+;PO%;W<FJ MYL
MJ!2"1LP HX&,Y^0=SWH\4>%XO$D0MYBP57# H0#D CN&X^:@#8K,\3PM-:7"
M("6:"4  9))0@  =2:TZ* .,^$VH1W%@D*,"\1<.O<;G9EX]"#P>G4=0<=;'
M=I*S1*REX\;E!!9=PR,CJ,CIGK7*W/PMM&E^U0M+ _/^H?8,G.2,@D9!Q@$#
M' %:OACPA!X;5D@#9?&YG;+-@G&>@&-Q' 'ODT <E\&+U8XIK!\K-'*6*MP<
M$*AX/.5*X;CC(]:N_&"X_P!$2V4*TDTRA5QN?C)R@ZYSA20#PV.]:&L_#6TU
M.7[6-\4N[<6A;:2W&&Y# $$9RN"223DT_2_AW;64WVQS)-,""'G?>05& > ,
MGIC.<8&,8H S_&UDUAHQMWP6BBMU)'3*O&#C...*Z+PG_P >=M_U[P_^@+4V
MOZ(FMP/9RE@DFW)0@-\K!AC((ZCTJQIUDMA$ENF2L2*H)ZX4 #.,<\4 </\
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MHHH ***KWNHQ6"[YG5%)P"[!1GKC)(YXH L451LM<M[]MD,L;L!DA'5CCIG
M)XYJ]0 45GW7B&VM&,4LT2.,95Y$5AD9&03GI3(?$]I,P1)XBS$  2H22>
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M .*H UJ*9#,LRAT(*L 00<@@\@@CJ#5>^U:'3\>?(D>[./,=5SC&<9(SC(H
MMT57LM1BOUWPNKJ#@E&##/7&03SS0^HQ)(+<NHE89"%@'(YY"YR1P?R- %BB
MBLR'Q/:3,$2>(LQ  $J$DG@  'DF@#3HJO>ZC%8+OF=44G +L%&>N,DCGBJ/
M_"66?_/Q#_W^3_XJ@#6HK/M?$-M=L(HIHG<YPJ2(S' R< '/2J^@>*(M;:6-
M RR6[[75P,@\CJI92,@C@]O3&0#8HHHH **** "BBB@ HHHH **** "BBB@
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MZQU-Q#%,I<] P9,DD  %PH))/ ')]* .@HJOJ&H1Z=&UQ,P6-!DD_P">2>@
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M>MUY_P##C_C\U+_KX_\ 9YJ .JT+PM;:#N^S)L\S;N^9FSMSC[Q/J>E:U%%
M'.:A\0[#3Y&@DF =#A@$=L'N,JI&1WYX/!YJ[HGBJUUO(MI%<C.5Y5L#'.U@
M#CD<XQGC.:R+OQ9IGAMI%#*)6+,XC4N[-N8D%@"-VXD ,PVY["N/T+7H-5UF
M*XLU:-94<2 X7<VQV)(5B,'"GW89(SR0#TJ\\26]E,+.5PLK(7 ((&U0Q+%L
M;0 %/4CI65#\3=.E8()QEB ,I(HY]25  ]R<#O7->,M'CUC6;:UFR8V@R0#C
M.TRMC/H<8..<="#S71>.?#4,]A+&B(GDQLZ$1K\NT^8P7&-N_;@X]<G/2@#J
MZY>;XFZ=$Q0SC*D@X21AQZ$*01[@X/:L+^VW_L#S\+N\GRNAQMW^1GKUV\^F
M>V.*VOA]X;BL+%!M5C<QAY"5^\'&0I!SD ';CH>3@$F@#C=/U"/4=?6XA8-&
MXR"/^O;]".A!Y!X/->NUY%8:?'I_B 0PJ%0%B%'0;K<L<#L,D\=!T'%>NT <
M_P"-?L7DK_:/^J\P8_UGWMK8_P!7STS[?I53XI?\@Z?_ +9_^C4K*^-?_'G'
M_P!?"_\ H$E:OQ2_Y!T__;/_ -&I0!S_ ("\!66JV45S/%ND??D[Y!G$C <!
M@.@':IO B/HFH7&C!V>".,.F\G*\JV ,X&?,.[ &X@'CI6#X<M]7BL%N+.5?
M)4.5C"JTG#MNP&C.3G)QNR1P.<"NF^$UM;/"UU&QDNG/[YG^^"3G'4_*>N[/
MSGD\C:H!@_$JU6[U:UAD&4D6%6&2,AIG!&1STKL/^%6Z=_SQ_P#(DO\ \77'
M_$J-I=6M4C;8Y6$*V VTF9\-@\'!YQWKMK30;^)U>2]WH&!9?LT:[@#RN0<C
M(XSVH E\3:NOA2R,D07]TJ)&K,<$\*HY.3@<D9R0#R.HY?PK\/8]9C&IZB6E
MFN!NP6VJ V-A^0@YVC@9  .W:,58^-?_ !YQ_P#7PO\ Z!)7:Z3Y?DQ^1_JO
M+39U^[M&W[W/3'7GUH YVW^',.FSQW=D[0%" Z@ET=,Y92&.<MQSD@8!"YYK
ME_'W_(9L_P#MW_\ 1[5ZK7E7C[_D,V?_ &[_ /H]J -#XQ7Y5;>S9]D4\A,C
M $D!"O8'Y@-V['<@8QBM7_A4^G[/+\MMVW&_S'W9QC=C.W/?[N,]L<5M>)?#
M47B*+[-/NVA@P*'# C(R,@CH2.0>OK@CB'MM4\$+O1A=6B#D-G<JC:#P264
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M *^&_P#0(Z[#1- @T1##;+L0L6(W,W) &<L2>@%8_P //"\OANW:WF*EFE+
MH21@JH[A>?EJQX*TBYTJ%HKR3S9#(2&WN^%*J ,N >H/'3F@#H**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ J&ZM$NU,4JJZ'&5<!E.#D9!XZU-10!#:VB6BB*)51!G"H JC)R<
M <=:FHHH **** "BBB@ KS_1O^0]=?\ 7NO\H*] K/AT""&=[]5Q/(NUFW-R
M!MXQG ^Z.@[4 <Y\4=":_MA=Q$B:T)D4@X.T8+X.1@C ;/)^7 ZUSOP\UO\
MMO5)KS&#):KN&,#<ODJV.3QD''.<8SS7JM8^E>$;7296N;>,)(X()!;&&(8@
M*3M R!T QT'% &Q7+^*/"5QK$HEANY(%"!2B;L$@D[N'7GG'3MUKJ** //\
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MD( )#.N<=,[6&3VR><8'0"B'P-9PB(+$!]G<NF&?AB02Q.[YC\H^]G@ =.*
M.=^-?_'G'_U\+_Z!)7=7=TMHC32'"1J68X)P%&2<#GI576] @UM!#<KO0,&
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M1Z+10!S_ (#T-]$LX[>7_6#<6&XL 68G [# QD+QG)&<Y//_ !'_ ./S3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK!UCQS9Z/)]GGE"R  D!7;&>F=JG![X/.,'H10!O45CZ/XO
MM-8.V"968D@*<JYP,G"MAB,=P,=?0UL4 %%%% !1110 4444 %%%% !1110
M4444 %%<5=?$U6E,-G!+<K&P$CQ E0#W7 .[OC.T''!(.:[6@ HIDTRPJ7<@
M*H)))P !R22>@%<U-\3=.B8H9QE20<)(PX]"%((]P<'M0!U%%0VMVEVHEB97
M0YPR$,IP<'!''6N=F^)NG1,4,XRI(.$D8<>A"D$>X.#VH ZBBJ.EZW!JJ[[>
M17& 3M8$C=TR.JGV(!Z^E7J "BBB@ HHHH **** "BN<UCQBMDUL(E$L5W+Y
M?F(_R*=P4<@,">3QD?=/OC;MM1BNF9(W5FC.'"L&*GD8(!X/!Z^AH L4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !16/XF\50>'(Q-.3\QPJK@N
MWK@$C@=R2 .G4@&'PKXCEUI7,UO);LA&!(#A@<\@E5R1CD8XXYYX -ZBBB@
MHHHH ***Q+7Q2ES>RZ6%8/#&KECC:<XR/7@,OUYZ8&0#;HHJIJFJ1Z5&US.V
MV-,9."<9( X )ZD=J +=%0VETMVBS1G*2*&4X(R&&0<'GI4U !1110 4444
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M0 ,EBQY)( X!J;X6W'VFYU"7#+OF4[7&&&7E.".Q'<>M2_!3_CSD_P"OAO\
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MMI.#@*.. <>YKF=,TJ[?5KB%;K;.L(+2^2AW#$7R[,X'4<CT]ZZ[X53*^G1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1(BM*=JABVT,?EY]<G!P, D6-+^)5I?&56WPFW4LXF7:0 =IZ%N02!MZDD
MG.,+X)Z?&+>2ZVCS3*4W=]H5&V^PR<G'7C/089XETJ*\URVBD165X=S CABH
ME()]?N@<]0,'CB@#3'Q=M0$=XYTCE)"NT:[#@X8@ACD+WP"?;-=;=W"20M+C
MS8S&3M0!]ZE<X Z-N'0=#FN=^*L*OITI(!*F,@D9P?,49'H<$CZ$BM?PG_QY
MVW_7O#_Z M 'CNI:3+*T+V@:VM[B>/R(Y)B27.5$P4990 %R3DC<-K%2,>D?
M#F**V22WCMW@DB95E\P[]S8.,2<;N,-@ *-V5&&R>@U+0(-2>*:9=SP-NC.Y
MA@Y!S@$ \J.N:T* "BBB@#/U_6TT2![R4,4CVY" %OF8*,9('4^M<O>?&"RM
MBH D?<BL=BJ=NX9VDEQ\P[XR >,Y! N_%+_D'3_]L_\ T:E6_ 6F)I]C L8^
M_&LC'C):0!B3@#.,X'?  SQ0 :_XUBT:5+0I+)+(I8)"F]L#//)'H>F>ASCC
M-2T^(\$LRV<L<T$DF-HGBV[BS;5 P6/)[D <'FK&M>,;;29O("M+<L%!2!-\
MFT!F&>G Y.,Y .<8.:\Z^)/B:76(E22TDA5)?DEE!!((;Y>4&"W!(#'[O?&:
M .[^(_BB+1[=K>0,6NHIE0J 0#M YR1Q\PZ9[USGPW\>PP0P:5LE:4LPRJJ5
M^9V;/WLX .6.. ":[KQ9_P >=S_U[S?^@-65\+?^0=!_VT_]&O0!I^)O%4'A
MR,33D_,<*JX+MZX!(X'<D@#IU(!RA\2H(Y$AGBG@\TD!KB,1IQ[[CQR,G&!D
M$X'-<IK>MRVFLR2K URT$2K&B9!4,BDM\JMD?.PY!^]UX%'BSQ+=^(;=K0Z?
M*I8J0Q5VVE2#D#RAR1D=1P30!Z1KNNQ:'$;F<X5>@'WF/90.Y/\ ]<X )'/C
MXF1*HF>"Y2)MO[QX?W8#$ ,6#'CGMG/;-9^J^&)]?TF"WV^7/"J$(YY/EJ4
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MC( XXJ]10 5GVOAZVM&$L4,2.,X9(T5AD8."!GI6A10!#=6B7:F*55=#C*N
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MXW9R!D]]N5/4'!P-WPQK4^K*TD]NUN.-N]\LW)!RNU2N,#J.<Y'%;=% '#^
M=.EM;O4'D1E62?*%E*AAOE.02.1R.GJ*/B[ITM_:(D*,["=20BECC8XS@ \<
MUW%% '/^/M,?4[&:"(9<J"!R2=C!R  "22%P!W.*RO!_B68K;:>]I,FV/8\D
MBLJ+Y:?*02O.['?;@G W5VM% !1110 4444 %%%% !1110 4444 ,FF6%2[D
M!5!)).  .223T JE:^(;:[81131.YSA4D1F.!DX .>E<EXVF;5KZVT0DK#(/
M,D /WPNXA#C! _=GOU8'&5%7?&?@RTDM)G6%$:.-W5HD5&RBD@9 Y!Z$']"
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ME!7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#\OH#R1VSNSN&!5?5!J/B.-K(P+:I)C?(TXD.W(W*JQ@')'J=I&0<9!KM:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?0C*D'(P :?P?T^2SLB9%*^;*SKGNI5 &QZ'!QZCD<$&L+P!_P AF\_[>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU0HR\AX(.T8X[YX#8*EFG6.H6,J"69;B%R0Y,2Q.F%8J5VG!!; .<D<8'4@
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MD+D X)RH!WM8.M^(&M;BWL(=IEG<E@_:- 2QX.0QQA,@@D'/2MN%"BA22Q
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M>Z=>K?Q)<)D+*BL >N& (SC//-6*X]_$/]@Z7;S*%,C0P)&'.U2S(,9;@
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M,?O$'M@8QP"2  =G17.>$=<FNS+97:@7-J4#LN-CAP2CC'0D#)&!]!G:O1T
M%9^OZVFB0/>2ABD>W(0 M\S!1C) ZGUK0KE/BE_R#I_^V?\ Z-2@#JZ*Y?Q_
MK%QI<4+6F/-DN8T (!#;@WRG/0$@<@@^XK,URXU'P]'_ &E).DJ(RF2 1!%P
MYVE5DY8X)&"<<<G/W2 =W17/^+=9EM!':6FW[3=,53?]U0HR\AX(.T8X[YX#
M8*EFG6.H6,J"69;B%R0Y,2Q.F%8J5VG!!; .<D<8'4@ Z.BBB@#/U_6TT2![
MR4,4CVY" %OF8*,9('4^M,\1>((M A-U-G:"  N-Q)., $C)[]>@)[5C_%+_
M )!T_P#VS_\ 1J5G^'=GB:]FO+C=OLY-D<+X*QXX\PD?*69E/0G;CJ<(0 =K
M:7'VE%EPR[U!VN,,,C.".Q'<>M35B>+_ !#_ &# 9E"F1F5(PYVJ6;IEN
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MGR7Z=<@8R#P0>>.[HH \TUV\_M92#ITRWV["R*N%5P=J/]H7:2%&",_+P.<
M-6]>V,YN]->0%VB2<2NJG8&,2C)(  #-G' ]A76T4 <9?^?X=O)+Y8FG@NP@
M<0J6E1HDPORYY4\Y/'7M@!ZOVRYUC4;2Y-O)%;1B;:TBX?+1D,7 )V#( 4'K
MU!.<#O:* /.IM+&A7$QN+3[5%<2/*DD4 ED4L1NC8-T ['/N,Y(7HO"L:2L\
MZ68MEP C,B)(P.=P**,J 0.I.X8(KHZ* "N$^'6HRZ?''I,]O,CQM(/,V9BQ
MEGR7Z=<@8R#P0>>.[HH YKP1:/;?:_,5EWWT[+N!&5.W##/4'L>E5(-&>[N=
M3C8,B7,<**Y4[3F%E)'0-M)YP?;BNPHH \TTP1Z4@M+S36DEA^7S(+994< #
M#[C@Y(Z^_7!RH[CP[;^3",P+;LQ):--I .< Y0 $D '].U:=% &#XQT>3485
M:#!FMY4FC#'"LT9^Z?8@GN.<9(&:I?\ ";R?ZO[%<^;TQL'E[NF/-SC;G^/&
M,?-BNKHH P?!VCR:="S3X$UQ*\T@4Y56D/W1[  =SSG!(Q4'PXM'M+"&*561
MQYF5<%6&9&(R#STKI:* .'T_3I4M-30HP:6>\* J<L&0!2HQR#VQU[5JPZ?)
M+I8M0I\UK((%/RG<8MNTYQ@YXYZ=ZZ.B@#BO#5X^KVG]DRP30.+4QEY(R(^%
M$8()VDD@[MN!W&>,G)TP1Z4@M+S36DEA^7S(+994< ##[C@Y(Z^_7!RH]+HH
M XS4_#TMY:1M;P1V\\,ZSB$;2A:,D %DVC+#!S]%)'45=;\57.KVLEO!9SK*
M\3!_-3:@4KA]I)!=N<*  3UQQM/>T4 9GAB%H;2W1P0RP1 @C!!" $$'H153
M7/$LFDRJGV:66)DSO@7S"&!QM*<8&.<D\] #@XWJ* ./LX6\0WD.H^2\"6JR
M#,Z!))"ZX"A<DA4!)W$\DD =346OW,ND:DE\()9HGM3$3"N]@1(7Z#\.I&<D
M@G!%=K10!P7B6!I;FWU*:VDGMC!M\H+O>-VRVYH3P21A3V!')R%RSPE TNH-
M<K:-:PFU95!0(&(F&"0% 5B!]TY.!G)&#7H%% '%:_<RZ1J27P@EFB>U,1,*
M[V!$A?H/PZD9R2"<$5#XFTYI)H=9^S^?$8522!XPTJAFW!PIR"P)P1VY'0EE
M[NB@#C-%,-[,GE:<8E4Y:2:&.$H0"4*C!+'(QQC;P:J^)=0CO&EANM.EE="5
M1XX]X91\R'S5PR@GJ!G&2#DY%=[10!D^%;>>WM8H[L[IPOS'.3U. 3W(& 3S
MD@G)ZGG?&%@R7D5[- US;+$R>6@\PHY)._RCP01@9Z<9/(7/<44 >?\ A*!I
M=0:Y6T:UA-JRJ"@0,1,,$@* K$#[IR<#.2,&MO0;1XK^^E96"2?9MK$$*VV,
M@X/0X/7'2NEHH YK[(_]K>?M;R_L.W=@[=WG9V[NF<<XZXK'T+4)_""'3)K>
M69(R3%+;1EPRNQ;YAGY6!/3/Z ,W>T4 <9X(CN7NKVXNXC$TI@P.JX56  <9
M#$#&XCOV'0;'B_P^==@,*-LE1E>-\D;77H?E.>F1GG&<@$@5MT4 <E#XSN(E
M$,UG/]IP ?+4& L>G[W<0%/&3SMY!SBH?&%A=:K9(7C!=95DE@C=OFC4L?*W
M#[S8VYQU8$KD[0>SHH \OOE&H36WV73WA2.Z@9Y&A$;8W'(VJ,[<<ELX! !
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M .#GW^IJE\1[1[NPFBB5G<^7A4!9CB12< <]*VM*TQ-+B2UB&$C4 =,G'4G
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M5BPC!^8\9+$L3CL,DX'.!W/6M.@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\ C.9=ZF/"M_/=70(MKT1;95RP5HD(VL ,Y;DC&>W7YMN@^MCQ/;W45JC%#
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M!*<D<'!XSQD#D5SOPM^V?9H/]3]D_>?W_.^\_P#P'[W_ ([[UJ_"W_D'0?\
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M("FIX^_Y<_\ L(6__LU97Q E#7<$4\<K1>7(T1M@#/YPZD'.X!%PW& 6P3N
MP "P=>U.TN[>QG6WVW!)W1^9T0;G RV0P7ID8R1SUQJZ/=+<7]VACC#0B "1
M4Q(PD3<0S=P-HQTX KG?#%Q:6MVK3"[%Q(I6)]0'IU1#V)W?K@$%L-M>'?\
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M !1110 445#'=I*S1*REX\;E!!9=PR,CJ,CIGK0!-116#K'C&'3I/LP62:8
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M/FK8H **** "BBB@ HHKFM?U^X6X33;)$,K1F5FF)\M4R5'"G<26_+C@Y)4
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M1EP.6R "6/W0 !6]16)I6MO=W=U9L%V6WD[2 =Q\Q"QSSCKTP!^- &W1110
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M-M8@A6VQD'!Z'!ZXZ5CZ%J$_A!#IDUO+,D9)BEMHRX978M\PS\K GIG] &8
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M!/))<ML.]45P&P&7[^ ,Y P>V1@F'P'I1_LV.TN$9=RRJZ."K89WX/0C(/\
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M#@<C/AO(;E0L>DMYQ ^62WCCCSU8>:PX YP2HR<# S0!W>G7JW\27"9"RHK
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MT8;Z.-9OLI<M"ZYWJX ;'7YAC(&#SR,D!6HVCV]\ZQ1:6PRPW-/;Q0JJYPS
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M1CYMN0&!9<_[0!'/!S@X&: .2UCQ'<Z&/M37L$S1N/,M5"+U.UE5@2^5)XR
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M!8ZA8V<@EF6XA<H')B6)TPX*E=IP06P#G)'&!U(ZW6=4DMKVSMD;$<_VC>,
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MS$#$L4*$C?LW;RS@9PQ.,#(*\@C@$@%CP%JDFJV45S.VZ1]^3@#.)& X  Z
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M(&X#D\ ^Y^M6* ,_4-$2_DAGD+?Z.S,JY&PL1@,5(.2O53P0:T*** "BBB@
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M[NPAEE9G<^9EG)9CB1@,D\]*W=1>1(G:$!I0C% >A8 [0>1P3[CZT 6**S]
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M%3Y]U+*NTDX5\8!R!SQSU'O3]$MKN&6=KJ17B9\PA0 57+<'Y5YP5[MT//J
M9GQ2_P"0=/\ ]L__ $:E177PT@NE,CNYO#@_:-S!]X.0P0,% &,!1C"@ $$;
MJU?&>B/K=I)9Q%0\FS!<D+\KJQS@$]!Z5CRZ-JHC^Q+<1&/ 7SRKBXV\9.,E
M=P&0#G)Z[@W( ,VWU^?7X+"V:1HWO&E\R2+Y6VV^<@>A? R00 <\%3MJUKW@
M"VTF%[ZR#03VZM(KJS-]Q22I#L00PX/ZY&0=/5?!*M!#':,8IK,?N7]R!N#
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M>7Y68C*KEB6V-S\NTK@H ,9 /?U,OBWX?-K-W'=HRB)@BSH2R%U5PW51\Q(
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MNJGHG[L8PO0$Y)ZD]A%=>$YWMKC:Z_;+T*)'.1'@?+L48)"A"5!(+$G)(.,
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M<8K/\6?\>=S_ ->\W_H#5BVNBZEHJBVM)8985SL-R)!(HSPF4X( Q@\>@
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M!IEQ:RV5O<VK/<)&YF5A&Z2'#*=[/D\9 X[GJ 1Z!XMT!M9B58GV2PR++&Q
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M&,GO(74@D#D<'D8R.01UJ1:-JIC^Q-<1"/!7SPKFXV\X.,A=Q& 3G(Z[BW)
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M#(XDNKM'\R1N!N9"JKD#.Q>PQQR0 #M&UH=DUA;PV[X+11(I(Z950#C...*
M.-\6ZF?$UO:6<!P=092V-KJJQ@-("21DH<' P3M(X/![V&%85"( %4   8
MX  '0"O-_AOX>,=U/,QW16;26\.X*6_UC,3D8((#<G'.\@' Q7I= 'G_ (S\
M2P17]O;7#JL%O^^?[S$R8(B7"*2"OWN2 0>>V8M"\4P7&K-]F=GCO(5W?+@"
M2(''W@K !%/3.2WY=/X>T&2QFN;N9@SW,H(V]!&@Q&,;1\P!P>O0<YR3%XV\
M-R:U'&UNRI/!*LB,XSTZC.#@=#T()4 CN #G_'<T+WL45^6-FL!<JA) ?<4W
MN$^<+@A5/3<<#C?57P3HMK/J#WEBC&UBBP';<%$K8!"[CN(V$YW9P2>@*5=D
MM9KO4[J.SN/(;RX3+N1)"S!<+M4_PA2-QSD,<8((Q=LM1NM(O8M/N9EN%N4<
M@[%B="@+9VKG*MC R>2#C&T[@#*\->$(M;EO)+DL\0O9@L6]E0,#DR?*1EL'
M ]!GKD8/%&IC4+V2TGCN);:W1 8K92RNSC?N<J5( XVCGE<@CD'K?#&B/I7V
MCS"I\^ZEE7:2<*^, Y YXYZCWJEK'ANXBN/[1T]U660!94F+&)PHPK?+DAEZ
M#&/J/F# &%X8/V2\B2SM[F&WD602K.KB,':&5QEF 8E=I)/3  R<UCV=]%X@
M#7E];7=QYCL8Q&C&&-<XVH5=,G@;C@9(Z9!)]"T2WOMYEO)(MNTJ(H$.W.00
MY=_FSU&WIC!ZUCVWAN^T%FBT]XC;,=RI<F0F,G.Y5*]5/7D_AG+, /\ A_+(
M#/#Y<T=NC1F$7(8. RX9 6)&U2HV@= >22:POA_X%@U:SCGN]TH8OL0NZI&
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M:ATB>[L(GDU)HBL2 [H0^<*"79@0.> ?E'KQTJQX5:=K6)KLYG9<MQM/S$D
MC"X(! (QU!Z]: ,KQ]_RY_\ 80M__9JB^)6_9:^5M\S[=#MWYV[L/MSCG&>N
M.<5J^)]$?5?L_EE1Y%U%*VXD95,Y P#SSQT'O1XGT1]5^S^65'D744K;B1E4
MSD# ///'0>] &?\ \3G_ *<__(]<O%,T7AW*D@X(R#CAKD@CZ$$@^HXKU.N?
M\+^&CI]BNFW&UOED5]A.TAV8X!PIZ-[>U &U:;-B^5M\O:-NS&W;CY<8XQCI
MCC%-U&R6_B>W?(65&4D=<,"#C.>>:Y>UT74M%46UI+#+"N=AN1()%&>$RG!
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M6(.4D4>6<CN0N3P,9'?(&/\ #^RU""SCEM)(FCE+G9<!_DVN5^4H3D-C)!P
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M@GKA70#.,<\58_XG/_3G_P"1ZT/&>B/K=I)9Q%0\FS!<D+\KJQS@$]!Z5MT
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MQNV]<9XSTS0!-15&+7+>63[.LL9ER1L#J7RN<C;G.1@Y]*PO'W_+G_V$+?\
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M#K5>+7+>63[.LL9ER1L#J7RN<C;G.1@Y]* +U%,FF6%2[D!5!)).  .223T
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ML=6AU#/D2))MQGRW5L9SC."<9P: +=%8-BUP][-NFC:V5% B4@R(S!2"V%R
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MR"#R"".H- #Z*HRZY;Q2?9VEC$N0-A=0^6Q@;<YR<C'K5N:985+N0%4$DDX
M Y))/0"@!]%5+'5H=0SY$B2;<9\MU;&<XS@G&<&B^U:'3\>?(D>[./,=5SC&
M<9(SC(H MT4R&99E#H058 @@Y!!Y!!'4&HK;48KIF2-U9HSAPK!BIY&" >#P
M>OH: +%%4=:UB/1X7NYL[(QDX&2<D  #U)('8>I YK"_L[4]0_>M<);9Z11Q
M+-@=1N=R,L,X.WY>,CK0!U=%9.A?:X]T5WL;;MV2Q\;QR#N0_=88!./E^; Z
M&N:TL7^MO</'=^4D-U+$J_9XWX0C')P>AQWZ=: .[HKDO#WBB:-+F*_ \ZP
M+F,##)LW*PY^\VTGHHY P.0*]I::GJT*WJW21-+&'6)8%*#<N5&]MS<\%N#@
MDXR * .UHJO#,T,0>X*AE0&0@X0$#+$%NBCGKVZTZUNTNU$L3*Z'.&0AE.#@
MX(XZT 3454OM6AT_'GR)'NSCS'5<XQG&2,XR*99:Y;W[;(98W8#)".K''3.
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MZ9$(5=[9VQAC@'!;MGIGGIWK,\3^)#ID"30*)9)W2.$ C86D!*DMD?+QV//
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MW9QMVYSG/&.N: -"BN4\??\ +G_V$+?_ -FKJ)IEA4NY 50223@ #DDD] *
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MY Y'YBK% &?IN@0:;$;2*-1$=V5/S [NN=V2V1QSGCCH*NPPK"H1  J@  #
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MC(! !)& #J**KOJ,22"W+J)6&0A8!R.>0N<D<'\C5B@ HHHH **** "BBB@
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M:U 'G6MZZWBJSM+2,8?4&PYP,*(&!E8 OV(RHR<KD<-BMB&%8=7"( %73@
M,  38  '0"F>'?ATFC7<FH!E8/OV((PH3>V>#N/097@#@]AQ6U_87^F?VEN_
MY=_*V;?]O?NW9_#&/QH P+4_V)JSPA?W>H1AP0F )(@VX9S@Y&6;C.67W)S]
M&NHIHKW7[M?W-U\B@+\_E+^Z R&)!<X4C(&Y=V<8(Z+QMX.7Q1$D18(R/N#[
M-YQ@@KU7 /!//8<58'A.)[(:4_,8C524&PDK@[P!G!+#=SG)ZYYR >>^*[=H
M+4RQ:>+=8C&T<XD19EPP"EE7Y]Q!P022"<G)&:[+Q]_RY_\ 80M__9JS]0^'
MEUJ<?V>XOG= H"CRPHR"IR^'R_ XW'.?FSU!Z77]"_M?R?FV^1<1R_=SG9GY
M>HQG/7G'I0!-K>@0:V@AN5WH&# ;F7D C.5(/0FM"N?\02M=3VUE"[*XD\Z3
M8P'[J/(*L-P)#LP4<$=3_#704 <I\,/DL(XCP\;2JZG[RL)&.TCJ#@C@\\TW
MXI2C[ \(R7F>-$4 DLV\-M  /.%/\NN*L7_@TK*]Y93-;2RX\S"+)&V,G<4;
MC=G^+/KQEB26'@TM*EY>S-<RQ9\O*+'&N<'<$7C=G^+/IQE00 7_ !!X:BUU
M567<K1L&22,[9$((.5;!QG'/X'J 1A?;+KPS/%%/(;BUN'6)&8*)8W)(0$C&
M\$?>8\G!/!X;;\0:--J!C>WN&@>,MT4.C!A@AD) )'8GISQG!%33_"\ID6:]
MG-QY1S&IC6-%;^^57.YA_"3]WDCDY !IS:!!-.E^RYGC7:K;FX!W<8S@_>/4
M=ZT*Q[G1)9KN.]$[+%&A4PC.QB0WS'Y@,_,/X3]T<^FQ0!P_@71(-9@_M.YC
M66:Z=V8R*'"[79550V=J@#COVS@ !^EZ8FF:E+I\0Q;3VIE:(X,>XR>6<*1P
M".HZ=N@4"P?!$MC([Z?<&WCE(9H_*61 W<J&(V@^@'Z  :OA_P -KI!DE+M+
M-.5,DCGJ5&  HX51DX'8'&2 , ''^'_$+>&K.[M74E].<JI*8#"5SY;$%LX+
M$DXQ\A&"33-5TN3P_I<&GJN9+F9$D"$(Y,N690X)&>!'N.X%>V.!M^(OATFL
MW<>H%E4)LWH8PP?8V>3N'487D'@=QQ70:[H46N1&VG&5;H1]Y3V8'L1_]8Y!
M((!P6H:%+<P-:II4:$IM5Q/#O4@?*V[ 8D'!.3\W0GDU:\2Z.=8FTRUO<EF2
M4R@$#++&C,,KQ@L,';VZ$<&M:'PC>,HAFOY#$  ?+B2.0XZ?O<LV<@9/)(R#
MUK7U'0OMES;WN['V;S?EVYW>:H7KD8QC/0Y]J *'B:&RTFU,$L/[J:1%\J!-
MK.Y(( "%>?ESU&<8YX!Y'4X9+>>SE-BMH?M<2^9%+&<ASAD*Q@9! ZG/ (_B
M.>]\2^'UUV+R69D96#QNA(9'7.UA@C.,]/R(.",)_ MQ=RQ7%S>-(898W5?+
M")\A)/RJV-QS@-U R,'(P 6/$7_(1T__ +>O_10H_P"8S_W#_P#VO6KJ.A?;
M+FWO=V/LWF_+MSN\U0O7(QC&>AS[4?V%_IG]I;O^7?RMFW_;W[MV?PQC\: +
MVHVS743Q(Q1G1E#CJI8$!A@CD=>H^M<%I-O'HHCAU&S2/RV0+=1JI0F-AM=W
M7#1Y.WEOO$G<%&17?W=O]I1HLLN]2-R'##(QD'L1V/K7)-X%N+U4M[R\::W4
MJ6C$8C+[>@9PQ8C."<Y)ZY#8( +'B+_D(Z?_ -O7_HH4>/O^7/\ ["%O_P"S
M5H>)?#7]L>7+'(T4\#$QR*,XSC<"N0&# <C^F0<>;P!+>RPW5S=-++;RJR_N
MU1-JD,5V*>&)'+9Z8&#@4 5]8T*+6-81)QN6.S#A3]TD2L ".X^;..^.<C(-
MCX@:0MI:I<VR*&L94E15CXP&RPPN,+SN;']WGU&[_87^F?VEN_Y=_*V;?]O?
MNW9_#&/QK3FA692C@%6!!!&00>""#U!H X?7;H>*9[*R1?W15+N3>H/R#A%Q
MNP=Q)5A@XR",@&M#_F,_]P__ -KTWP-X 7PLTCEQ(T@4 ^7M*@9)&=S<'C/3
MH.O;7_L+_3/[2W?\N_E;-O\ M[]V[/X8Q^- ',>'[]?#-Q?6+*?*0/=)L3;\
MA WJ,MC"\*N,#(;)'0'A](]-T^?4;Y1B\+RR!!SMFX5 0Q.#NR,D;=_.,$UH
M>.? "^*6C<.(VC# GR]Q8'! SN7@<XZ]3TK=U30HM2@:Q<8B90N$^7 7!7&.
M!M(&!C'&"".* /,O%=NT%J98M/%NL1C:.<2(LRX8!2RK\^X@X())!.3DC-=E
MX^_Y<_\ L(6__LU9^H?#RZU./[/<7SN@4!1Y849!4Y?#Y?@<;CG/S9Z@]+K^
MA?VOY/S;?(N(Y?NYSLS\O48SGKSCTH FU+0(-2>*:9=SP-NC.YA@Y!S@$ \J
M.N:T*Y^XE:]OXXXG8):QNTP5AM8RC;&C -G( 9^0<#']ZN@H \Z\-_;]]Y]C
M^S^7]NGSY_F;MV1G&SC&,>^<UU7AKPU_8_F2R2-+/.P,DC#&<9V@+DA0H/ _
MI@"70-"_LCSOFW>?<22_=QC?CY>ISC'7C/I6M0!Y/X=TO4'TL3VMR0NR4K"L
M2[N';<!(,ON/)7 SD@ CJ.Z\$&&2TCE@!Q*-S%B6<N3B0LQ +-N!!.,''&!@
M58\+:%_8-LEENW^7N^;;MSN8MTR?7'6J_ACPP=!:<*X,4TID5 @0)G.0""<C
M&T=@-O YH O:;H$&FO+-"NUYVW2'<QR<DYP20.6/3%8GQ2_Y!T__ &S_ /1J
M5IZ)HDNGRSRR3M*LS[D1LXC&6.T99N/F X Z#CTS/BE_R#I_^V?_ *-2@"Q-
M\/[.:$VSQ@E@<RG!G+$Y+F0C)8GGT[8V\5S5CK,=_I]FMY&UU/*[F)/[S1,R
M@L<@;0,!BV>"6(;!-:LO@.<Q_8EO)!:8"^68T,FSC*^;P<'D#C 7Y<$<'3UK
MP@MXD(@=H9+3'DNN6VC 4J5)^8$  Y/UR"00#E+&-[?4K0FT6S\Q9U(CD1ED
M"INP5C  VG!Y'/']T8T_'>CQZQ>6%K-DQL;@D XSM16QGT.,''..A!YJW8>"
M9H[F/4+BZ:9XB_!0*F'38 JAL*>Y('S<< @DZ^HZ%]LN;>]W8^S>;\NW.[S5
M"]<C&,9Z'/M0!2\3Z';PV-PB11A5BE< (H <1D!P .&'KUI_@O28;:V@GCC1
M9'MXMS*BACE%)RP&3D\GWK8U&R6_B>W?(65&4D=<,"#C.>>:Q/"OANXT0"*2
MY,T*)M5#$%QR"#OW,Q &0!T /'04 <UH-W;P:+"EVC21RN4$<8)=V,S,JC!7
MGY<]1G&.20#4U.&2WGLY38K:'[7$OF12QG(<X9"L8&00.ISP"/XCGJ(_ 2BQ
M33&D;="Q>.5 497W,RL &/3=C&?<$'!%=_ MQ=RQ7%S>-(898W5?+")\A)/R
MJV-QS@-U R,'(P 6/$7_ "$=/_[>O_10KJZR=1T+[9<V][NQ]F\WY=N=WFJ%
MZY&,8ST.?:M:@#S_ ,&^%[>^FO;N9%D?[9.@$@#* &#9"D8R2>OH,#'.:^LF
M74M2E'V472VB1JJ-*J(OFKN+%7R&8].,  #() ([+0-"_LCSOFW>?<22_=QC
M?CY>ISC'7C/I5+7/")NYEOK64V]R!M9U0.'7&,,A(!(XP3Z#KA=H!BZ-I=PE
M[%<K9K:QA)$E*21,&4C<GRKC!#@<@9/0G IESI#Z5//-<6BWD$LAD$BJDDR!
MN!'L?)8+@ 8P N3_ +*]+HFASVCF>YN7F<J5 VK'&!D'/EKQNSGYL]#C'%9]
M[X4O)&E\F^=(Y68[6C61EW#D*Y8%0/X0,;>W/) ,WQ>L-]:V*6SD0M=VZHT;
M$,%VLHP3DAE]^01SS5WQ1X-M(+21XHUC>WC,D;Q#;(&B4E3O')Z<Y))ZYW8(
MS_&OAJ*UM+/3$W"(WD29SEL/OW')&,DDGIC/08XK0N/ T]]M@N;MY;56!\HH
MJLP7[JM*I!;MDD<D9X." #/@_P"*EN+2WN_G1+%+DKT5Y&*KEE'! Y(&!U(.
M5)%2^/\ 08=)MCJ-JBPSVS*4:%53[S*A# ## @]#].A(.[XD\*KJ[)<1N8;F
M$C9*HR0.ZD9&Y3D\'U/8L#5M_!\L\D<U]<M/Y#AXU"+"@8?Q,%SN(XQR,<CD
M$B@#/\=Z/'K%Y86LV3&QN"0#C.U%;&?0XP<<XZ$'FCQ=HD&F26=Q;QK%)]MB
M3,2A,J^=RG;C(.,<]LCH3GHM1T+[9<V][NQ]F\WY=N=WFJ%ZY&,8ST.?:C7]
M"_M?R?FV^1<1R_=SG9GY>HQG/7G'I0!SNO:-+;7;WK6ZWD$J)E6"F2+RQSL5
M\[@V2VU<%FXXQEJGB;4HWT^.WL%(2XN1"T8/ER*79GDBYR$8M\I!!4*> 5Q7
M0:GX=NI9FGMKMHED"Y1HUE4%1C*[B-H/< <G))Z -M_ , M&T^7=)YC%WD8_
M.9#UD!.<'TZ\<-NRV0#E]0T*6Y@:U32HT)3:KB>'>I ^5MV Q(."<GYNA/)K
MMUTO^U;1+:^7<SQQ^:,XRPP3RA'\0[''X5D0^$;QE$,U_(8@ #Y<21R''3][
MEFSD#)Y)&0>M7?&4K2QI90NR3W,BJC(P#*%(>1_O*<*BG.#R2!WH VK2U6T1
M88QA(U"J,DX"C &3STKE;NU6[U9H9!E)--*L,D9#38(R.>E=A63_ &%_IG]I
M;O\ EW\K9M_V]^[=G\,8_&@#C=,\6GPM;7%A<,#/9';%N(S(K_ZHXWY(&<L!
M]U,#J*+K0FT:VL8Y"3-)J,$DI)R2[[B<G+9(X&0<'&>]=!K/@*+4KR+4]Q5H
MBI954?.4.4.>Q'0YSE0 -N,UI:_H7]K^3\VWR+B.7[N<[,_+U&,YZ\X]* ,7
MXE1M*EJD;;'-]"%; ;:2'PV#P<'G'>LK5+">UN[:'49FN+69BH 3RD\S@HLB
M("'!(&T$]<D_*#NZ_7]"_M?R?FV^1<1R_=SG9GY>HQG/7G'I3?%GAU?$-NUH
M2%+%2&*[MI4@Y R.2,CJ.": ,SQ]_P N?_80M_\ V:NKKG]?\-2:O##%YVV6
M"2.3S?+!RR*1G9D 9)SCD#IBL^Y\&7>H#RKJ^=HCG<L420L001C<I/'/(((/
MIT( '_#F47$=S<+GRYKV=T)!&Y3MPPR!QP1]01U%;NB:!!HB&&V78A8L1N9N
M2 ,Y8D] *L:?I\>G1K;PJ%C08 '^>2>I)Y)Y/-9_A?1)='B,4T[3L7+!WSD
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MZBA\,*)KJ:0[DO5C5DP1@(A0C<#D[@?;% '!:C:I/9NUMIH%N8F9)I)$64
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M8Y!&"015KQ=X'LQ92[(E0PQ,RL@ ?,:DC+8RP.,'.<]>N"-B?PG%>6B:;/\
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M )=_*W[?]C9NVY_'&?QH YCQ7,TVAAW)+-!;$DG))+1DDD]2:Z?Q9_QYW/\
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M2">(J4$=W*HC+[]@ 4[ W< D\]SD]ZS_ (8>$;66S2ZDB6228L29%5\;790
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M>6;!SSM4$XX/.,9XSF@#6HK/T;7X-:7S+:17 ZXX8<D#*G!&<'&0,]1Q6A0
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MD893CIG# 9'KCID9ZB@#8J&ZM$NU,4JJZ'&5<!E.#D9!XZUFZYXNM=#94N9
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MZC(H Z6BL&[\<V5I&D[S+ME *XRS$'/.U06 R"#D<$8.#Q5BX\4VT$"WY?\
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MHDS@@9(!SMPS %5((YW$8ZG H WJ*YSQQ#]HBCB%PULTDZ*KH&)9F# )\A7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*S_$%D=4GMK?:VR&3SV?! !CR$0':5)9FR1D$*I]0: .@KE/BE_R#I_^V?\
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M V*Y3P[_ ,A'4/\ MU_]%&NKKFM4\!Q7\[7RR30RNH5C!)LR!@<\$] . <<
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M GNQW,<D;@ 0#BM6ST2_GO(;ZY-NJQ+(K>09 S*R\*=PY ;! )P#D]:U=?\
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M'7# @XSGGFJ_]B)]F_L_+>7Y/E9R-VW9LSG&,X]L9[4 <?J7_'GI7_7Q9?\
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MVCZ;>17!3++<NJQ%O+57CSM4,!M .< <<^N:M-\.XD9F@FN(%=MQC@EV1@D
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M8YXJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pipeline03152019.jpg
<TEXT>
begin 644 pipeline03152019.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /2!=@# 2(  A$! Q$!_\0
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MVVET!Z)-[/8]7HKSKXS_ +0WP^_9[TS3M0^('B)/#]KJ,S06K&UGN&E=5W,
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M!%86.H7\4$]VY8*%B1V#2$D@84'D@5T-'2X!1110 4444 %%%% %=[AEOH8
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** (Y[I[*&2X0*7A4R*&Z9
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M9G]_E08[UU1<?:RY/AE=]FKQV\^D6O78Q?-[)*7Q1T[WM+\.]^UMSY=_9/\
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M+-7^%CZ!)K^H>"EN].;Q4)Q8F&1;MB9!#^\!\LG&.^,\5]U_"3_A8G_")_\
M%S_^$8_X2?[0_P#R*/VG[%Y/&S_CX^??][/;IBO#_C)^QGKOC;XW>&OB9X"^
M)@^&VK:!HRZ+:0IX>BU)4C'FC($LJJ!LE*X*G&,@^GK_ ,&/!/C_ ,$Z5J,'
MC_XE?\++O9YE>VN_[!M]*^S1A<&/9"Q#Y/.3SVK5./)RKIS;^<FU;Y/\S.7,
MYJ3UTCMW44G?Y_H0?&\?&%M-T\?"(^"UO2TGVX^,?M>T+M&SR?(_BSNSOXZ>
M]?,'_!-.^L]"\1?&'PAK^G7MC\6K?66OO$T\TT<MM=,SN%:#8JA%#,YVG/\
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M / 67_XFCS'_ .?6[_\  67_ .)H ?13/,?_ )];O_P%E_\ B:/,?_GUN_\
MP%E_^)H ?13/,?\ Y];O_P !9?\ XFCS'_Y];O\ \!9?_B: 'T4SS'_Y];O_
M ,!9?_B:/,?_ )];O_P%E_\ B: 'T4SS'_Y];O\ \!9?_B:/,?\ Y];O_P !
M9?\ XF@!]%,\Q_\ GUN__ 67_P")H\Q_^?6[_P# 67_XF@!]%,\Q_P#GUN__
M  %E_P#B:/,?_GUN_P#P%E_^)H ?13/,?_GUN_\ P%E_^)H\Q_\ GUN__ 67
M_P")H ?13/,?_GUN_P#P%E_^)H\Q_P#GUN__  %E_P#B: 'T4SS'_P"?6[_\
M!9?_ (FCS'_Y];O_ ,!9?_B: 'T4SS'_ .?6[_\  67_ .)H\Q_^?6[_ / 6
M7_XF@!]%,\Q_^?6[_P# 67_XFCS'_P"?6[_\!9?_ (F@!]%,\Q_^?6[_ / 6
M7_XFCS'_ .?6[_\  67_ .)H ?13/,?_ )];O_P%E_\ B:/,?_GUN_\ P%E_
M^)H ?13/,?\ Y];O_P !9?\ XFCS'_Y];O\ \!9?_B: 'T4SS'_Y];O_ ,!9
M?_B:/,?_ )];O_P%E_\ B: 'T4SS'_Y];O\ \!9?_B:/,?\ Y];O_P !9?\
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M=_\ @++_ /$T /HIGF/_ ,^MW_X"R_\ Q-'F/_SZW?\ X"R__$T /HIGF/\
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M-7/,?_GUN_\ P%E_^)H ?13/,?\ Y];O_P !9?\ XFCS'_Y];O\ \!9?_B:
M'T4SS'_Y];O_ ,!9?_B:/,?_ )];O_P%E_\ B: 'T4SS'_Y];O\ \!9?_B:/
M,?\ Y];O_P !9?\ XF@!]%,\Q_\ GUN__ 67_P")H\Q_^?6[_P# 67_XF@!]
M%,\Q_P#GUN__  %E_P#B:/,?_GUN_P#P%E_^)H ?13/,?_GUN_\ P%E_^)H\
MQ_\ GUN__ 67_P")H ?13/,?_GUN_P#P%E_^)H\Q_P#GUN__  %E_P#B: 'T
M4SS'_P"?6[_\!9?_ (FCS'_Y];O_ ,!9?_B: 'T4SS'_ .?6[_\  67_ .)H
M\Q_^?6[_ / 67_XF@!]%,\Q_^?6[_P# 67_XFCS'_P"?6[_\!9?_ (F@!]%,
M\Q_^?6[_ / 67_XFCS'_ .?6[_\  67_ .)H K2_\ABV_P"N$O\ Z%'5RJ$K
MO_:]M_HUU_J)?^763/WH_P#9JYYC_P#/K=_^ LO_ ,30 ^BF>8__ #ZW?_@+
M+_\ $T>8_P#SZW?_ ("R_P#Q- #Z*9YC_P#/K=_^ LO_ ,31YC_\^MW_ . L
MO_Q- #Z*9YC_ //K=_\ @++_ /$T>8__ #ZW?_@++_\ $T /HIGF/_SZW?\
MX"R__$T>8_\ SZW?_@++_P#$T /HIGF/_P ^MW_X"R__ !-'F/\ \^MW_P"
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M5_\ #='_ %)/_E6_^T4?\-T?]23_ .5;_P"T5\J44 ?5?_#='_4D_P#E6_\
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M2?\ RK?_ &BC_ANC_J2?_*M_]HKY4HH ^J_^&Z/^I)_\JW_VBC_ANC_J2?\
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M/_E6_P#M%?*E% 'U7_PW1_U)/_E6_P#M%'_#='_4D_\ E6_^T5\J44 ?5?\
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M)/\ Y5O_ +17RI10!]5_\-T?]23_ .5;_P"T4?\ #='_ %)/_E6_^T5\J44
M?5?_  W1_P!23_Y5O_M%'_#='_4D_P#E6_\ M%?*E% 'U7_PW1_U)/\ Y5O_
M +11_P -T?\ 4D_^5;_[17RI10!]5_\ #='_ %)/_E6_^T4?\-T?]23_ .5;
M_P"T5\J44 ?5?_#='_4D_P#E6_\ M%'_  W1_P!23_Y5O_M%?*E% 'U7_P -
MT?\ 4D_^5;_[11_PW1_U)/\ Y5O_ +17RI10!]5_\-T?]23_ .5;_P"T4?\
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MT@Z=;7$GE12?:(I<MC./D<XX!ZT[PG\'?&'CC0Y]8T31S>Z="[(\WVB*/#*
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MW<27-B_EW!:6)8U; .T2%@C'!'"D]:SB^9)]]2Y)1DXWV=CAKC_56W_7,_\
MH;5!73>./ >O^ +NTLO$&F3:;</$2F\JRN-QSM=25;&1G!XR*E\%?"WQ5\1/
M.;P]HTVH1PG#S;ECC!_N[W(7/(XSFFM=B7IN1>!_AOXC^)%U=6_AW3?[1FMD
M$DJ^='%M4G .791U]*I7'@[6[?Q)/X?_ ++N9]:@D:)[&V3SI-R\D )G.!Z9
MKZB_91^'OB+X>^+O$EKXATJ;399;.%HRY5DD <YVNI*G&1G!XR*X[2->UOP_
M^U9XFFT#0U\0W\LUS%]A-RMOE.&+"1N%QM'7Z4?;C%=4W]PM>63?1I?>CP+5
MM%U#0+UK/4["YTZ[4 M;W<+12 'H2K &J5>J?M):[KNO_$@S>(="7P[?1V<4
M2V*W27.$RQ#&1>"26/3VK.\/_L_?$'Q1I<6H:?X:N'M)1NCDGEB@+KV(61U)
M![''-3%N2N5*R=CSRBMZ^\!^(M-\2KX>N=&O(]:=MJ67E%I'Z\J!]X<'D9'!
MKM(_V8?B;-&'7PPP4C/S7MLI_(R9JMU<76QY;172R?#?Q-#XNM_#$VCW%OKM
MPVV*TFQ&7Z\AF(4KP?FSCCK7TQX@_99T[_A3D']E^&C_ ,)[]EM_,_T]O]=E
M?-^])Y73=TX]*/L\P+XN4^3])T74/$%ZMGI=A=:E=L"PM[2%I9"!U.U033=4
MTF^T2^DL]1L[BPO(\;[>ZB:.1<C(RK $<5[/\%-/\:_";XO7>FQ>$QJVN_V>
MRRZ:U]%#B)BC;Q+ED[+^=<M^T)KFLZ_\3[^?7M&70-0CBBB-@MPL^Q0@*DR+
MPQ(;/'KCM2DU[O+U'%/WK]/^ >;45Z#X=^ /Q \5:;'?Z=X:N'M)!NCDN)8[
M?>.Q D920?4<&L3QE\-?$_P^DC3Q!HUQIHDX21L/&Q] ZDJ3[9S3?NZ,2UV.
M9HKKM)^$WBS7/",_B>QTAKC1(-^^Y6:,'Y?O80MN./8&MNV_9Q^)%UIJW\?A
M:Y$#)O"R31)+C&?]6SA\^V,T;;BWV/-J*L?V?=?;OL/V:;[;YGD_9_+/F>9G
M&S;UW9XQUS7H]O\ LS_$NZM$N4\+RB-EW!9+J!'Q[HT@8'V(S1TN/K8\PHJU
MJ6FW6CZA<6-];R6MY;N8I89!AD8'!!%5:-]4/;1A1110(**** "BBB@ HHHH
M **** "BBB@"=O\ CSB_ZZ/_ "6H*G;_ (\XO^NC_P EJ"@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )U_P"/.7_KHG\F
MJ"IU_P"/.7_KHG\FJ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J>W_ -5<_P#7,?\ H:U!4]O_ *JY_P"N8_\
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MO+35TGAEVAMCK&Q4X((."!UJS\1/@#X1O/'<_C[Q!XC.GZ0Q2>XM9"J(\B@
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MM_\ 57/_ %S'_H:U!4]O_JKG_KF/_0UH @HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH W/ O_ ".WA[_L(V__ *-6BCP+_P C
MMX>_["-O_P"C5HH _3JO*?\ AEOX8?\ 0L_^3]U_\=KU:B@#RG_AEOX8?]"S
M_P"3]U_\=H_X9;^&'_0L_P#D_=?_ !VO5J* /*?^&6_AA_T+/_D_=?\ QVC_
M (9;^&'_ $+/_D_=?_':]6HH \I_X9;^&'_0L_\ D_=?_':/^&6_AA_T+/\
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M )/W7_QVC_AEOX8?]"S_ .3]U_\ ':]6HH \I_X9;^&'_0L_^3]U_P#':/\
MAEOX8?\ 0L_^3]U_\=KU:B@#RG_AEOX8?]"S_P"3]U_\=H_X9;^&'_0L_P#D
M_=?_ !VO5J* /*?^&6_AA_T+/_D_=?\ QVC_ (9;^&'_ $+/_D_=?_':]6HH
M \I_X9;^&'_0L_\ D_=?_':/^&6_AA_T+/\ Y/W7_P =KU:B@#RG_AEOX8?]
M"S_Y/W7_ ,=H_P"&6_AA_P!"S_Y/W7_QVO5J* /*?^&6_AA_T+/_ )/W7_QV
MC_AEOX8?]"S_ .3]U_\ ':]6HH \I_X9;^&'_0L_^3]U_P#':/\ AEOX8?\
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M3?[2M/\ GZA_[^#_ !H_M*T_Y^H?^_@_QH \R_X9;^&'_0L_^3]U_P#':/\
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M +^#_&@#S+_AEOX8?]"S_P"3]U_\=H_X9;^&'_0L_P#D_=?_ !VO3?[2M/\
MGZA_[^#_ !H_M*T_Y^H?^_@_QH \R_X9;^&'_0L_^3]U_P#':/\ AEOX8?\
M0L_^3]U_\=KTW^TK3_GZA_[^#_&C^TK3_GZA_P"_@_QH \R_X9;^&'_0L_\
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MW7_QVC_AEOX8?]"S_P"3]U_\=KTW^TK3_GZA_P"_@_QH_M*T_P"?J'_OX/\
M&@#S+_AEOX8?]"S_ .3]U_\ ':/^&6_AA_T+/_D_=?\ QVO3?[2M/^?J'_OX
M/\:/[2M/^?J'_OX/\: /,O\ AEOX8?\ 0L_^3]U_\=H_X9;^&'_0L_\ D_=?
M_':]-_M*T_Y^H?\ OX/\:L*P900<@\@B@#RK_AEOX8?]"S_Y/W7_ ,=H_P"&
M6_AA_P!"S_Y/W7_QVO5J* /*?^&6_AA_T+/_ )/W7_QVJUY^S+\-;>XLHX_#
M>U)YC'(/MUR=RB-VQ_K..54_A7K]4-2_X_-*_P"OEO\ T3)0!YQ_PRW\,/\
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MM_##_H6?_)^Z_P#CM>K44 >4_P##+?PP_P"A9_\ )^Z_^.T?\,M_##_H6?\
MR?NO_CM>K44 >4_\,M_##_H6?_)^Z_\ CM'_  RW\,/^A9_\G[K_ ..UZM10
M!Y3_ ,,M_##_ *%G_P G[K_X[1_PRW\,/^A9_P#)^Z_^.UZM10!Y3_PRW\,/
M^A9_\G[K_P".T?\ #+?PP_Z%G_R?NO\ X[7JU% 'E/\ PRW\,/\ H6?_ "?N
MO_CM'_#+?PP_Z%G_ ,G[K_X[7JU% 'E/_#+?PP_Z%G_R?NO_ ([1_P ,M_##
M_H6?_)^Z_P#CM>K44 >4_P##+?PP_P"A9_\ )^Z_^.T?\,M_##_H6?\ R?NO
M_CM>K44 >4_\,M_##_H6?_)^Z_\ CM'_  RW\,/^A9_\G[K_ ..UZM10!Y3_
M ,,M_##_ *%G_P G[K_X[1_PRW\,/^A9_P#)^Z_^.UZM10!Y3_PRW\,/^A9_
M\G[K_P".T?\ #+?PP_Z%G_R?NO\ X[7JU% 'E/\ PRW\,/\ H6?_ "?NO_CM
M'_#+?PP_Z%G_ ,G[K_X[7JU% 'E/_#+?PP_Z%G_R?NO_ ([1_P ,M_##_H6?
M_)^Z_P#CM>K44 >4_P##+?PP_P"A9_\ )^Z_^.T?\,M_##_H6?\ R?NO_CM>
MK44 >4_\,M_##_H6?_)^Z_\ CM'_  RW\,/^A9_\G[K_ ..UZM10!Y+<_LW_
M  ZT.WEU*Q\.^1>V:&X@E^W7+;)$&Y3@R$'! X(Q17I>O_\ (!U+_KVD_P#0
M310!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ///'7_+?_ *_?_:$5<?78
M>.O^6_\ U^_^T(JX^OH<%_!/)Q/\0****[SE"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVF*G?'&K=@KDC\\"I:* (V:7S0 B&/NQ<@_EC^M#M*%.Q$9L\!F(&/KBI**
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MH;! (!!/%/V4I-\BTU_#^NA/M%&*<GNOZ_IGTG1116!J%%%% !1110 4444
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M*^YQ5']M7]HWQ#\'?".C?\(AI^N?:KZ[M)?[?L=-ANK#R&D(:W+R$@2R*/E
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MBC36?AWPW8M>W\T:G#2",$!4'/S,P'!QG!I<ZBFYZ6;7W6_'R'RMVY=4U?\
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MF/V'?B)X7^%>I?$?2_&>K6?A[61<H[2ZE*(C*(S(LB MU8,<[1R=W .*^P]
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MYH]$_:?\&:5^SO\ \%,O@CXA\!VUOH#^*[JT34[&Q411.TMT;:9]B\ 21OR
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M "BBB@ HHHH **** "BBB@ HHHH \\\=?\M_^OW_ -H15Q]=AXZ_Y;_]?O\
M[0BKCZ^AP7\$\G$_Q HHHKO.4**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBMOPUX:FUZX!(*6R
MGYW_ *"LYU(TX\TMBHQ<W9!X:\-3:]< D%+93\[_ -!7J-G9PV%ND$"!(U&
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M?:3Z3?\ ?S_ZU=+11[:K_,_O#V</Y4<U_P *^TGTF_[^?_6H_P"%?:3Z3?\
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MAX[6,O$)958JL@$0/RIV'&<<U48N47+LTOO_ $[DN234>Z;^ZW^>A]+T5@>
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ML!?"IT,VWF/]J\_[1YN[;LV[-O?=G/;O7=.\JL)ON[_.,E^;.>G:-.<?)?\
MI4?T1X!X5^"^G?&[]K7X_P"F>)=4U1O"EE=:7+=>'[&Z>VAU&5[3"&=XRKE4
M"-A 0"6!/3![']FSP^/@U^TY\2_A7HEY>/X(M]*L]:TS3;JY>==/9R%D2,N2
M=I+$]>PSDY->F_"GX-ZSX%^.?Q>\:7]U8S:7XPFT^2PAMY'::(00LC^:"@49
M+#&UFXZXI_AWX/ZQI'[4'BWXD375BVB:OH5KI<%O&[FY66-P69E*;0N!P0Q/
ML*YJ=/V;H.*Z6E_X ]_27+;MTT-*TN;VJOU37WQO;Y<USUC4+7[?I]S;;MGG
M1-'NQG&01G'XU\I>%OV??CC\ ?AK#IW@KXN:/KMEH<$DEIX?U7PND,,PW-(R
M&X69I 22V#[]0.:^HO$]CJ6I>'-3M-&U)=&U::VDCM-0:!9Q;2E2$D,;</M.
M#M/!Q7SUK7@S]J3Q9IMUX=O_ !=\.-%TB[C:WEU[2+*];4Q&1@LL3GR@Y&>A
M&,\$'FBLI>][-/F:T?3K;RT\UU'3MISM6O\ Y?/[CTO]FWXS)\?O@[H7C3[#
M_9EQ>"2*YM%8LL<T;LCA2>JDKD>QQ7E_[<W_ !Z_!C_LH>E?^U*]K^#WPKT?
MX*_#?1/!NA^8^GZ9$4$TV/,F=F+/(V.,LS,>.!G%<?\ M(?!S6?C##\/TT:Z
ML;4^'_%5EKEU]ND=-\$.[>J;4;+G<, X'N*Z:BNXVZ2B_NDFWZ&5)\O-?M+\
M4['D7[5WA>[\;_M4_ GP_::]J'AL:C::S#/J&E.$N5A$*/(D;_P%U4KN'(W9
M%9GBSX0:%^RS^T'\'-0^'+7^BV'BK59='US39-0GN(;X,F5E?S78[U+$]>H&
M,<Y]O^(GP;UGQ=^T3\*O'MG=6,6C^%(=2CO8)Y'%Q(;B'RT\I0A4X/7<R\=,
MT_XW_!_6/B7X[^%&M:9=6-O:^$]=_M2^2[=U>2+8!MB"HP+9'1BH]ZYE3Y53
MDE[W.K_X7/7Y<M]/GN:5)WYDMN3_ ,FY7;YWL>1?$;PW%^TM^U]J/PW\4WEZ
MWP_\*:!%J,^AVMU);QZA=3,N&E,9#,JJPQR""O!Y;.!'\&-+^"O[<'PBTWP_
MJ.J/X=N-+U22ST?4+M[F/3<0D.D#R$L$;Y3M).""<\X'K/Q>^ _C=_C!9?%;
MX4Z[H^E^*_[/_LG4M-\1Q2M87]N&W*6:++JRG'0<[5Y&#NR/#O[/?Q-OOCYX
M(^*/C?Q=H^KWFF6][;WFEZ;%)!:64<D.R-+165FDRQ=G>1E)^4 ?+4T:;C*#
M<=4Y7?>_-;UT:7E;[ZJ2YHR5]&E9=K<M_P 4_6XO@D_\; OB1_V*%A_Z,6N!
M^#?P@T/]L2^\<^//BB^H>((X?$5UI>B:0NI3V]MI=O 5"E$B=?WAR,D]=N>]
M>[^'?@_K.D?M0>+?B1-=6+:'J^A6NEP6Z.YN5EC<%BRE-H7 X(8GV%>?VOP$
M^+GP;\9>*+GX/>(?"3^%?$NH/JEQHWBZWN3_ &?<28\QH&@Y8' X8@# &.,F
M*=-I0]I&Z_>:=FZC<7_X#?7S!RUGR2M\'S2@DU]]ON-CXG^$_!?PO^!FF^'_
M (F_$#Q'<^'+;4MD$JWDR7^I(QD\FQD,&99P%8 [<$^6I. #7S=9ZAX1^%_Q
MX^$]S\+?A_\ $#X:0:KKJZ5JHU^RN[73]6MY1M 'GR/O=?O 8![GD"OHGXB?
MLT^-/%W@7P5*GCN'5OB/X5UHZ_!JNL6A%E<S,Q)@,2',<0^55VY("^IXQ?$W
MP)^-OQ4\:?#OQ'XV\1^#;:+PMKT&HG0]!BN5@:)<EY1-*I=YCPH0A4 )YS6D
M8R]M&35K2CK_ '?=O=[O[2:ZK5[MBE)>RE%/I+[_ 'K66RZ-=MELD<-\7OV<
M?ASXD_;D\&:;J/AF*YL?$FD:CJ>K0FYG475RNXK(2'!4CT7 ]JZ_]KKPII7@
M7PC\!_#^A6:Z?H^G>/=)M[6U5V81QCS,+EB2?Q)KN?CY\%?&_B;XE>"OB/\
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M\*Z;XD\.WHU+1-1B\ZUNA&\?F+DC.UP&'((P0#Q5J2EL_P"GM]Y-FM_ZMO\
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M 4444 %%%% !1110 4444 4-?_Y .I?]>TG_ *":*-?_ .0#J7_7M)_Z":*
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M_C#X._$+2M>TFQUO2YM7@,MCJ5LEQ!)MB#+N1P5." 1D=0*Q?CG\+?!>D?\
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M^0>'?".A>-_^"I'CK3/$6BZ=K^FM:O(;/5+2.YA+"TM\-L<$9'8XKWGX/_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4Z.-II%1%+.QP *(XVFD5$4L['
MKTGPGX3728UN;E0UTPR ?X/_ *]<M>O&C'S-Z5)U'Y!X3\)KI,:W-RH:Z89
M/\'_ ->NHHHKYR<Y5)<TMSUXQ459!1114%!1110 4444 %%%% !1110 4444
M %4-2_X_-*_Z^6_]$R5?JAJ7_'YI7_7RW_HF2@"_1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!0U__D ZE_U[2?\ H)HHU_\
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MKPVNX\'^,-NRRO7XZ1RMV]C7BXK"\O[RGL>E0KW]V1W=4-2_X_-*_P"OEO\
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ME_'J+6+0:1=>'=?TD@7>F73[RH)(RK84G!!!!4$'%?-GCCXF>*_BG^T!XO\
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MRJ S6UL6(')_?SCFLGXD:YIWA'_@H=H.JZW>P:5IBVB%KR\D$<2AK25 68\
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MQ!X=M/ GQ3TSXC>#[^YVC08I5GDA0L"5**6\HG<<%2N6SE>U=CX_UZQ^'?\
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MXNCL_-;Q1_:,AW9MD8C[-C8#L;;NSGCWKB_C$NW]OWX9C).+. 9/UN*?H_\
MRDEUG_L'#_TABJ*.L(+RJ?H:UG[\_P#N'^AZ#\5/VQK+P;XZF\&>$O".J?$#
MQ):DBZMM-)58B!DJ"J2,S+WPN!ZYR!J? G]K#2?C)XBO?#%_H5[X1\66JL[:
M7?-OWA?O!6*J=R]2K*#CD9P<>"?LP^,M#^%?[2'Q6L?&^I6FA:C=W,PAO-2D
M6&,XN&=E\QL ;@R,,GD#Z5=\,ZUIWQ1_X*#0Z[X1D74-'T^U8WE_:C]U)MM6
MB+[AU&]T4'H<<9%%.G%J*:O>+=_E?[B:DY1<VG;E=K=_^"=_JW[<\&G^,_%?
MA.V\!ZIK'B#2]0>PT^RTR8SOJ!1G#N0(LQ@! < .?F]B:HZ!_P %!-)UK3+F
MU/@76SXT6X^SVWANS)N'G;!S\X0%=NT@C82,C /.,3]E6"-_VN?C7*T:M+'<
M701RH++F\.<'MG _*D_9_MH1^W5\5SY292*Z93M'RDSPY(],Y/YU-.$)**:U
M<.;[K?G_ ,,.I.47)IZ*?+]_^1ZY^SS^U-8?'35M8T*YT"Y\*^)-,4R2Z=<S
M>;N0,%8ABB$,K$ J5&,CKSCC?$?[:VL0:QJ\/ACX0^(_$^DZ7<2V]QJBF2.,
M-&Q5S\D,@ &T]6!QU KBOA+(;?\ X* ?$9HU)Q:73;$_B_U!Q^)KS?1OB5XG
M^-]QXMUOQ5\=)/AC#I\C"#1;>5XFD0[OD2))8R^,;?XV)ZBCDB^6:6CBI/?J
M[>KV'S27-!O:7*OZV/MOX$_''1OCUX-.NZ3!-8R0S&VN[*X(+PR  XR.&4@@
M@\9] 1BO1Z^._P#@FM_R('C'G=_Q-4Y]?W0K[$J<33C3JN,=M/Q28Z,G.%Y>
M?YA1117*;A1110 4444 >>>.O^6__7[_ .T(JX^NP\=?\M_^OW_VA%7'U]#@
MOX)Y.)_B'SA^W=KFM:+\)] CT/7M5\.7&H>)]/L);[1KM[6X$4C,'"NIR.WM
MP,@UYU\>/!/C+]D7P./B7X3^+?C;Q/%I=Y;KJ&A^-=374;>\@DE5"B913&V6
M'(YQG!%=C_P4.M[FZ^#OAB"SNOL-W)XNTQ(;KRQ)Y+EG"OM/#8.#@\'%7G_9
M)\3>/M6TJ3XO?%S4?B1HNF7*WD&A0Z-;Z3:2RK]TSK$3YH'H<=^<$@Q&,Y5)
M\FCYEKTMRP;5NO72UG<IRC%1YM5R[?.7]7OI8POVA/$EA9?M.?LWZ[J5S#I>
MG)#K%W//>2+''!']C1B78G  '4FO7/AO^U/\*?BYXFF\/^$_&=EJNLQ!C]D\
MN6%I0N=QB,B*)0 "?D+<<]*\A_:G\)Z/XT_:F_9TT;7-.@U/2IIM5>2SN%W1
M2;(8W4,O0@,JG!X.,'(J]^UQI=IIGQ8_9WUFTMX[;4XO%T6GI<1(%86\B_-%
MD?P\=.G)]:Z*<I*UOA=2WG[TDKW\K[?B9U$N57^)0O\ =S/\;'LWQ2^/OP_^
M"WV5?&?B>UT:>Z&Z"U*23W$JYQN6&)6<KGC.W%3?"OXY>!?C98W=UX*\1VVN
M):,%N(D1XIH2<XWQ2*KJ#@X)7!P<=*\X^)GQ>UJ/XZP^ /ASX,T76/'JZ+_:
M%YKVO3FVMK&T,F$0LB-+)ESG:N -P//./,?@K_PFUG^WQXEB\<Q^&K;7+SP0
MEQ<IX4:<VLH6ZC6-W,P#>8%R#VQMITZDI5%%[/F\OA4G\_AL]OP%."C!M;JW
MXM?=O?\ X<]R\:?M:_"/X>^+'\-:_P"-K*RUF)E2>!(9IDMV)P!-)&C)$?9V
M&.]>AZ]XVT#POX7D\1ZMK-CIV@QQ+.VI7$ZK!L;&U@Y.#NR,8ZY&.M?,>I>%
M_B%^R9-\0O$.BZ)H_P 1?AGJ]_=>(M4T^27[+JUGY@W3D,RF.>-54G:?F/3C
MOR?[5GBN?XCV/[-<G@NTTG_A&M?U1+NSL?$4;Q:<9A%']DAN$BR0H#R#:H(R
M,=*S5:?(K_$W%6MLY.VU]?)IZVMH5[-<^GPVD_7E5_EZ/:_4^A_AW^UE\)OB
MMXB30?#/C*UO=8D4M#:3V\]J\X&3^Z\Z-/,X!/R9X!->MU\A?%#X,?M#?&1?
M#,.O#X5Z7_8>KVVJVNI:1/J(N[=HVR1&7B(P1U!X.!Z5]>UTTY2E&\EK?[]M
M?+JOD8324K1[?Y_U\SQ;XA?L]:]\2O$6HWU[\8?''A_3F<'3]+\*746F1VJA
M "'=49YB6!;+$8W8[5QO[%OQ$\7ZY>_$SP+XNUQO%5QX'UK^S;;795 FN8B7
M $A'5AY?4DGYL$G&:ZO]H?X\7O@BXT_P+X%LUU_XI^(5*:;IX.4LHSD->7!_
MAC3DC/WB/0&M[]G/X&6GP%^'RZ/]L;5]=OIWU#6=7D!WWMY)R[G/.!T'L,GD
MFL:27M).'PI6]977Y).[\[=[:5'[B4OBO?T5G^>EEY7['8?$3QQI_P -/ NO
M>*M5W?V?H]G)>3*GWG"*3M7W)P![D5\'_"G3/C]^W';ZEXVD^*E]\+/"2W3V
M^FV>@K*I<KC<,1R1%U&<%W=B6#   5]7_MB>&[[Q9^S)\0]-TV)I[QM,:9(H
MP2SB-ED90.Y*H>*\F_X)E_$;0O$'[.NG^%[:]@77M"N;E+NQ+@2[))FE24+G
M)4A\;NF5(K+E5;$RIS>D8II;:MN[^5OU[FC?LZ$9QW<FGZ6_S->Q\=?$G]E/
MX&^/=6^+&L6WC<:')&OA[4T(274%D 1(YAC<I#E<EMQP6^9L UX]\*_A5^T+
M^U?X3A^(>N?&W5?A[9:DSR:9IFAQRQH80Q 8I%-$%7(.TL78@ DUZQ_P436'
MQI^S#XLM]%O+?4KO0KVSNM0M;6599+=-^#YBJ<IPV[GLI-=C^P_\0]#\;?LT
M^"X]-O;=[G1]/CTZ_M4<;[>6(;3O7.5W !@3U#9J815:K4C4=^51MKTM\6G6
M^EPDW3IP<%\3=_\ Y'];'A_[/_QQ^)_P@_::/P+^*^N#Q7;WB?\ $JUJ09ER
M8S)$V\@,RN%92'RP<  XZ^3?M@?$+XK/^U/\0-*\(>._$6CV/AW2(-5CTW3]
M2FA@\N.W@DE_=HP4GYW<Y!SC!KK/%NJV7QQ_X*=^$W\*SKJEAX:AA%[>VK"2
M)?LXDDD.X<8#R+'G^\<5T6FZ;;:U_P %3?&NGWD2SVEWX?,$T3#(=&L+=6!^
MH)KE_>5Z5-*6MZB3[I)\K^_J=$>6C4J-K3E@VNS<H\R\M/S/I_\ 9_\ C9:?
M$_\ 9[\/^/M0N8XC_9S2:K*<*L4T(*W!/H-R,WT(K\W%_: ^+7B_XP>$/')\
M;>(M,\+>*/&!M+#18=1FBMA;13VX*&%6$97;,J'@Y*MG-4[SXG:[^SOX%^,W
M[/:1W4U_J&M)::8Z@EO)D;;*?^VL2PX _P">AKUG]I;X8P_!N;]DOPA$JB73
MKT+<LO1[AKFT>9OQD9C6WMOK-6GB(Z1O!=M9:R^ZUOF9^S]C"=%ZNTONBM/O
MO?Y'=_\ !13QGXTTWXL_"7PSX7\:ZYX0@UQGMIY-'O9K<%I)XHP[K&Z[]H;@
M$^O3-<1\6-9^,_[!?CGP=J5]\6-2^)OAG6IF2YL]:,C,RQE/,0+++*4.UP5=
M''(Y&.#J_P#!3:#4[KXX?!:'1+B.SUF1V2QN)AE(IS<PB-V&UN V">#TZ'I7
M<:3^Q#\3_BM\1="\3_'WXC6'BBUT-U>VTK1H<1RX8-L;]U"J!BJ[B$+,!C(X
M(G#J<I\T;Z3=WTY4]OZ_X!51QBK3U7*M.M[;E?\ :X^)GBSPU^V)\#M'T7Q-
MJ^E:+J4UB+S3K.]DBM[D/>[&$L:L%?*\?,#Q7V/\0;R?3? /B6[M96@N;?3+
MF6*5#AD=8F*L#Z@@5\+?MM<?MR? $#@?:-._].-?<7Q._P"2:^+/^P1=_P#H
MEZKF?]GUI7UYJOZ"Y?\ ::2?:!^</[)GPJ^+G[47@?5?$?\ PT3XU\,_8=1:
MP^S?:[N[WXC1]^[[7'C[^,8/3K7U'XF_9+^(VN?#GP=X<M/VA?%.EZIHC79O
M=<A6X\[5/.D#QB3%VK?NP-HW._!XQTKY _8?_8I\#_M+?#C6O$'B?5?$%A>6
M6JM8QQZ3<01QE!%&^2)(7.[+GH0,8XK]0_ O@^R^'O@O0_#&G2W$]AH]E#8P
M273AY6CC0*I<@ %L#G  ]A753HQE3M.-KJ/5N^E[^7IY^1C.HXS]U[7Z+T/S
M+^"_P]^+GQ>^.?Q"^'7_  T+XUTG_A$I)H_[2^VWDWVKR[CR<^7]J79G[WWF
MQT]Z[K]N&]^(?P'^'GP8\)V'Q1\27.IR2W\-_K]O>SVMQ?'?"4:7;*6;:)"
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M[U87NHM6\KK5$5E_#E:S:=_DU9_U_D>HT445UF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '<>#_&&W997K\=(Y6[>
MQKJ]1YO-*(_Y^6_]$R5YEX>\/SZY=!4!2%3EY/2O2)K5;.31X4+,J7! +')_
MU,E?.XN%.%3W#U\/*4H^\:M%%%<)TA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG@DCDUWU%*[T\MO(=M_/<\Z\(_L\_#OP'XEM/$'A_P ,V^E:M:VQM(I[>:4
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MAA6G>8FGZ?!I=JD$";47\S[FK5%%>.>@%4-2_P"/S2O^OEO_ $3)5^J&I?\
M'YI7_7RW_HF2@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!0U__ ) .I?\ 7M)_Z":*-?\ ^0#J7_7M)_Z":* +]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZS?]^_\ Z]'_  L'2?6;_OW_ /7H]C5_E?W![2'\R.EHKFO^%@Z3ZS?]^_\
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M_P#KT?\ "P=)]9O^_?\ ]>CV-7^5_<'M(?S(Z6BN:_X6#I/K-_W[_P#KT?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *&O_P#(!U+_ *]I/_0311K_ /R =2_Z]I/_ $$T
M4 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SSQU_RW_Z_?_:$5<?78>.O
M^6__ %^_^T(JX^OH<%_!/)Q/\0****[SE"BBB@ HHHH **** "BBB@ HHHH
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MCE>T8WMUO=?HSZ\^&O[5WPE^+NJ)IOA7QQI]_J4AQ%93K):3RG!)"1S*C.<
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M>5LB5@-@;"Y*\'.[('0?<-%%%2I[3E5K65@A#E;=]W<****Q- HHHH ****
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M#7_^0#J7_7M)_P"@FBC7_P#D ZE_U[2?^@FB@"_1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >>>.O\ EO\ ]?O_ +0BKCZ[/QM&\K7 1&<_;,X49_Y815R7
MV.X_YX2?]\&O?P<HJE9L\O$1;J:(AHJ;['<?\\)/^^#1]CN/^>$G_?!KNYX]
MSEY9=B&BIOL=Q_SPD_[X-'V.X_YX2?\ ?!HYX]PY9=B&BIOL=Q_SPD_[X-'V
M.X_YX2?]\&CGCW#EEV(:*F^QW'_/"3_O@T?8[C_GA)_WP:.>/<.678AHJ;['
M<?\ /"3_ +X-'V.X_P">$G_?!HYX]PY9=B&BIOL=Q_SPD_[X-'V.X_YX2?\
M?!HYX]PY9=B&BIOL=Q_SPD_[X-'V.X_YX2?]\&CGCW#EEV(:*F^QW'_/"3_O
M@T?8[C_GA)_WP:.>/<.678AHJ;['<?\ /"3_ +X-'V.X_P">$G_?!HYX]PY9
M=B&BIOL=Q_SPD_[X-'V.X_YX2?\ ?!HYX]PY9=B&BIOL=Q_SPD_[X-'V.X_Y
MX2?]\&CGCW#EEV(:*F^QW'_/"3_O@T?8[C_GA)_WP:.>/<.678AHJ;['<?\
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M7_7RW_HF2LBR_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB5X,_:0N_@U\2-;L?&HN=(.M:7XCM;%+&8H&VF.6&/Y!RKXQR-HY.[Y?J(G
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M^5MW(/45Z5^Q%\4/$OQ@_9YT3Q-XMU :IKD]S=12W0@CAWJDS*ORQJJC  '
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M_H457ZH3?\AZS_Z]I_\ T**K]<!U!1110 4444 %%%% !1110 4444 %%%%
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M/"EW6.60!N2O8D=17HGQH\$Z5\1/V^O#>@:W";G2[FSA>>$-@2".&60*?8E
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M!5"O&26(*[%.6+9[\<5YA'^P!>26D>B77Q:UZ?P;'+YBZ$(&" 9SQF8QAO\
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MQ6C$^2NK*5';<84S_):].^)UIHG[-W[+>N:;HP:WM+/3I+*U,K9DEGFRF]B
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MKT^QY[_PK6[_ .?R'\C1_P *UN_^?R'\C7H5%'URO_-^"#ZO3['GO_"M;O\
MY_(?R-'_  K6[_Y_(?R->A44?7*_\WX(/J]/L>>_\*UN_P#G\A_(T?\ "M;O
M_G\A_(UZ%11]<K_S?@@^KT^QY[_PK6[_ .?R'\C1_P *UN_^?R'\C7H5%'UR
MO_-^"#ZO3['GO_"M;O\ Y_(?R-'_  K6[_Y_(?R->A44?7*_\WX(/J]/L>>_
M\*UN_P#G\A_(T?\ "M;O_G\A_(UZ%11]<K_S?@@^KT^QY[_PK6[_ .?R'\C1
M_P *UN_^?R'\C7H5%'URO_-^"#ZO3['GO_"M;O\ Y_(?R-'_  K6[_Y_(?R-
M>A44?7*_\WX(/J]/L>;K\/KAKN2W%W%OC19"=IQABP'_ *"?TJ;_ (5K=_\
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M?G_10!^@'_#4GPP_Z&;_ ,D+K_XU1_PU)\,/^AF_\D+K_P"-5^?]% 'Z ?\
M#4GPP_Z&;_R0NO\ XU1_PU)\,/\ H9O_ "0NO_C5?G_10!^@'_#4GPP_Z&;_
M ,D+K_XU1_PU)\,/^AF_\D+K_P"-5^?]% 'Z ?\ #4GPP_Z&;_R0NO\ XU1_
MPU)\,/\ H9O_ "0NO_C5?G_10!^@'_#4GPP_Z&;_ ,D+K_XU1_PU)\,/^AF_
M\D+K_P"-5^?]% 'Z ?\ #4GPP_Z&;_R0NO\ XU1_PU)\,/\ H9O_ "0NO_C5
M?G_10!^@'_#4GPP_Z&;_ ,D+K_XU1_PU)\,/^AF_\D+K_P"-5^?]% 'Z ?\
M#4GPP_Z&;_R0NO\ XU1_PU)\,/\ H9O_ "0NO_C5?G_10!^@'_#4GPP_Z&;_
M ,D+K_XU1_PU)\,/^AF_\D+K_P"-5^?]% 'Z ?\ #4GPP_Z&;_R0NO\ XU1_
MPU)\,/\ H9O_ "0NO_C5?G_10!^@'_#4GPP_Z&;_ ,D+K_XU1_PU)\,/^AF_
M\D+K_P"-5^?]% 'Z ?\ #4GPP_Z&;_R0NO\ XU1_PU)\,/\ H9O_ "0NO_C5
M?G_10!][Q_M-?#5-3N+D^),0R0QQJWV&YY96<L,>7Z.OYU9_X:D^&'_0S?\
MDA=?_&J^!F_X\XO^NC_R6H* /T _X:D^&'_0S?\ DA=?_&J/^&I/AA_T,W_D
MA=?_ !JOS_HH _0#_AJ3X8?]#-_Y(77_ ,:H_P"&I/AA_P!#-_Y(77_QJOS_
M ** /T _X:D^&'_0S?\ DA=?_&J/^&I/AA_T,W_DA=?_ !JOS_HH _0#_AJ3
MX8?]#-_Y(77_ ,:H_P"&I/AA_P!#-_Y(77_QJOS_ ** /T _X:D^&'_0S?\
MDA=?_&J/^&I/AA_T,W_DA=?_ !JOS_HH _0#_AJ3X8?]#-_Y(77_ ,:H_P"&
MI/AA_P!#-_Y(77_QJOS_ ** /T _X:D^&'_0S?\ DA=?_&J/^&I/AA_T,W_D
MA=?_ !JOS_HH _0#_AJ3X8?]#-_Y(77_ ,:H_P"&I/AA_P!#-_Y(77_QJOS_
M ** /T _X:D^&'_0S?\ DA=?_&J/^&I/AA_T,W_DA=?_ !JOS_HH _0#_AJ3
MX8?]#-_Y(77_ ,:H_P"&I/AA_P!#-_Y(77_QJOS_ ** /T _X:D^&'_0S?\
MDA=?_&J/^&I/AA_T,W_DA=?_ !JOS_HH ^]Y/VFOAJ^IV]R/$F88X9(V;[#<
M\,S(5&/+]$;\JL_\-2?##_H9O_)"Z_\ C5? R_\ 'G+_ -=$_DU04 ?H!_PU
M)\,/^AF_\D+K_P"-4?\ #4GPP_Z&;_R0NO\ XU7Y_P!% 'Z ?\-2?##_ *&;
M_P D+K_XU1_PU)\,/^AF_P#)"Z_^-5^?]% 'Z ?\-2?##_H9O_)"Z_\ C5'_
M  U)\,/^AF_\D+K_ .-5^?\ 10!^@'_#4GPP_P"AF_\ )"Z_^-4?\-2?##_H
M9O\ R0NO_C5?G_10!^@'_#4GPP_Z&;_R0NO_ (U1_P -2?##_H9O_)"Z_P#C
M5?G_ $4 ?H!_PU)\,/\ H9O_ "0NO_C5'_#4GPP_Z&;_ ,D+K_XU7Y_T4 ?H
M!_PU)\,/^AF_\D+K_P"-4?\ #4GPP_Z&;_R0NO\ XU7Y_P!% 'Z ?\-2?##_
M *&;_P D+K_XU1_PU)\,/^AF_P#)"Z_^-5^?]% 'Z ?\-2?##_H9O_)"Z_\
MC5'_  U)\,/^AF_\D+K_ .-5^?\ 10!^@'_#4GPP_P"AF_\ )"Z_^-4?\-2?
M##_H9O\ R0NO_C5?G_10!^@'_#4GPP_Z&;_R0NO_ (U1_P -2?##_H9O_)"Z
M_P#C5?G_ $4 ?H!_PU)\,/\ H9O_ "0NO_C5'_#4GPP_Z&;_ ,D+K_XU7Y_T
M4 ?H!_PU)\,/^AF_\D+K_P"-56O/VFOAK<7%E)'XDW)!,9)#]AN1M4QNN?\
M5\\LH_&O@BI[?_57/_7,?^AK0!]\_P##4GPP_P"AF_\ )"Z_^-4?\-2?##_H
M9O\ R0NO_C5?G_10!^@'_#4GPP_Z&;_R0NO_ (U1_P -2?##_H9O_)"Z_P#C
M5?G_ $4 ?H!_PU)\,/\ H9O_ "0NO_C5'_#4GPP_Z&;_ ,D+K_XU7Y_T4 ?H
M!_PU)\,/^AF_\D+K_P"-4?\ #4GPP_Z&;_R0NO\ XU7Y_P!% 'Z ?\-2?##_
M *&;_P D+K_XU1_PU)\,/^AF_P#)"Z_^-5^?]% 'Z ?\-2?##_H9O_)"Z_\
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M7Y_T4 ?H!_PU)\,/^AF_\D+K_P"-4?\ #4GPP_Z&;_R0NO\ XU7Y_P!% 'Z
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MGH>>#QTKA*E.ZNBFK!1113$%%%>\_LZ? /0?BYH>K7^LWNHVSVMRL$:6,D:
M@KN).Y&SU]J:5[B;M9=SP:BOKK3_ -EOX5:_=366D>-;N^U",'=#;ZE:3NF.
M"618\\&O /C%\)[[X0^*%TNYN%OK:>+SK:[1"@D7)!!7)PP(Y&3U'K4<R37F
M59Z^1PE%%%4(**** "BBB@ HHHH **]/C_9[\1R?#,^.1=Z9_9/V<W7D^;)Y
M^P,1T\O;GC^]7F%#TDXO= M4I+9A13X89+B:.*)&EED8*B("69B<  =S7T[X
M+_8[M8]!&J>.==DTK,8D>VM7CC%N/^FDK@KGU &!ZFG;2XKZV/E^BOI[Q/\
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M;_DG^O\ _82/_HI*\-_9R_Y+[H/_ %WN/_1,E;I)U.3HU?\  C>DY]4_\_\
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MJZM=R7VH7+;I9I,9/8# X  X '  K-HHI;:(&V]6%%%%,04444 3K_QYR_\
M71/Y-4%3K_QYR_\ 71/Y-4% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !4]O_JKG_KF/_0UJ"I[?_57/_7,?^AK0
M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!N
M>!?^1V\/?]A&W_\ 1JT4>!?^1V\/?]A&W_\ 1JT4 ?IU7YJ?\*G\<?\ 0F^(
M/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_
M /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E
M=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ
M?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<
M?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@
M_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__
M ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?
M\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?
M]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(
M/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_
M /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E
M=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ
M?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<
M?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@
M_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__
M ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?
M\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?
M]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(
M/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_
M /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E
M=% 'YJ?\*G\<?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ
M?\*G\<?]";X@_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<
M?]";X@_\%<__ ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@
M_P#!7/\ _$4?\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YJ?\*G\<?]";X@_\%<__
M ,11_P *G\<?]";X@_\ !7/_ /$5^E=% 'YJ?\*G\<?]";X@_P#!7/\ _$4?
M\*G\<?\ 0F^(/_!7/_\ $5^E=% 'YL2?"SQI(D2IX0UYFC7:X73)R5.2<'Y>
M#@@_B*C_ .%3^./^A-\0?^"N?_XBOT<TW_C\U7_KY7_T3'5^@#\U/^%3^./^
MA-\0?^"N?_XBC_A4_CC_ *$WQ!_X*Y__ (BOTKHH _-3_A4_CC_H3?$'_@KG
M_P#B*/\ A4_CC_H3?$'_ (*Y_P#XBOTKHH _-3_A4_CC_H3?$'_@KG_^(H_X
M5/XX_P"A-\0?^"N?_P"(K]*Z* /S4_X5/XX_Z$WQ!_X*Y_\ XBC_ (5/XX_Z
M$WQ!_P""N?\ ^(K]*Z* /S4_X5/XX_Z$WQ!_X*Y__B*/^%3^./\ H3?$'_@K
MG_\ B*_2NB@#\U/^%3^./^A-\0?^"N?_ .(H_P"%3^./^A-\0?\ @KG_ /B*
M_2NB@#\U/^%3^./^A-\0?^"N?_XBC_A4_CC_ *$WQ!_X*Y__ (BOTKHH _-3
M_A4_CC_H3?$'_@KG_P#B*/\ A4_CC_H3?$'_ (*Y_P#XBOTKHH _-3_A4_CC
M_H3?$'_@KG_^(H_X5/XX_P"A-\0?^"N?_P"(K]*Z* /S4_X5/XX_Z$WQ!_X*
MY_\ XBC_ (5/XX_Z$WQ!_P""N?\ ^(K]*Z* /S4_X5/XX_Z$WQ!_X*Y__B*/
M^%3^./\ H3?$'_@KG_\ B*_2NB@#\U/^%3^./^A-\0?^"N?_ .(H_P"%3^./
M^A-\0?\ @KG_ /B*_2NB@#\U/^%3^./^A-\0?^"N?_XBC_A4_CC_ *$WQ!_X
M*Y__ (BOTKHH _-3_A4_CC_H3?$'_@KG_P#B*/\ A4_CC_H3?$'_ (*Y_P#X
MBOTKHH _-3_A4_CC_H3?$'_@KG_^(H_X5/XX_P"A-\0?^"N?_P"(K]*Z* /S
M8;X6>-&@2(>$->,JLS,G]F3Y ( !(V]#@_D:C_X5/XX_Z$WQ!_X*Y_\ XBOT
M<A_Y#UY_U[0?^A2U?H _-3_A4_CC_H3?$'_@KG_^(H_X5/XX_P"A-\0?^"N?
M_P"(K]*Z* /S4_X5/XX_Z$WQ!_X*Y_\ XBC_ (5/XX_Z$WQ!_P""N?\ ^(K]
M*Z* /S4_X5/XX_Z$WQ!_X*Y__B*/^%3^./\ H3?$'_@KG_\ B*_2NB@#\U/^
M%3^./^A-\0?^"N?_ .(H_P"%3^./^A-\0?\ @KG_ /B*_2NB@#\U/^%3^./^
MA-\0?^"N?_XBC_A4_CC_ *$WQ!_X*Y__ (BOTKHH _-3_A4_CC_H3?$'_@KG
M_P#B*/\ A4_CC_H3?$'_ (*Y_P#XBOTKHH _-3_A4_CC_H3?$'_@KG_^(H_X
M5/XX_P"A-\0?^"N?_P"(K]*Z* /S4_X5/XX_Z$WQ!_X*Y_\ XBC_ (5/XX_Z
M$WQ!_P""N?\ ^(K]*Z* /S4_X5/XX_Z$WQ!_X*Y__B*/^%3^./\ H3?$'_@K
MG_\ B*_2NB@#\U/^%3^./^A-\0?^"N?_ .(H_P"%3^./^A-\0?\ @KG_ /B*
M_2NB@#\U/^%3^./^A-\0?^"N?_XBC_A4_CC_ *$WQ!_X*Y__ (BOTKHH _-A
M?A9XT6!XCX0UX2LRLJ?V9/D@ @D#;T&1^8J/_A4_CC_H3?$'_@KG_P#B*_1R
M;_D/6?\ U[3_ /H457Z /S4_X5/XX_Z$WQ!_X*Y__B*/^%3^./\ H3?$'_@K
MG_\ B*_2NB@#\U/^%3^./^A-\0?^"N?_ .(H_P"%3^./^A-\0?\ @KG_ /B*
M_2NB@#\U/^%3^./^A-\0?^"N?_XBC_A4_CC_ *$WQ!_X*Y__ (BOTKHH _-3
M_A4_CC_H3?$'_@KG_P#B*/\ A4_CC_H3?$'_ (*Y_P#XBOTKHH _-3_A4_CC
M_H3?$'_@KG_^(H_X5/XX_P"A-\0?^"N?_P"(K]*Z* /S4_X5/XX_Z$WQ!_X*
MY_\ XBC_ (5/XX_Z$WQ!_P""N?\ ^(K]*Z* /S4_X5/XX_Z$WQ!_X*Y__B*/
M^%3^./\ H3?$'_@KG_\ B*_2NB@#\U/^%3^./^A-\0?^"N?_ .(H_P"%3^./
M^A-\0?\ @KG_ /B*_2NB@#\U/^%3^./^A-\0?^"N?_XBC_A4_CC_ *$WQ!_X
M*Y__ (BOTKHH _-3_A4_CC_H3?$'_@KG_P#B*/\ A4_CC_H3?$'_ (*Y_P#X
MBOTKHH _-3_A4_CC_H3?$'_@KG_^(H_X5/XX_P"A-\0?^"N?_P"(K]*Z* /S
M4_X5/XX_Z$WQ!_X*Y_\ XBC_ (5/XX_Z$WQ!_P""N?\ ^(K]*Z* /S4_X5/X
MX_Z$WQ!_X*Y__B*DC^%GC2-)5?PAKRM(NU VF3@L<@X'R\G )_ U^D]4-2_X
M_-*_Z^6_]$R4 ?G'_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\
M_$5^E=% 'YJ?\*G\<?\ 0F^(/_!7/_\ $4?\*G\<?]";X@_\%<__ ,17Z5T4
M ?FI_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\ _$5^E=% 'YJ?
M\*G\<?\ 0F^(/_!7/_\ $4?\*G\<?]";X@_\%<__ ,17Z5T4 ?FI_P *G\<?
M]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\ _$5^E=% 'YJ?\*G\<?\ 0F^(
M/_!7/_\ $4?\*G\<?]";X@_\%<__ ,17Z5T4 ?FI_P *G\<?]";X@_\ !7/_
M /$4?\*G\<?]";X@_P#!7/\ _$5^E=% 'YJ?\*G\<?\ 0F^(/_!7/_\ $4?\
M*G\<?]";X@_\%<__ ,17Z5T4 ?FI_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]
M";X@_P#!7/\ _$5^E=% 'YJ?\*G\<?\ 0F^(/_!7/_\ $4?\*G\<?]";X@_\
M%<__ ,17Z5T4 ?FI_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\
M_$5^E=% 'YJ?\*G\<?\ 0F^(/_!7/_\ $4?\*G\<?]";X@_\%<__ ,17Z5T4
M ?FI_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\ _$5^E=% 'YJ?
M\*G\<?\ 0F^(/_!7/_\ $4?\*G\<?]";X@_\%<__ ,17Z5T4 ?FI_P *G\<?
M]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\ _$5^E=% 'YJ?\*G\<?\ 0F^(
M/_!7/_\ $4?\*G\<?]";X@_\%<__ ,17Z5T4 ?FI_P *G\<?]";X@_\ !7/_
M /$4?\*G\<?]";X@_P#!7/\ _$5^E=% 'YJ?\*G\<?\ 0F^(/_!7/_\ $4?\
M*G\<?]";X@_\%<__ ,17Z5T4 ?FI_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]
M";X@_P#!7/\ _$5^E=% 'YJ?\*G\<?\ 0F^(/_!7/_\ $4?\*G\<?]";X@_\
M%<__ ,17Z5T4 ?FI_P *G\<?]";X@_\ !7/_ /$4?\*G\<?]";X@_P#!7/\
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M3X!NENKR98HHQG&6=B !DCJ: +E%4M&US3O$>FPZCI-_:ZII\X)BN[.99HI
M"02KJ2#R".#VJ[3VT8KWU04444AA1110 4444 %%%% !117C7P2_:+7XR>./
M&_AT>'SI'_"-7!@^T_;/.^T_O)$SM\M=G^KSC+=?:JC%RO;IJ*345=^A[+11
M14C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,5=4M-+NM
M2-U,L(>Y 4MGG$,5/_X2S2/^?^/]?\*Y/QU_RW_Z_?\ VA%7'UZ>'PD:T.9L
MXZM=TY<J1ZY_PEFD?\_\?Z_X4?\ "6:1_P _\?Z_X5Y'171_9\?YC'ZT^QZY
M_P )9I'_ #_Q_K_A1_PEFD?\_P#'^O\ A7D=%']GQ_F#ZT^QZY_PEFD?\_\
M'^O^%'_"6:1_S_Q_K_A7D=%']GQ_F#ZT^QZY_P )9I'_ #_Q_K_A1_PEFD?\
M_P#'^O\ A7D=%']GQ_F#ZT^QZY_PEFD?\_\ '^O^%'_"6:1_S_Q_K_A7D=%'
M]GQ_F#ZT^QZY_P )9I'_ #_Q_K_A1_PEFD?\_P#'^O\ A7D=%']GQ_F#ZT^Q
MZY_PEFD?\_\ '^O^%'_"6:1_S_Q_K_A7D=%']GQ_F#ZT^QZY_P )9I'_ #_Q
M_K_A1_PEFD?\_P#'^O\ A7D=%']GQ_F#ZT^QZY_PEFD?\_\ '^O^%'_"6:1_
MS_Q_K_A7D=%']GQ_F#ZT^QZY_P )9I'_ #_Q_K_A1_PEFD?\_P#'^O\ A7D=
M%']GQ_F#ZT^QZY_PEFD?\_\ '^O^%'_"6:1_S_Q_K_A7D=%']GQ_F#ZT^QZY
M_P )9I'_ #_Q_K_A1_PEFD?\_P#'^O\ A7D=%']GQ_F#ZT^QZY_PEFD?\_\
M'^O^%'_"6:1_S_Q_K_A7D=%']GQ_F#ZT^QZY_P )9I'_ #_Q_K_A1_PEFD?\
M_P#'^O\ A7D=%']GQ_F#ZT^QZY_PEFD?\_\ '^O^%'_"6:1_S_Q_K_A7D=%'
M]GQ_F#ZT^QZC'XFTM=6N9C>Q^4\$2*W/)#2$C_QX?G5O_A+-(_Y_X_U_PKR.
MBC^SX_S!]:?8]<_X2S2/^?\ C_7_  H_X2S2/^?^/]?\*\CHH_L^/\P?6GV/
M7/\ A+-(_P"?^/\ 7_"C_A+-(_Y_X_U_PKR.BC^SX_S!]:?8]<_X2S2/^?\
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M_/\ Q_K_ (4?\)9I'_/_ !_K_A7D=%']GQ_F#ZT^QZY_PEFD?\_\?Z_X4?\
M"6:1_P _\?Z_X5Y'11_9\?Y@^M/L>N?\)9I'_/\ Q_K_ (4?\)9I'_/_ !_K
M_A7D=%']GQ_F#ZT^QZY_PEFD?\_\?Z_X4?\ "6:1_P _\?Z_X5Y'11_9\?Y@
M^M/L>N?\)9I'_/\ Q_K_ (5J13)/&LD;!T89##O7A]=+X3\6/I$@M[@E[1C_
M -\>]8U<"XQYH.YI3Q*D[25CTZBF13)/&LD;!T89##O3Z\H[@JAJ7_'YI7_7
MRW_HF2K]4-2_X_-*_P"OEO\ T3)0!?HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH0YV]1GCVO\ 88^%&M_#'X4W<WB"UDT_4=:O/M@LIEVR0Q!%5-Z_PL<,<'D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'GGCK_ );_ /7[_P"T(JX^NP\=?\M_^OW_
M -H15Q]?0X+^">3B?XA\P_\ !06UAOOA/X2MKF&.XMYO&.EQR0RJ&1U+N"K
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M?V=_C!X@\'^)/C5X>\%_#S5/B%XDD\=:E?200W45A9VT)944RW4ORAV*OM0
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M@%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM@NJ:O#;2/:63R",3RA240L2  3@9S6K17&]58Z4[.Y\&W'BKXMZ#^UA\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5_U\M_Z)DJ_5#4O^/S2O^OEO_1,E>(>D7Z*** "BBB@ HHHH **** "BBB@
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M^$3TC_GPC_7_ !H_M"/\H?57W/(Z*]<_X1/2/^?"/]?\:/\ A$](_P"?"/\
M7_&C^T(_RA]5?<\CHKUS_A$](_Y\(_U_QH_X1/2/^?"/]?\ &C^T(_RA]5?<
M\CHKUS_A$](_Y\(_U_QH_P"$3TC_ )\(_P!?\:/[0C_*'U5]SR.BO7/^$3TC
M_GPC_7_&C_A$](_Y\(_U_P :/[0C_*'U5]SR.BO7/^$3TC_GPC_7_&C_ (1/
M2/\ GPC_ %_QH_M"/\H?57W/(Z*]<_X1/2/^?"/]?\:/^$3TC_GPC_7_ !H_
MM"/\H?57W/(Z*]<_X1/2/^?"/]?\:/\ A$](_P"?"/\ 7_&C^T(_RA]5?<\C
MHKUS_A$](_Y\(_U_QH_X1/2/^?"/]?\ &C^T(_RA]5?<\CHKUS_A$](_Y\(_
MU_QH_P"$3TC_ )\(_P!?\:/[0C_*'U5]SR.BO7/^$3TC_GPC_7_&C_A$](_Y
M\(_U_P :/[0C_*'U5]SR.BO7/^$3TC_GPC_7_&C_ (1/2/\ GPC_ %_QH_M"
M/\H?57W/(Z*]<_X1/2/^?"/]?\:/^$3TC_GPC_7_ !H_M"/\H?57W/(Z*]1C
M\,Z6VK7,)LH_*2")U7G@EI 3_P".C\JM_P#")Z1_SX1_K_C1_:$?Y0^JON>1
MT5ZY_P (GI'_ #X1_K_C1_PB>D?\^$?Z_P"-']H1_E#ZJ^YY'17KG_")Z1_S
MX1_K_C1_PB>D?\^$?Z_XT?VA'^4/JK[GD=%>N?\ ")Z1_P ^$?Z_XT?\(GI'
M_/A'^O\ C1_:$?Y0^JON>1T5ZY_PB>D?\^$?Z_XT?\(GI'_/A'^O^-']H1_E
M#ZJ^YY'17KG_  B>D?\ /A'^O^-'_")Z1_SX1_K_ (T?VA'^4/JK[GD=%>N?
M\(GI'_/A'^O^-'_")Z1_SX1_K_C1_:$?Y0^JON>1T5ZY_P (GI'_ #X1_K_C
M1_PB>D?\^$?Z_P"-']H1_E#ZJ^YY'17KG_")Z1_SX1_K_C1_PB>D?\^$?Z_X
MT?VA'^4/JK[GD=%>N?\ ")Z1_P ^$?Z_XT?\(GI'_/A'^O\ C1_:$?Y0^JON
M>1T5ZY_PB>D?\^$?Z_XT?\(GI'_/A'^O^-']H1_E#ZJ^YY'17KG_  B>D?\
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M3TC_ )\(_P!?\:/^$3TC_GPC_7_&C^T(_P H?57W/(Z*]<_X1/2/^?"/]?\
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ML<:A$48"CM3Z**\H[@JAJ7_'YI7_ %\M_P"B9*OU0U+_ (_-*_Z^6_\ 1,E
M%^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"A
MK_\ R =2_P"O:3_T$T4:_P#\@'4O^O:3_P!!-% %^BBOBG_AM;QQ_P! KP__
M . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \
M_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\
M>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^
MUJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^
M*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\
MAM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;Q
MQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"
MO#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__
M (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S
M_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#Q
MZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_A
MM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ
M_P! KP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P!
MKP__ . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__
M . \_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \
M_P#\>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\
M>H ^UJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^
MUJ*^*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^
M*?\ AM;QQ_T"O#__ (#S_P#QZC_AM;QQ_P! KP__ . \_P#\>H ^UJ*^*?\
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M^:^ZWGP" $X_?=,(/UI?^&UO''_0*\/_ /@//_\ 'J /M:BOBG_AM;QQ_P!
MKP__ . \_P#\>H_X;6\<?] KP_\ ^ \__P >H ^UJ*^*?^&UO''_ $"O#_\
MX#S_ /QZC_AM;QQ_T"O#_P#X#S__ !Z@#[6HKXI_X;6\<?\ 0*\/_P#@//\
M_'J/^&UO''_0*\/_ /@//_\ 'J /M:BOBG_AM;QQ_P! KP__ . \_P#\>H_X
M;6\<?] KP_\ ^ \__P >H ^UJ*^*?^&UO''_ $"O#_\ X#S_ /QZC_AM;QQ_
MT"O#_P#X#S__ !Z@#[6HKXI_X;6\<?\ 0*\/_P#@//\ _'J/^&UO''_0*\/_
M /@//_\ 'J /M:BOBG_AM;QQ_P! KP__ . \_P#\>H_X;6\<?] KP_\ ^ \_
M_P >H ^UJ*^*?^&UO''_ $"O#_\ X#S_ /QZC_AM;QQ_T"O#_P#X#S__ !Z@
M#[6HKXI_X;6\<?\ 0*\/_P#@//\ _'J/^&UO''_0*\/_ /@//_\ 'J /M:BO
MBG_AM;QQ_P! KP__ . \_P#\>H_X;6\<?] KP_\ ^ \__P >H ^UJ*^*?^&U
MO''_ $"O#_\ X#S_ /QZC_AM;QQ_T"O#_P#X#S__ !Z@#[6HKXI_X;6\<?\
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M&R?&DD@O#I>@^;$#$H^SSXP^"<_ONOR#]:7_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
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M#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\
MX#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_
M /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ
M@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6
MHKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI
M_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&
MUO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''
M_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\
M/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\
M@//_ /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_
M /'J/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J
M/^&UO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&U
MO''_ $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_
M $"O#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O
M#_\ X#S_ /QZ@#[6HKXI_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\
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MUI?AW5M2M22!/:6,LJ''7YE4BLJ_T^ZTJ[DM;VVFL[J,X>&XC*.I]"I&11Y
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M (\XO^NC_P EJ"IV_P"/.+_KH_\ ):@H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"=?\ CSE_ZZ)_)J@J=?\ CSE_ZZ)_
M)J@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *GM_P#57/\ US'_ *&M05/;_P"JN?\ KF/_ $-: (**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -SP+_ ,CMX>_[
M"-O_ .C5HH\"_P#([>'O^PC;_P#HU:* /TZK\J:_5:ORIH *^U_AGX)\.?L]
M_"__ (3#7[<2:U);K-/,4#2H7QL@B!Z'D GN<DG &/BVU9([F)I%WQJX++G&
M1GD5]K?M?6LVH?!VSN;13):PWT$TI3H(RCJ"?;++^8JI/EI76[=OZ_KH$5S5
M$GM9L\SOOVW/$KZD7L] TJ'3\\0SF627'^^&4?\ CM<Q\<OCOIGQC\-Z-&NA
MR:9K5G.[2R,RR)Y97&U7X8Y."05&,=36[\%/B7\,M+\-Z/X?\0>#%U77I;DQ
M->OIEM.K%Y#LR[MNP 0.G&.*Z3]L/P3X>\,^&O#]QH^AZ=I,TEV\;O8VJ0EU
MV9PVT#/([UE5M&*OJKK\T.#YI/OK^IQW['O@S_A(/B1+K,J;K;1H#("?^>SY
M5/TWG\!7T=XDFT_XZ?#/QAI5CB26WGN+%.?^7B%MT;?0D*?H:Y;]GGPCJ/@[
MX#7-_IMG]IU_5HI;V"'<J%F*[8%W,0 , -R?XC5#]ESX?^.?ASJ>N6OB32&M
M--OD69)C=PRXF4X(PCDY8-UQ_"*VJ1YFZ;TLOQW_  U_ B#Y4JBZO\/^#O\
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MX)>!X_AS^U!KV@0RM-;6UA*T+O\ >\M_*=0?<!@#]*A\2?\ )[%C_P!=[?\
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MS^TU%XWO_&'A^R\6OHINI(-MHFC>:(0&?!+&0;LD@>V!7;^,?^3T=#_[8?\
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MNI"JWQ;41;NTH^]Q,"N/]T8KTW1?&WPE_9]\*W$&AZU#JLLQ\QDL[E;NXN9
M,#<R?*O'KM'7N:^(**J3;O;2Y*25KZV/;OA'\?O^$;^+NL>(M=#)IVO,PNQ"
M"WD?-F-@ ,L$'R\<X)ZGBO:M8\-_!3Q)XVC\;77BK3?MFY+A[4:K"L4KJ!M9
MXS\^>!D @''(ZY^)Z*2M%12^SL#U;OUW/<?VG/C98_$[5+'2]#=Y=$TXL_VA
ME*_:)2,;@I&0JC@9QG)]J]/^#W@GX4>!;S1?%$/CVV.L"T#26]WJUJL:O)'A
MP4P&&,G@G(QS7Q_11#W$TMV$O>:OL?9OQD\*_"KXEWESX@O?'EHFIV]B888;
M+5[78VS>R_*0S$DMV/-8W[&GA>'1_#GB#QC? 1))FVBE<8VQ1C?(V?0G _X!
M7R77T!=?M":!I_P%C\#Z%8:C;ZH]FMM/<31QB'+',[ ARQW9?'RCK25X1E*.
M[T7^?^8_CE%2VZGCOCSQ1+XT\9:QKDQ;=?7+RJ&ZJF<(OX* /PKUOX-^$OA)
MXP\$M;>*M571?$B3OON)+TVY,?&S;OS&>_;/KVKP:BG%*,>4)7E+F/MKP7)\
M&_@+9WNH:;XHM=0NIDV/.+U+RX9<Y"*D0P!G'\([9/%>&2?M"RS?'J+QU]EE
M734/V46>1YGV7:5(]-W)?&<9XSCFO&**+OF4GT"RY7'N?;'C33_@Q\:+[3O$
M.I^*[.VGBC"%1J,=J\L8)(21)!N&,GI@\]>E>>?M,?''0M=\.VW@OPE,MSI\
M;(;FYA!$.V/[D29'S $ Y''RC!/./FJBI:NK=-QIZW>^Q][_  Q\2?#OPE\-
M],TK3O%FB:4\EHDDT@U&W6<3.@WNP<GYP>S#C &,#%>=7_P1^#&J7L]Y>?$Z
M2YNIW,DLTNO63,[$Y))*<FODVBKD^:3D3%.,5&YH^([.TT[Q!JEI87'VNP@N
MI8K>XW!O,C5R%;(X.0 <CCFLZBBI6BL4PHHHIB"OKWXW>//#6K?LZVVFV/B#
M3+S43!8K]CM[N-Y@5V;@4!R,8.<CC%?(5%$O>CR^:?W"M[ZGY-?>%?97A7XM
M^ ?C3\-8?#GC:_M],U".)$G%W,( 73 $T4I^4$]<$YY(P1U^-:*=_=<6'521
M]I>&]8^$'[.^CZA>:/K\>MW]RN#Y-W'=W$N,E8QY8"H,]R![DX%>9?L^_$JT
MU#X[:]XF\1ZC9Z0-1M)F\R[G6*-29(]L89B!PJX'KMKYZHH3:ES/M;[QO;E7
MJ?3$GQ<T+PA^U1K&O/>PWN@WD"6DE]9N)D0&*+YP5SN 9 #CW],5WWBK2?@M
MJGC(^/=2\5VES>1[)VM(-31T=T VMY29D+#:OR@X..G6OBFBDM%%+=#?O-M[
M,^I_VO?''A[Q9X3\.)HVM:?J<JW32O%:7*2O&IC_ (@I.WKWKI_ /CSP!\2/
M@;9>%/$6O6NCO%:1V5S#<7:6TBM'C:Z,_!^ZK=QV-?&-%)))27=W_"P7=XM;
MH^D/ OQ(\'? GXP:MIVD7TFH^#KR""&6^1_/*3*N?,!4?.N68':._'3%=AXD
M^&/P.\;:S/KK>-+;3Y+QS/-#;:Q;QJ[L<L2D@+*23R!CZ5\?T4^BONA=7;J>
MH?'C3/ &CZSIEGX#G2ZAC@87LT<\DRM)GY3N8[2<?W>*\OHHJ8JR&W<^[-4U
M3X=?$CX5Z1X>UGQIIEE ;:U>00:I;Q3(Z(/E(?..>H(S61X1O/@Y^S]8W]_I
M?B6'5KRX38SQW<=Y<.HY$:B(!5!/<@=LGBOBJBKD[RE):7(C%1C&+U2/HKX+
M_%6RU_\ :(UGQ5KMY:Z+;7UI*D9O)UCC0 QA$W,0,[5_$@T>(?%FB2_M>6>M
M)J]C)HZSP9U!+A&@&+<*3Y@.W /&<U\ZT4H^ZXM?9*;;4T_M?\#_ "/?OVP/
M$^C^)_%VARZ/JMEJT45BRR26-PDRJWF$X)4D X[5W5KXZ\.+^R:VD'7],&K?
MV4\7V W<?G[]Y^7R\[L_A7R/14<O[J5+O_P?\QMWJ1J=O^!_D?67[._QB\*Z
MC\-Y/ WBZ]M[#RHY8%:^D$<-Q;N22N\X"L-Q&"1QC'?&]X$D^#7P:\2P0Z/K
M]OJ&J:DS1G4)KV.:.UBP6(:5<(BY4#^\21VZ?%]%:N5Y<W4A1M'EZ'TGXL\8
M:%/^UMH^LQ:Q8RZ1&80]_'<(T"XB(.9 =O!..M0?M1^+=$U[XE>$KK2]7L=2
MMK>)/.FL[A)DC_?9P2I(''-?.=%1!<G+_==RI^_S)_:27W'U5^V%XRT#Q-X7
M\/1:/K>G:K*EV\C)9723%5V$9(4G SQ5[]F7QSX<T#X-ZG9:GK^F:=>-<W#+
M;W=W'%(P,:X(5B"<^U?)UQ_JK;_KF?\ T-J@I*-E-?S?\#_(;U<7_+_P?\S[
M0_9;L))O@9J<&J1_V/I-S+<%-2BN/)D="NUY-W\&TJ0&SVZ<<K/\&?!WQ&A?
M2[;XLZYXBD"[Q:R:_#?*N.C&,#H/P^M>9?!O]IRP\%^#8_"OB;1)-3TN$.L<
MMN$=F1F+&-XW(##);G/3 QWKKK?]J;X:>%HYKGPQX%EL]09=H\NQMK,/[,\;
M,<?@:UJ6<F^EOR(A=1MUN?//Q0^'MW\+_&5YH%W.ET80LD5Q&NT2QL,JV,\'
ML1Z@]>M:OP!U2ST7XO\ AN]U"[AL;.&9S)<7$@CC0&)P"6/ Y(_.L'X@^.M0
M^(_BN]U[4MBW%P0%BCSLB0#"H,]@/S.37.5G3<E9RW+J)2ND>_?M@>)]'\3^
M+M#ET?5;+5HHK%DDDL;A)E5O,)P2I(SBO :**48\JL.4N9W/K7X<>.?#EC^R
MQ?:3<Z]IMOJIL+^,6,MW&LY9FDV@(3N).1CCG-?-OP[\93?#_P :Z3X@@C\Y
MK*;>T6<;T(*NN>Q*DBN<HK3F?M/:=2=X<GK^)]K>+KCX.?'^QL-2U/Q+;Z5>
M0)L5WO([.Y13R8V64$, 2>0".N#S6-\0/C'X(^%?PTF\'^!+N+4+N6%X(WM9
M/-2'?G?*TO1FY. "><=!7R%16<HIIQ6B8TVFI/='T-^R+\3]#\$ZEK>E:Y>Q
M:;'J BD@NK@[8MR;@59CPN0P()XX//2IOC%9^ /A_K%AXO\ !FOQ:OXCDUE;
MY[:"_CN(D3YG<?(/E4M@?,2>3BOG.BM)2;:DMU_7Z$I))I[,^T_$6M_"']HC
M1=/N]:U^/1;^V4@":\2TN(=V"R?O!M<9 Y /L>M>:?$_P)\'/!GP^U(:%KL>
MN>)'V"SD&H"X=3O7=Q#A -N[[P_7%?.]%0TNFA46TTWK8^M?A/XY\.:=^S#J
M6E7>O:;:ZH;/4$%E-=QI,6;S-H"$[CG(Q@<YJ']D'QOX=\,^"=<M]8UW3=*G
M>_\ ,2.]NXX69?*09 8C(R#TKY0HIO5M]U87V5'LV_O/0?@OJMEI/QFT"^O;
MN&SLH[UF>XGD"1H"K<ECP!R*[W]L#Q/H_B?Q=H<NCZK9:M%%8LLDEC<),JMY
MA."5) ..U> T5+5U%=O\K%N5YRG_ #?YW"BBBJ("BBB@ HHHH **** "BBB@
M HHHH G;_CSB_P"NC_R6H*G;_CSB_P"NC_R6H* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH G7_CSE_P"NB?R:H*G7_CSE
M_P"NB?R:H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "I[?_ %5S_P!<Q_Z&M05/;_ZJY_ZYC_T-: (**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -SP+_P CMX>_
M["-O_P"C5HH\"_\ ([>'O^PC;_\ HU:* /TZK\J:_5:OG_\ X8I\#_\ 05\0
M?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF
M@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6
M_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? _
M_05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\
M@1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_
MX8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\
M05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$
M'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XI
MHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&
M*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\
M0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_
M\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\
M#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0
M?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF
M@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6
M_P"&*? __05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? _
M_05\0?\ @1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\
M@1!_\9H_X8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_
MX8I\#_\ 05\0?^!$'_QF@#XIHK[6_P"&*? __05\0?\ @1!_\9H_X8I\#_\
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M&*? _P#T%?$'_@1!_P#&:/\ ABGP/_T%?$'_ ($0?_&: /BFBOM;_ABGP/\
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M_H*^(/\ P(@_^,T?\,4^!_\ H*^(/_ B#_XS0!\4T5]K?\,4^!_^@KX@_P#
MB#_XS1_PQ3X'_P"@KX@_\"(/_C- 'Q34]O\ ZJY_ZYC_ -#6OL__ (8I\#_]
M!7Q!_P"!$'_QFH+C]C;P7:S6L2:IKQ6YD,3[KB#( 1GX_<]<H/UH ^,**^UO
M^&*? _\ T%?$'_@1!_\ &:/^&*? _P#T%?$'_@1!_P#&: /BFBOM;_ABGP/_
M -!7Q!_X$0?_ !FC_ABGP/\ ]!7Q!_X$0?\ QF@#XIHK[6_X8I\#_P#05\0?
M^!$'_P 9H_X8I\#_ /05\0?^!$'_ ,9H ^*:*^UO^&*? _\ T%?$'_@1!_\
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M^!$'_P 9H_X8I\#_ /05\0?^!$'_ ,9H ^*:*^UO^&*? _\ T%?$'_@1!_\
M&:/^&*? _P#T%?$'_@1!_P#&: /BFBOM;_ABGP/_ -!7Q!_X$0?_ !FC_ABG
MP/\ ]!7Q!_X$0?\ QF@#XIHK[6_X8I\#_P#05\0?^!$'_P 9H_X8I\#_ /05
M\0?^!$'_ ,9H ^*:*^UO^&*? _\ T%?$'_@1!_\ &:/^&*? _P#T%?$'_@1!
M_P#&: /BFBOM;_ABGP/_ -!7Q!_X$0?_ !FC_ABGP/\ ]!7Q!_X$0?\ QF@#
MXIHK[6_X8I\#_P#05\0?^!$'_P 9H_X8I\#_ /05\0?^!$'_ ,9H ^*:*^UO
M^&*? _\ T%?$'_@1!_\ &:/^&*? _P#T%?$'_@1!_P#&: /BFBOM;_ABGP/_
M -!7Q!_X$0?_ !FC_ABGP/\ ]!7Q!_X$0?\ QF@#XIHK[6_X8I\#_P#05\0?
M^!$'_P 9H_X8I\#_ /05\0?^!$'_ ,9H ^*:*^UO^&*? _\ T%?$'_@1!_\
M&:/^&*? _P#T%?$'_@1!_P#&: /D7P+_ ,CMX>_["-O_ .C5HKZ[7]D/P=X:
M8:O:ZEKDESIY^UQ+-/"4+Q_, P$0.,@9P110![_1110 4444 %%%% !1110
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MO^^J/^$HU;_G_F_[ZK+HH]C2_E7W![2?\S-3_A*-6_Y_YO\ OJC_ (2C5O\
MG_F_[ZK+HH]C2_E7W![2?\S-3_A*-6_Y_P";_OJC_A*-6_Y_YO\ OJLNBCV-
M+^5?<'M)_P S-3_A*-6_Y_YO^^J/^$HU;_G_ )O^^JRZ*/8TOY5]P>TG_,S4
M_P"$HU;_ )_YO^^J/^$HU;_G_F_[ZK+HH]C2_E7W![2?\S-3_A*-6_Y_YO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO+^MCW6BO"/V9_VK_"_Q]T'1K%=2C;QRVF+?:IIMKIUW#! PVB0))(NP@,P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&O_P#(
M!U+_ *]I/_0311K_ /R =2_Z]I/_ $$T4 7Z*** ([B!+JWEAD&Z.12C#U!&
M#7Y^?#OQ)KO["GQ&\3Z9XH\.:CJ7@W59%\C4K&,$,$+&-T+84G:Y#(6!!_7]
M!Z*TIS]FV]TU9DSCSQ2?1W1\!?%SXE:]^V]J6@^$? /AC5+/PY;W0N;O5-2C
M"JCX*[G*ED555G(&XLQ/ XY]C_;"^#L-]^S+;V6F1--+X0CMYK;"_.88T$4G
M3_8.X_[E?35%5*I[JC!6L[_,F,?>YYN^EOEU/@S]B\:G\:OCEJ/Q"UU#)_8.
MDV]A"YY7SC$L((]RB2L?0O7GWBQ?#OA/]H;Q[)\:_"FO>*)+RYD?28[*5XUE
M!<^400Z$ILV ;2=N"-I[?II16KQ%ZBFE9)-??KOWN9QHV@X-[M/[M+>A\)?L
M%6;6?BWXM0_V5-H@$$>S3;C<9+52TQ6)BWS$J"!D\G'-=7_P3;4KX%\9Y&/^
M)LO_ **%?85%$J_-S:;I+[G<I4[6UV;?WJQ\;!3_ ,/)@<'']FD]/^G$UXIX
ML7P[X3_:&\>R?&OPIKWBB2\N9'TF.RE>-907/E$$.A*;-@&TG;@C:>WZ:45G
M"KR<NFT7'[W>_D.4.927=I_<DCX2_8*LVL_%OQ:A_LJ;1 ((]FFW&XR6JEIB
ML3%OF)4$#)Y..:ZO_@FVI7P+XSR,?\39?_10K["HK25?FYM-TE]SN)4[6UV;
M?WJQ\:_\$_5*^)OBYD$?\3&$<C_;N*^RJ**PG/GMY)+[E8N,>5R\VW]X4445
MF6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYXZ_Y;_P#7
M[_[0BKCZ[#QU_P M_P#K]_\ :$5<?7T."_@GDXG^(?+G_!0ZWN;KX.^&(+.Z
M^PW<GB[3$ANO+$GDN6<*^T\-@X.#P<5>?]DGQ-X^U;2I/B]\7-1^)&BZ9<K>
M0:%#HUOI-I+*OW3.L1/F@>AQWYP2#ZY\7O@_HWQHT+3-)URYOK:VT_4[?5HF
ML)$1VEA)**Q9&&TYY  /N*[FM:=%*<YRZRNODHK;:]T9RJ-J,8]K?C+KOLSY
M+_:G\)Z/XT_:F_9TT;7-.@U/2IIM5>2SN%W12;(8W4,O0@,JG!X.,'(J]^UQ
MI=IIGQ8_9WUFTMX[;4XO%T6GI<1(%86\B_-%D?P\=.G)]:]K\8?!W1?&WQ(\
M$^-KZYOHM5\)-<M8PV\B+!)Y\81_-!0L< <;67GKFE^)7P>T7XI:MX.U#5KF
M^@F\+:LFL62V<B*LDR @+)N1LIST4J?>G&FTH]U44OES)_DG^03FI;?R./SM
M+_-'G'Q,^+VM1_'6'P!\.?!FBZQX]71?[0O->UZ<VUM8VADPB%D1I9,N<[5P
M!N!YYQYC\%?^$VL_V^/$L7CF/PU;:Y>>"$N+E/"C3FUE"W4:QNYF ;S N0>V
M-M>Z?%;]FGPY\5/%5CXI_MCQ%X0\5VEO]C77/"NHFSNI+?);R7)5E9<DG[N?
M>JWPQ_95\'_"?XB3>-](O=<O/$%UIC:;>7.K:@;MKS=(LC3RLZ[S*2BKD,%
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M0!9%^8]@23ZU^CM>=?&G]G_P/^T!H,6E^,]'6_%N6:UO(7,5S;,1@F.0<@'
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MK31R2[RB)@%(T&W"#MGKS5/#^TK<T_A]G&/JUNGY![;EA:._,W]^WS/'[/\
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MY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKN/!_@_=LO;U..L<3=_<UA6K1HQO(UITW4=D'@_P?NV7MZG'
M6.)N_N:[KIP*.G I:^;J5)59<TCV(04%9%";_D/6?_7M/_Z%%5^J$W_(>L_^
MO:?_ -"BJ_6184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 50U+_C\TK_KY;_T3)5^J&I?\?FE?]?+?^B9* +]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7_ /D
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MCZS6_F#V-/L<7_PK.W_Y_I/^^!1_PK.W_P"?Z3_O@5VE%'UFM_,'L:?8XO\
MX5G;_P#/])_WP*/^%9V__/\ 2?\ ? KM**/K-;^8/8T^QQ?_  K.W_Y_I/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:_\
M\@'4O^O:3_T$T4:__P @'4O^O:3_ -!-% %^BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH H:;_Q^:K_U\K_Z)CJ_5#3?^/S5?^OE?_1,=7Z "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** *$/_ "'KS_KV@_\ 0I:OU0A_Y#UY_P!>T'_H4M7Z "BBB@ HHHH
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M[5/^?.T_\"V_^-T>=JG_ #YVG_@6W_QNK]% %#SM4_Y\[3_P+;_XW1YVJ?\
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M[5/^?.T_\"V_^-T>=JG_ #YVG_@6W_QNK]% %#SM4_Y\[3_P+;_XW1YVJ?\
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MT>=JG_/G:?\ @6W_ ,;J_10!0\[5/^?.T_\  MO_ (W1YVJ?\^=I_P"!;?\
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MV_\ C='G:I_SYVG_ (%M_P#&ZOT4 4/.U3_GSM/_  +;_P"-T>=JG_/G:?\
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M=U^I]"T5X#XB^,7Q$\9?%CQ+X'^%^E^&XSX7C@.JZKXJ>X,;23*62.*.'#=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sellas-logoa05.jpg
<TEXT>
begin 644 sellas-logoa05.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "L @D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZP_X*Y_\
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MAMJECI=PH>*[UF:'2UD4]&5)V61E/4,JD$=Z]%_XAZOVFO\ H6_#O_@_MO\
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M/_G^O_ 9?_(GI_ZBYY_SX?\ X%'_ .2/RAHK]7O^(6;7_P#HLFC_ /A.2?\
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MOB/_ -"%?UP5[_BKOAO^W_\ VP^?\*=L5_VY_P"WA1117Y&?KP4444 %%%%
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M=AX8\8:?'XAL+.(8CL#)))'- @[*)8F95'"K(JCI7]%=?B1_P=!?\G5?#O\
M[%0_^EDU??>'&*J0S;V47[LHNZ]%=?=_F?G_ (D86G4RGVLE[T)*S]79_?\
MHC\X_AUXYOOAC\0="\2:9(T.I>']0M]2M7!P4EAD61#GV917]6W_  L33?[T
MW_?%?R85_4A7TWB=0A-X:3W]_P#]M/F?"^O.*Q,5M[G_ +<>M3PK<P/&V[;(
MI4X8J<'T(Y'U%?/LO_!*#]G&>5G?X/\ @UW<EF9K4DL3U).ZL&3_ (+2_LOQ
M2,K?%K1]RG!Q87I'YB&FK_P6G_9?9@/^%M:/SQSI]Z/_ &C7YQA\OSFA?V%*
MK&^]HS5_N1^D8C,<EKV]O5I2MM>4';[V;W_#IO\ 9O\ ^B.^"_\ P$/^->X>
M!/ FC?#'P=IOA_P]IEGHVB:/ MM965I$(X;:->BJH_R3DGFOG?\ X?.?LP_]
M%<T/_P !+O\ ^,T?\/G/V8?^BN:'_P" EW_\9IU\#G5=<M:G5DO-3?YH,/CL
MEH/FH5*46^S@OR9]/45\P_\ #YS]F'_HKFA_^ EW_P#&:/\ A\Y^S#_T5S0_
M_ 2[_P#C-<O]AYC_ - \_P#P"7^1U?VYEO\ T$0_\#C_ )GT]17S#_P^<_9A
M_P"BN:'_ . EW_\ &:/^'SG[,/\ T5S0_P#P$N__ (S1_8>8_P#0//\ \ E_
MD']N9;_T$0_\#C_F?3U%>"_"+_@I_P# 7X\_$73/"7A'XCZ3K?B+6&=+.RAM
MKE7G*(TC %HPO"(QY(Z5[U7'B,+7P\N2O!Q>]FFG;YG9A\70Q$>>A-26UTTU
M?Y!7\V__  6H_P"4H'Q:_P"PA;?^D-O7])%?S;_\%J/^4H'Q:_["%M_Z0V]?
MH7A?_P C*K_@?_I43\\\4?\ D6TO^OB_])D<W_P2J_Y2-?!O_L9[7_T*OZ;*
M_E]_X)R^.]'^&/[=/PL\0>(-1M=(T72/$-O<WM[<OLAMHU/+L>P%?T _\/5_
MV<?^BR>!?_!@*[O$K!8BMC:4J-.4ER]$WU?8X?#/'8>A@JL:U2,7S]6ET7<^
M@:*^?O\ AZO^SC_T63P+_P"# 4?\/5_V<?\ HLG@7_P8"OS?^R<=_P ^9_\
M@+_R/TG^U\#_ ,_H?^!1_P SZ!HKY^_X>K_LX_\ 19/ O_@P%'_#U?\ 9Q_Z
M+)X%_P#!@*/[)QW_ #YG_P" O_(/[7P/_/Z'_@4?\SZ!HKY^_P"'J_[./_19
M/ O_ (,!1_P]7_9Q_P"BR>!?_!@*/[)QW_/F?_@+_P @_M? _P#/Z'_@4?\
M,^@:***\\] ^+?\ @X$_Y1?^-/\ L(:7_P"ET-?SRU_0U_P<"?\ *+_QI_V$
M-+_]+H:_GEK]X\,_^13+_&__ $F)^">)W_(VC_U[7_I4C]Y/^#:C_E'QJW_8
MYWW_ *36=?H17Y2?\$#_ -M[X1_L[?L3:EH/CCX@^&?"^LR^*KR\2SO[H12M
M"UO:JKX_NDHPS_LFOMK_ (>K_LX_]%D\"_\ @P%?FO%&6XR>;8B<*4FG)V:B
MVOR/TSA?,\'3RG#PG5BFHJZ<DG^9] T5\_?\/5_V<?\ HLG@7_P8"C_AZO\
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M:I[*S^9Q\$\&X/'8%XO'Q;YG:.K6BT;T:W=U\C\8/^(7#QM_T5?PM_X*I_\
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M?#%E7J(_$5K(WY*Y/Z4O[-QG_/J7_@+_ ,A_VG@_^?L?_ E_F>W5\M_MX_\
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M.UU=>JFO'J_J7_:L_8I^&O[:O@Z+1?B)X9M=:CM"S65VK-!>Z>S=3%,A#KG
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MTMQI_BKXE:3;R,6%JE]:31Q>RE[<MC_>+'WK/_XA@_@Y_P!#Y\3/^_\ 8_\
MR/7[)'Q$R9J_-+_P%GXQ+PYSI.W+'_P)'X>T5^X7_$,'\'/^A\^)G_?^Q_\
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M8J2OPC,,;/%XJIBJF\VW]_3Y;'[UEV!A@\+3PM/:"2^[K\]PHHHKC.P****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[]LSQ]\$/V(K[XW?$KQ-XD\;77B#6DT/PIH<^IO9V\H0L9[AVC7<?]7,HR"
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M#*2I!/IU<E:C4HU'2JIJ2=FGNF=="O3K4U5I-2C)736S045\[^$/V\W\5?\
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=T]_)GK8O!TL33]E65U=/MK%IK;S2"BBBN4ZC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>wt1cancersa01.jpg
<TEXT>
begin 644 wt1cancersa01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'C K # 2(  A$! Q$!_\0
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M)976.*-2SNQP% &22?2@!]%5K?4K2\D\N"ZAF?YOECD#'Y6VMT]&X/H>*LT
M%%%% !14%G>V^HVR7%I/%=6\G*2PN'1N<<$<&G7%U#:1AYY4A0LJ!I&"@LQ
M4<]R2 /<T 2T5BV?C3P_J'B&YT&UUO3[C7+5=\^FQ72-<1+QRT8.X#D=1WK3
MCOK:99VCN(G6!BDK*X(C8#)#>A /0T 3T5%;7,-Y;Q7%O*D\$J"2.6-@RNI&
M0P(X(([U+0 45#=7EO8K&UQ/';K)(L2&5PH9V.%49ZDG@#O3YIH[:&26:18H
MHU+/(Y 55 R22>@H ?12*P900<@\@BEH **** "BBB@ HHHH **** "BBB@
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M.C,L\XDN/-'F89V1I8PP P"AZ@YN>%O@#=>&_!/CC0&U^:\/B&20I<32W!9
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MDKR3P3QTH \T\4? _4-8L_A_#8Z['8S>%[>.W^T-"[;MJQJ71-X7<1&0-P.
MQP>N>?\ #_[+\\5M:Q>(?$1UU+>X:>.*03%4#RP/(H)E)^=8I%.?^>S#ID'W
MZB@#Y[TO]FO6FO99+WQ.8#!););W<".UQ*D45N S,SD+M:%V1<95G+9.<4GA
M+]F;5?"%[H-XFOQ7W]FQ7"26\WGR"59 _P"[4R2L%#E@6;&>#C@U]"T4 9WA
MS2WT/P]I>G23?:)+.UBMVF_OE$"EOQQFM&BB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"+[5#]H,'G1
M^>$\PQ[AN"YQNQZ9'6JG_"0Z5_9[7W]IV?V)6V&Y\]/+#9QC=G&<UY9XN\,W
MFI>,/%2:3HU];S:KHCV)U-E CDGW$@%RV0NWY0<8&352/PS>_P#"41^(AX8N
MHO#T<T8?0A%&96<6KQ>>(MVTX+*G7) W=J /9?[2M [H;J$.B"1E\P9"GHQY
MZ'UJS7B-C\.];T70]& MY);FTM4DN8L+,I;> D*C(+[%5,@MM_=C'4U[/9//
M)9P/<QK%<-&IEC4Y"MCD ^F: )Z8T,<DD<C1JTD>=C%02N1@X/:O.?VA?%^L
M?#OX+^,?$FC72PZGI]BTML[Q*X1\@ X(P<9[Y%?FG_P\#^-__0U0?^"JT_\
MC5>Q@\KKXVFZE-JU[:W\O+S/(Q>9T<%45.HG=J^G_#GZZT5^1?\ P\"^-_\
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M*/)F_P"?@_\ ? H L457\F;_ )^#_P!\"CR9O^?@_P#? H L457\F;_GX/\
MWP*/)F_Y^#_WP* +%%5_)F_Y^#_WP*/)F_Y^#_WP* +%%5_)F_Y^#_WP*/)F
M_P"?@_\ ? H L457\F;_ )^#_P!\"CR9O^?@_P#? H L457\F;_GX/\ WP*D
MB1TSOD\STX Q0!)1112 **** "BBB@ HHHH **** "BBB@#Q_P#:\_Y-I^(/
M_8,;_P!"6OQ>K]HOVN_^3:?B%_V#&_\ 0EK\7:_0>'_]TE_B?Y1/@<__ -ZC
M_A7YL6OVX_9M_P"3??AQ_P!B_8_^B$K\1Z_;C]FW_DWWX<?]B_8_^B$K#B'^
M#3]?T-N'_P"+/T_4Y#]IKXT>(?A+-H*Z&+0B]68R_:8B_P!TIC'(_O&O#O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9K^(7_8+?^8K\6U^Z*_0.'_]TE_B?Y(^"S__ 'J/^%?FQ:_;/]G'[1_PS_\
M#C;Y>/\ A'['KG_G@E?B97[<_LW?\F^_#C_L7K'_ -$)6/$/\&GZ_H:\/_Q9
M^GZGC'[;2NTWA3S-N=EQ]W/K'7R[Y=?57[;"[IO"W^Y<?SCKY=\NOU#A67_"
M/0_[>_\ 2F?*Y\O^%&K\O_24>B_LVJ1\:/#9 Y\U_P#T6]??@^T\9\K]:^"O
MV;U_XO+X=/\ TU?_ -%O7WY7YYQR[YA3_P "_.1]?PLK82?^+]$?F[\7D/\
MPL_Q1G&?[1N.G_71JY#97;?%Y/\ BYWBC_L(S_\ HQJY';7['@I?[+2_PK\D
M?G.(C^_GZO\ ,^NOV+5E7P3KOE[/^/\ 7[V?^>8_^M7H/[1 G/P9\3!_+V^3
M']W.?]:E<+^Q:NWP5KO_ %_+_P"BQ7H7[0_/P:\2C_IE'_Z-2OP_,7_QDU_^
MGD/_ &T_3\'_ ,B/_MR7ZGYW>73EC^8?6I_+IRQ_,/K7[_S'Y-RGZ,_"?S_^
M%8^%-GEX_LRW^]G^X*^,_P#@JEYGV7X<>9MSNO\ [N?^F%?:?PF_Y)CX6_[!
ML'_H KXP_P""JW_'K\./]^__ )05_-N#_P"1O+_%+]3]@Q__ "*_E']#\^J]
MK_8OS_PT]X!Q_P _K?\ HIZ\4KVO]B__ ).>\!?]?C_^BGK[3%?[O4_PO\CX
MG"_[Q3_Q+\S]CO\ 2?\ IE^M?FY\9%<?%7Q9DX/]IW&=O3_6M7Z55^;OQEC_
M .+J>+/^PG<?^C&KEX"=L56_PK\SWN+%>A2]?T.$^;^\?SK[(_8E\W_A"-?V
M;2?MZ_?S_P \Q7R!Y=?8_P"Q,NWP3KW_ %_+_P"@"OM>,I7R>IZQ_,^:X<5L
MQAZ/\CW;7M>A\,Z3<:GJES!:6%N 99F#$*"0!P!GJ17#?\-'> /^AIL?^_,W
M_P 15G]HH;O@OXG'_3!/_1J5^=/EU\!PUPWA<ZPTZ]><HM2MI;LGU3[GUN=9
MUB,MKQI4HIIJ^M^[[-=C]#O^&C? '_0TV/\ WYF_^(KO=)U4:YIMKJ%A-!<V
M5U&LL,RA@'0C((S[5^6RQ_,/K7Z5?!T;?A5X2'_4,@_] %9\3<.X;):-.I0G
M*3D[:V[>21>29Q7S*K.%6*22OI?]6S?72T2Z:Y6SLEN&!#3"+YSGKDXS20Z2
MMOJ$]_';VR7DT:0R3 '<40L57V +-Q[UYO\ 'GXZ2_!@Z-Y>D)J@U 2D[IS'
MLV;/]DYSO_2O)/\ ANFX_P"A2B_\#3_\17AX/AS,\?0CB</2O"6SO%;.W5]S
MU,3G6!PE5T:T[27D_7L?47]C0^0T/V&Q\EI#*8_)&TN>K8QU]ZM0PS6\:1QI
M!'$@PJ(" !Z =J^>_AG^UM/\0?'.D^'V\-QV:WTC(9UNBY3"ELXVC/3UKZ.K
MS<PRW%9745+%PY9-7W3TVZ-G;@\=0Q\'4P\KI.VS7YGC4_PP^(*6OBN/3_%&
MB:7+KNI)>&:VT^820Q")(GC1O.^5F2-<2#E2S$#IC;\'^ =7\/VM[*(='M;Z
MWLH]*TJ&..1K2WMXP"3LW;OGD))!8G")DDBNLNO'WABQN9;>Y\1Z3;W$3%)(
MI;Z)71AU!!;(-1?\+(\)?]#1HO\ X,(?_BJXUAJ[5U3?W,Z/;4E]M?>CRF/]
MFW5+[PSX6L]0\7S6VI>'S;QPS:7%LMY(8[F.<YBDWD2/Y84N&Z <=C[E_I/_
M $R_6J^DZ_IGB"*232]1M-2CC.UWM)UE"GT)4G!J_6,HR@^62LS6,E)7B[H\
MY\._&K2O$GC#7_#T*BUN-%,PN)[F>)5;RF"R%4#E]H)^\5 ]<9&:>F?'[1-7
M\7Z9X<MHI1?WT4<O[YHXO*\Q#)&I1G#L60!OE!P&&>^+7B7X*VOB/6/M\^LZ
MC,&>1!:W+JT4$$S*;F.+"AAY@0)EF;:I8 #-7-2^#.@:GXT3Q&SW<$OVBVO)
M[*%U6WN+BW4K;RN-N[**< *P!VKD'%24=I_I7_3']:/]*_Z8_K5BHKJYBL[>
M6XGD6&")#)))(<*B@9))[ "@!G^E?],?UH_TK_IC^M<SI_Q6\,:GX1TWQ-!J
M/_$FU'?]FF>&16?8'+_(5W# B<G(Z+5_P7XVTSQ]H_\ :>D&X:S+[%>XMGA+
M< Y < D<T :_^E?],?UH_P!*_P"F/ZT^ZNH;*WDN+B6.""-2SRRL%50.I)/
M%5TUK3Y)+5$O[5GNEWVZK,I,RXSE!GYA]* )?]*_Z8_K1_I7_3']:9=:M96+
M*+F\M[<M((E$LJKER,A1D]2.U.CU*SFOI;*.Z@>\A4/);K(#(BGH2N<@'WH
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MJ!CF@#A=4_:6FT>\U72[CPV6URVU*#3(+6">6199)(YI<<0^8=J0-DQHZL2
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MQ @R8QN/OCCZ<=*Z&B@#.NO#NF7L3Q3V%O+&ZHC*T8P50DH/H,G ]ZT% 4
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M 5\7?\%5_P#CS^&__72__E!7VE\+^/ASX:_[!\/_ * *^+?^"J__ !Y_#?\
MZZ7_ /*"OY\P7_(V?^*7ZGZIF'_(K^4?T/SYKVO]B_\ Y.>\!?\ 7X__ **>
MO%*]K_8O_P"3GO 7_7X__HIZ^VQ7^[U/\+_(^(PO^\4_\2_,_96OST^+R_\
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MSA^-48;XL>+#_P!1*X_]&-7Y/P$_]KK?X?U/O^+%?#TO\7Z'"_:9_P#GL_\
MWU7V+^Q$[R>$?$)=F8_;(^IS_ :^/_)%?87[$J[?"/B'_K\3_P! -?;<8M?V
M/4]8_FCYCAU?\*,/1_DSU#]H#QQJ7PU^#/BSQ/H_D_VGIEF9X/M";X]P8#D9
M&>OK7YV?\/*/B[_=T'_P ;_XNOO/]K[_ )-G^(?_ &#&_P#0EK\8*_+<DPM"
MOAY2JP3=^OHCZW.L57H5XQI3:5NGJSZK_P"'E'Q=_NZ#_P" #?\ Q=?I/\(_
M$][XU^%OA+7]2\O^T-3TNVO+CR5VIYCQJS;1DX&3ZU^%E?M]^SM_R07X>?\
M8!LO_1*U.>86A0HPE2@D[]/0O),36KU9JK-M6Z^ISO[1'QNU/X.+HC:=86E\
M+[SO,^U;OEV;,8VD?WC^5>,?\-P^)?\ H :5_P"1?_BZZ3]N1=T'A+ZW/_M*
MOE#RJ^_X;R/+<9E=*OB**E)WN]?YFNY\]G6:8W#X^I2HU6HJVFG9>1]:_"W]
MK'7_ ![X^T?0;G1].M[>]E,;R1>9N4;2>,L1VKZBK\\/V<X]OQH\+G_IX/\
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M5?*<3AZ;JU$K+S.6AFN&Q%14H-W?D?3]%%%>.>P%%%% !1110 4444 %%%%
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M_1'5Q(O]JA_A_5D"1_,OUK] /A;=1Q?#?PRK,0?[/A_A/]T5\#I'\R_6OO\
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MB#PIL.<?:>Q'_/*OECRZ^L/VUEW0>%?K<_\ M*OEGR_:OTKA27_"/1_[>_\
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M'_OD_P"%6** *_VZ'^\?^^3_ (5)%,DV2ASCKP14E% !1112 **** "BBB@
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M)=+Y_P#I3/'SC_?JGR_)'=_ 5?\ BZFA_P#71_\ T!J^U:^+_@.H7XI:&?\
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M_P"1K\Y?J?I.8?\ (L^4?S1^?->U_L7_ /)SW@+_ *_'_P#13UXI7M?[%_\
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M_P C]/\ O3_*1^F9G_R*7Z1_-'R_LKT+]G],?%[PX?\ INW_ * U<+Y=>@_
M-=OQ;\.G'_+=O_0&K]@S*7^PU_\ #+\F?GF#C_M-+_$OS1]U5^?7Q@3_ (N?
MXG_[",__ *,:OT!^T1?\]$_[Z%? GQ<4-\3/$Q'(.H3\C_KHU?F/!+MBJO\
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M%SPX3Q^_/_H+5]U_:(O^>B?]]"OA.-G?'4_\'ZL^IX9TPL_\7Z(_/[XS1_\
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MZH7Z#%.HH **** "BBB@ HHHH **** *>L:M;Z%I=UJ%V6%M;1F238I9L#T
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M7VO\.[6*3P'X?+*2?L47\1_NBLN+G^XI>K_(TX?5JT_3]3R3]K!=P\.?2?\
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MF;N3_P \Z_%\H?\ PNI_WI_E(_2,P_Y%3](_FCYI\NN]^!:8^*F@''_+8_\
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MY-H^(O\ V")?Z5^+M?+\/_[O/_%^B.OB#_>(?X?U8C?=-?N%^S]_R0GX>?\
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MZ\8O_017E/[5Z[K7P_\ 6;_VG7J_POX^'?AT?].,7_H(KRO]JI=UKH'UF_\
M:=?CF4_\CQ?XI?DS]$S#_D5OTC^:/G#RZ[GX(ICXH:$?^FQ_]!-<;MKN/@HN
M/B=H9_Z:G_T$U^IYA+_8ZW^&7Y'PN%7^T4_\2_,^S*_#+XU?\EB\=?\ 8=OO
M_2AZ_<VOPR^-7_)8O'7_ &';[_TH>ORSAW^)4]$?7<0_!3]6<97WE_P2J_Y#
MGQ$_Z]K+_P!#FKX-K[R_X)5?\ASXB?\ 7M9?^AS5]!F_^XU/E^:/ RG_ 'VG
M\_R9^AU%%%?F)^F!1110 4444 %%%% !1110 4444 %%%% !1110!F>);&^U
M/0;^TTR]73K^:)HXKID+B(GC=@$<X]Z\IT+X=^(_"MQ%>G3-/U)+2_O3!I]G
M)Y0,,\4:+)F1B,@H003G#L>37M-% 'CUK\+]:T'3-%6QVR7>FVD"N5E!66<*
M%)17^4!-JGGKQW6O78?,\F/S=OF[1OV=-V.<>U244 >3?M3PE?V=?B,WF.1_
M8MP=I(Q]VOQ77[H^E?M;^U1_R;C\1O\ L"W'_H!K\4E^Z/I7WO#_ /N\_P#%
M^B/@^(/]XA_A_5BU^V?[.-NS?L__  X/G2+_ ,4]8\ C_G@GM7XF5^W/[-W_
M ";[\./^Q>L?_1"5'$/\&GZ_H:</_P 6?I^IQO[2T91M#!=G^67EL>J5X9MK
MW?\ :8&6T/\ W9?YI7A>VOI\@?\ PG4_G^;./-%_MD_E^2.T^"Z_\7(T?G'S
MMT_W&KZM%JPQ^_E/XC_"OE7X+C_BX^D?[[?^@-7UE7R'%'^]P_P_JSZ'(_\
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M=_B5/1'U/$'P4_5G&5]Q?\$JRTGC7XEQ[V5?[.T\C:>A\VXKX=K[B_X)3_\
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M)9E_9K^(V^16']CS<!<>GO7XP5\_P_\ [O/U_1&O$'^\0_P_JQ&^Z?I7[A_
M'_DA?P\_[%ZP_P#2=*_#QONGZ5^WWP%28_ WX>;)%4?\(]I_!7/_ "[I[U'$
M/\*GZ_H:</\ \6?I^IQW[3HS#H/_ &V_G'7@>RO?/VEED\G0M[J_^NZ+CNGO
M7A.VOI^'W_PG4_G^;./-E_MD_E^2.N^#JX^(^B_]=?\ V4U]>5\C_!]3_P +
M%T7& ?-]/8U]8>7<_P#/9/\ OW_]>ODN*=<7#_#^K/H,B_@2]?T1\@_%!?\
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M_P#Y&B]9?DS[;,O^1:_2/YH_/:O:_P!B_P#Y.>\!?]?C_P#HIZ\4KVO]B_\
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MK]G#_DW_ .''_8O6/_HA*\_B'^%3]?T/0X?_ (L_3]3S;]LB/S-/\-^SS_\
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M4$'KD4Z@#RC]J1I?^&=OB."BA/[$N<'=S]P^U?BHGW5^E?M?^U-_R;G\1O\
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M;Z0=K+_K/O#'=:_+LM_Y&R]9?J?;8W_D7_)?H>'[:['X1_\ )0-)_P"NA_\
M037(UV'PE_Y'_2?^NA_]!-?HF._W6K_A?Y'R.&_CP]5^9]35\D_$8?\ %;ZU
M_P!?<O\ Z&U?5WVL?\\IO^^#7RG\0FW^--8;!&;J4X(P?OM7Q'#/\>IZ?J?3
M9U_"AZG-;:]__9W_ .1?U+_KLO\ (UX'7O7[/LOE>']1^5V_?+]U<]C7T6?_
M .X2]5^9X^5?[U'Y_D'[6W_)M/Q'_P"P/-_*OQ;K]H/VLK@2?LU_$<;)%_XD
MTWWE(["OQ?KR.'_X$_7]$'$'^\0]/U8C?=/TK]Q?@'_R0SX>?]B]I_\ Z3QU
M^'3?=/TK]P/@/<"/X'?#P;)&_P"*=T_[JD_\NZ5'$/\ "I^K_(KA_P#C5/3]
M3F/VCAF'1?\ MM_-*\.VU[?^T1()8=%^5E_UWWEQW2O$Z][(O^1?3^?YLSS3
M_>Y_+\D=9\)1_P 7 TC_ *Z_T-?55?*_PG^7Q]I'!_UO;Z&OJ#[8/^>4W_?!
MKY;B7_>H?X?U9[F2_P &7K^B/E3XE+_Q7&K_ /7Q)_Z$:YG;74?$CYO&VKG_
M *>'Z_[QKFJ^]PO^[T_1?D?*UOXLO5_F>^?L[_\ (NZC_P!=E_D:[+XF_P#(
MBZO_ -<U_P#0UKB_V?9!%X=U [6;]^OW5SV-=A\2+@2>!]6&R1?W:_>4C^-:
M_-\9_P C=_XH_H?88;_D7?\ ;K_4^4L4JK\P^M.Q0J_,*_4[GQ!]:_#W_D1]
M#_Z](_Y5YS^T;_QZZ/\ 67^:5Z#X!N!'X)T,>7(?]$C^ZA/:O/?VAI/.M='P
MK+S+]X8[I7Y=EO\ R-U_BE^I]OC/^1?\E^AX=MKL/A&,?$#2?^NA_D:Y+%=?
M\)?E\?:3_P!=/Z5^B8W_ '6K_A?Y'R&'_C0]5^9]3U^&7QJ_Y+%XZ_[#M]_Z
M4/7[C+=!B!Y4HSZH:_#CXT<_&'QR?^H[??\ I0]?"<._Q*GHCW>(/@I^K.-K
M[R_X)5?\ASXB?]>UE_Z'-7P;7W?_ ,$KI/+UKXB':S?Z-9?=&?XYJ]_-O]QJ
M?+\T>!E/^^T_G^3.K_X*H?\ (F^ _P#K^N?_ $".OSEK]%_^"IDHD\&> SM9
M?].NOO+C^".OSHK/)?\ <H?/\V:9Q_OL_E^2"OVZ_9P_Y-_^''_8O6/_ *(2
MOQ%K]M/V<[@1_ 'X<#RY&_XIZQY5"1_J$KS^(?X5/U_0]#A_^+/T_4YW]II=
MUCHO^]+_ .R5\_>57T'^T>PFT_1_E9<-)]Y<?W*\'\NOI.'Y6RZFO7\V<N;*
M^,G\OR1U'P?C"_$31C_TV_I7UY7R7\(TV_$'1S_TV%?6$4PE!(5EQ_>7%?*<
M4.^*A_A_5GO9&K4)>OZ(DHHHKXP^D"BBB@ HHHH **** (KFW2\MY8)0QCD4
MHVUBIP?0CD?A7,1_"OPO#IIL%TP_9?.:X"FYE)5VSN*L7W+NW-G!YR<YKK**
M ,:Z\'Z->0F&33XO+\N.$*N5VI'G8JX(V@9/ ]:UT18T5$4*JC 4#  ]*=10
M!Y;^U)_R;G\1O^P)<_\ H!K\3T^ZOTK]L/VI/^3<_B-_V!+K_P! -?B>GW5^
ME?></_P)^OZ(^$X@_P!XAZ?JQU?MS^S=_P F^_#C_L7K'_T0E?B-7[<_LW?\
MF^_#C_L7K'_T0E3Q#_!I^OZ%\/\ \6?I^ISG[1?71_\ =D_FM>*5[7^T5UT?
M_=D_FM>*U[V1_P"X4_G^;,\S_P![G\OR1V7P@_Y*!I?^\W_H)KZBKY>^$/\
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M /8&F_E7XM5Y'#_^[S]?T1/$'^\0]/U8C?=/TK]Q?@'_ ,D,^'G_ &+VG_\
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M4?98?^>,?_?(KQ*F,A4Q/UIQ?-=/?33Y'IPPSA1]@I:6MMW^9\"?\+@^'_\
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MW1'"W8(! YKB?C=^T1\+O$-OIJV7Q T"1HO,+*;P#J5QV]C7U#]EA_YXQ_\
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MPWAB$LJR#S;4L!F(LH(6;[NX[<@T 7?&GQ"-YJ$N@:3;O>*XFAN98Y3"\K*
M'@M9,;6G4$G:2/NXZYQ8^$/@W4O"]O>3W<@MK:\VR)IT3'RE;))E",H,18%0
M8QP-N3DDFG_#CP.UC'=:CJ4-P)KF<RQV]](DK[5(,4DN,J9E&5W@Y*[=Q)&:
M]!H *J:MJMKHFG3WU[*(+6!=SN03CMP!R23@ #KFJVK^)M+T/>MY>PQ3K"\Z
MVV\&:1%!)*)]YNAZ"O(]0UF[^*WB*ZTR*2\LK7[-Y0L6QMA?<V9)E5L3PR;=
M@D1LQNA'!YH ?XBU[5_&OB^/2#'=:;!#/#<Z=_H3B3?@&.<DG!5#O\R.0#@
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M8V>H7SZE>PQA9;I^2Y^IY..F3R<9/-1>&_"MCX;ML6UK!#/)EI6A0JNYN7"
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MGI/OC@B10(PX7",RL9&4X.T/@&N<TWX'>9K$&HW&IN;=Y%N)8?*,<C.K!T?
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M2-(VQ2QP!DX Y)]A7D/CKXA0^*+&/2[9X1I]U;R27#/8M?12HP'D95<$Q/\
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MG4XF1U'WEP021@C<*]%\.>&[7PS9RPV\D]Q)/*9Y[FZD,DLTA &YF]<*HXP
M * )]%T:VT.U:&WBCC,CF68Q)L5Y&^^X7HN3DX'<FK]%)UX- 'F6N?&:-HKZ
M7P_;Q7]C9W0L;O59G_T>TE.")'4?,T(R09!QGU&6&5X<\-ZWJWBZQO\ 7899
M48M^_1!'-:SPG*2+,F%DAD1RGW5+#:&!*G'H=]X)TZ\URSU6-6M+N"(VTGD
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M7=16QGD$,7F, 7<]%7U/M7C'_"+WNL64'A[4-,U=/$+ZDDU]JS2R/;LB;_\
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MER2Q4' )..Y(!1T'X<RKJ%AJNI1Z=9:C83YM5TJ$!8H/*\MH0Y4,48_.0>G
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M@_3?L]K'%Y\F&N)XXA&)7[D*.%'7"C@9JWX?T*#P_IZV\05I6/F7$RH$,\Q
MWR$#@%B,G'<UIT %<#XH^*$5GH.L7FFV%W>16+"-[QK1WMR/,\N5DQ@R;#NR
M!C[IYP":D^(7Q$C\*W%G:VES;G4/.CWVMRI6.56W!8C-]V*1\'86X)7!P#D4
MM)\$Q:[ EUIVK7UEX<O+M=1ET6XM@KQ3K+O959OFB!D7++R,[MI - &-\)_#
M4][>0:W!=QP6UN#!BS<O&W=H$=L^;;@ME"3NC9656*FO7P,< 8%(JK&H55"J
M.  , 4Z@ HHHH ***YSQIXHG\.0Z=%9VT-UJ&I70L[9;J;R80Y1G^=\$CA"
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M%%,F1I(75',;,I <#)4XZT 8WB_Q%#X=TAY&N?L]U-F*UVVSW+&3:3Q$GS,
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MH4,['EC@ 9/H*J^$?!NG>"=/>STP3+!(YE=9)"P,A^\X'12QRQ"@#))Q6[0
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MT3//QV.IX"E[:HFU>VA]245\&_\ #1GQ%_Z&67_P&@_^(H_X:,^(O_0RR_\
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MZ)I^EVJ+%:V-O';1(F=JHBA5 R2<8 ZDGW-7J "BBB@ HHHH **** "BBB@
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MP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\
M_"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL
M?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM
M 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM
M%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?
M\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_
M!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_H
MLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP_
M_P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"
MHL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_
M ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1
M_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -
M8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#
M_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLG
MP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\
M_"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL
M?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM
M 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM
M%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?
M\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_
M!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_H
MLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP_
M_P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"
MHL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_
M ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1
M_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -
M8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#
M_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLG
MP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6839121072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 21, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,425,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,176,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6837275872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,337<span></span>
</td>
<td class="nump">$ 2,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,838<span></span>
</td>
<td class="nump">13,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">16,915<span></span>
</td>
<td class="nump">33,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,755<span></span>
</td>
<td class="nump">11,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,974<span></span>
</td>
<td class="nump">24,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent consideration</a></td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,670<span></span>
</td>
<td class="nump">31,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at December 31, 2018 and December 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 350,000,000 shares authorized, 22,026,476 shares issued and outstanding at December 31, 2018; 5,766,891 shares issued and outstanding at December 31, 2017</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">87,098<span></span>
</td>
<td class="nump">56,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(81,855)<span></span>
</td>
<td class="num">(54,185)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">5,245<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 16,915<span></span>
</td>
<td class="nump">$ 33,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6396582&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6837310384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">22,026,476<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">22,026,476<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6839574128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,767<span></span>
</td>
<td class="nump">$ 6,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,772<span></span>
</td>
<td class="nump">15,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment charge</a></td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Severance costs related to Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses and operating loss</a></td>
<td class="num">(31,089)<span></span>
</td>
<td class="num">(23,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(3,032)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnSettlementOfWarrantsLiability', window );">Loss on settlement of liability-classified warrants</a></td>
<td class="num">(727)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating income (expense), net</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Loss before income taxes</a></td>
<td class="num">(29,048)<span></span>
</td>
<td class="num">(23,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">(1,378)<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,670)<span></span>
</td>
<td class="num">(23,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend arising from beneficial conversion feature of convertible preferred stock</a></td>
<td class="num">(4,436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="num">(8,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LiabilityClassifiedWarrantsAntidilutionProtection', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="num">(491)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeemedDividendOnDebtConversion', window );">Deemed dividend on conversion of 2015 Sely Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(675)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (41,251)<span></span>
</td>
<td class="num">$ (24,429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (3.15)<span></span>
</td>
<td class="num">$ (10.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">13,077,140<span></span>
</td>
<td class="nump">2,340,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeemedDividendOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend On Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeemedDividendOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LiabilityClassifiedWarrantsAntidilutionProtection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Classified Warrants, Anti-dilution Protection</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LiabilityClassifiedWarrantsAntidilutionProtection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnSettlementOfWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Settlement Of Warrants Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnSettlementOfWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6843912752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Patel vs Galena biopharma, Inc</div></th>
<th class="th">
<div>Patel vs Galena biopharma, Inc </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Patel vs Galena biopharma, Inc </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Secured Debt</div></th>
<th class="th">
<div>Secured Debt </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Secured Debt </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Convertible Notes Payable</div></th>
<th class="th">
<div>Convertible Notes Payable </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Convertible Notes Payable </div>
<div>Additional Paid-In Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,268,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="num">$ (4,997,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,434,000<span></span>
</td>
<td class="num">$ (30,431,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares', window );">Stock issued in connection with amendments to MSK license, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue', window );">Stock issued in connection with amendments to MSK license, amount</a></td>
<td class="nump">388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock as result of conversion</a></td>
<td class="nump">1,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, amount</a></td>
<td class="nump">6,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable', window );">Shares issued in connection with settlement of related party payables, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable', window );">Shares issued in connection with settlement of related party payables, amount</a></td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued upon the acceleration of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares', window );">Shares issued upon cancellation of Equilibria restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with acquisition of Galena, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,588,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued in connection with acquisition of Galena</a></td>
<td class="nump">12,487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">12,486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition', window );">Fair value of assumed options issued in connection with acquisition of Galena</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares', window );">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod', window );">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, value</a></td>
<td class="nump">6,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion', window );">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</a></td>
<td class="num">$ (675,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(675,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena, shares</a></td>
<td class="nump">119,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena</a></td>
<td class="nump">$ 941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForAntidilutionProvisionsShares', window );">Shares issued to MSK for anti-dilution provisions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForAntidilutionProvisions', window );">Shares issued to MSK for anti-dilution provisions</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">3,169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,754,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">2,070,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">56,254,000<span></span>
</td>
<td class="num">(54,185,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,898)<span></span>
</td>
<td class="nump">499,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,802)<span></span>
</td>
<td class="nump">3,748,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock as result of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,654,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,654,000)<span></span>
</td>
<td class="nump">$ 825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">6,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, amount</a></td>
<td class="nump">21,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">21,563,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 2,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PreferredStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of offering costs</a></td>
<td class="nump">9,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering</a></td>
<td class="num">(5,039,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,039,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature arising from Series A convertible preferred stock</a></td>
<td class="num">(4,436,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,436,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock', window );">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</a></td>
<td class="nump">4,436,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,436,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="nump">8,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendModificationOfWarrants', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="num">(491,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(491,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockDividends', window );">Convertible preferred stock dividends</a></td>
<td class="num">(487,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantExchangeAgreementsIssuanceOfCommonStock', window );">Issuance of common stock in connection with warrant exchange agreements (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantExchangeAgreementsAmount', window );">Issuance of common stock in connection with warrant exchange agreements</a></td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,049,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,670,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,670,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,026,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">$ 5,245,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 87,098,000<span></span>
</td>
<td class="num">$ (81,855,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Deemed Dividend On Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Stock Options Exercised In Connection With Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend, Modification Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PreferredStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Issued During Period, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PreferredStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares And Common Stock Warrants Issued Upon Conversion Of Notes During Period Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-funded Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Settlement Of Related Party Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Upon Cancellation Of Restricted Stock Units Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Settlement Of Related Party Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForAntidilutionProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Anti-dilution Provisions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForAntidilutionProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForAntidilutionProvisionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Anti-dilution Provisions, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForAntidilutionProvisionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued In Connection With Amendments To License During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued In Connection With Amendments To License During Period, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantExchangeAgreementsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exchange Agreements, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantExchangeAgreementsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantExchangeAgreementsIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exchange Agreements, Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantExchangeAgreementsIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109245112&amp;loc=d3e23524-113945<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6840099712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">$ (27,670)<span></span>
</td>
<td class="num">$ (23,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="num">(766)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Non-cash In-process research and development impairment charge</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(1,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">3,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices', window );">Fair value of common stock issued in exchange for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Fair value of common stock issued in connection with litigation settlements</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value of common stock issued in connection with litigation settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(5,302)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">3,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnSettlementOfLiabilityClassifiedWarrants', window );">Loss on settlement of liability-classified warrants</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs paid by Galena</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(7,936)<span></span>
</td>
<td class="nump">8,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(2,282)<span></span>
</td>
<td class="num">(2,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,422)<span></span>
</td>
<td class="num">(10,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Net cash acquired from acquisition of Galena</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used from investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">9,647<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">21,564<span></span>
</td>
<td class="nump">6,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(7,601)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,123<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</a></td>
<td class="num">(7,299)<span></span>
</td>
<td class="nump">6,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">6,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</a></td>
<td class="nump">5,451<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the periods for interest</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConversionwithSeriesAConvertiblePreferredStock', window );">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</a></td>
<td class="nump">4,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Repayment of interest and principal on long-term debt through issuance of common stock</a></td>
<td class="nump">3,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock', window );">Reclassification of warrant liabilities upon exchange for shares of common stock</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges', window );">Debt issued in connection with warrant exchange agreements</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilityUponExercise', window );">Shares issued in connection with acquisition of Galena</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition', window );">Fair value of options assumed in connection with acquisition of Galena</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable', window );">Related party payable settled in shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedToSettleAccountsPayable', window );">Memorial Sloan Kettering Cancer Center payable settled in shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance', window );">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember', window );">Convertible Debt Two Thousand Fifteen Shareholder Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gale_ConvertibleDebtTwoThousandSelyNoteMember', window );">Convertible Debt Two Thousand Sely Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConversionwithSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion with Series A Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConversionwithSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend Associated With Conversion Of Note And Common Stock Warrant Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock warrants issued in exchange for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Stock Options Assumed In Connection With Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfStockOptionsAssumedInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with common stock recorded as a cost of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt Issued In Connection With Warrant Exchanges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LongtermDebtIssuedInConnectionWithWarrantExchanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnSettlementOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Settlement Of Liability Classified Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnSettlementOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharesIssuedToSettleAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued To Settle Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharesIssuedToSettleAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharesIssuedToSettlerRelatedPartyAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued To Settler Related Party Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharesIssuedToSettlerRelatedPartyAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gale_ConvertibleDebtTwoThousandFifteenShareholderNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gale_ConvertibleDebtTwoThousandSelyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gale_ConvertibleDebtTwoThousandSelyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830176112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Organization and Description of Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SELLAS Life Sciences Group, Inc. (the "Company," or &#8220;SELLAS&#8221;) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As used in this annual report on Form 10-K, the words the &#8220;Company,&#8221; and &#8220;SELLAS&#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&#160;7, 2017 and amended November&#160;5, 2017 (the "Merger Agreement"), among the Galena, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company&#8217;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Immediately prior to the Merger, Galena effected a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-for-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> reverse stock split of its outstanding common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS&#8217; securityholders at an exchange ratio of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43.9972</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&#8220;RSUs&#8221;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&#8217;s common stock. Accordingly, immediately after the Merger, there were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,766,891</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock outstanding, with the former Private SELLAS securityholders owning </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">67.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company&#8217;s fully diluted common stock, and the Company&#8217;s pre-Merger securityholders owning the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The number of shares and per share amounts of common stock in the accompanying consolidated financial statements and notes to the consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon completion of the Merger, the Company&#8217;s name changed from &#8220;Galena Biopharma, Inc.&#8221; to &#8220;SELLAS Life Sciences Group, Inc.," the Company&#8217;s financial statements became those of Private SELLAS, and the Company's common stock began trading on The Nasdaq Capital Market under the new ticker symbol &#8220;SLS&#8221; on January&#160;2, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815424352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company completed an underwritten public offering (the "July 2018 Offering"), and issued (i) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock, (ii) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> pre-funded warrants exercisable for shares of common stock and (iii) accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the July 2018 Offering, on March&#160;7, 2018, the Company entered into a securities purchase agreement to issue shares of its Series A convertible preferred stock (&#8220;Series A Convertible Preferred&#8221;) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of Series A Convertible Preferred and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> year warrants to acquire an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share was completed in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> tranches and resulted in aggregate gross proceeds to the Company of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company completed the first tranche for approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> gross proceeds on March&#160;9, 2018. The Company completed the second tranche of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> gross proceeds on May 1, 2018, following stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2019, the Company engaged Cantor Fitzgerald &amp; Co. to explore a wide range of strategic alternatives to continue the Company's business plan, with the ultimate objective being an outcome that is in the best interest of the Company's shareholders.  Such alternatives may include, but are not limited to, a sale of the Company, a business combination, a merger or reverse merger with another company, a strategic investment into the Company, a sale, license or other disposition of corporate assets, a funded collaboration or partnership, or a financing which would allow the Company to continue with its current business plan of developing its development plans for its lead product candidates. To the extent that this engagement results in a transaction, our business objectives may change depending upon the nature of the transaction.  There can be no assurance that we will enter into any transaction as a result of the engagement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company had cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and a restricted cash balance of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company had outstanding accounts payable and accrued expenses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company expects its existing cash as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, together with the gross proceeds of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> the Company may receive in connection with the exercise of certain warrants to purchase shares of common stock beginning in March 2019, pursuant to a warrant exercise agreement, will enable the Company to fund its operating expenses through June 2019. In the event that not all of the warrants subject to the warrant exercise agreement are exercised, the Company will need to raise additional capital earlier than anticipated to fund our operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830201952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and our wholly owned subsidiaries, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Private SELLAS, SLSG US, Inc., Sellas Life Sciences Limited, Sellas Life Sciences Group UK Ltd., Apthera, Inc., and Mills Pharmaceuticals, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company&#8217;s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (&#8220;LIBOR&#8221;) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets are comprised of identifiable in-process research and development (&#8220;IPR&amp;D&#8221;) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&amp;D asset associated with the GALE-401 product candidate and recorded an impairment charge of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was equal to the acquired value of GALE-401 of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> recorded as deposits and other assets related to upfront milestone payments. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. See Note 5 for further discussion of the Company's intangible assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&#8217;s goodwill is less than the carrying value of the reporting unit&#8217;s goodwill. The Company did not recognize any impairment of goodwill during the years ended December 31, 2018 and 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Severance Costs Related to Merger</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognized and paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of exit costs during 2017 related to severance benefits for certain former Galena employees terminated immediately prior to the consummation of the Merger.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Fees and Insurance Recoveries</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Stock-based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#8212; Stock Compensation&#8221; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non-Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC740-10&#8221;). </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC740-10 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the Company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 22, 2017 the President of the United States signed into law the Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;). This legislation makes significant changes in the United States tax laws including, but not limited to, reducing the corporate tax rate to 21% starting in 2018. The 2017 Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of 21%. For the years ended December 31, 2018 and December 31, 2017, the Company recognized an income tax benefit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and an income tax expense of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively. Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. December 22, 2018 marked the end of the measurement period for purposes of SAB 118. As such, the Company completed the analysis based on legislative updates relating to the Act currently available, and no material adjustments have been recorded as of December 31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">986</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has no items of comprehensive income or loss other than net loss.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Convertible Instruments</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU No. 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU No. 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,337</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815571664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting, whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Private SELLAS, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Private SELLAS that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:585px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of the Company's pre-Merger shares outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Estimated fair value of the Company's pre-Merger stock options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:585px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets acquired:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,812</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34,775</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities assumed:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration of Apthera, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,673</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Qualitative factors supporting the recognition of goodwill due to the Merger include the Company&#8217;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company. The goodwill is not deductible for income tax purposes.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&#8217;s results of operations for any future period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss (in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-recurring&#160;pro forma transaction costs directly attributable to the Merger were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for the year ended December&#160;31, 2017 and have been deducted from the net loss presented above. The costs deducted from the year ended December&#160;31, 2017 period included a success fee and other transaction costs&#160;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">119,672</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock with a fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a fee to Equilibria Capital Management Limited (&#8220;Equilibria&#8221;). Additionally, the Company incurred approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in severance costs as a result of resignations of executive officers immediately prior to the Merger. These costs are excluded from the pro forma financial information for the year ended December&#160;31, 2017. The Company excluded a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> impairment charge incurred by the Company as well as combined transaction costs from Galena and the Company in the amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from the pro forma financial information for the year ended December&#160;31, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830087920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Goodwill and Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company completes its annual impairment test on October 1 each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company's goodwill balance at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets consist of IPR&amp;D acquired as part of the Merger. IPR&amp;D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE-302</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company's IPR&amp;D assets consist of the NPS program for the prevention of cancer recurrent in breast cancer patients, and the GALE-301 and GALE-302 programs for the prevention of cancer recurrent in ovarian and endometrial cancer patients in the adjuvant setting. In the fourth quarter of 2018, the Company abandoned future development efforts for the IPR&amp;D asset associated with the GALE-401 product candidate and recorded an impairment charge of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was equal to the acquired value of GALE-401 of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> recorded as deposits and other assets related to upfront milestone payments associated with that product candidate. The abandonment also resulted in an income tax benefit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830134304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period. These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Memorial Sloan Kettering Cancer Center</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 4, 2014, (the &#8220;MSK Effective Date&#8221;) the Company entered into a license agreement (the &#8220;Original MSK License Agreement&#8221;) with MSK under which the Company was granted an exclusive license to develop and commercialize MSK&#8217;s WT1 peptide vaccine technology. Under the terms of the Original MSK License Agreement, the Company is required to obtain certain levels of financing. If such financing is not met, MSK will have the right to terminate the Original MSK License Agreement with prior written notice, unless the Company manages to overcome the shortfall during the term of the notice period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the consideration for the rights, privileges and licenses granted under the Original MSK License Agreement, the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,199</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares to MSK representing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company&#8217;s fully diluted share capital as of the MSK Effective Date, which obligation was satisfied by assignment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,599</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares from each of the Company&#8217;s President, Chief Executive Officer, and co-founder, Dr. Angelos M. Stergiou, and the Company&#8217;s other co-founder, Dr. Miltiadis Sougioultzoglou (M.D.), to MSK, for which they received no consideration. Additionally, the Company was obligated to pay upfront license fees in an amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company recognized this amount as research and development expense during the year ended December 31, 2014, as it had no alternative future use. The Company would further be obligated to pay minimum royalty payments in the amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> each year commencing in 2015 and research funding costs of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in each year and for three years commencing in January 2015. In addition, to the extent certain development and commercial milestones are achieved, the Company will be required to pay MSK up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$17.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in milestone payments for each licensed product, in addition to royalties in the event of commercial sales of any licensed products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Original MSK License Agreement, unless terminated earlier in accordance with the terms of the Original MSK License Agreement, will continue on a country-by-country and licensed product-by-licensed product basis, until the later of: (i) expiration of the last valid claim embracing such licensed product; (ii) expiration of any market exclusivity period granted by law with respect to such licensed product; or (iii) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) years from the first commercial sale in such country.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 30, 2015, the Company and MSK entered into the License Amendment, Waiver and Share Issuance Agreement (the &#8220;First MSK Amendment&#8221;). The First MSK Amendment extended the date required for the Company to obtain financing from August 1, 2015 to December 31, 2016, modified the amount of required financing and waived past non-compliance with certain related provisions of the Original MSK License Agreement. In exchange for the First MSK Amendment, the Company agreed to issue an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,867</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares to MSK, which represented </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the fully diluted share capital of the Company at such date. The First MSK Amendment added certain anti-dilution protection clauses and entitled MSK to additional shares to the extent the Company was not able to obtain the required financing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 10, 2016, the Company and MSK entered into the Second License Amendment, Waiver and Agreement (the &#8220;Second MSK Amendment&#8221;). The Second MSK Amendment extended further the date required for the Company to obtain financing from December 31, 2016 to June 30, 2017, amended the anti-dilution provisions of the First MSK Amendment and waived past non-compliance with certain related provisions of the First MSK Amendment. Under the Second MSK Amendment, outstanding obligations of the Company to MSK in an amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,815</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares effective November 1, 2016 upon the Company&#8217;s re-domiciliation to Bermuda. In consideration for this amendment and pursuant to the anti-dilution provisions in the Original MSK License Agreement as amended by the First MSK Amendment and the Second MSK Amendment, the Company issued MSK </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30,314</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> additional shares and incurred accordingly </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of research and development expense, which reflected the fair value of the Company&#8217;s shares at such date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 25, 2017, the Company and MSK entered into an Amended and Restated Exclusive License Agreement (the &#8220;MSK A&amp;R License Agreement&#8221;). Under the MSK A&amp;R License Agreement, the Company expanded its license under the original MSK License Agreement, as amended, to include a license to commercially develop certain additional WT1 peptides through a program of exploiting certain patents and other rights covering such peptides.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The MSK A&amp;R License Agreement, among other changes, added certain milestone payments for each additional patent licensed product as defined in the MSK A&amp;R License Agreement, and amended the milestone payments due upon commencement of the Phase 3 AML and mesothelioma clinical trials from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In consideration for the MSK A&amp;R License Agreement, the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,799</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares to MSK. Pursuant to a side letter to the MSK A&amp;R License Agreement, dated May 25, 2017 (the &#8220;MSK Side Letter&#8221;), MSK converted the next milestone payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was due June 30, 2017, into shares. Further, in consideration for the MSK Side Letter, Dr. Stergiou, the Company&#8217;s Chief Executive Officer, assigned </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,399</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of his shares to MSK, for which Dr. Stergiou received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash consideration.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 11, 2017, the Company and MSK entered into a second Amended and Restated Exclusive License Agreement (the &#8220;Second MSK A&amp;R License Agreement&#8221;). Under the Second MSK A&amp;R License Agreement, the Company and MSK extended the dates for the Company to have obtained necessary financing, and certain milestone dates, in exchange for increased milestone payments, clarification regarding MSK&#8217;s anti-dilution rights, and termination of the MSK Side Letter dated May 25, 2017. In connection with the Second MSK A&amp;R License Agreement, the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74,795</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares to MSK. Prior to the Merger, the Company issued an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares to MSK in connection with their anti-dilution rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the year ended December 31, 2018 the Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of expenses relating to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of milestone payments, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in licensing fees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of guaranteed minimum royalty payments and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of research funding costs.  For the year ended December 31, 2017, the Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of expenses relating to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of milestone payments, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of guaranteed minimum royal payments and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of research funding costs. Such expenses have been included in research and development costs. Further, under the Second MSK Amendment, the Company is obligated to pay MSK </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in milestone payments in two equal installments, within </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days following the initiation of its Phase 3 AML and mesothelioma clinical studies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Merck &amp; Co., Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 21, 2017, the Company entered into a clinical trial collaboration and supply agreement through a Merck &amp; Co., Inc. subsidiary, Merck Sharp &amp; Dohme B.V. (&#8220;Merck subsidiary&#8221;), whereby the Company agreed with the Merck subsidiary to collaborate in a research program to evaluate GPS as it is administered in combination with Merck&#8217;s PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors.  The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab in patients with WT1+ relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: AML, ovarian, triple-negative breast, small cell lung, and colorectal (arm enriched in but not exclusive to patients with microsatelite instability-low tumors). This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pembrolizumab alone in comparable patient populations. This trial was initiated in December 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Advaxis, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 24, 2017, the Company and Advaxis, Inc. (&#8220;Advaxis&#8221;) entered into a research and development collaboration agreement, whereby both parties will collaborate in a research program to evaluate, through a &#8220;proof of principle&#8221; trial or trials (&#8220;PoP Clinical Trial&#8221;), a clinical candidate comprised of the combination of Advaxis&#8217; proprietary </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Lm-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">based antigen delivery technology and the Company&#8217;s patented WT1 targeted heteroclitic peptide antigen mixture (GPS). The term of the Advaxis agreement will expire upon the earlier of: (a) completion of the PoP Clinical Trial, (b) a decision by the parties to cease further development of the clinical candidate and (c) early termination of the Advaxis agreement pursuant to the terms thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and filing any investigational new drug application (&#8220;IND&#8221;), cost-sharing for preparation of the IND, and the Company being responsible for the costs (exclusive of product costs) of conducting the PoP Clinical Trial. The Company also agreed to make certain non-refundable milestone payments to Advaxis having an aggregate amount of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$108.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain targets, the Company agreed to make non-refundable sales milestone payments up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low double digits if net sales exceed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 11, 2006, the Company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a United States patent covering the nelipepimut-S peptide vaccine ("NPS") and several United States and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, the Company is required to pay an annual maintenance fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for clinical milestone payments, and to pay a tiered royalty in the mid-single digits based on sales of NPS or other therapeutic products developed from the licensed technologies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815544512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company did not transfer any financial instruments into or out of Level 3 classification during the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  See Note 12 for a reconciliation of the changes in the fair value of the warrant liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the change in the fair value of the contingent consideration liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2017 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration acquired as part of the Merger</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,032</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&#8217;s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> based on the achievement of certain development and commercial milestones relating to NPS. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial of trastuzumab (Herceptin&#174;) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830134304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Value-added tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rebates and returns of former commercial products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815617136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Debt</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current portion of Senior Secured Debenture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-current portion of Senior Secured Debenture</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Senior Secured Debenture</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company's predecessor company, Galena, entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with JGB (Cayman) Newton, Ltd. ("JGB") pursuant to which Galena sold to JGB, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> original issue discount, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> senior secured debenture (the "Senior Secured Debenture") and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,333</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The maturity date of the Senior Secured Debenture was November&#160;10, 2018, with accrued interest at&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company&#8217;s common stock, or a combination of cash and the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:1pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash and cash equivalents in a restricted account. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the outstanding principal balance of the Senior Secured Debenture was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition to the outstanding principal balance, the Senior Secured Debenture had&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of additional interest that was included in the current portion of long-term debt as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. During the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, JGB redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal, which the Company satisfied with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">659,529</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock and redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of restricted cash into unrestricted cash and cash equivalents, which was used to fund the Company&#8217;s ongoing operations. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2018, JGB commenced a lawsuit against the Company, as described in Note 10. On November 5, 2018, the parties to the JGB lawsuit entered into a settlement agreement, which required, among other things, that JGB make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, representing the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Short-term Convertible Promissory Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company issued convertible promissory notes in the principal amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in exchange for the surrender and cancellation of warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock pursuant to the February 2017 public offering by Galena. The convertible promissory notes accrued interest at a rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per annum and were convertible into shares of the Company's common stock at a conversion price equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. In November of 2018, the Company paid the remaining principal and interest of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to settle the debt. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was no principal balance and accrued interest outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830134304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings, Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company is now subject as a result of the Merger. The Company is also involved in litigation matters as follows: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 13, 2016, Galena filed a complaint against Aon Risk Insurance Services West, Inc. in the Circuit Court for Multnomah County, Oregon.&#160;The complaint seeks damages related to Galena&#8217;s coverage dispute with a certain insurer, including the amounts Galena was required to contribute to the settlements of In re Galena Biopharma, Inc. Derivative Litigation and In re Galena Biopharma, Inc. Securities Litigation as a direct result of certain insurer&#8217;s failure to pay its full policy limits. On November 30, 2018, the Company amended its complaint to seek punitive damages.&#160;Trial is scheduled to begin on May 6, 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February&#160;13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint and on December 21, 2018, plaintiffs filed their opposition to the motion to dismiss. On January 18, 2019, the Company filed a reply in support of its motion. The Company's motion to dismiss the amended complaint is currently pending in the U.S. District Court for the District of New Jersey.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in the U.S. District Court for the Northern District of California against the Company&#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018, refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On November 15, 2018, the defendants in the August 2018 lawsuit filed a motion to dismiss the complaint. On December 17, 2018, the plaintiff filed an amended complaint. The defendants filed a motion to dismiss the amended complaint on January 31, 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section&#160;225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena&#8217;s former board of directors and former interim chief executive officer regarding the proposals to amend Galena&#8217;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&#160;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On July&#160;24, 2017, Galena entered into a binding settlement term sheet, involving</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,250,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in unrestricted shares of common stock. The Court enforced the settlement term sheet on November&#160;30, 2017. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys&#8217; fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from its insurance carrier for previous amounts paid by the Company in excess of its retention amount and recorded the amount as a reduction to general and administrative expense in the Company's consolidated statement of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants certain members of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, inclusive of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> excess amount removed from the restricted account. The entire settlement amount was received in November 2018. The Company offset approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of legal fees incurred during the year ended December 31, 2018 previously recorded in general and administrative expense in the consolidated statement of operations with proceeds from the settlement. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Consideration related to Development, Regulatory and Commercial Milestone Payments and Business Combinations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. For additional information on the Company&#8217;s commitments under collaboration and license agreements read Note 6 to these consolidated financial statements. For additional information on the Company&#8217;s commitments of contingent consideration read Note 7 to these consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Commitments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company rents office space under a&#160;non-cancelable&#160;operating lease. Rental expense amounted to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for the years ended December&#160;31, 2018 and 2017, respectively. The Company&#8217;s contractual obligations that may require future cash payments as of December&#160;31, 2018 under the&#160;non-cancelable&#160;operating lease are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815617856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Series A Convertible Preferred </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March&#160;7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share at an aggregate purchase price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Series A Convertible Preferred was initially convertible into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,844,835</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock based on an initial conversion price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.80</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At the first closing of the Series A Convertible Preferred on March&#160;9, 2018, the Company issued an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,987</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">774,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The second closing of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,713</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">609,445</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock, for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, occurred on May 1, 2018 following receipt of stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders") had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and in Note 2 above, the Series A Holders exchanged an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7,871,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock and warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock. Following such exchange, there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and that amount is recorded as a deemed dividend in the consolidated statements of operations during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was automatically adjusted to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share from the original exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The Company recognized the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the consolidated statements of operations during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred generated a beneficial conversion feature (&#8220;BCF&#8221;), which arose as the equity security was issued with an embedded conversion option that was beneficial to the investor or in the money at inception because the conversion option had an effective conversion price that was less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a deemed dividend in the consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a deemed dividend related to the second closing on May 1, 2018.&#160;These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company completed the July 2018 Offering, issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per pre-funded warrant and common stock warrant.  Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance.  The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contracts in an Entity&#8217;s own Equity</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 815-40&#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock reserved for future issuance are as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830117248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants to Acquire Shares of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Warrants to Acquire Shares of Common Stock</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Canceled/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2018 Offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Pre-funded July 2018 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2017 Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(542</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">534,334</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,613</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">121,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock, as described in Note 11. The fair value of the common stock and promissory notes exchanged totaled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which exceeded the fair value of the warrant liability of the warrants canceled by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and is recorded as loss on settlement of liability-classified warrants in the consolidated statement of operations for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Liabilities </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 offering, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share of common stock, subject to standard adjustments for certain transactions affecting the Company&#8217;s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">94.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">829.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">94.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">888.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Adjustment to exercise price of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Equity</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company issued warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316,163</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the its common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December&#160;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90.10%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk free rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 11.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6660818752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split described in Note 1. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017 Equity Incentive Plan </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,686,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger.  Upon the consummation of the Merger, the Company assumed approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,171</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares subject to outstanding common stock options granted under the Company&#8217;s 2016 Incentive Plan that remained exercisable through December 29, 2018 for former Company employees and directors. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The number of shares reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1&#160;of each year, for a period of not more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, commencing on January 1, 2018 and ending on (and including) January&#160;1, 2027, in an amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31&#160;of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1&#160;of a given year to provide that there will be no January 1&#160;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,686,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> on January 1, 2019. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock were reserved for future grants under the Company&#8217;s 2017 Equity Incentive Plan. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> common stock options granted under the 2017 Equity Incentive Plan for the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80.83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average grant date fair value of options granted during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.73</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> stock options granted during the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur, therefore, outstanding stock options equal vested and expected to vest stock options.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.13</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes stock option activity of the Company for the year ended December 31, 2018:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted Average Remaining Contractual Term (in years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,240.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.01</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable stock options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.23</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">RSUs with Time-Based and Performance-Based Conditions </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and&#160;non-employees&#160;pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i)&#160;continued service either over a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year measurement period or at the end of the required service period and (ii)&#160;the achievement of a liquidity event. The initial vesting date for these RSUs was February&#160;27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of December&#160;31, 2018 and December 31, 2017, there were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> RSUs outstanding with a weighted average grant date fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$52.94</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company&#8217;s control and not deemed probable until it occurs. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017 Employee Stock Purchase Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also has an employee stock purchase plan (&#8220;ESPP&#8221;) which allows employees to contribute up to&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;of their cash earnings, subject to certain maximums, to be used to purchase shares of the Company&#8217;s common stock on each semi-annual purchase date. On each offering date, each eligible employee, pursuant to an offering made under the ESPP, will be granted a right to purchase up to that number of shares of common stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board of Directors, but in either case not exceeding fifteen percent (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) of such employee&#8217;s earnings (as defined by the Board of Directors in each offering) during the period that begins on the offering date (or such later date as the Board of Directors determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. As of December&#160;31, 2018, the Board of Directors has not established the various parameters under the ESPP and no shares have been delivered under the ESPP. There are approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock reserved for issuance under the ESPP, plus the number of shares of common stock that are automatically added on January 1st&#160;of each year for a period of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, commencing on the first January 1, 2018 and ending on (and including) January&#160;1, 2027, in an amount equal to the lesser of (i) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31st&#160;of the preceding calendar year, and (ii)&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830117248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Income Taxes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The loss before income taxes is as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non - U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(29,048</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of federal and state income tax expense are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(570</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax assets and liabilities are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,464</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,028</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,550</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Licensing deduction deferral</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,410</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,658</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development not subject to future amortization for tax purposes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">U.S. federal statutory income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State and local taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax rate change and true-up</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At December 31, 2018, the Company had domestic federal and state net operating loss carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$19.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, available to reduce future taxable income, which expire beginning in 2027. The Company also had federal research and development tax credit carryforwards of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, available to reduce future tax liabilities and which expire at various dates beginning in 2035. The income tax expense for the year ended December 31, 2018 and 2017 relates to both the indefinite lived deferred tax liabilities and the December 22, 2017 enactment of the Tax Cuts and Jobs Act. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Under the provisions of the Internal Revenue Code, the net operating losses (&#8220;NOL&#8221;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, as defined under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. Utilization of the net operating loss and tax credits carryforwards may be limited by &#8220;ownership change&#8221; rules, as defined in Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In assessing the need for a valuation allowance the Company may utilize indefinite-lived deferred tax liabilities from an indefinite-lived intangible asset as a future source of income.&#160;The Company&#8217;s IPR&amp;D, as recorded in acquisition accounting, can be utilized as a source of income arising from the future reversal of temporary difference that can be offset against post 2017 indefinite-lived NOLs.&#160;Therefore, the Company is permitted to offset the indefinite-lived DTL up to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> percent limitation for NOL&#8217;s generated subsequent to January 1, 2018. The valuation allowance increased by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for the year ended December 31, 2018 as a result of the impairment of one of the Company's indefinite-lived intangible assets and changes in the Company's state apportionment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to tax examinations for the 2014 tax year and beyond. The Company does not recognize tax benefits that are not more-likely-than-not to be supported based upon the technical merits of the tax position taken. In assessing its unrecognized tax benefits, the Company has analyzed its tax return filing positions in all of the federal, state and foreign filing jurisdictions where it is required to file income tax returns, as well as all open years in those jurisdictions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table indicates the changes to the Company&#8217;s unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Beginning of the Year - unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Increase/(Decrease) - prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Increase - current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">End of the Year - unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The unrecognized tax benefits, if recognized and in absence of full valuation allowance, would impact the income tax provision by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$55,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$72,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company does not believe that it is reasonably possible that its unrecognized tax benefits would significantly change in the following 12 months. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in the near term. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 22, 2017, the 2017 Tax Cuts and Jobs Act (Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring the Company's U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of the Company's deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allowed the Company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. As a result, the Company previously provided a provisional estimate of the effect of the Tax Act in the Company's financial statements. In the fourth quarter of 2018, we completed our analysis to determine the effect of the Tax Act and recorded no material adjustments as of December 31, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830145216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Management and Strategic Collaboration Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective in June 2016, the Company and Equilibria Capital Management ("Equilibria"), a company incorporated in Bermuda and a significant stockholder of the Company, entered into the management and strategic collaboration agreement. Under the Equilibria collaboration agreement, Equilibria, amongst other services, was engaged to provide certain strategic, management and capital raising advice to the Company. The Equilibria collaboration agreement was effective for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years and renewable thereafter only upon the mutual written agreement of both parties. The Equilibria collaboration agreement provided that it would automatically terminate upon the closing of an IPO or a strategic sale. During the term of the Equilibria collaboration agreement, the Company, in exchange for the services received, paid Equilibria a quarterly fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the &#8220;Equilibria Management Fee&#8221;). The Equilibria Management Fee can be paid in cash or, at the mutual agreement of the parties, in shares of the Company at a valuation equal to the Company&#8217;s most recent financing round. In addition to the Equilibria Management Fee, the Company agreed to pay Equilibria any expenses reasonably incurred in performing the services agreed. For the years ended December 31, 2017, the Company had incurred and paid in cash </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, of Equilibria Management Fees. These amounts are included in general and administrative expense in the consolidated statements of operations. As of December 31, 2017, the Company had an outstanding payable to Equilibria of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The management and strategic collaboration agreement was terminated upon consummation of the Merger in December 2017. There were no Equilibria Management Fees incurred during the year ended December 2018 and there was no outstanding payable as of December 31, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the provision of the management and strategic collaboration services, the Company also agreed to pay Equilibria an incentive fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the post-money market value of the Company on the date of its IPO. Such fee would be payable in shares with a per-share price equal to the price set for the sale of the Company&#8217;s shares to other investors in its IPO. The Company and Equilibria may have jointly agreed to settle the incentive fee earlier, if deemed appropriate for achieving a successful IPO, through either a cash payment, issuance of shares, or a combination of the two. In the event that the Company was sold as part of a strategic sale, the incentive fee would be equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the gross value paid by the purchaser in cash.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2017, the Company and Equilibria entered into an amendment of the Equilibria collaboration agreement. Under the amendment, in the event that the Company entered into a reverse merger transaction in lieu of an initial public offering, the incentive fee to Equilibria was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the post-merger fully diluted market value of the Company immediately after the closing of the reverse merger transaction, payable in a combination of cash and shares of common stock of the Company. The cash payment was based on the per share price equaling the intrinsic value of the Company&#8217;s shares in the Merger. The share-based component of the incentive fee was based on the post-closing fully diluted number of shares outstanding.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2017, the Company and Equilibria further amended the Equilibria collaboration agreement to fix the compensation payable to Equilibria in connection with the completion of the Merger, described above in Note 1. Accordingly, upon consummation of the Merger on December 29, 2017, the Company incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in fees to Equilibria and issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">119,672</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock to Equilibria at a fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. These amounts are included in general and administrative expense in the consolidated statements of operations. Also, upon consummation of the Merger and pursuant to the amended Equilibria collaboration agreement, such agreement was terminated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Other Related Party Transactions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s Chief Executive Officer, Dr. Angelos M. Stergiou (M.D., ScD h.c.) is a significant stockholder of the Company owning </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company&#8217;s outstanding share capital as of December 31, 2018 and 2017, respectively. Further transactions involving the Company and Dr. Stergiou are described in Note 6.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815571664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 6, 2019, the Company entered into a Warrant Exercise Agreement, or the Exercise Agreement, with one of the holders of our warrants issued in July 2018. Pursuant to the Exercise Agreement, such holder agreed that it would cash exercise up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,800,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of its warrants issued in July 2018 into shares of common stock at a reduced exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share for any warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the warrants, the Exercise Agreement also provides for the issuance of new warrants to purchase up to an aggregate of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,800,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, or New Warrants, to be issued on a share-for-share basis in an amount equal to the number of the warrants that are cash exercised by the holder by May 31, 2019. To date, the holder has exercised approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> New Warrants were issued. The Company may receive aggregate gross proceeds of up to approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from the cash exercise if all of the warrants under the Exercise Agreement are exercised.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6840402848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. The carrying amounts of the Company&#8217;s convertible notes that were outstanding as of December 31, 2017 approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate (&#8220;LIBOR&#8221;) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level 3 of the fair value hierarchy. The fair value of the warrants is determined using a Black-Scholes pricing model.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash consists of the minimum cash covenant as required by the debenture (see Note 9) and certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets are comprised of identifiable in-process research and development (&#8220;IPR&amp;D&#8221;) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on October 1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company performs its annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by FASB ASU No. 2017-04. Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&#8217;s goodwill is less than the carrying value of the reporting unit&#8217;s goodwill.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock', window );">Patents and Patent Application Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Fees and Insurance Recoveries</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Fees and Insurance Recoveries</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Stock-based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#8212; Stock Compensation&#8221; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non-Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASBASC 740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC740-10&#8221;). </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC740-10 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the Company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has no items of comprehensive income or loss other than net loss.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Convertible Instruments</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU No. 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The amendments in ASU No. 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both non-employees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (i) liability-classified nonemployee awards that have not been settled as of the adoption date and (ii) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-07 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU No. 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU No. 2016-02 is effective for interim and annual periods beginning after December 15, 2018, and the Company adopted the standard effective January 1, 2019. The standard requires the use of a modified retrospective transition approach, applying the new standard to all leases existing at the adoption date. The Company estimates that the adoption of the standard will result in the recognition of an ROU asset and lease liability of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. The Company's consolidated statement of cash flows for the year ended December 31, 2017 was reclassified to to conform to the current year presentation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,337</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Note 9, the Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash and cash equivalents in a restricted account. The Senior Secured Debenture was no longer outstanding as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents And Patent Application Costs, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6403650&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830164544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unvested restricted stock awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">986</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,337</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830092240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The purchase price was calculated as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:585px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Fair value of the Company's pre-Merger shares outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Estimated fair value of the Company's pre-Merger stock options outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:585px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:86px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets acquired:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,812</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34,775</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities assumed:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration of Apthera, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,673</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Summary of Pro Forma Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following summary pro forma consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&#8217;s results of operations for any future period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss (in thousands)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6661212752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets consist of IPR&amp;D acquired as part of the Merger. IPR&amp;D assets represent research and development assets that have not yet reached commercialization. The Company's intangible assets consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 and GALE-302</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830232704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the change in the fair value of the contingent consideration liability for the years ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2017 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration acquired as part of the Merger</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,032</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826172048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Value-added tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rebates and returns of former commercial products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830131408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has no debt outstanding at December 31, 2018. Debt outstanding consisted of the following at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current portion of Senior Secured Debenture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-current portion of Senior Secured Debenture</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830064288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s contractual obligations that may require future cash payments as of December&#160;31, 2018 under the&#160;non-cancelable&#160;operating lease are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830131408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Common Stock are Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock reserved for future issuance are as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6658169152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule Of Warrant Activity Table</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of the Company's warrants to acquire shares of common stock activity for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Canceled/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2018 Offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Pre-funded July 2018 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2017 Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(542</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">88.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">94.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">829.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">94.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">888.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">72.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the year ended December 31, 2018 were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Adjustment to exercise price of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830120512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the years ended December 31, 2018 and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the weighted average fair value of all its stock options granted during the year ended December 31, 2018:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80.83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes stock option activity of the Company for the year ended December 31, 2018:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted Average Remaining Contractual Term (in years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,240.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.01</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826246016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The loss before income taxes is as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non - U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(29,048</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of federal and state income tax expense are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deferred expense</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(570</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax assets and liabilities are as follows (in thousands): </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,464</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,028</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,550</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Licensing deduction deferral</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,410</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,658</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The components of net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In-process research and development not subject to future amortization for tax purposes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The net deferred tax liabilities are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gross deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net deferred tax liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before income taxes as follows: </font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Helvetica,sans-serif;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">U.S. federal statutory income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">State and local taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Foreign rate differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax rate change and true-up</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826999712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">5,766,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,026,476<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_GalenaBiopharmaIncMember', window );">Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember', window );">Private SELLAS Security Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfFullyDilutedShareCapitalOwned', window );">Common stock ownership percentage</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember', window );">Private SELLAS Security Holders | Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockConversionRatio', window );">Common stock conversion ratio</a></td>
<td class="nump">43.9972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_PreMergerSecurityholdersMember', window );">Pre-Merger Securityholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfFullyDilutedShareCapitalOwned', window );">Common stock ownership percentage</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageOfFullyDilutedShareCapitalOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Fully Diluted Share Capital Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageOfFullyDilutedShareCapitalOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gale_PreMergerSecurityholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gale_PreMergerSecurityholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6842877344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 16, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 07, 2018 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 21,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,337<span></span>
</td>
<td class="nump">$ 2,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">$ 10,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction | shares</a></td>
<td class="nump">6,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction | shares</a></td>
<td class="nump">4,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember', window );">Purchase Agreement | Series A Non-voting Convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember', window );">Purchase Agreement | Series A- Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6841946880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,550<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_GALE401Member', window );">GALE-401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast | Accounting Standards Update 2016-02 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D | GALE-401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment loss</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets', window );">Upfront milestone payments, deposits and other assets</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets, Upfront Milestone Payments, Deposits And Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_GALE401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_GALE401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815523824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Earnings per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">18,106<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">17,698<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6843790576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Components of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</a></td>
<td class="nump">5,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">$ 6,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=gale_CorporateCreditCardsMember', window );">Corporate Credit Cards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember', window );">Amendment Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Maximum prepayment of principle if demanded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=gale_CorporateCreditCardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=gale_CorporateCreditCardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830161792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Summary of Purchase Price (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationFairValueOfSharesOutstanding', window );">Fair value of the Company's pre-Merger shares outstanding</a></td>
<td class="nump">$ 12,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding', window );">Estimated fair value of the Company's pre-Merger stock options outstanding</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 12,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Estimated Fair Value Of Stock Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationFairValueOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Fair Value Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationFairValueOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6841944912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Total Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_GalenaBiopharmaIncMember', window );">Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Contingent purchase price consideration of Apthera, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Including Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827394128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Pro Forma (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss (in thousands)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted net loss per share (usd per share)</a></td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827793520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationProFormaTransactionCosts', window );">Business combination pro forma transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SuccessFeeAndOtherTransactionCosts', window );">Success fee and other transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares', window );">Stock issued for incentive fee payment in connection with acquisition during period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod', window );">Stock issued for incentive fee payment in connection with acquisition during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Production related impairments or charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_GalenaBiopharmaIncMember', window );">Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationProFormaTransactionCosts', window );">Business combination pro forma transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationProFormaTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Pro Forma Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationProFormaTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SuccessFeeAndOtherTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success Fee And Other Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SuccessFeeAndOtherTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827601632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_GALE401Member', window );">GALE-401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D | GALE-401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment loss</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets', window );">Upfront milestone payments, deposits and other assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets, Income Tax Effect Of Abandonment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IndefinitelivedIntangibleAssetsIncomeTaxEffectOfAbandonment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets, Upfront Milestone Payments, Deposits And Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IndefinitelivedIntangibleAssetsUpfrontMilestonePaymentsDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_GALE401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_GALE401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827870880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_NPSMember', window );">NPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_GALE401Member', window );">GALE-401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_GALE301AndGALE302Member', window );">GALE-301 And GALE-302</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_NPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_NPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_GALE401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_GALE401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_GALE301AndGALE302Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_GALE301AndGALE302Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6842233040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2017</div></th>
<th class="th"><div>May 25, 2017</div></th>
<th class="th"><div>Feb. 24, 2017</div></th>
<th class="th"><div>Aug. 10, 2016</div></th>
<th class="th"><div>Oct. 30, 2015</div></th>
<th class="th"><div>Sep. 04, 2014</div></th>
<th class="th"><div>Sep. 11, 2006</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,767<span></span>
</td>
<td class="nump">$ 6,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_MemorialSloanKetteringCancerCenterMember', window );">Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_UpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MinimumAnnualRoyaltyPayment', window );">Minimum annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ResearchFundingCosts', window );">Research funding costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementMilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementExpirationTerm', window );">License agreement expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials', window );">Milestone fee payments upon commencement of clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementOutstandingAmountPayable', window );">License agreement outstanding amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfFullyDilutedShareCapital', window );">Percentage of fully diluted share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_UpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember', window );">Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember', window );">Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials', window );">Milestone fee payments upon commencement of clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember', window );">First MSK Amendment | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfFullyDilutedShareCapital', window );">Percentage of fully diluted share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_SecondMSKAmendmentMember', window );">Second MSK Amendment | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement', window );">Stock issued during period shares conversion of debt in connection with licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement', window );">Additional shares issued in connection with licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementOutstandingAmountPayable', window );">License agreement outstanding amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumNumberOfDaysToMakePayments', window );">Maximum number of days to make payments</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember', window );">Second Amended and Restated Exclusive License Agreement | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement', window );">Additional shares issued in connection with licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_AdvaxisCollaborationAgreementMember', window );">Advaxis Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RoyaltyPaymentMaximumRate', window );">Royalty payment, maximum rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_AdvaxisCollaborationAgreementMember', window );">Advaxis Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NonrefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NonrefundableSalesMilestonePayments', window );">Non-refundable sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member', window );">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAgreementMilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=gale_ChiefExecutiveOfficerCoFounderMember', window );">Chief Executive Officer Co-Founder | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=gale_CofounderMember', window );">Co-founder | Memorial Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Shares Issued In Connection With Licensing Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AdditionalSharesIssuedInConnectionWithLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Expiration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAgreementOutstandingAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Outstanding Amount Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAgreementOutstandingAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumNumberOfDaysToMakePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Days To Make Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumNumberOfDaysToMakePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Fee Payments Upon Commencement Of Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MilestoneFeePaymentsUponCommencementOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Annual Royalty Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NonrefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NonrefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NonrefundableSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NonrefundableSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageOfFullyDilutedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Fully Diluted Share Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageOfFullyDilutedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ResearchFundingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ResearchFundingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RoyaltyPaymentMaximumRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment, Maximum Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RoyaltyPaymentMaximumRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Conversion Of Debt In Connection With Licensing Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gale_MemorialSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gale_MemorialSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=gale_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_LicenseAmendmentWaiverAndShareIssuanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_SecondMSKAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_SecondMSKAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_SecondAmendedandRestatedExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_AdvaxisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_AdvaxisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_TheUniversityofTexasM.D.AndersonCancerCenterandTheHenryM.JacksonFoundationfortheAdvancementofMilitaryMedicineInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_ChiefExecutiveOfficerCoFounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_ChiefExecutiveOfficerCoFounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_CofounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_CofounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6840182608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 1,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">11,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">5,339<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices In Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">11,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 5,339<span></span>
</td>
<td class="nump">$ 2,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RestrictedCashandCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6842271728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">$ (3,032)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Beginning Balance Liabilities</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration acquired as part of the Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">3,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Ending Balance Liabilities</a></td>
<td class="nump">$ 4,326<span></span>
</td>
<td class="nump">$ 1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member', window );">Apthera, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration payable, maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826066800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 1,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Value-added tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RebatesAndReturnsOfFormerCommercialProducts', window );">Rebates and returns of former commercial products</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,219<span></span>
</td>
<td class="nump">$ 3,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RebatesAndReturnsOfFormerCommercialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rebates and returns of former commercial products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RebatesAndReturnsOfFormerCommercialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826143744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of Senior Secured Debenture</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of Senior Secured Debenture</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of Senior Secured Debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of Senior Secured Debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828096272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Senior Secured Debenture (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2018</div></th>
<th class="th"><div>Nov. 05, 2018</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 16, 2018</div></th>
<th class="th"><div>May 18, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed', window );">Principal redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares', window );">Debt instrument, redemption, principal amount redeemed, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash', window );">Debt amount redeemed, settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInRestrictedCash', window );">Decrease in restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed coupon rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet', window );">Proceeds from issuance of debt and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember', window );">Amendment Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Final payment of interest</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Debt instrument, covenant, compensating cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gale_JGBActionMember', window );">JGB Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture', window );">Balance of restricted cash over senior secured debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReimbursementOfLegalFees', window );">Gain on reimbursement of legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Of Restricted Cash Over Senior Secured Debenture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed, Settled In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Long-term Debt and Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReimbursementOfLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Legal Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReimbursementOfLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_JGBActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_JGBActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6839510048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Principal and interest expense, debt</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockSharesAcquiredinExchangeforWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Acquired in Exchange for Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockSharesAcquiredinExchangeforWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826524512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2018 </div>
<div>counterclaim</div>
</th>
<th class="th">
<div>May 18, 2018 </div>
<div>USD ($) </div>
<div>counterclaim</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement with issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Litigation settlement insurance recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gale_JGBActionMember', window );">JGB (Cayman) Newton Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyNumberOfCounterclaims', window );">Loss contingency, number of counterclaims | counterclaim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Patel vs Galena biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement with issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossContingencyNumberOfCounterclaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Counterclaims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossContingencyNumberOfCounterclaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_JGBActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_JGBActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_PatelvsGalenabiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_PatelvsGalenabiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6839079616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6843437312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2018</div></th>
<th class="th"><div>May 01, 2018</div></th>
<th class="th"><div>Mar. 09, 2018</div></th>
<th class="th"><div>Mar. 07, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,647,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="nump">3,748,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities', window );">Convertible preferred stock converted to other securities</a></td>
<td class="nump">$ 7,871,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="nump">8,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability', window );">Increase (decrease) in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock warrant, shares to purchase</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember', window );">Purchase Agreement | Private Placement First Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsIssuedShares', window );">Warrants issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember', window );">Series A Non-voting Convertible | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Private Placement First Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock', window );">Deemed dividend on beneficial conversion feature of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Purchase Agreement | Private Placement First Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockIssuedShares', window );">Convertible preferred stock issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Purchase Agreement | Private Placement Second Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockIssuedShares', window );">Convertible preferred stock issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsIssuedShares', window );">Warrants issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="nump">3,748,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">4,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 2.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">6,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Issued Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend On Beneficial Conversion Feature Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock that was converted to other securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementFirstClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementFirstClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementSecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementSecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815589968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">17,698<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan', window );">Options reserved for future issuance under the Company's 2017 Incentive Plan (in shares)</a></td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan', window );">Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedStockSharesReservedforFutureIssuance', window );">Restricted stock units (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance (in shares)</a></td>
<td class="nump">18,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options reserved for future issuance under the Company's 2007 Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RestrictedStockSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock, Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RestrictedStockSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6837276176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Schedule of Warrant Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">21,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="num">(4,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">17,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember', window );">July 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">15,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">15,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Prefunded2018OfferingMember', window );">Pre-funded 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">4,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="num">(4,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember', window );">2017 Equilibria</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Canceled Or Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Prefunded2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_Prefunded2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6841120320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 16, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants', window );">Shares issued for cancellation of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock', window );">Surrender and cancellation of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConsiderationExchangedFairValue', window );">Fair value of consideration exchanged | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnSettlementOfWarrantsLiability', window );">Loss On Settlement Of Warrants Liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightCanceled', window );">Class of warrant or right canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding | $</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of units (in shares)</a></td>
<td class="nump">118,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Surrendered and Canceled to Purchase Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued During The Period For Cancellation Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockSharesAcquiredinExchangeforWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Acquired in Exchange for Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockSharesAcquiredinExchangeforWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConsiderationExchangedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration Exchanged, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConsiderationExchangedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnSettlementOfWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Settlement Of Warrants Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnSettlementOfWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6841893232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">17,698<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 9 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">88.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 1 month 13 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">94.12%<span></span>
</td>
<td class="nump">79.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.46%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="nump">$ 829.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 5 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">94.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantsClassifiedAsLiabilitiesOtherMember', window );">Warrants Classified As Liabilities, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 888.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantsClassifiedAsLiabilitiesOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantsClassifiedAsLiabilitiesOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827474192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">5,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(5,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">5,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(4,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants, Exercise Price, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6838899744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Warrants Classified as Equity (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 16, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>year </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair value of warrants granted, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input | year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted, per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6842025072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards', window );">Percentage increase in number of shares available for future issuance under stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, grants in period, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants', window );">Share based compensation arrangement by share based payment award percentage earning of participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Equity instruments other than options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Equity instruments other than options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Equity instruments other than options, outstanding, weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesReservedForIssuanceAdditionalShares', window );">Additional shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm', window );">Stock-based compensation arrangement by share-based payment award, equity instruments other than options, employee stock purchase plan issuance term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards', window );">Percentage increase in number of shares available for future issuance under stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, grants in period, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_IncentivePlan2016Member', window );">Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger', window );">Options assumed in merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2017 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockSharesReservedForIssuanceAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Reserved For Issuance, Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockSharesReservedForIssuanceAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Employee Stock Purchase Plan Issuance Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockbasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsEmployeeStockPurchasePlanIssuanceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gale_IncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gale_IncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815701536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 3,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826244960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions for Option Grants Issued (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">80.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6842576864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, canceled (use per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (usd per share)</a></td>
<td class="nump">$ 1,240.55<span></span>
</td>
<td class="nump">$ 37.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">9 years 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6841955408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage', window );">Operating loss and tax credit carryforwards limitations on use minimum change in ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss', window );">Maximum indefinite lived deferred tax liability as percentage of net operating loss</a></td>
<td class="nump">8000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, increase (decrease), amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits', window );">Impact on tax provision from unrecognized tax benefits</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards, research</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact On Tax Provision From Unrecognized Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Indefinite lived Deferred Tax Liability As Percentage Of Net Operating Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss And Tax Credit Carryforwards Limitations On Use Minimum Change In Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827330784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (17,179)<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non - U.S.</a></td>
<td class="num">(11,869)<span></span>
</td>
<td class="num">(23,766)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (29,048)<span></span>
</td>
<td class="num">$ (23,501)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6839842880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (106)<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(747)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(570)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(1,317)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="num">$ (1,378)<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6798996336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,464<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">2,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeferredTaxAssetsLicensingDeductionDeferral', window );">Licensing deduction deferral</a></td>
<td class="nump">5,961<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Other</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">12,838<span></span>
</td>
<td class="nump">6,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,410)<span></span>
</td>
<td class="num">(4,658)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">$ 1,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeferredTaxAssetsLicensingDeductionDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Licensing Deduction Deferral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeferredTaxAssetsLicensingDeductionDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6829265456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-process research and development not subject to future amortization for tax purposes</a></td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="nump">$ 3,438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="nump">$ 3,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830093472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">$ 1,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6827175616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">34.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change and true-up</a></td>
<td class="num">(13.90%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826342400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of the Year - unrecognized tax benefits</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increase/(Decrease) - prior year tax positions</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase/(Decrease) - prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase - current year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of the Year - unrecognized tax benefits</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6839819488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CollaborationAgreementTerm', window );">Collaboration agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Payment for management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AccruedCompensationIncentive', window );">Accrued compensation incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue', window );">Incentive fee percentage equal to post money market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash', window );">Incentive fee percentage equal to gross value paid by purchaser in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare', window );">Stock issued for incentive fee payment in connection with acquisition during period share</a></td>
<td class="nump">119,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gale_EquilibriaCollaborationAgreementMember', window );">Equilibria Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Management fee payable</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_Dr.AngelosM.StergiouMember', window );">Dr. Angelos M. Stergiou | Msk License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfOwnershipOutstandingShareCapital', window );">Percentage of ownership outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AccruedCompensationIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation Incentive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AccruedCompensationIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive Fee Percentage Equal To Gross Value Paid By Purchaser In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncentiveFeePercentageEqualToPostMoneyMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive Fee Percentage Equal To Post Money Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncentiveFeePercentageEqualToPostMoneyMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageOfOwnershipOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Ownership Outstanding Share Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageOfOwnershipOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gale_EquilibriaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gale_EquilibriaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_Dr.AngelosM.StergiouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gale_Dr.AngelosM.StergiouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gale_MskLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gale_MskLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826951568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 16, 2018</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantExerciseAgreementMember', window );">Warrant Exercise Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightOutstandingExercisable', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightNewWarrantsIssued', window );">Class of warrant or right, new warrants issued (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Warrant Exercise Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast | Warrant Exercise Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightNewWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, New Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightNewWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightOutstandingExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Outstanding, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightOutstandingExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantExerciseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_WarrantExerciseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NR"L3O[CXTO@FT#O^ZB_0)02P,$%     @ S4!V3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MB3DH,0_YN2<!0"*E7H 2BY#OUQJ 1(J-,]AQ61C!KS>$B50<1WR-@P@D<#:
MB10=@^9^P"2,X)<=PD3JCF'_8AI&\"L/82*EQ[#-<>ABXA<?PL148*_CT,JD
M]%4 S#RB AL>AW8F"U\%P,1R@3V/0T?3X(X!F-@=@VV/0U/3X(X!F-@=@YV/
M0U_3X(X!F(@*@;U/0E_3XJ/*SF$*BVG=?RXG15%&_C,$_@.0T-W4N\];AYE-
MM C%Y2PO_9N )@U%P^7)-FLJV8M+:SO%R>K8$#[8'@G]AP_=Y \F3U6KDA>A
M35MCFX^C$)J;#65W)NVS:6#'2<V/NA^69BR'+FZ8:-&Y#A6-;?+Z'U!+ P04
M    " #-0'9.MRJVVL(#  !^$0  &    'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;(68:X^K-A"&_PKB>P_,&!M8)9&:5%4KM=+J5&T_LXFS08=+"NSF]-_7
M7#8B,^/MEP3(._9CXSQ<-K>V^]9?K!V"[W75]-OP,@S7IRCJCQ=;%_V7]FH;
M]\NY[>IB<+O=:]1?.UN<IJ*ZBC".350791/N-M.QYVZW:=^&JFSL<Q?T;W5=
M=/_N;=7>MB&$'P>^EJ^783P0[3;7XM7^88<_K\^=VXONK9S*VC9]V39!9\_;
M\$=X.F ^%DR)OTI[ZU?;P3B4E[;]-N[\>MJ&\4AD*WL<QB8*]_5N#[:JQI8<
MQS]+H^&]S[%PO?W1^L_3X-U@7HK>'MKJ[_(T7+9A%@8G>R[>JN%K>_O%+@/2
M8;",_C?[;BL7'TE<'\>VZJ?/X/C6#VV]M.)0ZN+[_%TVT_=M:?^C3"[ I0#O
M!9!\6J"6 D4*HIEL&NI/Q5#L-EU["[KY;%V+<5' DW*3>1P/3G,W_>9&V[NC
M[SN5;J+WL9TELI\CN(K@8^+ $RJ[1R+7_QT"10B<ZM6Z/I?KE5BOIOID59_$
M9!!S1$^19HIH14=ZX"%4X"%)1)*$DP AF2-FU0E 0D"$3)PHD$FT2*(Y"3EM
M>\UZ41F=$B&SFK8'#B-R&,ZA"(=A?>ALM8!F$!X"%6<>E%1$23D*F?A]RGK)
M=$S6TH&'(#6KU -*)J)D'$43E(SWDK.%\C^A!Y)<),DYB2$D.>O$&'(.#SR3
MHY8Y()9-%',2IJ*8C]?DH*F/>$PIC<;#XS$C,"LE'JN!K#5 /J*<C@@9*EUN
M0B13J6?E@VQ(X(K45)%+YF'64LWFEJ=@/ <>'%F3P#VIJ2>!2Q 1<HK#4PIC
M'XVL2N"NU-25P$7(SA./.$5YM "R+8'K4E-=@N#+/*5F$%*8:..YFH%L3.#*
MU%29P'6H-+V,""$PJ?+ R,X$+DVZ.O<@"#$&*BLII6+?U,C>!"Y.3<4)W(J)
M0D-I> HP]T@<97DBER<]!WOD5J1+6(B@ <^_"65O(G"4C** ))&4X?"8@D1[
M/(Z>FTMN84TM+&0,@_DT\T@B2Q@5NZ(8W]S*WD3N34--A=R(;"B?11XY9&,B
M-R:](]@CUR%];A BOOF0=8E<EX;Z";D(LS3.Z?VE$-,&M>]O*/L2N2\-511R
M%?Z00<8NM%).)R[H(9*EB5R:AFH*N0XUTOO1@Y#"./6M&UF:R*5IF*9R]A0F
MW>,),>D>+UH]"(]O)GXONM>RZ8.7=G#/U-.3[[EM!^N:C+^XQBZV.-UW*GL>
MQLW4;7?S&X%Y9VBOR]N.Z/[*9?<?4$L#!!0    ( ,U =DYW?+4U30(  !L(
M   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC9;;CMHP$(9?)<H#8.<<
M4(A4J*I6:B6T5;?7!@R)UHE3VY#MV]=VLFEBAP,7^/3/S#>V&9.UE+WQ F/A
MO%>DYFNW$*)9 < /!:X07] &UW+E1%F%A!RR,^ -P^BHC2H"? AC4*&R=O-,
MS^U8GM&+(&6-=\SAEZI"[.\&$]JN7<_]F'@ISX50$R#/&G3&/['XU>R8'('!
MR[&L<,U+6CL,G];N)V^U];2!5KR6N.6COJ-2V5/ZI@;?CFL7*B),\$$H%T@V
M5[S%A"A/DN-/[]0=8BK#<?_#^Q>=O$QFCSC>4O*[/(IB[::N<\0G="'BA;9?
M<9]0Y#I]]M_Q%1,I5R0RQH$2KK^=PX4+6O5>)$J%WKNVK'7;=BM1TIO-&_B]
M@3\8>.%=@Z W" P#T)'I5#\C@?*,T=9AW6DU2%T*;Q7(S3RH2;UW>DUFR^7L
M-8_3#%R5GUZRZ23^2.)/%5M;$?QW F3\ <*?A?"U?3B&6!H0G231DEI+X )"
MZ!DD#V43FF"6)K!H$FC0=))X%":"^F/@/-9->,)9GM#F,=+>A%8<D^2>8L(0
MS3)$-H-Q"3;10X9[B@E#/,L0VPR!P1 _=TL>RB8TR2Q-8M.$!DUBY1OTQV_N
MS#/*"5,ZRY3:3)'!E%J1?!_Z<9C$!I(MC)(X3I<W-FDY"[2T@8PXF^6S0+;P
M+I 'Y^L=M)&2&QYN5$SO<7WH-6-8+XFLPP2C*JV>S1^(G<N:.WLJ9,'79?E$
MJ<#2)5S(7T\A7^IA0/!)J&XB^ZQ[KKJ!H$W_%(/A_T#^#U!+ P04    " #-
M0'9.N5 0PJP#  #O#P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;'V7
MVXZ;,!"&7P5QOXMGS'&51-JDJEJIE5:MVEZSB9.@ DZ!;-JWKSELEGC&>Q/
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M6GNM.V5\BGM3O*/IOJ\/I=IW_6UB[INQ!1T?.GV:VNO@VN.O_@-02P,$%
M  @ S4!V3KEF_ 29!@  >R0  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6R-FMMRXC@0AE^%XCZ#);5D>2I)U0;(''8.F:1V]]J3. DU@%EPDMFW7]L8
ML/I@^R8!\K6ZI;;^;BF<O^7;7[OG+"M&OU?+]>YB_%P4F_>3R>[^.5NENW?Y
M)EN7?WG,MZNT*-]NGR:[S39+'VJCU7*BH\A-5NEB/;X\KS^[V5Z>YR_%<K'.
M;K:CW<MJE6[_N\J6^=O%6(T/']PNGIZ+ZH/)Y?DF?<KNLN*OS<VV?#<YCO*P
M6&7KW2)?C[;9X\7X#_7^#GQE4!-_+[*W7>OUJ)K*SSS_5;WY]' QCJJ(LF5V
M7U1#I.6OUVR:+9?52&4<_S:#CH\^*\/VZ\/HU_7DR\G\3'?9-%_^LW@HGB_&
M?CQZR![3EV5QF[]]S)H)V?&HF?V7[#5;EG@52>GC/E_NZI^C^Y==D:^:4<I0
M5NGO_>_%NO[]UHQ_,.,-=&.@CP9*=QJ8QL"<#%RG 30&<#(PG0:V,;!' QUW
M&KC&P)T,NB<=-P;QT<"H3@/?&/BC 73/(6D,DJ.![9Z#B@Z9BX:NDSHF^Y1M
M;;M-#NE6IWR;I-ODD'!URKCVW2:'E"L8NE[JD'1URCIT)U$=TJY.>;?0;7)(
MO#IE7G<_O>J0>G7*O>F9_B'YJI7]>E--]KNWEH-96J27Y]O\;;3=*]HFK813
MO2^MRL&K3VN!J?]82L*N_/3U4D7F?/):C=0P5WM&!PR$S)1C;,C,.,:%S)QC
MXI"YYA@?,A\X)@F9CPRCHI#YQ#$J9#YSC Z9/SD&K?,7CD'K_)5CT#I_XQBT
MSM\Y!JWS#<>@=?[!,6B=;QE&HW6^XYC3.D_*A_CX)&O^2=;U"!",@+(PW3.N
M9M8U@^*844)IY\$G?"R&C\4PL>!=M6=LR],9)$D<12BD*05QT+W$G!+:@@'B
M[)J)RD1@5)L,5@#X%8!Z'!.L / C6'X$RZPA5A1+LN6-300_CO?C&#]HMUPY
MXL=X3Q9OWHL%\<1\/#$3#]J9LY@Z,I&UPH;QO"//.$+;^\HSVR&AC\V\GPLB
M2OB($B8B)":SA'JR!F(ES+WJ==BZ%U%?!LWJJH':SEP4T2TZ'P"&44G56#%1
MH7(S:Z"VL\0YIP57@EPJ1B^-Q@M Y=#$S(/?SX4Q";*I&-TT!D_?$%_@3&P$
M5X(^*6!< 78%Q)7UNM5KA*X$(5.,DAG2&U$I4]9[UVJB0F>"FBE&S@R6,T6%
MJE1G3Q_L64.VZX%BTL^/Y^0'0- ^Q8B?B7'TC/II)J@^+(Q($$G%J*3Q>)6H
M_#FC3:N,A+X$^5.,_ID$SYX*H(M-PLR_'PS;*D$I-:.4@)6R@8*^P<661J6I
M4F(PC$I02LTH)2@<%57*LCMU,9*Y63\7QB1UH(RD I;4!FJO5 +,GM)44A$7
MQB1(JF8D%;"D:BJI<2QZ$A15,XH*@&=/%=5QD^_#PH@$X=6,\(+%$5'A-<HQ
M^VD &$8E*+2F"IU@@=944"4O@I)JJJ0)2095R#-M8LL<"T14B$I04\VH*:#)
M3S554W)*HXB-G?.)=&04%%<SB@NXWF@JI+KN[?!!K0&[3FH,PCW^U*-UFLT+
M)<\L*"\+JA%DWD3#3VQ&$&7#B#(^NTP-%=LS[1-<4QFL/!X[C_3T&S=<V7HB
M[#N#F1B\\FA3W#*@4MZ!M!1"+3#<=02:XU=#:\&9=TR>;P:3/QC2:UJ([_JY
M<)[230=WU9'@E-/ZHJ*8-)L,YCS0V#\RH-:>U/4_&2Y65L>Q,$>ALAGNK( [
M($-+EE;6T0S-&K)' X3Q#"$_<./5F<1WF4/!SPQ8[E!'P"\#P'"%A4IMN$J-
M[R(,+<") ^8T/@ ,HQ(JM6'.4H#[<4-+]9F-N(9\"!G&)=1VPYR2+'D>F8H-
M8&@2YT/(,"ZANANFNEO<DQM:NH6P^L$P*J'&&UKC2;]E:!EEU74^  QO1X5J
M"_10E>"^ YBC$B2,5 P PZ"$\@U,^;;X_ ),O>6N#N8#P# JH9("4TDM/L$
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MFZ+_([R&32?OG71CW%>;9O@[NW]IVFH[]=)9V98_QM_U;OA]F_I_;X8;T-2
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MR9?.WG,H'PXGF_#8]H>^.Z['/<7QI*WVTW[IXK!I>_T_4$L#!!0    ( ,U
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M#?BRJ?^-M0%0RNX&1ZC##[88"IH0C_=X=M.834:P_?R#V/*-RU]02P,$%
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MY703!8&",D0&@=L5'D"I2(0R?DV<=$X9@<OS"_O'5#O6<A$>'JSZ*:O0YO1
M206UZ%5XM,,GF.JYI60J_@M<06%X5((Y2JM\6DG9^V#UQ()2M'@>=VG2/HPW
MMWR"K0/X!. SX)#RL#%14OY!!%%DS@[$C;WO1'SB[9%C;\KH3*U(=RC>H_=:
M<'Z7L6LDFF).8PQ?Q&SG"(;L<PJ^EN+$W\#Y.GRWJG"7X+M_%![6"?:K!/M$
ML/]OB6LQ[U\E88N>:G!-FB9/2MN;-,D+[SRP]^D1V=_P<=J_"M=(X\G%!GS9
MU/_:V@ H97.#(]3B!YL-!76(QSL\NW',1B/8;OI!;/[&Q1]02P,$%     @
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M^ \V&Q(J%XY[?S;CF(V&PV[Z06S^QOD[4$L#!!0    ( ,U =D[,"^#JM@$
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M!;4+QT_^;*8QFPR'_?R#V/*-B[]02P,$%     @ S4!V3AS_;3JU 0  T@,
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MXS6>[3AFH^%--_T@-G_C_!502P,$%     @ S4!V3O%JI22L @  $PL  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL=5;1;ML@%/T5RQ]0#'%LITHB
M-9VF3=JDJM.Z9YJ0Q*IM/"!)]_<#['H9.;S$@,\]YV(X-W=YD>I-'X4PR7O;
M='J5'HWI[PG1VZ-HN;Z3O>CLF[U4+3=VJ@Y$]TKPG0]J&\*RK" MK[MTO?1K
M3VJ]E"?3U)UX4HD^M2U7?S:BD9=52M./A>?Z<#1N@:R7/3^('\+\[)^4G9&)
M95>WHM.U[!(E]JOT@=YO&',!'O%2BXN^&B=N*Z]2OKG)U]TJS5Q&HA%;XRBX
M?9S%HV@:QV3S^#V2II.F"[P>?[!_]INWFWGE6CS*YE>],\=56J7)3NSYJ3'/
M\O)%C!N:I\FX^V_B+!H+=YE8C:ULM/]-MB=M9#NRV%1:_CX\Z\X_+\.;8C&&
MX0 V!K IH/(Z9!#RF7_BAJ^72EX2-7S\GKLSIO?,?INM6_2?PK^SR6N[>EZS
M>;8D9T<T8C8#AEUAZ(0@EGV28$ABPV["&0Z?P0QG/GQV'9Y%]'-(D'N"_+\M
MTF"+"!/)<@Y%YH!@%H@@3(Y%"BA2 ()Y(((P!18IH4@)",I !&$J+%)!D0H0
M+ (1@"DR++* (@M $!X\PD0.GF;801F@"(\>@B)G3R-.I8 B/'T(BAP_A79]
MH.R&(K^1N<6PHHS(8%O3&:"H0AT$6D1TL/LIL'9Y4^$0*%)D*"X %+B[9*$.
M LTB.K@&4&#P,@]U$&@>T<%E@ */YZ%[$*B,73=<"2BP>1G6&PB*%!R*BP$%
M3B_#DH- 5:3F,%P.V*W3:1;Z!X!8%?M3Q>6  :=7X7V#H,A]8[@<,&#U*KQO
M$!3>-W+5D[1"'7PWII.M/'6^%;Q:G3J^!]_PD7_PH5W\SM6A[G3R*HWMC'S_
MLI?2")M+=F<]=K0=ZC1IQ-ZX86G':FC3AHF1_=B"DJD/7O\%4$L#!!0    (
M ,U =DZ-P1PIP@$  #<$   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;'54[V[;(!!_%<0#%(<D;1K9EII.TR:U4M1IW6=BGVU4,![@N'W[ G8\+V-?
M G?^_;D#+NF@])MI "QZEZ(U&6ZL[?:$F*(!R<R-ZJ!U7RJE);,NU#4QG096
M!I(4A";)+9&,MSA/0^ZH\U3U5O 6CAJ97DJF/PX@U)#A%;XD7GC=6)\@>=JQ
M&GZ _=D=M8O(K%)R":WAJD4:J@P_K/:'K<<'P"N'P2SVR'=R4NK-!]_+#">^
M(!!06*_ W'*&1Q#""[DR?D^:>+;TQ.7^HOXU].YZ.3$#CTK\XJ5M,KS#J(2*
M]<*^J.$;3/UL,9J:?X(S" ?WE3B/0@D3?E'1&ZODI.)*D>Q]7'D;UF'2O]#B
M!#H1Z!6!C$:A\B_,LCS5:D!Z//N.^2M>[:D[F\(GPU&$;ZYXX[+GG.YN4W+V
M0A/F,&+H K.:$<2ISQ8T9G&@_]!IG+Z.5K@.]/62GOS'?Q,5V 2!S5\MWEVU
M&,/LXB;;J,DV(G!_91+!W"=7)F1Q<1)T'9ZL087JVS NB^P\%0\T7/P?^#A2
MSTS7O#7HI*Q[/N&2*Z4LN%*2&U=+XZ9X#@14UF_OW%Z/;WD,K.JF,27S?T7^
M"5!+ P04    " #-0'9.=*D!'<0!   W!   &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6QM5-MNVS ,_15!'U Y2KRU@6V@Z3!TP 8$'=8^*S9]075Q
M)3GN_GZ2[+ANIA=+I,XY)$71V:CTJVD!+'H77)H<M];V>T),V8)@YD;U(-U)
MK;1@UIFZ(:;7P*I $IS0)/E"!.LD+K+@.^HB4X/EG82C1F80@NF_!^!JS/$&
M7QQ/7=-:[R!%UK,&?H/]TQ^UL\BB4G4"I.F41!KJ'-]O]H?4XP/@N8/1K/;(
M5W)2ZM4;/ZH<)SXAX%!:K\#<<H8'X-P+N33>9DV\A/3$]?ZB_CW4[FHY,0,/
MBK]TE6US?(M1!34;N'U2XR/,]:08S<7_A#-P!_>9N!BEXB9\43D8J\2LXE(1
M['U:.QG6<3I)+[0X@<X$NA!N X%,@4+FWYAE1:;5B/1T]SWS+=[LJ;N;TCO#
M580SE[QQWG-![S89.7NA&7.8,'2%^4 0I[Z$H+$0!_H?G<;IVVB&VT#?KNG)
M75Q@%Q78!8'=IQ+I58DQS#8>)(T&22,"NZL@,4QZ%82L&B= -^')&E2J089Q
M67F7J;BGH?$?\&FD?C'==-*@D[+N^80FUTI9<*DD-RZ7UDWQ8G"HK=]^=7L]
MO>7)L*J?QY0L_XKB'U!+ P04    " #-0'9.9AB)S;@!  #2 P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6QU4]MNW" 0_17$!X0UNTFV*]M2-E75
M2(FT2M7VF;7'-@IX7,#KY.\+V''=U'T!9CCGS(4A'="\V ; D5>M6IO1QKGN
MP)@M&M#"7F$'K;^IT&CAO&EJ9CL#HHPDK1C?;&Z8%K*E>1I])Y.GV#LE6S@9
M8GNMA7D[@L(AHPE]=SS+NG'!P?*T$S5\ _>].QEOL5FEE!I:*[$E!JJ,WB6'
MXR[@(^"'A,$NSB14<D9\"<9#F=%-2 @4%"XH"+]=X!Z4"D(^C5^3)IU#!N+R
M_*[^)=;N:SD+"_>H?LK2-1G=4U)")7KEGG'X"E,]UY1,Q3_"!92'ATQ\C *5
MC2LI>NM03RH^%2U>QUVV<1_&F^OM1%LG\(G 9\(^QF%CH)CY9^%$GAH<B!E[
MWXGPQ,F!^]X4P1E;$>]\\M9[+SG_=).R2Q":,,<1PQ>89$8PKSZ'X&LACOP?
M.E^G;U<SW$;Z=DE/_B.P6Q7818'=7R7>?BAQ#;/_$(0M>JK!U'&:+"FP;^,D
M+[SSP-[Q^"9_X..T/PE3R]:2,SK_LK'_%:(#G\KFRH]0XS_8;"BH7#C>^K,9
MQVPT'';3#V+S-\Y_ U!+ P04    " #-0'9.W85;T,(!   W!   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6QU5-&.VR 0_!7$!QPV3MHFLBU=KJI:
MJ96BJWI])O;:1@?&!1Q?_[Z '==*Z4M@US.SL\ FGY1^-1V 16]2]*; G;7#
MD1!3=2"9>5 #].Y+H[1DUH6Z)6;0P.I DH+0)'E').,]+O.0.^LR5Z,5O(>S
M1F:4DNG?)Q!J*G"*;XEGWG;6)TB9#ZR%[V!_#&?M(K*JU%Q";[CJD8:FP(_I
M\;3W^ !XX3"9S1[Y3BY*O?K@2UW@Q!L" 97U"LPM5W@"(;R0L_%KT<1K24_<
M[F_JGT+OKI<+,_"DQ$]>VZ[ 'S"JH6&CL,]J^@Q+/WN,EN:_PA6$@WLGKD:E
MA F_J!J-57)1<58D>YM7WH=U6O1OM#B!+@1Z1R!SH>#\([.LS+6:D)[/?F#^
MBM,C=6=3^60XBO#-F3<N>RWIX9"3JQ=:,*<90S>8=$40I[Z6H+$2)_H/G<;I
M6=1A%NC9EIX>X@*[J, N".PV EF2W+48P_RGR7VTR#XB0.^*Q##971&RN3@)
MN@U/UJ!*C7T8ETUVG8I'&B[^+WP>J6],M[PWZ**L>S[ADANE+#@KR8/STKDI
M7@,!C?7;]VZOY[<\!U8-RYB2];^B_ -02P,$%     @ S4!V3IVC]VNW 0
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M\>'X'L]V'K/9\&98?A!;OW'Y!U!+ P04    " #-0'9.PC?+^[8!  #2 P
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MQW=XMO.8S88WP_*#V/J-J]]02P,$%     @ S4!V3BWL%3[2 0  G 0  !D
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M?2J6@$-EW'1OYVJZ,%-@9#^_!61YD/)W4$L#!!0    ( ,U =DZ(;;SBW0$
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M9BZ76[D$6HSK@T.V5Z_\!5!+ P04    " #-0'9.C7-PT8,"  !:"0  &0
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MX_<83WOI#?F@(=\*D($ @04(*$"L0' F$).1D1826TAE(6B"$!I[N0L;9!.
MV007V9 @&,U/BXG.XH1Q%"7I*)_E)<[WD1\%<31*_+[@(/,0S#P$,@]A@0@4
MB#X^DS$H$ ,9C*PN6DPZG"-"KL1)P#C)W16S2!Y:"BD8)@7LQ+  1G"QHX__
M4GQEO\! %A<;!@1*K\2!RQC[EQ(ANB(!%S(F#[B%JP\#Y1?BL=O@8@T%9)*F
M\95]"\/U@H&"":])P!6#'R@9#-<,AHKF8GX!4#B.XYT=0>;6\9V*?5Y)9\V5
M/LWLF;/C7#$MB";:^T%?=/I.P7;*-&/=%NUIWW84K[N;C-=?I[)_4$L#!!0
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M,"7 1@&Z;($K ?YA@2P*!$H@& 4X7Q0(E4#X69<B)1!]""R[%"N!^+-92I1
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M=',O<VAE970S.2YX;6R-5M&.FS 0_!7$!QS88" G$JE)+FJE5HJN:OOL)$Y
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MCK?Q0. DU#:6>];W^/X@:#O,+V<<HOD_4$L#!!0    ( ,U =DZ["Z*;HP(
M +,)   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;(U678^B,!3]*X3W
M'2A0!*,F"MGL)KO)9#:S^URU"AF@;%MU]M]O/QA$6D9?I"WGW)Y[J+=W<2'T
MC148<^>]KAJV= O.V[GGL5V!:\2>2(L;\>9 :(VXF-*CQUJ*T5Z1ZLH+?#_V
M:E0V[FJAUI[I:D%.O"H;_$P==JIK1/]M<$4N2Q>X'PLOY;'@<L%;+5ITQ+\P
M?VV?J9AY?91]6>.&E:1Q*#XLW368YP!*@D+\+O&%#<:.3&5+R)N<?-\O75\J
MPA7><1D"B<<99[BJ9"2AXV\7U.WWE,3A^"/Z5Y6\2&:+&,Y(]:?<\V+I)JZS
MQP=TJO@+N7S#74+0=;KL?^ SK@1<*A%[[$C%U*^S.S%.ZBZ*D%*C=_TL&_6\
MZ#>SI*/9"4%'"'J"-F>2$':$\$J(/R5$'2&Z$B+EEDY%>9,CCE8+2BX.U9^W
M1?(4@7DDW-_)166V>B?L86+UO(JB8.&=9: .L]&88( )$WB+R4P,Z!&>4-#+
M"&PR-H%!'XG([B)R$Q$F=@VAU8I0\<,;_LP>(+(&B%2 :.CER*:-AD %:;1-
M*8A&J3X"RN^ ;N1"JUQHR V39"1%8^+!+BF$_DB*"?+M.F*KCMBB(QWY%AM;
M)- ?Z<@> >4F",QB?T+PS"IX9@I.)TY[8@V0/'[24FN ] '+TD^^BO;K+B(W
M$2F8\@KX]@+C6]R"$R$F:A1XW"]@K2]K$-P_[)L.=)/NY-$ ]B("PON?)N]
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MU1.E@DB5SHO4E\G)W&\*<A)JN9!KUHZG=B-HW8U>T,__^!]02P,$%     @
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MU@DE%ZF'N1KS^5R>)Y*-RY4#UGNO_@M02P,$%     @ S4!V3B .=U8" @
M# 8  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULC57MCILP$'P5Q .<
M^0Y$@-2CJEJIE:*KVOYV8 GH#*:V$ZYO7]MP* &GZ1_LM6=G9UALTI&R5]X
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M]E\KI:7Q&5X9;UMS:3X."KG6[6MLWNO^YM@/M-K96W%PO)K/_@)02P,$%
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MQ^!Q!)[E$._2R3%U')5.RR%VZ72H" RF0'5S7,T$J)L)=_R)"(RO0/B.K2@
MOHX=F,#T"D ON5)@-,5[-IN.W:;7=M/F;N):/(R=\-EP"N^R*3"9PF>_*>RR
MZ5+!\ J?[:8 ^TW'R[? [ J?HBEL=K.Q :*KXY5*-EMSL-0&*W6HS:G6U=/+
MX=4=F>.9?^'GDZ]O>;,MZC9X4EJKRAS%;)32LNM*?-.MWD[FZ\M-*3>ZO\RZ
MZ^9\XG2^T6H_G*9%ER.]Q5]02P,$%     @ S4!V3B)<8,"  P  4P\  !D
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MAUSL5',;Z_NJ:_.Z!R6/IH4-^CYZ]1]02P,$%     @ S4!V3L>G(5=: P
MD0\  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULE5?M;MHP%'V5* ]
M8IM\4 %289HV:9.J3NM^IV @:A*SQ$#W]G.<- WV<47_D-B<^V7N.>;.+Z)^
M:0Z<2^^U+*IFX1^D/-X%0;,Y\#)K)N+(*_7-3M1E)M6RW@?-L>;95AN514##
M, [*+*_\Y5SO/=3+N3C)(J_X0^TUI[+,ZG\K7HC+PB?^V\9COC_(=B-8SH_9
MGO_B\O?QH5:K8/"RS4M>-;FHO)KO%OX]N5LSVAIHQ%/.+\WHW6M+>1;BI5U\
MWR[\L,V(%WPC6Q>9>ISYFA=%ZTGE\;=WZ@\Q6\/Q^YOWK[IX5<QSUO"U*/[D
M6WE8^*GO;?DN.Q7R45R^\;Z@R/?ZZG_P,R\4O,U$Q=B(HM&?WN;42%'V7E0J
M9?;:/?-*/R^]_S<S;$![ SH8T.F'!JPW8.\&D2Z^RTR7^B63V7)>BXM7=[_6
M,6N;@MPQ=9B;=E.?G?Y.5=NHW?,RGM)Y<&X=]9A5AZ$C#!D0@?(^A* HQ(I:
MYD: M8U@*8[ 8!%,V[-Q$72&'4RA@ZEV,!T["*?&*7286&.J[A22>)8:I=BH
M6<QP*A%,);)3H2%V$$,'\>V'D4 'R0V'D=B'P5(#M+9!CD)2F$=JYS%E1AX=
M)AV%H!-'<\Y@D!D(8A:+,!$.0D+,LA"XB$V:(5#BB.-@,P$N4C,. CDZA$!*
MWQ,*NI0Z7&#.DD^0EF#6DEMH2VQ&,J.+U@ 3Q:Z3Q[0E@+=6M_:@Z,-</L1<
MIX(%@,0W]#0"1:&9"P(YZ$6PF!"@)G;G U!D7A(0Y#H9K"@$28I%#P"*3&F#
M()<F8.4A0%:HHQZ*986&MW.(8L6@0 PL#O6@,3\2ZPZW,:E#[BD6%0I$Q:)0
M#QHK?DIGD]3Q?X%B\:'L!HH@4!0[XF"%HD"AK.Y'H,BA/A2K#T7J8S8V HT:
M^SH.EA:*!,%U]%@0:/*)GL4TIH!\9L^N>]!5S[I^/$Q0BNY]4ZY[T%4_ING$
M=1DR3&2&KGZS(@2*'"?',-L9NOIC,PX Q0XJ,TQEAJAL_E5&H-B\78+1(%/R
M>J]GOL;;B%,EVY%AM#O,E?=ZK#3V5VK>[*;#=S?=L/HSJ_=YU7C/0JHQ2P]#
M.R$D5SF&$\69@YJ/AT7!=[)]3=1[W0V)W4**8S\ !\,4OOP/4$L#!!0    (
M ,U =DZ5FOLL+ ,  *@.   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM
M;)6746^;,!2%_PKBO05?!Y)42:2FT[1)FU1UVO9,$R=!!9R!DW3_?L90EMK'
M$WLIV+F^YUYROM"[N,CZI3D(H8+7LJB:97A0ZG@71<WF(,JLN95'4>E/=K(N
M,Z67]3YJCK7(MN906404QVE49GD5KA9F[[%>+>1)%7DE'NN@.95E5O]>BT)>
MEB$+WS:>\OU!M1O1:G',]N*;4-^/C[5>14.6;5Z*JLEE%=1BMPSOV=V:\_:
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M<R]S:&5E=#8Q+GAM;)56T6Z;,!3]%<0' #882)5$6M-.F[1)5:=MSV[B)*B
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M,L-,CT5[5VDGBC?=/2SL+X/K?U!+ P04    " #-0'9./&E.8KH#  ">$@
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M?2]E)U32<*%6^$'DN_--*?9=?YFHZV;\8C+>=/*HOP8%YT]2Z_]02P,$%
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M^= /AX5DW=CKT?3#*?X!4$L#!!0    ( ,U =DZ%$IJ/Y $   $%   9
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MV>@@A.:&S@1%&)S,^7H8E/R@V]O,W,OND-D-M&CZ W0TG.)7_P!02P,$%
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MU<%KCL<38Y(JQ^A%>=7JQIPG+3U)/<S4F(_7QCB1;)BN1##?R^4_4$L#!!0
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MFLDY,YW,+ 0=IB;MS?\4U1]02P,$%     @ S4!V3D\F@F.! @  GPD  !D
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M#@@?<(KM$\*'EB^[8W3G)$* T9W*1G!IHR=J&\'%C8#J#A([W?")W8K@ D=
MA0?I'0FX>E'\1+IP:2*H-C/[W 9 H7U,@"![2KR;WY*^NOPD_%#4PMDPJ?YP
MYC^T9TQ2)>A/5'9'=5OJ.R7=2]U,5)NW5X:V(UG378>\_DZ6_P=02P,$%
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M9;4A$MXDF_;R_YJV_B0C_*7,@3$EE=!1Z[%W9<^+O\#L3CX7Y4,17:=)719
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MWN!(?-DW9?03J-UM[9*O;]E:,#,B]^>\;"O?:!OY)[)B7JZ ^F2 X[;^<9>
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MJ94?:5(XX5;[^!_?%_W/[G?M32<&P_JUB ;'_50#HGW-$-P#B!G-CLTCI:7
MW]OH8*&BAYIH+Z8@N=BF@XFS<\D9V\HJUBH;=LB-NAU,[<\&,%\-K+V@GM/5
M%^ 'K'F?]"PQ9'[*S2A@\R7CI%]><_\6E;=\NYTFVC3QEZ 3(#T\/QV,W83L
M$JW9T%,X:9UW<G+['%3-8*"DBV?JV6!5'EY$/^:&?5,^?58^E_C\$5%)6$"&
MJIR+(G6@(ZE+X<<MB&3\)ITUK>G>Z6)XI4Q2A%L9\.^_F1AS__2L6QB#QW:"
M@?E,@L&:_8+_%H&\R3/21- 9!OP?,Z(E]$WK0RW0\(M6W6)29Y*N8?0C2J,T
MC+HCB_6K#11UO_GIZ3D#/@' ZSI$EYAS@7Q,\J%]"AAGD&.\D]4 8LOD"M'\
MT#3ZN2"KB+1$GV7S\^!Z$/UP>?E!G:_ C\BYM02-D'4.$24NBP$$ JR8"-&I
MLK!P='A)29QDB[JQ\?XN2Z)2GLOA:B]N?.?3/Z\7P4(NKW]V_F.A8Z\:=X[P
MHH1_N/=?7UZ_\'OPP>\H#!8&R@^35"JBV!7:\4 H_EWF[ .8O'!ZY4/1R)R%
M@X&+9-4.4H$T5]0QYD2<H>JC,^3D_%2^4-^O"W/9<G+P\?HVH%091Y'D+Z=4
MP=)/'!2YE34].SQQ.)84K*I__5\Y@[29SG']]OJ'Z.?KQBCAA-^R9Z'G5T[-
M_OG/DH%ZN<:]2^SZ?@)66$<?@ISS6C*G/Y$?LY@K7R1C?/[8]HM@80S=+*/<
M9WQJ]&<&KX+39''UJF;'3*TA/6 H3GWAPSN$F%M)Q_YR2ZX#&N2%6O-PY*OD
M,\@$]_6$(1NV*ZGTX)0%KSIRVCIJ83[_JKN\4:"T@AHGC[#7]\XF"!_VWDHU
MZ;JFXX2JJ7*J'"(WYU!1$@2Z30JV6Q#\JVZX[,0;((J.VZ$M5<*#>@@6#%4C
MX/<J(B[CGQ<+Q[I6Z<**\P:#(>4JFX.J<)]59<$."2NZ@()7@6@G-Z4YJ"H-
M#HJ+*]'=)(G&;'RP"\&%2CHJ>GG586&L52_BW07_=0_"1Y"O$XX.##$I;NEW
M)0/)=L9"O*HB^>N>OA6@Z^8HAIB<7L>![,"=W'QMT8GH[!-?)3U"Q-"2/(P'
M)/W\Y"_5#?#O]+Y%-^PNJ0B<G:2RSR>;9]5\NT+E?4X"9+[A"A%VM<W).PA"
M%YFT$2P^HPI3W]R'!A'5;/U%%^S%ZYL"[(PM7R"2CKK7YO+L-@\S/T*0>MBJ
MGFS:'W&W 6)"C?:8Q+_!62!P;[G2SKH*2Q)U;C*#)ZVG1:#J4!2KWQE1G>;,
M[(!94U&@GPY%83@/0_WHY -23_LF8PW:<HBW8(G#+2/Y>),4GSE;(/J([ZDR
M]/;-B_<?G3J%0XJ :EWF]I*SVCL8%\+4$'H/V1(",">;#=ZE5;E(<YXH"$(,
M-=7.M-H6Y0T6C<G*UMN-[.02K13D!?#06[PPT<1Q<S^U.S D\%X]]DW:%']V
MS?5%G@!#NYZ#)I)2FB%YU&G" W:I%ALO0Z_@SF>;Z&-6?S97PM 03]W%Z#A@
MC'36]LC[D=F&Y*$K')IX3[WQU:(YZ09T0V B"T;G9T:YPFC,.D\;%TS2'$0<
MB3.@]LZI9:5%'YB[@A;;,EV(-0'O$WPA!5?@6KB6"/0OKXPK(HS4,\.LR5-S
ME]W>P5 Y98F:<$DM>?1P+<!D3A_5DT8AX5@C+Q%(1;"B$_(]4<8W'R>8H/@:
M-KD!GLH:+''$7F_)(#)]&OH7TFSF("?@;C^*O]5VI3^".4WY:74K^1,N+0R(
M+.:H3AF(,+I@TP8IGHT>E:M\C'"B=YP@M;D[@'7JR4:4!))3C!&]H>*H]4$E
MH:@Y&D#H"7#R\I+EY9NV!*72.E/KA- !.&>YG/N12I2IO/GPD6*2+WV>C]?5
M^#.N6@FCSK!$T%5.<JI([Q#M\A;^9ZTZBD%%X7)(O"5%]!YT)N2T(R21%09"
M#:UCY-:_)G8..I')!^5BT$8;V9,<2\6FP%H7V"PE%C4QEQ([FKLFSTH"[$FY
M7#;SR?D9]DT"3_+E\'ZJZ.EW[ARPKRN@E;]ODVK#U0WM?"\W*77 =B7V:J#
M'9?Z11O:&#[SP^7;5R>GF-?7]#-+QI%Z5HLV7@TY"2],FIL&#S"3"0X'Z%<D
MERM9<TS<?9?'\)[,=;ZMT;<Y=7^Q!?J+OA8F%GY\NP;EIT!/;HZI8(5#54,%
MB/:FK/E*E)2R0MR]<A5406Y!W+63_O@31M[!>W7/&AM(*M6W4!ZERRVV++A'
MY>M:6<>4CFB)Q\WQX_FVKKU!9TS%UJ4!BTV47O\O8CLBQZ]K+]9K 9+VNY]R
M\QZ=*H6GG'>\1OU1E WWS:+SWNIX+1.-->5!,#5R3;IMPC!_%A@OY"VDNF=#
M8,!,.Z*P"4;1;G-KLV'%F2L)4WM B$'<&72X]OEP8+#0T"O'.KG,Q W4F)(:
MH8WOYZ3(A%QJR25Y2^YX1:'4;LXU][! @;*OX8MR+IX$NC?D\\7]N[TEV$4N
M&[#S))Y7AV?@P]<-%LL*$VG3\-><D34VDLW1M0MT!Y>D;(%L1)=;='G],Y#U
M@!3@D^&IK:C$:ACU,,:=X^E%6H'QLS42E\D2_XM9RL8J\1ZGLWD2K/7P67JM
MD340C%OR[\[D#JV"8,V8<C%7CM))1&]::JO+7 SFE-6BTU!2$@KS8!UQX_P(
M@8P*VX7M;;I2+S!O&\X+3W3/]YW"<6L(PD^H>V,/&":\12 SZ*;CK,$,_94C
M>V99=F^-]X63P[DXO;N]#I(5\DZ%VKJB"/;'9K>)1F:GS()Y% ';/!\-+IQ,
M(5]0IN%PF0]9<$:.U.Z;TLR 1:O:.%(_J>7*<!SE8XI,AZP1&J2WRA85I>UJ
M9=UXKD0),<_5D<7_'EVRPYZ>YO5?=M6B._>"9$J@C>W'(J="3N?L$@L?V;<L
M\7I#D^8.8@8L*QMN&U@]A^%(L_/%6_(U&Q_5]<A64^$ ):M@&D.L]CZC[TC:
MQ  L0RRA?YV*J_!-H>D]'SD<G+$SU.< )6$T'R/M>7(+OVP>4LD7H#_2QG"!
M_C(55YG+UE#]+7.?J])L=8/Y'LS[;'X+*'RH4UG5D%:H4?_@$^XN:[H@-T"$
M?WT,IA!WSL$M>6F4%]G,OJ%=FD3?8LAP)BA/T/QN<%6#R*)%7EFX5GNW.,.:
M50Z/_.HB-BP1KJ)/Y3J;1S-48,5Z"(8D=C+^7LJ\F[]@E:0/"UWA,&IRN 05
M]5F3(<?2PP%FR/WW*7EMZ%E7.6N=GPKPA'@D"W2'+^BLW=V.28O7_P2F!Q]B
M7ZY4(Z);+FFXP(*RVZ R0G:\>WX\(XETWU+8=M%P*WE%LP=3)#P?V4D5+LH@
M:R[XX:\ZW9#V%U3M5%$9G7L<5>C^-?%4>=PP>=<B/,+P!=N)(.'MGC8\[6Z>
M=?<F]:Q;B,.%Z1I4.1U.3Z;#@,+X3Y[(E&8%I_\%'<8'A=,#FD XS%>.Y[M*
MYG>6/DJ?ZJ61]UO).$ ^)*DP]Y1%:R0%1?;XQ(,;WG-2"JZFYW,9H,V)%JJ^
MAF:TPXLE&8;WWRH"==IYT%1J"[KM7#J%>%4R]+[QNR>!$RXV9;8G3O7S([1U
MFMT5><(TG8D=T(JA]1:XG3?D* <I70@Y$2P#1ETXIU1F)%ZM-N99%_TCB*PE
M[(;9,W? HS0\"=BFV/6_=%,_:W,2IC9[YC>5R14C%CEK^>&]16.$L!OP\%'P
M!KW&7AK?PBOUR_=U(S,BJ5NF[WF1+1G,94PRYF>+>TUU$A.-\85)Z%/*B6-?
M'!3U\*AL$+9,\P8G4[@HQY/HZP)_.8BN!&H,]FR[>.19QESO"O<SU4X-NY%V
M\8TJ==&-GID 8:S3.1M?0A"40YC,U4OFJ+,V)2Y.0IAH9942[)H0CQBF2W5K
M:?8AVO";K;B%]8 <=V/T,W4(:;Z[8Q1<-@5B[]%G%LKW]!U6NLUPSA6#7[Y#
M)77QM $M686:CE??=M6\RW$,,(+?< JQF._(&^N85]VFOX#4* A0"VD0/(*5
MJ%K0YMQ"2U^;B*Z5'9?$Q<5\JJ_&$V0$C!_E6!FYY4Q/V!Y)F.S=%4T!M5%6
M]R'1ZFW9TL,=Q3CH1 X(?2)IWJ1W2;YLI<IXD 95GA^PG";V)H8ISG4Y<4;!
MMAF'--U#_-CPP-\H/]%[L&KUC7K@JUHT3+*,V*8%FB6_B)9CS4FY3^K,I*4&
M+P6%A,+"X=31UTMII)\083M8R+8675;F8UQKCZ#?@MI/XKP1@+: W8,H:$G<
MET8A&H5(1/45>U529HM#S!5%C+ACHQL;1YWY-VMG=21E=(9?77[HCAP1]J?"
M>:ZE(@EGA6ROJVDD<S<7'JD>E]Q6Z0D;TU!%P*ZGX!&^59%#D1-<^:)C%MTC
MNTN_2"B%#D/8$WLV,,U4'%@4, 1UH*R0>=OM4^ZF(]\XJR\EC ]!HP+5+F)'
M'FF5:(9IZIY#;2:[CYU.Y&O,L\^H4I*K!VF9Q"QEM+OFW*[6,0DS()@0!15K
M(QD*Q/2:9;1.1Z>H)-]@\3T[/P -Z>JDM)0#O;J;Y'-*TS"U$/@W9!\9Y^%I
M=\DJ!=JD]2TSPI;)I/(O\4/WKKQDL),:9[-C#98F2A=>T'L2[%!P/Y#%=9YN
MX(1@^LUL<A3&/'OHOI'!E/7>L,X$+[1ZR.8['9Z,AMZFN0QYB&5)'<8WO^T3
M*S^11="]5'&^4^H\'SE=C-(!-% 4P:]&> U?%>>RZ,K<<IRQO5]5[VW1R5MG
M 6&6=-VB&V*",-^LOM.+9/+A7):!K\3=><?H3I$>I?<LN&"'7BZ?:L8[0X$I
MD0I2GEP0 GNK@X/E<QWKK0-=,J;"5N!^&]$G)1!"M K\4^TF'TMHU1FPYBFN
M=]@6,,3XZ#Q;A/OR-TF09 IE <]7]Y[5]@)!#0@=C2#NYWAEJZIT]?4]F[!C
M X)Z.2PF[V.B&O4'RC$5*>*Q[7I'[2\&OR<JEW_O,EG-S)Q?!E\2ALGG;CU7
M5$IO/%M8<Z;JD7%3L[D0?LLRV]J3OW62_FV[N.7"A,26LS ( 6(ZD8!639@D
M,#=&>8CRY(':'CQPTA)87QN?\N+D.C]%"N@VI]Q=C.TD7TCF<Q=P3I![V<$L
MDS#1K1%:]S5G)LT17?,^EK;O:<]]U ;;YZB5:K+/1?E0-,"%QY+^A:]@[0!E
M6"C;"M/V)<I*1:FP0_0$L-[H:BO+_+&\J3'/CS&TA _3Z/@8_&!9,85R;K-:
MNO)AQFYXRHT=">=">8[)@Z:ZD_<' [3-&NP*F;<+FKE4%%6+D"S&HV]0&E72
M7-I@?MBI^\0:RSG(!&3/17"5=RAK0O9(@I4D!,,,-+Q_2%BIE;O7XWCDU =_
M=8UZ\WPT. WKM8(GG:..:K4F)DO"*[3D9-HDRZ".^,4V1\3%@J*J(YBO ]^Y
M?('_[;)O'A+;G"U9+"K-_D],P B^[U.]$84CVVP5F@*%' 91;ZE7/(JY />#
M]UC]#:;[A(^%Q*[$A2O8BR1_Q%T["N GUUOA$-0*U62Z F=.LEP ,0@31A)&
M A5%=4B[NY1X[G0#2V6#ULT\9]?=PCI&FW$#N>K-/&G9<RKR0U6S#Q&/9HV+
M1^7.>6;<Y83-W$J]2[/$$>^%!UXQ&TOBL'16>E G:2%&O7NXJ\1N$&&+%FKE
MC@VYJ64!53K-?=MMZ=)=RU&Q6YYZJ^$\75\L4S?4W8Y;H_</TEP[TN;:+<36
M9GV=3:X5+RUYKM6I_5+ 99M39N>G), 023!@#"(V^+BD0U?Q98"535C'>3D,
M'I_+:%-C,6\W-L[O=@1D6[ 7M0V+S#G$E*MME..[L-4\Z1'22*4/4_!-(2>D
MS+C=F;RP[=0%J.VP(V'_E/A$$3@5K\)-B6G[XN6GI9I<9JQDD,4Q(W$?YR24
MF&>%Q*] O8+P(>?FW9W^"^J6Q=R!.6?B^6Z3]YK&[&">;%:N_YH!5#*$9>JH
MOLCW'8T8)D5IG+*=K6WKZ@_/,WZ4(\9H@ITQ==/;: >[X^^BOV(RT*L>V42,
M[*H3-1!DU-G%>71Q-I&XH5+?Y&(:@97S<R\!2CQS-*'_.X]'P[/HXOR,V%B5
MPMG5.$_B$=;X8-Q7J3>1.*I_7)@QFF/X(NOR; 2EFMK8Z"H>HHHC-U&GE^?W
MM2OO0_I;L#*Y!:.,=$JC ]#1"2PLT9\M::$C#8N].]1IQD (D.[LG.6L3=1F
MA7,CCS#\GJXDOE?Y;S$?]IX[FT6N^:[.RT3Y\!JUH<1TK:K-^0-P(QM@?#PC
M(UQ;OW&:O;3<-+,DV$L39TFSC59=VYA#Z7SO@IV&%K7? #.@ VH),]2\QT=R
MU?"^UV6.)K+Y6 ]HPG'';GI? Y\VA3C)OF:2RU;(M%L;T1[(BBK%Y-<A+?!?
MLQKF:12;4ETB =P0U$2ZN%6(AZ=2=$,-NGN\J;*%B0T%9VWEV=I@,G3.5!1Q
M,1Q%I;[)EMMJ3EGFK;$<IP1ZO2L)]ZE!V?P9]92MJ&2X2M,3+]?=SG37#?G8
M*ZD70D5S8.2H_T@AC_R7"WN&.9/.W8K(PJ03:#4=IBRC-[?"[9\+GF)6?W8:
M)/+A!?)D,TT_.2>YYGE*D(&,)@%:(EW5P!@__)NTD7J< G1,?^>#-I^GDX8I
ME@L\*Y+*ATQ:S.;@.YJ4:T/O 2>2\C-?.6SKQ=O5Z=UE[%SOYZW/(#PM_CWD
M$4E5D&] 92@Q$YJX #6#,*>"UV!A'@J8$-ZI<8?H#7NVQ,EH4ZN0=#^K3"&X
M!G00N)5(FZYXRW<8]<6/JD6:)!RRTE")5WZKHW-U(G%4K)CF_&"G'K)?A?D"
M^LGYW_*L0)/&Z#J)07:@$<5!N4SN@7\R[D12!%S#:6 -WF(..E!9X1"52U!.
MCZI/#9;0T3^$[10"&"( <^=Y7(0=I;VO/8.IP)!PD3H*UH)#<6>>%2WD6K;%
MG+#R[NHP:M7*.#'IDDWD5M$7!0XS*$D.,,;D]K%=DMUWG+B=.,>[&\K(QW2>
M-M J*N N*&299WX0V+3+A60;@8T@#:"X?(1RG\1+8%*UST]&D]C6@_YD5*,C
MSI,Z'P^/P?)R==JO*[AM#V7U^41[V0K',\]\M*E7>)(]GQC09&0BF!6$4AK]
MA8N%@MVNRGM34B@I$G,Y1??!,-<K8#1!$@RVD=95"6P-=<5ROS8VAY4D=W2:
M+D@U%)J,:;+[Q=5)#M%LY9R*3N/!Z%_XN(>480QK9PN,N#G716N2"/C@.>JV
MT)!!=$N&&SG)"#M,2I:X@6/18<6@U6>\A%WEFE0U;G!%M5JS9W]]ZFJ!]@KM
MV2+L#FB5;X.?A(6\:C>M.:<=6*;WD D>7<ZNA14RFHIOA6XV^9TH7N&2VJ0+
MBC.TT:5.?1Y,.<82B(TO#2-S2#V1W^_VQ*A]BYD:,O2N[BN.WV YD*.A!97A
MOF+]0>]K1J;Z"LO(,/)0:)6._3LEH?K7(O90K@C4C*I*%JSC^FLA#4*M@Z%%
MWY0=D2=F+AIH\^@^P8B:1M:Q*,ONL]KXLS1<I&EWSA4C]KW[9#@%].RJMJI)
ML'M1+LA!HCA)4CG7R_Z&LSAZLR)D.)O4Z9(WR5%VPHF?AOUJ_K&KEVF9 Z[_
M1)A4W,P,](F!^ +61BB@-*>C\9[BE.OM&G%,T<WE4U7IV?3+.BFD)60]+]>I
M3?-%N'=%6<OSKBF%T+8-+;;1K;4]01;^I(J&B8XT,_VOH&E?S-=7SMAC#Q5N
MTLT:17<<73MJLZQU8 Z.&9%@EK7;(1![^RXXH+T[-V@25J \2>@M<1<;*Q11
MJ?;7-N JK$)(!!#3SA)T.G,)-=RKU9;=R2?2/<H[A=D\Y^R&0*^6[0XZ7G,>
M@6.&L9-O:#AU]ENV.R+^)%(D79H4.=:T<9K_K+O9KJB4S!Q68O=\ "<EL(N!
M]*"AM"L1._1\Z)XOC@6V"OW6 L#N &E[)?I^";U?Y-- _SRV/IS]3V;KF %M
M>'H+_E6CO91:G3I@<,_J79*/ P584BT*ZXM\S\W26M#;9SMEPMG)< S\_6U*
M"68B3*0CQQYA@NDU ?I94[*(ZGDZ=N.SPN1'&+E?CMS#Q]%)] E+K7%AP9#:
M-<5(27\%B.&BQG=2+D^0UU!H[N/[GZ/8HG9XWD3U@*D@QTJ].C[N<Q$3R@Y)
MC6=3A+(B4L)G4]^.+N>5L)E.UCFV15?_\&@L> \#7;*FX8?^.G%1\ODSXK9F
M_ E';')T)E\ER@2;@!<&^"E(KW"J(;FQG18Q:)$$)KT$=H#>>([Y&L5S/\LX
M;[6=XSLB$41_F.Z#VBIN9(T"]UQ0!K65YC1/DBR4QJA;%A"4*+=RECY?<]/F
MZXVD)8]L=-=\6AB#^T@S9:R1 \-9A"$MMBBQU>+$P@<<8$-?R@F\*7R#Y .X
M!1YF$X=DT'RDD7O6 G1U,4R%R.I%B"6_">X-\,+<!0"5WO"J:UT#ZE_%POQE
M4V)44=/IP*QY<.3ODW05BX98*@/*-A(*6ZOO)F/+YEW*(K:2:4!;B'W;*R*T
MIIA;D/@XN(J8()#PAP.@Q ,J;;[0LQ'.&T4V8W=&R8PR,>!H//=");I4Q,\F
M@!,-M388H\V@YD;"/I34R^JS''M0,>Q*46J=<]P!N-4@N5AK @(ZM(1F_;,[
M=CC@_,X5Q*2FXI]+F5KF>/?&UXV=;\9-^X*EO3?F>32-)Y,9_',<3T!;:^(!
M=;XT&IUB?ZC3R0B$]H8 ;K_2ON)T3J<C^.=H',_ A'O3C57L]_LZ+;!&YAI=
MO$1W"D/$GI4;WE&&(VI@]EH4(PI<9NRR3ASJD:L1 L9:<3[3N>&;"C]AXN<.
MN<K4J(&U7<PIE4"7G!4A<+68Q@Q+RTV"'*-O/A1Q7VN#8]+]?:4] F;CS&X2
M;IHY5C8V$GUEK6\%P,M2/V4!S;MAO1N)8KJQZ8(Z:XTMQ$ _D?7N$?*!WE-_
MX'B\J%+[\>C.=^&"VXE;*'&<[W.[D+ZQ>[+H;');W N#]8>O!H!%_;_\N?1(
MZ]G)$&[(M?I(?K*ZNE$,!LUW4,.LV,TC325"S[?TC*\\/#ZG]G<[#1Z,RA9Z
M!+B89&6GY5U*DNEI35JF^6Y_*0XG!>RJ!TJ=A^LLWC;*6TKN$WW;!SJU9Z*X
MIZ$3U'A =^L=?([[]8YP1YZFA31)X.OK(4W(\DOO:VNAF:N;XLJW.=K5P=D,
M%>8H7W1QKS!_\2?3**G1%AYQ?QBGRLB<$>^=OI;42K,IISI(DYV@"Y.'-K4.
MQJX"-XH45NG-8W,N#P9:@)D]G\R\([>8*;FC^EU3/+%).-A-<;L"7_:FA=#2
M1)X.,R#O4NS7!$3RM](C'*;1?2F9T6&SK+DVSY4$?FG;JJ"U(8""" W>3KM[
M(0BF9.QKE-/4+Z0FCNPM,\_]9 >KF"\,.GP2W)HFTC;'T&G3L;N$ZRLJGT+D
M[\K[_UKCIP$-QM3[)I-L8^Q8:Y<FL]7=;=21N@P X!]HXR6W!D<5UM X*"Y^
MXTYQ.S]#AQAJOP%]&$W]S@/W!$?'\=V'$".!4/3S3N7V=1_DP1\HK'0BEZR=
M?LCJY.GYS &%=V%"=0\69!':,2=C47X;ZZ%O34&5-O?>AKS1)WN3^LPE800>
MV>&02]^ =TD\)/@>X#DMG-3$?>WKX[?#^L/M5+P/HVF$$4Q3Y:H;!1;,,(7&
M#FGTY, 9]T^G12&7X9#?L>$#)Q*?C\8MVP9,F,GI&28S6F2$#N#$23P:3CI@
M0S';=#CT,'*C^ (L(Z:*YNJ>1Y/3>#:;1F_;2_Q.]:L]'6?0.CJ[&,,0F^R6
M=]ADU8SB"4SF+6B^C/A,,,JPQHOS<\S2.03NFT2[A?2'0<<7I]$O LWB'4KX
ML8NP:-C^>#:;R#YTG>AS+#H83\\H[;Z]47)__GN;P'N2#"<MK^KM6L53AQO,
MH*<Y*I,;:#M5M&J>3">6M+A#I6IA6W51^E!G0Q<\I=N$ZTH%DU=_$B"4DN:+
MZ'"\ 5CMR,&50)S=-M @32UH6,/NI'+S*O(E1 RUDF#7DCX=RY:H@ C,N9ZX
MH=H(8AL6S[@6H9+#2IIRZ'&=M4I" K=9(UHAJGI[PG9FL@^: Y51G-#[@^ZE
MW5C2W9*K,TIB93(Q8!+,ED0X6W_'.F.U SA!?\.^+@R8,6S"$R9#RA]9^Z;"
M;K K\7U&UX42R4.^!U?F:'P:#\\OHF,I6]E=[H",9#":$A)3A<1=L>M #\**
M*X'_(Q@O-$<:$ >6<-#1\'QJ&E$?Y!>D!&!W)DSXJ:DZ\--W+K+DIM0J!YE>
MZZV=G_2P*.Q53E#CH0N\3&T;BO8^H OH=' >> +$DAZ-+H#MC?NJ=R0Z':H=
MSX<&<)&8PY)#3(BIE6<WF,5[)0S%]$B0%BVNZ,T_;1H<+7RB?&C0>#281M-S
M,Q=,)G/0C@*'XW,4!-8GNU5;B\)'0$AR,<$^1Q6Q%]K1:(,!4%^[Y,339#<#
M.X3"FF@H[M"!5KT+IPW=[/9)*K8ZD%F<;=*F%%J"LM%&.$O49N\A?'YN;\U7
M77S3^'7*2D*HD4UL]".T6NOC)[YEDAO[S>[=8S2>CKZL\N_J=3)/_^L97?SJ
M/GWVQVC//.Q!J]T>H!8WP8I+"TA,U72<ZM&-0PRL[_8VY<J[>W%2<L,H1M>H
M:2[^&XW.\8P@RLT1'&:!B=Q["*_8),A[IYEG3%6:PPA%T$R;/::$$T]F]))K
M;:T_JK7\S. ;-",_3B511S+(VG[X63+C A8RZ%"8#1Z3P0LW2$,(HQ2Z$@9M
M9'&G".Q 6!)<@R#[YC'U0$4M%//F\MN8W@TP*:=Z'5*M]N[#-6GO,]#0]9\.
MWUV!/B_ S) _3^#/N";YCW$TCL_A-_[?Y]%Y/*5_B@$2SKRU7XV)XUR M=Q6
MR<JQD#5!<3DP4#QOI#*-Q@%EW50$?2$_@;*<A2FMW=.6[]1/^%!)%0.%AFA!
M[]V0*['Q9<=$%W_;TE5 2X@<P?]_KX!_5J^ CBU(-NVEB_N8]YJO)U<[H"[!
MOM+#  1:PNPJZ!:/BW@K4'R7VK6SU?NR_42_S.J10H=\%D-CRLUPAS67KM$F
M#?ES+5 7- 8Y ?THLJT68HXVF?%'-$[BCX:HK'Q,<C!=W3$%.+ET)4WT4, +
M%6]'>ZD&W+2P#)/;)_?A!#ZRATFQ\I8$6I6@*([99]R'7T@8B&0TXQ: SI4$
MZ(*WV"BPG1G4^*#KR=>S!SP#ZPN%6:"%42>YMUQE2DRWY'T!$;SE G#YCO/1
MHY_9I@@3,3^JP)7I>7P"J6]5/"10\/(MXK@@:C'J?2X;Q5F$G]K?0' R*NF4
MH%#H\"T1C%Z"@_@-Q5H/CK2Q^;*M%$I([LMLX4%5O>-(MO)[; V.QD'#K, 0
MLE_7G#*0["<SDY&!,66QN1A=52 O05@IINA&,'M+*JSE]B _I:"5X3Y>YR6P
MC#^GF+V&#UVQ<+BB^X1!G6LLO"-!?$IR&/[7@L7\=/WGZ)6+Y;V$W7&((:WK
MF0H43>)P/GU+8#OF>VW=A(.W&()'),$;C8\P"?G>#38OP2%$2QT^59/KYTW%
M27@SL:< C.P\#[]\ D$$&X&-V.^3^1S1G3RNO>U"(3%:/J'="VF=NKU[Y0T7
MI$I!$H&KTKBBYI)\%D Z]R=UJ !1Q_1-4CL=N@JE:9+H<Y2\?Y:\S6QU2@,B
M_$:&NO76MX#U; 2-:W+@(4H:2Z([::!'#=D,+C)Y5[4(@\;TP-*A"MM&]W8+
MHG+L[!Y8Z&VJX#US=O/JX?LXX--.A-T1DWAT<>$JWDMZU6G.N)318/I-(_;A
M.V]M'5A$*M7BWNGI"*5]BU1E*6]R]5 C.2,H<TU1]IM'::.C7.@LGOII<G4W
MFF$]\W+(47%T!0QC&;UR;H?W['90G/D3ZL6,__VRPKR:6[@O=?038@F!79&5
MVY8L<1]A1:@Y!$B[398L@%:O04#" /GFU_(V+[?1T4^#EX/C6#8Y-BGY&RS7
ME;;K!%03$,0N)PWNFFRB>!B31Z>)*2.@Y@FL/8DOP:F)H#=-C"EF[5 3_J$
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MBJFW2/JXD%<+E*L;=79J,YB8$-T$I0D9SPE<0T1>98QPA:#HF1LGE)'VS4
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M\.C.K+6 SGA-8G/:7**E340AFZ3KH85$AAQ*6M.H=/=JAX"(=[,YU9$\ L^
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M[ %N?.H;$49<V[Y=8^#2;<#Z4PZ3&@!9J8&@0+\#T>5X2%A3XZ'6?!K2$:6
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M!A*).S]:Q;?UG>$7KP4O^ U(D&B\^EB#R (FNR=\PG%\'-CJ^Y4Q3V==W7F
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MDJBP!22+^\J,$9/#4X H/J7N^6MS+13X24Y46;D6#3^Z75,:VA=;%0:ELE^
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MMVX'.$'/J PP,B-1Z807<>F$3IJ]+>B2K<# 2G^7J)7 E>['J.0*BVI$_98
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M<;.CWD5R\J.XW7ZJLWYOF+!*CE)!"JK62-Q*XGVH1)(86[8P2?3]N#=+?-]
M_.*L-_S >6P\_Q+,@:_>IQS1&!TAVWK)0,5PZJBV/8(2'UBC-$-\]7L%913I
MLX^<@]X5IH =4U#+THR^L] HV0M_.7MILQ?.064WK!*+#B*_W!**8/9K\XED
MC;=_] J"Y)\VVH^, _"AVD$)=EW2(;MW.4?Q7X\;&XX86<X)*F^>ALK+CJ*E
M!HP'$RBAZF72\R$Z/-Q8AIE4K.DG\'K>>4]S4I1@.GA&9PLDF7<M(-:;<CC^
M%QH\MK"Y!S!=U(]F>("(DLX&;F_H#J]<<J(]5"N\G,2YM,MEH/_+P#<C@2!?
MTC6ST*KZ>T?LJV #,[AW+W> ''5GI!W$D;HR1'.WVA[!/;3_K1T[SH>Y<XJW
M-IZUP-U=Q Q]EHIW"_U'76! 3PWRH.RW:;HZ@5>H)G[XF'T6>;Z:CK/S>2F8
M>".KK$G ZA*T*Z%+UC+M02.T%""PL3FAP3%G\L\%ZX)8]<V-MQW)P@N1^J/X
MKEFHN@Q/;.<O^_WAW_X/4$L#!!0    ( ,U =D[CYX7260(  &0,   -
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MH#%#C$GY(V#V!TJSQ 64]L63GD+Y)&#V"9EO=5N:\DG [)-G$IEC.#$FI9:
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M>I!? QG7_"2$-5]K#[CV?*\] -OSQ?: ;,\WVP.T/5]M#]CV?+<]@-OSY?:
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M?+T-Z&U\O0WH;7R]#>AM?+T-Z&T+/&N"'C;AZVU ;^/K;4!OX^MM0&_CZYV
MWHFO=P)Z)[[>">B=^'HGH'?BZYV WHFO=P)Z)[[>::)W.=9]WOT8^E-S*+<N
M^6?XES43N,OP<<ZWS[A._7+_1.EAW)+=]?7F?_'KU#\1;EI1GGX#4$L#!!0
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MK!6*K!6*K!6*K!6*K-4)99V/Y6"[\:,D]\[MWN:S^1^^5\]02P$"% ,4
M" #-0'9.'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    " #-0'9.)^B'#H(   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,U =DX<Z%-[[P   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ,U =DZ97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ S4!V3H"_>H;! @  ,@L  !@
M         ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ,U =DZW*K;:P@,  'X1   8              "  >\+  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #-0'9.=WRU-4T"   ;"
M&               @ 'G#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ S4!V3KE0$,*L P  [P\  !@              ( !:A(  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,U =DZY9OP$F08
M 'LD   8              "  4P6  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #-0'9.@C3 !7$%  # '0  &               @ $;
M'0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ S4!V3K8+
M><^S 0  T@,  !@              ( !PB(  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( ,U =DX4$$AKL $  -(#   8
M  "  :LD  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #-
M0'9.@W;V*[4!  #2 P  &               @ &1)@  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ S4!V3EWW\1FU 0  T@,  !D
M         ( !?"@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #-0'9.Y1X37;8!  #2 P  &0              @ %H*@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,U =D[4Y_M#M0$  -(#
M   9              "  54L  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ S4!V3J?TB&:T 0  T@,  !D              ( !02X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #-0'9.NJ ;
M?;,!  #2 P  &0              @ $L,   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( ,U =DYK(KY#M $  -(#   9
M  "  18R  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MS4!V3D*6]H:U 0  T@,  !D              ( ! 30  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #-0'9.=B7,A;,!  #2 P  &0
M            @ 'M-0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( ,U =DXA' N<M0$  -(#   9              "  =<W  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ S4!V3J.V]#2U 0
MT@,  !D              ( !PSD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #-0'9.S O@ZK8!  #2 P  &0              @ &O
M.P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,U =D[6
ME)[AM@$  -(#   9              "  9P]  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ S4!V3AS_;3JU 0  T@,  !D
M     ( !B3\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,U =D[=A5O0P@$  #<$   9              "
M 3M*  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ S4!V
M3IVC]VNW 0  T@,  !D              ( !-$P  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #-0'9./ZB_.;<!  #2 P  &0
M        @ $B3@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( ,U =DZX]Y*VM@$  -(#   9              "  1!0  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ S4!V3L(WR_NV 0  T@,
M !D              ( !_5$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #-0'9.+>P5/M(!  "<!   &0              @ 'J4P
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,U =D[4,><0
MT@$  )P$   9              "  ?-5  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ S4!V3HAMO.+= 0   04  !D
M ( !_%<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #-
M0'9.C7-PT8,"  !:"0  &0              @ $06@  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,U =DX?!"9E$ 0  !T4   9
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M970T,"YX;6Q02P$"% ,4    " #-0'9.]& 9>-8"   P"P  &0
M    @ %,:P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M ,U =DX\R4!U]@$  !L%   9              "  5EN  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ S4!V3E:3[J11 @  4 <  !D
M             ( !AG   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #-0'9.NPNBFZ,"  "S"0  &0              @ $.<P  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,U =D[39P/"( (
M   '   9              "  >AU  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ S4!V3IV)5=+$!   F1H  !D              ( !
M/W@  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #-0'9.
M-_H,<.0#    %0  &0              @ $Z?0  >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,U =DXUY/;J;0(   L(   9
M      "  56!  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ S4!V3G@[SJTS @   P<  !D              ( !^8,  'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #-0'9.( YW5@("   ,!@
M&0              @ %CA@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( ,U =D[BH[/Y; ,  *8/   9              "  9R(  !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ S4!V3HYG<5IO
M @  &P@  !D              ( !/XP  'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " #-0'9.OI,\4^P"   J#   &0
M@ 'EC@  >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,U
M=D[L<,,9P0$  "0$   9              "  0B2  !X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ S4!V3B34#M0:!0  \QL  !D
M         ( ! )0  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
M    " #-0'9.^M+@ P8"  #O!0  &0              @ %1F0  >&PO=V]R
M:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( ,U =DX(W@A#NP,  -X3
M   9              "  8Z;  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
M4$L! A0#%     @ S4!V3B)<8,"  P  4P\  !D              ( !@)\
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #-0'9.QZ<A
M5UH#  "1#P  &0              @ $WHP  >&PO=V]R:W-H965T<R]S:&5E
M=#4Y+GAM;%!+ 0(4 Q0    ( ,U =DZ5FOLL+ ,  *@.   9
M  "  <BF  !X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
MS4!V3@+\WZ2I @  & H  !D              ( !*ZH  'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    " #-0'9./&E.8KH#  ">$@  &0
M            @ $+K0  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( ,U =DZQ$ZC6* (  'P&   9              "  ?RP  !X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ S4!V3H42FH_D 0
M 04  !D              ( !6[,  'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    " #-0'9.3OH_(=X"  #1"P  &0              @ %V
MM0  >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( ,U =DY8
M0 "@8 (  $((   9              "  8NX  !X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ S4!V3O,34Q(4 @  @P4  !D
M     ( !(KL  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,U =DZ<;O(U:P(  +<(   9              "
M =#&  !X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ S4!V
M3EIF-D@C @  -08  !D              ( !<LD  'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6Q02P$"% ,4    " #-0'9.3R:"8X$"  "?"0  &0
M        @ ',RP  >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0
M   ( ,U =D[*'AB*^ (  &0,   9              "  83.  !X;"]W;W)K
M<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ S4!V3O_JNV!IL0  I-,"
M !0              ( !L]$  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ S4!V3N/GA=)9 @  9 P   T              ( !3H,! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #-0'9.8FDFJ]P%  "N,0  #P
M    @ '2A0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ S4!V3F[%".EF
M @  ]BP  !H              ( !VXL! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ S4!V3M\)R204 @  Z2L  !,
M ( !>8X! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %0 5 #^%@  OI !
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>420</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Goodwill and Intangible Assets (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes</Role>
      <ShortName>Goodwill and Intangible Assets (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Legal Proceedings, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Warrants to Acquire Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Income Taxes (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesNotes</Role>
      <ShortName>Income Taxes (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Related Party Transactions (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes</Role>
      <ShortName>Related Party Transactions (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2303302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Acquisition</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNotes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Legal Proceedings, Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesNotes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization and Description of Business (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>Organization and Description of Business (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Liquidity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesBasisOfPresentationAndSignificantAccountingPoliciesEarningsPerShareDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Basis of Presentation and Significant Accounting Policies - Components of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Components of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Acquisition - Summary of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionSummaryOfPurchasePriceDetails</Role>
      <ShortName>Acquisition - Summary of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Acquisition - Total Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionTotalPurchasePriceAllocationDetails</Role>
      <ShortName>Acquisition - Total Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Acquisition - Pro Forma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionProFormaDetails</Role>
      <ShortName>Acquisition - Pro Forma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionDetails</Role>
      <ShortName>Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AcquisitionTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Debt - Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails</Role>
      <ShortName>Debt - Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Debt - Senior Secured Debenture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails</Role>
      <ShortName>Debt - Senior Secured Debenture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Debt - Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails</Role>
      <ShortName>Debt - Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Legal Proceedings, Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Legal Proceedings, Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeasesDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Warrants to Acquire Shares of Common Stock - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Classified as Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Warrants Classified as Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Income Taxes - Components of Net Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesComponentsOfNetDeferredTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Income Taxes - Schedule of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/IncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2420401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/RelatedPartyTransactionsNotes</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="gale-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2421401 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gale-20181231.xml</File>
    <File>gale-20181231.xsd</File>
    <File>gale-20181231_cal.xml</File>
    <File>gale-20181231_def.xml</File>
    <File>gale-20181231_lab.xml</File>
    <File>gale-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001390478-19-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-19-000017-xbrl.zip
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M&J/#SN4:]- J'GI%Z XJ7KG[7BL27#;Z!0=-3?>9S@XV_'"T/7S2T=@)8^@
M3JET]ZHN 3W'.2%E?6P++TVY^YZL7?RN-=0+/3^E(DYPN5YK-/IP<S4>M/\L
M7U<.N]G(+%EUV4TV!%TV[[FBSJW)N-MPJW?J5#17X)OP-+^^W 91>U+OUN7=
M?<3MZ3[M#?H*Z3W?8QZ28*\FUZ-NI]L:/ERU4DK/E=D^#KM?X7,?>ZUI6=78
M'8[@PX/1V;WD/BGZ;<3ZC(8WHOUX#+M,T%LP['+W,V#8.]+_-*GWTDY<>/]I
MGYV:+;M(H:<%TFYW!-\#.0S&*0WU@BXN1V;YR#3CZ,73Z/[#:"N2XJFZS?=
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MBX7CI/W'1/D8G2;>I2OT%&8QQ:@!FYM5?$.'Q6BXN4D)!K^F5/F#NPP4C$\
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M#(M4!71V>8&L;8R->GY0GWX.C0W"I<K(CD;"24AASH7*@ V(U!KB7B]'M\3
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MT3.NO99"6K"&)&C<5>RH)9?<>N#K<92JGHS.#5%41JV)%M'&8$ 3ELYS0)0
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MCZAXF,.)M%ZS)G!!37]-R'Y 5H?=42>C"(P1HC4-5@E,BB>+29*'$ Z]HSN
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MXWGJ$@V8@MJ"> YL"(Z5]CD,\=')#J*>)*<Z@')%V/U<W3]/)E>_#D>C/5M
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MFN, #JD(SJ7D!F'$*($J7A A:47[J4Z@W93&\MAJ?^J7[.PI/4Q94CTZ>&%
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M3/3&_5FO,'K-5LKI&\ Z"H-J:HNL>>>6*0>F(3KL)<36+A:3 Y"CMIRC7L&
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M%IC1!D)\Z:F6:7^ZXAS"OH!\Q84K+P^HA>( ,!O<8BR4XUXZ+ %23-($#EJ
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M3F-2-]#@A> B+?B5B!MOB)$0%QEO+<6J<LPKX&WX_8- W';"UCI%@!DQ\F"
MO5-!TQQ$I82@NI(C+6UT;A/,;0>-4U4M]2*"LRJQ)5()G\!46A L<.6@2RKY
M<#!!;4ZS_BROT+X;S4%!Q^GDYMUT.)DN+F'@O>\F&\MQF_9_Z*!32DLXQ0W'
MC 3$ 2V=I"X87BTWE;N@M1?,.]  =&;-]Q5"LPL5FO8Y*V%H-,A09Y@)SKFT
MG<MH01G7-3,;B-J%"GM"?0XZ-'"#IY&:=!L8$0Z>,A\]*NC@!(H5;K@<&NPL
M#TWKVB7Q6%L$;)"FT. 845S(0]!8^4J])6.'<\(.\I N6!>#WD:CR:]II[DO
M'/+D0,QFV=Q]20/&WHSK7(\-)[[J!S!$!68(.V>#C8H[Q(@FUD5P0)64U7)Z
M5G($]H5P%;O_[$_S0;YF?/4^C4/;.'OHS7T?*D47UX.Z3D_/D:2!&2)H&O-M
M+2X6Z1(L":[6ZY;(N8TDNY+N9V"UNVD>F+P9W]XU^*/E=U<(47Y#W0K2YGYR
MB/^,<B18P2VB*!:5<]0ZJJRM<]9W(TH9N@LA4MV&S,9V0.L"!^G# N(_8!QB
M,"[&S*;=2 UK9L].I+7E@F?E)AE8L 0"%?@'822$5\4L6>\T7ENR\OP(E116
M(R=I'2QEV@%Y7+KR &^T&+8+OO;:3=(WB!;!6WWRY,F';3ZL]-V>.[!44TL"
M$4)YJZ,DH)F+12L\E6;4Y@XTL-J3)]-N>FF55LY+:R@U@6.$+0I(&E<(&\3D
M0=;G60AI@U;K0U+7%GBN?(7MSX8#^&X_'-W-R[MFZWT^M-:%33"3,BAP>;GE
M5.)BQ1HEWC)6.UB1)K]I95K'89"> M>JO[>*:U2@#[Q!EF#"'(^@#(H*=HB\
M(T4UN&**I 2WKPUDDW_VP\(?!)_X?M#^V^N"0WX:]C_EXOLQ3TP"8G8T&?QK
MA_&^@(EC2 2'I-+(2Q2T+O(P:;F@_.Y/_WLT__%J^+4WFW\;97_\[AJ^\M5U
M_V8X^O;#Q^%--NO]DOW:>S^YZ8]_S%^;@0__ T:W\Q^_^]^?YS^6/CX:CK-7
M7W)"_( )^MV/";Y7PS&8L/D/3-W^MO%+TM_K@/B_V>AK-A\.^M_/^N/9JQG$
M!=>U7_+Q2]8;+&C8&XY[UT#%WM=\#\WDNC>'%W]=$+,W6E*S=SV9YJ\D9=\#
M(PN, WHD%_L>Q=_W$D5[OX)"Z/5G\.;DR<]ZOX<OGQ<# F?_YX<$^Q\2/$M$
M_@#DV(4R#SCH%NCP\!W]F]L?_PT+]&,+D&T\Y]O^5>+E5Z/L>OX#@F-=/>?T
M?/5+QY,IB-R/R\_,)[?IBW][^.(\W]X;9*-1\9Y<.M/SV6U_L'R^/X?^.KR:
M?X&'@-.GR?0JF[X:P"'V;V?9#\L'"\#[H^'G\0\)F16@IO>/DCY)H(S_^!T!
M&S %-LB?X/LW_V%^]?!P6OL5!?@%3/)W/ZY]T<,OU'YIY?-'?OS8SS_ICS]M
MZ#OD.^0[Y"\;^08;D"?0!OU187<^3>;SR<W21"V>_8!O?^O-)J/A5>_?\EP8
M^G'-YA*PGZL&=?5Y\0VK?YKFACC]I1&-%2M?MHTG<ED*+[>7VF52IG2KX[)^
M2/?PT^\NCKC;"9HVFV734Y/TWM?]ON+9RCW(O)6TY^?+"0!R#<[X#U^&5^!Q
M[AU3#,=?@'#S^L_MYC]W;+@+&\:U(*P(P&:]S^F?[*ICP(X!'X<!!\G,C#H.
M[#CPY!QHKO[K;C9/>=S>?-++BAU8O=M\S>P*3[;%BI?G17:L^D18=9&!KB9/
MVV;1C@4[%CP\;E&[DOFP(+P_^-?GZ>1N?)5RQ9/I#_\V&&39]75+A"Z.,T^!
M5\[R D/S#_!"-NN9WDK93^^^^^$Q%<+&@SH#B5N^N?I?K=G^)N;=1L\3D"WG
M^]/1;:%Y%<%D']5[& 4OAJNVFB+XW*=I;S#*^M,_?C>>C+/O_G!/A'/PUPNV
MZ)V"ZQ1<VW3CWR.J.]76J;9.M76J[7FIMLYWZQ1<I^ Z!?=L%1S3N%-LST"Q
MM4;C3NL]/I]V6N_$6N_W['M.T-F(]R"FCT3.TW+A_WDB.K)3@YT:[-3@RI?@
M[Q$^O1:\&'XZI?MWT"WNLRV57DP#Z\7LT_2N/_VV;QWO0QM30]G!(03<HXC@
MY.)'$6]+_)Z+(%V>S%R<*_!"Q.,$N==.2#HA>5Y"\GM.1-M<LU>X>I$!06L1
M:2=(+T60.FO3"4DG)$W61LK.VG36IA.D8UF&=C:FA?S9!=T7G#>Q]G8.)W$*
MJ6J5HI<C;JPM<=M(G^<BAT](Y)ZN[7JF4G;.8LE.WCIYZ^2MD[=.WCIYZ^2M
MD[=.WIZ?O/W^]&%;EX3L)+*3R,X"7EIFLY.U!JY9FS=$;W_K74WNTM"78P8.
M74RAZB,4/N]*S^=6 $U1>Y,+FFAX,?S5%0MTFJW3;,]:L[4[DZ73;)UFZS1;
MI]DN0;.U6?&\,PF[#MY.!W8ZL-.!%Z(#VYS:TOEVCR6W5<7W0J>X=%JQTXJM
M>(;?4]3>/(/.-^Q\PTX+=EKPB6G!--2EM?:2SCM</)P^/$Q+H&O?7_/XW_]P
MX,[TAW7KDYN;R?C#'/YFIMG[#,[]:W85)]-X-[^;9LM=E'MO7-?6"J.00%X[
M950(U!4;U[U1:97\.3>N"W%[PHWK^6;[6=H0-,B)"5^6:#0M:)FO5[_.J=D;
M%N3L]4^S3/U\2!_$\MM W^&,U^S32]JV3EM9MJ[8D<M_^>4O#[ZDQKR3U$:=
MK*#L92W86F[3>B#J<UBK=9%\^Y_+;:.3N_EL#@8.8&[-?3Q9&>3EN-OR>Z%W
MYLJN&K*S&NO.:>Z+3F[GP\GX)"+X?"2-ZFY88F?D#N.=MX6 ;0WZ@"+9%.*\
MK =1-P#][;[<7?XXRV>8]L)_WT&LWGLS3N[/\&O6>S?JCSMKN?O%)3G]NHD7
M+=S/6(:+/,Z.(AQN;D>3;UG66UC8=W?3P9?^K%V!?3YRB7%G6SO;>ACOO,]F
M\^EP,,^NBLSJW7C8WA;VIL3'"S":I[K.V8.8+UJHG['L?IS,^Z.M)O4TK'?!
MM]NG%F;UO6#D;%3M[F>W/5[>SQYRR7I_1?NN/X=@<&;&5XM'YO9V!">5 DXW
MF<UG[X#F@V^+_^YS1>M]0$Q0&[7!E DE;/#::LTC\5H3>9XKVA-KH<73]-D?
MAJ"*AH/%UQ8T[?7'5[W%X]X*67LY7;=RQV/C=9I+V#+DJQ>L3)WR/MF,TOWW
MYR^KZ9'>IVPTS+X"G\V_].<]</IZMROGEL=BHV^@LGOS;/!E# [%YV^]+_VO
M6<[\P_%=>NEK*H?X/O_:_@UX'O-T45_8H$_9.+M.7SN?P.,>?-TPMU+3R4W^
M@>6O#6?P8P-0D/WA^/627P:)1])%?O[ETPQL&SS,?KO-QC/XDCY\;#RXFTZS
MJ]?;]<RZKCA(VN]UQ8?!E^SJ;O10_V$&\^'72OG'#MHA(D*X(]IH3I!6BH@H
M\@(.)HU2]$S:X2R\]Q&.>E&)D1@&#KO?F]W=W*3%0L K*PSY_\UZORYOLX!E
M^H/_OAL"&\WJ"T#Z!>ESKR=]RS<0TUX&&%WU*AQQ-!)[W&@>_5NMU:N<Z'9W
MQZOR%U2.HO5KA3B(+R$"\%.\O>(4+%NI3B'BR.H2<M;JE)8_KCO@.^!?&M-C
M>H:*L$<H;+J,4>Z% ]A[LW^BI:L:JR?IVX?RB>][2X>K5_A9^RR@O+!TX,7U
ML70,N&$]0Y+H[*KCM([33LQIX;=L.AC..E[K>.WDO.:2>S+*KOX0?KL=3CN6
MZUCN<3VYUJJM.P:\.*;;/38[M7T%59=G]7<EYB76"YWA]K=5JO_E;O0ME_#>
MV^MK>-.%=J(\P;*#<T[N?A$U!T^H$O")&9T7+JF8?T_$Z1O*.B'MA/1""/<$
MA;0SIYVD=I+:26HGJ9VD7B3AGJ"D=HYO)Z0O2TA;RX66)5.U()BJE)0C.W>A
M/?DFJU9SFN^FV:OKN[RJ^'3IS>?3['@"?^VE*/5.=[\4(6'?"]DU['?BT8E'
M[9?\GGV/>&N#X*L\<#K"=*/<.U&Z*%'JW+%.2#HA:1 203IGK!..1Q>.+IUT
MZ7FZ4^:9/L +V:QG>FXRSFF2^I7?3;/K;-IBS?8+&+=USAO#EZ+N+T@<GY8=
M> 'RAK^GBG62=HD,TTG:LY*TSK)U\G9.>=N]N^V,1'P*A+L88CTUCGOI&K[S
MI3K=_MPD[6FDM3YDM_-%EW)7*G5H"NM^Q<IH^&DZ[#]F+O4RU3O%HBVBO!0=
MWJGJER(<W55U)R2=D'1"T@G)XR=TNKQ-QS\O5\EV;GHG'!<@'$\C<7(_W8T@
MLO->I*XF:+=YM/U1-N[W8O9I>I?69;0Y!OD%9-.Y.#VU7HJ"OR#A>UJ:_P7(
M65>7T,E;)V^=O'7RULG;<Y2WWW-Z^J*,*L^<CEY/I$VUD\E+(-QERB1M;ZEZ
M9_HZ,7OJA#M7MF\E%77B;-]S3^J]35N-'S.]?)EZ7;4V]^.EJ.].2[\4V>B*
M/SHAZ82D$Y).2#HA.3*CU?H.MBYMU8G1BQ,CN7,(W)F83C8NDSYGFQO5'Y\G
M<71!6;FGQ7OKZT+I[6^]J\E=FD*UW*[PTC=<:-'>I</!M.[V7W0RWLGXR62<
MX.\I::]LM!/S3LP[,;\\,6]WQ/SQY-XK?7(QNJ$K">HTPK/1")RUELWI]$&G
M#SI]\+3U 9;?"]W>.LLN$.C$_&67*%X6X592RW^8]T$2:]]?\_C?__"Y/\I^
M^##XDEW=C;*WU__9GT[[X[D9S(=?A_-O'].7?019LZ/)X%]_^I__X]_KW__W
M_NBN/Q].QF8VN[NY38]FZY\%>HZ3T+[/KO_X7?1I\>1?V3\^^N]ZPROX0W\P
M?R4Y\T(S$Q36PG"-<9 *"86)5P$K\=V?2H>P2M"/PYMLUOLE^[7W?G+3WWP@
M*Q\?#<?9JR]9?OZ8H-_]6%8J^?/A&,YW_@-3P"$GT\\?OV2]Z_YPVOL*A,QZ
MD^O>'/[RZX*XL]YPULMF\^%-?YY=]>YFP+:]?L^.0!Q>P5%,1H#Y[70X2'^_
MF5QEH]ZOP_F7_"NN)R/@TO3"<'Q[-Y_]T-O*4]NH\P!WJQ6D!VG;W>#<>/)K
M^@+!P:Z>='J^^J7CR?2F/UI3*3B]Y_Z+<XGK#;+1J'C/'[]#W^7/08$,EL_W
MY]E?AU?S+_ 0<"KL)NBD4?]VEOVP?%!AV0>@5J^8'G09KQUCL_LMU0(FPG_7
MK"UK%7N!$SWR\T_ZX^1)0\\>]^>?-N><EWB;9'E-'9S[!G^[,S\ #9Q-3V=H
MS2P9U_LQ+Q1_G^_ /L#1.G?S1VNA4]EU+<P</\"_>>HSW7:GZ1.CXT71[CGP
M(^WXL>/'CHX='3LZ=O:ZX\=+I6/'C^UFD_<H5%Z[$ZI2XU%KP4][_UODP'MO
M9K.[_GB0G8)?'X&\CQNHO[V;S^;]<0*P]_OAN#?_,KF#CUS-NLZF1PAO7AS[
M?9A/A__*\EN5K/?[VVS:FWWI3[..^1ZEHN/"S,FIF2_\=IL-TE4?_,I-[_??
MLOZT4WN/X26^.+7W]\FH/Q^.AO-OO=]U#-<QW,D9[OUP]J]7U],LZTW[\VQW
MIKO$9LHS%+>U6GGQ 5[(9CW3<Y-Q3K!4QO!NFEUGTVEVU9HE?^FEEV?9@ML5
M5G;U@><UT9?/BCN+Z/\Z&P,^+]5&7N/VNLXNGITZS?8$-=L3=/E.++3LM6QM
M(5S'EI= N"?(A$J];F\V[DOO/VPM4].)\R40[@F*,WG=XOB!3IHOOA;Y I-9
MI]PN>0C1+E-0VULT\E(BK\[T78QL/)$DT!-6#J]1M["BTP^/KA]:<SA.+3"O
M<6M3=CH^NA@[<^K!J^P$;//T)]9W]2:=).V==F"MI;)?H"!=8@W-Y6866EUQ
M]P)VFK:W3J+;:7HY,O?\3=U%<-O3*EVY3 6DB'ZMVIMY> ELT2FA)ZB$+HAP
M9W7-3[_3O..\%^]E:O9:GH_17E!PV EE)Y27D)?I9/+)57QL&&Q!TM#41Y?-
M,T\(.7 (R&70JN.K _CJ/)/B.KYZ(7S5T:JC56<'.[YZ*K3J^.I(9W[WX=PO
M;EA$_?#NG<N\N[EVW5R[1^?A;J[=)05C+X[]NKEVCYS]O61STLVU>]J<UUG=
M;JY=QW 7P7#/::[=Y=;DGJ3;]Z4W\W-Q>E)>3%M^5U%WF9;E?&6]%\.*3ZOF
M]PDJME;[FR^?GSK5]@156S>OKOPE;7;+=FQY"81[@DPH]6NBST;,;L)5)\Z=
M.)^T0!EUTGQN:7XBU<M/N*O\$&)=IH"V-Z+XI41<G<F[&-EX(MF?)ZL<E%*O
M26LQ8:<@.@7QZ)[&R?U=V=H*HHZ/+L;0G'R"3S=?ZY3IBTZ27HHDD18OGEZ@
M(*UD#OXP[W\:9;7OKWG\[W_X#&'V#Q\&7[*KNU'V]KHH:?][?W37GP\G8S.;
MW=W<ID>SC^F+/P+N=C09_.M/__-__/O=[-7G?O_V!S,83.[&\]F[_K?T'G@Z
MO<NN?AKV/Z6*LF$V,^.K/(Y?^9,?S@:CR>QNFKF[Z30;S^^_&:@_3B1^GUW_
M\;OH"<+JK^P?'_UWO>$5_*$_F+\*7@JO.*%18:X#"BHXA83"),!?(O[N3Z4C
M6R7_Q^%--NO]DOW:>S^YZ6^6\96/CX;C[%71&8,)^MU)CKQ(CB'$M"Q>_'7Q
MDY\FHZNBP6-!VEXJ%!W/ (W^^&J1(ND59.RMT'@K^VQ#+^?PX1@TX/P'P6_W
M[P3:F<4/<NIW!9VI_Y^]-^UN'+<2AC_/_ J>>J>?N,[(BG9+5<F<X[6G>JJ[
M*NWJY.0C1$(6TQ2I)DB[G%__WGL!D* VRS8I43*>>=)E25R B[NO52Y=GP4W
MSR*BLW#5603Y62!6"U\D6* #USB3*  YLUSD\*&<0QL<WJ%ME7=H/*4@_;!<
MS00 ?C9?$T;QC 4%2=#&:[('$]MT7!X$ZIJ_OFN]H\\@"5S]^?GL9,;B.S^4
MBV1I$NDOI'2B;QY\+YG"U0 (Y=T&5A"PN> ?]!\?%V5.ONZ5I7'#E9F>V_N:
MY9+.VC\\+1A72F:UI5?>WMGOZ]_2Y@\D]E [_?R("JF&)<B([!FZ!C4'JBI&
M+:W?I$4^BWS/1;Z**Z'KDVVQ,Q/U:QQ-N!!@'[+ F? G; [;F;AN6<KU= ?U
M>]6G(;^5L%:-N%+M!*CE0)8#K09-NW'6*RTB6 NLJ)(''8CUN#/"NHQFZ!,D
M#SJY!6,>,*SK'_.03_SD.5I2I?VBGJ&R5TQP@[-^6>1V+%15/P*JG0!_(\31
M']AT3VNAOU 6!7Z(D'"2V(?_NI&H1OQ4U[9]KZ0W[-L).=84K9$D.U(ZZ[<M
MF5EKZT6H@\E*_!36BHW3V'>K/JYF2,-.NU,:*S\66JH?V1RN9#IL(NEUK(UE
M;:P7-K/C8Y:H#,"8)VD<4B/N213/,!LPFL$_+EI?\SCR4M<:8,_QQ'>M 68-
ML!J)N2.ELTZG^C&1QT)GU@(K/N2Y31K>B$I9FN Z%KJI'XD<KA@Z;-)HCTKS
M]QT+<51I;;6.2MP\K_*J-*VFD$3=G7]WO"C%HJ'79%'7OTOJ'K+)G@+T&VO+
MVVETVN5U8WLQ<&N#D=:"KJ?J8KFGY9[UXY[=1J=57FS9<L\M5=CG]J&HII>$
MV:7B@@E??)FH%P!B?X4S<!_E?Y_3?>)J.&A?M*Z&P![/>[UVMWLS&%#WB=ZP
M==&_Z%;>?6(73$E^Q'L_^ F\RY6/)2!B;.-KS 5 6J8X;\2/?>_DY9C]G)7O
MKN_$MREW&"#Q#'C$(S:0P,X2R$XHPWSBARRD6). P^$S6(]PINR>.V/.0V<>
M\SF+X3H_Q/LP0H4SOQ[\9$H/E92!XP_A(?, 4/6.ASQF0?"(O_-Y(N_%%A:_
MA3Y^NDTH]G6BLPPZK8^_-6^;SH_GYU^S[]H?WS>=\_#1B?F$ XFZ7#U%<">,
M\/XD<MA\#HA&C1CN4M@/726<&<<AJ_ [W8M_X/-S%05?Y##A3)#MZL7E9(X+
M##T6>\*YC#Q_ F\@I#UY=WY[^>X]&8\KK_YM[BWM[/SV-W-/NIO'30;UE4^Z
MB."?PG-NSF\OBL#9S&.7^.1VW*S _U(!2"S$N?M'Z@L?8? UCFZP,<8G0@0"
MRW,8X4VKU1M>#WN7G?/NX/*B?=.^N)9M>,X[9^?=X6X8X<Z(+F_9(M+9#*=J
MS>.(@KQL'0WZ.6 1>P/N C4BPOS,XSO 9:([U>D8,-B?.'X"U.HYD4N>#/@C
M='YB(<WP4C7,^$9GGL;S"%T?"@$-8H=OHCF0+#5M:CK?ID!"RPLV5P87  TZ
M(7<!/5@,@('%SC,&#[P#GODP90F]ZE)RGBRIZ.RC@,M%&BR^VWF(TL SF ]N
MS-@\4.H$T&C37AM$G6I]/N!C2$E>$6[D7P#,9RX((0=7.I,T 67!@1_\R&N6
M(0-LVYHRVM;T2VE;,^S;QB^V\<NAE0X?&7R.J#=)J6,-_@D&B'--8DRW*7%L
M=Y**M+9?>.($D1 +/?:L,_@ ^6,MDHIL:X77@^:DTVNTAC4=+U1+9-J:81V(
M,K<SP*&3Q"43TO.#%$WS4$L$L/T<,64QMSI??7E^+9'*SI?I-]NV64?YH:]G
M.FA7^78OH]G8#^FZ/"CV')=N[_+JNG?=.;ML#2Y'H_.+B]:P+5VZHZO6S>CJ
MB#NK9T!_L3_PP*)7.W&<?PF=Y7:<G9%V[QK^6ZR3F@<<I?2BA_QK[-^SA#NW
MUY\_G]^BI]P#[$Z%D,&H7R+XK8VN[OPVN$;%L] ACWY?^,*).7 AP9V9O J4
M1@PH44 M.W[X$4Q%#UW'>42LX3P [^#CQ\6UX(NHM3L\2;JFR=]-SXO55O0&
M<1EY;"#F\RB6T3;MS!]SEZ6"-QQ_-N.>#Z\)'IUT'H4:-K@\Y?&7&VTLKD<D
M0.A30&O8IS/E@0>[GK%_13&&^=2M]Q&]%OWI,<];TKO$/+CGJ-CB$S&I>N!7
M-:119F#W*:E36&4I@2K )W?*!,\04X5Y0H,"3(3W@9Z [N(9G3Y17!ZF!8PF
MG,$B>\04#O<!*B4Z'&1$C172 U*2NP4>ZS+$YB**-LRX$(6$(EB!2+-710\A
M(J_"RN7G\P+;:.!M=QBDPB_G,3\UMZ96JPE"/5,3)$7.V(PB0>CV8W<\IPK8
MPP)MT9Y%ZDZ?>@W1G0I$ZW>9))U'$G-*ENPK.[IY[ /PB;NPP$UE^S@*<N.M
MBQZM5TZ-J$JGVLZ(L"&VS2&VP;";I]Z].L;6*R7&UA_VMS%/-L2IAJ^]?_#*
M!_2>>;_UNF\I@FZ8'^?RPN"!?Q+$.)6*1MX78,EI(C!1!C9FW<O6O?QJT+0[
MC=YPZU":+66V+N/"0ZY%XL]D%M>6; P-+B>2,_)>R,W>2-%GU\ZDMCK%"\W:
M*,'V.07KJ#0>;TN3;&G2GE25OJWLK%. 9F<+JV=IB>&PV?S7X6W-B TD,5S*
M7'+<@321N>G%8 &&T^ZV#@SX+CI,R3<II).0"<$3D4<!, 7!' ;+<*PRS8.
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MIH5'S#.98?)E[=Q6;[B<4F9(5M1$61#XX0ILW0?0M_4X=4.QGJ<Q"0K,R!#
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MR,>R<#3"J:H#P('S:5!G-156=-DKC7%] J)K]%B1$8CE$0Q+C;F0V3$/##T
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M]8V7H[$#=6U$D8N0=H_!U\@1D802SE4Z78YMR#@ML1OL7BI506I4B$,[C-/
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M0["M9"K2=&VGF!TAX)'QM4:GUVKVR^ND57N4LMSM +E;C0"W0]ILKIBE6D\
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MA.42;X-+5!F:&AZ5-^,;3>%0=0-YG4#HY<,$"T4#I?DI=UH"7IM6)4=6'WZ
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M#L?@YKW4)9AY/I4A%T=*AV:)DSME\1T5_BXAX>NETJ@YJ*Z.IN$\3'UW2C5
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M90/U4G9.JP1[=PC.0R#[V@#K>/FEQ;A2=<364;&Z&^E7VJ<B4TNXE!9?J X
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MA7/N)LV7]]TTN65[L%=V^1N\)"[V*A5ZVY]0"(5  K\"UH<ITHC')2]=9I(
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M_(^4T'GA1TD8DS3&[#N'D1.*GE*D![5QQ%51E*I3)J@%<L"Q![* LT31"MC
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MZS/;-K0>&1N*D((BUH:KI&75)Z8/GY1PHNDS=O/>OX8G-*Y.4E6M32;M<6<
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MY%\9%A"SA@P3D ?[%)=@<A Q*GC/\A]\E')VQ1H1+!C]#;9E<SGC>.XYCO>
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M.@EG2(.(MW8RY4 )6+6AP\F0DK&.S$#8FX"\59/75L]/-ZE8SZTG:?4FU&B
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M29,5N/$HDG1JD:3*LB.:35OO!J/2V@Z06"-3YF0)J5=:&].3%D&G::95E^5
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MK,B4U2PJ[9+&[;P C(/6I,11G\>N"S:($)LKU8Z4TKHMHT-6%UE=K\.>3R'
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M&0"_BY4V0%!6_ Y&%WRZQ?<$.:7O]_9MF_TRG7[.ZGR@?$C%<P[J*4I-]90
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MD0N;I58:\U_D:Y7 M@2KD-"WL)/2PG84 /8%4@N//3^)"-!&MX?1^4@#A]6
MY?"]%($$4"B=B1G.#>K<1$]&/^&A)3'M9YHF!&=0_]D:T*[]MU<'?=>[K)H=
M$GP47;0%USZH/HHAPZK1AHKY2TT;LT/U0_@7"(^@73;]=.344.R4@;_&X'^9
MZ4]F\"6VPX@=R3_!.B%8A-,VB2JI.ZSIB8)F-O.OP?VBOG&FT[96VK0 EVRY
MHUB%GFE0&FV5B<U&=V*63/#V+K:MI#[>+0C36  WT@X?W XJG+#_$;R BJ86
M@C* G8<=A'.BP-=2<_0:DQ9$Y1N8@(J8ZX4%0"P"YU9H81SZU2(;C-:5Y3+(
M&+9/D(D(]S*!9?$GYHIH<0B"ZQH%<P?.N/W%Z^->>>$'?U_XJ";$A&S/X]\2
M\$3PCLG^U6^*';&+*4O67DWJT*,U/T7>13['LP:[U3K,_B4X3!>??B?X)OR7
MH_YQ9R=HH!]0Y_^7=/X7)Y+SFMG(1H/>&^]]D*(/B[>'#PEX4C=Q\N7H4IPV
M\6:=SWQT"<[0C-6_8JN3HZET:05E]9 ("R,4B(@XG8I7K98Q7KCTI4&(4R9B
M$\T,BA1M!:^TP/D$CS#+M/%T[HOQ5DW=DQ>%+W<PWJD9<TG..'1ES+/F>40H
MB$SSW,Y@<> :1DAS#"Y%0)3!TH XFC@4@HP7/SY6<+6E$*(_@R_9;N'^"<%,
MG7>]\BAAT9U;01YIS%9O3F@LA) 7IZFFY$N(YXO('<H@$PCEXD $YE$\1OX<
M@4M?(2!AGO*M3!@HO)^)^.9XW;9;6N (N]1HT:8JA3OG2D->N#%1B_1YYZ4+
M VM!00*B^[6X;K34<10R7M 2G;>$K;5>;4))(\!80R^G4A5E]O ,$,\462_L
M%A BKAAST!$3X7/6NSJP1&6%H:&3'(9FN^U[M5,!:V6%"+T!V-4KO@3+NPDF
M'L/)64;8KQ'+V%WA[\0?:K_F,3XAZBTA)8M63QUU37D(+FQ01<*)7R3TG;%H
M@.:IC@\7GZC9W&IFY3IUB YEX-<T8*]FOS, 2X+:8UY9' +B.NJ0B^8OQ6LG
MILF9#Z$& ?P@7?F7$^^#8_SO>:3D$,<=6WN0]\YV<Y#_M,0KK7)9.0U1)F')
M'3%SIW7\MG_8:++A%"0^I-.W#I&1$@E%!N$RI:-E=,0OS.-83G!-M\9:B.N<
MYF ZX$GP4<N32I]5MRM$">( T"1>*9?3%UZC8X-$:EP=DD<MR'-9T%+PSF$A
MPJ=6!\AW<(K %1DJ:63Z-T*&].4NWV&++U9AG@<,[D\'-@_:3]-X$C +$X:V
MS/[6K:A+J:P?S&#6CG/C3.O^U%['AK4+&_3@RG7+VE"(80A,MF^. GAZCK%$
M:^@+!Q%?+06Q&VG5?$35I,7PP1(O<\;+/&*;[:!><J*-B3<*X419;NNC:$Y0
M>WYVC$^$\6*3B#QRLF#NB@@9-L5S##45064)S+_S6G,6T/59XIEO));TP MP
M4*QN?L'AH$=Q#82\UX';9\6QPE7&+USE\,&)-T;Z&02$7>L%/NS5/>PFTH-V
MYPB [.VQ(X#4M8X7@*I:\ (T,CMQX@IO-2BY=0X,_PPE'9"B%\LR]<V']=R9
M6NM!/+<'\4&-DQSS[R"=I_=Z$:='O<$N?(@.W'W\.E+<+=S-R64*[S9QF8B^
M9@?3O20;(@=>V7^2F_UPT-RB\$W23KN_FVGS=$R(9SAXXQUYG_UD3F#4[CHT
M(0>?RU<>>SJ1+X3*>13/CL -V$I,I0I(]O28"IP_'W_]?6^'1QSP[(!8%\L+
MX3Q7BATAS$+ GV 2#MN?3\0TRBFUDMOHV _I0(4M4IEQAD(6(TZR4FXUC,'K
MDV+*_@"&$64+.-]_UA]D&OAB\9#43/$Q1F69AE-/'+NR8\JGL#Y;_0SY.YD'
MA>']7587$Q2AFD]S?>Z6C2N>W\40F'9<F$; ";D\[/F,;(3()'_PJ!>D=ROX
MYH5_]R,Z"/HZ'O;9_9Q#JD3DI,QP]!@'F8@"]9(5E$_".K*7EA$QJ[JG);XD
MH6L41[<NL&%>4N;8*E'O,$]?418KDCCCZ=S22^$8V;[:?-?KGC3'X/ M0C3O
M4U;K@C7P #W%E^7T_@-]"Z+7>-CI!4MZ3_J_$2DR$ >7<(%J*D7E3- K,N8Y
M& MT@QL;-/^I70D^%?&?S4T/'P*73I)T*BU ^PK7PM!@XNLS"UTKR1U0*"J:
M.G_)8@3:UQR&Z2*^,4>HI=+%C@ISN^S:8?WD<E*61EO>UC6'HWL'-O2729IY
M_X;C,6-@?DNVM/[^/ VFEHC&MRPH^OY=J)?^[W2#<+M[]I6_L&9I3 D'Y6#J
MZ9G.B(<'-LOZ1!AA)/9V),PQE',<6^!'2>Z%W*'V%O_L!3X60#^3U@)B0N;
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M9&A/C_]U=SL6HC_XY2^.(X8"6JX"$CJX),(9H%,!24DH1'!X<GK(A1 /GMO
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MKJ+LFRF_GX\YR=1=P"7XY2__!5!+ P04    " #-0'9.4F*26](G   NK@$
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M@B%/JWSF-;0G<0+6_ML5G%Z,J(QRSD:AD$J:(QZL@1U@'0*;( K8'-S0#O<
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MSI;5+?9?OE<V:V=:E9;R]P#?9]/F1(%3.YO=INGL=SL+.['(Z[-4&L2?$1R
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MRY]<3EXV@;W+J"_H66H#\89NM9?->3.OK[-?\[=<2?!D;$%L>&!Y&+O4EZY
MGL 7/T]#'!\7.D?*G@^1#NNGR[L9VX!93)"U >;NF9<=;-\FVOH@RC\<J$7_
M^6__'U!+ P04    " #-0'9.CYD7$_N!  !%3@8 %0   &=A;&4M,C Q.#$R
M,S%?9&5F+GAM;.R]:7,CMY8F_'U^A5_/9]O8EXZY,X'54]WE4D55N>]\RV"1
M*2G[4DR9299+_>M?@&12&Y=D;DS*[HB^5DD $N<Y!\#!P5G^U__Y?C?]X5LZ
M+[)\]H\?X<_@QQ_2V3B?9+.;?_SX^^>?U&?S[MV/_^=__X__]?_]]-/_TY_>
M_V#S\?(NG2U^,/-TM$@G/_R9+6Y_^.<D+?[UP_4\O_OAG_G\7]FWT4\_K3O]
ML/IAFLW^]6_Q?[Z.BO2'[T7V;\7X-KT;O<_'H\7JV[>+Q?V__?++GW_^^?/W
MK_/IS_G\YA<$ /YEVVMOB_BOG\IF/\5?_0313QC^_+V8_/A#H'!6K+Y=X2-E
M\_C7R6+;X6EC^LOZC]NFKX;^$Z_:0BGE+ZN_;IL6V:Z&85#XR__[[?WG%20_
M9;-B,9J-TQ__]__XX8<U<O-\FGY*KW^(__W]T[MG@]R,INEL]#7+[V]'\[O1
MS^/\[I?8[A<U'L^7Z<1]OT]G15JHV>1J<9O.S7(^#_Q[GX4^TVR1I468WNHK
MM_/T^A\_QO$"B%! M(;P?YX\T.+A/OW'CT5V=S\-B/[2%QTV78RR:7ODO!CO
M3%1]&7V=MLBCY\.U3=,?RZS(XH(^/M]733N;2V6YV->CLYE]G.<^#W\\?89[
M>G8VT\_+N[O1_.'J^N-R/KX-.^7'>39.3Y]WI7$ZHZ+J6MK3H;MYY8O1]!DB
M:CK='(VG8WS":.U2I$=%5@36SM,B;#JK[X6-Z'-V,\NNL_%HM@B[5+Z<+8)V
M\3&?9N,*9T^#(<].6XTN;C2?A7\6']/YYS"!J@ML$),[.]XFO[O/9Z%UZ&=&
MQ6UWX!WYTMF1^#":ST/#;QW*S[Y/G)WV#G>6P>TPU<ZSQ@.W2Z?)I]/1UWQ>
M3N1].*""SJINYFD:;Y9'Z:D\0,_S5I/)ZOP=3=_-KJ-R=L+QW<K@;=,[*X(X
M3.(M7X^F\4KZ^39-J_#G2,>>YOEQ%.\^M^DB"/FT]J1WCM(=!9_# EUQ_.KZ
M\R(?_^LVGT[2>>&"=K=X.(6(2@/U0,?FB/33_,^3).?@ /W,^^H^72_(VA-_
M/4*[,[?IU\6QN3UMT_[7 ^7?TODB"^=%_&?%[>YXS_9G^CF=9?G\<SI>SM-)
M^$7@T+*RAEUY@ [F75Z93\3W4+_V9UE-%7G=LN69;*S3X01U0:%9/#PY+(_.
MK4+?=F?K1]G\/T?39?I;.BJ"*%72?@YVZF%^8=E&33'\^,S$$'? ;++9[3;M
M)VKABD5V%W?%[5A7LT]Q!<W#&"O%M*)$GV,N/: 9OI_/QMDT6\WUZOI]^BV=
MXM.-VJT,W@.]U;:)"EW;G>NO>3[Y,YM.P]I_%ZY(LYMX*JFB"/K?J7?I&D/U
M1TN^. Y^U?Z]S7I[D+W\0W..5!VZ-UJKK8_* [0[[W>S\&/Z9?3]N05L^^O-
MZY-.9^EU5E55:31H+_1]2,-GK]-Y.$3"WTX2O?HCGH&RTT^=AL-V1N/IT^]K
M9I5VX'WM.YM5]#R8+*=IN&G?AMTD+;[DD9^CV4/Q^VP>M(B;6?;?*V9NEF$-
MA!M_HP?J2ZEM)$JG#-<#3>_SHM!IN,FD+5%59< >Z/HXS[]ET6\I2M$R6NT>
MU/W]]"'H\CZ-RO\T&F*6BWS^\"DH_4TH;O:ISK"HIBOL[=#NO-ZGX4\!J'&:
M1N^Q>![<98NUZ7HVV5[4JKS,U!CJ;+14%*OZ(YZ-LD?Q]\MHY_HMFV5WR[M/
M\0EI^J2?S^<;*^?LYGVXKG6!26MS.1N:U=9J[0%;IBO[8YE-*KPWO&K8T3RJ
M2M2>]NW.ZFI^,PJJ2OE29]-B/,_NUQ86O2RR65H<G>DI8_0_^U--'DW&;)>Z
M3^DT&O@^CN:+AR_ST:P8C5>O+Q4)J=B]GSE7NBI4ZMSN?%>OB3ILKI.H#H6[
M>27K^N%>?<QPXP07'^AV_;FBB+0Q=B_4%L7R;K4&UZ=B_.G7(""+XEWX2WR_
M:D+N:8/W0>^I>]9IH_1!P>JW:RQ56,3?JI][=<?K@ZIJBD^5OAW,]B3GBKZ\
M*%Y_)ZJ!&WZJ>1BP2.??TDE8>6MM.*ZYZ*]RBK2T,'[75-=:T95&Z'KF)\C\
M@7XMSW+YM4C_6(:KA/M6Y9EY7_MN9W4RSROV;W?6_XQ?B2^2^<KK?IZNW*&C
MG]+C0CHV\U/&Z'_V&Q/MN]GC4_GUIE]ISJ]Z.'7TN?XQ>3VWH.UL?0I^+Z(3
MP70T_M?G<5C4H>_].DXG&X<__)9/TFF+@+4]E_[1/'6E-QFS?^H>#5:;UB=J
M=&U^HW_JJYU_IX_4/R5E&S,=%45VG:43M3FK6V1DY8_LI7\T'Y<0;'Y\BL(V
M>CF;+7Z99'>_;-K\,IJ^<(O>$Q]=ACS'V&JZ(NM)S[8G%7X.^G_8KGZ:I->C
MY711<XI[Q^EPPOG=*)LUG^^S85J?[FKTG^[2NZ_IO.Y<=XW1]D1OPWCS\?)K
M^M,6FIK3/3#2WDD'H<EFJXB+]^&?F]9Q7AT%WZ\GDGY?I+-).CG+5';N-F>=
MT:[MOYL)[8E&[_ACAQ&/7RR_.<W'NV1_)??7H^+K2OB7Q4\WH]']+_$$^B6=
M+HKR-ZLSZ2< -TDQ_N?FUTEIG'\RI4!2^FZ1WFTG-1U]3:?_^#%,(*G2+6'.
M B4!\4):PQEUBC@%%41 *V^X?4[LRFR:SS?X=DOMH\*T@X!"/[R,^SZ P*E#
M)0Y(!KRWG&KI"*">:;5!14(O>154'N5.S<<_Y/-).O_'C[#LN=DV3SKU8\*6
M+EB;]XI6("S\8K7G_]MXFA?IY!\_+L(&\_C+?+8(J\I-5X[$8;M/;^(/O0C=
M#HK5]^S$U15[))8QY[!12@D&J=2$.UZ"(@"&/8K0@0/UM4AUQ_V\"^!6TG0F
MP5A?$5+[3 &L*"+/^B82$6"0M<I( )D'G$-1TDP<9<E.I;A3H=FKD%?:A4[C
M9 7): .OOX:LG$=&GM%U"2)RJFB\-A;$WR2_KO1&7>J-[V;CWYY=LYZP^&#[
MQ"NF$6;&.T$8D)QR42*A)&2D3[;NNB]6XVE-'N3M(U2;HR59)K_[FLU&3],W
M/7'9,'FQV*46G#I$XJBGSDL'!>/( T6=+8]/18$P%\'W^DIGQWC5EH+/R_$X
MS,BG:7G?K<K\XST3K!"U)* CJ646"6N@W]"@)=7UUSJZ')ZW#E-]5D>K[MH3
M)HA<V&_"92/[EH:9?1P]Q)O'NS"?V2Q=S>R?V>+VJ4E@&:-1/Z;S+)^L;<5[
MQ:+5KR3>XW!D,F,-P$X%FIQ&)3:48%I;A/ %B= Y(3V[N'4M: D)9#/(,,$:
M>@*<0IJ6>'@@ZN]2Y*\G8B>"V==-Y7/Z+9U'9Z'5A@MWB-2>EHEG0$ LI65:
M<BZ0-T"6]%C.7&WAH!<A'.W TA>;@S(U6:Y$=.. _.[N?I3-UUEOYB9L?S<[
M#ZZ3^B=.2R\H8]H@)RDP-(AZ23M@HOZ1Q"Y*)+H ZU%0_M<O.QXUNGCL.)BR
MMN.'EA/2SG8\DS,\:9V<#_;"7Z"L5QX@$A1ZJR0-!R0Q1@$A% BW.P<JV;/>
MW@L4,] HK[GT"ENM(*6,KU%QGA/O+^(%JC)KF[Y G8;67^0%2BLBC /6*665
MIEI)R4I0! =]6A2[?8&JS/V*+U"G ?<V7A6(MU8[+AVSG$@E +6FI!D"0B[S
M!:HR)T]^7JB'UU]#5B[J!>I\(C*X%RA$@"9$">5MN,-B!#@O3VO##.J3K6V]
M0%7F0;47J),0ZGNQ/WD]^;1-T/-N$BU6U]EHFW)L@]!DE;9ZZ[NWBA&-KLRK
M)E^+Q7PT7E38)=K_:,*U%!)0(1&0C A@,,(ER@'S^J:E\[R(U56"!X/P)<IQ
M3$$=,\.&)M_B:M[Y7-?/AQ, N(:*:"LUA9ZA<-R4NP:V7JCARO,Y1:_#U="8
M1VWZ%M2FXE,:(,W&BS4])[@BM/3%A!+J+%4F'*/&2&B !N7&AGWXVW!?L0<@
MU\-BSD5N\>OX@W7+C_/T?I25,0JE1\'Z;WWM_%7GDW A@/ &48XQY,S; %;)
M&P)<_873^=O] !;.);'N$I?5RPS%:]><V]&LS&+<TW(Z.H_$H, #X3"26%K&
M'3$0E+Q@@4O#]4]XH\NH;9;UM7PJ2/:6 JRD,@B$Z[_BPEGN-2TI(!R1^LI\
MYWX/ Q*ZFFCVK7:/]D/P;C:>+F/2QP.RT]>G$\Z)\%I[I)EA1&M! 0HH&L2@
MTE#HX3I>#$ F!\JE2U0=GOZF7POBCB\G%"H$!+3*@7"Q=\ASH<N]A6I;/T[F
M/$[60S C-H=Y$):3UY'KFY*:Q<?1PVJ,V>1%T'L?YI4:TTJT$8H"R*P%FG"K
M@=[N=@2Y:N';EVM;;"2/71EBNF?C(!;1^_"/FW7FRG2Q6'O*]+%*=GTWX0!(
MCB&3"FO&B(2.L1(_HRD>[E[_9I=!"WRZ1!WH]>I_G\]NOJ3SNZ>%/?LQ1>Z9
M1!+NWM9I&&[A IIP&Z?&\JUL(%#_H?\B[(]MK);!,^TBE\ZV/.0VBV1?Z^7U
MEQ.)*352*:H]8$9XA[>F*AIO;V_;NCC81=*84X-0GEYF2^U#<7KYS003I3E$
M+JB=#%NAO"A]HSR%7 PXA&LH$CXT'EWBKK^[]&!/&__NCR=,6D2" #"K,%1,
M2R-A0-U22) UK/[>?Q$&U:'N_:TPZQ*72/_KXBF^GB JC2/ .NNE]1C8DO54
M>%H_K)/_O1C.P:&!KX GQ9)?4_TA[> *?>R+"9"466T,9TH"KQB5>GL(<ZGK
M.QJ(OU? .3C45S2U'A59$>N1ID4L?;AB_FSR.0OD7F?C50KXE6$X9HG(I]GK
M"IE=1!K7F%2-+FXTG\62B!_3^2J[RKD#EU68W22;+F/RCL_I>#E?29#['A]I
MTXD/"\BLBL6NB+NZ?CG][3/<@=VGK4\DAFG$&0)!?K47P"JOC=0$&RJ(Y[12
M>%77 =$-B:T>+MW&AQ)J@?(*,(2M14IC*A';((HDQWV^DAT,INY?A/8&7I\!
M]T&'93?$0S_L'N!(:'>'7TT $RBHC(0YAB"(3!*X9(X1JL]%43,\O%\9S8?*
MFKX4^MT3_C"Z.QY3?*QK$G:J<(DAP#-(,;-,.5YN6 @&G6[8X>>#D(5*\MD8
M\K^"L)U'R([$K[])&3N/;&VL['O#Y'>V2[A'C&'%/<5$4"6XL7!#"Z8.]IG0
MOZ(5H#WVY.T!TQ>3W=W]-'](TR=U=8\R?&^?Q  $HH'9,P&-1Y8*2DL:F>$#
MS-C;&?/; JDO07@,C%S-^*@0[&R?2"8X50!#YP7!$%'MP%;(%:SO8]^9STQG
M M &0.=5(RJ?FNHNVK6ZNZ"MQP\+AWH2%@_$'A%(E0FHE==UAUQ]]\6>CY8>
M+17G '[ =N-(;#Y;I1B]CO'?Y[:W;E(LQ/\\2;-0Q8QZI&?BI0;"<FI$](2C
MD! D-RQS#.!*]1*ZMH[NIJ&ZT?- _\0*C*DE@#J!"3#<"H V]&L%S& 20[;&
MQ[TFRO90&K3E,7I_OIN%(W<9/WG$8/BZ<<*)LUIZ;+"E3'AN$"LO=\9Y=P&%
MR%IA=-XR4'UI,,\G6LD LJ]+HJ0AX7B%UD*"N/9*(EY2J"!4P[:R-6'90>XW
M1N@MRL(@C6!#$(&6W(E5^.QD1<7-/%T=*X?3-NYKG\1D5<AK[H  GAKM'2D/
M4FNH'6"ZO.;0Y^T#T]<:CD$=BTU0QY?PY2,'^J[F":4ZW-JQY,0;K27S%I46
MMZ!1-:@9=KHU:D!'>@M0G4L(CF[CNSLDFC,1=CRB+>*>$XF=%"5U %DX[ .]
M&<..<+\10F]-#@9YF ^!_>=A^\I@%1W:OQY_A'K5-D%""!1F3S$EQCC-$=W2
MY 7OLSAYQ0._*7->%5UJ!DG_+P^[C[O=OSVB$-0?-+$4(4 9-B36'2+6,;!%
MB3+9YQO&@-2&W@ =MMB=\"YV^K!)P(.']6FLBJX&WB'G5&GM(]"(82LJ?8A(
M*U+9".V_Y7,_8H-4H-Z:6+9D63'Y_#Z?CQ:I"4I"MC"C^62_]!SID6@0L DZ
MB@.(<X>,](24<XYOW,-3MOIA4=X%?'WM0'L61ISY_"&;W?SG:+H\]%)7J7\2
M5I;FVAC,,9$<$ )EZ5GLC30#=!CKZLVN"[R&<EI5EYH31TJ0PL9(:8$'5DA)
MF+;E'NU9^'%X/F==R4^WR/6YZ[R8^"O"GO^B6OF21N,F!BDK%"4,!3U >BT-
M*%U@/%&F_CM09XYM7>Y2?>%86[EY_G9B\F_I;)4P),PD'+T/Y2_V:3H5NR<6
M<*HLA<J@<*]&2#'H2FJ04P.L_=ZV5'0(UWF.KLHG4T*M5%" <.8*H WCE*)2
M:?.*F?H&QLX2 _5S\)P(S(#=!3]$!_[H.GEN/T$?"4_?AYF\JA[POH*S8)7N
MB8.826^4EHXP:*W6EB@HPS\=L897"O?IVF/P "'5W0:/#9( Y)7'B%!IN>-0
M(@7L&@FKI$"#\1ULEZU['0A;QFO07H3O9AO&[:97/_PV^J]\;J:CXM@#Q(DC
M)0$U2+BGD'+,?;C_4X5*$+''%^!_V)Z<Y'U"V9>:<82*1QHJ.:S5&"UQ6@=0
M-,*6&XAE@"DH76M<M&3.#_MUH3,I.$W:6D3V;\DK\1GDN\$E"]RY!.WC/!^G
M130(I.&C\;)ATV_I-+\_Z+EY4O^$.@HYM,P*K>.U@BNJ2MJQ:O ^WYG!N%,.
MOY*F]C'LS>$G7,M62M_G<;C#S;/\B(ZULWVB!7#2ARLH98(+9JRSY3K4G)#Z
M\M&;VV=GFE0;@/4F#)LI_CXK[M-QN*.GDZ-GT]X^"8'$>&&Q8UX9)Q%'QF]I
M5&3@+J -^?;J:M<N2F]3(@:IDPQ%$,XK #Z?I^-14<$K=&>'Q"$$)$1(:N&D
ML"@<@G!#G0F_'6"I^18XM8?WC:#I+3_!Y+^6Q2+*?1'F^R']\XFM=I[/PH_C
MU:HXFBCNE'$23RP1F'&&A7<>8Z,8*[%PTO19 &9HBD270/8E5-'%^NI:3?)J
M66]V-4\,U192PKR@ FI*F62TI,Q@9(>M5G3$Q;PSX-Z2: Q2OQBP1)SIY-G2
M'U2OV23Z[/U^/PE*6&C/ #HJ&I7Z)^'L=E01C"&W"DL<[N5X0[L5U-7W8>I,
M(6G&PI>G20<@]::3+K\6Z1_+L";<M_ _%6)5]_1(E$7 4$X$4I@()8(:O]'B
MPW\MJE^)]W1GDJ&I&^U =D:1.'Y/W=<G\8P X;A!'B+ E09*J9)&YM30+1=-
M.7=<$AKA]#9E8I"ZQ7!$81 B<-QXL:M]HH@V+(:?<.<X0@)"##:TX;"']IJ5
MMZ+MHCF?#G.^%C)]<7U'M?HC^L&>'@E&D3(75!V@O5 V4+:EC[ &*<U.]S<<
MFG[0#F3G%(EU"9_C9\+1O@G&DF(H&<.46*6%0XB5-$/&!AY#VIB3%22C#;S^
M&K(R2#UB>")RJFCL"5KX5;UW!,##09C/&B7:(( 5%LA(3*2DWA-?SHR1?AEX
M6LVU%M#.6X*E-_>8N_M1-H_FLZOKE^??HXO(-!Z/ZPR]V>RFK.EVR&NFP; )
MTHX)'Y8-<4%Y,HPX*TKW8$?H ',J=^KUW".6?9\@;10Y? G)U>(VG7^Y'<TJ
MB&FO\T@@YIXARC #E##&-72FY 75JKZRW%E4:*=R/63P:Y^7+Q;DRWG]?A]
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ML;;^OL <DH ]<>F.II9X#WDTM_ATM%@>+$G8UB<2$9:D9\I0$2NW6F0=+[V
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M^"JH4Z-%-KM1XT7V;95647TM%O/1^%!B\],'2R#6#D+LO= "8 ^$TKC4S#$
M?5XJZM=+J'N]Z!ROOJ3HT<X0S4YA2839+P,!&TK");_E%/K=?#"Q!C(4E %
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MDC  N4$EC<R92AX-_:HPW6T>;:'4FY_FXY%<3W.I-D 2%'DK+8"Q6B704 I
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M2LM%2=5;<1]D6&' #41*"P4=<XC*K=4#-W#.&(C;<64^GN ^>!IFO<M&<W7
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M!L<JC<.S:;>(<MX")'V^+%ELG$;20"(!Y\ACQ=AV9DP-,*BL(V8U@:41PS"
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M<V#WMTP-4ET9MBBUY7:[G(]OH^FX6GSKGN9A2U;8D7#@ DN A%9"YLO9$M+
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M4^233.*'7Y3K[0$9#]G3HL;;)P-#4,JX:>PMBW*U!I[NUVB<&+)%3M-PJ(S
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MO:OVZ+BU<.+IWMWH]J;(?%Z4WB='C,,)3>L*CLP(XS* 7Y7%?+8^7Q[Z\(#
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M9+N=ZJ@:@2&],9V2Z9H2[()DNHN0F;0#[]=BMGXHMR_^9?GCH4G1P6-#@B.
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M;XN[9A7%!"<N(*GOI5Z$,29A,!HE(%3?3,]O:KF-8@RCTX'4L5E,@-QIG5Z
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M#)DG3DU^%IK0ODC+A.ZHT6B'WBCZ4.EL6()GCZJ[NVK_I:TVOX\OJ@4DQ$&
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MHTCH)BQU:X:'0^SAQ*.6E/TF@Y\&J?FKX"*I!F[YE&9>6L6DYQ2;,^S:^&F
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M,W&NK(MGZ+9$'L^S**"1&D)AIU#J<.P5M=3&G:QDLD=[-FVQS<IOY;;8;T\
M!(&;I1C%,'6CB(1N&*)D $!"*';GL4:S\TOF"-89T6I03!7>Y11S)LJ5%?-E
MMBT1S/,D"@BFADC8*9@Z''M%,+5Q)W+%UO'6W:ZZ&+B)E^9A# /B>H'GQR@
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M705!%J9QC'(29@#F <X#.B9+7)3F)/!2KCUH&LR8EB@&CMVY\$</CS8>IV8
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MM_/[>PXQZ6^KKTZFO^,/S2RY4N1.**_98-DAP(9]?'J&< 9&=4R_GUZ4N@H
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MURD19F?3K$>$":J7'-GVZIBD/QR*IL(4UZK%W^E_]NNTK.YOU_7=^OU^,^R
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M/A>[=5ML/ZWK]L?7>KUOUAN&^.0%R3QDD[LT"7WB(0\F2= MV9+4S3+HOW9
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MSZ!W4QQR2Z"60-BHBGH<FQ1*C=S):>?)L+'_:U-6^T^L].JM_!2%H9]"&.&
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M,&S0?ONY:!_J?7-Y3:KZKJCI-(S^=T,',G0VO'W8M,TJRZ(,AG$"4(3<D/@
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M1*H?ZRC@\??DLVE;EA=+>K,HZJ?]6<IKGA[]R_I[>?=P-WQ^[N*$9!%._3A
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M.F3.3XS&ORYTG&22JPGQU,.Q'2JHR9?*1"N4>W*DLSA8<JF-*$2>YV4)B*D
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M>]U/(6#\5O_CIECG99V_-N9Z'J.1#YT L@3''HW#81\G8BR4*D <:<)R6.#
M0(],*Q*,X$Y"_*>A34WOWV5,1^)'4*>@ZM-0J"?DFE3*:?=9Q\_)]7BF%J#0
M!IRHC/8>(TL--T697S?Y8[UB, X)82GVP\!A#D.A/^R+14D42]TW8<S8? L.
M B-H09I9=% @>-2Z@QUNC2T]R- ZY?+#@2[U%0AUIA>]"*'ACMPZA"Y/4IGE
M^YGLUWSWN$IB!_L^Q0G!+@W\P/5"#[EAG#@I]0F6?ZQDA W+^O5R<I8-T*Z
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MHOK*/&MH__M<2 6 D30N+0J,=>=L*##"D]P1_1>7 /33B\]9DZ]8DD1Q#)V
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MEPN1FS$>O-:9T6Q(+^&LU^(NQKJ_C'$PY@91G/BQ+YZ%AG%"7,[(8(R@1*W
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M!X"K'6C!7H&3HZM_%XA!#_E\U8!5ZB\KW(RL*Z[ _VD(5SE(-0OQFD>G3#:
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M$'$3GT1.Q!P4A4G@1"GL/SP0)6S2BYWR'VE9\3@0A=F- A,2,T0[)*A)#\<
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MXLYI8#P%B=9-\;UHGE\#PP%V0^+"**"$BCT=CPW 8A\JU1E. ,?VY.E$A\
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M!5CP8BE2#-CM /CG]0&QSC38< M(Q+'YR%<+82WOMWR.>N2=![ #5G $>YC
MSL>[0MR:CW^]D&6R'20WV508.KO'9H7F!40H2XY5_U][[]H<-XYEBWX_OP*?
M[G1'R'/Y?L2-.!$  5;HCJODL%U=<:,^9%"9E,WN%*DFF2YK?OT%^,B'E)D"
M2 "$?:9FNDJ6Y,3::Y-K;P ;&\H?4<&JU_P;#7R4CJ1JVL9>P=1R21@E:63!
M(+23./+'4TJ>[;EH17_]ON(N>!7\=)'7[!@(?[7F"(BF?101>,J*KAG*+]0?
M9298Z"I*'=_NEDK.Q$+#@:P.BN:*UE,:KI6R3B3,C-VER>A?%J_.8D&@\62=
MTY09Y_U_C_JN)-E3T6;;?=.5%"<P"'"4>HF%HBATW7 LX_$PA$*]Q"4.JSB-
M[2<<S8MN6MT%[]WN[_9P?Z5@9RV9U'/NLR_#NN F^P 2_&V$^7=&_J&GU0!U
ML896_"Q>VU^7[PHSY$^%8:^;):KA;KIH?JASEGF,)YV&&Z=AN3DTH6A6)$Y<
M+TTM'+B$^"0@R7Z/W[/]))K0/4H1$CUKW0/4\2AWKZ=5UY6E%]BY>BK'*U.U
M59\G9.KLZ)0![M&=Z?"Z3S1I+0^K0KHKU4VF:K!<(]_48P6<3M=FN%Y7.SKA
M_I ]=U>=!A%!:8R\P(]2.V(]S/PQ)OBAYPH=6Y\_FN+T=81#)\8=GKF2*DSF
M5/54R:,4H=PS^^$-9C4)XPO"A#1P*MFFRMUD>]Y4MGE,S1*Q>I=OWA]FFRN'
MW=/L6@%R8R>!$"7QOG+#AP[R9^N8Z(#JI8PA.I<NKG=U=Q3Q:#(N0>B$"9^A
M=2JYEB5W'?OO.2C6IW@O:!,5O:FL&ZQ[DTWBD;YY?,F_A6P%W2CVW)!.\W%"
M(D(<SQV/\ONV8R6KMFJS+9\&2AQ62 GW"+E?T=]X^ORKNG7L;<[Y9' ANL7$
M<,(M8Z9>+79%&Q6XP@R%5&'8Y"O$!+F;J9:WY;>\N= ^'_F)39+()VF4D!1;
M-%$=N]\&ONL)-:55,+SJ'9T7=S86(U3I=S;.\L$L%=5%OU0UW8,VX=H2<6+%
M!5:&EXP66BD&\@FN/"YYA9>A@.M_[XHZW[!;N[JOFZ*K9".^A],D#;$%B1<E
MED]BM!_1PD)S\SGC*);2?2*:#?AZ1<T."%G-YY1:G%GD\DFG+E[%-++31WA"
MYQ$PO1IXA:$K8B>#5S-438HEE?RG3E6"N H<.F)JNW'BQH'K1UZ:[@'$#@HD
M3*>G#*MU.GTQ)U25$K[-NNQ44"KARE- 4_,^*?D>MRO,4$05ADW.[P2YFZF7
M^S.S9Q),"R:N&^ XM3W'22R4(N2-0"R<!A(FU'.&USRAWI]QESZAGN6#62JJ
MBWZI:KH';?"$^@JQX@(KPTM&"ZT4 _D$5QZ7W-=GL9ON\DUW!?:A>]*'>J@B
MZIH<]'_*Z4]>=E5:V4[L.*[K^1%.4$P#@Q^/L_PPM2.ANA[%4!0+\HA^R&6/
MNY;E-=, R Y)?\OKMKC?YN!I-&OH:L+VU<^V.;GI;IBF'[/_R/75<R2+>)E/
MY@URL)CDG_KVN"/='GS?GN@&'/"/WSEN5Z?YXK%9?%^)!)H<:494T&7LR\O/
M='(\+UH<]<-9^:D=.AYTP]@*4^0[0;*OS0K]R$'S X+(:(MI_K&4*U1P(>;G
MB+0JTF7I\'&/.!-$]H@O81V=PK7)4CG)'BXUG,X4_^VRSUU#W[L'7+!,O=PT
M*TC<$*9V$KAN2)!'O-1/QI$"VYMR(?V48;A>L]GGA?9XNE/>HE?,3B"/4Z54
M$3;QDMD>#5.B/1[=E\R^(N2:\,R@SQ"IF6/!JWMFY[+!*R<?\Z?]6.^K\@M]
M(1]Q?M^NHM2V$C^(XQ %OH,PM/!8U!G%21Q/T)3)8^D1E@]U4:Z+IVP+GO9O
M3PFV%.@[FHD]@@V%*B8WT\GETQRUA$X2G@,D)CWO]^3A:^0IT9]+Y%P1H=E\
MFJ%$\\VH)#]GJK9>5G8:N2F)O)A@"^&$)$DX=G6+:(KE2MBJGC*LKJWJIZ,%
M_W/[+:JV6][F7?8VBU3*E6^OF+JG(F4OA=L59JBA"L,F[YT(<B=2A,C^Q_HZ
M?V-U=FWS,6_:NEC35*BK-2HWI]\X^LT/>5U4F]<G?=;;W8:"'^_R^DC3*O+P
MD+.-GY1U(;(PC",+N]!+@M@>C2#=E=_\JFL8= W*O1E@=GWBJ3TWO9;G![-N
M0+VW>/@5MF;_XIO'?T.\K-(@S@4J-0U"K;;X\Z8/.>3XH3@8U_^0/1,OOW?R
M%WJCP9FSG#=@;_KA:DYF/.BMUU]AJL^S;Q2M&OB(F1%(327G3&FMB3#U!?15
MZ-N1E<81M@/+03[R2.*,F!(W=E=/G9F?VJQN-43I-_&(2.E+Z(*J.C_4@JP%
M[=<<W.=?BK)D EH]@![5#Z2:JD20V]<_@:;QVRI3H@09UJ,X'K;\(+!MY*4I
M#OTDPC#88T+8'A2'E!L=>O,6&G&]&8$OIC8YZW+R/SHC[N.?06>X;96J,V(,
M<W<FWST]]7W1LRT;,=U6?]V6#U7]V#76WQ>7>H&# CI8B*!%O# )2#".'H=V
M(E2V(VM,Q<4[QS#!IFC6VZK9U7WUSEA<#XH#;L%J>FG,\TW7ER!=;)Y]PG<W
M>V88P1'(Q<KD.<F[HJZRZ3=#1Z5;];+=NA+6)A4SEE1!J#9_S-=Y\2W?K%!"
M$*097TB%V';<($Q).@X)(T_H=-&L@12K8/<BU@,8L-G5;(K%4J ^]^DOV"X&
MT#-*%H7YY:P#TD6M8$'0::'B  R,R!:L4'S!$6]QXE1JS= Q.:9<*TF<QP]_
MB\I^F ]9L?DM;U<!28/ ]1S/"5+VT;8?C4>"8L>UL5@W2K'/UJ%+75-LJ9HD
MS""?#*DD3TQY]EK#H-RPW89AWV'HTE_\=W=I=O]+-P8T4WM!W15!FDJR&1HT
M&?VK'I%S6!!9GV+9V&_4./KEX2!XN3FSSX[WLZ=]RH9#V_/C *4P0,2R/63M
M3RO&.+4BT68\2L$L-],LJ_)=-]L\:GY1;F2<YE;O0?Y]9&.<)[XSW$U2;\"
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MDXBK<DW!L(K#]NWC4[;N)D 45?%N4VQWG3X\U54[K/>S*="UK3\!B9?L$8Z
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M7\#H:M%W1G"BL/Z:;W;;_.Z!U=U]9E.2S_GW%FW982<Z'+8#W\<6#B"*$X]
M+[*"R$;(27W'%IHXS!E(]41BP,:"]M4+X!50R#FYT,6>X&3C!7'@SPX:8-A
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M7'%LW^,%V0CXYC2N9PST#0W^KZ[TN '9]65(3>[A6^%=U#-B(?K@%'APRHF
MP]XIAWM6\,$I2ZP-BY)[9<%8F9_,6$569UZEZ7D7N2_I\2E;MW<E'?'#>-E7
M2BGYO:SS=?6E9*V7Z<_ZWO)MLW)L/T:N[R/H1T%WY-\;BS,#DH;\]RG+'EBQ
M"O=PV6(O4]S]O6C]96R[(\S=S^\'U )IMW1'<,R5EO2!F-X.]-^5G;;NP0*&
M%AS#[7Z.#*!?8'*SI!NFS6$DNX/S]C QFB[-1E2Q;<"D0YEIE8:G5>06L>&A
M'?\+RPTI6SJ;N2T?JOJQCZGW35M3H"L7VCAUDB!QD\2.W32V+2?&MH58 0E.
M$=?=4C('5*>2(SRP_X+M6O1(P1%4\.<(EK-45@'K(G=!+<7^Q!N?7GDAF^P%
MSEN=! BZ)(M*2#9 $]785:E^//G4<),7JWZLC_F7@@U1MJROS0HBZ ;$)CAP
M$\>"2>2D^V$2/XQYTO3)'ZXX%1_>I .HKG43GY!-)^QZE-#"E5@P$*3IS*)#
M,ZXZ-/GZ/[]4W_YO:F6_X$"_>+G.<(F!,WHSFZQE964^_$K20\,O$I_KC#4G
M__3\>%]M5Q[Q72I$3A '?D!\"&DV-GR^$SM\9QW%/U5U26L/!O1H^.5 D)JW
M=4 =*V("P$F(C!?_Q.0+;_PT6I9_U2?BKN8^$*(90$)3CSK;LCV?[_^5/Z\L
M!UF.[Y'4M@+/\FWBV60<!Q(8B:4 HI^N)P<84'5[J=\!Q26:!0B3QIL&J.1K
M4A[ 3Y6\3. %"5=3@:F$+2\0,_&_2@;F,<$C&,FNKND@:=&LL^W_EV<U*3<X
M:_.5$_EAXJ<H02B L4__SX/#4*X;\]UE.&L Q;(QX (],,"0T8GY!C!L_-(Q
MG;ZWU4,+<V(",HDT&2)RB8L+.C*;NN6E9+X)E<1'230#28MM7B=TA"]5_;P*
M41Q2P:*?;1/7#@/+QV@<)4WXNC=-_6P]V4>'"8R@1%,/0;9X$P]U1$U*.S@Y
MDI=SG-A_->.8QM3R(C$+_:ML8PX+/-(PKHI^IG]C18+ L8(460%T462%$*;^
M^/$^B;GS"Z$/52P&^U5^!H9?!,1X>?OM5T;)Q"VHJVS(>-V/#;[PGD_B9/D7
M?!KL:N:S(/Y*?\CKHMJ,607]U#2R',?V(4I3@GV'C(N6KAU!K@.FTS]=UTO>
MHYHP:9A(&O^+KXZOB0K 2Y5,,3@AX0U5F$:8.?(P$?\9G9C#A(A@'*8B*?U.
MLR+8AFE(G 0CEP0XMBPGW8_D.MQ3A*F?KTLTCF?.'3)QV1"FCE\X5+(V43KX
M"9,I'B^(>$,^IM)FCH!,MN",A,QC0UQ$>LGJQ[(\G$30(2A EH6M",=),HSE
MN9[/=;/.O!$T"\D066=)B1"!HF*BBKMY<L)%FWQ!.2*#2U*FD&>:J$RRX:*L
M3&>$1U@@'6C3#;;-OJP<)W2(Z]+/L^CTB,2L%>+X^<@+'5XQ$?M4Q0*R!P,8
M&G[)$*3F;9E0QXJ8-' 2(D,,3DR^( #3:%G^I9^(NYK[0(CN3)#'O/Y2E%]^
MJ:N_VJ])]?B4E<^K&.&0(,_#;I#@( W2-,7C:)X=<YTJG3N&GIV*$1OHP8$!
MG>B6Q40:>;<NU#,X:0M#E#QY>QEG";FZIS&/PN4%18H5K_8X9+#"+S:?'K/M
M%NV:HLR;9A4&*,0A<B+'2AS7<OS <??Y2I@*5F*+?;8><>DP@1&4J*8(LL6K
M)>J(FJ0AG!S)DXX3^Z]*QC2F3)&*B>A?2<0<%@2DX6N^W8[ZDT";FIRBP$7$
MMN@TQL?!,(CO>%BP0%/HHS4) X,T-=<0HXI;%E2Q-$T5N B2* I'UE_7A"DT
M&2,)D\"_5H3I' @4;?<U6A_SIZIF37?8Y3*[9I58H<_N7W!P0*@"1:&?IC%V
MV?9+Z/L>5X.[V8/H$8FQNG"/#O3PA"NY)S+)JQP:2)RD(<+\22SO/DO)56&9
MR:(I$C/7C-<UWS)XX9>=?U3;7=EF=5_]U:SL&%IN'+A.G!"7T(D0H5]B%WJN
M:Z6AP[V#,NW3]0C-'E5?DR@L,,*<\2J+2KHF20HW4_*DY 4'5S5D*E^FB,=D
M_*]48QX3_'+Q!\V$_JNL_BH_Y5E3E?GFMFEV>;UR8L<.DP [40 #@J!'O(B.
MAT([C",8<=W=-'\4/?+!T+W[%X,'1GR@!R@J))/9Y!44'41.$I8)',J3F NL
M7)6:N4R:(CFS[7@E/7*8X9>@#[O[;;%.MU76KM(T26P7^IX=>="-8@_9+AW#
M\R/Z[=@C8K(C\LEZI*9'!#I(HN(BQ!.OH*BB:)*(<+$C3S:.;+\J%5,X,D4>
M)F%_)0G3&1!8+ZD>'ZOR4UNM__7I:T8?EKM=V[19R<[7KT+H.19V/.CXB9]8
MMA_Y^T6:U VX+L&5-)2FM9,.(N@PWH >)3B"*;R&,HM=[I447<1.6T^9RJG$
M=94K!%U?79'!K"FB),>8URLM\CCB;7?^*TV1=G7.JEQNRZ==2[X_Y>LVWWS.
MZ\?ATG _#4,[(FYJN4&8^($=)1&THHB=N?,)XJHZDSB<8ODZ0@@ZB#=@! D8
M2K%VY3+HO:Y="S$KIE]OD0K^["%JOLS[;<[.2)H"PLWH+2[3H$K9PRG0BC7-
MBIKU,<^KAS^RFG4P:WYA_\XW3WG=">S*\X,0^81$L8,@U=$ N>.H2>JY/G?+
M< EC*18VAA!\8Q#9I4I_#2#!EQ[E#;MT"30,J$#;51D,7Y>W)<@5T[:.UW^,
MO([XP"_'O'Y:@%>!)K::^9W6NG8^SWP-:]\FXTQ0D$VC <UI95I3J7G8Q%)=
M\O! @T[Q+;\MU]5C_CG[_C%K\X\Y(Z/8%GTOW#;-*:G9MMODI-P_G_SR"KF6
M1;-P/X6.%T W9,UJH)42XCHDM4)O5>9?LCZP\:;$.F!QO9UQ_W:^LH#[#?W]
M/S_])WCH@8)F1,KN_J%0N[LG:NYCZ5J=QI=A&^.H:4L((WK0(^IN/V"8P*D%
M-R!KP6 $V%OQ\B_=C/>^Z4W8);C@2D:OT\%FI/Q:+:Z6>YWD!PH&*(?EYCWU
MX';_>WFSBIPHMCTO] DFB04CVXOM 5+J>+&E*$),QJ,G-'3PNKL&V"._9<$@
M;V[ZJUT?]C%CN)I(?H28[BUYH4&MAQ3'A(/_.OA'O\_<:&PLN,3YS" PVY4_
MCOK/-W6"[$OB5Z;>IU6=%U_*D]_ !?V+K#2RR+:KT$N3((+((BB(O-BQ(4I'
M:&X00T6Z/QN7'OT?8'83 + YPB=?Z^=[2I[FZ_&.8NT????R]XX-,3@&O.6#
MF;% FHM_G)@@S^0)L4$RWUP;"3RXZ//_F)44PPAF3>-5"MW(11ZVV"$]G,8P
M]=&()?)C6R HJ 6B)PKLH>U# ,4FL"RNS@\<FQ#+<J]4X\'!,=@PQPCL8ACA
MH&E[&XH<Q;?A,96W2]L@ROU@P.:(>ALKG4^V_/G2>#LX*;-NHW]8L(O\*$$I
M]B+/=P,'NXE/O!$0PD&H:)8T$8V>J/AYV!@!ZPYEM\K2UKO\W>Y)_NQHJE_D
MS8E4^D+Q3*B'#HH2#.!_A/V0\WS/G/7,=.*/,]>9:^B$&8X4;F5J^5W[-:_A
MYI^[IF6I3;/RHB"P8>QXV$8(I5&<A$$/Q;5P9*O:XQ#&H4>_.UCRE5J<=7D:
MK89IQ>K<@09'J T6Y9<$SY3CR?[Z<81XNHD3)'@FGRH2:9S3K+[NP@%LFKQM
M6 U5OTF^W59_993HE8W#,(ZBR'/".([MD" W'E'ZR,&*LVL9$/5(]AX8R$9D
MZE)M*9Z3GW]K\Y:VI'RTJ/O=WB9P\/3>*H/#@H!O)"7P,I^"'R>8*+%^1JHO
MWPLR0Q#]9D+!%30.VDZ2A"@)W82DL1UX"#GN""*BPBQR%DSRT(J/3S!-6?=0
MY(<*$8;E10)%Y*H2>O:#'J_!"G[@=*9 3W#.CZ._4XR;(*^3.9RGGDE5MD6Y
M*\HO=T]YW2%I5CC 09K&KN?:GN4$%$Z*1P )M@XKWU6;;><(Z*31IZ3=>Z 3
MWG4%9P*FL3Y'3=4QK5A)#5+/<QP**^<L1YBLFO,,XU),"=SQJN6G]==\L]OF
M=P^WY29_*,JBS=]3/)O;LJ4/<G&_S?OL]W-&O_R<?V\1I>A?*R=*?1(YV$4)
M1)X5H=B%,<(VBHA-11V)))VJ,"C./D?8K%K^@'28Y(JIIS(O\$FI"0X0T]53
M[D?,[SK0KYT!_NR  X8<=- U-S682/ 5T57M,C,46+F5E=X70:"^<;Q;(*D>
M[XNR+R>IJ[2J'[//=58VV;I;K*@:FD@3GPZ?QL2.@M!)+>@3#*$-;<="T+<B
MKFO2I0^J6'U'J&!]P J>Z@H\,+2@/<"EO]'P"K)\ZJ\K\**LBTGNGO CF(#B
M!!U0<(04)$L2+E"=N!3QTPH2I3F KP11@)Q+58<J^#6@T%")697BYU(@]'S:
MK==T]#1GY[VZ;==7H[K0\;$7!G[L8]:\%2=V.HR*8A]Q784G:RS5:7Z/$#SD
M?1E@U94TS(DO,OCE""N:J15,X =6*3I X0V%(G."B Q6!6*'9G:GA8RY+/-%
MBK>IN!0@)))H0%R0:4VEYE$3B0*LY677I7M#(\]MR58GZ52(HOB0/?==XY*J
M+/,.Q1]%^Q6N_[TKFH+]$>_JHOS27\/<=\U<I:D+HR!(<&*Y!-)GB"!G1.BS
MWEC?\OJ^XHL9>I&)O*;'1O"_I<P>4'0&L>D+6XGO3>J"SE-O%*NF6._- G]1
MNT!V, QL.LM8RRUV:7G7-4Y(/C6[FR> F>MGP6#7.;BWA&7K8&]+I\R#-?2[
MX& /8 :!(XM ;])X*_TGTQTL$DO-=?3$N*O?X9RA6BK3%\/Z,OXT(058R/)J
M^;=I@=1BY5$(@1VXGHOLU+,(=) _8DNMR%L@J7@3TX^83BP09M[VK<8,0JI3
M%\\=C/3F NF"5*\:DR@8DB&HS@VXG?<3907\-JO(!P09YZU ^5!7FUTW]L=\
MRXK8;A^?LJ+NSOC<U0E-0K[0+(2@.(W\($")0V+?2GR*81S;"B*NIO!R1U2\
M['P ">H>)2@.,.D#RXZF,Z!BE2:2V.:K*]%/M%AL/>)X  AN3SE.WN!82;4(
M%VU7:D/DTFY&)8ADFRJ5#ZK 3.A09K(]5V:RKPKLZP3O'N!]5FZJD@%;)<1S
M6<=%RTKL*+#]*$)T?@9=%\'(2J.4>P].)0C%*GE[J%G.OS_E99.#OPT=:_\N
MD.8J=0/'/,44#XC)YU'AW?9\X=W-<=ES#Q[</8 C^*8X26#Z88JSILTXE#J-
M;XHQ@\!+LPH=/C%@(J'%S$KSLSZU8'VLDCF:KC3H^>A/A_I,XL#(MCTW31P[
M)D[BN@X)26 CQ_&=-.*Z 5@I (VEZOLRLF/8-^#^^?@;4\O79?J$;XZQN#L$
ME_-$/6%0[3H_P5R%ZPK\9<9<1:V)%TO6E?')*\UG (QEB[=E5Y9]B@)Y$41^
M$G9'Y5V"_8BX(?%CE%I.;/--8%2-K;RH\/$QJY^9"APJ>(^ BNFO=.+YI'=)
MSL54]YS2WIQG?G&]%63UBM2J\H\9*JO,NDK/4RZFK7VF_;YJFI0R<>Z *,HI
MF,,YTKS!](NF+=8KC!TG2K 763%T(^RXH8.ZJ_N0:R4^%KHL6B4.Q9K+KL(3
MTU6EI/-IK"E\BZX,=0L(?V.X_P[8NPL.T,$!.[COP+^XNF@T0*_NSF#ZB@;K
M\)\9>JS%TDK_VZ%<IX?;,U9!FI# 2XCG.[9+$_'8<MT1$/$C5[%,\\)0K-*_
MT13L'="BU=S$*Y-J%9SK5.H!O_%"/>"4J].BSOMA95K8T/DJ/8U;A2)-OK=U
M1IU3E'3:?MOFCPT5*DIY2[FG(WVY+:G6T<"R"K'G>QAC&*2V$X2)DT3.B#B%
M@;UJ^9M)+8E32.;%VTYUG:J4*[P\KRD+ 8LX3&>,.#4'C/88'S-X'2,WJ$A_
M''[8J".?B?EA29%WN/<^V8D,E#7Y)JD>6;5+WXZVKEG'6K;GBIX/OS(4=\*_
MLGIS]]39<[=KFS8K*?PO'RE@&F39#U<Q\BQ( F*E-,ZZ*<%6&O5@$T3H/T*[
MH\M 5+U<SR"_NV>8P;%=X,@PMF]W_'MC[79GW0T8[*-?'"P$?S(;P6#DY75F
MHQX&SFU9\Y\#P8W;91\!-5N[2IQT;?-WV:?"C%BX- DO-Y!-\,D"$?"WW>-]
M7J\PCJ$/21HY0>"%*/)"Q]WC= A7[[3ET"F.>P,N4!V W= L_TM1EDR[[K,M
M:X,/_E:40\.!RT6WI@M83[@>[1)T[D\G6Z+VJU.L29[0)5:_T%]D-9;]\:M?
M:CI3H1,+F 20N)C$?AJZ"?;I=T:D(0EURM44?(H%JX-$,R\>13+'9WI2:M7N
M6BZ?[BUC)]I[V]AWJ'4_5BPZXQZ%T6C.P_!SQ*-9#$B.2/.]H2LFT?3^(2_:
M'7VS1[@K&T78<;!-8B_V RLA"88#T@3%*)APQ=T2,+FT;O8U=PG+F+=+AJA)
M+M03HI2Y;?$0=639(4[]6 'JC',4!J@YC\+/$:!F,2 Y0,WWQG(K/':"6*67
M@]+$=4D4VL1+1IS03>-5W^.(E)NE5GG>0B@B<:?&S%OIR?LEZO]9YM'BW9]#
MM6;8KWR91\P3NA2+?,_K==&P4R<#3A+&*+%IEA^P&0!*W=@=U\Z3T,50YR*/
M.#K%2SQ'@);+H2?X3$\&K=9=R^7/1W;=@-ZR'RL&O7*,PA@T_2'X.6+0#/LE
MQZ"YGE@@:_XC+[Y\;?,-_);7V9=\L"#_4!?KG&WP/@P;O,BWD)=$/G)LBMY&
ME@?3P1 <)Z[0J3(#X?^8%44W8+0?# 2,RIF#C@)32HZD/67:RY&6>,",*%7B
M>+;@?=/6V;K]<>N8.+VK9P(I^U'[.:*[2H+434'5^-*P_&!%@BBV<$S2,+:C
M&/M6:J$1O86(,ZRU?6JSNC4J-7@3N?@:W,%(;N7>"VPV"&P^"NP3 WFV]FK7
M;%B7]GX>K'D:+.VQ,"J*2WT6?HS0_5/&Z^6#-/>3]']49.9G99EP+.@U:3&X
M$:H2N6J!ZV+LI\3V66^O*"*>YSC[+"(,Y$[.->)6/"M_,_Y^&>L+E49=G0^"
MI,AKZ#,@/_HVTXL2?ZP8+,^C<^+P L_5#Q*+EV!&-!XOYCUM,?E,8<Q5,P(O
M@G$<A\A- R=(4M=/]V98H2_4Y,<X\$M'Y_6^MG+'OKE4>);^3&B*T4L^#@L&
MZK.EF3];M!;TK<J0K>HQ^TGBMC)Z9 =OM7XT;F7;1SB &*>^Y488)WYL#_OV
MV$%.XBU813H+MX;:TC?C]LLZ4\[)]?^L36IY,GX07=7-RE)KDT)>6Z"&]2IZ
MR[4L)X'(M^D_%G93$L0#>A=:3K109>LLS$O/>O+C@M@E=P.E/03:2V6U^=^0
M MH?:VXCQX]ZZFVE/$D_1\25SHJZVER)7A.*N/=OH[\7SA<^YH]9P6I$6$M#
M5HVWR[:?\_K16;DA21,'VU8:!RBFLS"8^*,EOH4LX>AK&'[=D;@>D8+U 2J@
MG_QX<WR0KCNF\IQG]:13*H9Q+!*<#8/^8P3JZV4[>^O!D?F V;] T-;KW[<"
MN*%/FT'!W%2&S@5V4[%J#?*74Y1+EM@KUXN"V$F=T*,YBQ-X&.%]NA)[CM"M
M>B;B-RK(#Z?F3Z;@"P5[)<^*GF"_]&-BZJS\9PGV$_RK,-BK?-I^CF"OE"')
MP5Z]-]\*]MU%Z6^:<<^=L\ O7^JNO=@MA5V43;'^1[;=Y<?-E5'H!3BRH>,G
M,4%!X)'8'@UP;(NK"ZB!L'_4,[=[T\'>=M 9/^FTK8&.>2,/,!#QCQ'^_P][
MBC;5>L>&Z%#\K$_3B9$&/U6\*21S1Y<8VLZ0%NIWT)ELT."G9-DDT&1B*N/?
M\,6*STZAKQ+/(5Z*D.W$)()A8L-DGZ*&0>PN>I!:$*N6H].?VFK]K_V"#,WV
MBV]%^WP#LKW^%7O]^\9@GSE,O=CA:5'GZRF0T.-Q0[*OB='1C!*(BY[24V8X
M\>DP:+%D61[4E1+.\@S_PL<,L"];W],_8:K6%T+Z*H5."K&%(HC2P(4)#,/A
M:#;V8A)PE3"8B%OUTH=X=!R..HO.-LVAE'O1PAS(BN,F0-?C)AKBYO![)W%S
M#)OCN>;;\:14_PW S)XPV33_*1)=M# 'NJ95"P.?*H$E#&WNNKJ&8=Y#8\HB
MAH',O%K%,!"CO@2.?'\JZGPSFO "<!!Y(7&B,+;<-$Q="\,@' $';HRTY6OS
M8)J7GHUGW35&UIF>UI".Z7/R4MG78.%1H%PNTYKY/&A,K/0]%TOG4=.?#STY
MTU5/J$J1Y+C_)\B()!$A,P&2Z9OEMVV\R/&#$%FI@Z,X\A",X'@ZU_-]#!?L
M$B"(5$-?@ E9SVFG@/]9I%?O_Y]]D9Z;!VV+]&*>T:5Y_\@;5EI9;JA@YVMV
M]VG%OG54?GEISHI<9/MLVAI 0I((>S ^V(-2\5.'1EIAW@SQZ%""WHUMA8^*
MGHUO,YZ2Y3;&>_L!52<P,@#:JOOVBR,+LY=FS0C-DQVN,'2K?PA_CM"N@2?)
MH5^79[E3 YJ^YPW\0%_(O*9SL2[6_)IWUY4EF$ZT4.!&+L88N;$;)OUU)"0B
M/D18*'C/&$=U>.V@ 0CVX$"'3C!PSB&2,[1IXE P^%R@#_S90]-]']1EDJX)
MM@1J#9%4&9:\%#UI[/#*TNE0G:(>SYI6)'"#U+8(\CU$H!?&/@Z'4=.46+&(
M-,T=2[$\'5ZKAN&[&2Z]?=5DI/^VX,'CV3SS*9=.BL74ZX5HW?0Y<G-<'ZI7
MO]Z@ZHJ&R2+9#!V39DVEYE$4TS.:+#Y6Y=&0MTVSRS<KB&(O]"T/VG&*(8X=
MC+Q^M-CR4234$W'J&(KUJX?U0KR*#MITW9K,)Y]>Z:!23*<&%D]$Z@;TL/0*
MU 5NK@C37#;-$*395E1RGS$Q 4J+,BO71;:]+9NV[K:I&UPTZVW5[.K\<_Z]
M1=38?ZT<;,=V@(C#KL&*+!Q'*(RL(+(AL?S XZK9D3VF8H%*LZ(>#MO^FF<,
M6H=43)"D\<LG4$M0*R98>X3@""(X8 1_,I2@@ZEYBLA)WA5%DTV_&0HGW:I*
M[4,KIH#OBW_OBDVW7(>RIFCN'N!Z7>W*EF9]A[$M"X?(L^.8I!:V(^S R.G'
M#E'L6IZ(_LD94;'Z]2"+]EE,[R2QR:=V^HD4T[HC?* #"*H'<("XH-1Q,7=%
MZ.0R;X;,2;:I4OFLBM1RK[_FF]TVOWOX(V/;$2T<-HH_LUV%P] P#)W(#Y&#
M+&)'<9I$*>Z'=BT[3@2JLB4-J'IY?X )[A[  !2,2,%G_AURN21?%[[%^!5<
M^K]&[9\=3, C?0IY%BDT7H#OB27#5WB?6^/+1\+%:EW)')I0=RO;I$KA,S<G
M7K I<+^;W32[QWZ[^@4,*XV<)+)=%P81]*/(LH(##!=R;;LH&US?,D&U?^W8
M2B8@35L\9JQ0YO>&I7MHFZW_]8Z:2$=JALJ:[G(-]L-?JTV^G:.$,MPT)?IH
M]M#\2+0'#(X02PY+,IPQ)T1I=HJ\<'76.;)CU]OL<,<QB42;&--DFG<UODGG
MD2O6)5]9>59S6S(1[S1\#^A]D=T7V]<1UX/(9DOQ=,3(BA&.G=0>4-B>S7=;
MF:JQ5>_8]8C9A;AG@Q[8XQ:03A4NX AC"[,ON,DW$'][0OS=&>+GA3$5OA"(
M8@O[9%H0X_?-S"@FSLZE(*:09P-BF$KK*CU/J^ &1L56$.M'G-^WR:ZNZ2.\
M2E ,[0#;(8ZQ3SP8(MA7W^$@<"TG7'W+Z_N*>\-BP@@B;]XQ&/X7KP<"GJJZ
MRQ=I'/J4ET55T_^L=ZQRB\*EOT"_U+RV_IJM:ROI,[@U9-U\C@4O5\EGLS'E
MK?F-&CH,AD-,D .]!%EQZ*(P07XX#A9BCTQ_<00&4?[N4"SOUC_"^W,@C?,5
MFL"R>6_1%".NO$B3.>%]E]@@;$!V 1(L-Y^^TD>*?9U4C_=%F6_@(]OH6D$_
MB=(X#L,P<./ AJGEX6'PT",A7K55FVWYWBQ)0PK-F/;HN-^SS^RO@ W%*K:+
M+HM0OFWT!;@4F_\P@#> 07S'<'6'$#N4[_HKMT:@H$>J5Z[XV+LB7Y+I-T/.
M9!M5*7UD!<_&T2EB5PMX]]"5:7ZMMI3-AOQ[1U-^>-]T%PNMO 0&;N1C5K3D
MQ<@._9C5;D(20'9[,'?#;BF#*5QA'_%U"<01PO\ /4;PYXA2]XDO'N:NO)=R
MF3?CM91LT\OS8 H8XS])4=)4N"WHA/OL>;0H<4*+OO*^[2 ;!]CS\3AJB ,/
MBIVHF#>6ZG7: [QY9U=G<\HG<3KI%%QXO<SD0L=8W^#JBIS)8MD,(9-FS:O3
M%S)9FG:L=3Q!Z[H!]N/41LCW@\CRPL ?AD(1Q$(]<B8-H%BF9DG3-,;X]$@Y
M66(B9(;P"*K-+ [-D)AY)EP]7CJ)#UXQ@9M-P5;TLNV'K-C<EDGV5+39=A@3
M>:'K8F)[-HR0;:78LLDP9HJ]5*AYQ[R1%,O+ 1Q@Z-[=EF# )Z8T,^GDDQQ]
M3(IISTL2BSV)"\G05:*NZ)$<@LT0)DFV5"H>03&I^IBW&5NN(5G-[EQKAL$"
MVPG<-,4)]I/8<6(_\:)Q,-OS;1&-FCB$:G%:KW>/NVU7'(KSAV)="*X03V6.
M3XXTD":F0R,@,"):2'[.$W-%=V8R:8;@S#6BDOITB4G,;;FN\ZS)<=[_][9\
MO33U\>A24.C;H9\$'@[3)':3A&9GXP0O]7Q?:-8E>VS%HC3"!7\; ?^=U?J=
M7]3]*'[]M#*7\(G:DMX04SL%CE"BAH*,7I%)5;XQ0S^565?I><(G=)4^Z9UD
MN0EQ(Q<%/HECCP1A8*.]L@<83[RX6&@,D;=U\H7#Z.7MP=,[&4U@D7-#42EU
M@IN'0[^BQ;JJB?11FTZ<&2HT _^Y9K<SF.#?:'^I7E3AMCLVXH>^:@VV;5W<
M[]JNSK9BA4Y5V5)2MGT+_9S";%<8HC!)?9]X88B",$E(."26R(I<?XK\Z &V
MC&8)ZI0F'_%62QCG&-%RBM<Y'KN(?# "#%: 8S-8'_930\!HB>Z*"QGL7RW)
MT.I>0W1;L]&OBCH6X)SOI#I#UG?'NRV3JBSS-8/S1]%^A8]YN>D:27VNWA?K
MO*1)\:YFD'N9[ +8RK;L%%F(^+$7A0B?8++LA*LF1 \2Q3/_?F-Q:+Y),];U
MW@3P%[4!9'LCF-;\^NF_P+8W96S<*7)66KG7KH<*\QPV(4(,'3[9J;,#>L#@
M@P-^\+D"@P6@-V&X_V]L%&J4UT2.NYODO8EGWS5XD?-T_$PRSX1KO4XRX,RA
M/ENK)5X#+3&YO\T$NQ2%BVP+!0Z*7#<(O6" 9,>AEV@(R7Q S(W(V?5#$ OX
M3&E EN^N!>*Q\#7-JEVF)1K+=]V"P5C*3<KSJ)0?BL4\]$-'8D%3Y03B*?P*
MK9[VJ%['_K[.N:$H[QZ.:IZ[H[]%6]#D((:AY4,K39#CABYT/"\8DP,;VPX2
M.PFM&(R(1DPZ,<V@=QLZU0.-Q8>;*V9L\"AVC\""J1E^F1%VS\Z+V+G0$3]S
MV_%ACH,)"ZR03J;[K951]7XT:$54@['G5D)U<3Q3Y;O \C:F*';2,$X(\J!C
MATD,/8ILP,0.R@I=Y:@4B>K:ITOZGC6 _K7=MNU_,IHA1>ME.6F6U"_@'WE*
M_X_^6NL?1NCYR!;7><E.-%KF9=O*I_)*&):2RO^6_]7]J%DA'Z=^"&&$,8QL
M&V+L6>/@7AIQ+9Y)'E*C;*O,QP4XEI!WJZ%7?GY-<?:_88:XOB!O:K8LSK[1
M<CG9*)'L=RIG,K+<P]@P<&.8.(Y+7"NQ4$Q0,-2S(B=V0J%+ZN2,J%O^Q%;_
M);,[/PU50ZST=-,PW3NE;F+R*$Z]T:HWU2:!9' J8Z+[J*_5]E/>MMNAT<['
MO#M%^"&KV^?A1JGF0_;,:K%6 8Q0Z 0I"2S'I3FIG:1PQ(7MF.O2.GUH5.^H
MGMPP?&9+M=G;P>2T[BT!3\P4^N_.AF9>O9-"3XIML9KA1%FZ/-[-?K"!]=\>
MK "=&>.M>PT8##'.@=,V7,UPI(1=5W4.%=YYG<PIQ_:K>G^9M0>KP=X+&[&Z
MF)X3S;LT@A<6\5PGB@.;A!&Q8MN+(GO<)'9()'(_HP8P/T8LGU,II<Z/TT/Y
M8BZ4%LG[VS/T!G*YWIL?QQ?SHO0P+M&;LZ*X"*."05R)L\R-X6K,Y0CA"GF6
ML@GS,6_:NEBW0X,WR,[7_U)73;-*DQ@G*+&#@")QW="/0[Q?''!#>9LRTR%H
MC=:[)QJDVZ\YR-;K?)O7V7C[1+W'/VSE[,JB%9QQJ_:5A,T=/6Z2O]ESP#WT
MH>R0WX .NQ'KH&_P.W4_:+[#C%XIE6:DR'Z1+$[GS+Y^IT*4L-V3[;;3(!93
M3E#]SO1G."H3IR'T$Q\&=A A1'#DQ>.DT(V0X\^=?4D%HU_/UT?0F9:S@\+;
MXKXN,BFRKL^-TR=?BWE0VN2+60".3>CS]1>RWYDQZP"I.N_-GWPMYD7IDR^)
MWIPU^1)A5'#RI<19YDZ^U)C+,?E2R+.4R1=<TW#3=-UKFU7H0 *#A$"'>(%E
MDS3!SCA^X/BNM/F6T*A++XAF![ L/O]"O5UF"N968JZ0,)U2Y@7Y,ZACJ 9-
MF(YA39TC3?+"#S MFF:7R$QH!G,RBN=.AH>AC^+4]S%.0Q?1D5,T#N_1!TO:
M:1"A08U43GGU=6(.F%]BIXQ[Z55VQLGE*_XFEMI-<H'18CG#+(&"NQF\<:T3
MP<T_=TT['-:^<!U"A^_NJ<- ON?UNFC.'/H^ %W%)'8<G")DD]!SG<1R[/%
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MU;=B[VF?68$QM010)S !AEL!T(9^K8 YLV3=;0!AIW&Z/3;WM0G&V(!WL\"
MNQB<<\!4_/SAC!-GM?388$N9\-P@5AEUC/.N5WM%GXI9*Y(N6V;O:4!3R\ZZ
MJTFFI"%A:X;60H*X]DHB7E&H(#RSK(DI(MZ+EL8<;1R3H,)K)RLJKN?Y*K1O
M?Y;M7<]G,9,B6JVZ GAJM'=$;L9K#;5GED,V76QE^TSM:^&($6G+343:I_#F
M _O-2X]GE&K@PQ3AQ!NM)?,65;NTY8%7YVH*Z&+':8'!IX+.P1WGY0:9YDR$
M-99HB[CG1&(G144=0/;,%)8T 1] 2R..]H67U>$]!E!\/GP%]^S9# DA4!@]
MQ908XS1'=$N3%[R6.^5KNH9+%>W3$U$B0_N_.WEY=7WYTP.[5O-.,TL1 I1A
M0QC3AEC'P)9+E"7YL [P%J;;O:TW,0P;K$?<!Q[?;1;XP<.L-E9%YP[OD'-J
MPRE'H$F).!S@;MH'I%I!<2/I-#X)FG)^6\Y'R]P$415+,YI/=L/N0(M,@\";
ML.4X@#AWR$A/2#7F>''Z-Z*.%V_9!>O[6O9>9D&=V^<#+3,O-8@:KQ$Q*0J%
MA*#JC!RF)TXY20XP14>WNVV[O#XMME2<%?/[8G;]GZ/IW;X+EEKML[#B:ZZ-
MP1P3R0$A4%;W[]Y(<W8^?:UAH1;&TK@]%.6M/N:.["E#"ALCI04>6"$E8=I6
MFH=GX=<^[66O&7W=\KW/%>_)P)\1]OB#>K6UDOK-#%)6*$H8"KJQ]%H:4/E+
M>*),RB70\>?>SB/&NUP?^Y)!X\/"X_L/4W[-9ZO,06$D01V]KS[8=7*HV3RS
M@%-E*50&!94&(<6@JZA!3J4X# Y0MVL;41VR^C0;;NW]-*-6*BA T!0$T(9Q
M2E%U"/**F13+[P SD_6S61[)U('[P_T>(TNB?^"Y.<)A[3C%3IA8<<0& 4ML
M%)1:.JN",ETKPW_7CG"^F!7+_'W@_K.R//6]X0YUD@'DE<>(4&FYXU B!6S%
M"2G0VW&)JPV)G2YQ+?.ZK^WC79C#5[N'KN]_&_U7.3?3T>+0=="1/66! 9!P
M3R'EF'M/"%6HX@?V^,PNJ+L 2MFG  8"R.\TU'+':]!;YK0.3-$(6VX@EH%-
M0;M;\T5+YLYL4>P,-<>ALP5)](?0RWDYSA?QT)F'ET;%TN9?\VEYN]<[\*CV
M&744<FB9%5I'%9(KJBK:L>HWS=/)49B&CF=(;)__O7G[!&&NW!\_CH.>/R_*
M YORB\]G6@ G?3BJ4":X8,8Z6\UAS0E)P=:@70L[VWK;8'-O$-H,\8_9XC8?
MA]-?/CFXC>YLDQ%(C!<6.^:5<1)Q9/R61D7.38M+D_.SPT,[7.T;.;Z<Y^/1
MHH:_X8L-,H<0D! AJ863PJ*PPL(-=29\>F:A$"U(>0=NDMC:6_3QY+_N%LLX
M9Q9AO+_G?STXA<_+6?AUO)I1!]-W'=-/YHDE C/.L/#.XW"89ZSBA9/FS,K^
M]+##=<G^OJ 8'7XOKM2DK)>!YJ7',T.UA90P+ZB FE(F&:TH,QB=6::WCJ1>
MML[HWE:S+?U!%9A-HE/9'[>3H!2$YQE !S%5JWT6]@-'%<$8\G"HEC@<0O"&
M=BNH2W%E&"#(TL3_=)WJ@,&]Z5=WGQ?YO^X"R]S7\$^-P+$=+3)E$3"4$X$4
M)D*)H))N--+PTZ*4&L8#O!7NXX#7"J-/"*3#1[Q=;3+/"!".&^0A EQIH)2J
M:&1.G=L1+U72AY'3B*\GPL[A,]Y+SV>*:,.BRS]WCB,D(,1@0QL.$^W,LHFV
M(./]J&G$U;X0\T()^0/;UHX6&4:1,A=V8*"]4#90MJ6/L*0,+0/T2>EAVVJ'
MT:<$TKI:R^'MZV#;#&-),92,84JLTL(AQ"J:(4LJ&C? )2E9\C60E,+?QGZ5
MOZKWC@"X/^[JT4.9-@A@A04R$A,IJ??$5R-CY"U(OJ&DRI98VM<"LF<=?5\C
MCJI.\\Q!S*0W*I!*&+16:TLVE!-K>(IF,\#:DSWL41UPO3=/@)O;43&/!K"+
MJZ=C_WZC/8VDK3,K%K/KJN[8/@>!A&XSI!T3/BSQQ 5=T3#BK*@XY0CM-8]F
M'V$P[<+GJ:M ?Y+H6\EJHXS?4Y9<++_D\T]?1K,:(.]U'!G$W#-$&6: $L:X
MALY4LJ!:I9PL!NCQT.F<&++@&FN53R;STW']<1N8'([AQ31?+,M9?CFZ7UU[
MV/RV#"K6(A"W&OKZZ5U:::LOR0 16&)'M766<*B8994*1HP%*0O] *\X.X'T
MR:727Y*HL!6/9N/<E(OE NY9EI\\F5F)E:-.(&ZEL-(9:/1V$^,HY>PTP)N$
M3A?.--;VY]TZ+F_R3Z-O[MMM/EOD.I^%Z;$OTF9'B\R%<Z5ST' 53@"!6*M)
M11\%).FJ?(#6O&[UT%98W!>$+F[S&#@VNWZ?CP+7-[O^_1X([6B1.0Z Y9X(
M"S3B-"C4RGVG3Z5D+AG@8;M3"+7#XM- Z$-Q_26<P/Y8K+E1&TA/VF48<:U0
M6':MD%#;P$=:\8Y"6R_P;P><^)N&4QJC!QX'>W8UU#4A0DAM$8.$>D28=9M,
MW H24"_I9T?&B;5TGHS]?OUOG1KJ]3K(@&0BJ./"8A5K,D:W'UAQ $-\9M?3
M;4#AJ1&@"S[WEANFG"W"0"<KT=7'UKYF&1;624(8)T!09H6A!&PI]2Y%V1V@
M@:D#1+7(W;YP%+:[BRNW6!8WHV6^[V+I\8.9D9):P2CSD&(#G-9A:F@9&&6E
M\C1%#1F@Y:8#K"3QL[?+R%$Q7V7(6MV=A7-_,9I^3S.SUBKVG8EJM0^:%G ,
M8ZDDPUQA2%"5E$9!I$!*H,, [3,=8*D+-O>XD8W#(.=K(WRQ^.<ZUVG\;?\^
MMJM5AC0S C+ML80* DR5]6$J!3(1XCXI-&N -IMNMK&6F-L;B%Y,C72$6E2G
M?9Q 2"K-PK*LG8V^1UQ&VI'F1EE$S\N2TP6P.F#S:2%V*-'DP1TRI=M,&:^-
MX@PC3%%@$*4Z<DI[)F)]HI25;H"VH-X V0GW^\)I=>L<AOW<VV.7]\?*P'80
MJZE=9T9IR'V8TN$_)3G")DSMP#%@G1!.I2R@XDW@M6<)# "SU5<IX'S<1P:E
M0D'W!813X"S47L7R#E(QX+66-.5"1KYU%":QNK'GRV4X0L]6;@SKW]3M;7C]
M2CBK>^JZ%MCFG66 !XT8,0\0QV'Q]RIH*X%223W$7N*DF&IPUJCJC>E]K6;O
M\T#2@U'7.8#L;)-9(+$BRH4?$E"(XS57H%&8F.*5TZ3(Q;=AYV^+M[TY.L7B
M]'JT".IG>1-=)=;UZV\W]WSO5H?SL*=?3D>SPP>,!KUEV'D4#EHR\,!:K!!%
M)@;9<!\F&: B*=CD;=P$=,_UOM#X<H*YC0_/0?35:)UI:X2 6CJIC>'>F[5.
MR@U"7F.=Y.W_-NX2VN=R[YYZ];?*74TR#!DP!#O./#-4&ZP=C10"P<-?/"GG
MZ=NX1VB)M7V!QXWFLT#^XC*?K];;^A@ZT#+S3$+I"->8(&&TD0"P0"^CF/)P
M4DZYD8)OXPZA70[W=QEU$V3S)2R;86]>SX9CO7?J=I$9B)%!0<LD@:..8>F1
MBMYEQGEE'4JI>@+?R'5"-ZSN3<]?AK%]*:=!9(MH75[>_UXN\P_Y),]O8NS1
M927!U8/O%HN[P_I6XSXSKS 64'(5YA\$%(N@%U1",,@D:6%OXS*A+][WA4^;
MSXNOJ^(I1Q@R=C?*)-!!AT"*4T>,Q![:6%A&>R4\-P FZ6=OP_S?&G/[@M">
M;(O'[JO'=I59H[0W5H=_G=+11QSJ#9.1 6GIF]Z&G;]CE@_<97Z5$>*,'.8Q
MH$S$8QNW2",C/.)KV4A+4;U0VX[TH&U^#A6&/BFF=W&%^YB/[^:K..MU5H)\
MX@/FH\IWMY;?Q=73,T:=9:3]EV5"4T$D5,(@9H$%!E:[M[3.G5N>N#8@MK,
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M<5LZ)U-L)TFVV5<'OVX9WQ<0+^?Y[:B8;.Z\ A6K] :/.+4'?#5:9P!YH9!
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MCA!9T44U3RD?,B!7X#8%_!0SR4SM32<:CZ/_Z&+C0%K#.O-B@PQ2+B06. ;
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MNTPZ;91"UBD>_I&.,&\J6J6P*>&L0_9T:LE(VP)+^X+/DZ$>/,Z\^'P&,;.
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M$1\0$4 L60%+5WP@W293^]I<_IA,Y\L$X6+Y?N[^22B^GRZ_;29_(CG_Y-C
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M!Y5RR0G'5$D)="I!%+V)BG/"Y@3HU3_A[SM9]M+PW:5(!UX,4>=UN1C.>GV
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MMJ+0&99SL#9"]9,CXJ-H:<S1QC'M*G[V=DW%W:(HT@\'U<K1YP,A"!D'@45
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M)U7+OYDL:Q1ZVCL@*&115 61.4Q:PS6SL-(&<>G1G/#<,6(F7\H'<)/%UKY
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M$"/#;+&\64Q_;*H>ZOME9,QRN'*DCU5</Y2S:2I47:/&Z.%!@7B!@#$(Q?U
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M@+RK:. ZJS_ZR #2@5S++GF=@9?BSV)Q5RRJ67RKAY5CHX*U0%#I""(*1G\
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MVF%K?HV#Q08B++M@;V]E$B8/:8:^7/PYF4\VR?N^.'9J?6!$( A2JIW'$"N
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M0HCDSE)'"(4.(;:CQ&*3$PXUZHO]H?17!O/[AM%)3?7\P9 \5L\L140*S#D
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ML<?)0\&-2YF$$#'&'ZE P%R7Q]X77/(Y/<11\=OIO'BS*KX?LWCV/A_2[0L
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M"),ET2 F:YF0,I)'KB3LFVE&3D'EW,_,)<XCARQ# =V;.N%_-^TH\L,/*\]
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M_7JS^.<__@]02P$"% ,4    " #-0'9.RNR:#3>U 0!S8!8 $0
M    @ $     9V%L92TR,#$X,3(S,2YX;6Q02P$"% ,4    " #-0'9.3"_A
MEXL=  #!50$ $0              @ %FM0$ 9V%L92TR,#$X,3(S,2YX<V10
M2P$"% ,4    " #-0'9.4F*26](G   NK@$ %0              @ $@TP$
M9V%L92TR,#$X,3(S,5]C86PN>&UL4$L! A0#%     @ S4!V3H^9%Q/[@0
M14X& !4              ( !)?L! &=A;&4M,C Q.#$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( ,Y =DY=[4O+"Q@!  SA#@ 5              "  5-] @!G
M86QE+3(P,3@Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #.0'9._6U*"MBS  #?
M\ @ %0              @ &1E0, 9V%L92TR,#$X,3(S,5]P<F4N>&UL4$L%
3!@     &  8 B@$  )Q)!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
